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A B S T R A C T
Background
Attention deficit hyperactivity disorder (ADHD) is one of themost commonly diagnosed and treated psychiatric disorders in childhood.
Typically, children with ADHD find it difficult to pay attention, they are hyperactive and impulsive.
Methylphenidate is the drug most often prescribed to treat children and adolescents with ADHD but, despite its widespread use, this
is the first comprehensive systematic review of its benefits and harms.
Objectives
To assess the beneficial and harmful effects of methylphenidate for children and adolescents with ADHD.
Search methods
In February 2015 we searched six databases (CENTRAL, OvidMEDLINE, EMBASE, CINAHL, PsycINFO, Conference Proceedings
Citations Index), and two trials registers. We checked for additional trials in the reference lists of relevant reviews and included trials.
We contacted the pharmaceutical companies that manufacture methylphenidate to request published and unpublished data.
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Selection criteria
We included all randomised controlled trials (RCTs) comparing methylphenidate versus placebo or no intervention in children and
adolescents aged 18 years and younger with a diagnosis of ADHD. At least 75% of participants needed to have an intellectual quotient
of at least 70 (i.e. normal intellectual functioning). Outcomes assessed included ADHD symptoms, serious adverse events, non-serious
adverse events, general behaviour and quality of life.
Data collection and analysis
Seventeen review authors participated in data extraction and risk of bias assessment, and two review authors independently performed
all tasks. We used standard methodological procedures expected within Cochrane. Data from parallel-group trials and first period data
from cross-over trials formed the basis of our primary analyses; separate analyses were undertaken using post-cross-over data from cross-
over trials. We used Trial Sequential Analyses to control for type I (5%) and type II (20%) errors, and we assessed and downgraded
evidence according to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach for high risk of
bias, imprecision, indirectness, heterogeneity and publication bias.
Main results
The studies. We included 38 parallel-group trials (5111 participants randomised) and 147 cross-over trials (7134 participants ran-
domised). Participants included individuals of both sexes, at a boys-to-girls ratio of 5:1, and participants’ ages ranged from 3 to 18 years
across most studies (in two studies ages ranged from 3 to 21 years). The average age across all studies was 9.7 years. Most participants
were from high-income countries.
The duration of methylphenidate treatment ranged from 1 to 425 days, with an average duration of 75 days. Methylphenidate was
compared to placebo (175 trials) or no intervention (10 trials).
Risk of Bias. All 185 trials were assessed to be at high risk of bias.
Primary outcomes. Methylphenidate may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.77, 95%
confidence interval (CI) -0.90 to -0.64; 19 trials, 1698 participants; very low-quality evidence). This corresponds to a mean difference
(MD) of -9.6 points (95% CI -13.75 to -6.38) on the ADHD Rating Scale (ADHD-RS; range 0 to 72 points; DuPaul 1991a). A
change of 6.6 points on the ADHD-RS is considered clinically to represent the minimal relevant difference. There was no evidence
that methylphenidate was associated with an increase in serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44
to 2.22; 9 trials, 1532 participants; very low-quality evidence). The Trial Sequential Analysis-adjusted intervention effect was RR 0.91
(CI 0.02 to 33.2).
Secondary outcomes. Among those prescribed methylphenidate, 526 per 1000 (range 448 to 615) experienced non-serious adverse
events, compared with 408 per 1000 in the control group. This equates to a 29% increase in the overall risk of any non-serious adverse
events (RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants; very low-quality evidence). The Trial Sequential Analysis-adjusted
intervention effect was RR 1.29 (CI 1.06 to 1.56). The most common non-serious adverse events were sleep problems and decreased
appetite. Children in the methylphenidate group were at 60% greater risk for trouble sleeping/sleep problems (RR 1.60, 95% CI 1.15
to 2.23; 13 trials, 2416 participants), and 266% greater risk for decreased appetite (RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962
participants) than children in the control group.
Teacher-rated general behaviour seemed to improvewithmethylphenidate (SMD-0.87, 95%CI -1.04 to -0.71; 5 trials, 668 participants;
very low-quality evidence).
A change of seven points on the Child Health Questionnaire (CHQ; range 0 to 100 points; Landgraf 1998) has been deemed a minimal
clinically relevant difference. The change reported in a meta-analysis of three trials corresponds to a MD of 8.0 points (95% CI 5.49
to 10.46) on the CHQ, which suggests that methylphenidate may improve parent-reported quality of life (SMD 0.61, 95% CI 0.42
to 0.80; 3 trials, 514 participants; very low-quality evidence).
Authors’ conclusions
The results of meta-analyses suggest that methylphenidate may improve teacher-reported ADHD symptoms, teacher-reported general
behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. However, the low quality of the
underpinning evidence means that we cannot be certain of the magnitude of the effects. Within the short follow-up periods typical of
the included trials, there is some evidence that methylphenidate is associated with increased risk of non-serious adverse events, such as
sleep problems and decreased appetite, but no evidence that it increases risk of serious adverse events.
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Better designed trials are needed to assess the benefits of methylphenidate. Given the frequency of non-serious adverse events associated
with methylphenidate, the particular difficulties for blinding of participants and outcome assessors point to the advantage of large,
’nocebo tablet’ controlled trials. These use a placebo-like substance that causes adverse events in the control arm that are comparable
to those associated with methylphenidate. However, for ethical reasons, such trials should first be conducted with adults, who can give
their informed consent.
Future trials should publish depersonalised individual participant data and report all outcomes, including adverse events. This will
enable researchers conducting systematic reviews to assess differences between intervention effects according to age, sex, comorbidity,
type of ADHD and dose. Finally, the findings highlight the urgent need for large RCTs of non-pharmacological treatments.
P L A I N L A N G U A G E S U M M A R Y
Benefits and harms of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Review question
We reviewed the evidence of the effects of methylphenidate on the behaviour of children and adolescents with ADHD.
Background
ADHD is one of the most commonly diagnosed and treated childhood psychiatric disorders. Children diagnosed with ADHD find
it hard to concentrate. They are often hyperactive (fidgety, unable to sit still for long periods) and impulsive (doing things without
stopping to think). ADHD can make it difficult for children to do well at school, because they find it hard to follow instructions and to
concentrate. Their behavioural problems can interfere with their ability to get on well with family and friends, and they often get into
more trouble than other children. Methylphenidate is the drug most often prescribed to treat children and adolescents with ADHD.
Study characteristics
We found 185 randomised controlled trials (RCTs; studies in which participants are randomly assigned to one of two or more treatment
groups), involving 12,245 children or adolescents with a diagnosis of ADHD.Most of the trials comparedmethylphenidate to a placebo
- something designed to look and taste the same as methylphenidate but with no active ingredient. Most trials were small and of low
quality. Treatment generally lasted an average of 75 days (range 1 to 425 days), making it impossible to assess the long-term effects of
methylphenidate. Seventy-two of the 185 included trials (40%) were funded by industry.
The evidence is current to February 2015.
Key results
Findings suggest that methylphenidate might improve some of the core symptoms of ADHD - reducing hyperactivity and impulsivity,
and helping children to concentrate. Methylphenidate might also help to improve the general behaviour and quality of life of children
with ADHD. However, we cannot be confident that the results accurately reflect the size of the benefit of methylphenidate.
The evidence in this review of RCTs suggests that methylphenidate does not increase the risk of serious (life threatening) harms when
used for periods of up to six months. However, taking methylphenidate is associated with an increased risk of non-serious harms such
as sleeping problems and decreased appetite.
Quality of the evidence
The quality of the evidence was very low for all outcomes. It was possible for people in the trials to know which treatment the children
were taking, the reporting of the results was not complete in many trials and for some outcomes the results varied across trials. These
considerations limit our confidence in the overall results of the review.
Conclusions
At the moment, the quality of the available evidence means that we cannot say for sure whether taking methylphenidate will improve
the lives of children and adolescents with ADHD. Methylphenidiate is associated with a number of non-serious adverse events such
as problems with sleeping and decreased appetite. Although we did not find evidence that there is an increased risk of serious adverse
events, we need trials with longer follow-up to better assess the risk of serious adverse events in people who take methylphenidate over
a long period of time.
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Given that methylphenidate is associated with adverse events, designing high quality trials is challenging. It can be easy for clinicians,
researchers and participants to work out whether a child is in the experimental group (receiving methylphenidate) or in the control
group (receiving the placebo). This is a serious risk of bias that can make us less confident in the results of a trial. One way to avoid this
is to design trials that compare methylphenidate with a placebo that can produce similar adverse events, but which has no other active
ingredient. These trials are known as ’nocebo trials’. For ethical reasons, nocebo trials should first be undertaken with adults. Only if
the results suggest that methylphenidate is effective for adults, should researchers consider recruiting children to trials with this design.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M ethylphenidate compared with placebo or no intervention for ADHD
Patient or population: children and adolescents (up to and including 18 years of age) with ADHD
Settings: out-pat ient clinic, in-pat ient hospital ward and summer school
Intervention: methylphenidate
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no interven-
tion
M ethylphenidate
ADHD symptoms: all
parallel-group trials
and first-period cross-
over trials
ADHD Rating Scale
(Teacher-rated)
Average study durat ion:
74.8 days
Mean ADHD symptom
score in the inter-
vent ion groups corre-
sponds to a mean dif -
ference of 9.6 (95% CI
11.25 to 8.00) on ADHD
Rating Scale
SM D
-0.77 (-0.90 to -0.64)
1698
(19 studies)
⊕©©©
Very lowa,b
The analysis was con-
ducted on a standard-
ised scale with data
f rom studies that used
dif ferent teacher-rated
scales of symptoms
(Conners’ Teacher Rat-
ing Scale (CTRS),
Strengths and Weak-
nesses of ADHD Symp-
toms and Normal Be-
haviour (SWAN) Scale,
Schedule for Non-
adapt ive and Adap-
t ive Personality (SNAP)
- Teacher, Fremd-
beurteilungsbo-
gen für Hyperkinet ische
Störungen (FBB-HKS))
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. The ef fect size has
been translated on to
the ADHD Rating Scale
f rom the SMD
Total number of seri-
ous adverse events
Trial population RR 0.98
(0.44 to 2.22)
1532
(9 studies)
⊕©©©
Very lowa,c
-
16 per 1000 16 per 1000
(7 to 36)
Total number of non-
serious adverse events
Trial population RR 1.29
(1.10 to 1.51)
3132
(21 studies)
⊕©©©
Very lowa,b
-
408 per 1000 526 per 1000
(448 to 615)
General behaviour: all
parallel-group trials
and first-period cross-
over trials
General behaviour rat-
ing scales (Teacher-
rated)
Mean general be-
haviour score in the in-
tervent ion groups was
0.87 standard mean
deviations lower (95%
CI 1.04 to 0.71 lower)
SM D
-0.87 (-0.71 to -1.04)
668
(5 studies)
⊕©©©
Very lowa,d
-
Quality of life
(Parent-rated)
Mean quality of lif e
score in the inter-
vent ion groups corre-
sponds to a mean dif -
ference of 8.0 (95% CI
5.49 to 10.46) on the
Child Health Quest ion-
naire
SM D 0.61
(0.42 to 0.80)
514
(3 studies)
⊕©©©
Very lowa,e
-
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ADHD: Attent ion def icit hyperact ivity disorder; CI: Conf idence interval; RR: Risk rat io; SM D: Standardised mean dif ference
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded two levels due to high risk of bias (systematic errors causing overest imation of benef its and underest imation
of harms) in several risk of bias domains, including lack of suf f icient blinding and select ive outcome report ing (many of
the included trials did not report on this outcome).
bDowngraded one level due to inconsistency: moderate stat ist ical heterogeneity.
c Downgraded one level due to imprecision: wide conf idence intervals.
dDowngraded one level due to indirectness: children’s general behavior was assessed by dif ferent types of rat ing scales with
dif f erent focus on behavior.
e Downgraded one level due to indirectness: children’s quality of lif e was assessed by their parents.
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B A C K G R O U N D
Description of the condition
Attention deficit hyperactivity disorder (ADHD) is one of the
most commonly diagnosed and treated childhood psychiatric dis-
orders (Scahill 2000). The prevalence of ADHD in children and
adolescents is estimated to be 3% to 5% (Polanczyk 2007), de-
pending on the classification system used, with boys two to four
times more likely to be diagnosed than girls (Schmidt 2009). In-
dividuals with ADHD exhibit difficulty with attentional and cog-
nitive functions such as solving problems, planning, orienting,
maintaining flexibility, sustaining attention, inhibiting response
and sustaining a working memory (Pasini 2007; Sergeant 2003).
They also have difficulty handling affective features such as mo-
tivational delay and mood dysregulation (Castellanos 2006; Nigg
2005; Schmidt 2009).
Diagnosis of ADHD is confirmed through recognition of exces-
sive inattention, hyperactivity and impulsivity in a child, before
12 years of age, that impair his or her functioning or development
(APA 2013; WHO 1992). This diagnosis may be based on 18
symptoms indicative of inattention, hyperactivity and impulsiv-
ity, according to the principal diagnostic classification systems -
International Classification of Diseases, 10 th Revision (ICD-10;
WHO 1992), and theDiagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5; APA 2013). The criteria of the
ICD-10 and the DSM-5 require that inattention, hyperactivity
and impulsivity are pervasive, that is, are seen in a range of sit-
uations for at least six months and are present before the age of
six (ICD-10; WHO 1992) or 12 years (DSM-5; APA 2013), and
that some impairment resulting from these symptoms is observed
in two or more settings. Clinically significant impairment in so-
cial, academic or occupational functioning must also be evident
(APA 1994; APA 2000; APA 2013; WHO 1992). The Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV; APA 1994), provides three different subtypes to identify and
classify particular symptoms, namely ’predominantly inattentive
type’, ’predominantly hyperactive-impulsive type’ or ’combined
type’, the last of which presents with both hyperactive-impulsive
and inattentive symptoms (Willcut 2012).
ADHD is seen increasingly as a developmental psychiatric dis-
order that extends into adulthood and occurs with high hetero-
geneity and comorbidity with other psychiatric disorders (Schmidt
2009). Comorbid disorders are common in ADHD. The Mul-
timodal Treatment of Attention Deficit Hyperactivity Disorder
(MTA) trial identified one or more comorbid disorders in almost
40% of participants (MTA 1999). These included oppositional
defiant disorder, conduct disorder, depression, anxiety, tics, learn-
ing difficulties and cognitive deficits (Jensen 2001; Kadesjö 2001).
Rising rates of ADHD diagnosis, possible harm to children re-
sulting from drug treatment (Zito 2000), and variation in preva-
lence estimates are matters of increasing concern (Moffit 2007;
Polanczyk 2014). The need for a validated diagnostic test to con-
firm the clinical diagnosis of ADHDhas given rise to debate about
its validity as a diagnosis (Timimi 2004). Professional and na-
tional bodies have developed guidelines on assessment, diagno-
sis and treatment of ADHD in an attempt to ensure that high
standards are maintained in diagnostic and therapeutic practice
(American Academy of Pediatrics 2011; CADDRA 2011; NICE
2009; Pliszka 2007a; SIGN 2009). Psychosocial interventions,
such as parent management training, are recommended in the first
instance for younger children and for those with mild to moderate
symptoms (American Academy of Pediatrics 2011; NICE 2009;
Pliszka 2007a), and stimulants (given alone or in combination
with psychosocial interventions) are recommended for children
with more severe ADHD (American Academy of Pediatrics 2011;
CADDRA 2011; NICE 2009).
Description of the intervention
Methylphenidate, dexamphetamine and atomoxetine (a non-
stimulant selective noradrenaline reuptake inhibitor) are rec-
ommended medical treatments for children and adoles-
cents with ADHD (Greenhill 2006b; NICE 2009). Globally,
methylphenidate, the drug of choice, has been used for longer
than 50 years for the treatment of children with ADHD (Kadesjö
2002; NICE 2009). Research suggests that the combination of
behavioural therapy (e.g. behavioural parent training, school con-
sultation, direct contingency management) and pharmacotherapy
might benefit children with ADHD (Gilmore 2001; MTA 1999).
Methylphenidate is approved for the treatment of individuals with
ADHD and narcolepsy (Kanjwal 2012). Pharmacological treat-
ment of children and adolescents with ADHD is reported to have
a beneficial effect on the major symptoms of hyperactivity, im-
pulsivity and inattention. The dosage of the intervention can vary
significantly between children, with some responding to relatively
low dosages and others requiring larger doses to achieve the same
effect (Stevenson 1989). Therefore, it is important that the dose of
methylphenidate is titrated to anoptimal level thatmaximises ther-
apeutic benefits while producingminimal adverse events. The dose
can range from 5 mg to 60 mgmethylphenidate administered two
to three times daily (Pliszka 2007a). Furthermore, treatment with
methylphenidate should not be provided without pause. Medica-
tion-free periods are recommended to reassess effects of treatment
on symptoms (Kidd 2000; NICE 2009).
How the intervention might work
It is presumed that the effects of methylphenidate on ADHD
symptoms are related to its effects on dopaminergic and nora-
drenergic neurotransmissions within the central nervous system
(CNS) (Engert 2008). Methylphenidate acts by inhibiting cate-
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cholamine reuptake, primarily as a dopamine-norepinephrine re-
uptake inhibitor, modulating levels of dopamine and to a lesser
extent levels of norepinephrine. Methylphenidate binds to and
blocks dopamine and norepinephrine transporters (Heal 2006;
Iversen 2006), and increased concentrations of dopamine and
norepinephrine in the synaptic cleft lead to escalated neurotrans-
mission.
The bioavailability of oral methylphenidate is 11% to 52%. In-
stant-release methylphenidate has a duration of action of around
2 to 4 hours, and sustained-release and extended-release formula-
tions of methylphenidate have a duration of action of 3 to 8 hours
and 8 to 12 hours, respectively (Kimko 1999). Methylphenidate
is thought to activate self regulated control processes to amelio-
rate what are believed to be the core neurofunctional problems of
ADHD (Barkley 1977a; Schulz 2012; Solanto 1998). Evidence
suggests that symptom control is strongly related to functional
improvement (Biederman 2003b; Cox 2004a; Swanson 2004a).
Studies indicate that methylphenidate is effective for treating both
the core symptoms of ADHD (inattention, hyperactivity and im-
pulsivity), and aggression (Connor 2002), with the result that chil-
dren can manage their impulsivity better (Barkley 1981; Barkley
1989a; Shaw 2012). However, a child or adolescent may become
less responsive to methylphenidate. In a supplementary analy-
sis of the trial ’A Comparison of Methylphenidates in an Ana-
log Classroom Setting’ (COMACS), investigators found that girls
had a superior response to methylphenidate (Sonuga-Barke 2007;
Swanson 2004a). In addition, Barkley 1991b noted differences
in response to methylphenidate between ADHD inattentive and
combined subtypes: children with the inattentive subtype were
judged to have a less favourable response to methylphenidate than
those diagnosed with the combined subtype. Furthermore, debate
continues regarding whether it is valid to diagnose pre-school chil-
dren with ADHD, and whether methylphenidate is efficacious
and safe for use by pre-school children with ADHD (Greenhill
2006b).
Why it is important to do this review
Over the past 15 years, several published systematic reviews have
investigated the efficacy of methylphenidate for ADHD (with
or without meta-analysis). Fifteen reviews have pooled results
on methylphenidate treatment for children and adolescents with
ADHD (Bloch 2009; Charach 2011; Charach 2013; Faraone
2002; Faraone 2006; Faraone 2009; Faraone 2010; Hanwella
2011; Kambeitz 2014; King 2006; Maia 2014; Punja 2013;
Reichow 2013; Schachter 2001; Van der Oord 2008). However,
none of these were conducted asCochrane systematic reviews, thus
most (Bloch 2009; Charach 2011; Charach 2013; Faraone 2002;
Faraone 2006; Faraone 2009; Faraone 2010; Kambeitz 2014;
King 2006; Schachter 2001; Van der Oord 2008) did not ad-
here to the guidelines of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011) nor to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Liberati 2009; Moher 2015), and for none of these re-
views was a peer-reviewed protocol published before the analyses
were conducted. Thirteen did not undertake subgroup analyses
examining the effects of comorbidity on treatment effects (Bloch
2009; Charach 2011; Charach 2013; Faraone 2002; Faraone
2006; Faraone 2009; Faraone 2010; Hanwella 2011; Kambeitz
2014; Maia 2014; Punja 2013; Schachter 2001; Van der Oord
2008); some did not control for treatment effects by ADHD sub-
type (Bloch 2009; Charach 2013; Faraone 2002; Hanwella 2011;
Kambeitz 2014; King 2006; Maia 2014; Punja 2013; Schachter
2001; Van der Oord 2008); and others did not consider effects
according to dose of methylphenidate (Charach 2011; Charach
2013; Faraone 2006; Faraone 2009; Hanwella 2011; Kambeitz
2014; Maia 2014; Punja 2013; Reichow 2013; Van der Oord
2008). In addition, as regards the outcomes, most meta-analy-
ses pooled data from parents, teachers and independent asses-
sors (Bloch 2009; Charach 2011; Charach 2013; Hanwella 2011;
Kambeitz 2014; King 2006; Reichow 2013), and did not sepa-
rate outcome measures for inattention and hyperactivity/impul-
sivity (Bloch 2009; Charach 2013; Faraone 2002; Faraone 2006;
Faraone 2009; Hanwella 2011; Kambeitz 2014; Van der Oord
2008). Moreover, most previous reviews investigated only the ef-
fects of methylphenidate on symptoms of ADHD; review au-
thors did not present data on spontaneous adverse events (Charach
2013; Faraone 2002; Faraone 2006; Faraone 2009; Faraone 2010;
Hanwella 2011; Kambeitz 2014; Maia 2014; Van der Oord
2008), nor on adverse events as measured by rating scales (Bloch
2009; Charach 2013; Faraone 2002; Faraone 2006; Faraone 2009;
Faraone 2010; Hanwella 2011; Kambeitz 2014; King 2006; Maia
2014; Punja 2013; Reichow 2013; Schachter 2001; Van der Oord
2008), and they did not try to explain why such information
was not provided. Finally, these reviews did not systematically as-
sess risk of random errors, risk of bias and trial quality (Bloch
2009;Charach2011;Charach 2013; Faraone 2002; Faraone 2006;
Faraone 2009; Faraone 2010; Hanwella 2011; Kambeitz 2014;
King 2006; Van der Oord 2008). These shortcomings plus other
methodological limitations, including potential bias in excluding
non-English publications (Charach 2013; Faraone 2010; Punja
2013; Van der Oord 2008), and in not searching the principal
major international databases nor reporting search terms clearly
(Bloch 2009; Faraone 2002; Kambeitz 2014; Reichow 2013), may
have compromised data collection, consequently calling the results
of these previous meta-analyses into question.
Given mounting
concerns regarding increasing use of methylphenidate in children
younger than six years of age, it is vital that researchers explore risk
versus benefit of treatment in this younger population (US FDA
2011). Although stimulant medications may have a favourable
risk-benefit profile, they might carry potential risks of both seri-
ous and non-serious adverse events. Adverse events most often as-
sociated with methylphenidate include headache, sleep problems,
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tiredness and decreased appetite. Serious adverse reactions, such as
psychotic symptoms and mood disorders, affect about 3% of chil-
dren treated with methylphenidate (Block 1998; Cherland 1999;
MTA 1999; NICE 2009; Pliszka 1998). Some studies indicate
that methylphenidate can decrease children’s height and weight
(Schachar 1997b; Swanson 2004a; Swanson 2009). Other stud-
ies report sudden death though it remains unclear whether these
deaths are directly related to methylphenidate treatment (Vitiello
2008); researchers are currently exploring the link between sudden
death and treatment with methylphenidate (US FDA 2011).
Given the limitations of existing reviews, we conducted a system-
atic review of the benefits and harms of methylphenidate for chil-
dren and adolescents with ADHD while adhering to the recom-
mendations of The Cochrane Collaboration (Higgins 2011) and
to PRISMA guidelines (Liberati 2009; Moher 2015).
This systematic review focuses on the beneficial and harmful ef-
fects of methylphenidate in randomised controlled trials and is
the first of two systematic reviews. A second review focused on
harms reported in non-randomised studies is under way (Storebø
in press).
O B J E C T I V E S
To assess the beneficial and harmful effects of methylphenidate for
children and adolescents with ADHD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of methylphenidate for the
treatment of children and adolescents with ADHD. We included
trials irrespective of language, publication year, publication type
or publication status.
Types of participants
Children and adolescents aged 18 years and younger with a diag-
nosis of ADHD, according to theDiagnostic and StatisticalManual
of Mental Disorders (DSM), Third Edition (DSM-III; APA 1980),
Third Edition Revised (DSM-III-R; APA 1987), Fourth Edition
(DSM-IV; APA 1994), and Fifth Edition (DSM-5; APA 2013),
or with a diagnosis of hyperkinetic disorders according to the In-
ternational Statistical Classification of Diseases and Related Health
Problems, Ninth Revision (ICD-9), and 10 th Revision (ICD-10;
WHO1992).We includedparticipantswithADHDwith or with-
out comorbid conditions such as conduct or oppositional disor-
ders, tics, depression, attachment disorders or anxiety disorders.
Trials eligible for inclusion were those in which at least 75% of
participants were aged 18 years or younger, and the mean age of
the trial population was 18 years or younger.We also required that
at least 75% of participants had a normal intellectual quotient (IQ
> 70).
Types of interventions
Methylphenidate, administered at any dosage or in any formu-
lation as part of any medical treatment regimen, compared with
placebo or with no intervention.
We permitted cointerventions if intervention groups received
cointerventions similarly. Consequently, we did not permit
polypharmacy as a cointervention in one of the groups.
Types of outcome measures
Primary outcomes
1. ADHD symptoms (attention, hyperactivity and
impulsivity), measured over the short term (within six months)
and over the long term (longer than six months) by psychometric
instruments or by observations of behaviour, using, for example,
Conners’ Teacher Rating Scales (Conners 1998a; Conners
2008). Raters could be teachers, independent assessors or
parents. We chose to report the results of teacher-rated outcomes
as primary outcomes (see Results).
2. Numbers of serious adverse events. We defined a serious
adverse event as any event that led to death, was life-threatening,
required in-patient hospitalisation or prolongation of existing
hospitalisation or resulted in persistent or significant disability,
or as any important medical event that may have jeopardised the
patient’s life or that required intervention for prevention. We
considered all other adverse events as non-serious (ICH 1996).
Secondary outcomes
1. Non-serious adverse events. We assessed all adverse events,
including, for example, growth retardation and cardiological,
neurological and gastrointestinal events, as described in ICH
(International Conference on Harmonisation of technical
requirements for registration of pharmaceuticals for human use)
Harmonised Tripartite Guideline. Guideline for Good Clinical
Practice E6(R1) (ICH 1996).
2. General behaviour in school and at home, as rated by
psychometric instruments such as the Child Behaviour Checklist
(CBCL; Achenbach 1991), measured over the short term (within
six months) and over the long term (longer than six months).
Raters could be teachers, independent assessors or parents. We
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chose to report the results of teacher-rated outcomes as primary
outcomes (see Results).
3. Quality of life, as measured by psychometric instruments
such as the Child Health Questionnaire (CHQ; Landgraf 1998).
Raters could be teachers, independent assessors or parents.
Search methods for identification of studies
Electronic searches
We ran the first literature searches in October 2011 and updated
them in November 2012, March 2014 and most recently be-
tween 26 February and 10 March 2015. We searched the follow-
ing sources.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 2; part of The Cochrane Library, which
includes the Specialised Register of the Cochrane
Developmental, Psychosocial and Learning Problems Group),
searched 10 March 2015.
2. Ovid MEDLINE (1948 to current), searched 10 March
2015.
3. EMBASE (Ovid; 1980 to current), searched 10 March
2015.
4. CINAHL (Cumulative Index to Nursing and Allied Health
Literature; EBSCOhost; 1980 to current), searched 10 March
2015.
5. PsycINFO (Ovid; 1806 to current), searched 10 March
2015.
6. Conference Proceedings Citation Index - Science (CPCI-S)
and Conference Proceedings Citation Index - Social Science &
Humanities (CPCI-SS&H) (Web of Science; 1990 to 17 March
2015), searched 19 March 2015.
7. ClinicalTrials.gov (1999 to current), searched 26 February
2015.
8. World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; who.int/ictrp/en; 1999 to
current), searched 26 February 2015.
The search strategy for each database is shown in Appendix
1. We searched CENTRAL, Ovid MEDLINE, EMBASE and
PsycINFO using two separate search strategies (one for efficacy of
methylphenidate and one for adverse events of methylphenidate).
For the remaining databases, we used one broad strategy to capture
trials on efficacy and trials on adverse events. To overcome poor
indexing and abstracting, we listed individual brand names within
the search strategies. We did not limit searches by language, year of
publication or type or status of publication. We sought translation
of relevant sections of non-English language articles.
Searching other resources
To find additional relevant trials not identified by electronic
searches, we checked the bibliographic references of identified
review articles, meta-analyses and a selection of included trials.
Furthermore, we requested published and unpublished data from
pharmaceutical companies manufacturing methylphenidate, in-
cluding Shire, Medice (represented in Denmark by HB Pharma),
Janssen-Cilag and Novartis (Appendix 2). We also requested data
from unpublished trials from experts in the field.
Data collection and analysis
We conducted this review according to the recommendations pro-
vided in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011), and performed analyses using Review
Manager (RevMan), Version 5.3 - the statistical software of The
Cochrane Collaboration (Review Manager 2014).
Selection of studies
Eleven review authors (ER, FLM, HBK, KBR, MH, MS, OJS,
TDN, SR, TK and TB) worked together in groups of two and
independently screened titles and abstracts of all publications ob-
tained from the literature searches; uncertainty or disagreements
were resolved by consensus or by consultation with a third review
author. We obtained full-text articles of trials presenting poten-
tially relevant data and assessed them against our listed inclusion
criteria. We discussed disagreements, and if agreement or con-
sensus could not be reached, we consulted a third review author
(OJS).
Data extraction and management
Working together in groups of two, 17 review authors extracted
data (CGr, CRMM, DGa, DGi, ER, ES, FLM, HK, KBR, MH,
MJR, MS, MZ, OJS, RK, SR and TDN). We resolved disagree-
ments by discussion and we used an arbiter if required. When data
were incomplete, or when data provided in published trial reports
were unclear, we contacted trial authors to ask for clarification of
missing information. We contacted the authors of all cross-over
trials to obtain first period data on ADHD symptoms.
We developed data extraction forms a priori (after performing data
extraction pilots, we updated these forms to accommodate extrac-
tion ofmore detailed data and to facilitate standardised approaches
to data extraction among review authors). These extraction forms
were used by all data extractors (see Appendix 3; Appendix 4).
Six review authors (CRMM, FLM, MH, HK, ER and OJS) en-
tered data into RevMan (Review Manager 2014).
Assessment of risk of bias in included studies
For each included trial, data extractors independently evaluated
risk of bias domains (listed below), resolving disagreements by
discussion. For each domain, we assigned each trial to one of the
following three categories: low risk of bias, unclear (uncertain)
risk of bias or high risk of bias, according to guidelines provided
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in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Given the risk of overestimation of beneficial in-
tervention effects and underestimation of harmful intervention
effects in RCTs with unclear or inadequate methodological qual-
ity (Kjaergard 2001; Lundh 2012; Moher 1998; Savovi 2012a;
Savovi 2012b; Schulz 1995; Wood 2008), we assessed the in-
fluence of risk of bias on our results (see Subgroup analysis and
investigation of heterogeneity). Risk of bias components were as
follows.
Random sequence generation
1. Low risk of bias. The method used was adequate (e.g.
computer-generated random numbers, table of random
numbers) or was unlikely to introduce selection bias.
2. Unclear risk of bias. Information was insufficient for
assessment of whether the method used could introduce
selection bias.
3. High risk of bias. The method used was likely to introduce
bias.
Allocation concealment
1. Low risk of bias. The method used (e.g. central allocation)
was unlikely to bias allocation to groups.
2. Unclear risk of bias. Information was insufficient for
assessment of whether the method used could bias allocation to
groups.
3. High risk of bias. The method used (e.g. open random
allocation schedule) could bias allocation to groups.
Blinding of participants and personnel
1. Low risk of bias. The method of blinding was described
sufficiently and blinding was conducted in a satisfactory way that
was unlikely to introduce performance bias.
2. Unclear risk of bias. Information was insufficient for
assessment of whether adequate blinding was used and whether
it was likely to introduce performance bias.
3. High risk of bias. No blinding or incomplete blinding was
described.
Blinding of outcome assessment
1. Low risk of bias. The method of blinding was described and
blinding was conducted in a satisfactory way that was unlikely to
introduce detection bias.
2. Unclear risk of bias. Information was insufficient for
assessment of whether the type of blinding used was likely to bias
the estimate of effect.
3. High risk of bias. No blinding or incomplete blinding was
described.
Incomplete outcome data
1. Low risk of bias. Underlying reasons for missing data
probably would not affect outcome measurement regarding
effects of methylphenidate, as all missing data can be considered
as missing at random or all data were reported.
2. Unclear risk of bias. Information was insufficient for
assessment of whether missing data or the method used to
handle missing data was likely to bias the estimate of effect.
3. High risk of bias. The crude estimate of effects could be
biased given the reasons for the missing data.
Selective reporting
1. Low risk of bias. The trial protocol was available and all
pre-specified outcomes of interest were reported.
2. Unclear risk of bias. Information was insufficient for
assessment of whether selective outcome reporting could have
occurred.
3. High risk of bias. Not all of the primary outcomes specified
beforehand were reported or participants were excluded after
randomisation (selection bias).
Vested interest bias
1. Low risk of bias. The trial was not funded by any parties
that might be considered to have a conflict of interest (e.g. a
manufacturer of methylphenidate).
2. Unclear risk of bias. The source of funding was not clear.
3. High risk of bias. The trial was funded by parties that
might have had a conflict of interest (e.g. a manufacturer of
methylphenidate) or potential conflicts of interest were reported
by trial authors.
Other potential sources of bias
1. Low risk of bias. The trial appeared to be free of other
sources of bias.
2. Unclear risk of bias. Information was inadequate for
assessment of other possible sources of bias.
3. High risk of bias. Other sources of bias were identified.
Sevenof the above domains are specified in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011). We added
an eighth domain - vested interest (Storebø 2012). Andreas Lundh
and colleagues have shown that there are many subtle mechanisms
through which sponsorship and conflict of interest may influence
intervention effects onoutcomes. TheAMSTAR(AMeaSurement
Tool toAssess systematicReviews) tool for methodological quality
assessment of systematic reviews also includes funding and con-
flicts of interest as a domain (amstar.ca). For more information,
please see editorials by Bero 2013 and Sterne 2013, and the com-
mentary by Gøtzsche 2015.
We defined low risk of bias trials as trials that had low risk of bias
in all domains. We considered trials with one or more unclear or
high risk of bias domains as trials with high risk of bias.
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Some trials excluded methylphenidate non-responders, placebo
responders and/or participants who had adverse events due to
the medication. We did not consider these trials to be at risk of
bias as participants were excluded before randomisation. How-
ever, to identify whether this ’cohort selection bias of all partic-
ipants’ had an effect on estimates of effectiveness, we conducted
subgroup analyses based on these criteria (Subgroup analysis and
investigation of heterogeneity).
Measures of treatment effect
The treatment effect was defined as an improvement in ADHD
symptoms, general behaviour and quality of life.
Dichotomous data
We summarised dichotomous data as risk ratios (RRs) with 95%
confidence intervals (CIs). We calculated the risk difference (RD).
Continuous data
If the same measure of a given continuous outcome was used in
all trials in a meta-analysis, we calculated mean differences (MDs)
with 95% CIs. If different measures were used, we calculated stan-
dardised mean differences (SMDs) with 95% CIs. If trials did not
report means and standard deviations but did report other values
(e.g. t-tests, P values), we transformed these into standard devia-
tions.
For primary analyses of teacher-rated ADHD symptoms, teacher-
rated general behaviour and quality of life, we transformed SMDs
into MDs on the following scales to assess whether results ex-
ceeded theminimum clinically important difference: ADHDRat-
ing Scale (ADHD-RS; DuPaul 1991a), Conners’ Global Index
(CGI; Conners 1998a) and Child Health Questionnaire (CHQ;
Landgraf 1998).We identified aminimal clinically relevant differ-
ence (MIREDIF) of 6.6 points on the ADHD-RS, ranging from
0 to 72 points, based on a trial by Zhang 2005, and a MIREDIF
of 7.0 points on the CHQ, ranging from 0 to 100 points, based
on a trial by Rentz 2005. We could find no references describing
a MIREDIF on the CGI (range 0 to 30 points).
Unit of analysis issues
Many ADHD trials use cross-over methods. We aimed to obtain
data from the first period of these trials and to pool these data
with data from parallel-group trials, as they are similar (Curtin
2002). We requested these data from trial authors if they were not
available in the published report. When we were not able to ob-
tain first-period data from cross-over trials, we established another
group comprising only endpoint data. Our original intention was
to adjust for the effect of the unit of analysis error in cross-over
trials by conducting a covariate analysis, but data were insufficient
for this. As cross-over trials are more prone to bias from carry-over
effects, period effects and unit of analysis errors (Curtin 2002), we
conducted a subgroup analysis to compare these two groups. We
tested for the possibility of a carry-over effect and a period effect
(Subgroup analysis and investigation of heterogeneity). We found
similar treatment effects in the two groups and no significant sub-
group differences. However, we noted considerable heterogeneity,
and so we presented the results of the analyses separately (Effects
of interventions).
For dichotomous outcomes in cross-over trials, we were unable
to adjust the variance to account for the correlation coefficient as
advised by Elbourne 2002 due to insufficient information, or to
estimate the RR using the marginal probabilities as recommended
by Becker 1993. Consequently, we used endpoint data for estimat-
ing RRs. As these effect estimates are prone to potential bias, we
performed a sensitivity analysis by removing these trials to assess
the robustness of the pooled results.
We used endpoint data when these were reported or could be
obtained from trial authors. However, when RCTs reported only
’change scores’, we pooled these with endpoint scores.We explored
whether inclusion of change data affected outcomes by performing
sensitivity analyses (see Sensitivity analysis).
Dealing with missing data
We obtained missing data by contacting trial authors. When we
were not able to obtain missing data, we conducted analyses using
available (incomplete) data. Although some trials reported that
intention-to-treat (ITT) analyses were used, data were missing for
many primary outcomes (Hollis 1999). We could not use ’best-
case scenario’ and ’worst-case scenario’ analyses on our assessment
of benefit as there were no dichotomous outcomes. Also, we de-
cided not to use ’best-case scenario’ and ’worst-case scenario’ anal-
yses in our assessment of adverse events because we evaluated these
analyses to be imprecise due to the high number of trials not re-
porting adverse events, and due to the high number of dropouts
in the trials reporting adverse events.
Assessment of heterogeneity
We identified three types of heterogeneity: clinical, methodologi-
cal and statistical. Clinical heterogeneity reflects variability among
participants, interventions and outcomes of trials.Methodological
heterogeneity reflects variability in the design of trials, and statis-
tical heterogeneity reflects differences in effect estimates between
trials. We assessed clinical heterogeneity by comparing differences
in trial populations, interventions and outcomes, and we evalu-
ated methodological heterogeneity by comparing the design of tri-
als. We identified potential reasons for clinical and methodologi-
cal heterogeneity by examining individual trial characteristics and
subgroups. Furthermore, we observed statistical heterogeneity in
trials both by visual inspection of a forest plot and by use of a
standard Chi² value with a significance level of α (alpha) = 0.1.
We used I² to quantify inconsistency, with I² values between 30%
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and 60% indicating a moderate level of heterogeneity (Higgins
2011).
Assessment of reporting biases
We followed the recommendations for reporting bias, includ-
ing publication bias and outcome reporting bias, provided in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We drew funnel plots (estimated differences in treatment
effects against their standard error) and performed Egger’s statisti-
cal test for small-study effects; asymmetry could be due to publi-
cation bias or could indicate genuine heterogeneity between small
and large trials (Higgins 2011). We did not visually inspect the
funnel plot if fewer than 10 trials were included in the meta-anal-
ysis, in accordance with the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data synthesis
Weperformed statistical analyses as recommendedby theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We synthesised data statistically when clinical heterogeneity was
not excessive (e.g. variability in participant characteristics wasmin-
imal). Furthermore, we included and analysed trials undertaken in
any configuration or setting (e.g. in groups, at home, at a centre).
We used the inverse variance method, which gives greater weight
to larger trials, to generate more precise estimates. For some ad-
verse events we combined dichotomous data and continuous data
using the generic inverse variance method. We synthesised data
using change from baseline scores or endpoint data. If data were
available for several intervals, we used the longest period assessed.
We used both the fixed-effect and the random-effects models in all
meta-analyses. However, we reported the results of the random-ef-
fects model, which gives greater weight to smaller trials; statistical
significance did not change when we applied a fixed-effect model
(Jakobsen 2014). We performed separate meta-analyses for three
types of raters (teachers, independent assessors, parents), for data
from parallel-group trials combined with data from the first period
of cross-over trials and for endpoint data derived from cross-over
trials.
ADHD symptom scales describe the severity of inattention, hy-
peractivity and impulsivity at home and at school; high scores in-
dicate severe ADHD. We judged that, in spite of the diversity of
psychometric instruments, they could be used for our outcomes,
and we integrated different types of scales into the analyses. We
used MDs if the same measure was used in all trials and SMDs
when different outcomemeasures were used for the same construct
in different trials.
When separate measures of hyperactivity, impulsivity and inatten-
tion were available, we used combined scores. When symptoms
were measured and reported at different time points during the
day (after ingestion of medication or placebo), we used the time
point closest to noon.
Two outcomes - ADHD symptoms and general behaviour - were
measured by three types of raters: teachers, independent assessors
and parents. We considered these data as showing different out-
comes. We presented the results of teacher-rated measures as the
primary outcome because symptoms of ADHD are more readily
detectable in the school setting (Hartman 2007).
When trials reported data for different doses, we used data for the
dose that we defined as moderate/high (> 20 mg/d) in our primary
analyses.
We summarised adverse event data as RRs with 95% CIs for di-
chotomous outcomes. For the purposes of this review, we used
only dichotomous outcomes that reflected the number of partici-
pants affected by the event per the total number of participants.
Heterogeneity-adjusted required information size
and Trial Sequential Analysis
Trial Sequential Analysis is a method that combines the required
information size (RIS) for a meta-analysis with the threshold for
statistical significance (Brok 2008; Brok 2009; Thorlund 2009;
Wetterslev 2008) to quantify the statistical reliability of data in a
cumulative meta-analysis, with P value thresholds controlled for
sparse data and repetitive testing of accumulating data (Brok 2008;
Brok 2009; Thorlund 2009; Wetterslev 2008).
Comparable with the a priori sample size estimation provided in a
single RCT, a meta-analysis should include an RIS at least as large
as the sample size of an adequately powered single trial to reduce
the risk of random error. A Trial Sequential Analysis calculates the
RIS in a meta-analysis and provides trial sequential monitoring
boundaries with an adjusted P value.
When new trials emerge, multiple analyses of accumulating data
lead to repeated significant testing and hence introduce multiplic-
ity. Use of conventional P values exacerbates the risk of random er-
ror (Berkey 1996; Lau 1995). Meta-analyses not reaching the RIS
are analysed with trial sequential monitoring boundaries analo-
gous to interimmonitoring boundaries in a single trial (Wetterslev
2008). This approach will be crucial in coming updates of this
review.
If a Trial Sequential Analysis does not result in significant findings
(no Z-curve crossing the trial sequential monitoring boundaries)
before the RIS has been reached, the conclusion should be that
more trials are needed to reject or accept an intervention effect
that was used to calculate the required sample size, or when the
cumulated Z-curve enters the futility area, the anticipated inter-
vention effect should be rejected.
For calculations with the Trial Sequential Analysis programme, we
included trials with zero events by substituting 0.5 for zero (CTU
2011; Thorlund 2011).
For the outcomes ’total serious adverse events’ and ’total non-se-
rious adverse events’, we calculated the a priori diversity-adjusted
required information size (DARIS; i.e. number of participants in
the meta-analysis required to detect or reject a specific interven-
tion effect) and performed a Trial Sequential Analysis for these
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outcomes based on the following assumptions (Brok 2008; Brok
2009; Thorlund 2009; Wetterslev 2008; Wetterslev 2009).
1. Proportion of participants in the control group with adverse
events.
2. Relative risk reduction of 20% (25% on ’total serious
adverse events’).
3. Type I error of 5%.
4. Type II error of 20%.
5. Observed diversity of the meta-analysis.
’Summary of findings’ tables
We used the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) approach to construct a ’Sum-
mary of findings’ table in which to document all review outcomes
(GRADEpro 2014). The GRADE approach appraises the quality
of a body of evidence based on the extent to which one can be
confident that an estimate of effect or association reflects the item
being assessed. Considerations are due to within-trial risk of bias;
directness of the evidence; heterogeneity of the data; precision
of effect estimates; and risk of publication bias (Andrews 2013a;
Andrews 2013b; Balshem 2011; Brunetti 2013; Guyatt 2011a;
Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e;
Guyatt 2011f; Guyatt 2011g; Guyatt 2011h; Guyatt 2013a;
Guyatt 2013b; Guyatt 2013c; Mustafa 2013). When possible,
that is when the MD or the RR was available, we used the results
from the Trial Sequential Analysis as the rating for imprecision
(Jakobsen 2014). We reported two primary outcomes (teacher-
rated ADHD symptoms and serious adverse events) and three sec-
ondary outcomes (non-serious adverse events, teacher-rated gen-
eral behaviour, and quality of life) in Summary of findings for the
main comparison.
Subgroup analysis and investigation of heterogeneity
We performed the following subgroup analyses of teacher-rated
ADHD symptoms (primary outcome) to test the robustness of
this estimate.
1. Age of participants (trials with participants aged 2 to 6 years
versus those with participants aged 7 to 11 years versus those
with participants aged 12 to 18 years).
2. Sex (boys versus girls).
3. Comorbidity (children with comorbid disorders versus
children without comorbid disorders).
4. Type of ADHD (participants with predominantly
inattentive subtype versus participants with predominantly
combined subtype).
After learning about other factors that may affect the impact of
methylphenidate, we performed the following additional post hoc
subgroup analyses on teacher-rated ADHD symptoms to test the
robustness of the estimate.
1. Types of scales (e.g. Conners’ Teacher Rating Scale (CTRS;
Conners 1998a) versus Strengths and Weaknesses of ADHD
Symptoms and Normal Behavior (SWAN) Scale (Swanson
2006).
2. Dose of methylphenidate (low dose (≤ 20 mg/d or ≤ 0.6
mg/kg/d) versus moderate/high dose (> 20 mg/d or > 0.6 mg/kg/
d)).
3. Duration of treatment (short-term trials (≤ six months)
versus long-term trials (> six months)).
4. Trial design (parallel-group trials versus cross-over trials
(first period data and endpoint data)).
5. Medication status before randomisation (medication naive
(> 80% of included participants were medication naive) versus
not medication naive (< 20% of included participants were
medication naive)).
6. Risk of bias (trials with low risk of bias versus trials with
high risk of bias).
7. Cohort selection bias (trials with cohort selection bias of all
participants versus trials without cohort selection bias).
Sensitivity analysis
We conducted sensitivity analyses to determine whether findings
were sensitive to the following.
1. Decisions made during the review process such as our
assessment of clinical heterogeneity (listed below).
2. Combined ’change scores’ and ’endpoint data’ in the meta-
analyses.
No sufficiently well-designed method has been used to combine
the results of trials with high risk of bias and trials with low risk of
bias (Higgins 2011). We performed sensitivity analyses by group-
ing together trials with similar classifications of bias, as described
above, and investigated the impact on intervention effects.
We excluded the following trials from the sensitivity analyses.
1. IQ < 70: Oesterheld 1998; Pearson 2013; Smith 1998;
Taylor 1987.
2. Change scores: Carlson 2007; Findling 2007; Newcorn
2008; Palumbo 2008; Tucker 2009.
3. Older than 18 years of age: Green 2011; Szobot 2008.
R E S U L T S
Description of studies
For more information, please see Characteristics of included
studies, Characteristics of excluded studies, Characteristics of
studies awaiting classification and Characteristics of ongoing
studies.
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Results of the search
We carried out electronic searches over four periods. Searches up
to October 2011 produced 6358 records after duplicates were re-
moved (10,249 initial records). Searches up to November 2012
produced an additional 713 records after duplicates were removed
(1080 initial records). Searches up to March 2014 produced an
additional 654 records after duplicates were removed (1274 ini-
tial records). Searches up to February 2015 (ClinicalTrials.gov and
ICTRP) and March 2015 (all remaining databases) produced an
additional 1178 records after duplicates were removed (1460 ini-
tial records). We identified 368 additional publications by reading
the reference lists of included articles and reviews, and by corre-
sponding with authors of relevant literature and with pharmaceu-
tical companies. We contacted the authors of 161 trials twice for
supplemental information and data; 92 responded.
From the 9271 screened records, we excluded 7811 clearly irrel-
evant reports on the basis of title and abstract. We retrieved the
full texts of the remaining 1460 reports, which we assessed for
eligibility. Of the retrieved publications, 69 were written in lan-
guages other than English, including Danish, Norwegian, Ger-
man, Dutch, French, Italian, Spanish, Portuguese, Czech, Turk-
ish, Farsi, Japanese and Chinese; we had these articles trans-
lated to assess their eligibility. We excluded 691 full-text reports
(please see subsection on Excluded studies and Characteristics
of excluded studies tables), and identified 2 trials (from 2 re-
ports) as awaiting classification (see Characteristics of studies
awaiting classification), and 5 ongoing trials (from 6 reports; see
Characteristics of ongoing studies). We included 761 reports, of
which 449 described 185 RCTs and 312 described 243 non-ran-
domised studies. (We are currently assessing and synthesising data
from the 243 non-randomised studies. These findings will be pub-
lished in the forthcoming review on adverse events in observa-
tional studies (Storebø in press). This review focuses on RCTs only
(see Figure 1; Moher 2009). For more information on these trials,
please see the Characteristics of included studies tables.
16Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Flow chart.
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Included studies
We included 185 trials (from 449 reports) in this review (Figure
1). Of these, 38 are parallel-group trials (from 138 reports) and
147 are cross-over trials (from 311 reports). One study - Kollins
2006 (PATS) - includes a parallel-group trial and a cross-over trial.
Included parallel-group trials
We included 38 parallel-group trials described in 138 reports.
Duration
Most trials (n = 34) were short-term (< six months in duration).
Only three were long-term trials (conducted for ≥ six months;
Jensen 1999 (MTA); Perez-Alvarez 2009; Schachar 1997a). The
duration of one trial was unclear (Tucker 2009). Average trial
duration was 74.8 days (range 1 to 425 days).
Location
Twenty-one of the 38 trials were conducted in the USA. Two trials
were conducted in the USA and Canada (Biederman 2003; Jensen
1999 (MTA)); one in the USA, Canada and Australia (Findling
2006); and one in USA, Canada, Taiwan, Mexico and Puerto Rico
(Lin 2014). Two trials each were conducted in Brazil (Martins
2004; Szobot 2004), Canada (Butter 1983; Schachar 1997a), Is-
rael (Green 2011; Jacobi-Polishook 2009) and Germany (Coghill
2013; Lehmkuhl 2002), although Coghill 2013 also included par-
ticipants in Sweden. Single trials were conducted in New Zealand
(Heriot 2008), Norway (Duric 2012) and the Netherlands (Van
der Meere 1999a). The locations of two trials were not clear
(Firestone 1981; Tourette’s Syndrome Study Group 2002).
Setting
All but the following three trials were conducted in out-patient
clinics: one was carried out in a naturalistic classroom setting (
Greenhill 2006), one in a research unit at a hospital (Schachar
1997a), and one provided no information on setting (Brown
1985).
Participants
The 38 trials included a total of 5111 participants (with the per-
centage of girls ranging from 0% to 50% (mean 20.7%), equiva-
lent to a boy-to-girl ratio of 5:1). All participants were between 3
and 20 years of age (mean 9.7 years).
Twenty-six trials described the percentage of methylphenidate-
naive participants (range 0% to 100%; mean 58.2%).
Twenty-three trials described the proportion of participants with
combined subtype ADHD (range 25% to 100%; mean 72%);
19 trials reported the proportion of participants with hyperactive
subtype (range 0% to 56%; mean 5%) and 20 trials revealed the
proportion with inattentive subtype (range 0% to 72.4%; mean
24%).
Five trials excluded children and adolescents with a comorbidity
(Findling 2010;Greenhill 2002; Perez-Alvarez 2009;Tucker 2009;
Wigal 2004), but it was not clear whether such participants were
included in 11 trials (Arnold 2004; Biederman 2003; Brown 1985;
Butter 1983;Duric 2012; Findling 2006; Findling 2008; Firestone
1981; Greenhill 2006; Jacobi-Polishook 2009; Wilens 2006b).
Oppositional defiant disorder was the most common comorbidity
(range 8% to 53%; mean 36.3%), followed by conduct disorder
(range 2% to 32%; mean 11.6%).
Participants taking other medications were specifically excluded
from 10 trials (Green 2011; Heriot 2008; Ialongo 1994; Jacobi-
Polishook 2009; Kollins 2006 (PATS); Martins 2004; Palumbo
2008; Perez-Alvarez 2009; Schachar 1997a;Wigal 2004), andwere
permitted in two trials (Lehmkuhl 2002; Van der Meere 1999a).
Riggs 2011 allowed inclusion of participants using drugs and al-
cohol.
Interventions
Twelve trials
used extended- andmodified-releasemethylphenidate (Biederman
2003; Childress 2009; Coghill 2013;Green2011;Greenhill 2002;
Greenhill 2006; Lehmkuhl 2002; Lin 2014; Newcorn 2008; Riggs
2011; Tucker 2009; Wilens 2006b). Two trials used immediate-
and extended-release methylphenidate (Findling 2006; Wolraich
2001), and two trials used transdermal methylphenidate patches
(Findling 2008; Findling 2010). All other trials used immediate-
release methylphenidate.
The method of reporting the dosage of methylphenidate varied
considerably between trials, but overall daily dose ranged from 5
mg to 60 mg with a mean reported total daily dose of 28.2 mg/
d or 0.73 mg/kg/d. The average dose of any type of modified- or
extended-release methylphenidate was 41.0 mg, and the average
dose of immediate-release methylphenidate was 23.1 mg.
Twenty-eight trials used placebo as control, and 10 trials used no
intervention as control (Brown 1985; Connor 2000; Duric 2012;
Firestone 1981; Heriot 2008; Jensen 1999 (MTA); Perez-Alvarez
2009; Riggs 2011; Schachar 1997a; Tucker 2009).
Four trials used clonidine (Connor 2000; Palumbo 2008;
Tourette’s Syndrome Study Group 2002) or atomoxetine (Carlson
2007) as a cointervention in both intervention and control groups.
Three trials used parent training (Firestone 1981; Heriot 2008;
Schachar 1997a), two used cognitive-behavioural therapy (Brown
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1985; Riggs 2011) and five used other behavioural therapies
(Duric 2012; Horn 1991; Jensen 1999 (MTA); Perez-Alvarez
2009; Tucker 2009) as cointerventions for intervention and con-
trol groups.
Included cross-over trials
We included 147 cross-over trials described in 311 reports.
Eighty-three trials were described in a single publication. Ten trials
yielded five or more publications (Brams 2012; Döpfner 2004;
Gadow 1995; Grizenko 2012; Kollins 2006 (PATS); Rapport
1987; Sharp 1999; Swanson 2002a; Swanson 2002b; Swanson
2004b). The PATS (Preschool Attention Deficit Hyperactivity
Disorder Treatment Study) trial reported the greatest number of
publications per trial, with 23 publications (Kollins 2006 (PATS).
Duration
Three cross-over trials did not report duration (Kelly 1989;
Sunohara 1999; Tannock 1993). The remaining cross-over trials
had a duration of less than six months.
Location
A total of 103 trials were carried out in the USA; 21 in Canada;
and one in both the USA and Canada (Quinn 2004). Five trials
were conducted in Israel (Lufi 1997; Lufi 2007; Moshe 2012;
Tirosh 1993a; Tirosh 1993b); five in Germany (Bliznakova 2007;
Döpfner 2004; Konrad 2004; Konrad 2005; Schulz 2010); four
in the Netherlands (Buitelaar 1995; Flapper 2008; Lijffijt 2006;
Overtoom 2003); two each in the UK (Coghill 2007; Taylor
1987), Norway (Ramtvedt 2013; Zeiner 1999) and Brazil (Szobot
2008; Zeni 2009); and one in Australia (Nikles 2006). One trial
did not specify the country of origin (Hicks 1985).
Setting
Seventeen trials were completed as a part of summer treat-
ment programmes or summer schools. Five trials were con-
ducted in in-patient wards (Carlson 1995; Gonzalez-Heydrich
2010; Kent 1995; Konrad 2005; Solanto 2009), and five in both
out-patient clinics and in-patient wards (Garfinkel 1983; Hicks
1985; Kaplan 1990; Konrad 2004; Wallander 1987). Twelve tri-
als were conducted in a laboratory classroom setting (Brams
2008; Lopez 2003; Oesterheld 1998; Schachar 2008; Sharp
1999; Silva 2006; Swanson 1998; Swanson 1999; Swanson
2002a; Swanson 2002b; Wigal 2003; Wigal 2014). Eight trials
did not report the setting (Ben 2002; Bliznakova 2007; Froehlich
2011; Pliszka 2007; Stoner 1994; Tervo 2002; Ullmann 1985;
Urman 1995). All remaining trials were conducted in out-patient
clinics only.
Participants
The 147 cross-over trials included a total of 7134 participants
(range 1 to 430 per trial; mean 48.5). In 131 of these trials,
a total of 6597 participants were randomly assigned, 6018 of
whom were followed up in analyses. In 13 trials, 537 participants
were randomly assigned, but it was unclear how many partici-
pants were followed up (Ben 2002; Chronis 2003; Coghill 2007;
Douglas 1995; Fitzpatrick 1992a;Gadow2011;Hale 2011; Leddy
2009; Pelham 1989; Rapport 1987; Shiels 2009; Smithee 1998;
Wallander 1987). In two trials, it was unclear how many partici-
pants were included, but 191were followed up in analyses (Epstein
2011; Sharp 1999). In one trial, it was unclear how many partic-
ipants were included or followed up (Rapport 1987).
Nine trials did not state the ratio of boys to girls (Epstein 2011;
Fine 1993; Leddy 2009; Pliszka 1990; Rapport 1987; Samuels
2006; Solanto 2009; Sumner 2010; Wallace 1994), and 30 trials
did not specifically comprise girls. In the 108 trials that included
participants of both sexes and reported proportions, the percentage
of girls ranged from 4% to 50% (mean 21.8%). Participants were
between 4 and 21 years of age with an average age of 9.7 years
(17 trials did not report average age; however, all of these trials
reported age range).
A total of 98 trials described the percentage of methylphenidate-
naive participants included (range 0% to 100%; mean 51%). In
26 trials, all participants were methylphenidate naive. Only par-
ticipants previously treated with methylphenidate were included
in 30 trials.
Sixty-four trials described the proportionof participantswith com-
bined subtype ADHD (range 0% to 100%; mean 69.1%), 63
reported the proportion with hyperactive subtype (range 0% to
100%; mean 12.3%) and 63 reported the proportion with inat-
tentive subtype (range 0% to 72%; mean 20.2%).
Eighty-eight trials reported the presence of comorbidity. Opposi-
tional defiant disorder was the most commonly reported comor-
bidity (61 trials; range 1.4% to 84%;mean 42%), followed by con-
duct disorder (49 trials; range 0% to 100%; mean 24%). Four tri-
als reported participants with Tourette’s syndrome (range 12% to
100%; mean 75%; Castellanos 1997; Gadow 2007; Gadow 2011;
Kent 1999). One trial included only participants with epilepsy
(Gonzalez-Heydrich 2010), one included only participants with
cerebral palsy (Symons 2007), and one included only participants
with bipolar disorder (Findling 2007). Fourteen trials reported
that participants had no comorbidity (Borcherding 1990; Brams
2012; Garfinkel 1983; Lufi 1997; Moshe 2012; Quinn 2004;
Schachar 2008; Sumner 2010; Swanson 1998; Swanson 2002a;
Tirosh 1993a; Tirosh 1993b; Wilens 2008; Wilkison 1995).
Thirteen trials reported that participants were taking other med-
ications (Buitelaar 1995; Carlson 1995; Castellanos 1997; Cox
2006; Findling 2007; Gadow 2007; Gonzalez-Heydrich 2010;
Kaplan 1990; McBride 1988a; Pearson 2013; Pelham 1989;
Szobot 2008; Zeni 2009), and 42 trials stated that comedication
was not used. It was not clear whether the remaining 92 trials
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permitted comedication.
Interventions
In all, 101 trials reported use of a single type of methylphenidate
(without specifying the type), whereas 12 trials reported use of
a single type of immediate-release methylphenidate (Ahmann
1993; Chronis 2003; Fabiano 2007;Gadow 2007; Johnston 1988;
Kollins 2006 (PATS); Moshe 2012; Smith 2004; Solanto 2009;
Swanson 1999; Swanson 2002a; Tervo 2002), and 19 reported use
of a single type of extended-release methylphenidate. Seven tri-
als used both immediate- and extended-release methylphenidate
(Döpfner 2004; Fitzpatrick 1992a; Pelham 1990a; Pelham 2001a;
Schachar 2008; Swanson 2002b;Wigal 2003), four trials used two
different types of extended-release methylphenidate (Lopez 2003;
Schulz 2010; Silva 2005a; Swanson 2004b), and four used trans-
dermal methylphenidate patches (Pelham 2005; Pelham 2011;
Wilens 2008; Wilens 2010).
The method of reporting the dose of methylphenidate varied
considerably between trials, and three trials did not report dose
(Bliznakova 2007; Nikles 2006; Wallace 1994). Overall daily
dose ranged from 4 mg to 77 mg, with mean reported total
daily dose of 24.5 mg or 0.6 mg/kg. Doses of immediate-release
methylphenidate ranged from 4mg to 54 mg, with mean reported
total daily dose of 25 mg or 0.7 mg/kg. Doses of extended-re-
lease methylphenidate ranged from 15 mg to 77 mg, with mean
reported total daily dose of 36 mg or 1.1 mg/kg. Duration of
methylphenidate treatment ranged from 1 to 56 days, with an av-
erage duration of 15.6 days.
All trials used placebos as control.
Three trials used concomitant cointerventions (antidepressant:
Carlson 1995; behaviour modification: Kolko 1999; and antipsy-
chotic: Zeni 2009) in both intervention and control groups.
Outcomes
Some psychometric ADHD instruments measured total score for
ADHD symptoms, whereas others assessed only specific symp-
tom domains of ADHD (e.g. inattention, hyperactivity, impulsiv-
ity). We categorised all scales into five subgroups: ADHD symp-
toms; serious adverse events; non-serious adverse events; general
behaviour; and quality of life. Some psychometric instruments are
abbreviated versions or revised versions, but all have been vali-
dated.
ADHD symptoms
Conners’ questionnaires were the most frequently used measures
of ADHD symptoms; more than 30 different versions measured
core symptoms of ADHD (normative data are generally well in-
tercorrelated in revised versions; Goyette 1978).
Table 1 presents the list of all measures used to assess ADHD
symptoms in the included trials. This list primarily refers to orig-
inal articles describing the psychometric properties of measure-
ment scales, but in a few cases, we refer to trials describing use of
a specific measurement scale.
Serious and non-serious adverse events
Adverse events were measured by rating scales or by spontaneous
reports and/or were recorded by investigators at regular interviews
or visits. Some trials included physical examinations or paraclin-
ical examinations, or both, such as blood testing, electrocardio-
gram (ECG), blood pressure reading, measurement of heart rate
and assessment of weight and height. Serious adverse events were
recorded in accordance with the ICH classification (ICH 1996).
However, when in doubt, we asked trial authors which classifica-
tion or definition they had used in their trial.
Some trials combined all of the above modes of measurement;
others used a single measure such as spontaneous reports or rating
scales. Fifty-two trials employed rating scales; the Barkley Side
Effects Rating Scale (SERS) was used most frequently (Barkley
1990).
Other scales used included the Significant Adverse Event Reviews
Questionnaire (SAERS; Barkley 1990; Zeni 2009), the Pittsburgh
Side Effect Rating Scale (PSERS; Pelham 1993b; Pelham 2005a)
and Subject’s Treatment Emergent Symptom Scale (STESS; Guy
1976a).
For the purpose of measuring specific adverse events, some tri-
als used rating scales such as Paediatric Sleep Questionnaire
(PSQ; Chervin 2000), Sleep Disturbances Scale for Children
(SDSC; Bruni 1996), Children’s Sleep Habits Questionnaire
(CSHQ; Owens 2000), Child Depression Rating Scale (CDRS-
R; Poznanski 1983), Young Mania Rating Scale (YMRS; Young
1978), Yale Global Tic Severity Scale (YGTSS; Leckman 1989),
Tic Symptom Self Report Scale (TSSR; Leckman 1988), and the
Massachusetts General Hospital (MGH) Abuse and Diversion
Questionnaire (Wilens 2006a).
General behaviour
Manydifferent scales canbe used to assess general behaviour. These
scales have different foci, such as aggression or oppositional be-
haviour, but all describe participants’ behaviour and the influence
of methylphenidate.Higher scores on general behaviour symptom
scales signify better outcomes.
Table 2 presents the list of all measures used to assess general be-
haviour. This list refers primarily to the original articles describing
the psychometric properties of measurement scales used to mea-
sure general behaviour in the included trials. In a few cases, we
refer to trials that describe use of a specific measurement scale.
Quality of life
Seven scalesmeasured quality of life in relation to bothADHDand
life in general. All of these scales produced higher values equating
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to better health. Only three could be used in meta-analyses: Child
Health Questionnaire (CHQ; Landgraf 1998); Children’s Global
Assessment Scale (CGAS; Shaffer 1983); and Child Health and
Illness Profile, Child Edition: Parent Report Form (CHIP-CE:
PRF; Riley 2004).
See Table 3 for additional information on types of rating scales
used to assess quality of life in the included trials.
Excluded studies
We have taken a very inclusive approach by reading 1460 full
text reports, 603 of which were subsequently excluded for the
following reasons: 367 reports of non-randomised studies, 131
reports with no description of an acceptable ADHD diagnosis, 15
reports describing no treatment with methylphenidate, 5 reports
that only included patients older than 18 years of age, 40 reports
of patients with a IQ below 70, 31 reports with polypharmacy,
and 14 reports excluded for various ’other’ reasons (see Figure 1).
We formally excluded 78 trials (88 reports) that examined the im-
pact of methylphenidate on very specific domains that were out-
side the focus of this review such as motor co-ordination, reaction
time, memory tasks, and reading skills. For more information on
these trials, please see Characteristics of excluded studies tables.
Risk of bias in included studies
We assessed the risk of bias of each included trial using the
Cochrane ’Risk of bias’ tool (Higgins 2011). A summary of our
assessment is displayed in Figure 2 and Figure 3. As shown, we
assessed six cross-over trials (3%) as having low risk of bias in
all domains. We assessed the remaining 179 trials (97%) as trials
with high risk of bias. However, even the six cross-over trials had
likely breaks in their blinding due to prevalent adverse events to
methylphenidate (see below). Accordingly, we judged all 185 trials
to be trials with high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Parallel-group trials
None of the 38 included parallel-group trials had low risk of bias
in all bias domains.
Allocation
Random sequence generation
We considered random sequence generation to be at low risk
of bias in 22 trials, at high risk of bias in 3 trials (Connor
2000; Green 2011; Heriot 2008), and at unclear risk of bias in
13 trials (Brown 1985; Butter 1983; Findling 2006; Firestone
1981; Greenhill 2002; Greenhill 2006; Ialongo 1994; Lin 2014
; Newcorn 2008; Perez-Alvarez 2009; Tucker 2009; Wigal 2004;
Wilens 2006).
Allocation concealment
We considered allocation concealment to be at low risk of bias in
18 trials, at high risk of bias in 1 trial (Green 2011; Szobot 2008),
and insufficiently reported in 19 trials.
Blinding
We considered the method of blinding of participants and per-
sonnel to be adequately described in 28 trials but insufficiently
reported in 6 trials (Biederman 2003; Childress 2009; Findling
2010; Greenhill 2006; Lin 2014; Tucker 2009). Four trials were
not blinded (Brown 1985; Duric 2012; Jensen 1999 (MTA);
Perez-Alvarez 2009).
We considered the method of blinding of outcome assessment
to be adequately described in 23 trials but insufficiently re-
ported in 11 trials (Biederman 2003; Butter 1983; Childress
2009; Findling 2006; Findling 2008; Findling 2010; Green
2011; Greenhill 2002; Greenhill 2006; Lin 2014;Martins 2004).
Four trials did not include blinded outcome assessors (Brown
1985; Duric 2012; Jensen 1999 (MTA); Perez-Alvarez 2009).
Incomplete outcome data
Twenty-four trials adequately addressed incomplete data, and
10 trials did not (Findling 2006; Findling 2008; Findling 2010;
Heriot 2008; Ialongo 1994; Lin 2014; Pliszka 2000; Schachar
1997; Tucker 2009; Wilens 2006). In four trials information was
insufficient for assessment of whether the method used to handle
missing data was likely to bias the estimate of effect (Coghill 2013;
Firestone 1981; Palumbo 2008; Wigal 2004).
Selective reporting
Twenty-five trials reported all pre-defined or otherwise expected
outcomes, and two trials did not (Greenhill 2006; Lin 2014).
In 11 trials it was unclear whether trial authors reported all pre-
defined or otherwise expected outcomes (Butter 1983; Firestone
1981; Greenhill 2002; Heriot 2008; Horn 1991; Ialongo 1994;
Perez-Alvarez 2009; Schachar 1997; Szobot 2004; Tucker 2009;
Wolraich 2001).
Vested interests (industry bias)
Twenty-two trials were funded by industry. In seven trials infor-
mation was insufficient for assessment of whether potential vested
interests were likely to bias the estimate of effect (Horn 1991;
Ialongo 1994; Jacobi-Polishook 2009; Martins 2004; Schachar
1997a; Tourette’s Syndrome Study Group 2002; Riggs 2011). No
vested interests were described in the remaining nine trials (Brown
1985; Butter 1983; Connor 2000; Duric 2012; Firestone 1981;
Green 2011; Heriot 2008; Jensen 1999 (MTA); Perez-Alvarez
2009).
Other potential sources of bias
We identified no other sources of bias.
Cross-over trials
Only 6 of the 147 included cross-over trials had low risk of bias
in all bias domains (DuPaul 1996; Flapper 2008; Gorman 2006;
Rapport 2008; Stein 1996; Wilkison 1995), and even these were
considered at risk of deblinding due to prevalent adverse events
(see below).
Allocation (selection bias)
Random sequence generation
We considered random sequence generation to be at low risk
of bias in 58 trials, at high risk of bias in 10 trials (Carlson
1995; Fitzpatrick 1992a; Kaplan 1990; Kelly 1989; Manos 1999;
McBride 1988a; Szobot 2008;Tirosh 1993b;Whalen1990;Wigal
2014), and at unclear risk of bias in 79 trials.
Allocation concealment
We considered allocation concealment to be at low risk of bias in
53 trials, at high risk of bias in 5 trials (Carlson 1995; Fitzpatrick
1992a; Szobot 2008; Ullmann 1985; Wigal 2014), and not suffi-
ciently reported in 89 trials.
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Blinding (performance bias and detection bias)
We judged the method of blinding of participants and personnel
to be adequately described in 109 trials but unclear in 29 trials.
Nine trials were not blinded (Lopez 2003; Manos 1999; Pearson
2013; Pelham 2014; Ramtvedt 2013; Stein 2003; Ullmann 1985;
Whalen 1990; Wigal 2013).
We judged the method of blinding of outcome assessment to be
adequately described in 79 trials but unclear in 62 trials. Six trials
did not include blinded outcome assessors (Cox 2006; Douglas
1986; Manos 1999; Whalen 1990; Wigal 2013; Wodrich 1998).
Incomplete outcome data (attrition bias)
Sixty-four trials adequately addressed incomplete data. In 54 trials
informationwas insufficient for assessment of whether themethod
used to handle missing data was likely to bias the estimate of effect.
Twenty-nine trials had incomplete outcome data.
Selective reporting (reporting bias)
Forty-nine trials reported all pre-defined or otherwise expected
outcomes, and eight trials did not (Castellanos 1997; Chacko
2005; Gonzalez-Heydrich 2010;McGough 2006;McInnes 2007;
Stein 2003; Sunohara 1999; Taylor 1993). In 90 trials it was un-
clear whether trial authors reported all pre-defined or otherwise
expected outcomes.
Vested interests (industry bias)
Fifty trials were funded by industry. In 41 trials we judged in-
formation to be insufficient for assessment of whether potential
vested interests were likely to bias the estimate of effect. The re-
maining 56 trials reported no vested interests.
Other potential sources of bias
We identified no other sources of bias.
Cohort selection bias of all participants
Ten parallel-group trials and 49 cross-over trials excluded
methylphenidate non-responders, placebo responders and/or pa-
tients with methylphenidate adverse events before randomisation.
Such trials have limited external validity.
Effects of interventions
See: Summary of findings for the main comparison
Methylphenidate compared with placebo or no intervention for
ADHD
Below, we present the results of meta-analyses performed for two
primary outcomes (ADHD symptoms and serious adverse events)
and three secondary outcomes (non-serious adverse events, general
behaviour and quality of life). For a summary of key results, please
see Summary of findings for the main comparison.
Comparison: methylphenidate versus placebo or no
intervention
Primary outcomes
ADHD symptoms
We were able to combine data on ADHD symptoms from 25
parallel-group trials and 74 cross-over trials. The evidence was
assessed to be of very low quality (see GRADE assessment below).
Teacher-rated ADHD symptoms
Parallel-group trials and cross-over trials (first period data only)
Meta-analysis suggested that methylphenidate significantly re-
duced teacher-rated ADHD symptoms compared with placebo
(standardised mean difference (SMD) -0.77, 95% confidence in-
terval (CI) -0.90 to -0.64; I² = 37%; 19 trials, 1698 participants;
Analysis 1.1). The SMD of -0.77 for ADHD symptoms corre-
sponds to a mean difference (MD) of -9.6 points (95% CI -13.7
to -6.4) on the ADHD Rating Scale (DuPaul 1991a).
Our subgroup analyses revealed that the intervention effect varied
according to the following.
1. Types of scales used (test for subgroup differences: Chi² =
24.81, df = 10 (P value = 0.006); I² = 59.7%; Analysis 1.2).
2. Medication status before randomisation, with a seemingly
better effect in trials with no medication-naive patients (SMD -
1.06, 95% CI -1.33 to -0.79; I² = 0%; 2 trials, 286 participants)
compared to trials with medication-naive patients (SMD -0.63,
95% CI -0.94 to -0.31; I² = 51%; 4 trials, 431 participants (test
for subgroup differences: Chi² = 4.18, df = 1 (P value = 0.04); I²
= 76.1%; Analysis 1.3).
3. Duration of treatment, with seemingly lesser effect in long-
term trials (SMD -0.47, 95% CI -0.72 to -0.22; 1 trial, 253
participants) compared to short-term trials (SMD -0.81, 95% CI
-0.94 to -0.68; I² = 25%; 18 trials, 1445 participants) (test for
subgroup difference: Chi² = 5.37, df = 1 (P value = 0.02); I² =
81.4%; Analysis 1.4). The SMD effect of -0.47 for ADHD long-
term trials corresponds to an MD of only -5.75 points (95% CI -
4.2 to -9.2) on the ADHD-RS (DuPaul 1991a).
No evidence suggested that dose (Analysis 1.5), trial design
(Analysis 1.6) or risk of cohort selection bias (Analysis 1.7) in-
fluenced the estimated intervention effect. All 19 trials were at
high risk of bias (Analysis 1.1). Inspection of the funnel plot in
Figure 4 suggested potential bias (asymmetry), although we found
no evidence of significant publication bias: Egger’s regression in-
tercept (bias) was -0.2260 (two-tailed, P value = 0.81). Finally,
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one of the trials in this meta-analysis used change from baselines
scores (Palumbo 2008), but removing this trial did not signifi-
cantly change the estimate.
Figure 4. Funnel plot of comparison: 1. Teacher-rated ADHD symptoms, outcome: 1.8 All data at low and
high risk of bias (parallel-group and cross-over trials).
Cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced teacher-rated ADHD symptoms compared with placebo
(SMD -0.93, 95% CI -1.06 to -0.80; I² = 77%; 59 trials, 5145
participants; Analysis 1.8). The estimated intervention effect did
not vary according to risk of bias (Analysis 1.8), but did vary ac-
cording to dose of methylphenidate (Analysis 1.9). Three of these
trials included some participants with an IQ less than 70 (Pearson
2013; Smith 1998; Taylor 1987). Removing these trials did not
significantly change the estimate.
Parallel-group trials and cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced teacher-rated ADHD symptoms compared with placebo
(SMD -0.91, 95% CI -1.01 to -0.80; I² = 72%; 75 trials, 6344
participants; Analysis 1.10). No evidence suggested that the in-
tervention effect varied according to risk of bias (low risk of bias
versus high risk of bias; Analysis 1.11).
Independent assessor-rated ADHD symptoms
Most independent assessors were clinicians.
Parallel-group trials and cross-over trials (first period data only)
Meta-analysis suggested that methylphenidate significantly re-
duced independent assessor-rated ADHD symptoms compared
with placebo (SMD -0.64, 95% CI -0.89 to -0.39; I² = 85%; 10
trials, 1907 participants; Analysis 2.1). The SMD effect of -0.64
for ADHD symptoms corresponds to anMD of -8.0 points (95%
CI -5.8 to -12.5) on the ADHD-RS (DuPaul 1991a). No evidence
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indicated that the intervention effect was influenced by types of
scales (Analysis 2.2), duration of treatment (Analysis 2.3), trial
design (Analysis 2.4) or risk of cohort selection bias (Analysis 2.5).
We were unable to test for subgroup differences according to dose,
as no low-dose methylphenidate trials were identified (Analysis
2.6). All 10 trials were at high risk of bias (Analysis 2.1). Two trials
reported change from baseline scores (Findling 2008; Newcorn
2008). Removing these trials did not significantly change the es-
timate.
Cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced independent assessor-rated ADHD symptoms compared
with placebo (SMD -1.00, 95% CI -1.16 to -0.84; I² = 69%; 19
trials, 2471 participants; Analysis 2.7). All 19 trials were at high
risk of bias (Analysis 2.7). The intervention effect was significantly
influenced by the dose of methylphenidate, with the highest esti-
mate reported in the high-dose group (SMD -1.13, 95% CI -1.31
to -0.95; I² = 66%; 12 trials, 1853 participants; Analysis 2.8).
Parallel-group trials and cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced independent assessor-rated ADHD symptoms compared
with placebo (SMD -0.83, 95% CI -0.98 to -0.67; I² = 82%; 28
trials, 4215 participants; Analysis 2.9).
Parent-rated ADHD symptoms
Parallel-group trials and cross-over trials (first period data only)
Meta-analysis suggested that methylphenidate significantly re-
duced parent-rated ADHD symptoms compared with placebo
(SMD -0.66, 95% CI -0.82 to -0.51; I² = 60%; 21 trials, 2187
participants; Analysis 3.1). The SMD effect of -0.66 for ADHD
symptoms corresponds to an MD of -8.2 points (95% CI -6.0 to
12.9) on the ADHD-RS (DuPaul 1991a).We found evidence that
the intervention effect varied by types of scales (test for subgroup
differences: Chi² = 22.34, df = 10 (P value = 0.01); I² = 55.2%;
Analysis 3.2). However, duration of treatment (Analysis 3.3), dose
of methylphenidate (Analysis 3.4), medication status before ran-
domisation (Analysis 3.5), risk of cohort selection bias (Analysis
3.6) and trial design (Analysis 3.7) did not seem to significantly
influence the intervention effect. All 21 trials were at high risk of
bias (Analysis 3.1). Two trials in themeta-analysis reported change
from baseline scores (Carlson 2007; Tucker 2009), but removing
these trials did not significantly change the estimate.
Cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced parent-rated ADHD symptoms compared with placebo
(SMD -0.78 (95% CI -0.90 to -0.67; I² = 59%; 41 trials, 3734
participants; Analysis 3.8). This effect was not significantly influ-
enced by risk of bias (Analysis 3.8) or dose of methylphenidate
(Analysis 3.9). Two trials included some participants with an IQ
less than 70 (Pearson 2013; Taylor 1987), but removing these tri-
als did not significantly change the estimate.
Parallel-group trials and cross-over trials (endpoint data)
We observed comparable findings when combining data from par-
allel-group trials with endpoint data from cross-over trials (SMD
-0.74, 95% CI -0.83 to -0.65; I² = 58%; 59 trials, 5861 partici-
pants; Analysis 3.10).
Additional subgroup analyses
We tested for differences between raters (teachers, independent
assessors and parents) and found no significant differences (test
for subgroup differences: Chi² = 2.00, df = 2 (P value = 0.37); I²
= 0.0%; Analysis 4.1).
We found no evidence suggesting that age (Analysis 4.2) or comor-
bidity influenced the intervention effect (Analysis 4.3). However,
the intervention effect was significantly influenced byADHDsub-
type, with a greater intervention effect noted for the inattentive
subtype (SMD -1.31, 95% CI -1.61 to -1.01; 1 trial, 204 partic-
ipants) compared with the combined subtype (SMD 0.65, 95%
CI -1.30 to 2.60; I² = 99%; 2 trials, 559 participants) (test for
subgroup differences: Chi² = 3.79, df = 1 (P value = 0.05); I² =
73.6%; Analysis 4.4). This difference rested upon one single trial.
We foundno evidence of a ’carry-over effect’ in the cross-over trials.
We conducted a subgroup analysis to investigate the difference
between first period data and endpoint data from four cross-over
trials (372 participants), and we found no significant subgroup
differences (test for subgroup differences: Chi² = 2.47, df = 1 (P
value = 0.12); I² = 59.6%; Analysis 4.5).
Numbers of serious adverse events
We were able to combine data on serious adverse events from nine
parallel-group trials (Carlson 2007; Childress 2009; Coghill 2013;
Findling 2010; Jacobi-Polishook 2009; Lehmkuhl 2002; Palumbo
2008; Riggs 2011; Wolraich 2001) and eight cross-over trials (
Brams 2008; Brams 2012; Buitelaar 1995; Cox 2006; Grizenko
2012; Schachar 2008; Silva 2008; Wigal 2013).
The evidence was assessed to be of very low quality (see GRADE
assessment below). Therefore, we cannot exclude that harms may
be worse than reported.
Parallel-group trials and cross-over trials (first period data
only)
We found no significant differences between participants in the
methylphenidate group and those in the control group as regards
the numbers of serious adverse events (RR 0.98, 95% CI 0.44 to
2.22; 9 trials, 1532 participants; Analysis 5.1), and we found no
evidence of heterogeneity between trials (I² = 0%).
Serious adverse events reported by participants in the
methylphenidate group were cyst rupture (n = 1), kidney infection
(n = 1) and psychosis (n = 2). Serious adverse events reported by
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participants in the control group included loss of consciousness
(n = 1), drug toxicity (n = 1), asthma (n = 1) and concussion
(n = 1). Severe adverse events reported by both groups included
syncope (methylphenidate n = 3, control n = 1) and aggression
(methylphenidate n = 1, control n = 2) (Analysis 5.1).
Cross-over trials (endpoint data)
We found no differences between those in the methylphenidate
group and individuals in the control group regarding the incidence
of serious adverse events (RR 1.62, 95% CI 0.34 to 7.71; I² = 0%;
8 trials; n = 1721; Analysis 6.1). However, data from only four
trials contributed to this meta-analysis because zero events were
reported in the other four trials.
Trial Sequential Analysis
We conducted a Trial Sequential Analysis on the ’total serious ad-
verse events’ outcome, involving nine parallel-group trials. We had
planned to use a relative risk reduction of 20%, but the distance
between the accrued information and the required information
was too large, and the program failed to calculate and draw an
interpretable figure. We therefore increased the relative risk reduc-
tion to 25%.We included trials with zero serious adverse events by
substituting zero with a constant of 0.5 (Jacobi-Polishook 2009;
Wolraich 2001). We calculated the DARIS on the basis of serious
adverse events in the control group of 2%; a relative risk reduction
or increase in the experimental group of 25%; type I error of 5%;
type II error of 20% (80% power); and diversity (D²) of 0%. The
DARIS was 21,593 participants. The cumulative Z-curve did not
cross the conventional or trial sequential monitoring boundaries
for benefit, harm, or futility (see Figure 5). As only less than 7%
of the DARIS was accrued, risks of random type II error cannot
be excluded. The Trial Sequential Analysis-adjusted intervention
effect was RR 0.91 (CI 0.02 to 33.2).
Figure 5. Trial Sequential Analysis: serious adverse events.
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Secondary outcomes
Non-serious adverse events
We were able to combine data on non-serious adverse events from
26 parallel-group trials and 67 cross-over trials in a meta-analysis.
The evidence was assessed to be of very low quality (see GRADE
assessment below). Therefore, we cannot exclude that harms may
be worse than reported.
Parallel-group trials and cross-over trials (first period data
only)
Overall adverse events
Participants receiving methylphenidate were significantly more
likely to experience non-serious adverse events overall (RR 1.29,
95% CI 1.10 to 1.51; I² = 73%; 21 trials, 3132 participants;
Analysis 7.1). Substantial heterogeneity between trials was ob-
served (Tau² = 0.07; Chi² = 69.75; df = 19 (P value < 0.00001); I² =
73%). However, this heterogeneity did not appear to be related to
dose, as no differences were reported between low-dose and high-
dose methylphenidate trials (test for subgroup differences: Chi² =
1.11; df = 2 (P value = 0.57); I² = 0%; Analysis 7.2).
Non-serious adverse events included those affecting the nervous
system (Analysis 7.3), aswell as the digestive (Analysis 7.4), urinary
(no data), circulatory and respiratory (Analysis 7.5), reproductive
(no data), skeletal and muscular (Analysis 7.6), and immune sys-
tems (Analysis 7.7). Other reported adverse events included physi-
cal differences in height (Analysis 7.8), weight (Analysis 7.9), body
mass index (BMI) (Analysis 7.10), vital signs (Analysis 7.11), and
several less common events (Analysis 7.12).
Compared with those in the control group, participants in the
methylphenidate group were more likely to:
1. report trouble sleeping or sleep problems (RR 1.60, 95% CI
1.15 to 2.23; I² = 0%; 13 trials, 2416 participants; Analysis 7.3);
2. report a decrease in appetite (RR 3.66, 95% CI 2.56 to
5.23; I² = 28%; 16 trials, 2962 participants; Analysis 7.4) and a
decrease in weight (RR 3.89, 95% CI 1.43 to 10.59; I² = 0%; 6
trials, 859 participants; Analysis 7.4);
3. weigh significantly less (SMD -1.12, 95% CI -1.55 to -
0.70; I² = 83%; 5 trials, 805 participants; Analysis 7.9);
4. have a lower body mass index (BMI) (MD -0.60, 95% CI -
0.84 to -0.36; 1 trial, 215 participants; Analysis 7.10); and
5. have a higher pulse (MD 3.41, 95% CI 0.87 to 5.94; I² =
70%; 8 trials, 1240 participants; Analysis 7.11).
Cross-over trials (endpoint data)
Overall adverse events
Significantly more adverse events were reported in the
methylphenidate group (RR 1.33, 95% CI 1.11 to 1.58; I² =
18%; 21 trials, 2072 participants; Analysis 8.1). In addition, dif-
ferences were noted in the numbers of events reported in trials of
low doses of methylphenidate compared with trials of high doses
of methylphenidate (test for subgroup differences: Chi² = 5.68, df
= 2; P value = 0.06, I² = 64.8%; Analysis 8.2).
Categories of non-serious adverse events included those affecting
the nervous system (Analysis 8.3), as well as the digestive (Analysis
8.4), urinary (Analysis 8.5), skeletal and muscular (Analysis 8.6),
and immune systems (Analysis 8.7), and skin (Analysis 8.8).Other
reported adverse events included physical differences in vital signs
(Analysis 8.9), height (Analysis 8.10) and weight (Analysis 8.11).
Compared with the control group, participants in the
methylphenidate group were less likely to report:
1. anger (RR 0.45, 95% CI 0.26 to 0.77; I² = 0%; 3 trials,
264 participants; Analysis 8.3);
2. behavioural complaints (RR 0.55, 95% CI 0.35 to 0.86; 1
trial, 82 participants; Analysis 8.3); and
3. an increase in appetite (RR 0.20, 95% CI 0.08 to 0.50; 1
trial, 136 participants; Analysis 8.4).
However, they were more likely to report:
1. compulsive acts (RR 2.57, 95% CI 1.45 to 4.56; 1 trial, 90
participants; Analysis 8.3);
2. daydreaming (RR 0.66, 95% CI 0.44 to 0.98; I² = 0%; 3
trials, 222 participants; Analysis 8.3);
3. headache (RR 1.21, 95% CI 1.01 to 1.45; I² = 0%; 37
trials, 3752 participants; Analysis 8.3);
4. insomnia or sleep problems (RR 1.57, 95% CI 1.20 to
2.06; I² = 47%; 31 trials, 3270 participants; Analysis 8.3);
5. being overly meticulous (RR 40.77, 95% CI 2.35 to
706.72; 1 trial, 96 participants; Analysis 8.3);
6. obsessive thinking (RR 2.35, 95% CI 1.53 to 3.62; 1 trial,
90 participants; Analysis 8.3);
7. tics or nervous movements (RR 1.33, 95% CI 1.03 to 1.72;
I² = 10%; 19 trials, 1403 participants) (Analysis 8.3);
8. a decrease in appetite (RR 3.04, 95% CI 2.35 to 3.94; I² =
40%; 35 trials, 3862 participants; Analysis 8.4);
9. stomachache (RR 1.61, 95% CI 1.27 to 2.04; I² = 22%; 33
trials, 3777 participants; Analysis 8.4);
10. somatic complaints (MD 0.85, 95% CI 0.79 to 0.91; 1
trial, 82 participants; Analysis 8.6); and
11. higher pulse/heart rate (MD 5.06, 95% CI 2.88 to 7.24; I²
= 57%; 14 trials, 939 participants; Analysis 8.9).
Trial Sequential Analysis
We conducted a Trial Sequential Analysis on the ’total non-seri-
ous adverse events’ outcome involving 21 parallel-group trials. We
included one trial with zero non-serious adverse events by substi-
tuting zero with a constant of 0.5 (Jacobi-Polishook 2009). We
calculated the DARIS on the basis of adverse events in the control
group of 47%; relative risk reduction in the intervention group of
20%; type I error of 5%; type II error of 20% (80% power); and
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diversity (D-square) of 79%. The DARIS was 4133 participants.
The cumulative Z-curve (blue line) crossed the trial sequential
monitoring boundaries for harm (red inward sloping line) after
the 7th trial, and again after the 17th trial (Figure 6). Accordingly,
risk of random error in the finding can be excluded according
to the Lan-DeMetz-O’Brien-Fleming monitoring boundary. Trial
Sequential Analysis-adjusted intervention effect was RR 1.29 (CI
1.06 to 1.56).
Figure 6. Trial Sequential Analysis: non-serious adverse events.
General behaviour
We were able to include in our analyses data on general behaviour
from 7 parallel-group trials and from 19 cross-over trials. The ev-
idence was assessed to be of very low quality (see GRADE assess-
ment below).
Teacher-rated general behaviour
Parallel-group trials and cross-over trials (first period data only)
Meta-analysis suggested that methylphenidate significantly re-
duced teacher-rated general behaviour compared with placebo
(SMD -0.87, 95% CI -1.04 to -0.71; I² = 0%; 5 trials, 668 par-
ticipants; Analysis 9.1). The SMD effect of -0.87 for general be-
haviour corresponds to anMDof 5.0 points on the CGI (Conners
1998a). However, the evidence was assessed to be of very low qual-
ity. All five trials were at high risk of bias (Analysis 9.1). Neither
type of scale (Analysis 9.2) nor dose (Analysis 9.3) seemed to sig-
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nificantly influence the intervention effect. We were not able to
test for subgroup differences according to duration, as all trials
were of short duration, that is, less than six months (Analysis 9.4),
or according to trial design, as all trials in the analysis were parallel-
group trials (Analysis 9.5).
Cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced teacher-rated general behaviour compared with placebo
(SMD -0.69, 95% CI -0.78 to -0.60; I² = 0%; 16 trials, 2014
participants). The intervention effect was not influenced by the
dose of methylphenidate (Analysis 9.6). However, the evidence
was assessed to be of very low quality. All 16 trials were at high
risk of bias (Analysis 9.7).
Parallel-group trials and cross-over trials (endpoint data)
We observed comparable findings when combining data from par-
allel-group trials with endpoint data from cross-over trials (SMD -
0.79, 95%CI -0.88 to -0.70; I² = 0%; 21 trials, 1976 participants;
Analysis 9.8).
Independent assessor-rated general behaviour
We found no parallel-group trials that provided data on indepen-
dent assessor-rated general behaviour. However, for cross-over tri-
als, methylphenidate significantly reduced independent assessor-
rated general behaviour symptoms compared with placebo (SMD
-0.60, 95%CI -0.75 to -0.46; I² = 32%; 8 trials, 1241 participants;
Analysis 10.1). All trials were at high risk of bias (Analysis 10.2).
We were not able to test for subgroup differences based on trial
design, as all trials in the analysis were cross-over trials (Analysis
10.3).
Parent-rated general behaviour
Parallel-group trials and cross-over trials (first period data only)
Meta-analysis suggested that methylphenidate significantly re-
duced parent-rated general behaviour compared with placebo
(SMD -0.53, 95% CI -0.78 to -0.27; I² = 42%; 6 trials, 670 par-
ticipants; Analysis 11.1). All trials were deemed to have high risk
of bias (Analysis 11.2). Furthermore, the intervention effect was
significantly influenced by the type of scale (test for subgroup dif-
ferences: Chi² = 8.52; df = 3 (P value = 0.04); I² = 64.8%; Analysis
11.3). However, no evidence was found to suggest that trial design
influenced the intervention effect (Analysis 11.4). We were not
able to test for subgroup differences according to duration, as all
trials were of short duration, that is, less than six months (Analysis
11.5), or according to dose, as no low-dose methylphenidate trials
were conducted (Analysis 11.6).
Cross-over trials (endpoint data)
Meta-analysis suggested that methylphenidate significantly re-
duced parent-rated general behaviour compared with placebo
(SMD -0.75, 95% CI -0.93 to -0.56; I² = 7%; 6 trials, 550 partic-
ipants; Analysis 11.7). The effect was not significantly influenced
by the dose of methylphenidate (Analysis 11.7). All trials were at
high risk of bias (Analysis 11.8).
Parallel-group trials and cross-over trials (endpoint data)
We observed comparable findings when combining data from par-
allel-group trials with endpoint data from cross-over trials (SMD
-0.68, 95% CI -0.86 to -0.50; I² = 39%; 12 trials, 1054 partici-
pants; Analysis 11.9).
Additional subgroup analyses
We found significant differences between raters, with a higher
intervention effect for teacher-rated trials (SMD -0.87, 95% CI -
1.04 to -0.71, I² = 0%; 5 trials, 668 participants) compared with
parent-rated trials (SMD -0.53, 95% CI -0.78 to -0.27; I² = 42%;
6 trials, 670 participants) (test for subgroup differences: Chi² =
5.10, df = 1 (P value = 0.02), I² = 80.4%; Analysis 12.1).
We found no evidence that comorbidity influences the interven-
tion effect (Analysis 12.2), and we found no evidence of a ’carry-
over effect’ in the cross-over trials (Analysis 12.3).
No data were available for subgroup analyses by age, sex or type
of ADHD.
Quality of life
We could include data on quality of life from only three parallel-
group trials in our analyses. The evidence was assessed to be of
very low quality (see GRADE assessment below).
Meta-analysis suggested that methylphenidate significantly im-
proved quality of life compared with placebo (SMD 0.61, 95%CI
0.42 to 0.80; I² = 0%; 3 trials, 514 participants), and no evidence
indicated that the type of rating scale - all of which were parent- or
clinician-rated - influenced the effect of the intervention (Analysis
13.1). The SMD of 0.61 for quality of life corresponds to an MD
of 8.0 (95%CI 5.49 to 10.46) on the Child Health Questionnaire
(CHQ; Landgraf 1998), which ranges from 0 to 100 points. All
trials were at high risk of bias.
D I S C U S S I O N
Summary of main results
We included 38 parallel-group trials and 147 cross-over trials in
this review. Altogether, these trials randomised more than 12,000
participants, and were reported in 449 publications. The majority
compared methylphenidate with placebo in short-term trials less
than six months duration. The average trial duration in the 38 par-
allel trials was 75 days. Most were conducted in out-patient clinics
in high income countries, particularly the USA. Participants’ ages
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ranged from 3 to 18 years across most studies (in two studies ages
ranged from 3 to 21 years (Green 2011; Szobot 2008). Both boys
and girls were recruited, in a ratio of 5:1 respectively.
All included trials were judged to be at high risk of bias. This raises
important concerns, which are discussed following a summary of
the results.
The two primary outcomes of this review were ADHD symptoms
(with teacher-rated outcomes taking precedence over outcomes
reported by parents or independent raters), and number of seri-
ous adverse events. Secondary outcomes were non-serious adverse
events, general behaviour in school and at home, and quality of
life.
Primary outcomes
ADHD symptoms
A meta-analysis of data from parallel-group trials combined
with data from the first period of cross-over trials suggests that
methylphenidate may improve ADHD symptoms as reported by
teachers (SMD -0.77, 95% CI -0.90 to -0.64; I² = 37%; 19 trials,
1698 participants; Analysis 1.1). This corresponds to a MD of -
9.6 (95%CI -13.75 to -6.38) on the ADHD-RS (DuPaul 1991a),
which ranges from 0 to 72. Clinically, this represents a modest
improvement in ADHD symptoms.
Subgroup analyses revealed no differences in the effects of
methylphenidate based on age, comorbidity or subtypes of
ADHD, though the paucity of trials meant we lacked the power
to investigate these thoroughly. The quality of the evidence was
judged to be ‘very low’ (see Quality of the evidence).
Serious adverse events
Methylphenidate does not appear to be associated with an in-
creased occurrence of serious adverse events. However, data for
this outcome were only available in 9 of the 185 included trials
(4.9%) and the quality of the underpinning evidence was judged
to be ‘very low’ (see Quality of the evidence).
Secondary outcomes
Non-serious adverse events
Amongst those in the experimental groups, 526 per 1000 (range
448 to 615) experienced non-serious adverse events, compared
with 408 per 1000 of those in the control group. This equates
to a 29% increase in the overall risk of any non-serious adverse
events (RR 1.29, 95% CI 1.10 to 1.51; I² = 73%; 21 trials, 3132
participants; very low-quality evidence; Analysis 7.1). The most
common non-serious adverse events were sleep problems and de-
creased appetite. Children in the methylphenidate group were at
60% greater risk for trouble sleeping/sleep problems (RR 1.60,
95% CI 1.15 to 2.23; I² = 0%; 13 trials, 2416 participants; Anal-
ysis 7.3.18 in Analysis 7.3), and 266% greater risk for reduced
appetite (RR 3.66, 95%CI 2.56 to 5.23; I² = 28%; 16 trials, 2962
participants; Analysis 7.4.1 in Analysis 7.4) than children in the
control group.
The overall quality of the evidence for this outcomewas also judged
to be ‘very low’, and as a result, we are uncertain of themagnitude of
the harmful effects. Further, for methodological reasons, we used
only dichotomous outcomes reflecting the number of participants
affected by the event per the total number of participants. As
most participants reportedmore than one adverse event, the actual
increase in risk of non-serious adverse events may well be higher
than the 29% calculated.
General behaviour
Meta-analyses of data from five parallel-group trials indicated that
methylphenidate was associated with a significant improvement
in children’s general behaviour, as reported by teachers (SMD -
0.87, 95% CI -1.04 to -0.71; I² = 0%; 668 participants; Analysis
9.1). This effect corresponds to an MD of 5.0 points on the
CGI (Conners 1998a). We could find no references describing
a MIREDIF on this scale (range 0 to 30 points), and therefore
cannot state anything about the clinical significance of this result.
Comparable findings emerged from meta-analyses of cross-over
trials (endpoint data) as reported by teachers, and frommeta-anal-
yses of eight cross-over trials (endpoint data) as rated by indepen-
dent assessors. This evidence was judged also to be of ‘very low’
quality (see Quality of the evidence).
Quality of life
Changes in children’s quality of life were assessed in just three trials
(n = 514), each of which used a different scale. Measures were
scored by parents or clinicians, rather than children. The result
(SMD 0.61, 95% CI 0.42 to 0.80; I² = 0%; Analysis 13.1) is
equivalent to a MD of 8.0 points (95% CI 5.49 to 10.46) on the
CHQ (Landgraf 1998), a change estimated to represent a clinically
important improvement on this scale, which ranges from0 to 100.
The quality of the evidence was judged to be ‘very low’ (seeQuality
of the evidence).
The very low quality of the evidence, as assessed using theGRADE
approach, undermines the confidence that can be placed in the
magnitude of any effect. In particular, the prevalence of non-seri-
ous adverse events raises questions about the effectiveness of blind-
ing in these trials. If blinding was broken in just 20% or 30% of
patients given methylphenidate, the resulting bias might well ac-
count for the small but statistical significant findings concerning
the possible benefits of methylphenidate.
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Overall completeness and applicability of
evidence
This review highlights two major issues concerning the overall
completeness and applicability of the evidence of the benefits and
harms of methylphenidate for children with ADHD: the dearth of
trials conducted in children and adolescents in low- and middle-
income countries, and the lack of follow-up beyond six months.
Here, we focus on the impact on the applicability of findings of
decisions taken as part of this review (choice of rater for assessing
change in ADHD symptoms and quality of life, choice of dose and
diagnosis), together with issues relating to rating scales, diagnostic
criteria, choice of comparators and adverse events.
ADHD symptoms - choice of teacher report
We chose to use teacher-rated outcomes as the primary measure
for both ADHD symptoms and general behaviour, although a
number of trials used or relied on parent reports. Some researchers
have argued that parent evaluations of ADHD symptoms may
not be as reliable as those of other raters such as teachers of pre-
school children (Murray 2007) or college students (Lavigne 2012).
For example, Caye 2013 suggests inconsistency in ratings between
parents, and in theMTA trial, informationprovided by parentswas
not always thought to be strong (Efstratopoulou 2013). We tested
the robustness of our decision by conducting subgroup analyses
and found no significant differences between this score and those
of other raters.
Importantly, we do not really know what a lower score on an
ADHD symptom scale (like that reported in this review) means
for a child’s quality of life and ability to live, learn and function
with other people.
Short-term versus long-term effects
Based on a subgroup analysis comparing 18 short-term trials (≤ six
months) with a single long-term trial (> sixmonths), we found that
the treatment effect for teacher-rated ADHD symptoms decreased
over time (test for subgroup differences: P value = 0.02). This was
not the case for independent assessor- and parent-rated ADHD
symptoms, for which no significant differences between short-
term and long-term duration were found (P value = 0.09 and
0.53, respectively), but here the power of the subgroup analysis
was limited.
We identified no trial that examined the effects of more extended
exposure on children’s general behaviour. Overall, evidence on
the long-term effects of methylphenidate for children and young
people with ADHD is lacking, and it is possible that when used
for longer periods, any beneficial effects may be diminished or
offset by an increase in the risk of harm (Light 2015). Decisions
to initiate and persist with treatment will need to weigh potential
improvement in ADHD symptoms against adverse events, such
as lack of sleep, since this may impact effects on quality of life and
learning abilities. This review indicates that these important issues
have not been studied sufficiently.
Quality of life
ADHD can exert a significant, negative impact on children’s qual-
ity of life, broadly defined. Yet only 7 of the 185 included trials
measured quality of life in relation both to ADHD and life in
general, and it was only possible to synthesize data from three of
these trials. In each case the assessments were made by parents,
teachers or independent assessors, rather than by children them-
selves. These external assessors observed small beneficial effects
of methylphenidate on quality of life. Children might well have
had different views on their own quality of life, and the failure
to include child-reported ratings of quality of life is a significant
limitation on the completeness of the evidence. Furthermore, ob-
servations of quality of life reported by parents, teachers and inde-
pendent assessors may be subject to both systematic and random
errors.
Dose - choice of moderate/high dose
For children weighing 25 kg or less, the maximum recommended
dose is 30 mg/d compared to 60 mg/d for children weighing more
than 25 kg. After careful consideration, we renamed the high-dose
group as ’moderate/high’ dose because doses are not always ’high’
in heavier children.
Guidelines from the National Institute for Health and Care Excel-
lence (NICE) recommend that methylphenidate can be increased
to 0.7 mg/kg per dose up to three times a day, or a total daily
dose of 2.1mg/kg/d. European guidelines recommend that dosage
should begin at a low level of 0.2 mg/kg per dose up to three times
a day and should increase according to response, to a ceiling of 0.7
mg/kg per dose (up to three times a day), or a total daily dose of
60 mg/d.
In the parallel-group trials included in this review, the mean dose
of extended-releasemethylphenidatewas 41.0mg/d, and themean
dose of immediate-release methylphenidate was 23.1 mg/d. In the
cross-over trials included in this review, the mean reported total
daily dose of immediate-releasemethylphenidate was 25mg/d and
extended-release methylphenidate 36 mg/d.
With average doses ranging between 23.1 mg/d and 41.0 mg/
d, our cutoff of 20 mg/d seems low. However, many of the in-
cluded trials were short-term trials, involving medication-naive
children who consequently received lower doses. Furthermore,
many of the cross-over trials used only morning and midday doses
to achieve a cross-over for trial purposes, with no afternoon dose
given. However, extended-release methylphenidate is designed to
reduce symptoms in the late afternoon too, so the average expected
daily dose would be higher.
We performed subgroup analyses to test differences in the estimate
of effect based on differences in dosage. These analyses revealed
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no differences between low doses (≤ 20 mg/d) and moderate/high
doses (> 20 mg/d) of methylphenidate. Given the many adverse
events that can result when this medication is used, evidence sug-
gests that higher doses may not be needed.
Rating scales
This review included trials from several countries conducted be-
tween 1981 and 2014. Pioneers in ADHD research conduct trials
in different countries, and psychometric instruments change with
trends over time; this is reflected in the variety of rating scales
used by investigators in the included trials. Scales based on the
diagnostic criteria of the DSM and the ICD measure slightly dif-
ferent constructs. We found significant differences between scales
measuring ADHD symptoms, but not between scales measuring
general behaviour; we found fewer differences when we performed
sensitivity analyses in which we pooled subgroups of scales mea-
suring the same ADHD subtype (e.g. scales measuring the inat-
tentive subtype). All trials using subjective rating scales as proxy
measures of outcomes are affected by these problems.
Diagnostic criteria
The diagnostic criterion as regards the age by which ADHD symp-
toms should first be observed has been much debated (APA 2013;
Todd 2008). As regards DSM-IV age of onset (APA 1994), tri-
als have found no differences in phenotype of neuropsychological
impairment, course or treatment response, whether children were
diagnosed before or after seven years of age (Kieling 2010). By
limiting age of onset to six years or younger, the ICD-10 criteria
for hyperkinetic disorder may under-identify children with persis-
tent ADHD symptoms and related impairment (Lahey 2006). In
addition, extending age of onset is not implicated in prevalence
changes (Polanczyk 2010). It is important to highlight that age of
onset is considered only for diagnostic scales, not for rating scales.
The criteria of both the DSM-IV (APA 1994) and the current
DSM-5 (APA 2013) encompass a broader spectrum of children
with ADHD when compared with the criteria for hyperkinetic
disorder in the ICD-10 (WHO 1992); whilst the criteria are vir-
tually identical (Lee 2008; Tripp 1999), the ICD-10 criteria are
more restrictively applied. Nonetheless, all have an equal ability
to predict ADHD/hyperkinetic disorder, even in the presence of
comorbidity (Schachar 2007). Consequently, we believe that our
efficacy results would not be changed by any change in diagnostic
criteria.
Comparators
The majority of trials in this review compared methylphenidate
with placebo, and we earlier highlighted the problems of threats to
blinding in these trials, due to the prevalence of non-serious adverse
events of methylphenidate. Trials that assess methylphenidate us-
ing an ‘active placebo’ (or ’nocebo tablets’ - tablets with a placebo-
like substance that causes similar adverse events as in the experi-
mental drug arm), can strengthen double blinding and are recom-
mended (Jakobsen 2013; Jakobsen 2014; Moncrieff 2004). We
identified no such trials, and as the use of nocebo tablets in all
diseases is ethically questionable, any decision to conduct nocebo
tablet controlled trials in children should be deferred pending the
results of such trials in adults. If these show that methylphenidate
is superior to nocebo in treating ADHD symptoms, a rationale
would exist for conducting such trials in children. (If another ra-
tionale could be mounted, nocebo controlled trials in children
would not be ethically questionable, but currently no such case is
evident to us).
Adverse events
Methylphenidate non-responders, placebo responders and/or par-
ticipants with methylphenidate adverse events before randomisa-
tion were excluded in 10 parallel-group trials and in 49 cross-over
trials. The intervention effect of methylphenidate in these trials
was compared with that in the remaining trials in subgroup analy-
ses (Analysis 1.7; Analysis 2.5; Analysis 3.6), which found no dif-
ferences in terms of the intervention effect of methylphenidate - a
surprising finding. However, some of our included trials involved
participants who were not medication naive before randomisa-
tion, whichmay have exaggerated the benefits ofmethylphenidate.
They might have detected the physiological effects (for example,
improved concentration or adverse events such as appetite suppres-
sion) through prior exposure to the effects of methylphenidate.
To investigate this, we performed post hoc subgroup analyses and
found that effects of methylphenidate were different in trials in-
volving medication-naive participants (> 80% of included par-
ticipants were medication naive) than in trials involving partic-
ipants already taking methylphenidate before randomisation (<
20% of included participants were medication naive) for teacher-
rated ADHD symptoms (P value = 0.04), but not for parent-rated
ADHD symptoms (P value = 0.52). One might expect the issue of
prior exposure to be of greatest concern in cross-over trials. How-
ever, we found no differences between parallel-group trials and
cross-over trials in both ADHD teacher-rated and parent-rated
outcomes. Consequently, we believe that prior exposure is not a
major concern when effects of methylphenidate are assessed.
We are currently preparing a second systematic review for the pur-
pose of assessing harms of methylphenidate in observational trials
with a duration of up to 36 months (Storebø in press). Preliminary
results from this review show a small proportion of serious adverse
events reported after treatment with methylphenidate, but one
case control trial highlights the risk of sudden death for adolescents
(Gould 2009). Just over a quarter of children appear to experience
non-serious adverse events after methylphenidate treatment.
Many claims have been made about significant increases in global
rates of methylphenidate prescribing; this drug usually is pre-
scribed for long-term use and seldom with medication-free peri-
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ods. However, a recent paper reports that children in primary care
in the UK did not continue methylphenidate treatment for longer
than six months (Raman 2015). Furthermore, the incidence of
ADHD diagnoses in the UK fell between 1998 and 2010 (Holden
2013). In theUSA, however, almost 70%of childrenwith ADHD,
estimated at 6.4 million children, take medication (Visser 2014).
Thismightmean that clinicians in theUK aremore cautious about
using methylphenidate, while US clinicians assume that evidence
for the safe use of methylphenidate is sound.
Our assessment of the evidence does not preclude that individ-
ual patients may benefit from intervention with methylphenidate.
However, despite more than 50 years of research in this field, we
do not yet know how to identify those patients that may obtain
more benefits than harms. Individual patient data meta-analyses
are needed to try to identify such patient characteristics.
Quality of the evidence
As assessed by the GRADE approach, the overall quality of evi-
dence in this review is ’very low’ because of high risk of bias (in-
cluding loss of blinding (explained below) and outcome report-
ing bias), inconsistency, and indirectness; this led to uncertainty
in the robustness of our estimates. We rated the risk of outcome
reporting bias for adverse events to be high, as we only managed
to obtain data on total serious adverse events from 9 of the 185
included trials, and on total non-serious adverse events from 21
of the 185 included trials. We found no evidence for publication
bias.
It is likely that the trials initially judged to be at low risk of biasmay,
in fact, be trials at high risk of bias because methylphenidate gives
rise to various prevalent and easily recognisable adverse events,
which can lead to loss of blinding and hence can bias the ratings of
symptoms, resulting in an overestimation of benefits and an un-
derestimation of harms (Kjaergard 2001; Savovi 2012b; Wood
2008). To ensure adequate blinding, it is therefore important for
researchers to use a nocebo (’active placebo’) in the control group.
As we found no trials employing nocebo tablets in the control
group, the extent of this bias cannot be assessed. The fact that the
intervention effect of methylphenidate on ADHD symptoms did
not differ significantly between trials at low risk of bias compared
with trials at high risk of bias may be taken as an indication that
deblinding has occurred among former trials.
Also, the average duration of treatment was no longer than about
two months. Therefore, little can be concluded about the benefits
and harms of methylphenidate used for longer than six months.
Potential biases in the review process
The present systematic review has many strengths. We developed
a protocol for this review according to instructions provided in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). Our protocol was published before we embarked on the re-
view itself. We conducted extensive searches of relevant databases,
and we requested published and unpublished data from phar-
maceutical companiesmanufacturingmethylphenidate, including
Shire, Medice (represented in Denmark by HB Pharma), Janssen-
Cilag and Novartis. Two review authors, working independently,
selected trials for inclusion and extracted data.Disagreements were
resolved by discussion with team members. We assessed risk of
bias in all trials according to the recommendations provided in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We conducted Trial Sequential Analyses to control the risk
of type I errors and to estimate how far we were from obtaining the
DARIS to detect or reject a certain plausible intervention effect.
In the meta-analyses on non-serious adverse events, the Trial Se-
quential Analysis showed that observed intervention effects were
not likely to be due to type I error and confirmed that sufficient
data had been obtained.
We excluded 78 trials described in 88 reports, which assessed the
effects of methylphenidate on specialised outcomes (e.g. experi-
mental/neurocognitive/functional outcomes) in children or ado-
lescents with ADHD (see Characteristics of excluded studies).
This raises the issue of bias in our review process as we did not
write to these authors asking whether they collected data on other
outcomes. This potential bias, however, is not likely to change
our conclusions. Another limitation of this review is that we did
not search the Food and Drug Administration (FDA) and Euro-
pean Medicines Agency (EMA) homepages for unpublished data
(Schroll 2015). However, it is also unlikely that these searches
would have changed our results.
Agreements and disagreements with other
studies or reviews
Over the past 15 years, several reviews investigating the efficacy of
methylphenidate for ADHD(with or withoutmeta-analyses) have
been published. Some 15 reviews have pooled results derived from
ADHD rating scales on the efficacy of methylphenidate treatment
for children and adolescents with ADHD (Bloch 2009; Charach
2011; Charach 2013; Faraone 2002; Faraone 2006; Faraone 2009;
Faraone 2010; Hanwella 2011; Kambeitz 2014; King 2006; Maia
2014; Punja 2013; Reichow 2013; Schachter 2001; Van der Oord
2008). Each of these reviews, however, has several shortcomings
and these are described in detail in the subsection Why it is
important to do this review. The most important concerns are
that none of these reviews are based on a pre-published protocol,
and most assessed neither the risk of bias of included trials nor
adverse events. Moreover, none of these reviews considered the
risk of random errors. Therefore, their interpretation of findings is
unlikely to have taken into account the poor reporting of adverse
events, the impact of combining data from small trial samples,
or the impact of risk of bias on their analyses; information about
adverse events is also missing from several RCTs.
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A recent Cochrane systematic review evaluated the effects of
methylphenidate in adults with ADHD (Epstein 2014). The ef-
fect sizes across the different assessments of symptoms were similar
to those found in our analyses (SMD 0.60). The authors noted
that data on adverse events were limited by the short duration of
the included trials (Epstein 2014). Despite the similar effects of
methylphenidate on symptoms observed in our reviews, readers
will notice that we have judged the quality of evidence in our re-
view, as well as that in Epstein 2014 (Storebø 2015b [pers comm]),
to be lower than Epstein and colleagues.
In order to address uncertainties over the frequency and sever-
ity of long-term adverse events of methylphenidate, we are cur-
rently preparing a second systematic review of observational stud-
ies (Storebø in press), which will investigate the long-term harms
of methylphenidate as reported by non-randomised studies with
a duration of up to 36 months. We hope this will help us to un-
derstand the long-term safety profile of the drug.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Methylphenidate may improve ADHD symptoms, general be-
haviour and quality of life in children and adolescents aged 18
years and younger with ADHD. We rated the evidence to be of
very low quality and, as a result, we cannot be certain about the
magnitude of the effects from the meta-analyses. The evidence is
limited by serious risk of bias in the included trials, under-report-
ing of relevant outcome data, and a high level of statistical varia-
tion between the results of the trials. There is also very low quality
evidence that methylphenidate causes numerous adverse events.
The risk of serious adverse events seems low, but data were avail-
able from only 9 of the 185 included trials. It is also problematic
that only 93 of the 185 included trials reported on specific and
overall non-serious adverse events. Accordingly, we cannot rule
out the possibility that non-serious harms are more prevalent than
reported in our review.
If methylphenidate treatment is considered, clinicians might need
to use it for short periods, with careful monitoring of both benefits
and harms, and cease its use if no evidence of clear improvement
of symptoms is noted, or if harmful effects appear.
Implications for research
To assess whether any benefits are provided by methylphenidate,
large, randomised, nocebo tablet (’active placebo’) controlled trials
are needed to compare the drug with a nocebo tablet, if deblinding
can be excluded. A problem with many pharmacological trials is
that participants in the experimental drug group experience ad-
verse events that compromise the blinding, as fewer adverse events
occur in participants in the placebo group.However, given the eth-
ical dilemmas regarding the use of nocebo tablets in children, such
trials should be conducted first in adults with ADHD, unless one
can provide a rationale to justify nocebo controlled trials in chil-
dren (Moncrieff 2004; Po gain 2014). Nocebo controlled trials in
adults demonstrating that methylphenidate is superior to nocebo
in treating ADHD symptoms would provide a rationale for con-
ducting such trials in children. In addition, such trials ought to be
designed according to the SPIRIT (Standard Protocol Items: Rec-
ommendations for Intervention Trials) guidelines (Chan 2013),
and reported in keepingwith theCONSORT (Consolidated Stan-
dards of Reporting Trials) standards Moher 2010).
The prevalent use of cross-over trials needs to be reconsidered
because they usually provide only short-term interventions, and
this can limit the assessment of benefits and harms. However,
we were not able to identify major differences when comparing
parallel-group trials with cross-over trials.
Future trials ought to publish depersonalised individual partici-
pant data and should report all outcomes, including adverse events,
to ensure that future systematic reviews and meta-analyses can ac-
cess and use individual participant data. Only through meta-anal-
yses will we be able to assess differences between intervention ef-
fects according to age, sex, comorbidity, type of ADHD and dose.
Reviews show thatmany different rating scales are used for children
with ADHD. Consistent use of good validated scales is needed,
as is a country-wide adverse events reporting system, such as the
FDA, to increase awareness of adverse events.
This review highlights the need for long-term, high-quality trials
with low risk of bias and with sufficient numbers of participants,
investigating the benefits and harms ofmethylphenidate treatment
versus placebo for children and adolescents with ADHD. Pre-
published protocols could help reduce inconsistent measurement
of benefits and harms caused by the use of many different rating
scales and by lack of assessment of adverse events. In addition, the
findings in this review clearly show the urgent need for large RCTs
to investigate the efficacy of non-pharmacological treatments.
As with RCTs, systematic reviews of RCTs assess average effects in
groups of individuals. Such average effects may comprise strong
benefits for a single participant or a few participants and no ef-
fect or negative effects for others. Despite more than 50 years of
research in this field, we have no knowledge on how to identify
patients that may obtain more benefits than harms. Individual pa-
tient data meta-analyses are needed in order to identify such pa-
tient characteristics. Therefore, it would be extremely helpful for
review authors to gain full access to anonymised individual par-
ticipant data for inclusion in meta-analyses examining these data
(Gluud 2015b). Particular patient subgroups may benefit from an
intervention if those with reduced rates of adverse events can be
identified.
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Abikoff 2009
Methods Eight-week double-blind, randomised, placebo-controlled, cross-over trial with 2 inter-
ventions
1. OROS methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participant included: 19 (15 boys, 4 girls). Participants randomly assigned
to 1 of 2 possible drug condition orders
Number of participants followed up: 19
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV (combined (42%), hyperactive-impulsive (0%), inatten-
tive (58%))
Age: mean 10.05 years (SD 1.62, range 8 to 13)
IQ: mean 107.1 (SD 14.3)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: ODD (26.3%), anxiety disorder (10.5%), dysthymic disorder (5.3%),
conduct disorder (5.3%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV criteria for ADHD (combined or inattentive type)
2. Meeting dimensional criteria for ADHD symptom severity on Conners’ Teacher
Rating Scale - Revised, long form, defined as a score ≥ 1.5 SD above age and sex norms
3. Impaired Organisational, Time Management and Planning treatment (OTMP),
defined by a mean total score ≥ 1 SD below the norm on the Children’s Organizational
Skills Scale - Parent, and the Children’s Organizational Skills Scale - Teacher
4. Score ≥ 80 on the Wechsler Abbreviated Scale of Intelligence
Exclusion criteria
1. Diagnosis of autism, major depression, substance abuse, obsessive-compulsive
disorder, post-traumatic stress disorder, panic disorder, tic disorders, significant
suicidality
2. Lifetime history of psychosis or mania
3. Learning disability according to a school individualised educational plan
4. Taking other CNS medications
Interventions Participants were randomly assigned to 1 of 2 possible orders of OROSmethylphenidate
and placebo
Mean methylphenidate dosage: 48.3 mg (range 18 ± 54 mg); weight-based final OROS
methylphenidate dose was 1.3 mg/kg
Administration schedule: not stated
Duration of each medication condition: 4 weeks: 2 weeks titration and 2 weeks optimal
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dose
Washout before study initiation: 2 days between interventions
Titration period: 2 weeks after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Nolan and Pelham Scale, Fourth Edition, parent-rated at baseline, after
weeks 1 and 2 (during titration) and at end of treatment (4 weeks)
2. Swanson, Nolan and Pelham Scale, Fourth Edition, teacher-rated at baseline, after
weeks 1 and 2 (during titration) and at end of treatment (4 weeks)
Notes Sample calculation: no
Ethics approval: Study protocol was reviewed and approved by the University’s institu-
tional review board
Comment from study authors
1. The 4 weeks of OROS methylphenidate treatment was relatively brief, and post-
treatment measures were obtained after children had been taking their optimal titration
dose for 2 weeks
Key conclusion of study authors
1. OROS methylphenidate reduced children’s OTMP deficits, and these
improvements were associated with improvement in ADHD symptoms. Some children
remained impaired in OTMP even after effective stimulant treatment for ADHD
symptoms. These youngsters may require other treatments that target OTMP deficits
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Email correspondence with study authors: December 2013. No supplemental informa-
tion provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-treatment scores for all 19 study chil-
dren were obtained from parents. Because
1 child’s treatment was delayed and ran be-
76Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abikoff 2009 (Continued)
yond the end of the school year, teacher
data on 18 youngsters were analysed
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No protocol published. All pre-specified
outcomes of interest have been reported
Vested interest bias High risk Investigator-initiated trial funded by a
grant from Ortho-McNeil Janssen Scien-
tific Affairs to Dr. Abikoff
Conflicts of interest: Drs. Abikoff and Gal-
lagher have a contract with Multi-Health
Systems to further develop the Children’s
Organizational Skills Scale (COSS) used in
this study. Dr. Abikoff has served on the
ADHD Advisory Board of Shire Pharma-
ceuticals and of Novartis Pharmaceuticals.
Dr. Boorady has served on the ADHD Ad-
visory Board and Speakers’ Bureau of Shire
Pharmaceuticals. Other study authors re-
port no conflicts of interest
Ahmann 1993
Methods Three-week double-blind, placebo-controlled, cross-over trial, inwhich participantswere
randomly assigned to
1. Methylphenidate (low and high doses; Ritalin)
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 234. Participants were randomly assigned to low-dose
methylphenidate (0.3 mg/kg), high-dose methylphenidate (0.5 mg/kg) or placebo
Number of participants followed up: 206
Number of withdrawals: not stated, but it is described in the text that 4 children expe-
rienced severe side effects while taking Ritalin and could not complete the protocol
Regarding the 206 participants
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: 5 to 15 years
IQ: > 70
Sex: 161 boys, 45 girls
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
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Sociodemographics: not stated
Inclusion criteria
1. Informed consent from parent
2. DSM-III-R diagnosis of ADHD
In addition, ≥ 3 of the following criteria had to be met
1. Attention score on the ADD-H Comprehensive Teacher Rating Scale: at or below
25th percentile
2. Hyperactivity score on the ADD-H Comprehensive Teacher Rating Scale: at or
below 25th percentile
3. Inattention/Passivity score on Conners’ Teacher Rating Scale (28 items): ≥ 2 SD
above the mean
4. Hyperactivity Index on Conners’ Teacher Rating Scale (28 items): ≥ 2 SD above
the mean
5. Hyperactivity Index on Conners’ Parent Rating Scale (48 items): ≥ 2 SD above
the mean
Childrenwere divided into responders andnon-responders based on the following criteria
1. Parent reported 1 SD improvement on the Hyperactivity Index of the Conners’
Parent Rating Scale (48 items) or gave a positive narrative comment, and
2. Teacher reported ≥ 2 of the following
i) 10 percentile improvement in Attention Score on the ADD-H
Comprehensive Teacher Rating Scale
ii) 10 percentile improvement in Hyperactivity Score on the ADD-H
Comprehensive Teacher Rating Scale
iii) 1 SD improvement on the Inattention/Passivity Scale of Conners’ Teacher
Rating Scale (28 items)
iv) 1 SD improvement on the Hyperactivity Index of Conners’ Parent Rating
Scale (48 items)
v) Positive narrative comment
Exclusion criterion
1. Children with a history of seizures, mental retardation, Tourette’s syndrome or
other significant neurological history were not eligible for the study
Interventions Participants were randomly assigned to different orders of low-dose Ritalin (0.3 mg/kg)
, high-dose Ritalin (0.5 mg/kg) or placebo
Administration schedule: 3 times a day
Duration of each medication condition: 7 consecutive days
Washout before study initiation: not stated
Titration period: not stated
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADD-H Comprehensive Teacher Rating Scale (24 items): rated each week
2. Conners’ Teacher Rating Scale (28 items): rated each week
3. Conners’ Parent Rating Scale (48 items): rated each week
Non-serious adverse events
1. Barkley Side Effects Questionnaire: parent-rated, weekly
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Notes Sample calculation:no
Ethics approval: yes; protocol was approved by the Institutional Review Board at the
Marshfield Medical Center
Key conclusion of study authors
1. The Barkley Side Effects Questionnaire proved to be clinically effective in
tracking Ritalin side effects and should be incorporated into the routine evaluation and
monitoring of ADHD patients for whom stimulants are prescribed
Comment from review authors
1. Study divided participants into 2 groups: responders and non-responders. 147
children were determined to be Ritalin responders. Both responders and non-
responders (n = 206) were included in the analysis of side effects
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Email correspondence with study authors: not able to find study authors’ contact infor-
mation; therefore not able to obtain supplemental information regarding study design
and data on ADD-H Comprehensive Teacher Rating Scale, Conners’ Teacher Rating
Scale, Conners’ Parent Rating Scale
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, but not described how
and/or by whom
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial, identical appearingpills
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind trial, identical appearingpills
Incomplete outcome data (attrition bias)
All outcomes
Low risk 206 had sufficient data for analyses
Selection bias: Participants were divided
into responders and non-responders. How-
ever, data from this article pertain to side
effects only and include both groups
Selective reporting (reporting bias) Unclear risk Not able to obtain protocol or other infor-
mation
Vested interest bias Low risk Study was funded by Marshfield Clinic
grants
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Methods Two identical, concurrently conducted, phase 4, double-blind, randomised, cross-over,
analogue classroom trials with 2 interventions
1. OROS methylphenidate
2. Placebo
Phases
1. Screening/washout phase: up to 28 days
2. Titration: up to 6 weeks
3. Double-blind assessment period, with the following subperiods
i) Open-label OROS methylphenidate
ii) School day 1: OROS methylphenidate or placebo
iii) Open-label OROS methylphenidate: ≥ 7 days
iv) School day 2: OROS methylphenidate or placebo
Participants Number of participants screened: not stated
Number of participants included: 78 (55 boys, 23 girls)
Number of participants followed up: 71
Number of withdrawals before randomisation: 7
Number of withdrawals after randomisation: 0
Diagnosis of ADHD:DSM-IV-TR (combined (81%), hyperactive-impulsive (0%), inat-
tentive (19%))
Age: mean 10.1 years (range 9 to 12 years)
IQ: > 80
Methylphenidate naive: not stated
Ethnicity: Caucasian (58%), African American (28%), other (14%)
Country: USA
Setting: out-patient clinic
Comorbidity: anxiety (0%), depressive disorders (0%), learning disability (32%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. 9 to 12 years of age
2. DSM-IV-TR diagnosis of ADHD
3. Baseline score on ADHD Rating Scale, Fourth Edition, in the 90th percentile or
greater relative to the general population of children of the same age and sex
4. Participants receiving medication for ADHD at the time of study enrolment
exhibited an inadequate response to their then-current stimulant dose and completed a
washout equivalent to 5 half-lives of the given medication before completing baseline
assessments
5. Attendance at regular school
6. Ability to read and understand English
7. To be eligible for the double-blind, randomised assessment period, participants
had to reach their individualised dose of OROS methylphenidate, defined as
i) Score on the ADHD Rating Scale, Fourth Editiion (as scored by parent or
guardian): ≤ 75th percentile for age and sex
ii) Score on the ADHD Rating Scale, Fourth Editiion (as scored by parent or
guardian): between 75th and 85th percentiles for age and sex after (1) dose decrease for
tolerability (1 dose decrease by 18 mg to a minimum of 18 mg/d was allowed) or (2)
having reached dosage of 54 mg/d
Exclusion criteria
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1. History or current diagnosis of epilepsy, severe anxiety or conduct or psychotic
disorders
2. Pervasive developmental, eating, obsessive-compulsive, sleep, major depressive,
bipolar or chronic tic disorder, substance use disorder
3. Personal or family history of Tourette’s syndrome
4. Known cardiac abnormalities: clinically significant abnormalities in ECG results;
family history of sudden death or ventricular arrhythmia
5. Inability to take or tolerate OROS methylphenidate
6. Allergies to MPH or other ingredients of OROS methylphenidate
7. Known gastrointestinal narrowing or significant gastrointestinal problems
8. Glaucoma
9. Use of medication with CNS effects (excluding bronchodilators)
10. Clinically significant laboratory and ECG abnormalities and blood pressure in the
95th percentile or greater for age, sex and height
11. Study participants were prohibited from using any caffeine-containing products
on study visit days or laboratory assessment days, and were limited to 1 (12-ounce)
caffeinated beverage a day during study participation
12. Estimated full-scale IQ 80, as measured by the Wechsler Abbreviated Scale of
Intelligence
13. Scores of ≥ 2 SD less than mean scores for age on the Gray Oral Reading Test
(GORT), the Comprehensive Test of Phonological Processing (CTOPP), or the
Wechsler Individual Achievement Test - Second Edition (WIAT-II AB13))
14. Weight < 3rd percentile for age
15. History of hospitalisation for treatment of a mood, anxiety or psychotic disorder
16. History of failed response to methylphenidate
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of OROS
methylphenidate and placebo
Mean OROS methylphenidate daily dosage: 40.5 mg
Administration schedule: once daily (morning)
Average duration of OROS methylphenidate treatment: 40 days
Duration of placebo intervention: 1 day
Washout before study initiation: up to 28 days
Medication-free period between interventions: no
Titration period: before randomisation, up to 6 weeks
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Atkins, M-Flynn and Pelham Scale, observer-rated, 4 hours
post dose (on the 2 laboratory days)
Serious adverse events
1. Serious adverse effects assessed on the 2 laboratory days and during the open-label
period
Non-serious adverse events
1. Adverse effects, vital signs and body weight, assessed on the 2 laboratory days
Notes Sample calculation: yes
Ethics approval: yes
Key conclusions of study authors
81Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Armstrong 2012 (Continued)
1. Wigal 2011 (Armstrong 2012): OROS methylphenidate dose to reduce core
symptoms of ADHD to within the normal range also improved performance on a
variety of academic tasks in school-aged children compared with placebo. Reported
adverse effects were consistent with those of prior studies
2. Armstrong 2012 (Armstrong 2012): Robust treatment effect occurred with
OROS methylphenidate; onset was at 1 hour post treatment and persisted for ≥ 12.5
hours after dosing
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while tak-
ing methylphenidate before randomisation: yes; a history of failed response to
methylphenidate was an exclusion criterion. Only children demonstrating the required
decrease in ADHD symptoms with MPH-OROS within the labelled dosing range were
included in the randomised phase of the study. Children who may have required a dose
> 54 mg to achieve full therapeutic effect may also have been excluded
Any withdrawals due to adverse events: yes (n = 2)
Email correspondence with study authors: June 2013 to June 2014. Obtained supple-
mental efficacy data (Swanson, Kotkit, Agler, M-Flynn and Pelham Scale) and safety
data. Awaiting data through the Yale Open Data Access Project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Wigal 2011; computer-generated ran-
domisation schedule
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Wigal 2011; blinding of investigators and
participants maintained throughout the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Wigal 2011; blinding of investigators and
participants maintained throughout the
study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on incomplete outcome
data
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk All outcomes reported according to proto-
col
Vested interest bias High risk Supported by Ortho-McNeil-Janssen Sci-
entific Affairs, LLC. Phase IV study
Conflicts of interest: Several study authors
had affiliations with pharmaceutical com-
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panies producing methylphenidate
Arnold 2004
Methods Seven-centre US study consisting of a 6-week, open-label, dose-titration phase (Part A)
and a 2-week, double-blind, randomised, parallel-group, placebo-controlled withdrawal
study (Part B) with 2 arms
1. Dexmethylphenidate
2. Placebo
Participants Number of patients screened: 116
Regarding Part A
1. Number of participants included: 89 (72 boys, 17 girls)
2. Number of participants followed up: 76
3. Number of withdrawals: 13
4. DSM-IV diagnosis of ADHD (combined 80%)
5. Age range: 6 to 16 years
6. IQ: not stated
7. Methylphenidate naive: 71.9%
8. Ethnicity: not stated
9. Country: USA
10. Comorbidity: not stated
11. Comedication: not stated
12. Sociodemographics: not stated
Regarding Part B
1. Number of participants included: 75 (61 boys, 14 girls)
2. Number randomly assigned: methylphenidate 35, placebo 40
3. Number followed up in each arm: methylphenidate 34, placebo 39
4. Number of withdrawals in each arm: methylphenidate 1, placebo 1
5. DSM-IV diagnosis of ADHD (combined (80%), hyperactive-impulsive (0%),
inattentive (20%))
6. Age range: 6 to 16 years
7. IQ: > 70 (mean not stated)
8. MPH-naive (methylphenidate 82.9%, placebo 62.5%)
9. Ethnicity: Caucasian (methylphenidate 80%, placebo 75%), African American
(methylphenidate 14.3%, placebo 12.5%), Hispanic (methylphenidate 5.7%, placebo
12.5%)
10. Country: USA
11. Setting: out-patient clinic and hospital
12. Comorbidity: not stated
13. Comedication: antihistamines, non-steroidal anti-inflammatory agents, multi-
vitamins, nasal decongestants or other analgesics or antipyretics (methylphenidate 34.
3%, placebo 40.0%)
14. Sociodemographics: not stated
No significant differences in baseline demographics were noted between the 2 groups.
Thus, slightly more treatment-naive participants were receiving d-MPH than placebo
Inclusion criteria
1. 6 to 17 years of age
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2. Enrolled in school
3. DSM-IV diagnosis of ADHD, any subtype
4. Within 30% of normal body weight
5. Able to participate for the full 8 weeks
Exclusion criteria
1. History or evidence of cardiovascular, renal, respiratory (other than asthma/
allergy), endocrine or immune system disease
2. History of substance abuse
3. Hypersensitivity to d,l-MPH or other stimulants
4. Treatment with any investigational drug within 30 days of screening
5. Other significant CNS disorders
6. Treatment with antidepressants, neuroleptics/antipsychotics, mood stabilisers,
anticonvulsants, beta-blockers, alpha-2-agonists, other stimulants, thyroid
medications, long-term oral steroids or sedatives/hypnotics
7. Concurrent treatment with other psychoactive drug
Interventions Part A
Dexmethylphenidate dosage: 2.5 to 10 mg, twice daily depending on individual partic-
ipants’ prior medication experience. Children who had received d,l-MPH began with
half their total daily d,l-MPH dose administered as dexmethylphenidate but not more
than 20 mg/d; those who had not previously received d,l-MPH started d-MPH at 2.5
mg twice daily
Duration of intervention: 6 weeks
Treatment compliance: not stated
Part B
Participants were randomly assigned to dexmethylphenidate or placebo
Mean methylphenidate dosage: 68.6% of dexmethylphenidate continuers and 79.5% of
placebo participants were receiving 20 mg at end of Part B, mean (SD) not stated
Administration schedule: 10 mg twice daily. Time points 7 AM to 8 AM and 11:30 AM
to 12 PM
Duration of intervention: 2 weeks
Titration period: 6 weeks, initiated before randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms (Part B)
1. Swanson, Nolan and Pelham Scale, teacher-rated at baseline and at end of
treatment
2. Swanson, Nolan and Pelham Scale, parent-rated at baseline and at end of
treatment, 3 and 6 hours post dose
Non-serious adverse events (Parts A and B)
1. Monitoring of adverse events and changes from baseline in vital signs (pulse and
blood pressure), physical examination and clinical laboratory parameters throughout
the study
Notes Comments from study authors
1. Limitations
i) Study design: Treatment effects in such trials may be larger than those seen
in unselected populations because, in the randomised withdrawal phase, responders
were pre-selected from the open-label titration phase to the drug phase.
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ii) Another possible limitation is the duration of discontinuation (2 weeks)
Key conclusion of study authors
1. Dexmethylphenidate is safe, tolerable and effective, with a 6-hour duration of
effect suggested by significant differences from placebo at 6 hours on double-blind
discontinuation
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Email correspondence with study authors: October 2013. Supplemental information
regarding additional information was received. However, study authors advised us to
contact the sponsoring drug company for additional information. This process has been
difficult, andno further communicationwas attempted to request additional information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was central, irrespective of
whether the drug was pre-packaged and
pre-randomised, or if it was bottled and la-
belled by an unblinded dispenser who had
no contact with participants and kept the
other staff blind
Allocation concealment (selection bias) Low risk Randomisation was central. “In all indus-
try studies I have been involved with, ei-
ther the drug was pre-packaged and pre-
randomized or it was bottled and labeled by
an unblinded dispenser who had no con-
tact with patients and kept the other staff
blind”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Dou-
ble-blind. In Part B, participants/guardians
and medical personnel were blinded to the
drug. Also, d-methylphenidate was avail-
able in tablets, each identical in appear-
ance to a matching placebo. Study drug
(or placebo) was dispensed in bottles con-
taining a weekly supply, labelled for use at
“Home” and “School”, with the strength
designated “A,” “B” or “C”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. In Part B, participants/
guardians and medical personnel were
blinded to the drug
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Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT sample was used in analysis of effi-
cacy parameters: Participants who received
dexmethylphenidate and had a Part B base-
line efficacy evaluation and ≥ 1 post-base-
line assessment
Selective reporting (reporting bias) Low risk No protocol published. All pre-specified
outcomes of interest have been reported
Vested interest bias High risk Study was supported by the Celgene Cor-
poration
Conflicts of interest: Drs. Arnold, Wigal
and Bohan received research funding from
Celgene for the study reported. Dr. Wigal
andDr.West are on the Advisory Panel and
Speakers’ Bureau for Novartis. Dr. Arnold
and Dr. Bohan are on the Speakers’ Bureau
for Novartis. Dr. Zeldis is Chief Medical
Officer and Vice President of Medical Af-
fairs at the Celgene Corporation
Ashare 2010
Methods Three-day, double-blind, randomised, placebo-controlled medication assessment (cross-
over)
Participants Number of patients screened: not stated
Number of participants included: 50. Participants were randomly assigned to
methylphenidate (low dose, high dose) or placebo
Number of participants followed up: 36 (28 boys, 8 girls)
Number of withdrawals: 14
Diagnosis of ADHD: DSM-IV (combined (61%), hyperactive-impulsive (8%), inatten-
tive (31%))
Age: mean 10.5 years (range 9 to 12)
IQ: mean 102 (SD 13)
Methylphenidate naive: 7 participants
Ethnicity: Caucasian (80%), African American (17%), mixed race (3%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (47%), conduct disorder (17%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD
2. 9 to 12 years of age
Exclusion criteria
1. Full-scale IQ < 80
2. History of seizures, neurological disorders and other medical problems
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3. Contraindicating psychostimulant treatment
4. Current use of non-ADHD psychotropic medications
5. History or concurrent diagnosis of pervasive developmental disorder or psychosis,
and sensory problems that would make it difficult to complete the task
Interventions Participants were randomly assigned to 2 doses of long-acting methylphenidate (OROS
methylphenidate; Concerta) once a day and placebo
1. One (low dose) provided equivalent effects to t.i.d. immediate-release
methylphenidate at 0.3 mg/kg dose, producing a total daily dose of 0.9 mg/kg
2. The other (high dose) was equivalent to t.i.d. immediate-release methylphenidate
0.6 mg/kg dose, producing a total daily dose of 1.8 mg/kg
Methylphenidate dosage: low dose: mean 40 mg (SD 9.2); high dose: mean 76.5 mg
(SD 13.2)
Administration schedule: once daily, morning, 90 minutes before trial
Duration of trial: 3 days
Washout before study initiation: 24 hours before participation. No washout between
interventions. To promote reasonable tolerability of the medication in participants who
were stimulant naive or were previously prescribed only very low doses (0.4 mg/kg/d),
13 children were order-restricted, so they received the 0.3 mg/kg t.i.d.-equivalent dose
before receiving the 0.6 mg/kg t.i.d.-equivalent dose. Among those who were not order-
restricted, 6 possible drug orders were counterbalanced across participants
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Adverse events were rated daily by camp counsellors and parents using the
Pittsburgh Side Effects Rating Scale
2. Blood pressure was rated daily during time of peak medication effects
3. Pulse rate was rated daily during time of peak medication effects
Notes Sample calculation: no information
Ethics approval: yes
Comment from study authors
1. No child had marked elevation of either cardiovascular parameter
Key conclusion of study authors
1. Findings of the study fit with the clinical literature on ADHD and the hypothesis
that methylphenidate enhances interference control for important environmental
stimuli
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: wrote to study authors in July 2014 to ask for
data on side effects, pulse and blood pressure; have received no response as yet
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information about randomisation
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further information
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk Supported by grants from the National
Institute of Mental Health (NIMH) and
from the National Institute on Drug Abuse
(NIDA)
Barkley 1989
Methods Triple-blind, randomised, cross-over trial with 3 interventions
1. Placebo
2. Methylphenidate low dose (0.30 mg/kg)
3. Methylphenidate high dose (0.5 mg/kg)
Participants Number of participants screened: not stated
Number of participants included: 83 (71 boys, 12 girls). Participants were randomly
assigned to 1 of 6 possible drug condition orders
Number of participants followed up: 80
Number of withdrawals: 3
Diagnosis of ADHD: DSM-III-R (subtype distribution not stated)
Age: mean 8.2 years (range 5 to 13)
IQ: mean 105.1
Methylphenidate naive: 85%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics:mothers, married (n = 48), divorced (n = 13), unmarried or widowed
(n = 13)
Inclusion criteria
1. 6 to 13 years of age
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2. ADHD according to DSM-III-R
3. Complaints from teacher, parents or both, of significant inattention, overactivity
and impulsivity
4. Appearance of symptoms before 7 years of age
5. Symptoms for 12 months
6. Above the 93rd percentile of the hyperactivity scale on parent or teacher report
forms of the Child Behavior Checklist (CBCL)
7. Simple language IQ score > 80 on the Peabody Picture Vocabulary Test - Revised
Exclusion criteria
1. Gross sensory or motor deficits
2. Tic disorders, Tourette’s syndrome or an immediate family history of such
3. Seizures
4. Gross brain damage
5. Autism
6. Thought disturbance or schizoid, schizotypal or frank psychotic features
7. Significant cardiac problems or high blood pressure
8. Excessive levels of anxiety or fear
9. Levels of depression that exceed or equal the problems of ADHD
10. Most participants (n = 74) were subdivided into children placed 2 SD above the
normal mean on the Aggressive scale of the parent form of the Child Behavior
Checklist (T score > 70) and those who did not have ≥ 2 SD above the normal mean
to form aggressive (n = 37) and non-aggressive subgroups (n = 37). Groups did not
differ in age, years of education, maternal age or maternal years of education
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of 0.3 mg/
kg methylphenidate, 0.5 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: morning and noon
Duration of each medication condition: 7 to 10 days
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: unused capsules returned to the clinic each week for adherence
check
No family was discontinued from the study because of non-compliance with the drug
regimen, defined as more than 1 day of failure to take medication, or 2 missed capsules
per week
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale - Revised: parent-rated at the end of each drug
condition
2. Conners’ Teacher Rating Scale - Revised: teacher-rated at the end of each drug
condition
3. Child Attention Profile: teacher-rated at the end of each drug condition
General behaviour
1. Home Situations Questionnaire: parent-rated at the end of each drug condition
(7 to 10 days)
2. School Situations Questionnaire: teacher-rated at the end of each drug condition
(7 to 10 days)
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Adverse effects
1. Barkley Side Effects Rating Scale: parent- and teacher-rated at the end of each
drug condition (7 to 10 days)
Notes Sample calculation: not stated
Ethics approval: Study was approved by the Human Subjects Committee at the medical
centre
Comments from study authors
1. Limitations
i) Rates of side effects were based on a large sample that was screened before
admission to the drug trial
ii) Low doses of medication to detect side effects
iii) Use of rating scale rather than direct behavioural observation
Key conclusions of study authors
1. In their drug responding, aggressive and non-aggressive participants were quite
similar. The few exceptions involved measures of conduct, on which aggressive
participants were initially rated as more extreme and subsequently showed a greater
degree of improvement from medication than non-aggressive participants
2. With this dose range, stimulants result in few/mild side effects; systematic
monitoring of side effects suggested before/during clinical trials of stimulants
Comment from review authors
1. The Barkley Side Effects Rating Scale was labelled generically as a “behaviour
questionnaire” to disguise its intended use as a monitoring tool for potential side
effects. The purpose was to prevent prejudice on the part of respondents, who might
potentially distort their ratings if they knew these could be side effects of the medication
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Anywithdrawals due to adverse events: yes; 3.One child discontinued because of nervous
facial tics, headache and dizziness; a second as the result of excessive thinking and dis-
jointed thinking (during high-dose methylphenidate); and a third because of headache,
dizziness and increased hyperactivity
Email correspondence with study authors: July 2013. We obtained additional informa-
tion regarding funding and ethics approval. Unfortunately, it was not possible to receive
from the study authors supplemental data on ADHD symptoms and general behaviour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A completely counterbalanced design was
used, with participants randomly assigned
in relatively equal numbers to 1 of 6 possi-
ble drug conditions
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both medication and placebo were crushed
and placed within orange opaque gelatin
capsules to disguise distinctive differences
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in flavour betweenmedication and placebo
and dose differences across conditions.
Children and their parents and teachers, as
well as the research assistant evaluating the
children, were blinded to medication con-
ditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Children and their parents and teachers,
as well as the research assistant evaluating
the children, were blinded to medication
conditions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on incomplete outcome
data
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
information
Selective reporting (reporting bias) Low risk No selective reporting
Vested interest bias Low risk Study was internally funded by themedical
school
Barkley 1991
Methods Triple-blind, placebo-controlled, cross-over design with participants randomly assigned
to the following conditions
1. Three doses of methylphenidate (5 mg, 10 mg and 15 mg b.i.d.)
2. Placebo
Each intervention period lasted 1 week
Participants Number of participants screened: not stated
Number of participants included: 40. Participants were randomly assigned to 1 of 6
possible drug condition orders (only 6 drug orders, so the highest dose was never given
unless preceded by the moderate dose)
Number of participants followed up: 40 (36 boys, 4 girls)
Number of withdrawals: 0
Diagnosis of ADD: DSM-III-R (+H: 58%, -H: 42%)
Age: mean 8.6 years (range 6 to 12)
IQ: 103.5
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: borderline and low internalising symptoms. No others stated
Comedication: not stated
Sociodemographics: 54.8 on Hollingheads 2 Factor Index
Participants were divided into different categories
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1. Based on type of ADD
i) ADD with hyperactivity (n = 2)
ii) ADD without hyperactivity (n = 17)
2. Based on severity of internalising symptoms by maternal ratings on the
Internalising scale of the Child Behavior Checklist (CBCL)
i) ’High internalising group’ (> 70) (n = 12)
ii) ’Borderline internalising group’ (65 to 70) (n = 17)
iii) ’Low internalising group’ (< 65) (n = 11)
Inclusion criteria
1. Diagnosis of ADD(H) according to DSM-III-R
2. IQ estimate of 80 or higher on a standardised IQ test given within the past year or
on the Wechsler Intelligence Scale for Children - Revised, given at study screening
3. Was the biological child of both current parents or had been adopted by them
shortly after birth (within the first year)
4. No evidence of deafness, blindness, severe language delay, cerebral palsy, epilepsy,
autism or psychosis, as established through medical history, parental interview and
child play diagnostic interview
Additional criteria for children with combined ADHD
1. Teacher complaints of short attention span, impulsivity and overactivity as
revealed by parent reports
2. Duration of 6 months for these problems
3. Age of onset of these problems before 7 years
4. Score > 93rd percentile on the Inattention and Overactivity scales of the Child
Attention Problems Rating Scale
5. No history of treatment with stimulant drugs, or, if such a history, physician
consent to stop taking medication for 48 hours before evaluation in the study
Additional criteria for children with ADD-H
1. Same criteria as for children with combined ADHD, with the exception of the
fourth criterion. Instead, score > 93rd percentile on the Inattention scale of the Child
Attention Problems Rating Scale, but a score < 84th percentile on the Overactivity
scale of the Child Attention Problems Rating Scale
Differences regarding the 2 ADHD groups
1. They differed significantly on child’s IQ score, with the ADD without
hyperactivity group scoring significantly lower than the ADD with hyperactivity
group. Child IQ was correlated with all of the dependent measures (Measures that we
used in this review were not affected by differences in IQ)
Exclusion criteria
1. History of tics or Tourette’s syndrome, given the controversy over whether
stimulants may create or exacerbate these conditions
2. Those with a history of cardiac surgery, high blood pressure or cerebral vascular
accident, given the known cardiac pressor effects of stimulants
3. Those with a history of adverse reactions to a stimulant
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate (5 mg, 10 mg and 15 mg) and placebo
Administration schedule: b.i.d., morning and noon
Duration of each medication condition: 1 week
Washout before study initiation: no
Titration period: none, but highest dose was never given unless preceded by moderate
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dose
Compliance: Children were permitted to miss 1 day of medication over 7 days and
still remain in the study. No families were removed from this study because of non-
compliance as defined in this way
Outcomes ADHD symptoms
1. Parent-rated
i) Attention Deficit Hyperactivity Disorder Rating Scale: rated at the end of
each drug condition order
ii) Home Situations Questionnaire: number of problem settings and mean
severity of problems, rated at the end of each drug condition order
2. Teacher-rated (teachers completed questionnaires at the conclusion of each
medication condition)
i) Self Control Rating Scale
ii) Child Attention Problems
iii) School Situations Questionnaire: number of problem settings and mean
severity of problems
Non-serious adverse events
1. Home Side Effects Rating Scale: parent-rated at the end of each drug condition
order
2. School Side Effects Rating Scale: parent-rated at the end of each drug condition
order
Notes Sample calculation: no
Ethics approval: Study was approved by the Institutional Review Board at the medical
centre
Key conclusion of study authors
1. This study indicates that ADHD, inattentive type, and ADHD, combined type,
do not show dramatic differences in their manner of responding to methylphenidate
across 3 dose levels (5 mg, 10 mg and 15 mg), with both groups displaying generally
positive drug responses. However, more children with ADHD, inattentive type, had
minimal or no response or did best on the low dose of medication, whereas the vast
majority of children with ADHD, combined type, showed a positive response,
primarily to moderate to high doses of methylphenidate
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; excluded those
with history of adverse reactions, but includedboth naive andprior users of antipsychotics
Email correspondence with study author: 18 January 2013. Dr. Barkley informed us that
data from the study on side effects, for example, are no longer available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to 1 of 6 possible drug
conditions
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Allocation concealment (selection bias) Low risk Hospital pharmacy prepared placebo (lac-
tose powder) and methylphenidate by
crushing and placing them into 6 orange
opaque gelatin capsules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple-blind design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Triple-blind design
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selection bias: no
Selective reporting (reporting bias) Unclear risk Protocol not available
Vested interest bias Low risk Researchwas supported by theNational In-
stitute of Mental Health (NIMH)
Conflicts of interest: no information
Barkley 2000
Methods Double-blind, placebo-controlled, within-participant, cross-over trial with 3 interven-
tions
1. Methylphenidate: 5 mg, 10 mg, twice daily
2. Amphetamine and dextroamphetamine mixed salts (Adderall): 5 mg, 10 mg,
twice daily
3. Placebo
Phases: 5, but high doses of each stimulant always followed lower dose of the same
stimulant
Participants Number of participants screened: 46
Number of participants included: 38. Participants were randomly assigned to 1 of 4
possible drug condition orders
Number of participants followed up: 35 (30 boys, 5 girls)
Number of withdrawals: 2. One was a post hoc exclusion
Diagnosis of ADHD: DSM-IV (subtype not described)
Age: mean 14 years (range 12 to 17)
IQ: mean 103.9 (range 80 to 141)
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
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Inclusion criterion
1. Adolescents, 12 to 17 years of age, with a DSM-IV diagnosis of ADHD
Exclusion criteria
1. History of motor or vocal tics, Tourette’s syndrome, cardiac surgery, high blood
pressure, cerebral vascular accident, hyperthyroidism or pregnancy or lactation
2. Adverse reactions to stimulant medications
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of 5 mg
methylphenidate followed by 10 mg methylphenidate, 5 mg Adderall followed by 10
mg Adderall and placebo
1. 5 mg, 10 mg methylphenidate; placebo; 5 mg, 10 mg Adderall
2. 5 mg, 10 mg Adderall; placebo; 5 mg, 10 mg methylphenidate
3. Placebo; 5 mg, 10 mg methylphenidate; 5 mg, 10 mg Adderall
4. 5 mg, 10 mg Adderall; 5 mg, 10 mg methylphenidate; placebo
Mean methylphenidate dosage: low dose 10 mg/d; high dose 20 mg/d
Administration schedule: AM and midday
Duration of each medication condition: 1 week
Washout before study initiation: none
Medication-free period between interventions: none
Titration period: none, although 5 mg dose was given before 10 mg, initiated after
randomisation
Treatment compliance: Parents were required to return all unused capsules, but nothing
further was said about this
Outcomes ADHD symptoms
1. Parent- and teacher-rated ADHD/ODD Rating Scales: completed over previous
treatment week
Non-serious adverse events
1. Barkley Side Effects Rating Scale: completed by adolescent, parent and teacher at
the end of each treatment week
Notes Sample calculation: not described
Ethics approval: yes
Comments from study authors
1. Teens are more independent of their parents than are younger children, spending
more time outside parental supervision. This raises serious questions about the
sensitivity of parental reports to drug and dose response
2. Limitations: Most noteworthy was the poor co-operation of teachers. As a
consequence, the statistical power of the study to detect drug effects on these measures,
often the most sensitive to stimulant drug effects, was greatly reduced
Key conclusion of study authors
1. In conclusion, the present study suggested that both Adderall and
methylphenidate may have been clinically effective in the management of teens with
ADHD when non-blinded, global clinical judgements of improvement, which were
based on multiple sources of information, were used. Even so, these positive drug
responses could not be documented at the group level of statistical analysis by using
more specific and systematic ratings by parents and teachers. Clinicians undertaking
stimulant trials in such contexts need to be aware of the many challenges to the internal
validity of these procedures that are likely to occur in drug trials with teens
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Comment from review authors
1. To exclude participants with low IQ was a post hoc decision
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse eventswhile takingmethylphenidate before randomisation: yes; excludedpatients
who had a history of adverse events to stimulants
Email correspondence with study authors: January 2014. We received additional infor-
mation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Email correspondence with study author:
“Randomization was done by me as best as
I can recall” (Krogh 2014a [pers comm])
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Opaque gelatin capsules were prepared by
the pharmacist
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Completer analysis reported 11/46 teens
LTFU, 15 parents LTFU, 33 English teach-
ers and 31 Maths teachers LTFU
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Email correspondence with study author:
“All planned analyses were done and all
measures we collected as treatment end-
points were analyzed” (Krogh 2014a [pers
comm])
Vested interest bias Low risk University of Massachusetts Medical
School
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Methods Four-day randomised, double-blind, placebo-controlled, cross-over trial with 2 inter-
ventions in 2 groups
Interventions
1. Methylphenidate
2. Placebo
Groups
1. ADHD with anxiety
2. ADHD without anxiety
Participants Number of participants screened: not stated
Number of participants included: 130. Participants were randomly assigned to 1 of 11
possible drug condition orders
Number of participants followed up: 130 (110 boys, 20 girls)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (63%), hyperactive-impulsive (30%), inat-
tentive (6%))
Age: mean 9 years (SD 1.46, range 6 to 12)
IQ: mean 104.11
Methylphenidate naive: 70%
Ethnicity: Caucasian (90%)
Country: Canada
Setting: out-patient clinic
Comorbidity: specific learning disorder (34%), conduct disorder (24%), oppositional
defiant disorder (26%), generalised anxiety disorder (17%), separation anxiety disorder
(11%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. DSM-IV diagnosis via clinical diagnostic assessment: confirmed by Parental
Interview for Child Symptoms (PICS) and Teacher Telephone Interview (TTI)
Exclusion criteria
1. IQ < 80
2. Evidence of neurological dysfunction, poor physical health or uncorrected sensory
impairments
3. History of psychosis based on physician enquiry
4. Primary language spoken at home not English
Interventions Participants were randomly assigned to 1 of 11 possible drug condition orders of
methylphenidate and placebo. Children weighing < 25 kg received 5 mg, 10 mg and 15
mg of methylphenidate; children weighing ≥ 25 kg received 10 mg, 15 mg and 20 mg
of methylphenidate
Mean methylphenidate dosage: 0.28 mg/kg, 0.45 mg/kg, 0.61 mg/kg
Administration schedule: not stated
Duration of each medication condition: 1 day
Washout before study initiation: none
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: not stated
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Outcomes ADHD symptoms
1. Iowa-Conners’ Rating Scale. Scale was completed by the examiner at the end of
each session
Notes Sample calculation: no
Ethics approval: approved by the institutional ethics review board
Comment from study authors
1. We cannot predict that similar results would hold with longer-term treatment or
with extended-release preparations
Key conclusions of study authors
1. Findings provide insight into potential mechanisms underlying individual
differences in treatment response in ADHD, which may facilitate more targeted
treatments
2. Results from the present study demonstrate that methylphenidate produces
moderate but beneficial effects on selected aspects of working memory that are known
to be impaired in ADHD. Furthermore, comorbid anxiety may be a predictor of
working memory treatment response
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: December 2013.Not able to get supplemental
information from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Master randomisation tables were prepared
by the research support pharmacist at the
hospital by using simple randomisation
with restrictions (high dose not to be given
on the first possible drug day nor immedi-
ately following placebo; no directly ascend-
ing or descending dose order). Therefore, a
balanced block 22 design was used
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Examiner, psychiatrist, participant and
participant’s family were not informed
about participant’s randomisation order or
daily medication status until completion.
Placebo and active medication were pre-
pared by the hospital pharmacist and were
powdered and packaged in an opaque cap-
sule to prevent identification of contents by
colour, taste or volume
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained clinicians, blinded to other aspects
of the participant’s assessment, conducted
interviews independently
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Low risk Funding and operating grant from the
Canadian Institute of Health Research and
funding from the Canada Research Chairs
Programme
Conflicts of interest: none
Ben 2002
Methods Two-week, double-blind, placebo-controlled, cross-over trial with 1 intervention
1. Methylphenidate 0.5 mg/kg/d
2. Placebo
The purpose of the study was to investigate the relationship between SLC6A3 3’ end
variable number tandem repeat (VNTR) polymorphism and behavioural/therapeutic
response to methylphenidate
Phases: not stated
Participants Number of participants screened: not stated
Number of participants included: 42 (all boys). Participants were randomly assigned to
1 of 2 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.2 ± 1.8 years (range not stated)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: Canada
Setting: not stated
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. Not stated
Exclusion criterion
1. Not stated
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate (0.5 mg/kg/d) and placebo
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Mean methylphenidate dosage: not stated
Administration schedule: not stated
Time points: not stated
Duration of each medication condition: not stated
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: not stated. No information
Treatment compliance: not stated
Outcomes General behaviour
1. Conners’ Continuous Performance Test Overall Index: before and 45 minutes
after administration of placebo or methylphenidate
2. Restricted Academic Situation Scale: before and 45 minutes after administration
of placebo or methylphenidate
3. Conners’ Global Index Scale: parent and teacher reports, time points not stated
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusion of study authors
1. Although preliminary, these results suggest that the SLC6A3 3’ end variable
number tandem repeat may modulate therapeutic response to methylphenidate as
evaluated by teachers
Comments from review authors
1. Abstract only. Abstract includes no raw information on clinical effectiveness;
includes mostly details of the relationship gene/methylphenidate effect
2. No information on adverse events was provided in this abstract
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
Any withdrawals due to adverse events: not stated
Email correspondence with study authors: October 2013 and April 2014. We wrote to
the study authors twice to request supplementary information on data. No reply was
received. Therefore we have no useable data from this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inadequate information contained in the
abstract
Selection bias: not stated
Selective reporting (reporting bias) Unclear risk Protocol not available
Vested interest bias Unclear risk Not stated
Biederman 2003
Methods Fifteen-site, multi-centre, double-blind, randomised, 2-week parallel trial with 2 arms
1. Extended-release methylphenidate (Ritalin LA)
2. Placebo
Phases: 3. Pre-randomisation (4 weeks titration plus 1 week washout), randomisation,
double-blind treatment and open-label extension
Participants Number of participants screened: unknown
Number of participants included: 164
Number of participants titrated: 161 (122 boys, 39 girls)
Number of participants randomly assigned: methylphenidate 66, placebo 71
Number of participants followed up: methylphenidate 63, placebo 71
Number of withdrawals: methylphenidate 3, placebo 0
Diagnosis of ADHD:DSM-IV (combined (75.8%), hyperactive-impulsive (1.2%), inat-
tentive (18.6 %))
Age: mean 8.81 years (range 6 to 14)
IQ: not stated
Methylphenidate naive: 94 (58.4%)
Ethnicity: Caucasian (85.7%), African American (3.7%), Asian (1.2%), other (9.3%)
Country: USA and Canada
Setting: out-patient clinic (naturalistic school setting)
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated. No significant difference in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Boys and girls 6 to 14 years of age who met DSM-IV criteria for ADHD and were
receiving treatment with methylphenidate, or de novo patients
2. Meeting ADHD criteria in the structured diagnostic interview (National Institute
of Mental Health Diagnostic Interview Schedule for Children, Fourth Edition)
3. Attending school in a classroom setting with the same teacher, who, for the
duration of the study, would perform weekly assessments
4. Functioning, in the opinion of the investigator, at age-appropriate levels
academically
5. Female patients of childbearing age needed to have a negative pregnancy test and
if sexually active had to be using adequate and reliable contraception for the duration
of the study
6. Ongoing behavioural therapies for ADHD were permitted to continue, but
participants were not to initiate behavioural therapy during the trial
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7. Informed consent
Exclusion criteria
1. Patients with somatic or psychiatric disorders that could contraindicate treatment
or confound efficacy or safety assessments, or those who required treatment with drugs
other than methylphenidate
2. Known hypersensitivity to the study drug
3. Likelihood of non-compliance
4. History of substance abuse
5. Living with a person with a substance abuse disorder
6. Pregnancy
7. Use of other investigational drugs during the study period
Interventions Participants were randomly assigned to extended-release methylphenidate or placebo
Mean methylphenidate dosage: not stated
Administration schedule: once daily in the morning
Duration of intervention: 2 weeks (mean: methylphenidate 13.91, placebo 13.96)
Titration period: 1 week before randomisation
Treatment compliance: 130 completed treatment (methylphenidate 61, placebo 69)
Outcomes ADHD symptoms
1. Primary efficacy outcome measure
i) Conners’ ADHD/DSM-IV Scale, Teachers: Total subscale, school day
weekly assessments
2. Secondary efficacy measure
i) Conners’ ADHD/DSM-IV Scale, Teachers: Inattentive subscale
ii) Conners’ ADHD/DSM-IV Scale, Teachers: Hyperactive-Impulsive subscale
iii) Conners’ ADHD/DSM-IV Scale, Parents: Total subscale, weekends
iv) Conners’ ADHD/DSM-IV Scale, Parents: Inattentive subscale
v) Conners’ ADHD/DSM-IV Scale, Parents: Hyperactive-Impulsive subscale
Non-serious adverse events
1. Monitoring of adverse events
2. Routine laboratory tests (haematology, blood chemistry, urine)
3. Vital signs (sitting blood pressure and pulse)
4. Height, weight and performance of physical examinations and drug screening
Notes Sample calculation: yes. A total of 128 participants (n = 64 per treatment group) were
required for analysis of the primary efficacy variable, based on an effect size of 0.5 with
a power of 80% and a 2-tailed α-level of 0.05
Ethics approval: yes. An institutional review board approved this study at each partici-
pating site
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Any withdrawals due to adverse events: yes
Comment from study authors
1. Limitations: First, participants in this study were primarily male Caucasians with
ADHD. Second, the short study duration does not predict long-term efficacy or safety.
Third, selection of responders during the titration phase may have affected the
outcomes of this study. In clinical practice, response rate may be lower than that
observed among the current sample
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Key conclusion of study authors
1. Results demonstrate that extended-release methylphenidate (Ritalin LA)
administered once daily for up to 2 weeks achieved outcomes statistically superior to
placebo in children with ADHD
Comments from review authors
1. Mean methylphenidate dosage not stated, only range (10 mg/d to 40 mg/d)
2. IQ not stated
Email correspondence with study authors. April 2014. Emailed study authors for addi-
tional information/data but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by Novartis
Drug Supply Management, which used a
validated system that automates randomas-
signment of treatment groups to randomi-
sation numbers
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clear whether investigator was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear whether investigator was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF analysis of ITT population. ITT
population included all participants who
received the double-blind study drug, and
from whom ≥ 1 Conners’ ADHD/DSM-
IV Scale, Teachers, was obtained
Selective reporting (reporting bias) Low risk No protocol was published. Outcomes of
interest have been reported
Vested interest bias High risk Funding was received from Novartis
Bliznakova 2007
Methods Eleven-day N-of-1 randomised, double-blind, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
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Participants Number of participants screened: 1 boy
Number included: 1. The participant was randomly assigned to methylphenidate and
placebo across the 11 days
Number of participants followed up: 1
Number of withdrawals: 1
Diagnosis of ADHD: ICD-10 (predominantly hyperactive type)
Age: 15 years
IQ: not stated
Methylphenidate naive: no
Ethnicity: not stated
Country: Germany
Setting: not stated
Comorbidity: not stated
Comedication: not stated
Sociodemographics: 2 parents
Interventions The participant was randomly assigned to methylphenidate and placebo across 11 days
Mean methylphenidate dosage: not stated
Administration schedule: not stated
Duration of each medication condition: The condition was changed daily, but placebo
was given for 6 days and methylphenidate for 5 days
Washout before study initiation: not relevant
Medication-free period between interventions: no
Titration period: none
Treatment compliance: 100% according to Table 6
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale: rated daily
2. Parent/Teacher Rating Scale: rated daily
Non-serious adverse events
1. Assessment of stomachaches (yes/no) daily
Notes Sample calculation: yes
Ethics approval: not stated
Key conclusion of study authors
1. Double-blind study showed significant symptom reduction under the medication
condition, which was also noted by the participant himself. Furthermore, towards the
end of the study, the somatic complaints were gone
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: December 2013. Emailed study author to
request information about missing data but received no response. Not possible to use
data from this study
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No
Vested interest bias Unclear risk Not stated
Conflicts of interest: not stated
Blum 2011
Methods This double-blind, placebo-controlled, cross-over trial with the child’s clinically most
effective dose as identified by a systematic open-label titration procedure investigated
whether components of attention and executive functioning improve when children with
ADHD are treated with OROS methylphenidate
Two-week, cross-over trial with 2 interventions
1. OROS methylphenidate
2. Placebo
Participants Number of participants screened: 41
Number of participants included: 34. Participants were assigned to OROS
methylphenidate and placebo in random order
Number of participants followed up: 30 (24 boys, 6 girls)
Number of withdrawals: 4
Diagnosis of ADHD: DSM-IV TR (combined (100%))
Age: mean 8 years 6 months (range 6 years 5 months to 12 years 6 months)
IQ: mean 97.8 (range 77 to 132)
Methylphenidate naive: number not stated
Ethnicity: Caucasian (80%), African American (13.3%), other (6.7%)
Country: USA
Setting: out-patient clinic
Comorbidity type: oppositional defiant disorder (40%), specific learning difficulty (33.
3%), anxiety (6.67%), dysthymia (3.3%)
Comedication: not stated
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Sociodemographics: not stated
Inclusion criteria
1. Children 6 to 12 years of age, in first grade or higher
2. DSM-IV-TR diagnosis of ADHD combined type
3. Parent and teacher ratings on the ADHD Rating Scale, Fourth Edition, of at least
the 85th centile for hyperactivity/impulsivity and inattention, or both (if the child was
not taking medication at enrolment)
4. IQ > 75 on the Wechsler Abbreviated Scale of Intelligence
Exclusion criteria
1. Children with a past or current diagnosis of a chronic tic disorder, a pervasive
developmental disorder, cerebral palsy, bipolar disorder, major depression, head injury
requiring hospitalisation, psychotic disorder, glaucoma, cardiovascular disease, epilepsy,
obsessive-compulsive disorder serious enough to warrant separate treatment or suicidal
or homicidal behaviour or ideation
2. History of side effects with methylphenidate requiring discontinuation of the
medication
3. Children were also excluded if they were known to be unable to swallow a tablet
4. Use within 14 days of a monoamine oxidase inhibitor
5. Long-term treatment with coumarin, clonidine or tricyclic antidepressants
Interventions Participants were randomly assigned to OROS methylphenidate and placebo
Methylphenidate dosage: 9 children treated with 18 mg, 13 with 36 mg and eight with
54 mg of OROS methylphenidate
Administration schedule: not stated
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: 2- to 3-week open-label, multi-dose-titration protocol to determine
the child’s optimal dose as recommended by practice guidelines
Treatment compliance: 30 children completed the study; however, compliance regarding
study medication is not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition, both parent- and teacher-rated: rated at the
end of each week of the different medication trial
Non-serious adverse events
1. Stimulant Drug Side Effects Rating Scale, parent-rated: rated at the end of each
week of the different medication trial. These data are not reported in the article
Notes Sample calculation: not stated
Ethics approval: yes; approved by the Committee for the Protection of Human Subjects
at The Children’s Hospital of Philadelphia
Comment from study authors
1. In conducting analyses for the cross-over study, our team examined the effects of
crossing participants from the first treatment condition to the second treatment
condition (i.e. the carry-over effect).(.....) Because no statistically significant sequence
effects were noted, data from both periods were combined, and final analyses were
reduced to paired comparisons
Key conclusion of study authors
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1. When OROS methylphenidate was used to treat children with ADHD at the
clinically most effective dose, general improvement was noted on tasks requiring
response inhibition; response to treatment in other domains was variable or was not
demonstrated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Email correspondence with study authors: January 2014: Emailed study authors twice
to request additional information but received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned and counterbalanced
across participants
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Referred to as double-blind but no infor-
mation provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Referred to as double-blind but no infor-
mation provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Completer analysis reported
Selective reporting (reporting bias) Low risk Clinical trial ID: NCT00530257
Vested interest bias High risk Study was supported by an investiga-
tor-initiated grant from Ortho McNeil
Janssen Scientific Affairs, the manufacturer
of OROS methylphenidate (Concerta)
Borcherding 1990
Methods Eleven-week, double-blind, placebo-controlled, cross-over study with 3 interventions
1. Methylphenidate
2. Dextroamphetamine
3. Placebo
Participants Number of participants screened: not stated
Number of participants included: 46 (all boys). Participants were randomly assigned to
1 of the possible drug condition orders
Number of participants followed up: 45
Number of withdrawals: 1
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Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 8.6 years (range 6 to 12)
IQ: mean 106.1 (range > 80)
Methylphenidate naive: 13 have not received past stimulant treatment
Ethnicity: Caucasian (72%), African American (22%), Asian/Hispanic (6%)
Country: USA
Setting: out-patient clinic
Comorbidity: medically healthy
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Medically healthy
2. Full-scale IQ score > 80 on the Wechsler Intelligence Scale
3. Score 2 SD or above age norms on Factor 4 (Hyperactivity) of Conners’ Teacher
Rating Scale
Exclusion criteria
1. Medical or neurological disease, including chronic motor tics or Tourette’s
syndrome
2. Other primary Axis I psychiatric disorders
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of
methylphenidate, dextroamphetamine and placebo
Mean methylphenidate dosage: 1.3 mg/kg
Administration schedule: twice daily, 9:00 AM and 1:00 PM
Duration of each medication condition: 3 weeks
Washout before study initiation: 2 weeks
Medication-free period between interventions: none
Titration period: During the 3 weeks, low dose was given week 1, intermediate dose
week 2 and high dose week 3
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Subject Treatment Emergent Symptom Scale completed weekly by the physician
and the child’s parents; reflected both symptoms and observed effects
2. Attention given to onset and duration of abnormal movements or obsessive-
compulsive behaviours. Collected from several sources
Notes Sample calculation: no
Ethics approval: not stated
Comment from study authors
1. Most movements and compulsive behaviours were seen only by staff sensitive to
these possible effects
Key conclusions of study authors
1. Dextroamphetamine tended to produce more compulsive behaviours, which were
also more likely to resemble obsessive-compulsive disorder, than did methylphenidate
2. Abnormal movements and compulsive behaviours tended to co-occur with
methylphenidate only; no general Tourette’s-obsessive-compulsive disorder diathesis
was found for this population
3. An important clinical point from these data is that abnormal movements and
108Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Borcherding 1990 (Continued)
compulsive behaviour due to treatment with 1 stimulant should not necessarily be a
cause for discontinuation of stimulant drug treatment; rather, the same stimulant at a
different dose or a different stimulant should be tried
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Double-blind random fashion
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Oral medication in identical capsules was
administered at 9:00 AM and 1:00 PM
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants except 1 (who experienced
adverse events) completed the study
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol; however, all outcomes stated
in the Methods have been reported
Vested interest bias Unclear risk Not stated
Conflicts of interest: not stated
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Brams 2008
Methods Randomised, double-blind, cross-over, multi-centre study evaluating the efficacy of the
following over an 8-hour laboratory classroom day in children with ADHD
1. Extended-release dexmethylphenidate (20 mg/d)
2. Placebo
Phases
1. Baseline: day 0
2. Period 1: days 1 to 7 (Sunday to Saturday), when Saturday is assessment day (8-
hour laboratory classroom day)
3. Period 2: days 7 to 15
4. Final visit: day 15
Participants Number of participants screened: 92
Number of participants included: 86 (53 boys, 33 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 86
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (87.2%), hyperactive-impulsive (0%), inat-
tentive (12.8%))
Age: mean 9.5 years (range 6 to 12)
IQ: > 70
Methylphenidate naive: 0%
Ethnicity: Caucasian (48.8%), African American (24.4%), Asian (2.3%), Hispanic (23.
3%)
Country: USA
Setting: multi-centre, out-patient clinic
Comorbidity: not stated
Comedication: no antidepressant or other antipsychotic medication
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV criteria for a diagnosis of ADHD of any type, as established by the
Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime
Versions
2. 6 to 12 years of age
3. Only children whose parents or legal guardians, or both, provided written
informed consent before any study-related procedures were performed were enrolled
4. Females of child-bearing potential were required to have a negative urine
pregnancy test before enrolment and, if sexually active, to be using adequate and
reliable contraception (e.g. double-barrier method), which was documented in the
medical record
Exclusion criteria
1. Children or their parents/guardians were unable to understand or follow
instructions as needed to participate in the study
2. Children deemed by investigators to have below-average cognitive capacity, or to
be home-schooled
3. Previously diagnosed with Gilles de la Tourette’s syndrome or a tic disorder
(medication-induced tics were not excluded)
4. History of seizure disorder, or history of, or concurrent, significant medical or
psychiatric illness or substance abuse disorder
5. Taking an antidepressant or other antipsychotic medication; those who initiated
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psychotherapy within the 3 months preceding screening and those with a positive urine
drug screen were deemed ineligible
6. Poor response or known sensitivity to all methylphenidate or dexmethylphenidate
formulations based on past medical history
7. Taking other medications for ADHD
8. Prospective participants taking or planning to take any other investigational drug
within 30 days of the start of the study
9. Previously participated in an analogue classroom study within 6 months before
screening.
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of once-
daily, extended-release dexmethylphenidate 20 mg (Focalin XR (Novartis Pharmaceuti-
cals Corporation) and placebo
Mean methylphenidate dosage: 20 mg
Administration schedule: once daily in the morning
Duration of each medication condition: 7 days
Washout before study initiation: 1 week before the study
Titration period: Before study participation, all participants were stabilised on a to-
tal daily dose or nearest equivalent dose of methylphenidate 40 mg to 60 mg or
dexmethylphenidate 20 mg to 30 mg for ≥ 2 weeks before screening
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Primary efficacy outcome
i) Change on the Swanson, Kotkit, Agler, M-Flynn and Pelham Scale:
combined score from pre-dose to the 0.5-hour post-dose time point during the 8-hour
classroom day. Rated by observer
ii) Change in Swanson, Kotkit, Agler, M-Flynn and Pelham Scale: combined
scores from pre-dose to 1, 2, 4, 6 and 8 hours post dose. Rated on classroom day by
observers
iii) Change from pre-dose on Swanson, Kotkit, Agler, M-Flynn and Pelham
Scale: Attention and Deportment scores at all time points (0.5, 1, 2, 4, 6 and 8 hours
post dose)
iv) Conners’ ADHD/DSM-IV Scales, Parent: completed by parent/legal
guardian on classroom day
Non-serious adverse events
1. Vital signs: recorded at each visit (days 0, 7, 14)
2. Spontaneously reported adverse events, including serious adverse events, at the
end of each treatment period
3. Heart rate and blood pressure measured at pre-dose, 4 and 8 hours post dose at
days 7 and 14
4. Weight at screening and at day 15
5. ECG at screening and at day 15
Notes Sample calculation: yes
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; children with
poor response or known sensitivity to methylphenidate or dexmethylphenidate were
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excluded
Comments from study authors
1. Several limitations with regard to the design of this study should be considered in
interpretation of these data
2. Participant population was required to have had previous exposure to
methylphenidate or dexmethylphenidate. It is likely that this patient population
already demonstrated a therapeutic response to methylphenidate or
dexmethylphenidate, as well as tolerance to these drugs
3. Only a fixed dosage of 20 mg/d was evaluated, making it difficult to compare
results observed in the current study with those of other doses currently available, or
when treatment is optimised
Key conclusions of study authors
1. Compared with placebo, once-daily, extended-release dexmethylphenidate 20 mg
provided rapid and significant improvement at 0.5 hours post dose in attention,
deportment and academic performance, which was sustained for 8 hours post dose
2. Overall, once-daily extended-release dexmethylphenidate 20 mg was well tolerated
3. In an analysis of parental assessment of diary responses, children appeared better
organised, and morning preparation for school was smoother and less frustrating, with
once-daily extended-release dexmethylphenidate compared with placebo
Email correspondence with study authors: September 2013. We received an email from
Dr. Brams, in which we were told that Novartis had control and ownership of study data.
Consequently, we had to contact the Public Affairs Department at Novartis to request
the information (e.g. protocols) (Krogh 2013a [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation list was generated by
the study sponsor, who used an automated
random assignment of treatment sequences
to randomisation numbers in the specified
ratio
Allocation concealment (selection bias) Low risk All study medications and packaging were
identical in appearance for blinding pur-
poses
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, parents, study centre person-
nel and those who assessed outcomes were
blinded to study treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, parents, study centre person-
nel and those who assessed outcomes were
blinded to study treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The safety population consisted of all par-
ticipants who took≥ 1 dose of study medi-
cation.The efficacy population included all
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randomly assigned participants who pro-
vided valid efficacy measurements for both
treatment periods
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias High risk Sponsored by Novartis Pharmaceuticals
Corporation
Conflicts of interest: First study author has
been a speaker, consultant and advisory
board member for Novartis and Shire
Brams 2012
Methods Randomised, double-blind, 3-period × 3-treatment cross-over study in a 12-hour labo-
ratory classroom setting with 3 interventions
1. 20 mg extended-release dexmethylphenidate
2. 30 mg extended-release dexmethylphenidate
3. Placebo
Each period lasted 7 days
Participants Number of participants screened: not stated
Number of participants included: 165. Participants were randomly assigned to 1 of 6
possible drug condition orders
Number of participants followed up: 157
Number of withdrawals: 8
Diagnosis of ADHD:DSM-IV (combined or predominantly hyperactive-impulsive sub-
type)
Age: mean 9.6 years (range 9.3 to 10.0)
IQ: above normal
Sex: 57% boys, 43% girls
Methylphenidate naive: 0%
Ethnicity: Caucasian (38.2%), African American (31.5%), Hispanic (22.4%), other (7.
9%)
Country: USA
Setting: out-patient clinic (laboratory classroom)
Comorbidity: no significant medical illness
Comedication: no information
Sociodemographics: no information
Inclusion criteria
1. Males and females 6 to 12 years of age
2. Meeting DSM-IV criteria for primary diagnosis of ADHD combined subtype or
predominantly hyperactive-impulsive subtype
3. Female of childbearing potential required to have a negative urine pregnancy test
before enrolment and, if sexually active, to use adequate and reliable contraception
4. Stabilised on a total daily dose or nearest equivalent dose of 40 mg to 60 mg of
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methylphenidate or 20 mg to 30 mg dexmethylphenidate (36 mg and 54 mg of
extended-release methylphenidate and 10 mg to 20 mg of transdermal
methylphenidate were allowed) for ≥ 2 weeks before screening
Exclusion criteria
1. Children or their parents/guardians were unable to understand or follow
instructions necessary to responsibly participate in the study
2. Children were deemed by the investigator to have below average cognitive ability
3. Home-schooled
4. Previously diagnosed with Gilles de la Tourette’s disorder or similar tic disorder
(medication-induced tics were not excluded)
5. History of a seizure disorder
6. History of or concurrent long QT syndrome or QTc > 450 milliseconds at
screening, or any clinically significant ECG abnormality
7. Significant medical or psychiatric illness or substance abuse disorder
8. Children were taking an antidepressant or other antipsychotic medications
9. Children initiated psychotherapy within the 3 months before screening
10. Positive urine drug screen
11. Children with a poor prior response, or known sensitivity, to all methylphenidate
or D-MPH products, based on medical history
12. Children currently taking non-methylphenidate-based medications for ADHD
13. Those taking or planning to take any other investigational drug within 30 days of
study start
14. Children who had previously participated in an analogue classroom study within
6 months before screening
15. Alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase
or serum creatinine > 2× the upper limit of normal at screening
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of 20 mg
extended-release dexmethylphenidate, 30 mg extended-release dexmethylphenidate and
placebo
Administration schedule: once daily, morning
Duration of each medication condition: 7 days
Washout before study initiation: 1 week
Medication-free period between interventions: no
Titration period: none (fixed doses)
Treatment compliance: no information
Outcomes ADHD symptoms
1. Swanson, Kotkit, Agler, M-Flynn and Pelham Scale (-combined, -attention and -
deportment): performed by independent blinded raters throughout the 12-hour testing
period
Serious adverse events
1. Spontaneously reported serious adverse events were recorded weekly
One participant experienced 2 serious adverse events (peritonsillar abscess and oral bul-
lae) while receiving 20 mg extended-release dexmethylphenidate and was hospitalised
for 6 days for the peritonsillar abscess. Serious adverse events were considered not related
to study drug. Participant discontinued the study for missed study drug during hospi-
talisation
Non-serious adverse events
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1. Vital signs were assessed, and spontaneously reported adverse effects were
recorded weekly
2. Heart rate and blood pressure were measured after weeks 1 and 2
3. Weight was measured and ECG tests were conducted at screening and at the final
visit
Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; children with a
poor prior response, or known sensitivity, to all methylphenidate or dexmethylphenidate
products based on medical history were excluded
Comments from study authors (limitations)
1. Limited exposure to both doses of extended-release dexmethylphenidate for each
participant to 1 week
2. Potential for carry-over effects between study periods due to cross-over design
3. Children with the inattentive subtype of ADHD were excluded from this analysis
4. Efficacy data presented as change from pre-dose scores, rather than as effect sizes
or response rates
5. Pharmacokinetic and pharmacodynamic data were not collected and analysed
6. Results reported for school-aged children may not be relevant to other ADHD
patient populations
7. Higher percentage of females recruited
Key conclusions of study authors
1. Significantly greater improvement in ADHD symptoms was noted with 30 mg
extended-release dexmethylphenidate compared with 20 mg extended-release
dexmethylphenidate at hours 10 through 12
2. Tolerability was comparable between doses. 30-mg dose of extended-release
dexmethylphenidate may provide further benefit to patients who do not maintain
optimal symptom control later in the day with 20-mg extended-release
dexmethylphenidate
3. ADHD symptoms significantly improved with 30 mg extended-release
dexmethylphenidate compared with 20 mg extended-release dexmethylphenidate at
hours 10 to 12 in all ethnic parameters, with a statistically significant difference in the
Caucasian subgroup
4. 30 mg extended-release dexmethylphenidate may provide further benefit to
patients of all ethnic backgrounds who do not obtain optimal late-day symptom
control with 20 mg extended-release dexmethylphenidate
Email correspondence with study authors: September 2013. Not possible to contact
study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to 1
of 6 treatment sequences. All participants
were given the lowest available number
from the randomisation numbers provided
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at each site. A randomisation list was pro-
duced by using a validated system that au-
tomated the random assignment of treat-
ment sequences to randomisation numbers
in the specified ratio
Allocation concealment (selection bias) Low risk Randomisation data were kept strictly con-
fidential until the time of unblinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study medications and packaging were
identical in appearance for blinding pur-
poses. Participants, parents, study centre
personnel and thosewho assessed outcomes
were blinded to study treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study medications and packaging were
identical in appearance for blinding pur-
poses. Participants, parents, study centre
personnel and thosewho assessed outcomes
were blinded to study treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eight drop-outs from the methylphenidate
group. The ITT population included all
randomly assigned participants who took
≥ 1 dose of study medication and had ≥
1 post-dose efficacy measurement. The sa-
fety population consisted of all participants
who took ≥ 1 dose of study medication
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias High risk Funding by Novartis Pharmaceuticals Cor-
poration with the following involvement
reported: design and conduct of the study;
collection, management, analysis and in-
terpretation of data; and preparation, re-
view and approval of the manuscript. All
study authors are employees or consultants
or have received research grants from phar-
maceutical companies
Conflicts of interest: All study authors are
employees or consultants or have received
research grants from pharmaceutical com-
panies
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Methods Four-week cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 2 weeks of placebo and 2 weeks of methylphenidate treatment with sequence
according to randomisation
Participants Number of participants screened: not stated
Number of participants included: 11 (all boys). Participants were randomly assigned to
1 of 2 possible drug condition orders
Number of participants followed up: 11
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III
Age: mean 10 years, 5 months (range 9 years 1 month to 12 years 1 month)
IQ: > 80
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. DSM-III diagnosis of ADD
Exclusion criteria
1. Known neurological or sensory impairment
2. IQ > 80
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.3 mg/
kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: b.i.d.
Duration of each medication condition: 2 weeks
Washout before study initiation: not stated
Medication-free period between interventions: time of day the pills were taken not stated
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale: rated at the end of each school week
2. Conners’ Teacher Rating Scale: rated at the end of each school week
Non-serious adverse events
1. Cardiovascular measures: heart rate, systolic and diastolic blood pressure. Heart
rate was recorded after the child had rested for 5 minutes by placing a stethoscope over
the precordium and measuring the rate for 1 minute. Blood pressure was obtained with
a sphygmomanometer with the child seated after he had rested 5 minutes. Tested at the
end of each 2-week drug period
2. “No deleterious side effects”
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Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Of additional importance in the present study was the finding that
methylphenidate had no deleterious side effects and was well tolerated by all children
participating in the research project
2. Table 2 shows that individual variations in heart rate and blood pressure
associated with methylphenidate trials are quite large
Key conclusions of study authors
1. Results demonstrated significant improvement in sustained attention and impulse
control, as well as in ratings of social behaviour, by both teachers and parents
2. Cardiovascular functioning did not significantly increase as a function of
methylphenidate
Email correspondence with study authors: November 2013. We received additional
information regarding ethics approval, sample calculation, etc., from study authors.
However, it was not possible to receive all requested data, as the study author no longer
possessed raw data from the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The sequence of the 2 medication condi-
tions was randomly assigned, but no infor-
mation was provided on methods
Allocation concealment (selection bias) Low risk Triple blinding; dosage was administered
twice daily in the form of opaque capsules
packaged by hospital pharmacists to con-
ceal the contents
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Child and parent, teacher and the physi-
cian were blinded to the child’s medication
condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physician was blinded to the child’s medi-
cation concealment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data provided on all 11 participants
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No
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Vested interest bias Unclear risk Funded by National institute of Mental
Health and National institutes of Health.
Placebo and methylphenidate were sup-
plied by CIBA-GEIGY Corporation, Sum-
mit, New Jersey
Conflicts of interest: not stated
Brown 1985
Methods Twelve-week, randomised, parallel trial with 4 arms
1. Cognitive training
2. Methylphenidate combined with cognitive training
3. No treatment (not randomly assigned)
4. Cognitive training programme: individual, twice-weekly, 1-hour sessions for a
total of 24 sessions spanning a 3-month period
Participants Number of participants included: methylphenidate + cognitive training 10, cognitive
training 10
Number of participants followed up: methylphenidate + cognitive training 10, cognitive
training 10
Number of withdrawals: methylphenidate + cognitive training 0, cognitive training 0
Diagnosis of ADHD: DSM-III (types not stated)
Age: mean 11.36 years (range 6.4 to 11.9)
IQ: 101.92 (range 91 to 136)
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: not stated
Comorbidity: not stated
Comedication: no. No child was receiving any psychopharmacological treatment
Sociodemographics: not stated. No significant differences in baseline demographics be-
tween the 2 groups
Inclusion criteria
1. Demonstrating ADHD symptoms in serious and persistent form, agreed by
parents and teachers
2. Symptoms present for ≥ 12 months (parents to verify)
3. Meeting criteria for ADD including hyperactivity
4. According to DSM-III
5. Reading deficit of ≥ 2 grade levels
Exclusion criteria
1. Symptoms seem to stem from stress at home or from inconsistent child
management
2. No major diseases or obvious physical defects (gross neurological, sensory, motor
impairment or psychosis)
Interventions Participants were randomly assigned to methylphenidate + cognitive training or to cog-
nitive training only
Mean methylphenidate dosage: 0.3 mg/kg (range 5 mg/d to 15 mg/d)
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Administration schedule: twice daily (morning and lunch)
Duration of intervention: 12 weeks + 3 months (only with medication)
Titration period: none
Treatment compliance: not stated
Cognitive training programme: individual, twice-weekly, 1-hour sessions for a total of
24 sessions spanning a 3-month period
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale and Conners’ Abbreviated Teacher Rating Scale:
baseline, 12 weeks, 3 months
2. Teacher Rating of Attention: baseline, 12 weeks, 3 months
3. Teacher Rating of Impulsivity: baseline, 12 weeks, 3 months
Notes Sample calculation: no
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Children in the 2 medication treatment conditions demonstrated improvement in
attentional deployment and in behavioural ratings
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label methylphenidate
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants followed up
Selective reporting (reporting bias) Low risk No protocol/design published. All pre-
specified outcomes of interest have been re-
ported
Vested interest bias Low risk Funding: research supported by US Public
Health Services Grant from the National
Institute of Mental Health (NIMH), and
by the Biomedical Research Award from
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the National Institutes of Health (NIH)
. Methylphenidate provided by CIBA-
GEIGY Corporation, Summit, New Jersey
Conflicts of interest: not stated
Brown 1988
Methods Eight-week, double-blind, randomised, cross-over trial with 4 interventions
1. Placebo
2. 0.15 mg/kg methylphenidate
3. 0.30 mg/kg methylphenidate
4. 0.5 mg/kg methylphenidate
Participants Number of participants screened: not stated
Number of participants included: 11 (all boys). Participants were randomly assigned to
possible drug condition orders
Number of participants followed up: 11
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 13 years, 7 months (range 12 years and 10months to 14 years and 10months)
IQ: full-scale mean 92.91 (range 86 to 104)
Methylphenidate naive: not stated, but none of the participants had been treated with
stimulants during the year preceding the study
Ethnicity: African American (100%)
Country: USA
Setting: out-patient clinic
Comorbidity: conduct disorder, socialised aggressive (45%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. Sexual rating of ≥ 3 according to Tanner’s classification of stages of development,
to ensure post-pubertal status
2. ADD according to DSM-III
3. Score of ≥ 15 on the Abbreviated Conners’ Teacher Rating Scale
Exclusion criterion
1. Mental retardation or gross neurological disorders
Interventions Interventions (mean dosage)
1. Placebo
2. Methylphenidate low (0.15 mg/kg)
3. Methylphenidate medium (0.30 mg/kg)
4. Methylphenidate high (0.5 mg/kg)
Mean methylphenidate dosage: methylphenidate low (4.38 mg), medium (12.55 mg),
high (21.28 mg)
Administration schedule: twice daily; morning and noon
Duration of each medication condition: 2 weeks
Washout before study initiation: none (but no stimulant treatment for the past year)
Titration period: none
Treatment compliance: Compliance was determined to be satisfactory
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Outcomes ADHD symptoms
At the end of each 2-week trial, parents and teachers completed the following rating
scales
1. Conners’ Parent Rating Scale - Revised
2. Abbreviated Conners’ Parent Hyperactivity Index
3. Abbreviated Conners’ Teacher Hyperactivity Index
4. ADD/H Comprehensive Teacher Rating Scale
Non-serious adverse events
1. Side Effects Rating Scale (includes questions about sleep disturbances, dysphoria,
decreased appetite, physiological complaints such as headaches and generalised anxiety)
, parent-rated (assessing the preceding week)
2. Cardiovascular measures (heart rate, resting systolic and diastolic measures for
blood pressure) assessed ≥ 1 hour after administration of methylphenidate or placebo.
Apical pulse rates taken for 1 full minute
3. Weight (during every clinic visit)
Notes Sample calculation: no
Ethics approval: yes; Institutional Review Board (IRB) at Emory University
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Significant drug effects were found for most measures. In general, higher doses
resulted in the most beneficial response in behavioural, academic and laboratory
measures of attention and impulsivity. However, a significant linear increase occurred
in diastolic blood pressure. Results suggest that methylphenidate is an effective adjunct
to the treatment of ADD in adolescents
Comment from study authors
1. We do not know whether our findings can be generalised in non-black
populations
Email correspondence with study authors: October 2013. We received from study au-
thors additional information about ethics approval, planned outcomes and participants
followed up. Unfortunately, it was not possible for study authors to provide other data
that we needed because the study was conducted many years ago, and study authors no
longer had the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Drug order was randomly assigned across
participants; no further description
Allocation concealment (selection bias) Low risk All medication was prepared in identical
capsules by hospital pharmacists. Medica-
tion was dispensed in dated envelopes
Blinding of participants and personnel
(performance bias)
Low risk All medication was prepared in identical
capsules by hospital pharmacists. Medi-
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All outcomes cation was dispensed in dated envelopes.
Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Researchers administered all measures that
were proposed and reported these data in
the published report
Vested interest bias Low risk Biomedical Research Support Grant Pro-
gram, Division of Research Resources, Na-
tional Institutes of Health and Emory Uni-
versity Research
Conflicts of interest: none reported
Brown 1991
Methods Double-blind, randomised, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: methylphenidate 10 mg, methylphenidate 15 mg, methylphenidate 20 mg,
placebo
Participants Study consisted of 22 participants, but only 7 had ADD. As outcomes were reported
separately for these 7 participants, we were able to include the study
Number of participants screened: 25
Number of participants included: 22 (all boys). Participants were randomly assigned to
1 of 4 possible drug condition orders (in counterbalanced order)
Number of participants followed up: 22
Number of withdrawals: 0
Diagnosis: DSM-III (conduct disorder, with 7 of 22 also diagnosed with ADD)
Age: mean:15.8 years (range 12.9 to18.9)
IQ: 96.22 (SD 15.12, range 80 to 123)
Methylphenidate naive: not stated
Ethnicity: Caucasian (100%)
Country: USA
Setting: hospital/out-patient clinic
Comorbidity: conduct disorder (100%)
Comedication: no
Sociodemographics: middle and upper-middle class
Inclusion criterion
1. Hospitalised adolescents diagnosed with conduct disorder
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Exclusion criterion
1. Mental retardation, psychosis and organic brain disorder
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of
methylphenidate (10 mg, 15 mg, 20 mg) and placebo
Mean methylphenidate dosage: 0.15 mg/kg, 0.22 mg/kg and 0.31 mg/kg
Administration schedule: twice daily, 8:00 AM and 12:00 PM
Duration of each medication condition: 4 days
Washout before study initiation: not stated
Titration period: 1 day before first phase
Treatment compliance: 100%
Outcomes General behaviour
1. Conners’ Teacher Rating Scale (conduct factor): teacher-rated daily
Non-serious adverse events
1. Side Effects Rating Scale (including 17 known adverse events for
methylphenidate): observer-rated daily
2. Cadiovascular measures were recorded 90 minutes after 12:00 PM administration
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; initially partic-
ipants received a 1-day open trial of methylphenidate. Three participants were excluded
because of intolerability
Comments from study authors
1. ... in our study, mean milligram per kilogram doses were lower than in previously
published reports … doses may simply have been too small to induce any real change
in behaviour
2. Another limitation that may have influenced the results is timing of the
measurements of behaviour. As behavioural ratings were made by teachers at the end of
the day, it is possible that medication effects (particularly for lower doses) had
dissipated by the time the ratings were made
Key conclusions of study authors
1. In summary, results are of theoretical importance and with additional research
may suggest the potential efficacy of stimulants for treating adolescents with conduct
disorders in the absence of ADD
2. The present data may be interpreted to suggest that ADD may be managed with
stimulant medication when it presents comorbidly with conduct disorder
Comment from review authors
1. Data on the conduct disorder + ADD group were reported separately in the study
- that is why we could use the data
Email correspondence with study authors: unable to locate contact details for study
authors
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk All participants received each of the 4 doses
in 1 of 24 possible randomly assigned se-
quences
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Methylphenidate and placebo were pack-
aged in coloured gelatin capsules by the
hospital pharmacist to avoid detection of
dose, visually or by taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Under double-blinded conditions
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants followed up
Selective reporting (reporting bias) Unclear risk No protocol published. Not all pre-spec-
ified outcomes of interest have been re-
ported (e.g. scores on Conners’ Teacher
Rating Scale)
Vested interest bias Unclear risk Conflicts of interest: not stated
Buitelaar 1995
Methods Randomised, cross-over trial with 3 interventions
1. Pindolol
2. Methylphenidate
3. Placebo
Phases
1. Phase 1: 4-week treatment block
2. Phase 2: 2-week drug-free interval
3. Phase 3: 4-week treatment block
First 32 participants were randomly assigned to interventions 1 to 3 in the first treatment
block, and to intervention 1 or 2 in the second treatment block.Next 20 participants were
randomly assigned to intervention 2 or 3 in the first treatment block, and to intervention
2 or 3 in the second treatment block
Participants Number of participants screened: not stated
Number of participants included: 52 (46boys, 6 girls); however, because of an incomplete
block design, only 46 were treated with methylphenidate and 31 were treated with
placebo in first or second treatment block
Number of participants followed up: 52
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 9.3 years (range 6 to 13)
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IQ: mean 94.2
Methylphenidate naive: 100%
Ethnicity: not stated
Country: the Netherlands
Setting: out-patient clinic
Comorbidity: conduct disorder (38%); depressive disorder, dysthymia or major depres-
sive disorder (15%); anxiety disorder, overanxious disorder or avoidant disorder (42%);
psychomotor epilepsy (2%)
Comedication: antiepileptic medication (carbamazepine) at a fixed dosage (2%)
Sociodemographics: 20% were from families of high socioeconomic status, 50% of
middle socioeconomic status and 30% of low socioeconomic status (on theHollingshead
Index). No significant difference in baseline characteristics were noted between groups
of children treated with methylphenidate, pindolol or placebo
Inclusion criteria
1. ADHD according to DSM-III-R criteria
2. Scores in the clinical range on both the Child Behavior Checklist and Conners’
Teacher Rating Scale, Hyperactivity factors
3. Deficits in attention performance on a reaction time task or a continuous
performance task in neuropsychological testing
4. No previous treatment with psychotropic medication
5. Clinical indication for drug treatment
Exclusion criteria
1. Diagnosis of tic disorder or pervasive developmental disorder
2. Family history of tic disorder
3. Contraindications to treatment with blockers such as cardiac disease, in particular,
conduction abnormalities and bradycardia, hypotension, obstructive pulmonary
disease and insulin-dependent diabetes
Interventions Participants were randomly assigned to possible drug condition orders of 40mg pindolol,
20 mg methylphenidate and placebo
Fixed dosage: 10 mg methylphenidate, twice daily (approximately 0.6 mg/kg/d)
Administration schedule: morning and noon
Duration of each medication condition: 4 weeks
Washout before study initiation: no (medication naive)
Medication-free period between interventions: 2 weeks
Titration period: yes. After randomisation, during the first 3 days of a treatment pe-
riod, participants received 1 morning dose (10 mg methylphenidate, 20 mg pindolol or
placebo). After completion of endpoint assessment, medication was tapered off (3 days
with 1 morning dose)
Treatment compliance: good to very good in 96% of children. Two children had poor
compliance under methylphenidate treatment as the result of side effects
Outcomes ADHD symptoms
1. 10-Item Abbreviated Conners’ Rating Scale: rated by parents, teachers and a
psychologist
2. 93-Item Conners’ Parents Rating Scale
3. 39-Item Conners’ Teachers Rating Scale
Parents and teachers completed ratings at baseline, at week 2 and at endpoint of each
treatment period. The psychologist completed ratings at baseline and at endpoint of each
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treatment period. Furthermore, ACRS was rated 30 minutes after drug administration
Non-serious adverse events
1. Adverse effects checklist (encompassing 20 possible side effects, modified from the
Stimulant Drug Side Effects Rating Scale, rated by parents after 2 and 4 weeks of
treatment
2. Treatment-emergent adverse effects were further assessed systematically at
endpoint by research psychiatrist
3. Pulse and blood pressures were recorded at each clinical visit
Notes Sample calculation: yes; for comparison of pindolol with methylphenidate (50 partici-
pants)
Ethics approval: yes; approved by the Committee for Research on Human Subjects of
Utrecht University Hospital
Comments from study authors
1. Interim analysis of side effects indicated that pindolol was associated with
significantly more intense adverse effects when compared with placebo and
methylphenidate. Consequently, pindolol was dropped from the study design, and the
next 20 participants were included in a randomised methylphenidate-placebo cross-
over design
2. Study was limited by use of fixed dosage, with exclusive focus on behavioural
symptoms - not on improvement in neuropsychological measures of information
processing, and with an incomplete and unbalanced block design
Key conclusions of study authors
1. Beta-blocker pindolol appeared to be modestly effective in the treatment of
behavioural symptoms of children with ADHD. Data suggest some utility for pindolol
in treating hyperactivity and conduct problems in children with ADHD, but safety
concerns about troubling side effects clearly limit use of pindolol in ADHD
2. Only strong levels of response could be predicted by baseline characteristics.
Severity of disorder based on clinical judgement and improvement after a single dose of
methylphenidate are found to be important contributors to response prediction
Comments from review authors
1. Study designed to compare usage of pindolol and methylphenidate
2. Few participants
3. Study design changed during the study because of adverse effects. Phase 2 changed
intervention from pindolol versus methylphenidate to methylphenidate versus placebo
4. Phase 1: Given the relatively small sample sizes, effects of single treatments (i.e.
methylphenidate vs placebo, and pindolol vs placebo) were not robust enough to reach
conventional levels of statistical significance
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: no; onlymedication-
naive participants
Any withdrawals due to adverse events: no; however, in 4 participants, dosages of
methylphenidate had to be adjusted in the first 2 weeks of the study because of in-
creased agitation, restlessness and insomnia. Two participants remained on 5 mg of
methylphenidate for 4 weeks, whereas dosage for the other 2 participants could be grad-
ually increased to 10 mg methylphenidate in the last 2 weeks
Email correspondence with study authors: January to March 2014. Requested but did
not receive from study authors supplemental efficacy and safety data and information
regarding randomisation, allocation concealment and blinding
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, not further described
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, not further described.
Methylphenidate and placebo were admin-
istered in identical-looking tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants from
the methylphenidate group had bad com-
pliance but were included in the analyses,
as an ITT analysis was planned
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no,
but design of study changed during the
course of the study because of adverse
events
Selective reporting (reporting bias) Unclear risk Protocol not identified
Vested interest bias Unclear risk Not stated
Conflicts of interest: no affiliations with
pharmaceutical companies stated
Bukstein 1998
Methods Cross-over trial with 3 interventions
1. Methylphenidate 0.3 mg MPH/kg
2. Methylphenidate 0.6 mg MPH/kg
3. Placebo
Phases: Study included 2 phases: a baseline phase and the medication trial itself. The
baseline phase occurred during the first 2 weeks (9 days) of the programme, when the
children were medication-free. Each medication condition was administered for 7 days
of the programme during the 21-day trial
Participants Number of participants screened: not stated
Number of participants included: 18. Participants were randomly assigned to 1 of 3
possible drug condition orders
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Number of participants followed up: 18 (14 boys, 4 girls)
Number of withdrawals: 0
DSM-III-R criteria for ADHD and oppositional defiant disorder or conduct disorder
Age: mean 9.4 years (range 6.1 to 12.2)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: Caucasian (17%), African American (83%)
Country: USA
Setting: out-patient clinic (summer school at clinic)
Comorbidity: oppositional defiant disorder (56%) and conduct disorder (44%)
Comedication: no
Sociodemographics: Participants were predominantly from lower socioeconomic classes,
with an average Hollingshead Index of Social Status of 3.83 (SD 1.65, range 1 to 5)
. Thirteen (72%) of the participants’ families were receiving public assistance. Only 4
of the children lived with both biological parents; 12 (67%) lived with their biological
mother only. Inner city environment characterised by higher than average rates of poverty
and community violence. No significant differences in baseline demographics between
groups
Inclusion criterion
1. DSM-III criteria for ADHD and oppositional defiant disorder or conduct
disorder, while attending the Summer Treatment and Enrichment Program (STEP)
Exclusion criterion
1. Not stated
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate (0.3 mg/kg or 0.6 mg/kg) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 8:30 AM, 11:45 AM and 3:00 PM
Duration of each medication condition: 7 days
Washout before study initiation: 9 days
Medication-free period between interventions: none
Titration period: none
Treatment compliance: poor compliance with the weekend medication condition; most
families missed ≥ 1 dose each weekend of the trial. Poor compliance with the 3-dose
regimen was so widespread that trialists omitted from the trial all data on weekend doses
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale: rated by staff daily
2. IOWA Conners’ Parent Rating Scale: rated by parents daily
3. Conners’ Teacher Rating Scale: rated daily
Non-serious adverse event
1. Side Effects Rating Scale: adaptation of the Barkley Side Effects Rating Scale,
rated daily by staff and also rated by parents
Notes Key conclusions of study authors
1. Staff ratings of behaviour of children in the programme and in an academic
classroom showed that children displayed significant improvement in ADHD
symptoms and aggressive behaviour with low- and high-dose methylphenidate
conditions
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2. At home, parents and guardians reported few significant differences in behaviour
ratings between placebo and methylphenidate
3. In both settings, methylphenidate was well tolerated, with few side effects found
during active drug conditions
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Schedule for each condition was randomly
assigned across the 5 weekdays to min-
imise programme effects; the only qualify-
ing condition was that approximately one-
half of the 7 days of each medication con-
dition would occur during each half of the
21-day trial
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Nurse and other Summer Treatment and
Enrichment Program (STEP) staff, chil-
dren and parents were blinded to dosages
and schedules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Each child’s daily data were collected and
entered by trained research associates, who
were unaware of medication status
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included in the analyses
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk None
Butter 1983
Methods One-week, double-blind, parallel trial with 3 arms
1. Adrenocorticotropic hormone
2. Methylphenidate (10 mg, 15 mg or 20 mg, weight adjusted)
3. Placebo
Participants Number of participants screened: not stated
Number of participants included: 30 (all boys)
Number of participants randomly assigned: methylphenidate 10, placebo 10
Number of participants followed up: methylphenidate 10, placebo 10
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Diagnosis of ADHD: DSM-III
Age: mean in years (range 6 to 12)
IQ: above 85
Methylphenidate naive: not stated
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated. No information about significant differences in baseline
demographics between groups
Inclusion criteria
1. Clinical ADHD diagnosis of attention deficit disorder with hyperkinesis (DSM-
III)
2. Hyperkinesis rating required a score of 15 or higher on Conners’ Short Form
Rating Scale, and hyperkinetic behaviour had to be apparent throughout most of the
day
3. Untreated behaviour had to be a cause of severe difficulty both at home and at
school
Exclusion criterion
1. Wechsler Intelligence Scale for Children (WISC) score < 85 or abnormal
perceptual functioning
Interventions Participants were randomly assigned to adrenocorticotropic hormone, methylphenidate
or placebo
Mean methylphenidate dosage: 0.5 mg/kg
Administration schedule: once daily, 7.30 AM
Duration of intervention: 1 week. One week drug-free followed by 1 week of placebo
treatment. After placebo washout, randomly assigned to adrenocorticotropic hormone,
methylphenidate or placebo
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Short Form Rating Scale: completed by parents and clinicians
2. Conners’ Rating Scale Teachers: rated during placebo and active drug phases
Non-serious adverse event
1. EEG, haematology, liver and kidney function test, blood pressure and pulse,
blood chemistry, urinalysis before and after treatment
EEG, haematology, blood chemistry and urinalysis were within normal limits before
treatment and remained so after treatment
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Children treated with methylphenidate show significantly greater vasomotor
reactivity, behavioural improvement and learning receptivity than children treated with
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adrenocorticotropic hormone and placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk After placebo washout, treatment was as-
signed in a double-blind and randomman-
ner
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Neurologist assessing EEG blinded. Dou-
ble-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Low risk Funded by the Scientific Development
Group, Organon International B.V., Oss,
the Netherlands
Conflicts of interest: none
Carlson 1995
Methods Double-blind, placebo-controlled, repeat-measures (across drug and dosage), cross-over
trial with 6 interventions
1. Methylphenidate at 10 mg twice daily
2. Methylphenidate at 15 mg twice daily
3. Methylphenidate at 20 mg twice daily
4. Desipramine alone
5. Desipramine + methylphenidate
6. Placebo
Phases: Each child received placebo, desipramine, each of the 3 doses of methylphenidate
(10 mg, 15 mg, 20 mg) and combined desipramine and methylphenidate (at the same
3 doses)
Participants Number of participants screened: not stated
Number of participants included: 16 (all boys). Participants were randomly assigned to
different drug condition orders and placebo
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Number of participants followed up: 16
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (62.5%), inattentive (12.5%), “in partial
remission” (25%))
Age: mean: not reported (range 7.9 to 12.10 years)
IQ: mean not stated (range overall 81 to 121; range verbal 74 to 113, range performance
73 to 126)
Methylphenidate naive: 4 (25%)
Ethnicity: Caucasian (87.5%), African American (12.5%)
Country: USA
Setting: in-patient ward
Comorbidity: yes; major depressive disorder (68.75%), dysthymic disorder (31.25%).
“All had ODD, CD or both”
Comedication: yes
Sociodemographics: not stated
Inclusion criteria
1. Initial team diagnosis of ADHD, non-bipolar major depressive disorder,
dysthymic disorder or a combination thereof
2. ≥ 7 years old
3. Wechsler Intelligence Scale for Children, Revised, full-scale IQ > 80
Exclusion criteria
1. Medical contraindication to medications being investigated
2. Family history of bipolar disorder in first- or second-degree relatives
3. Abnormal baseline laboratory values or ECG
Interventions Participants were randomly assigned to different possible drug condition orders of
methylphenidate (10 mg, 15 mg and 20 mg), twice daily at 7:30 AM and 11:30 AM ×
6 days, then 1-day washout; the titrated therapeutic level (125 ng/mL to 225 ng/mL)
of desipramine twice daily at 3:30 PM and 7: 30 PM × 3 weeks minimum before final
measures taken; and placebo
Mean methylphenidate dosage: not stated
Duration of each medication condition: 1 week
Washout before study initiation: 14 days
Medication-free period between intervention: 1 day
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADD/H Comprehensive Teacher Rating Scale (ACTerRS): teacher-rated
General behaviour
1. Humphrey’s Teacher Self-Control Rating Scale
2. Inpatient Global Rating Scale
Non-serious adverse events
1. Subjective Treatment Emergent Symptom Scale: side effect ratings, collected
weekly by nurse
2. Somatic factor of the Inpatient Global Rating Scale: collected weekly by nurse
3. Childrens’ Depression Rating Scale - Revised: Appetite and Sleep disturbance
items collected weekly by research psychologist
4. Cardiovascular side effects (daily morning blood pressure and pulse rates + weekly
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ECG)
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusion of study authors
1. “With regard to differential efficacy, the major findings of this study were that a
combination of MMI and MPH (at 20 mg) was somewhat more effective than DMI or
MPH alone for improving hyperactive, inattentive and oppositional defiant, and
’aggressive’ behaviours across both school and unit settings. Efficacy was also
demonstrated for MPH and DMI alone in school, but less so on the unit”
Comment from review authors
1. Small sample of 16 participants entering the trial seems heterogeneous and
opportunistic rather than clearly defined, with a mixture of diagnoses including mood,
ADHD and oppositional defiant disorder/conduct disorder. This makes it difficult to
believe that the results are reliable
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: maybe; hence ex-
clusion criterion number 1: medical contraindication to medications being investigated
Email correspondence with study authors. Emailed first study author to ask for outcome
data in mean and SD format. Study authors replied in July 2014 to say that they were
unable to help us
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not stated
Allocation concealment (selection bias) High risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medications were packaged in identical
grey capsules (size 00) that were adminis-
tered 4 times per day
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk For this protocol, all raters (including
teachers, nurses, psychologist and physi-
cians, except for the attending child psy-
chiatrist, who controlled the desipramine
dosage but did not rate the children), chil-
dren and parents were blinded to all medi-
cation conditions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Unclear risk Not stated
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Methods Six-week, multi-centre, double-blind, parallel, randomised controlled trial (RCT) with
2 arms
1. Atomoxetine + methylphenidate
2. Atomoxetine + placebo
RCT was preceded by a 4-week, open-label, atomoxetine and placebo phase, during
which participants who had adequate response were removed
Participants Number of participants screened: not stated
Number of participants included: phase 1 (4-week open-label atomoxetine and placebo
phase) 25 (1 boy, 20 girls); phase 2 (6-week, double-blind RCT) 17
Number of participants randomly assigned: methylphenidate 9, placebo 8
Number of participants followed up: methylphenidate 8, placebo 7
Number of withdrawals: methylphenidate 1, placebo 1
Diagnosis of ADHD: DSM-IV (combined (79% in phase 1))
Age: phase 1 mean 9.6 years (range 6 to 12)
IQ: > 70
Stimulant-naive: 4%
Ethnicity: Caucasian (83%), other (17%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (50% in phase 1)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria, including assessment details
1. 6 to 12 years of age
2. DSM-IV diagnosis of ADHD, any type
3. Rating on ADHD Rating Scale, Fourth Edition, Parent Version - Investigator
Administered and Scored Version of ≥ 1.5 SD above age and sex norms
4. Severity rating of at least moderate on the Clinical Global Impressions Severity
Scale
5. History (preceding 12 months) of insufficient response to an adequate stimulant
trial, which was defined as gradual titration of stimulant medication for ≥ 2 weeks at
specified doses for each medication. Inadequate response was determined by the child’s
prescribing physician, who also documented his or her opinion that a change in
treatment was needed
6. Patients must be of normal intelligence, as assessed by the investigator (i.e.
without a general impairment of intelligence, and likely, in the investigator’s
judgement, to achieve a score ≥ 70 on an IQ test) (Administration of a formal IQ test
is not an entry requirement for this study. Specific learning disabilities are not
considered general impairments of intelligence)
7. Patients must be able to swallow capsules
Exclusion criteria
1. Weighed < 22 kg or > 60 kg at study entry
2. Had any other Axis I diagnosis, including pervasive developmental disorder,
mood or anxiety disorder (Presence of comorbid oppositional defiant disorder was not
an exclusion criterion)
3. Bipolar disorder, autism
4. Any medical conditions that would contraindicate the use of atomoxetine or
extended-release methylphenidate
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5. History of any seizure disorder and/or Rolandic seizures (other than febrile
seizures) or prior ECG abnormalities in the absence of seizures, or history of taking (or
are currently taking) anticonvulsants for seizure control
6. History of severe allergies to > 1 class of medication or multiple adverse drug
reactions, including hypersensitivity to methylphenidate
7. History of intolerance or non-response to atomoxetine
8. Used any concomitant psychotropic or excluded medications
9. Ingestion of any excluded medications 5 days before baseline ratings and
randomisation
Interventions Participants were randomly assigned to extended-release OROS methylphenidate or
placebo
Cointervention: atomoxetine
Methylphenidate mean dosage: 1.02 mg/kg
Administration schedule: once daily
Duration of intervention: 6 weeks
Titration period for methylphenidate: after randomisation to target dose of 1.08 mg/kg/
d (max 1.2 mg/kg/d)
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition, Parent Version - Investigator Administered
and scores: parent-rated
2. Conners’ Parent Rating Scale Revised, Short Form: parent-rated at baseline and at
weeks 4, 5, 6 and 10
General behaviour
1. Weekly Parent Ratings of Evening and Morning Behaviour: parent-rated at
baseline and at weeks 4, 5, 6 and 10
Non-serious adverse events
1. Vital signs, at each visit
2. Weight, at each visit
3. Spontaneous adverse event reports, at each visit
Notes Sample calculation: Included sample (25 participants) is too small in relation to the
sample calculation (85 participants)
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no, but exclusion of
atomoxetine/placebo responders before study phase 2
Comment from study authors
1. The present findings can be applied only to children with an inadequate stimulant
response. Given the small study sample, particularly in the combination treatment
groups, the findings must be considered preliminary
Key conclusion of study authors
1. Methylphenidate appears to be safely combined with atomoxetine, but
conclusions are limited by small sample
Comment from review authors
1. For the review, we used data from study phase 2, that is, the RCT with 2 arms
(intervention: methylphenidate + atomoxetine; control: placebo + atomoxetine)
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Email correspondence with study authors. June to November 2013. We received from
study authors and sponsoring pharmaceutical company, supplemental information re-
garding IQ and blinding procedures, as well as data on weight, treatment-emergent ad-
verse events and ECG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned via an interactive voice
response system to receive extended-release
methylphenidate or placebo
Allocation concealment (selection bias) Low risk Investigators and participants were blinded
to the precise visit at which randomisation
to blinded placebo or Concerta occurred,
as this visit is not identified in the inves-
tigator’s copy of the protocol, and as use
of blinded study drug begins at visit 2 and
continues up to visit 8
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy outcomemeasures were conducted
on the ITT sample by using an LOCF
method
Selection bias: no
Selective reporting (reporting bias) Low risk Protocol identified
Vested interest bias High risk Funding: Research was funded by Eli Lilly
and Company, Indianapolis, Indiana
Conflicts of interest: Dr. Carlson has re-
ceived research support or has consulted
with the following companies: Abbott Lab-
oratories, Cephalon, Eli Lilly and Com-
pany, Janssen, McNeil, Otsuka and Shire
Pharmaceuticals. Dr.Dunnhas received re-
search support or has served on Speakers’
Bureaus of the following companies: As-
traZeneca, Eli Lilly and Company, NIH,
Otsuka and Pfizer Pharmaceuticals. Drs.
Kelsey, Ruff, Ball and Allen and Ms.
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Ahrbecker are employees and/or sharehold-
ers of Eli Lilly and Company
Castellanos 1997
Methods Nine-week, double-blind, cross-over trial with 3 interventions for 3 weeks each
1. Methylphenidate
2. Dextroamphetamine
3. Placebo
Study was followed up by an open clinical follow-up of 22 months
Participants Number of participants screened: 64
Number of participants included: 22 (all boys). Participants were randomly assigned to
different possible drug condition orders
Number of participants followed up: 20
Number of withdrawals: 2
Diagnosis of ADHD: DSM-III-R
Age: mean 9.4 years (range 6 to 13)
IQ: mean 98.8
Methylphenidate naive: 0
Ethnicity: Caucasian (80%), African American (10%), Asian (5%), Hispanic (5%)
Country: USA
Setting: out-patient clinic
Comorbidity: Tourette’s disorder (95%), chronic motor tics (5%), conduct disorder
(5%), oppositional defiant disorder (30%), reading disorder (5%), overanxious disorder
(5%), obsessive-compulsive disorder (10%), enuresis (20%)
Comedication: 4 received haloperidol
Sociodemographics: no information
Inclusion criteria
1. DSM-III criteria for Tourette’s disorder, with tics confirmed by a knowledgeable
clinician ≥ 1 year before referral
2. Symptoms of ADHD present in ≥ 2 settings
3. Conners’ hyperactivity factor scores from home teacher ≥ 2 SD > age norms
Exclusion criteria
1. Full-scale IQ < 75 (Wechsler Intelligence Scale for Children - Revised)
2. Evidence of medical or neurological disease
3. Any other Axis I psychiatric disorder except obsessive-compulsive disorder,
conduct or oppositional disorder, overanxious disorder and specific developmental
disorders
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of
methylphenidate and placebo. Methylphenidate was increased weekly. For body weight
> 30 kg, weekly methylphenidate doses were 15 mg/dose, 25 mg/dose and 45 mg/dose
b.i.d. (for weight ≤30 kg, 12.5: 25 mg/dose and 45 mg/dose, b.i.d.)
Mean methylphenidate dosage: main cohort 1.20 mg/kg, second cohort 0.69 mg/kg,
third cohort 1.22 mg/kg
Administration schedule: twice a day: breakfast and lunch
Durationof eachmedication condition: 3weeks. First cohort underwentweekly increases
in stimulant doses described as low,medium and high. Second cohort underwent increase
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described as low, medium and medium, and the third cohort as low, high and high
Washout before study initiation: minimum 4 weeks
Medication-free period between interventions: 20 hours
Titration period: during the first 3 weeks of intervention
Treatment compliance: no information
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale: completed by day programme teachers, weekly
ratings
Non-serious adverse events
1. Adverse effects
2. Tic severity: Unified Rating Scale (Tourette Syndrome Association): variety,
frequency, intensity, complexity and interference of motor and vocal tics based on
observations by programme staff and derived by consensus at weekly meetings
Notes Sample calculation: no
Ethics approval: approved by the National Institute of Mental Health (NIMH) Institu-
tional Review Board
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Limitations
i) Small sample size
ii) Drug dosage was not randomly assigned
iii) Allowed 4 participants to continue on a constant dose of haloperidol
iv) Exploration of different dose schedules
v) As methylphenidate undergoes much more rapid and complete metabolism
than dextroamphetamine, we would expect blood level curves of the 2 stimulants to
differ markedly
Key conclusion of study authors
1. Substantial minority of comorbid participants had consistent worsening of tics
while taking stimulants, although most experienced improvement in ADHD
symptoms with acceptable effects on tics
Comment from review authors
1. Study consists of a main study of 12 boys followed by 2 smaller cohorts of,
respectively, 6 and 4 boys
Email correspondence with study authors: January 2014. Corresponding author was not
able to supply us with further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned
Allocation concealment (selection bias) Unclear risk No information
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsule formulation prepared by a phar-
macy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Two drop-outs; their data are not included
in subsequent analyses. One of these was
dropped from the study because of acute
exacerbation of tics, and 1 because of ex-
cessively disruptive behaviour
Selective reporting (reporting bias) High risk Yes; they seem to have reported only hyper-
activity scores from Conners’ Teacher Rat-
ing Scale
Vested interest bias Low risk None declared
Conflicts of interest: not stated
Chacko 2005
Methods Six-week within-participant, randomised, placebo-controlled, double-blind, daily cross-
over trial with 3 interventions
1. Methylphenidate at 0.3 mg/kg given at 7:45 AM and 11:45 AM
2. Methylphenidate at 0.6 mg/kg given at 7:45 AM and 11:45 AM
3. Placebo given at 7:45 AM and 11:45 AM
Phases: daily cross-over between medication conditions. Two weeks of baseline and
adjustment period before 6-week medication trial. Data from this paper pertain to 5-
and 6-year-old children attending a summer treatment programme between 1987 and
1997
Participants Number of participants screened: not stated
Number of participants included: 36 (32 boys, 4 girls). Participants were randomly
assigned to 1 of 3 possible groups
Number of participants followed up: 36
Number of withdrawals: 0
Diagnosis of ADHD:DSM-III-R (n=35, subtype not stated);DSM-IV (n= 1, combined
type)
Age: mean 6.13 years (range 5 to 6)
IQ: mean 102 (SD 15.50)
Methylphenidate naive: not reported
Ethnicity: Caucasian (86%), other (14%)
Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: oppositional defiant disorder (50%), conduct disorder (27.7%)
Comedication: not stated
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Sociodemographics: not stated
Inclusion criteria
1. Diagnosis of ADHD according to DSM
2. Between 5 and 6 years of age
3. Parental consent
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned, daily, to 1 of 3 possible interventions: 0.3 mg/kg
methylphenidate, 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: b.i.d. 7:45AMand11:45AMfromMonday throughThursday
Duration of each medication condition: daily shifted
Washout before study initiation: not stated
Medication-free period between interventions: maximum 18-hour gap between doses
(11:45 AM to 7:45 AM the following day) and no medication Thursday to Sunday
Titration period: Before the 6-week trial began, participants underwent a 2-week baseline
and adjustment period
Treatment compliance: not stated
Outcomes Serious adverse events
1. None reported
Non-serious adverse events
1. “Classroom teachers, counselors, and parents completed daily ratings of the
presence and severity of common stimulant side effects”
Side effects are reported as occurring: “none” (i.e. symptom was assessed and was found
absent), “mild” (i.e. symptom was present but was not sufficient to cause concern among
child, peers or adults), “moderate” (i.e. symptom caused impairment of functioning or
social embarrassment to the degree that benefits of medication must be considerable
to justify risks of continuing medication) or “severe” (i.e. symptom caused significant
impairment of functioning or social embarrassment to the degree that the child should
not continue to receive medication). Rating of “moderate” or “severe” signifies clinically
significant side effects. Side effects are based on staff/parent subjective report on severity
of the side effect. Children were considered to have significant side effects in a particular
area if clinically significant side effects were reported within that area for ≥ 50% of
observations in a given condition
Notes Sample calculation: no information
Ethics approval: no information
Comments from study authors
1. Study limitations. Most participants were white males, limiting the
generalisability of findings to females and ethnic minorities
2. Furthermore, the sample size did not allow statistical analyses of ADHD subtype
or comorbidity
Key conclusion of study authors
1. Stimulant medication is an effective treatment for young children diagnosed with
ADHD; however, multiple domains of functioning must be assessed for the most
effective dose for young children with ADHD to be determined
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
141Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chacko 2005 (Continued)
adverse events while taking methylphenidate before randomisation: unclear; 2 weeks of
adjustment period before the medication condition - no information on how many were
screened and how many participated during baseline weeks
Comments from review authors
1. Participants in this study were attending a summer treatment programme
between 1987 and 1997
2. Other articles from summer treatment programme
i) Pelham and Hoza, 1987
ii) Pelham and Smith, 2000
iii) Pelham and Hoza, 1996
iv) Pelham et al., 1990
v) Pelham et al., 1993, 1999, 2002
Email correspondence with study authors: December 2013. We emailed study authors
to request additional information about study sample and side effects. Study authors
replied to say that the data are no longer available. Data from this study could not be
used in meta-analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Active medication and placebo were dis-
guised in opaque capsules and were dis-
pensed in daily pill reminders. Each condi-
tion occurred one or two times per week,
with the order of the conditions random-
ized on a daily basis. Data were aver-
aged across days within conditions for each
child”
Allocation concealment (selection bias) Unclear risk “Each condition occurred one or two times
per week, with the order of the conditions
randomized on a daily basis”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Active medication and placebo were dis-
guised in opaque capsules and were dis-
pensed in daily pill reminders”
Double-blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Side effects were measured for 30 partici-
pants
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Selective reporting (reporting bias) High risk Unclear how the population sample was se-
lected from the group of attendees at these
programmes over a 10-year period
Vested interest bias High risk During the conduct of this research,
Dr. Pelham was supported by grants
from the National Institute of Mental
Health (NIMH) (MH48157, MH47390,
MH45576,
MH50467, MH53554, MH62946), NI-
AAA (AA06267, AA11873), National In-
stitute onDrug Abuse (NIDA) (DA05605,
DA12414), National Institute of Neuro-
logical Disorders and Stroke (NINDS)
(NS39087), National Institute for En-
vironmental Studies (NIES) (ES05015)
and National Institute of Child Health
and Human Development (NICHHD)
(HD42080)
Conflicts of interest: Several study authors
have affiliations with medical companies
Childress 2009
Methods Five-week, multi-centre, multiple-setting, phase III, double-blind, randomised, placebo-
controlled, parallel trial with 4 arms
1. Placebo
2. Extended-release dexmethylphenidate hydrochloride 10 mg
3. Extended-release dexmethylphenidate hydrochloride 20 mg
4. Extended-release dexmethylphenidate hydrochloride 30 mg
One to 3weeks titration and 2 to 4weeksmaintenance period dependent on the allocated
active drug group
Participants Number of participants screened: 332
Number of participants included: 253 (163 boys, 90 girls)
Number of participants randomly assigned: extended-release dexmethylphenidate hy-
drochloride 188 (10 mg, n = 66; 20 mg, n = 62; 30 mg, n = 60), placebo 65
Number of participants followed up: extended-release dexmethylphenidate hydrochlo-
ride 161 (10 mg, n = 56; 20 mg, n = 54; 30 mg, n = 51), placebo 57
Number of withdrawals: extended-release dexmethylphenidate hydrochloride 27 (10
mg, n = 10; 20 mg, n = 8; 30 mg, n = 9), placebo 8
Diagnosis of ADHD:DSM-IV (combined (73.9%), hyperactive-impulsive (2.8%), inat-
tentive (21.7%), missing data (1.6 %))
Age: mean 8.7 years (SD 1.84, range not reported)
IQ: not stated
Methylphenidate naive: 69.2%
Ethnicity: Caucasian (57.7%), African American (28.9%), Asian (0.8%), other (12.6%)
Country: 34 centres in the United States
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Setting: out-patient clinic
Comorbidity: respiratory, thoracic and mediastinal disorders (methylphenidate 26.9%,
placebo 38.1%), immune system disorders (methylphenidate 22.5%, placebo 14.3%),
nervous system disorders (methylphenidate 18.7%, placebo 19.0%), surgical and med-
ical procedures (methylphenidate 15.4%, placebo 11.0%), infections and infestations
(methylphenidate 14.3%, placebo 17.5%) and skin and subcutaneous tissue disorders
(methylphenidate 11.0%, placebo 9.5%)
Comedication: ≥ 1 concomitant medication or non-drug therapy after start of study
(methylphenidate 39.0%, placebo 44.4%). Themost common concomitantmedications
were analgesics, antihistamines and allergy medications
Sociodemographics: not stated. Treatment groups were well balanced in relation to par-
ticipant background characteristics, and baseline demographics were comparable among
treatment groups
Inclusion criteria
1. 6 to 12 years of age
2. DSM-IV-TR diagnosis of ADHD
3. Patients attending school had to have the same teacher (English or Math) for the
entire duration of the study, who was willing and able to spend sufficient time with the
patient to make valid weekly assessments
4. Drug naive or not treated with any methylphenidate-related medication during
the month before the study
5. Patients receiving psychological or behavioural therapies before the screening visit
were considered eligible to participate, provided that therapy had been ongoing for ≥ 3
months with the same therapist
6. Patients had to have academic competence appropriate to their age and the
following subscale total scores on Conners’ ADHD/DSM-IV Scales - Teacher Version:
For boys, baseline scores on Conners’ ADHD/DSM-IV Scales - Teacher Version, Total
subscale were required to be 27 for those 6 to 8 years old, 24 for those 9 to 11 years old
and 19 for those 12 years old. For girls, respective baseline cutoff scores on Conners’
ADHD/DSM-IV Scales - Teacher Version, for the same age groups were 16, 13 and 12
Exclusion criteria
1. Home-schooled children
2. Any medical condition that interfered with study assessments or that was not
stable for ≥ 3 months before screening
3. Clinically significant abnormalities detected during screening
4. Family history of long-QT syndrome, current diagnosis or history of cardiac
abnormalities, seizures, psychiatric disorders such as schizophrenia, schizoaffective
disorder, severe obsessive-compulsive disorder, conduct disorder, autism, chronic tic
disorder, Tourette’s disorder or any mood or anxiety disorder
5. Antidepressants, antipsychotics, herbal preparations with psychotropic effects,
amphetamine-based medications, benzodiazepines, barbiturates, sedatives or
hypnotics, monoamine oxidase inhibitors and atomoxetine had to be stopped 1 to 4
weeks before randomisation according to their half-lives. All concomitant medications
that could interfere with absorption, metabolism and distribution of study drug were
excluded from the start of screening until the end of all evaluations. Over-the-counter
analgesics, short-term antibiotic treatment for minor infections and any medication
needed to treat adverse events were allowed
6. Additionally, patients who were judged by the investigator as likely to be non-
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compliant with study procedures, including those with a suspected history of substance
abuse and those living with a person diagnosed with a substance abuse disorder, or
whose parent or guardian was unable or unwilling to complete Conners’ ADHD/
DSM-IV Scales - Parent Version
7. Pregnancy or lactation
8. Positive drug screen
Interventions Participants were randomly assigned to extended-release dexmethylphenidate hydrochlo-
ride or placebo
Fixed methylphenidate dosage: 10 mg, 20 mg or 30 mg
Administration schedule: once daily, morning
Duration of intervention: 5 weeks
Washout before study initiation: up to 28 days (duration dependent on the half-life of
any previous psychotropic medication)
Titration period: 1 to 3 weeks, initiated after randomisation
Treatment compliance: 86% completed
Outcomes ADHD symptoms
1. Conners’ ADHD/DSM-IV - Teacher Version: rated by teacher at baseline and
each week
2. Conners’ ADHD/DSM-IV - Parent Version (including 12-item ADHD Index
and 18-item DSM-IV Subscale total): rated by parent or guardian at baseline and each
week
Non-serious adverse events
1. Regular monitoring and recording of adverse events, serious adverse events, vital
signs, body weight, ECG, physical examination, haematology parameters, blood
chemistry and urinalysis. While vital signs were recorded at every visit, physical,
laboratory and ECG evaluations were completed during the screening visit and the
final study visit. Weight was recorded at baseline and at the final visit. Notable value for
weight loss was defined as a decrease from baseline weight at study end of 7%
Notes Sample calculation: yes; 252 participants (63 per treatment group)
Ethics approval: Institutional review boards or ethical review committees at each centre
approved the study
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Limitations: short duration of study, forced-dose titration, not powered to assess
differences in treatment effects within extended-release dexmethylphenidate
hydrochloride groups
Key conclusions of study authors
1. All 3 doses of extended-release dexmethylphenidate hydrochloride (10 mg, 20 mg
or 30 mg a day) were significantly more effective than placebo in improving ADHD
symptoms, as confirmed by teacher, parent and clinician
2. Additionally, extended-release dexmethylphenidate hydrochloride was well
tolerated and demonstrated a consistent safety profile. Mean changes from baseline in
vital signs in extended-release dexmethylphenidate hydrochloride groups were small,
clinically irrelevant, unrelated to dose and similar to placebo
3. Despite the forced-titration design of the study, the cardiovascular safety profile of
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extended-release dexmethylphenidate hydrochloride (10 mg/d, 20 mg/d and 30 mg/d)
is similar to placebo in children with ADHD
Comment from review authors
1. Additionally, participants judged by the investigator as likely to be non-compliant
with study procedures were excluded
Email correspondence with study authors in December 2013. We have contacted study
authors twice in an attempt to obtain supplemental information regarding blinding,
allocation concealment and weight loss. We have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by using a
validated system that automated the assign-
ment of treatment arms to randomisation
numbers in the specified ratio
Allocation concealment (selection bias) Low risk Allocation concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no detailed description
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no detailed description
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT population. LOCF
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No
Vested interest bias High risk This study was funded by Novartis Phar-
maceuticals Corporation. Novartis Pharma
has been helping with development of the
manuscript
Conflicts of interest: Several study authors
have received research support from, are
speakers for, are consultants of, are on the
Advisory Board, have served on the Speak-
ers’ Bureaus of or are employees of several
pharmaceutical companies
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Methods Eight-week within-participant, placebo-controlled, randomised, cross-over trial (Sum-
mer Treatment Camp (STP) with 3 interventions)
1. Methylphenidate
2. Adderall
3. Placebo
Phases: 2-week baseline assessment followed by 6-week medication trial
Participants Number of participants screened: 48
Number of participants included: 21 (19 boys, 2 girls). Participants were randomly
assigned to 1 of 7 drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 10.26 years (±1.9, range 6 to 12)
IQ: mean 109.9 (±18.8)
Methylphenidate naive: 14 children had received methylphenidate before start of the
study
Ethnicity: White (100%)
Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: learning problems (42.9%), oppositional defiant disorder (66.7%), con-
duct disorder (23.8%)
Comedication: not stated
Sociodemographics (median family income = $35,000/y (< $15,000/y to > $100,000/
y); 66.7% of parents married
Inclusion criterion
1. DSM-IV diagnosis of ADHD
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to 1 of 7 possible drug condition orders of imme-
diate-release methylphenidate, Adderall and placebo
1. Placebo at 7:30 AM, 11: 30 AM and 3:30 PM
2. 0.3 mg/kg methylphenidate at 7:30 AM, 11:30 AM and 3:30 PM
3. 0.3 mg/kg methylphenidate at 7:30 AM and 11:30 AM with 0.15 mg/kg at 3:30
PM
4. 0.3 mg/kg methylphenidate at 7:30 AM only
5. 0.3 mg/kg Adderall at 7:30 AM and at 3:30 PM
6. 0.3 mg/kg Adderall at 7:30 AM with 0.15 mg/kg received at 3:30 PM
7. 0.3 mg/kg Adderall at 7:30 AM only
Mean methylphenidate dosage: not stated
Administration schedule: methylphenidate once, twice or 3 times daily according to the
randomisation procedure
Duration of each medication condition: All participants received medication eachMon-
day through Friday throughout a period of 6 weeks for a 24-day clinical assessment
period. Assessment period was divided into three 8-day segments. Within each segment,
placebo occurred twice and each other condition occurred once, with the order of con-
ditions randomly assigned on a daily basis
Washout before study initiation: not stated
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Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale: rated by counsellors at the end of each day, by
teachers after the classroom period each day and by parents in the evening
Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale: rated by counsellors and teachers daily, rated
by parents each evening with the addition of an item assessing difficulty falling asleep
Notes Sample calculation: no
Ethics approval: yes
Any withdrawals due to adverse events: none during the trial
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Additional (late-afternoon) stimulant dose has beneficial effects on parent-child
interactions
2. At the end of the Summer Treatment Programme (STP) for the 21 children, it
was determined that 5 children did not show a sufficient positive response
Key conclusions of study authors
1. Single morning dose of Adderall had effects for an entire school day
2. Single dose of Adderall was equivalent to immediate-release methylphenidate
twice/day
Comments from review authors
1. No mean methylphenidate dose
2. Behavioural intervention was also implemented during the entire 8-week study
period
3. As intervention sequences were switched on a daily basis according to
randomisation, we did not ask about first period data from this study
Email correspondence with study authors: July 2014. Emailed study authors twice to
request additional information. Study author was not able to provide us with additional
data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized by day”, no description of
how randomisation took place
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To ensure blinding, placebo capsules were
given at 11:30 AM in the Adderall condi-
tions and for applicable doses in the other
conditions. Active medication and placebo
were disguised in opaque gelation capsules
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by a local pharmacy and were dispensed in
daily pill reminders by the study doctor.
Furthermore, children were informed that
they would be receiving 2 different kinds
of medication to see how well they worked,
and that some days theywould receive inac-
tive pills, but that they, their counsellors or
teachers and their parents would not know
what kind of pill they would get each day
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Childrenwere informed that theywould be
receiving 2 different kinds of medication to
see how well they worked, and that some
days they would receive inactive pills, but
that they, their counsellors or teachers and
their parents would not know what kind of
pill they would get each day
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of drop-out
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk All outcomes reported
Vested interest bias High risk Supported by a grant fromShire-Richwood
Pharmaceuticals, Incorporated - manufac-
turer of Adderall - and from the National
Institute of Mental Health (NIMH)
Coghill 2007
Methods Twelve-week randomised, placebo-controlled, double-blind cross-over trial with 3 inter-
ventions
1. Methylphenidate 0.3 mg/kg
2. Methylphenidate 0.6 mg/kg
3. Placebo
Participants Number of participants screened: not stated
Number of participants included: 75 (all boys). Participants were randomly assigned to
1 of 6 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined type); ICD-10 (hyperkinetic disorder)
Age: mean not reported (range 7 to 15 years)
IQ: > 80
Methylphenidate naive: 100%
Ethnicity: not stated
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Country: United Kingdom
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (41.3%), conduct disorder (28%), depressive
disorder (4%), generalised anxiety disorder (2.7%), separation anxiety disorder (4%), tic
disorder (2.7%), social phobia (1.3%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Eligible boys (scoring 1.5 SD from the mean on both Conners’ Parent Rating
Scale, Short Version, and Conners’ Teacher Rating Scale, Short Version) were
interviewed by an experienced child and adolescent psychiatrist using the Kiddie-
Schedule for Affective Disorders and Schizophrenia Present and Lifetime
2. Those meeting criteria for hyperkinetic disorder (HD F 90) (ICD-10) and
combined subtype (DSM-IV) were invited to participate
Exclusion criteria
1. History of neurological impairment/learning disability
2. IQ < 80
3. Chronic physical illness
4. Sensory or motor impairment
5. Current or previous exposure to stimulant medication
6. Abuse of any illegal drugs
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders: 3 mg/kg/
dose methylphenidate or 6 mg/kg/dose methylphenidate and placebo
Administration schedule: twice daily
Duration of each medication condition: 4 weeks
Washout before study initiation: no
Titration period: none
Treatment compliance: assessed by pill count and clinical enquiry but not further de-
scribed
Outcomes ADHD symptoms
1. Conners’ Global Index, Parent Version and Teacher Version (10 item): rated by
parents and teachers, each after 4 weeks
Notes Sample calculation: no
Ethics approval: yes
Key conclusions of study authors
1. Chronic methylphenidate predominantly enhanced neuropsychological
functioning on “recognition memory” component tasks with modest “executive”
demands
2. Neuropsychological measures offer only modest contributions to the prediction of
clinical responses to methylphenidate in ADHD
Comment from study authors
1. Doses (0.3 mg/kg and 0.6 mg/kg) were chosen to reflect low- and high-dose
regimens, respectively
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors in 2013. Emailed study authors twice with
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a request for additional information regarding protocol and number of participants on
which analyses were based. Have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned by an
independent clinical trials pharmacist (us-
ing a computer-generated random number
sequence with block design to ensure equal
numbers in each treatment arm)
Allocation concealment (selection bias) Low risk Participants were randomly assigned by an
independent clinical trials pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo-controlled, double-blind, no fur-
ther information
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical status was assessed by interview
conducted by an experienced, blinded child
and adolescent psychiatrist. Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk No description about how many partici-
pants were included in analyses
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Unclear risk This work was supported by a local trust
through a Tenovus Scotland initiative
Conflicts of interest: Some study authors
have affiliations with different pharmaceu-
tical companies
Coghill 2013
Methods Seven-week, multi-centre, double-blind, parallel, dose-optimised trial with 3 arms
1. Lisdexamfetamine dimesylate
2. OROS methylphenidate
3. Placebo
Participants Number of participants screened: not stated
Number of participants included: 221 (181 boys, 40 girls)
Number of participants randomly assigned: methylphenidate 112, placebo 111
Number of participants followed up: methylphenidate 74, placebo 42
Number of withdrawals: methylphenidate 38, placebo 68
Diagnosis of ADHD: DSM-IV-TR (combined (methylphenidate 86.4%, placebo
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79.1%), hyperactive-impulsive (methylphenidate 0.9%, placebo 6.4%), inattentive
(methylphenidate 12.7%, placebo 14.5%)
Age: mean 10.9 years (range 6 to 17)
IQ: normal
Methylphenidate naive: methylphenidate 60 (54.1%), placebo 58 (52.7%)
Ethnicity: Caucasian (methylphenidate 96.4%, placebo 98.2%), African American (0%)
, Asian (0%), Hispanic/Latino (methylphenidate 1.8%, placebo 0%)
Countries: Germany, Sweden, Spain, Hungary, France, the UK, Italy, Belgium, Poland,
the Netherlands
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (methylphenidate 9.0%, placebo 7.3%),
concomitant psychiatric diagnosis (methylphenidate 26.1%, placebo 18.2%)
Comedication: not stated
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Any sex
2. 6 to 17 years of age
3. Meeting criteria for ADHD according to DSM-IV-TR
4. Baseline ADHD moderate severity with ADHD-RS-IV score of 28 or higher
5. Age-appropriate intellectual functioning
6. Blood pressure measurements within the 95th percentile for age, sex and height
7. Ability to swallow a capsule
8. Girls of childbearing potential had to have a negative urine pregnancy test at
baseline and to comply with any contraceptive requirements of the protocol
Exclusion criteria
1. Failure to respond to previous OROS methylphenidate therapy
2. Presence of a conduct disorder (excluding oppositional defiant disorder)
3. Pregnancy or lactation
4. Weight below 22.7 kg; body mass index (BMI, kg/m2) > 97th percentile for age
and sex
5. Positive urine drug test (with the exception of patient’s current ADHD therapy)
6. Clinically significant electrocardiogram or laboratory abnormalities
7. Suspected substance abuse or dependence disorder (excluding nicotine) within the
previous 6 months
8. History of seizures
9. Tics or Tourette’s disorder
10. Known structural cardiac abnormality
11. Any other condition that might increase vulnerability to the sympathomimetic
effects of a stimulant drug
12. Patients whose current ADHD medication provided effective control of
symptoms with acceptable tolerability
13. Patient currently considered a suicide risk, with previous suicide attempt or with
history of, or currently demonstrating, active suicidal ideation
14. Patient with glaucoma
15. Patient with documented allergy, hypersensitivity or intolerance to amphetamine
or methylphenidate
16. Patient with documented allergy, hypersensitivity or intolerance to any excipients
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in test or reference products
17. Patients with known family history of sudden cardiac death or ventricular
arrhythmia
18. Patients with pre-existing severe gastrointestinal tract narrowing (pathological or
iatrogenic)
19. Patients unable to tolerate the study drug were withdrawn from the study
Interventions Participants were randomly assigned to OROS methylphenidate or placebo
Mean methylphenidate dosage: 45.4 ± 12.7 mg/d (9.9% 18 mg, 19.8% 36 mg, 53.2%
54 mg)
Administration schedule: once a day, 7:00 AM
Duration of intervention: 7 weeks
Titration period: 4-week stepwise dose-optimisation period after randomisation. Three-
week dose-maintenance period followed by 1-week washout and safety follow-up
Treatment compliance: 2 discontinued in placebo group because of non-compliance, 3
in methylphenidate group
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition: total score at endpoint, investigator-rated
at baseline and weekly for 7 weeks. Endpoint was defined as the last on-therapy, post-
randomisation treatment visit with a valid ADHD Rating Scale, Fourth Edition, total
score
Quality of life
1. Health Utilities Index-2: parent-rated at baseline and at weeks 4 and 7. Scoring
ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health
status
2. Child Health and Illness Profile, Child Edition: Parent Report Form: parent-rated
at baseline and at weeks 4 and 7. Questionnaire comprises 76 items classed into 5
domains and 12 associated subdomains. Most items relate to the past 4 weeks; the
remainder are not associated with a specific time period. Parents use a 5-point response
format to assess each item. Achievement is considered the primary health-related
quality of life outcome
Non-serious adverse events
1. Safety assessments included treatment-emergent adverse events, clinical laboratory
evaluations, physical examinations, vital signs and ECGs, observer-rated weekly for 8
weeks
Notes Sample calculation: yes
Ethics approval: approvedby an independent ethics committee/institutional reviewboard
and regulatory agency at each centre (as appropriate) before study initiation
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Comments from study authors
1. Individuals with comorbid conditions, such as post-traumatic stress disorder,
bipolar affective disorder or severe anxiety disorder, were excluded from this study
2. As a result of European regulations, the maximum dose of OROS
methylphenidate administered in this study was 54 mg/d. However, it is possible that
the smaller than usual placebo response did, at least in part, contribute to this large
treatment effect. ADHD is currently less frequently diagnosed in Europe than in North
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America, with evidence of underrecognition and underdiagnosis (
healthcareimprovementscotland.org). Consequently, it is likely that individuals who
are diagnosed are at the more severe end of the spectrum and therefore would be less
likely to show a response to placebo. Consistent with this suggestion, reassessment of
data from the Multimodal Treatment of ADHD (MTA) study revealed that children
who had been diagnosed with ADHD on the basis of DSM-IV criteria, but also met
the more restrictive International Classification of Diseases 10th Revision criteria for
hyperkinetic disorder, showed a more robust response to medication compared with
those who met DSM-IV criteria alone
Key conclusions of study authors
1. In this European 7-week phase III study, lisdexamfetamine dimesylate was more
effective than placebo in improving symptoms in children and adolescents with ADHD
2. Compared with placebo, significant improvements in both ADHD core
symptoms and global functioning were observed
3. Lisdexamfetamine dimesylate was well tolerated, with treatment-emergent adverse
effects consistent with those reported in previous studies
4. Robust efficacy outcomes were also observed for OROS methylphenidate, which
was included in this study as a reference arm
Comment from review authors
1. Very confused on the number of participants included in the different analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive voice/web response system was
used to allocate a unique randomisation
number to each participant. Randomisa-
tionwas stratified by country and age group
(6 to 12 or 13 to 17 years of age)
Allocation concealment (selection bias) Low risk Interactive voice/web response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were overencapsulated and ap-
peared identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking: double-blinded (participant,
caregiver, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk LOCF approach was used when efficacy as-
sessments were incomplete for a participant
owing to early withdrawal from the study
or for missing data. However, as the review
authors cannot understand the relationship
between the n of the full analysis set and
the endpoint data, risk of bias was assessed
as unclear
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Selection bias (e.g. titration before ran-
domisation→ exclusion): none
Selective reporting (reporting bias) Low risk Outcomes according to protocol
Vested interest bias High risk Funded by Shire Development LLC
Conflicts of interest: C. Anderson, R. Civil,
N. Higgins, A. Lyne and L. Squires are em-
ployees of Shire and own stock/stock op-
tions. Some study authors have received
compensation for serving as consultants or
speakers, or they or the institutions they
work for have received research support or
royalties from different companies or or-
ganisations
Connor 2000
Methods Three-month, randomised, blind, parallel-group study with 3 arms
1. Methylphenidate and clonidine
2. Clonidine monotherapy
3. Methylphenidate monotherapy
Participants Number of participants screened: 24
Number of participants included: 24 (methylphenidate + clonidine 8 boys, 0 girls;
placebo + clonidine 8 boys, 0 girls)
Number of participants randomly assigned: methylphenidate + clonidine 8, placebo +
clonidine 8, placebo + methylphenidate 8
Number of participants followed up: methylphenidate + clonidine 8, placebo + clonidine
6
Number of withdrawals: methylphenidate + clonidine 0, placebo + clonidine 2
Diagnosis of ADHD: DSM-III-R (combined (100%))
Mean age: methylphenidate + clonidine 10.1 years, placebo + clonidine 9.3 years (range
6 to 16)
IQ: > 70
Methylphenidate naive: 54%
Ethnicity: Caucasian (11%), African American (1%), Asian (0%), Hispanic (0%), other
(0%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder or conduct disorder (100%)
Comedication: not reported
Sociodemographics: No significant differences in baseline demographics were noted
between groups
Inclusion criteria
1. DSM-III-R for ADHD
2. DSM-III-R for oppositional defiant disorder or conduct disorder, score of 1.5 SD
above the mean for age and sex on the Parent Child Behavior Checklist, Attention
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problems scale (T score > 65) and a score on the Teacher Child Attention Problem
Rating Scale of ≥ 93rd percentile
3. Score 1.5 SD above the mean for age and sex on the Parent or Teacher Child
Behavior Checklist, Delinquency or Aggression problems scale
4. Normal findings from general physical examination by family physician within 6
months before study entry
Exclusion criterion
1. Medical history that contraindicated use of stimulants or clonidine
Interventions Participants were randomly assigned to methylphenidate + clonidine or placebo + cloni-
dine
Methylphenidate dose: 35.0 (5.67) mg/d
Administration schedule: b.i.d.
Duration of intervention: 12 weeks
Titration period: 4 weeks after randomisation
Treatment compliance: “All subjects were acceptably compliant with the protocol”
Outcomes General behaviour
1. Disruptive Behavior Disorders Rating Scale: parent- and teacher-rated monthly
2. Home Situations Questionnaire: parent-rated monthly
3. School Situations Questionnaire: teacher-rated monthly
Non-serious adverse events
1. Possible side effects of methylphenidate and clonidine: Combined Stimulant/
Clonidine Side Effects Rating Scale, parent- and teacher-rated monthly
2. Pulse and blood pressure obtained monthly. ECG measured after first month.
Height and weight obtained monthly
Notes Intervention group: methylphenidate + clonidine; control group: placebo + clonidine
Ethics approval: yes
Sample calculation: no
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: June 2013. We obtained additional informa-
tion from study authors, but it was not possible to receive supplemental data. We could
not perform a meta-analysis on any of the outcomes, as we did not have relevant data
and transformation was not possible
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Eight participants were randomly assigned
to each group. Three participants were
previous methylphenidate treatment fail-
ures and refused randomisation to the
methylphenidate-alone study arm. These
3 participants were partially randomly as-
signed to methylphenidate and clonidine
or to clonidine alone. All other children
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were fully randomly assigned
Allocation concealment (selection bias) Low risk After study completion, the medication
blind was broken. All medication capsules
and placebo capsules were prepared by the
UMMS (University ofMassachusettsMed-
ical School) Pharmacy in identical capsules
to disguise taste and smell. All participants
in all study groups received an equal num-
ber of capsules per day
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All teachers, school nurses, parents, chil-
dren and research assistants completing
dependent measures were blinded to the
child’s treatment group for the study du-
ration. Completion of electrocardiograms
(ECGs) for only 2 clonidine treatment
groups may have broken blinding for par-
ent raters and for the child (but not for
teacher raters nor for research assistants
administering the GDS, who remained
blinded as towhether the child had received
an ECG). This is not relevant to us, as we
are using data only on the 2 groups com-
pleting ECGs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As stated above
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF
Selection bias: no
Selective reporting (reporting bias) Low risk Reply from study author on our request
for the protocol: protocol described in the
study
Vested interest bias Low risk Supported by aUMMS (University ofMas-
sachusetts Medical School) Small Grants
Project Award
Conflicts of interest: not stated
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Methods Six-week, double-blind, single cross-over, placebo-controlled study conducted on a group
of 15 participants with ADD and a comparison group of 10 age-matched participants
who did not have ADD
ADD group was randomly assigned to 1 of 2 experimental groups
1. Methylphenidate
2. Placebo
Participants Regarding the ADD group
Number of participants screened: not stated
Number of participants included: 15. Participants were randomly assigned to 1 of 2
possible drug condition orders
Number of participants followed up: 15
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (100% met DSM-III criteria for ADD with hyperactiv-
ity)
Age: mean 104.5 months (range 6 to 10 years)
IQ: mean 110.5 (SD 7.15)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: central auditory processing disorder (80%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Male
2. 6 to 10 years of age
3. IQ > 85
4. Clinical diagnosis of ADD from paediatrician and met DSM-III criteria for ADD
on both Parent and Teacher Versions of the Swanson, Nolan and Pelham Scale; scored
≥ 15 points on the Parent Version of the Abbreviated Conners’ Rating Scale
Exclusion criteria
Participants were excluded if they had
1. Seizures
2. Cerebral palsy
3. Learning disabilities
4. Speech or language problems
5. Vision or peripheral hearing problems
6. Thought disorder
7. Abnormal auditory brainstem evoked potentials
8. Previous drug treatment for ADD
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 0.30 mg/kg (0.057)
Administration schedule: not stated
Duration of each medication condition: 3 weeks
Washout before study initiation: not relevant, 100% treatment naive
Medication-free period between interventions: minimum of 48 hours between the 2
interventions
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Titrationperiod:Dosewas titrated up to amaximum (methylphenidate tablets or placebo
tablets) over the first 3 weeks of the experimental period
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Nolan and Pelham Scale: teacher- and parent-rated, only items on the
Inattention and Impulsivity subdomains, measured at the end of each treatment
condition
2. ADD/H Comprehensive Teacher Rating Scale: measured at the end of each
treatment condition
3. Abbreviated Conners’ Rating Scale: parent-rated, measured at the end of each
treatment condition
Notes Sample calculation: no information
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Limitations: The conclusion should not be generalised to results obtained with
measures other than the 3 behaviour rating scales. The sample is small. Stimulant
treatment periods were brief, and results may not have been maintained at the same
level if the study had been conducted over a longer period
Comment from review authors
1. Read relevant parts of Dr. Cook’s Ph.D. dissertation to get additional information
about the study
Key conclusion of study authors
1. The implications of these results are 3-fold. First, sustained attention is a critical
feature of performance on tests of central auditory processing disorder, and current
diagnostic criteria for central auditory processing disorder make clinical separation of
the 2 disorders problematic. Second, stimulants appear to be a useful treatment for
symptoms of both ADD and central auditory processing disorder. Third, tests of
central auditory processing disorder may provide a useful measure of ADD symptoms
and response to stimulants
Email correspondence with study authors: September 2013. Emailed study author re-
questing additional information about the study and data. Dr. Cook referred to his Ph.
D. dissertation, which we managed to get
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to groups by a
table of random numbers known only to
the pharmacist
Allocation concealment (selection bias) Low risk Drugs were coded and administered by a
pharmacist, and clinical titration of dosage
was done by the participant’s paediatrician;
neither practitioner was involved in data
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collection
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Physician, audiologist, teachers andparents
involved in behaviour ratings and partici-
pants themselves were blinded to assigned
treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physician, audiologist, teachers andparents
involved in behaviour ratings and partici-
pants themselves were blinded to assigned
treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No
Vested interest bias Low risk Supported by theMedical Center Rehabili-
tation Hospital Foundation and the School
of Medicine, University North Dakota;
the Veterans Hospital; the Dakota Clinic;
and The Neuropsychiatric Institute, Fargo,
North Dakota
Conflicts of interest: not stated
Corkum 2008
Methods Three-week, blind medication trial with cross-over design, in which children were ran-
domly assigned to the following
1. Two different doses of methylphenidate (low and moderate)
2. Placebo
Participants Number of participants recruited: 28
Number of participants included: 21 (15 boys, 6 girls)
Number of withdrawals: 7 children excluded from final data analyses
Diagnosis of ADHD: DSM-IV (combined type (52%), hyperactive-impulsive type
(10%), inattentive type (38%))
Age: mean not reported (range 6 years 1 month to 12 years 1 month)
IQ: no intellectual disability
Methylphenidate naive: All participants were stimulant medication-naive
Comorbidity: learning disabilities (29%), oppositional defiant disorder (10%), conduct
disorder (0%), generalised anxiety disorder (0%), depression (0%)
Setting: out-patient clinic
Country: Canada
Ethnicity: All participants were Caucasian
Sociodemographics: predominantly middle-class families
Inclusion criteria
1. Stimulant medication-naive
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2. DSM-IV criteria for 1 of the 3 ADHD subtypes
3. Received a recommendation to initiate a trial of methylphenidate following
assessment
4. Parents/caregivers agreed to initiate a stimulant medication trial through the clinic
paediatrician
Exclusion criteria
1. IQ < 1 SD below the mean on the Wechsler Intelligence Scale for Children,
Fourth Edition
2. Known neurological, metabolic or seizure disorder
3. Currently taking other psychotropic medications or medications for sleep
disturbances
4. Symptoms of an intrinsic sleep disorder (i.e. sleep apnoea, restless legs syndrome
or periodic limb movements in sleep) or a sleep-onset disorder based on parent report
5. Reached criteria for another mental health disorder that was considered
6. Primary to the ADHD diagnosis (e.g. autism)
Interventions Participants were randomly assigned to 1 of 3 medication-dosing schedules, including
1 week of baseline, placebo and low and moderate immediate-release methylphenidate
(ritalin) dose condition. Children weighing ≤ 25 kg received 5-mg and 10-mg doses;
children weighing > 25 kg received 10-mg and 15-mg doses. Children received medica-
tion
t.i.d. (8:00 AM, 12:00 PM, 4:00 PM)
Treatment compliance: no information
Outcomes ADHD symptoms
1. Conners’ Parent and Teacher Rating Scale - Revised, Short Form: rated weekly
Non-serious adverse events
1. Sleep Disturbances Scale for Children based on child’s sleep over previous week:
rated by parents
2. Actigraphy
3. Sleep diary
Notes Sample calculation: not stated
Ethics approval: yes
Key conclusion of study authors
1. Based on findings from the current study, we would encourage physicians and
parents to closely monitor children’s sleep when treating ADHD with stimulant
medication, and to carefully weigh the benefits of improved behavioural functioning
while taking medication against the potential negative consequences of sleep
Comment from review authors
1. Paper includes data on adverse effects: sleep disturbance (actigraph data, sleep
diary data, Sleep Disturbances Scale for Children data) related to methylphenidate
treatment compared with placebo
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: August to October 2013. We received supple-
mental information regarding additional data from study authors, but we never received
first period data from the cross-over trial
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Baseline data from 1 week were collected,
followed by a 3-week medication trial with
random assignment of children to 1 of 3
medication-dosing schedules. The original,
fully randomised schedule was modified af-
ter a pilot study, conducted before the cur-
rent study, indicated that children receiv-
ing a moderate dose before the low dose
of methylphenidate reported increased side
effects and were more likely to stop taking
the third dose (4:00 PM) of medication
Allocation concealment (selection bias) Low risk Pharmacy local to the ADHD clinic pre-
pared both placebo and active medication,
which were packaged into identical gelatin
capsules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Child, family, school personnel and study
investigators were unaware of the ran-
domisation schedule. This informationwas
made available only to the paediatrician
and the pharmacist
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Child, family, school personnel and study
investigators were unaware of the ran-
domisation schedule. This informationwas
made available only to the paediatrician
and the pharmacist
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7 children excluded fromfinal data analyses
for the following reasons: actigraphic prob-
lems (i.e. data failure/loss of actigraph/re-
fusal to wear actigraph) (n = 5), withdrawal
of consent due to marital discord (n = 1)
and decision to try alternative medication
immediately before the start of the medi-
cation trial (n = 1)
Selective reporting (reporting bias) Low risk No subsequent correspondence with first
study author regarding additional informa-
tion on reporting
Vested interest bias Low risk Researchwas supported by a grant from the
Izaak Walton Killam
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IWK Health Centre in Halifax, Nova Sco-
tia
Conflicts of interest: “none declared”
Cox 2006
Methods Randomised, double-blind, placebo-controlled, cross-over trial of adolescent drivers with
ADHD who were assessed on a driving simulator after taking
1. 72 mg of OROS methylphenidate
2. 30 mg of extended-release mixed amphetamine salts
3. Placebo
Phases: 3 (2 relevant phases)
Participants Number of participants screened: not stated
Number of participants included: 35 (19 boys, 16 girls). Participants were randomly
assigned to 1 of 2 relevant (n = 3) possible drug condition orders
Number of participants followed up: 35
Number of withdrawals: 2
Diagnosis of ADHD: DSM-IV (combined 21 (60%), hyperactive-impulsive 2 (6%),
inattentive 12 (34%))
Age: mean 17.8 years (range 16 to 19)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: agoraphobia (2.9%), conduct disorder and marijuana abuse (2.9%), ob-
sessive-compulsive disorder (2.9%), obsessive-compulsive disorder and hypomania (2.
9%), nicotine dependence (5.7%)
Comedication: 2 were taking no medication, 21 were taking methylphenidate and 12
were taking amphetamine formulations at the start of the study
Sociodemographics: not stated
Inclusion criteria
1. Adolescent drivers
2. 16 to 19 years of age
3. ADHD according to DSM-IV. To meet inclusion criteria for a diagnosis of
ADHD, adolescents first needed to surpass clinical cutoffs for ADHD on a commonly
used parent rating scale, the ADHD Rating Scale, Fourth Edition
4. Psychiatrist confirmed ADHD diagnosis with the Standardized Interview for
Adult ADHD (DSM-IV)
5. Positive history of stimulant responsiveness, as disclosed by adolescents and by
parent reports; current licence to drive and reported daily driving activity
Exclusion criteria
1. Adolescents were excluded when they had a history of tics or any adverse reaction
to stimulant medication
2. History of substance abuse disclosed by patient or parent
3. Co-existing medical condition or medication usage known to interfere with safe
administration of stimulant medications
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Interventions Participants were randomly assigned to 1 of 2 relevant drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 72 mg/d
Administration schedule: 2 overlaid capsules/tablets in blister packs each day on awak-
ening
Duration of each medication condition: 17 days
Washout before study initiation: not stated
Medication-free period between interventions: 4 to 21 days between OROS
methylphenidate and mixed amphetamine salts
Titration period: half dose (36 mg/d OROS methylphenidate) days 1 to 5, full dose (72
mg/d OROS methylphenidate) days 6 to 17 initiated after randomisation
Treatment compliance: not stated. Pill counts were completed at each study visit
Outcomes Non-serious adverse events
1. Throughout the study, only 1 adverse event was reported - urinary difficulty. This
adverse event occurred during treatment with 36 mg of OROS methylphenidate and
was resolved after 2 days without discontinuation of the medicine
2. Self-Reported Stimulant Drug Side Effects Rating Scale on days 5 and 10
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors
1. Automobile accidents are the leading cause of death among adolescents, and
collisions are 2 to 4 times more likely to occur among adolescents with ADHD
2. Studies have demonstrated that stimulants improve driving performance
3. Results provide evidence supporting most literature on children with short-acting
stimulants; longer-acting stimulants appear equally effective for female and male post-
pubertal adolescents with ADHD
4. Limitation of this study is that few participants with hyperactive subtype were
included, limiting extrapolation of results to this subgroup
Key conclusions of study authors
1. This study validates the use of stimulants to improve driving performance in
adolescents with attention deficit hyperactivity disorder
2. In this study, OROS methylphenidate promoted significantly improved driving
performance compared with placebo and extended-release mixed amphetamine salts
Comments from review authors
1. Effects of methylphenidate were also measured, but not in comparison with
placebo. Therefore, we could not use these data in the review
2. Some participants are older than 18 years. However, as mean age is > 19 years, this
study is still included but was tested by sensitivity analyses
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; excluded if any
history of adverse events to stimulant medications
Email correspondence with study authors: February 2014. We received additional infor-
mation from study authors. Data from the Self-Reported Stimulant Drug Side Effects
Rating Scale are no longer available
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a random-numbers table, each par-
ticipant was assigned”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatments were provided in different
forms: “Participants took 2 overlaid cap-
sules/tablets in blister packs each day on
awakening”. Participants and research as-
sistants were blinded to medication condi-
tions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Participants were either tested on placebo
or were not required to come in for test-
ing”. Participants and research assistants
were blinded to medication condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk Email correspondence with study author:
no drop-outs and all were followed-up (
Krogh 2013b [pers comm])
Selection bias (e.g. titration after randomi-
sation→ exclusion): none described
Selective reporting (reporting bias) Low risk Email correspondence with study author,
who stated that all planned outcome mea-
sures and analyses are described in the pa-
pers (Krogh 2013b [pers comm])
Vested interest bias High risk Study was supported by funding fromMc-
Neil Pediatrics, a division of McNeil-PPC
Incorporated
Conflicts of interest: none described
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Douglas 1986
Methods Five-day cross-over trial with 2 interventions
1. Methylphenidate (0.3 mg/kg capsules each dose, morning + afternoon)
2. Placebo (100 mg lactose capsules)
Phases
1. Screening session about a week before testing (given practice on all tasks in the
test battery; appropriate level was established for each child on tasks graded for
difficulty level)
2. Five days of testing. Children received drug (D) or placebo (P) according to 1 of 4
possible orders: (1) PDDPP: (2) DPPDD; (3) DDPPD; (4) PPDDP. Testings were
received each morning according to 4 test orders: (1) ABCDEF; (2) ACBEDF; (3)
ADEBCF and (4) AEDCBF
Before the study was undertaken, 16 drug and test order combinations for the morning
test battery were ordered randomly. As participants entered the study, they were assigned
to these drug-plus-test order combinations until all 16 participants had been assigned.
The order of the 2 tests in the afternoon battery (arithmetic and word discovery) was
alternated over children, and each child received tests in the same order over 5 days of
testing
Participants Number of participants screened: not stated
Number of participants included: 16 (15 boys, 1 girl). Participants were randomly as-
signed to 1 of 2 possible drug condition orders
Number of participants followed up: 16
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (subtypes not stated)
Age: mean 9.2 years (range 6 to 11.6)
IQ: mean103.19 (range 89 to 125)
Methylphenidate naive: 13 (81%)
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: Children’s families varied from I to V on the Hollingshead and
Redlich Index (with most families falling within level III to IV (V being the poorest)
Inclusion criteria
1. Met criteria for a DSM-III diagnosis of ADHD (American Psychiatric
Association, APA 1980)
2. Had to receive ratings above 1.5 (on a 0 to 3 scale) on the Hyperactivity Index of
Revised Conners’ Parent and Teacher Rating Scales
Participants were referred to the Hyperactivity Project at Montreal Children’s Hospital
by paediatricians or school personnel. Referral was based on presence of the following
symptoms
1. Inattentiveness
2. Impulsivity
3. Hyperactivity
4. Restlessness
5. Poor compliance and poor self control
Symptoms were of sufficient severity to prompt referring physicians to consider a trial
on stimulant medication
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Exclusion criteria
1. Psychosis
2. Serious visual, auditory or language deficits
3. Diagnosed as brain damaged
4. Restless behaviour attributable to emotional problems or a stressful home
environment
5. Appearance of symptoms before age five and evidence that symptoms were
chronic and pervasive
Interventions Participants were randomly assigned to 1 of 4 possible orders of drug (D) or placebo
(P): (1) PDDPP; (2) DPPDD; (3) DDPPD; (4) PPDDP. On days when participants
were assigned to active medication, they received a capsule containing the quantity
of medication closest to a calculated dose of 0.3 mg/kg for each dose (morning and
afternoon)
Mean methylphenidate dosage: not stated
Administration schedule: morning capsule administered approximately 1 hour after
breakfast and 45 minutes before morning test battery was administered. Second capsule,
identical to the morning capsule, administered before child left for lunch and returned
to school. Time between morning and afternoon capsule was approximately 3½ hours
Duration of each medication condition: 1 day each; in all 2 or 3 days, depending on
order of drugs assigned
Washout before study initiation: 24 hours before screening, 48 hours before first testing
day
Titration period: none
Treatment compliance: capsule administered by examiner
Outcomes ADHD symptoms
1. Hyperactivity Index from Conners’ Revised Teacher Rating Scale: examiner-rated,
at end of each morning of individual testing
2. Hyperactivity Index from Conners’ Revised Teacher Rating Scale: teacher-rated,
each afternoon
Score for the Index is based on the mean of item ratings on a 4-point scale (0 to 3)
Notes Sample calculation: no
Ethics approval: yes
Key conclusions of study authors
1. Results indicate methylphenidate-induced improvement in most measures
2. Drug-induced changes reflected increased output, accuracy and efficiency and
improved learning acquisition. Evidence of increased effort and self correcting
behaviours was found
3. It is argued that review authors have underestimated the potential of stimulants to
improve performance of ADD-H children on academic, learning and cognitive tasks
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: none stated
Email correspondence with study authors: July 2014. Emailed study authors to ask for
additional information. Received information on ethics approval, but first study author
was not able to provide additional data or information on the study
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Capsule was administered by examiner
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In a few cases in which data were missing,
scores from 1 or 2 days were used to com-
pute means for drug and placebo condi-
tions. No information on drop-out rate
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias Low risk Research was supported by Grant Num-
ber MA 6913, from the Medical Research
Council of Canada
Conflicts of interest: no information
Douglas 1995
Methods Eight-day, double-blind, cross-over trial in which participants were randomly assigned
to different doses of methylphenidate and placebo
1. 0.3 mg/kg methylphenidate
2. 0.6 mg/kg methylphenidate
3. 0.9 mg/kg methylphenidate
4. Placebo
Phases
1. Assessment week 1: 4 different doses given on 4 different days
2. Assessment week 2: same structure as assessment week 1
Participants Number of participants screened: not stated
Number of participants included: 17 (16 boys, 1 girl). Participants were randomly as-
signed to 1 of 24 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R. Also had to meet DSM-III criteria for ADD with
hyperactivity
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Age: mean 9 years 5 months (range 6 years 3 months to 11 years 9 months)
IQ: mean 104.3 (range 89.0 to 127)
Methylphenidate naive: 53%
Ethnicity: not stated
Country: Canada
Setting: treatment centre (hospital) or out-patient clinic
Comorbidity: oppositional defiant disorder (71%), conduct disorder (18%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DMS-III-R criteria for ADHD
2. DSM-III criteria for attention deficit disorder with hyperactivity
3. Ratings from both mothers and teachers at or above a criterion score of 1.5 on the
Hyperactivity Index of the Revised Conners’ Rating Scale
Exclusion criteria
1. IQ < 85
2. Serious visual, auditory or speech deficits
3. Evidence of organic damage
4. Evidence suggesting that symptoms could be attributed to emotional problems or
a stressful home environment
Interventions Participants were randomly assigned to 1 of 24 possible drug condition orders of
methylphenidate (0.3 mg/kg, 0.6 mg/kg, 0.9 mg/kg) and placebo
Mean methylphenidate dosage: 0.3 mg/kg: 9.71; 0.6 mg/kg: 19.42; 0.9 mg/kg: 29.14
Administration schedule: once daily
Duration of each medication condition: 1 day; each child received each dosage twice
during the study (i.e. during first and second assessment weeks)
Washout before study initiation: In the case of children currently receiving stimulants,
medication was discontinued ≥ 48 hours before screening
Titration period: none
Treatment compliance: To ensure compliance, medications were administered at the
laboratory
Outcomes Non-serious adverse events
1. Not described as a measure for the trial, but the Barkley Side Effects Rating Scale
is mentioned
Notes Sample calculation: no information
Ethics approval: no information.
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Under acute dosage conditions as used in this study, methylphenidate doses up to
0.9 mg/kg had an increasingly positive effect on measures of mental flexibility and
other cognitive processes
Email correspondence with study authors: October 2013. Emailed last study author
twice to get supplemental information (protocol, ethics approval, data on side effects,
etc.) but received no response. Therefore we included no data from this study
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Drug order was determined by consecutive
assignment to a randomly ordered list of
24 possible combinations of 4 medication
levels for each of the 2 testing weeks
Allocation concealment (selection bias) Low risk Drug order was determined by consecutive
assignment to a randomly ordered list of
24 possible combinations of 4 medication
levels for each of the 2 testing weeks. To
maximise blindness of examiners, all par-
ticipants received a different drug order for
assessment weeks 1 and 2
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medications containing active drug and
placebo were prepared in identical opaque
gelatin capsules and were administered in a
double-blind fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk To maximise blindness of examiners, all
participants received a different drug order
during assessment weeks 1 and 2
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated whether any participants were
LTFU
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Low risk Funded by grants from the Medical Re-
search Council of Canada and by William
T. Grant Foundation Faculty Scholar Pro-
gram
Conflicts of interest: none
DuPaul 1996
Methods Four-week, double-blind, placebo-controlled, cross-over trial in which participants were
randomly assigned to 3 doses of methylphenidate
1. 0.16 mg/kg
2. 0.29 mg/kg
3. 0.42mg/kg
4. Placebo
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Participants Number of participants screened: not stated
Number of participants included: 24 (19 boys, 5 girls). Participants were randomly
assigned to 1 of 6 possible drug condition orders
Number of participants followed up: 24
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 11.09 years (range 9 to 15)
IQ: > 70
Methylphenidate naive: not stated
Ethnicity: Caucasian (100%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (21%), conduct disorder (% not reported)
Comedication: not stated
Sociodemographics: Children were primarily from lower middle class and middle class
families
Inclusion criteria
1. Parent and/or teacher referral to an out-patient ADHD clinic due to reported
problems with inattention, impulsivity and/or overactivity
2. Parent interview indicating that child met DSM-III-R (American Psychiatric
Association, APA 1987) criteria for ADHD
3. Independent diagnosis of ADHD by psychologist and paediatrician using DSM-
III-R criteria for ADHD
4. Parent or teacher ratings on the Attention problem scale of the Child Behavior
Checklist (Achenbach 1991), resulting in a T score ≥ 65 (i.e. 1.5 SD above the mean)
5. ≥ 9 years old and able to read self report questionnaires independently
Exclusion criteria
1. Evidence of mental retardation, gross sensory or motor disabilities, seizure
disorder, autism, psychosis, tic disorders or Tourette’s syndrome, or significant cardiac
problems
2. Currently receiving psychotropic medication
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of low- (0.
16 mg/kg; SD 0.08), moderate- (0.29 mg/kg; SD 0.11 kg) and high-dose (0.42 mg/kg;
SD 0.14) methylphenidate and placebo
Administration schedule: b.i.d., morning, noon
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Titration period: none
Treatment compliance: No participant was removed from the investigation for non-
compliance (e.g. > 1 day of failure to administer medication as scheduled)
Outcomes ADHD symptoms
1. ADHD Rating Scale: teacher and parent ratings
Non-serious adverse events
1. Barkley Side Effects Rating Scale (17 items, 0 = absent, severity rated from 0 to 9)
: rated by participants at the end of each dosage condition
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Notes Sample calculation: no information
Ethics approval: Human Subjects Research Board at the University of Massachusetts
Medical Center
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Conclusions based on present findings are limited by several factors
2. Among others, sample size may have diminished power to detect methylphenidate
effects on key variables, especially analyses of side effect ratings
3. Also results are generalisable only to children with ADHD between 9 and 15
years of age
Email correspondence with study authors: January 2013 to August 2013. Emailed first
study author regarding additional information. Not able to get all data requested, as
study author no longer has these data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Children were randomly assigned to 1 of 6
possible orders of methylphenidate dosage
Allocation concealment (selection bias) Low risk Medication was prepared by the hospital
pharmacy in increments of 5 mg and pack-
aged within opaque gelatin capsules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, their parents and teachers and
the research assistant in charge of collecting
data were blinded to the order of medica-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, their parents and teachers and
the research assistant in charge of collecting
data were blinded to the order of medica-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Analyses on all dependent measures in the
study are reported in the article
Vested interest bias Low risk No conflicts of interest
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Duric 2012
Methods Randomised, controlled trial, parallel with 3 arms
1. Neurofeedback group
2. Methylphenidate group
3. Methylphenidate + neurofeedback group
Participants Number of participants screened: 628
Number of participants included: 130
Number of participants randomly assigned: methylphenidate 44, control 42
Number of participants followed up: methylphenidate 30 (23 boys, 7 girls), control 30
(22 boys, 8 girls)
Number of withdrawals: methylphenidate 14, control 12
Diagnosis of ADHD: ICD-10 (subtype not stated)
Age: methylphenidate 11.2 (SD 2.8), control 11.4 (SD 3.1)
IQ: mean 87
Methyphenidate-naive: not stated
Ethnicity: not stated
Country: Norway
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: No significant differences in baseline demographics were noted
between the 2 groups
Inclusion criteria
1. ICD-10 criteria for diagnosis of ADHD
2. 6 to 18 years of age
3. IQ > 70
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to methylphenidate and neurofeedback (interven-
tion group) or to neurofeedback (control group)
Methylphenidate dosage: 20 mg daily to 60 mg daily. No placebo pill
Administration schedule: twice per day
Duration of intervention: 11 to 13 weeks
Titration period: not stated
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Two core ADHD symptoms - attention and hyperactivity, Assessment of
Disruptive Behavior Disorders Rating Scale for parents: rated at baseline and 1 week
after neurofeedback had been completed (between weeks 11 and 13 after start of
intervention)
Notes Ethics approval: yes
Comments from study authors
1. Factors that may result in ADHD symptom improvement: extraordinary amount
of time spent with therapist during neurofeedback, better motivation for change in
ADHD symptoms and cognitive-behavioural training induced under neurofeedback
2. For Attention rating, methylphenidate + neurofeedback and methylphenidate, no
significant differences were noted between pre-treatment and post-treatment values
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Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: March to June 2013. Emailed first study
author. All questions were answered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Children with ADHD were randomly
placed into 3 groups
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, as it is not a “pure” placebo
group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of parents
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
Vested interest bias Low risk No
Conflicts of interest: Study authors declare
no potential conflicts of interests with re-
gard to authorship or publication of this
article
Döpfner 2004
Methods Randomised, double-dummy, double-blind, cross-over, multi-centre trial with 3 inter-
ventions
1. Immediate-release methylphenidate 10 mg to 40 mg
2. Extended-release methylphenidate 10 mg to 40 mg
3. Placebo
Phases: Trial was subdivided into 5 stages: pre-screening, run-in phase (duration: 1
workday), trial phases 1 and 2 (duration in each case: 4 workdays plus weekend) and
trial phase 3 (duration: 4 workdays). Participants also received a behavioural therapy
intervention and social skills training at school
Participants Number of participants screened: not stated
Number of participants included: 82. Participants were randomly assigned to differ-
ent orders of immediate-release methylphenidate, extended-release methylphenidate and
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placebo
Number of participants followed up: 79 (71 boys, 8 girls)
Number of withdrawals: 3
Regarding the group followed up
Diagnosis of ADHD: DSM-IV or ICD-10 (combined (92.4%), hyperactive-impulsive
(0%), inattentive (7.6%))
Age: mean 10 years (range 6 to 16)
IQ: 103 ± 10.4
Methylphenidate naive: 0%
Ethnicity: not stated
Country: Germany
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder/conduct disorder (44%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Meeting criteria for an ICD-10 diagnosis of Hyperkinetic disorder (F90) or for a
DSM-IV diagnosis of ADHD
2. Between 8 and 15 years of age
3. Methylphenidate responders on the basis of clinical assessment and after careful
titration
4. All patients had to be treated with immediate-release methylphenidate at least
twice daily or once daily with a retard preparation
5. During previous month, methylphenidate dosage had to be unchanged. Daily
methylphenidate dosage was ≥ 10 mg
6. IQ ≥ 85
7. Body weight > 20 kg
8. Written informed consent of parents and participants to join the trial
Exclusion criteria
1. Patients attending schools for mentally handicapped, sensory handicapped or
physically handicapped children
2. Patients who, during the past 4 weeks, were treated with other medication
because of ADHD, apart from methylphenidate
3. Diagnosis of a severe developmental disorder or psychosis
4. Previous convulsive disorder; EEG indicated susceptibility to convulsions
5. Case history of pathological changes in liver function or liver disease
6. Severe depressive disorder (Child Behavior Checklist, teacher-rated, > 70 on the
Anxiety-depression scale) or a severe anxiety disorder according to clinical diagnosis
Interventions Participants were randomly assigned
Mean methylphenidate dosage: 22 mg ± 6 mg. Dosage was identical in methylphenidate
groups but did not exceed 1 mg/kg body weight. Thus, 9 (11%) participants received a
daily dose of 10 mg, 54 (68%) received 20 mg, 14 (17%) received 30 mg and 2 (3 %)
received 40 mg
Administration schedule: 9:00 AM and 1:00 PM
Duration of each medication condition: 4 days, and for trial phase 1 + 2 (also weekends)
Washout before study initiation: none
Medication-free period between interventions: none
Titration period: had to be oriented to the optimum individual dosage previously deter-
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mined in clinical treatment trials initiated before randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkit, Agler, M-Flynn and Pelham Scale: rated by clinic personnel/
caregiver staff for each child at 9:00 AM, 11:00 AM, 12:30 PM, 3:00 PM and 4.15 PM
2. Fremdbeurteilungsbogen für Hyperkinetische Störungen: staff/personnel-rated, at
1:00 PM and 4:45 PM
Non-serious adverse events
1. Questionnaire on side effects (Side Effects Rating Scale)
Notes Sample calculation: not stated
Ethics approval: approved by local university ethics committees
Comment from study authors
1. Althogh the analogue classroom attempts to mimic many aspects of a regular
school classroom, it represents a unique setting that may influence behaviour. Analogue
assessments included only ADHD participants; no control or normal participants were
available for comparison
Carry-over effect: As no evidence for possible carry-over effects was noted, no secondary
analyses for carry-over effects were performed
Key conclusions of study authors
1. These data provide support for the benefit of this novel, once-daily
methylphenidate preparation for the treatment of ADHD
2. On all measures analysed, both b.i.d. immediate-release methylphenidate and
extended-release methylphenidate produced significant improvement relative to
placebo. Moreover, extended-release methylphenidate was not significantly different
from b.i.d. immediate-release methylphenidate, even longer than 7 hours after dosing
3. Longer duration of action of Medikinet Retard has the potential to simplify
psychostimulant treatment, thus reducing dose diversion and eliminating the need for
in-school administration
Comments from review authors
1. For the article in German (Döpfner 2003 in Döpfner 2004), only 1 review author
who knew German extracted the data. All other articles have been assessed for data by
2 review authors. We received Döpfner 2003 from HB Pharma
2. Eighteen participants in the sample from Clinic for Neuropediatrics, University of
Kiel, received response cost token-based behaviour training (RCT) (Gerber 2012 in
Döpfner 2004)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate: yes; included only methylphenidate re-
sponders
Email correspondence with study authors. We received some data from study authors in
July 2013. We sent 2 additional emails to different study authors to request data in July
2014 but received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Order in which participants were allocated
to respective treatment arms was randomly
assigned
Allocation concealment (selection bias) Unclear risk Order in which participants were allocated
to respective treatment arms was randomly
assigned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To guarantee a double-blind trial, the dou-
ble-dummy method was used (i.e. partic-
ipants took the capsule once a day and
the tablets twice daily). Only 1 of the 2
galenical forms contained the active sub-
stance; the other form contained placebo.
In the placebo group, participants took
both placebo capsules and placebo tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk No protocol obtained
Vested interest bias High risk Study was conducted and sponsored by
MEDICE Arzneimittel Pütter GmbH &
Co. KG as part of the drug approval process
for Medikinet-RetardT M
Conflicts of interest: Some study authors
have affiliations with medical companies
Epstein 2011
Methods Cross-over trial with 2 interventions
Three preliminary phases to determine optimal dose followed by 2-phase trial of the
following
1. Optimal dose of methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: not clear
Number of participants followed up: 93 (numbers of boys and girls: not stated)
Number of withdrawals: not clear
Diagnosis of ADHD: DSM-IV (combined (n = 45), hyperactive-impulsive (n = 48),
inattentive (n = 0))
Age: mean 8.11 years (range 7 to 11)
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IQ: mean 105.58
Methylphenidate naive: 100%
Ethnicity: Caucasian (75%), African American (22%), other (3%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 34), conduct disorder (n = 4), anxiety
disorders (n = 31), mood disorders (n = 2)
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. Children 7 to 11 years of age who met the diagnostic criteria for ADHD, plus 6
non-overlapping symptoms in a symptom domain on the Diagnostic Interview for
Children - Parent Report and Vanderbilt Teacher Rating Scale; both parents and
teachers reported ≥ 4 symptoms in that domain
Exclusion criterion
1. Children with an IQ below 80 (on the Wechsler Abbreviated Scale of
Intelligence) or a score below 80 on the Reading or Numerical operations subtests of
the Wechsler Individual Achievement Test or possible organic brain injury
Interventions Participants were randomly assigned to an optimal dose of methylphenidate and placebo
Mean methylphenidate dosage: 1.13 mg/kg
Administration schedule: testing 1 to 4 hours after medication ingestion
Duration of each medication condition: 1 week
Washout before study initiation: no apparent washout
Titration period: Each of the 3 doses was trialled for 1 week before random assignment
to identify an optimal dose
Treatment compliance: not reported
Outcomes ADHD symptoms
1. Vanderbilt ADHD Rating Scale: completed by parents and teachers at the end of
1 week
Non-serious adverse events
1. Referred to the Pittsburgh Side Effects Rating Scale: completed by parents and
teachers at the end of each week, but data were not reported
Notes Sample calculation: not stated
Ethics approval: not stated
Funding: National Institute of Health (NIH) and National Institute of Mental Health
(NIMH)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Although we used a placebo-controlled, double-blind titration trial to determine
optimal dosage, the highest dosage used in this trial was 54 mg for children
>
= 25 kg
and 36 mg for children < 25 kg
2. Also, a significant minority of children (24%) exited the titration trial, with the
placebo dosage as their optimal dosage, which is comparable with the stimulant
response rate in other studies. The fact that 19% of children in the optimal dose
condition received the same stimulant dosage (i.e. placebo) as was received by the
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placebo control group may have affected the ability of this study to detect between-
group differences for some study outcomes (e.g. accuracy)
Key conclusion of study authors
1. None regarding our outcomes of interest
Email correspondence with study authors: April 2014. We were able to obtain supple-
mental information regarding data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”; capsules were “identical”
(p 2, p 1063)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind”, capsules were “identical”
(p 2, p 1063)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear whether any participants were
LTFU
Selective reporting (reporting bias) Low risk No selective reporting
Vested interest bias Low risk No evidence of vested interests
No evidence of conflicts of interest
Fabiano 2007
Methods Randomised, double-blind, within-participant design, cross-over trial with 2 interven-
tions
1. Methylphenidate
2. Placebo
Phases: 0.15 mg/kg, 0.30 mg/kg and 0.60 mg/kg. Medication was randomly assigned
for each child and varied daily during a 9-week summer treatment programme
Participants Number of participants screened: not stated
Number of participants included: 48 (44 boys, 4 girls). Participants were randomly
assigned to 1 of 4 possible drug condition orders
Number of participants followed up: 47
Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV (combined (not stated), hyperactive-impulsive (not
stated), inattentive (not stated))
Age: mean 9.35 years (SD 1.98, range 5 to 12)
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IQ: 106.33 (SD 14.61)
Methylphenidate naive: not stated
Ethnicity: Caucasian (79%); African American (12.5%); Hispanic, Native American or
mixed race (8.5%)
Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnostic
criteria for ADHD
2. Estimated full-scale IQ ≥ 80
3. No documented adverse response or non-response to methylphenidate
4. No medical condition that would contraindicate use of methylphenidate
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of imme-
diate-release methylphenidate (0.15 mg/kg, 0.30 mg/kg and 0.60 mg/kg) and placebo
Mean methylphenidate dosage: 5.03 mg (range 2.5 to 10), 10.8 mg (range 5 to 20) and
21 mg (range 12.5 to 30)
Administration schedule: 3 times daily (7:45 AM, 11:45 PM and 3:45 PM)
Duration of each medication condition: varied daily
Washout before study initiation: none
Titration period: none/duration initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale (inattention-impulsivity-overactivity): teacher- and
observer-rated, daily
General behaviour
1. IOWA Conners’ Rating Scale (oppositional defiance): teacher- and observer-
rated, daily
Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale: teacher-rated daily
2. Clinically significant adverse events: observer-rated daily
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors
1. “The study was conducted in an analogue classroom setting” (as opposed to a
community classroom)
2. “The treatments used were of short duration”
3. “Observers and raters were blind to medication condition but not to behaviour
modification conditions”
4. Ratings from the Pittsburgh Side Effects Rating Scale were averaged across days
within drug condition (regardless of behaviour modification condition) for the 47
children. One participant’s medication was discontinued because of parental concerns
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about side effects (mainly buccal-lingual movements) after 2 days of treatment, and 1
child’s afternoon dose was reduced on 0.60 mg/kg days because of parent-reported
anxiety and mood symptoms. No other children had side effects rated by the teacher at
an average level of moderate or severe
Comments of review authors
1. This study of placebo versus methylphenidate was conducted during different
conditions of behaviour modification. We should consider whether to use only data
from the non-behaviour modification condition or data from all conditions
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes
Email correspondence with study authors: April 2014. We obtained supplemental in-
formation regarding risk of bias. No further information was received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation and allocation conceal-
ment were completed with a random num-
ber generator by a researcher not involved
in treatment
Allocation concealment (selection bias) Low risk Randomisation and allocation conceal-
ment were completed with a random num-
ber generator by a researcher not involved
in treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Medication assessment procedure was
double-blinded” (p 201) “children, their
parents, and all clinical staff members were
blinded to medication condition” (p 202)
Medication was prepared in opaque cap-
sules by a pharmacist not otherwise in-
volved in the study. It was administered
to children by research staff who were not
involved in administration of behavioural
treatment nor in daily activities
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Observers and raters were blinded to med-
ication conditions
Incomplete outcome data (attrition bias)
All outcomes
High risk One child’s parents elected to stop medi-
cation for the child after 2 days because of
their concerns about possible side effects
of the medication. This child was not in-
cluded in the analyses
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Selective reporting (reporting bias) Low risk No protocol/design was published. All pre-
specified outcomes of interest have been re-
ported
Vested interest bias Low risk This study was funded by the National In-
stitute of Mental Health (NIMH) grant
MH62946
Conflicts of interest: supported only byNa-
tional Institutes
Findling 2006
Methods Three-week, randomised, double-blind, parallel trial with 3 arms
1. Immediate-release methylphenidate (Ritalin)
2. Modified-release methylphenidate (Equasym, EqXL)
3. Placebo
Participants Number of participants screened: 346
Number of participants randomly assigned: 327
Number of participants included: 318; immediate-release methylphenidate 133, modi-
fied-release methylphenidate (EqXL) 139, placebo 46
Number of participants followed up: immediate-release methylphenidate 120, modi-
fied-release methylphenidate (EqXL) 120, placebo 39 (number in each arm is only per
protocol population)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined (71%), hyperactive-impulsive (6%), inatten-
tive (23%))
Age: mean 9.5 years (range not reported)
IQ: above 80
Sex: 252 boys, 66 girls
Methylphenidate naive: 0%
Ethnicity: Caucasian (86%), African Caribbean (5.2%), Asian (0.3%), Hispanic (1.6%)
, other (6.9%)
Country: Australia, Canada, USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Male and female children
2. 6 to 12 years of age
3. Stable dose of methylphenidate 3 weeks before screening
4. Diagnosed with ADHD on the basis of DSM-IV criteria for any subtype and
confirmed by administration of the Kiddie-Sads-Present and Lifetime Versions
interview at screening
5. Attending a school setting in which a single teacher could make morning and
afternoon assessments of the child’s behaviour
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Exclusion criteria
1. Female who had experienced menarche
2. Comorbid psychiatric disorder requiring medication
3. History of seizure or tic disorder or family history of Tourette’s disorder
4. IQ test score below 80, or functioning at a level of intelligence indicative of an IQ
below 80
5. Use of unapproved medication(s)
6. Use of an investigational product within 30 days before study entry
7. Concurrent chronic or acute illness, disability or medication that might confound
the results of rating tests
8. Diagnosed with hyperthyroidism, glaucoma or eating disorder
9. Current substance abuse disorder or living with someone with a current substance
abuse disorder
10. Demonstrated lack of response to methylphenidate
Interventions Participants were randomly assigned to immediate-release methylphenidate, extended-
release methylphenidate or placebo
Mean methylphenidate dosage: not stated
Administration schedule: twice daily, morning and lunch
Duration of intervention: 3 weeks
Titration period: All participants were stable while taking methylphenidate medication
before randomisation
Treatment compliance: not stated. Children with a previous total daily dose of 10 mg to
20 mg immediate-release methylphenidate or 20 mg extended-release methylphenidate
were randomly assigned to receive 10 mg immediate-release methylphenidate twice
daily, 20 mg modified-release methylphenidate (EqXL) once daily or placebo; children
given a previous total daily dose of 25 mg to 40 mg immediate-release methylphenidate
of > 20 mg to < 40 mg extended-release methylphenidate were randomly assigned
to receive 20 mg immediate-release methylphenidate twice daily, 40 mg modified-re-
lease methylphenidate (EqXL) once daily or placebo; children given a previous to-
tal daily dose > 40 mg immediate-release methylphenidate or < 40 mg extended-re-
lease methylphenidate were randomly assigned to receive 20 mg immediate-release
methylphenidate twice daily, 60mgmodified-releasemethylphenidate (EqXL) once daily
or placebo
Outcomes ADHD symptoms
1. Swanson, Nolan and Pelham, Fourth Edition: teacher-rated at baseline and weekly
2. Swanson, Nolan and Pelham, Fourth Edition: parent-rated at baseline and weekly,
at the end of the child’s day
3. IOWA Conners’ Scale (Inattention-Impulsivity-Overactivity): teacher and parent
General behaviour
1. IOWA Conners’ Rating Scale (oppositional defiance): teacher- and parent-rated,
at baseline and weekly (2 hours post dose and 2 to 4 hours post lunch)
Serious adverse events
1. Only 1 serious adverse event (neutropenia) was reported during the study in
EqXL treatment, but the investigator considered it unlikely to be related to the study
medication
Non-serious adverse events
1. Barkley Side Effects Rating Scale: parent- and teacher-rated at baseline and weekly
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2. Adverse events, laboratory parameters, vital signs, physical exam, observer-rated,
time point not specified
Notes Sample calculation: yes
Ethics approval: yes; independent ethics committee at each clinical site before study
initiation
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Key conclusion of study authors
1. Modified-release methylphenidate (EqXL) given once daily was non-inferior to
immediate-release methylphenidate given twice daily. Both treatments were superior to
placebo in reducing ADHD symptoms
Comment from review authors
1. September 2013. Not possible to contact study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” but did not state how
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both EqXL (modi-
fied-release methylphenidate) capsules and
immediate-release methylphenidate tablets
were overencapsulated in hard gelatin cap-
sules identical to the placebo capsule
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Stated LOCF but primary efficacy popula-
tion was the per protocol (PP) population,
defined as participants who received study
treatment and had ≥ 1 efficacy measure-
ment after the first dose
Selective reporting (reporting bias) Low risk No protocol/design was published. All pre-
specified outcomes of interest have been re-
ported
Vested interest bias High risk Funding for this study was provided by
Celltech Americas Incorporated, currently
part of UCB (Union Chimique Belge)
Conflicts of interest: Drs. Hatch and
DeCory and Miss Cameron were em-
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ployees of Celltech at the time of this
study. Dr. Findling received research sup-
port, acted as a consultant and/or served
on a Speakers’ Bureau for Abbott, As-
traZeneca, Bristol-Myers Squibb, Celltech-
Medeva, Forest, GlaxoSmithKline, John-
son & Johnson, Lilly, New River, Novartis,
Otsuka, Pfizer, Sanofi-Synthelabo, Shire,
Solvay and Wyeth. Dr. Quinn claims no
competitive interests. Dr. McDowell has
consulted for Janssen-Cilag and Lilly
Findling 2007
Methods Four-week, double-blind, randomised, placebo-controlled, cross-over trial with 4 inter-
ventions
Methylphenidate (at 3 different doses, in the morning and at midday)
1. 5 mg
2. 10 mg
3. 15 mg
4. Placebo
Phases
Participants were assigned to receive, at random, 1 of 6 possible dosing orders that
included the following
1. Placebo, 5 mg, 10 mg, 15 mg
2. Placebo, 10 mg, 15 mg, 5 mg
3. 5 mg, placebo, 10 mg, 15 mg
4. 5 mg, 10 mg, 15 mg, placebo
5. 10 mg, 15 mg, placebo, 5 mg
6. 10 mg, 15 mg, 5 mg, placebo
Schedules were designed in such a way that participants did not receive the 15 mg dose
before the 10 mg dose, so in the event that a participant experienced adverse events while
taking a lower dose, the 15 mg dose was not administered
Participants Number of participants screened: not stated
Number of participants included: 20. Participants were randomly assigned to 1 of 6
possible drug condition orders
Number of participants followed up: 16 (12 boys, 4 girls)
Number of withdrawals: 4
Demographic data regarding the 16 who completed the study
Diagnosis of ADHD: DSM-IV (combined (94%), inattentive (6%))
Age: mean 10.43 years (range 5 to 17)
IQ: > 70
Methylphenidate naive: not stated
Ethnicity: White (75%), African American (6%), Hispanic (19%)
Country: USA
Setting: out-patient clinic
Comorbidity: bipolar (100%), oppositional defiant disorder (50%), conduct disorder
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(25%), enuresis (12.5%), encopresis (12.5%)
Comedication: 100% divalproex sodium. Some received clonidine for sleep at night
Sociodemographics: not stated. No statistically significant differences in distribution
based on sex, ethnicity, age group, rate/proportion of comorbid oppositional defiant
disorder or comorbid conduct disorder were found between 6 six dosing order groups
Inclusion criteria
1. 5 to 17 years of age
2. Individuals meeting DSM-IV criteria for a diagnosis of bipolar spectrum disorder
and a comorbid diagnosis of ADHD were eligible for study participation
3. Treated with fixed doses of mood stabilisers at the time of study enrolment for ≥
5 days before receiving study medication
4. Eligible if study physician’s clinical assessment indicated the need for a
psychostimulant for treatment of “dysfunctional residual symptoms of ADHD”
Exclusion criteria
1. Mental retardation
2. Pervasive developmental disorder
3. Inability to swallow pills
4. History of alcohol or other substance abuse or dependence within 6 months
before enrolment
5. Active neurological or other medical condition suspected to be related to mood
symptoms
6. Pregnant females, those intending to become pregnant and sexually active female
patients who were using an inadequate form of birth control were not permitted to
participate
7. Participation required a negative qualitative pregnancy test within 2 weeks of
receiving the first dose of double-blind treatment for female patients of childbearing
potential
8. Significant symptoms of mania (Young Mania Rating Scale score > 13) or
depression (CDRS-R > 40) during the week before enrolment and anticipated dosing
changes for mood-stabilising agents
9. Individuals receiving a tricyclic antidepressant or antipsychotic agent and those
with symptoms of psychosis or suicidal ideation
10. Females nursing an infant and patients experiencing significant medical or
neurological illness were not permitted to participate
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate (5 mg b.i.d., 10 mg b.i.d., 15 mg b.i.d.) and placebo
Mean methylphenidate dosage: not provided, as the trial compares methylphenidate at
different doses
Administration schedule: morning and midday
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: between lunchtime dose and morning
dose the following day
Titration period: none. Dosing schedules were designed in such a way that patients did
not receive the 15 mg dose before the 10 mg dose, so in the event that a participant
experienced adverse events while on a lower dose, the 15 mg dose was not administered
Treatment compliance: One of 20 screened participants was withdrawn from the study
because of poor compliance. Among the 16 who participated, no compliance issues were
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reported
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition: rated weekly by parents
2. Conners’ Parent Rating Scale (48-item): rated weekly
General behaviour
1. Conners’ Parent Rating Scale, Conduct problem subscale
Non-serious adverse events
1. Child Depression Rating Scale - Revised: rated weekly
2. Young Mania Rating Scale: rated weekly.
3. Side Effects/Behavior Monitoring Scale: rated weekly at the study visit
4. Resting blood pressure and pulse recorded each week
5. Weight documented at baseline and at end of study
Notes Sample calculation: yes
Ethics approval: yes
Comments from study authors (limitations)
1. Small sample size
2. Full consideration of dosing order effects was not possible because of the modest
size of this study cohort
Key conclusion of study authors
1. Euthymic youths with bipolar disorder and ADHD may benefit from short-term
concomitant treatment with methylphenidate
Comment from review authors
1. All participants have a bipolar disorder
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: yes; 2
Email correspondencewith study authors:November 2013.Wewrote to the study author
twice to request a copy of the protocol and information about sample size and allocation
concealment but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomnumbers tablewas generated and
was used by a pharmacist to assign dose or-
ders to participants. Counterbalancing was
applied in such a way that as each dose or-
der was used, its number was eliminated
from the next dose order assignment
Allocation concealment (selection bias) Low risk Placebo and methylphenidate in identical
capsules. No participants were discontin-
ued from this trial because of broken in-
tegrity of the blind
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk At the conclusion of the 4-week study,
study physician, participant and partici-
pant’s guardian determined a “best dose
week”, taking into consideration behaviour
ratings and reports of any adverse events.
After all assessments had been completed,
the study blind was broken to reveal the
dose that had been prescribed during the
previously identified ’best dose week’. No
participants were discontinued from this
trial because of broken integrity of the blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “After all of the assessments had been com-
pleted, the study blind was then broken to
reveal the dose that had been prescribed
during the previously identified ’best dose
week”’
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data present
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Unclear risk Stanley Medical Research Institute
Conflicts of interest: Some study authors
have affiliations with pharmaceutical com-
panies
Findling 2008
Methods Seven-week randomised, phase III, double-blind, multi-centre, parallel-group, placebo-
controlled, naturalistic home and school trial with 3 arms
1. Methylphenidate transdermal system patch + placebo capsule
2. OROS methylphenidate capsule + placebo patch
3. Placebo capsule + placebo patch
Five-week titration phase, 2-week maintenance phase
Participants Number of participants screened: not stated
Number of participants included: 282 (187 boys, 95 girls)
Number of participants randomly assigned (and administered ≥ 1 dose of study medi-
cation): methylphenidate transdermal system 100, OROS methylphenidate 94, placebo
88
Number of participants followed up: methylphenidate transdermal system 71, OROS
methylphenidate 66, placebo 32
Number of withdrawals: methylphenidate transdermal system 27, OROS
methylphenidate 25, placebo 53
Diagnosis of ADHD: DSM-IV-TR (combined (80.5%), hyperactive-impulsive (1.4%)
, inattentive (17.0%), unclassified (1.1%))
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Age: mean 8.8 years (range 6 to 12). Methylphenidate transdermal system 8.9, OROS
methylphenidate 8.8, placebo 8.5
IQ: ≥ 80
Methylphenidate naive: 86%
Ethnicity: Caucasian (77.3%), African American (14.5%), Asian (0.7%), Hispanic (not
stated), other (7.4%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated. No significant differences in baseline demographics (age,
sex, ethnicity, ADHD subtype, prior ADHD medication use) among the 3 groups
Inclusion criteria
1. 6 to 12 years of age, inclusive
2. ADHD, DSM-IV-TR
3. Stimulant-naive or known to be stimulant-responsive
4. IQ ≥ 80
5. Total score of 26 on ADHD Rating Scale, Fourth Edition, while unmedicated
6. Normal laboratory parameters and vital signs, including ECG
7. Females of childbearing potential must have a negative serum beta human
chorionic gonadotropin (HCG) pregnancy test at screening and a negative urine
pregnancy test at baseline
Exclusion criteria
1. Comorbid psychiatric diagnosis (except oppositional defiant disorder)
2. History of seizures during the past 2 years
3. Tic disorder
4. Any concurrent illness or skin disorder that might compromise safety or study
assessments
5. Ingestion of clonidine, atomoxetine, antidepressants, antihypertensives,
investigational medications, hepatic or cytochrome (p 450) enzyme-altering agents,
medications with central nervous system effects, sedatives, antipsychotics or anxiolytics
within the 30 days before study entry
6. Overweight (body mass index (BMI)-for-age > 90th percentile)
Interventions Participants were randomly assigned tomethylphenidate patch,OROSmethylphenidate
or placebo
Titrationperiod: 5weeks (after randomisation) of optimisation to 1of 4 total daily dosage
strength. OROS methylphenidate: 18 mg, 27 mg, 36 mg and 54 mg. Methylphenidate
transdermal system and placebo transdermal system: 10 mg, 15 mg, 20 mg and 30
mg over a 9-hour period in patches of 12.5 cm², 18.75 cm² , 25 cm² and 37.5 cm²,
respectively
Administration schedule: Treatments were administered at approximately 7:00 AM each
morning; patches were applied to the hip area and were worn for approximately 9 hours
daily, different hip each day
Mean patch wear time: 8.70 (0.51) to 9.46 (0.53) hours
Duration of intervention: 7 weeks
Washout before study initiation: up to 28 days if applicable
Treatment compliance: mean compliance 97% to 99% during both study phases
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Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition: clinician-rated, weekly
2. Conners’ Teacher Rating Scale: teacher-rated, twice weekly
3. Conners’ Parent Rating Scale: parent-rated, twice weekly
Non-serious adverse events
1. Evaluations for safety were performed at the end of each week during both dose-
optimisation and dose-maintenance phases. Furthermore, adverse events were
spontaneously reported as coded via MedDRA (7.0) Adverse Event Dictionary
2. Blood pressure, pulse, oral temperature, weight: weekly
3. Laboratory parameters: week 7
4. Sleep-related behaviours rated by parents each week using Children‘s Sleep Habits
Questionnaire
5. Skin reactions due to the patch investigated each week; Dermal Response Scale
6. ECG: final dose-optimisation visit and final study visit
Notes Sample calculation: yes (258 participants)
Ethics approval: yes
Comments from study authors
1. It is important to note, however, that effects reported are for baseline and
endpoint reports of sleep problems; thus, these results may not generalise to the
titration period. For example, sleep problems may have resulted in dosage adjustments
and attenuation of sleep problems during titration
2. Respondents did not enter the maintenance phase if spontaneously reported side
effects could not be controlled by adjusting the dose. Thus, participants with extreme
insomnia would not have entered the maintenance phase
3. Rating scales for sleep problems may lack validity
Key conclusions of study authors
1. Results of this study suggest that the methylphenidate transdermal system is an
efficacious treatment option for children with ADHD
2. Results of our analysis suggest that emergence or worsening of sleep problems in
response to treatment of ADHD symptoms with OROS methylphenidate or
methylphenidate transdermal system generally should not be a major concern to
clinicians, children with ADHD or their parents after titration to an optimal dose, as
described for this protocol. However, these suggestions should be considered in the
light of other research that supports an effect of methylphenidate on insomnia and
other sleep difficulties, especially when methylphenidate will be administered to
children with pre-existing sleep difficulties. These findings should not be generalised to
children who have not been titrated to an optimal dose
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes. An inclusion criterion is that participants
are stimulant-naive or stimulant-responsive
Any withdrawals due to adverse events: yes; 11
Email correspondence with study authors. June to September 2013. We attempted to
obtain supplemental efficacy and safety data from study authors but without success
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
schedule
Allocation concealment (selection bias) Low risk Computer-generated random numbers
schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy: Partici-
pants received both a patch and a capsule to
be administered each day.Methylphenidate
and placebo capsules were overencapsu-
lated to blind the identity of the capsule’s
content
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT, LOCF
Selection bias: yes; non-responders ex-
cluded during the study. Participants who
did not reach an acceptable condition by
the final dose-optimisation visit (week 5)
were withdrawn from the study
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
Vested interest bias High risk This study was funded by Shire Develop-
ment Incorporated, Wayne, Pennsylvania
Conflicts of interest: Some study authors
received research support, acted as consul-
tants and/or served on a Speakers’ Bureau
for several pharmaceutical companies
191Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Findling 2010
Methods Phase IIIB, randomised, double-blind, parallel-group, placebo-controlled, multi-centre,
dose-optimisation study evaluating the efficacy and safety of the following in adolescents
13 to 17 years of age with ADHD
1. Methylphenidate transdermal system (10-, 15-, 20- or 30-mg/9-hour patches)
2. Placebo transdermal system
Study consisted of 4 experimental periods
1. Screening and washout
2. Dose optimisation (5 weekly visits)
3. Dose maintenance (5 monthly visits)
4. Seven-day post-treatment follow-up
Follow-up consisted of an open-label extension study conducted to evaluate the safety
and efficacy of the methylphenidate transdermal system (10-, 15-, 20- or 30-mg/9-
hour patches) for participants who completed all required study visits; consisted of 3
experimental periods
Participants By using 85% power to detect an effect size of 0.5 between active treatment and placebo
at the significance level of 5%, it was estimated that 112 participants were needed for
methylphenidate transdermal system groups and 56 for placebo transdermal system
groups. Assuming a 20%drop-out rate, ~ 210 participants (methylphenidate transdermal
system 140, placebo transdermal system 70) were required for the study
For the double-blind, randomised, controlled trial
Number of participants screened: not stated
Number of participants included: 217 (162 boys, 55 girls)
Number of participants randomly assigned: methylphenidate 145, placebo 72
Number of participants followed up (ITT population): methylphenidate 143, placebo
72
Number of withdrawals: methylphenidate 2, placebo 0
Number that completed 7-week dose-optimisation/dose-maintenance phase:
methylphenidate 95, placebo 72
Diagnosis of ADHD: DSM-IV (types not stated)
Age: mean 14.6 years (SD 1.3, range 13 to 17)
IQ: ≥ 80
Methylphenidate naive: 122 (56%)
Ethnicity: Caucasian (77%), African American (18%), Asian (0.5%), other (4.5%)
Country: USA
Setting: out-patient clinic
Comorbidity: 0%
Comedication: not stated
Sociodemographics: not stated. No significant difference in baseline demographics were
noted between the 2 groups
For the open-label extension (regarding safety measures)
Number of participants included: 163 (previously taking methylphenidate 110, placebo
53)
Number of participants followed up: 162 (121 boys, 41 girls)
Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV (types not stated)
Age: 14.5 years (SD 1.24, range 13 to 17)
IQ: ≥ 80
Methylphenidate naive: 122 (56%)
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Ethnicity: Caucasian (78%), African American (17%), Asian (0.6%), other (4.4%)
Country: USA
Comorbidity: 0 %
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Male or female adolescents
2. 13 to 17 years of age
3. Primary diagnosis of ADHD according to DSM-IV
4. IQ score > 80
5. Total score ≥ 26 on the ADHD Rating Scale, Fourth Edition, at baseline
6. Participants were required to have ECG results within normal range or variants
that were not clinically significant, as judged by investigators in conjunction with the
central laboratory
7. Blood pressure measurements within the 95th percentile for age, sex and height
8. No current or past skin disease or other skin problems, including sensitive skin or
signs of skin irritation
9. Females must have a negative urine pregnancy test at entry and must agree to use
acceptable contraceptives throughout the study period and for 30 days the last dose of
IP
Participant and parent of legally authorised representative (LAR) are able, willing and
likely to fully comply with study procedures and restrictions
1. Regarding the 6-month open-label study: Participants must have completed all
required study visits or a 5-week dose-optimisation period without achieving an
acceptable condition (i.e.
>
= 25% decrease from baseline in a participant’s ADHD
Rating Scale, Fourth Edition, score with minimal side effects)
Exclusion criteria
1. Conduct disorder or comorbid psychiatric illness (such as clinically significant
obsessive-compulsive disorder, depressive or anxiety disorder; post-traumatic stress
disorder; psychosis; bipolar illness; or pervasive developmental disorder); history of
structural cardiac abnormality, cardiomyopathy, cardiac rhythm abnormalities or other
serious cardiac problems; suicidal ideation; alcohol or other substance abuse (except
caffeine or nicotine) within the past 6 months
2. Seizures during the previous 2 years and a history of being non-responsive to
psychostimulant treatment; use of clonidine, atomoxetine, antidepressants, sedatives,
antipsychotics, anxiolytics, P450 enzyme-altering agents or other investigational
medications within 30 days before screening
3. Female participant who is pregnant or lactating
Regarding the 6-month open-label study
1. Participants were not eligible to participate in the extension study if they were
discontinued from the antecedent study because of a protocol violation (including
non-compliance) or had experienced an adverse event for which continued treatment
would be medically contraindicated, or a serious adverse event
2. Participants with considerable general medical illness (except mild, stable asthma)
or an unstable medical condition, disability or other condition the investigator believed
might interfere with or prevent completion of the study
Interventions Participants were randomly assigned to methylphenidate transdermal (patches) or
placebo
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Mean methylphenidate dosage at week 7: 10 mg (4.2%), 15 mg (16.7%), 20 mg (24.
0%), 30 mg (55.2%); median exposure time: 48 days (range 4 to 57)
Administration schedule: single patch in the morning, once daily for 9 hours
Duration of intervention: 7 weeks
Titration period: 5 weeks, initiated after randomisation
Treatment compliance: 124 fulfilled the protocol. However, it is not stated in the article
how compliance regarding the medication had to be assessed to fulfil the protocol
Mean methylphenidate dosage at month 6: 10 mg (5.6%), 15 mg (7.9%), 20 mg (32.
6%), 30 mg (53.9%); median exposure time: 168 days (range 3 to 200)
Administration schedule: single patch in the morning, once daily for 9 hours
Duration of intervention: 6 months
Titration period: 5 weeks of the 6 months
Treatment compliance: not stated. 88 fulfilled the protocol. However, it is not stated
in the article how compliance regarding the medication had to be assessed to fulfil the
protocol
Outcomes Regarding the 7-week parallel study
ADHD symptoms
1. ADHD Rating Scale, Clinicians: rated baseline and weekly for 7 weeks (each
study visit)
2. Conners’ Parent Rating Scale - Revised, Parents: rated baseline and weekly for 7
weeks (each study visit)
Serious adverse events
1. None
Non-serious adverse events
1. Adverse events monitored at each study visit. All AEs were coded using the
MedDRA, Version 7.0
2. Height measurements were performed at screening and at the final double-blind
study visit
3. Vital signs (systolic and diastolic blood pressure, pulse) and weight, at screening,
at baseline and at each study visit
The investigator determined the clinical significance of any physical examination, height
or vital sign measurement that was outside the normal range. Clinically significant devi-
ations from measurements recorded at screening were reported as AEs. A 12-lead ECG
evaluation was obtained at screening, at baseline, at week 5 and at the final double-blind
study visit.Dermal skin reaction: Dermal Scale (DRS) was used to evaluate observed skin
findings: range 0 to 7, where 0 shows no evidence of irritation
Regarding 6-month open-label study
1. Dose optimisation (5 weekly visits); dose maintenance (5 monthly visits)
i) AEs were monitored at each study visit and were assessed by an open-ended
inquiry along with specific dermatological questions asked by an investigator or a
qualified evaluator. AEs were considered treatment-emergent if they began or worsened
on or after application of the first patch, and occurred before or at the same time as
application of the patch. AEs coded and defined using the MedDRA, Version 7.03, at
7-day post-treatment follow-up
ii) Height: measured at month 6 visit by the investigator
iii) Weight: recorded at all visits (5) by the investigator
iv) Vital signs (systolic blood pressure, diastolic blood pressure, pulse): measured
at all study visits by the investigator. 12-Lead ECG performed at entry, week 4, month
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3 and month 6 by the investigator
v) Blood and urine samples collected at entry, week 4, month 4 and month 6
vi) Dermal skin reaction: measured by DRS at each study visit.
vii) Sleep: measured by non-validated Post-Sleep Questionnaire. Measured at 6-
month visit
Changes noted between evaluation data at study entry and data obtained at schedule
visits deemed to be clinically significant by the investigator were considered an adverse
event
Notes Sample calculation: yes
Ethics approval: yes
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Comments from study authors
1. Given the short duration of this study, results do not characterise the long-term
effects of treatment with methylphenidate transdermal system
2. It is important to note that participants who failed to respond to
psychostimulants in the past and those with conduct disorder and other psychiatric
comorbidity were excluded from the study
3. Regarding the 6-month study: no clinically significant findings between
laboratory evaluation parameters obtained post entry relative to screening values
obtained at the antecedent study
4. Limitations: This study used an open-label design; thus tolerability and
effectiveness assessments are susceptible to observer bias. Another way in which results
of long-term, open-label continuation studies may be biased is that participants who
enrol in a study after participating in an antecedent trial may represent that subset of
patients who have had improvement in ADHD symptoms and/or who did not
experience substantial adverse events in the antecedent study
Key conclusions of study authors
1. Methylphenidate transdermal system therapy was generally well tolerated and
resulted in significantly greater improvement in ADHD symptoms among adolescents
when compared with the placebo transdermal system
2. Reported adverse events included those typically observed for oral
methylphenidate, with the exception of generally mild application site erythema
associated with transdermal delivery
3. Regarding the 6-month open-label study: Methylphenidate transdermal system
was generally well tolerated, and adverse events were generally typical of those
associated with oral methylphenidate, with the exception of application site reactions
associated with transdermal delivery of methylphenidate
Comments from review authors
1. As already stated, people who earlier had failed to respond to psychostimulants
were not included in the study. Therefore, results can be generalised only to responders
2. Risk of bias table done only for the 7-week parallel-group study
3. Regarding the 6-month open-label study: Participants who had not reached an
acceptable response by the end of week 5 were withdrawn from the study
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participantswere allocated the next sequen-
tial randomisation number and received
treatment that corresponded with that ran-
domised number as given by an interactive
voice response system
Allocation concealment (selection bias) Low risk Randomisation schedule was produced by
computer software that incorporated a
standard procedure for generating random
numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no information on
methylphenidate and placebo blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Efficacy analyses were performed on the
ITTpopulation, defined as all randomly as-
signed participants who received ≥ 1 dose
of study medicine and ≥ 1 post-baseline
primary efficacy assessment. Safety popu-
lation was defined as all randomly assigned
participants who received≥ 1 dose of study
medicine
Selection bias (e.g. titration after randomi-
sation→ exclusion): yes. No further dose
titration was permitted for any participant
after week 5, and participants who had not
reached an acceptable response by the end
of week 5 were withdrawn from the study
Selective reporting (reporting bias) Low risk Protocol registered 12 July 2007. First par-
ticipant consent was obtained 29 August
2007 for the open-label study
Vested interest bias High risk This study was funded by Shire Develop-
ment Incorporated, which was involved in
study design, conduct and data analysis.
The open-label study was industry-spon-
sored
Conflicts of interest: Dr. Findling has acted
as consultant to, has served on Speak-
ers’ Bureaus of and/or has received re-
search support fromAbbott, Addrenex, As-
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traZeneca, Biovail, Bristol-Myers Squibb,
Eli Lilly, Forest Pharmaceuticals, Glaxo-
SmithKline, KemPharm, Johnson & John-
son, Lundbeck, Neuropharm, Novartis,
Noven, Organon, Otsuka, Pfizer, sanofi-
aventis, Sepracor, Shire, Solvay, Supernus,
Validus and Wyeth. Dr. Turnbow receives
or has received research support, acted as
a consultant and/or served on Speakers’
Bureaus for Eli Lilly, Novartis US, sanofi-
aventis, Shire and UCB (Union Chimique
Belge). Dr. Burnside has acted as consul-
tant to, has served on Speakers’ Bureaus of
and/or has received research support from
Eli Lilly, Johnson & Johnson, Shire and
Wyeth. Dr. Melmed has acted as consul-
tant to, has served on Speakers’ Bureaus of
and/or has received research support from
Bristol-Myers, Eli Lilly, McNeil, Novartis
and Shire. Drs. Civil and Li are full-time
employees of Shire Development Incorpo-
rated
Fine 1993
Methods Three-week double-blind, cross-over trial with 2 interventions
1. Methylphenidate b.i.d. (2 doses: 0.3 mg/kg and 0.6 mg/kg)
2. Placebo b.i.d.
Phases: medical trial or typical clinical procedure, concluded with recommendation for
treatment, follow-up (6 weeks and 3 months)
Participants Number of participants screened: 24
Number of participants randomly assigned: 12 “typical clinical procedure”, 12 “medical
trial”
Number of participants included: 12 (sex not stated). Participants in the medical trial
group were randomly assigned to different possible drug condition orders
Number of participants followed up: 12
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 101.58 months (range 6 to 10 years)
IQ: not stated
Methylphenidate naive: 12
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics (socioeconomic status calculated using Blishen Index; lower score
indicates higher SES): medical trial: mean 3.42 (SD 0.90); typical clinical procedure:
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mean 3.50 (SD 1.88)
Inclusion criterion
1. ADHD diagnosis. Parent interview with psychiatrist, several parent (mother
AND father) and teacher ratings. Included if any positive
Exclusion criteria
1. Physical or intellectual handicap
2. Tic disorders
Interventions Participants in the medical trial group were randomly assigned to different possible drug
condition orders of 0.3 mg/kg and 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: b.i.d.
Duration of each medication condition: “the different interventions were randomly
assigned across days”
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: not stated
Treatment compliance: missed pills mean 1.92 (SD 1.44). Furthermore, compliance was
assessed by urine test. By 6-week follow-up, parent-reported compliance was 83%; by 3
months, it was 73%
Outcomes ADHD symptoms
1. Abbreviated Conners’ Rating Scale: rated on weekdays by teachers and on
weekends by parents
2. Swanson, Nolan and Pelham: rated daily, but not stated by whom
Non-serious adverse events
1. Side effects questionnaire: rated weekly by parents (“Across the 12 children,
ratings were available from an average of 2.58 placebo days, 1.33 low-dose MPH days
and 1.75 high-dose MPH days”)
Notes Sample calculation: not stated
Ethics approval: not stated
Comments from study authors
1. Small sample size
2. Rely on parent ratings to assess side effects
Key conclusions of study authors
1. Fine 1993: “Our analyses revealed that several side-effects appeared equally often
on placebo as on active medication and the parents’ reports of side effects are
significantly related to reports of ADHD symptomatology” (p 28)
2. Johnston 1993 (in Fine 1993): “In summary, this study finds mixed support for
the prediction that medication trials would enhance acceptability, satisfaction, and
compliance associated with MPH” (p 728)
Comments from review authors
1. This trial aims to examine differences in attitudes of parents whose children
participate in a medical trial or are subjected to “typical clinical procedure”
2. Only the medical trial group represents a cross-over design
3. Fine 1993 deals only with the medical trial group, and Johnston 1993 (in Fine
1993) deals with both
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
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adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: June 2014. Emailed study authors for sup-
plemental information and received the following response: “I did look at the questions,
but unfortunately, given how long ago the study was conducted, I do not still have the
data necessary to answer” (Krogh 2014b [pers comm]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 24 children were matched in pairs on sex
and age and then were randomly assigned
to the medication trial or to the typical
clinical procedure. Higher and lower doses
of methylphenidate and placebo were ran-
domly assigned across days by the hospital
pharmacy
Allocation concealment (selection bias) Low risk Higher and lower doses ofmethylphenidate
and placebo were randomly assigned across
days by the hospital pharmacy. Active med-
ication and placebo were packaged in cap-
sule form to disguise taste and visual differ-
ences, and were dispensed in envelopes for
daily use
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, teacher, child and resident were
blinded to the daily medication status of
the child. “Active medication and placebo
were packaged in capsule form to disguise
taste and visual differences, and were dis-
pensed in envelopes for daily use”. All eval-
uations were conducted by psychiatric resi-
dents blinded to the hypotheses of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents, teacher, child and resident were
blinded to the daily medication status of
the child. All evaluations were conducted
by psychiatric residents blinded to the hy-
potheses of the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Across 12 children, ratings were available
for an average of 2.58 placebo days, 1.33
low-dose methylphenidate days and 1.75
high-dose methylphenidate days. Ratings
for each child were averaged across each
of the 3 treatment conditions. Data for all
participants were available for measures of
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missed pills and appointments. One partic-
ipant was missing on measures of parent-
reported compliance at 6-week follow-up,
and 2 participants at 3-month follow-up.
Three participants lacked data for the num-
ber of missing envelopes. Four participants
did not provide urine for analysis, and 4
were missing physician reports of compli-
ance (6-week and 3-month follow-ups). As
the result of intervening school holidays,
teacher reports of compliance are available
for only 16 children (8 in each condition)
at each follow-up.
Methylphenidate non-responders were not
excluded. Did not state the method used to
account for missing outcome data
Selective reporting (reporting bias) Unclear risk All analyses mentioned are described, but
no protocol was identified
Vested interest bias High risk Funding from CIBA-GEIGY Canada
Firestone 1981
Methods Three-month, randomised, double-blind, placebo-controlled, parallel study, wherein
participants were randomly assigned to 3 arms
1. Parent training + placebo (control group)
2. Parent training + methylphenidate (intervention group)
3. Methylphenidate
Participants Number of participants screened: 91
Number of participants included: not stated (includes boys and girls)
Number of participants randomly assigned: not stated
Number of participants followed up: intervention 18, control 13
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III
Age: mean 7.32 years (range 5 to 9)
Methylphenidate naive: not stated
Ethnicity: not stated
Country: not stated
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
IQ: 116
Sociodemographics: all children living at home with ≥ 1 parent. No significant differ-
ences in age and IQ between treatment groups. No data on remaining parameters
Inclusion criteria
1. 5 to 9 years of age
200Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Firestone 1981 (Continued)
2. Fit DSM-III criteria for attention deficit disorder with hyperactivity, showing
overactivity, short attention span, impulsivity, aggressiveness and oppositional
behaviour, both at home and in school, since before 4 years of age
3. Hyperactivity Index of Conners’ Behavior Rating Scale for teachers ≥ 15
4. IQ > 85
Exclusion criteria
1. Brain damage
2. Epilepsy
3. Psychosis
Interventions Participants were randomly assigned to methylphenidate + parent training (interven-
tion group) or to placebo + parent training (control group). First 3 to 4 weeks:
Methylphenidate was titrated (after randomisation), starting with 5 mg b.i.d. (morning,
noon), 7 days a week. After the titration period: Methylphenidate was given only on
school days
Average methylphenidate dosage: 22 mg/d (range 10 mg/d to 30 mg/d)
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale 2, Conners’ Parent Rating Scale subscale
2. Hyperactivity Index: rated by mothers post treatment
Notes Ethics approval: no information
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Key conclusions of study authors
1. All groups showed improvement at home and in school; only with
methylphenidate administration were gains in measures of attention and impulse
control also seen
2. Results also revealed greater improvement in academic achievement and in
classroom behaviour in medication groups as compared with placebo groups
3. No evidence showed significant benefit from the addition of parent training to
administration of medication
Comment from review authors
1. First study author has retired; we were not able to get data from him (e.g.
protocol, randomisation method)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children were randomly assigned; no de-
scription of how
Allocation concealment (selection bias) Unclear risk No data
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, teachers, therapists and those test-
ing the children were unaware of medica-
tion conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents, teachers, therapists and those test-
ing the children were unaware of medica-
tion conditions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders):
none
Selective reporting (reporting bias) Unclear risk No data
Vested interest bias Low risk Ministry of Health
Conflicts of interest: not stated
Fitzpatrick 1992a
Methods Cross-over trial with 4 interventions
1. Sustained-release methylphenidate
2. Standard methylphenidate
3. Combination
4. Placebo
Phases: 4 pharmaceutical conditions, each lasting 2 weeks (including weekends), with
different dosage schedules based on weight of child and type of intervention
Participants Number of participants screened: not stated
Number of participants included: 19 (17 boys, 2 girls). Participants were randomly
assigned to 1 of 24 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADD: DSM-III during Diagnostic Instrument for Childhood and Adoles-
cence (ADD with hyperactivity 16/19) (ADD without hyperactivity 3/19)
Age: mean 8.71 years (SD 1.33, range 6.9 to 11.5)
IQ: 114.11 (SD 13.34)
Methylphenidate naive: 18
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional disorder (n = 12), oppositional + conduct disorder (n = 1)
, enuresis (n = 2), encopresis (n = 2), phobia (n = 1), overanxious (n = 1), adjustment
disorder (n = 1)
Comedication: not stated
Sociodemographics: middle class (Hollingshead 4-factor mean 38.11, SD 13.18)
Inclusion criteria
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1. Not explicitly stated
Exclusion criteria
1. Not explicitly stated
Interventions Participants were randomly assigned to 1 of 24 (3 methylphenidate and 1 placebo)
possible drug condition orders of sustained-release methylphenidate (SR), standard
methylphenidate (SA), methylphenidate combination and placebo
Mean methylphenidate dosage: SRSA-MPH 17.1 mg (0.56 mg/kg), SASR-MPH 20 mg
(0.67 mg/kg), combination 11.8 mg SA MPH + 20 mg SR MPH (0.38 mg/kg SA, 0.
67 mg/kg SR)
Administration schedule: sustained-release methylphenidate, mornings (8:00 AM) daily,
SA MPH morning (8:00 AM) and noon daily
Duration of each medication condition: 2 weeks
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: not stated
Treatment compliance: parents phoned weekly to encourage compliance. School nurse
contacted at the beginning of each individual’s participation to promote co-operation
and to check on compliance
Outcomes ADHD symptoms
1. Conners’ Hyperactivity Index: parent- and teacher-rated, weekly (although results
were averaged over treatment phase)
2. IOWA Inattention/Overactivity and Aggression/Non-compliance Scales: parent-
and teacher-rated, weekly
3. Hyperactivity, Attention and Aggression subscales of Loney’s Time on Task Scale
(TOTS): every 2 weeks
General behaviour
1. Selected items of Child Psychiatric Scale: observer, end of each laboratory session
(i.e. after 14 days of treatment)
Non-serious adverse events
1. Interviewed: 12 side effect symptoms: drawn from Subject’s Treatment Emergent
Symptom Scale, parents, end of each treatment phase
2. Body weight: start of each laboratory session
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusions of study authors
1. Methylphenidate conditions were superior to placebo and were comparable with
one another
2. Findings suggest comparable effectiveness for sustained and standard preparations
of methylphenidate
3. Improved behaviour and improved information processing under stimulant
conditions
Comment from review authors
1. This study was not actually randomised; therefore we cannot use data on ADHD
symptoms and general behaviour - only data on adverse events
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not clear
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Double-blind trial consisting of 4 pharma-
cological conditions, each lasting 2 weeks
and ordered according to a Latin square (i.
e. not randomly assigned)
Allocation concealment (selection bias) High risk Not randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Blindness was maintained
by administering placebo tablets consisting
of the vehicle for the SA and SR prepara-
tions, respectively, as appropriate for each
condition
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data for 6 participants on Paired Associate
Learning Test excluded, as they could not
read well, but this was not 1 of our out-
comes
Selection bias (e.g. titration after randomi-
sation): no, but because of emergent side
effects, reductions of 2.5 mg SA MPH per
dose were performed blindly for 1 partic-
ipant in the combined condition. Simi-
larly, blinded (but sham) adjustments of SA
placebo were made for 2 participants in the
placebo phase and for 1 in the SR condi-
tion
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk Research was supported by National In-
stitute of Mental Health (NIMH) grant
MH38118
Conflicts of interest: not stated
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Methods Four-week, double-blind, randomised, placebo-controlled, cross-over study of
methylphenidate and placebo with weekly switches of 4 dosage levels; capsules of
1. 0.5 mg/kg
2. 0.75 mg/kg
3. 1 mg/kg
4. Placebo
Methylphenidate-sensitive children continued in an open-label study for 4 weeks
Participants Number of participants screened: 80
Number of participants included: 30 (22 boys, 8 girls). Participants were randomly
assigned to 1 of the possible drug orders of low-dose, moderate-dose and high-dose
methylphenidate and placebo
Number of participants followed up: 30
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (37%), inattentive (57%), hyperactive-im-
pulsive (7%))
Age: mean 105.2 months (SD 25.1, range 7 to 12 years)
IQ: > 70
Methylphenidate naive: 100%
Ethnicity: not stated
Country: the Netherlands
Setting: out-patient clinic
Comorbidity: developmental co-ordination disorder (100%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD, DSM-IV
2. Developmental co-ordination disorder, DSM-IV
3. ADHD symptoms had to be severe for ≥ 6 items on the DSM-IV ADHD Rating
Scale, Parent Version, investigator administered and scored
4. Total score on the Movement Assessment Battery for Children below the fifth
centile
Exclusion criteria
1. Comorbid disorders (including pervasive developmental disorder)
2. Not medication-naive
3. IQ score below normal range (< 70), as assessed by the Wechsler Intelligence Scale
for Children - Revised (Dutch Edition)
Interventions Participants were randomly assigned to possible drug orders of the 3 daily doses of
methylphenidate (0.5 mg/kg, 0.75 mg/kg, 1 mg/kg) and placebo
Mean optimal dosage: 0.66 mg/kg/d (SD 0.22)
Administration schedule: b.i.d.
Duration of each medication condition: 1 week
Washout before study initiation: none. All were medication naive
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
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Outcomes ADHD symptoms
1. 18-Item ADHD Rating Scale, Fourth Edition: rated weekly (each Friday) by
parents and teachers
Notes Sample calculation: yes
Ethics approval: Procedures were performed in accordance with the ethical standards of
the University Medical Centre, University of Groningen
Comment from study authors
1. One aim of the study was to investigate the effectiveness of methylphenidate in
improving the fine motor performance of children with ADHD and developmental co-
ordination disorder (DCD). To prevent confounding by fluctuations in ADHD
symptoms, these had to be reduced by selecting methylphenidate-sensitive children
Key conclusions of study authors
1. Children with ADHD/DCD and their parents rated overall quality of life as
poorer than for healthy controls, manifested in domains of motor and autonomic
functioning, as well as cognitive and psychosocial functioning
2. In our study, significant improvements in health-related quality of life were noted
after treatment with methylphenidate, as was improvement in symptoms of ADHD
and motor functioning
3. Fine motor performance in children with ADHD-DCD was poorer before use of
methylphenidate than afterwards
4. Impairment in manual dexterity and poor quality of handwriting and drawing
improved after methylphenidate use, but performance remained poorer than in the
control group
Comment from review authors
1. Only data from the 4-week cross-over trial are useful for the review; therefore all
data extracted were derived from the cross-over period
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: August 2013 to January 2014. We obtained
supplemental information regarding participant demographics and efficacy data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random order by pharmacist
Allocation concealment (selection bias) Low risk Medication codes were broken at time 2
(endpoint)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, teachers, children and paediatri-
cian were kept blinded to the child’s drug
condition and dosage level
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents, teachers, children and paediatri-
cian were kept blinded to the child’s drug
condition and dosage level
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participant withdrew; no ITT was
needed. Seven children whose ADHD
symptoms were not sensitive enough to
methylphenidate (effect < 25%) were ex-
cluded from the 4-week open-label period.
However, as we are using in this review only
data from the preceding cross-over period,
exclusion of these children does not cause
high risk of bias
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No reporting bias
Vested interest bias Low risk For this study, no funding was avail-
able. This double-blind placebo-controlled
(DBPC) trial of methylphenidate was per-
formed as a clinical treatment programme
as best clinical practice to determine the ef-
fects of methylphenidate and optimal dose
compared with placebo
Conflicts of interest: no affiliations with
pharmaceutical companies or similar stated
Forness 1992
Methods Double-blind, placebo-controlled, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 4
Participants Number of participants screened: 82
Number of participants included: 71 (all boys). Participants were randomly assigned to
different possible drug condition orders of placebo and 3 doses of methylphenidate
Number of participants followed up: Conners’ Teacher (n = 47), Conners’ Parent (n =
69)
Number of withdrawals: Conners’ Teacher 33.8%, Conners’ Parent 12.6%
Diagnosis of ADHD: DSM-III-R (hyperactive-impulsive (100%))
Age: mean 9.3 years (range 7 to 11)
IQ: mean 106.2 (range 67 to 137)
Methylphenidate naive: 100%
Ethnicity: ethnic minority (11.3%)
Country: USA
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Setting: out-patient clinic
Comorbidity: conduct disorder (30/71)
Comedication: no; had no psychotropics for a month before
Sociodemographics: Alll participants were middle to upper class
Inclusion criteria
1. Boys
2. 7 to 11 years of age
3. Recruited from referrals to 2 clinics: University of California, Irvine Child
Development Center for Children with ADD, and University of California, Los
Angeles Child Psychiatry Outpatient Department for children with psychiatric
disorders
4. Meet cutoff for inattention/overactivity
Exclusion criterion
1. IQ below 85
Interventions Participants were randomly assigned to different possible drug condition orders of 0.3,
0.6 and 1.0 mg/kg MPH (unless dosages would exceed 20 mg, so the low dose would
be 0.15 mg/kg) 3 times a day and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 3 times a day - 7:30 AM, 11:30 AM, 3:30 PM
Duration of each medication condition: 7 days
Washout before study initiation: not stated
Titration period: nil
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Rating Scale: teachers and parents
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. At the very least , teachers may be cautious about optimistic claims of positive
response to methylphenidate
Email correspondence with study authors. Emailed study authors to ask for additional
information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-blind but not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-blind but not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation → exclusion): no, but high loss to
follow-up for teachers’ scores on Conners’
Teacher Rating Scale
Washout period between medication con-
ditions: unclear
Selective reporting (reporting bias) Unclear risk Not clear
Vested interest bias Low risk Study supported by National Institute of
Mental Health (NIMH) grant MH38686
Conflicts of interest: no affiliations de-
scribed
Froehlich 2011
Methods Randomised, double-blind, placebo-controlled, cross-over trial of multiple
methylphenidate doses in stimulant-naive school-aged children
Phases: 3 active dosage weeks and 1 week of placebo
Participants Number of participants screened: 162
Number of participants included: 105. Participants were randomly assigned to 1 of 6
possible drug condition orders
Number of participants followed up: 89 (65 boys, 24 girls)
Number of withdrawals: 16
Diagnosis of ADHD: DSM-IV (combined (48%), hyperactive-impulsive (0%), inatten-
tive (52%))
Age: mean 8.13 years (range 7 to 11)
IQ: mean: 105.34 ± 12.65
Methylphenidate naive: 100%
Ethnicity: Caucasian (79%), African American (18%), Hispanic (2%), other (1%)
Country: USA.
Setting: out-patient clinic
Comorbidity: anxiety disorder (17%), mood disorder (2%), disruptive behaviour disor-
der (36%)
Comedication: not stated
Inclusion criteria
1. ADHD according to DSM-IV criteria for onset age, pervasiveness and
impairment, inattentive or combined type
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2. Stimulant-naive
3. 7 to 11 years of age
4. 6 non-overlapping symptoms in a symptom domain (as per Diagnostic Interview
Schedule for Children, and Vanderbilt ADHD Teacher Rating Scale), and both parent
and teacher reported ≥ 4 symptoms in that domain
Exclusion criteria
1. Hyperactive-impulsive-type participants
2. IQ
<
= 80
3. Mania/hypomania
4. Comorbid oppositional defiant disorder, conduct disorder, depression and
anxiety, if they were determined to be the primary cause of ADHD symptoms, or
required different treatment
5. Medical history suggesting significant brain injury
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of OROS
methylphenidate (18 mg, 27 mg, 36 mg for children ≤ 25 kg; 18 mg, 36 mg or 54 mg
for children > 25 kg; sample mean maximum dose 1.57 mg/kg/d) and placebo
Administration schedule: once daily
Duration of each medication condition: 1 week
Washout before study initiation: drug naive
Medication-free period between interventions: not stated
Titration period: none initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Parents and teachers: Vanderbilt ADHD Rating Scales: completed at baseline and
each week of the trial
Notes Sample calculation: yes
Ethics approval: yes; Cincinnati Children’s Hospital Institutional Review Board
Comments from study authors
1. Additional limitations include restricted duration of follow-up and heterogeneity
of our sample due to recruitment from a variety of sources. Further, our sample had
more inattentive (52%) than combined subtype (48%) participants
2. Although consistent with subtype distribution in many epidemiological samples,
this differs from clinic settings, where combined type is most common
Key conclusions of study authors
1. Results of this double-blind, placebo-controlled, ADHD pharmacogenetic trial of
psychostimulant-naive school-aged children suggest that dopamine active transporter
(DAT) and dopamine receptor (DR) D4 variations may be associated with unique
methylphenidate dose-response curves
2. Children lacking the DAT 10-repeat allele and those with the DRD4 4-repeat
allele had a more robust methylphenidate response compared with those of alternate
genotypes, consistent with improved response for the ADHD susceptibility low-risk
alleles
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study author: October/November 2013. Contacted study
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author to obtain mean and SD for ADHD symptoms. Never received additional data.
Therefore no further email correspondence regarding allocation concealment, randomi-
sation, etc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to different drug or-
ders. No description about how
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study medication consisted of identical
capsules filled with an inert white powder
(placebo) or prescribed dose of Concerta
overencapsulated to preserve double-blind
Double-blind, but not specified who was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study medication consisted of identical
capsules filled with an inert white powder
(placebo) or prescribed dose of Concerta
overencapsulated to preserve double-blind
Double-blind, but not specified who was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data provided on 89 participants who
completed the study
Selective reporting (reporting bias) Unclear risk Not able to find protocol or trial identifier
Vested interest bias Low risk National Institute of Mental Health
(NIMH) and Cincinnati Children’s Hos-
pital Center for Education and Research
Therapeutics Award
Conflicts of interest: Dr. Epstein receives
funding from Eli Lilly and Co. Dr. Stein
has received research support from Eli Lilly
and Co., McNeil Pharmaceuticals, Novar-
tis and Shire. He has served on a Speak-
ers’ Bureau for Novartis and has served as
consultant to Novartis, Shire and Shinogi
Pharmaceuticals
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Gadow 1990
Methods Six-week double-blind, cross-over trial in which participants received the following in
random order
1. Low dose of methylphenidate
2. Moderate dose of methylphenidate
3. Placebo
Furthermore, a single case report from the study is described
Participants Number of participants screened: not stated
Number of participants included: 11 (11 boys, 0 girls). Participants were randomly
assigned to 1 of 6 possible drug condition orders
Number of participants followed up: between 9 and 10, depending on ratings
Number of withdrawals: 1 to 2
Diagnosis of ADHD: DSM-III (type not stated)
Age: mean not reported (range 5.9 to 11.9 years)
Case report: 10 years of age
IQ: > 75
Stimulant-naive: 6
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: disruptive behaviour disorder
Comedication: not reported
Sociodemographics: Children represented a full range of socioeconomic backgrounds
Inclusion criteria
1. Boys
2. 5 to 12 years of age
3. ADHD diagnosis according to DSM-III
4. Scored above research cutoff (> 7) on the Aggression scale of IOWA Conners’
Teacher Rating Scale OR were considered aggressive by their classroom teacher and
were above cutoff on ≥ 1 other conduct problem scale
5. Scored ≥ 15 on the Abbreviated Teacher Rating Scale
6. Above cutoff on the Oppositional DIsorder or Conduct Disorder Index of the
Parent or Teacher Version of the Stony Brook Child Psychiatric Checklist, Version 3
Exclusion criteria
1. IQ < 70
2. Psychosis, pervasive developmental disorder, dangerous to self or others
3. Seizure disorder, major organic brain dysfunction, medical illness,
contraindication to medication treatment
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of low-dose
(0.3 mg/kg) and moderate-dose (0.6 mg/kg) (upper limit 25 mg) methylphenidate and
placebo
Mean methylphenidate dosage: not stated
Administration schedule: b.i.d., morning, noon, 3.5 hours apart, 7 days a week
Duration of each medication condition: 2 weeks
Washout before study initiation: yes
Titration period: When moderate dose was not preceded by low-dose condition, the
child was gradually built up to the moderate dose. Data from these titration days were
excluded from the analyses
Treatment compliance: pill count, no further information
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Outcomes ADHD symptoms
1. Conners’ Abbreviated Teacher Rating Scale
2. Conners’ Abbreviated Parent Rating Scale
Non-serious adverse events
1. Stimulant Side Effects Checklist: rated systematically
Notes Sample calculation: no information
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Sample size was small, which decreased the probability of detecting clinically
significant group differences between treatment conditions
Key conclusion of study authors
1. Results of this study indicate that methylphenidate-induced improvements in the
classroom behaviour of aggressive hyperactive boys are associated with concomitant
changes in the demeanor of classmates sitting in close proximity to the drug-treated
child
Email correspondence with study authors: July 2013. Emailed first study author twice
to get additional information (funding, ethics approval, etc.) and data from the study.
Study authors not able to provide us with additional data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Dose schedules were assigned on a random
basis
Allocation concealment (selection bias) Low risk Medication and placebo pills were identical
and were dispensed to parents and school
nurses in dated, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, teachers, observers, treating physi-
cians and childrenwere blinded to dose and
order
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents, teachers, observers, treating physi-
cians and childrenwere blinded to dose and
order
Incomplete outcome data (attrition bias)
All outcomes
Low risk For classroom analyses, data on 10 boys
were analysed, and for lunch room analy-
ses, data on 9 boys were analysed
Selection bias (e.g. titration before ran-
domisation→ exclusion): no
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Selective reporting (reporting bias) Unclear risk Email sent to first study author. No answer;
therefore not able to get information
Vested interest bias Unclear risk Email sent to first study author in July
2013. No answer
Ciba Pharmaceutical Company supplied
methylphenidate placebo
Conflicts of interest: not stated
Gadow 1995
Methods Randomised, placebo-controlled, double-blind, cross-over trial with 2 interventions
1. Methylphenidate in 2 or 3 dosages
2. Placebo
Phases
1. Washout if medications before trial
2. Eight-week randomised, controlled trial (RCT) with 2 weeks on each arm
3. Open-label follow-up at 24 months
Participants Number of participants screened: not stated
Number of participants included: 34 (31 boys, 3 girls). Participants were randomly
assigned to different orders of the 3 dosages
Number of participants followed up: RCT 34,MED (minimal effective dose, after RCT)
27; 12-month follow-up 30; 18-month follow up 26; 24-month follow-up 26
Number of withdrawals: RCT: 0
Diagnosis of ADHD: DSM-III-R (subtypes not stated)
Age: mean 8 years and 10 months (range 6.1 years to 11.9 years)
IQ: mean 105.9 (SD 13.7, range no information)
Methylphenidate naive: 24 (71%)
Ethnicity: Caucasian (85%), African American (3%), Asian (3%), Hispanic (9%), other
(0%)
Country: USA
Setting: out-patient clinic
Comorbidity:Data fromonly 21 children fromGadow et al. (1995): tics (100%); anxiety
or depressive disorder, or both (8/21; 38%); obsessive-compulsive disorder (3/2; 14%)
; most of the children also had oppositional defiant disorder or conduct disorder and
academic problems
Comedication: not during RCT. Four children were treated with an anti-tic medication
in combination with methylphenidate at some time during the course of follow-up
(neuroleptic 3, clonidine 1)
Sociodemographics: no information
Inclusion criteria
1. Meet DSM III-R diagnostic criteria for ADHD and chronic motor tic disorder or
Tourette’s disorder
2. ADHD had to be a primary reason for seeking clinical services
3. In general, had to be above the cutoff on 2 or 3 parent- and teacher-rated
hyperactivity and/or ADHD behaviour rating scales
4. Written signed statement from parents consenting to their child’s participation
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Exclusion criteria
1. Dangerous to self or others
2. Tics: the major clinical management concern
3. Psychosis
4. IQ < 70
5. Seizure disorder
6. Major organic brain dysfunction
7. Major medical illness
8. Contraindications to medication (other than tics)
9. Pervasive developmental disorder
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of doses:
0.1 mg/kg (mean 4.4 mg), 0.3 mg/kg (mean 9.0 mg) and 0.5 mg/kg (mean 14.0 mg) of
methylphenidate and placebo
Upper dosage limit was 20 mg. When the 0.5-mg/kg dose was not preceded by a low-
dose condition, the child was gradually built up to the moderate dose. Build-up days
occasionally fell on scheduled school observation days. Observers were unaware of these
days and observations were conducted as usual, but these data were excluded from the
analyses
Administration schedule: b.i.d. (or t.i.d.) at morning and noon, approximately 3.5 hours
apart, 7 days a week
Duration of each medication condition: 2 weeks
Washout before study initiation: methylphenidate 1 week, antipsychotic 3 weeks, cloni-
dine 2 weeks
Medication-free period between interventions: none
Titration period: none
Treatment compliance: Parents and nurses were asked to return unused medication
envelopes, which allowed researchers to assess compliance. No further information was
provided in the paper
Regarding 24-month follow-up: Total daily dose of methylphenidate, MED (minimal
effective dose - after RCT) mean 16.5 mg (range 5 mg to 40 mg); second visit mean 28.
5 mg (range 15 mg to 60 mg); third visit mean 29.2 mg (range 10 mg to 90 mg); and
fourth visit mean 34.5 mg (range 15 mg to 92 mg)
Outcomes During 8-week RCT
ADHD symptoms
1. Parents
i) Conners’ Abbreviated Parent Rating Scale: rated Saturday and Sunday each
week
ii) Mothers’ Objective Method for Subgrouping: rated by parents Saturday and
Sunday each week
2. Teachers
i) Conners’ Abbreviated Teacher Rating Scale, 10-item: rated 2 days per week
for each intervention period
ii) Iowa Conners’ Teacher Rating Scale: rated 2 days per week for each
intervention period
General behaviour
1. Peer Conflict Scale: parent- and teacher-rated, 2 times a week
2. Classroom Observation Code: observer-rated, 4 days for each treatment condition
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3. ADHD School Observation Code: observer, 3 to 4 days for each treatment
condition
4. Code for Observing Social Activity: observer, lunch and playground, 20 to 30
minutes, 4 days for each treatment condition
Non-serious adverse events
1. Side Effects Checklist: 13 items, rated by parents on Saturday and Sunday and
rated by teacher twice a week
2. Global Tic Rating Scale: rated by parents on Saturday and Sunday and rated by
teacher twice a week
3. Motor and vocal tic category: Observers coded presence or absence of tics in the
classroom, lunchroom or playground, 4 times for each medication condition
Physician evaluations
1. Yale Global Tic Severity Scale: rated every second week
2. Tourette Syndrome Unidentified Rating Scale: rated every second week
3. Global Tic Rating Scale (assessed in only 22 participants): rated every second week
4. Shapiro Tourette Syndrome Severity Scale (assessed in only 22 participants): rated
every second week
5. Motor tic frequency tics: rated in 180 five-second intervals in a simulated
classroom; tics were coded as present or not present in each interval, rated every second
week
6. Weight: assessed every second week
7. Heart rate: assessed every second week
8. Blood pressure: assessed every second week
During 24-month follow-up
Physician evaluations
1. All rated at minimally effective dose (right after RCT) 6 months, 12 months, 18
months and 24 months
2. Yale Global Tic Severity Scale
3. Shapiro Tourette Syndrome Severity Scale
4. Three subscales from Tourette Syndrome Unified Rating Scale
5. Total number of tics
6. Number of tics observed in 2 minutes of quiet conversation with physician
7. LeWitt Disability Scale, which assesses tics and symptoms of comorbidity
8. Global Tic Rating Scale
9. Blood pressure
10. Heart rate
11. Pulse
12. Weight
Parent ratings
1. Based on last 2 weeks and rated at MED (right after RCT) 6 months, 12 months,
18 months and 24 months
2. Stimulant Side Effects Checklist
3. Global Tic Rating Scale
Notes Sample calculation: yes
Ethics approval: no information
Comments from study authors
1. Magnitude of clinical improvement associated with 0.3 mg/kg dosage vs 0.5 mg/
kg dosage was generally trivial for many children
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2. 0.5 mg/kg dosage was associated with more side effects, but fortunately they were
generally of limited clinical significance
3. Generalisability of findings from this study is subject to several qualifications.
First, our data pertain to observed treatment effects over an 8-week period and
therefore cannot address the issue of tic exacerbation as a function of long-term drug
exposure. Furthermore, the findings pertain only to children with ADHD with tics of
mild to moderate severity that occur frequently enough to be observed during 15-
minute intervals
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no; children were
not excluded from participation in the study if they had prior experience with stimulant
drug therapy, or if such therapy purportedly had exacerbated their tics
Any withdrawals due to adverse events: no
Key conclusions of study authors
1. During the course of this short-term drug evaluation, physician, teacher and
parent ratings were in agreement that methylphenidate did not lead to worsening of
the severity of children’s tic disorders
2. Methylphenidate is an effective drug for the treatment of ADHD and
oppositional and aggressive behaviour
3. Follow-up study showed that long-term treatment with methylphenidate seems to
be safe and effective for the management of ADHD behaviours in many (but not
necessarily all) children with mild to moderate tic disorders. Nevertheless, careful
clinical monitoring is mandatory, to rule out the possibility of drug-induced tic
exacerbation in individual patients
Comments from study authors (limitations)
1. Two-year follow-up component was not blinded. Although obstacles to creating
and maintaining a long-term double-blind study with a placebo group are daunting,
failure to do so does introduce the possibility of bias
2. Absence of a no-treatment group does not allow inferences about natural changes
in tic status over time
Comments from review authors
1. Well-designed study
2. No exclusion of methylphenidate non-responders/children who have previously
experienced adverse events while taking methylphenidate. Twenty-six children received
stimulant medication throughout the follow-up interval; of these children, 1 was
switched to dextroamphetamine. However, we have chosen to use in our analyses
results for all 26
3. In the article, “Gadow 2001, Anxiety and Depression…”, n = 38. We have
included it because it is part of the study, but we have not used data from this article
4. Sverd 1992 and Gadow 1992; preliminary results from Gadow 1996 are described
5. All included articles include a mix of different protocols, so total numbers of
included participants differ from article to article
Email correspondence with study authors: April 2013. We emailed study authors for
supplemental information regarding cross-over data. Data were not available. Also no
further data for the interventions were available
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Dose schedules were counterbalanced and
assigned on a random basis
Allocation concealment (selection bias) Low risk Medication and identically matching
placebos were dispensed to parents and
school nurses in dated, sealed envelopes at
2-week intervals
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, teachers, participants, observers
and physicians were blinded to the identity
of those conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication was administered under dou-
ble-blind conditions (i.e. no one involved
in clinical management of the participant,
data collection or interaction with the
school knew the identity of treatment con-
ditions)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study describes how many people were in-
cluded in the different analyses
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol identified or received
Vested interest bias Low risk Research grants from the Tourette Syn-
drome Association and the National Insti-
tute of Mental Health (NIMH)
Conflicts of interest: not stated
Gadow 2007
Methods Double-blind, randomised, cross-over trial with interventions
1. Methylphenidate
2. Placebo
Phases
1. Washout if previously medicated
2. Eight-week trial, 2 weeks on each arm. Performed in 2 cohorts (several years
apart, same personnel)
Participants Number of participants screened: not stated
Number of participants included: 71 (39 + 32, cohorts 1 and 2, respectively). Participants
were randomly assigned to 1 of 4 possible drug condition orders
Number of participants followed up: 71 (57 boys, 14 girls)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R or DSM-IV (subtype not stated)
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Age: mean: 8.9 ± 1.9 years (range 6 to 12)
IQ: mean 103.8
Methylphenidate naive: not stated
Ethnicity: Caucasian (87%), African American (6%), Asian (1%), Hispanic (6%)
Country: USA
Setting: out-patient clinic
Comorbidity: Tourette’s syndrome (96%), chronicmotor tic disorder (4%), oppositional
defiant disorder (56%), conduct disorder (7%), overanxious or generalized anxiety (30%)
, simple phobia (7%), obsessive-compulsive disorder (11%)
Comedication: yes
Sociodemographics: not stated
Inclusion criteria
1. DSM-III-R or DSM-IV diagnosis of ADHD
2. Chronic motor tic disorder or Tourette’s syndrome
3. ADHD clinical criteria at both school and home
Exclusion criteria
1. Too severely ill (dangerous to self or others)
2. Psychotic
3. IQ < 70
4. Seizure disorder
5. Major organic brain dysfunction
6. Major medical illness
7. Medical or other contraindication to medication (other than tics)
8. Pervasive developmental disorder
9. Tics so severe at intake that the parent or the child requested immediate
intervention
10. Extremely mild tics at intake
Interventions Participants were randomly assigned to placebo or to 1 of 3 possible drug condition
orders of immediate-release methylphenidate (0.1 mg/kg (mean 4.5 mg; SD 1.6), 0.3
mg/kg (mean 9.3 mg; SD 3.0) and 0.5 mg/kg (mean 14.3 mg; SD 3.3)), twice a day for
2 weeks, each under double-blind conditions. Upper limit was 20 mg/d
Administration schedule: twice daily, 3.5 hours apart. Most days, a morning dose and a
noon dose, 7 days a week
Duration of each medication condition: 2 weeks
Washout before study initiation: Minimum washout periods for children receiving med-
ication at referral were as follows: 1 week for stimulants (n = 10), 3 weeks for neuroleptic
or selective serotonin reuptake inhibitor (n = 2) and 2 weeks for clonidine (n = 1)
Medication-free period between interventions: none
Titration period: not stated initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Teachers
i) Abbreviated Teacher Rating Scale (total score (Hyperkinesis Index) and
ADHD (factor 1) and Emotional lability (factor 2) subscales)
ii) IOWA Conners’ Teacher Rating Scale (Inattention-Impulsivity-Overactivity
and Oppositional Defiant subscales): twice a week, weekdays
2. Parents
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i) Abbreviated Parent Rating Scale (Total score (Hyperkinesis Index) and
ADHD (factor 1) and Emotional lability (factor 2) subscales): Saturdays and Sundays,
every week
General behaviour
1. IOWA Conners’ Teacher Rating Scale (Oppositional Defiant subscale)
Non-serious adverse events
1. Physician
i) Assessment of clinical status and heart rate, blood pressure and weight:
biweekly (n = 57)
ii) Tics: Yale Global Tic Severity Scale (includes 4 behaviourally anchored
subscales: Total Motor Tic score, Total Phonic Tic score, Overall Impairment Rating
and Global Severity score), completed for all but the first 12 participants. Additional
measures: Shapiro Tourette Syndrome Severity Scale (tic frequency, severity and
impairment), Global Tic Rating Scale and Two-Minute Tic and Habit Count,
completed for first 12 participants only. Both rated at 2-week intervals
2. Parents and teachers
i) Global Tic Rating Scale: twice a week for each week of the study
ii) Stimulant Side Effects Checklist: rated twice a week
Notes Sample calculation: no
Ethics approval: yes
Comment from study authors
1. Children were not excluded if previous treatment with stimulants had
purportedly induced or exacerbated their tics
Key conclusion of study authors
1. In this study, immediate-release methylphenidate was found to be a safe and
effective short-term treatment for ADHD in children with chronic tic disorder (CTD),
but complete normalisation of all problem behaviours often is not achieved at
acceptable doses
Comments from review authors
1. Given our concern about the possibility of a type II error (i.e. erroneously
concluding that methylphenidate did not have an adverse effect on tics), follow-up
repeat-measure ANOVAs were performed on each respondent category, even when the
main effect of dose was not significant
2. Use of a cross-over design may result in carry-over effects. However, differences in
change scores for tic frequency (simulated classroom) and severity (Yale Global Tic
Severity Scale - Global Severity score), respectively, between baseline and placebo in
children who received placebo first and last were non-significant and minuscule (i.e.
effect size = 0.08 and 0.19, respectively)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April 2014. We obtained supplemental in-
formation from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Dose schedules were counterbalanced and
assigned on a random basis
Allocation concealment (selection bias) Low risk Medication was administered twice daily,
approximately 3.5 hours apart, 7 days per
week, and was dispensed in dated, sealed
envelopes at 2-week intervals
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk None required withdrawal of medication
Selective reporting (reporting bias) Unclear risk No information to assess this
Vested interest bias Low risk This study was supported in part by a re-
search grant from the Tourette Syndrome
Association Incorporated, and by Pub-
lic Health Service (PHS) grant number
MH45358 from the National Institute of
Mental Health (NIMH)
Conflicts of interest: Study authors have no
financial relationships to disclose
Gadow 2011
Methods Eight-week, placebo-controlled, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 54 (42 boys, 12 girls). Participants were randomly
assigned to the different possible drug condition orders: ADHD without anxiety 37,
ADHD with anxiety 17
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III or DSM-IV (subtype not stated)
Age: ADHD without anxiety 8.9 years, ADHD with anxiety 9.1 years (range 7 to 12)
IQ: ADHD without anxiety mean 103.5, ADHD with anxiety mean 103.1
Methylphenidate naive: 48 (89%)
Ethnicity: not stated
Country: USA
221Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gadow 2011 (Continued)
Setting: out-patient clinic
Comorbidity: Tourette’s (n = 52), chronic multiple tic disorder (n = 2), anxiety (n = 17)
, major depressive episode or dysthymia (n = 11), overanxious disorder or generalised
anxiety disorder (n = 12), separation disorder (n = 6), social phobia (n = 1), oppositional
defiant disorder (n = 36), conduct disorder (n = 4)
Comedication: not stated
Sociodemographics: ADHDwithout anxiety 37.1, ADHDwith anxiety 35.4 (according
to Hollingshead)
Inclusion criteria
1. DSM-III-R or DSM-IV diagnostic criteria for ADHD
2. Chronic multiple tic disorder or Tourette’s disorder according to research
diagnostic criteria
3. Each child met ADHD clinical criteria at both school and home (the “and rule”)
Exclusion criteria
1. Tics were the major clinical management concern
2. Too severely ill (dangerous to self or others)
3. Psychotic
4. Mentally retarded (IQ < 70)
5. Seizure disorder
6. Major organic brain dysfunction
7. Major medical illness
8. Medical or other contraindication to medication (other than tics)
9. Pervasive developmental disorder
Interventions Participants were randomly assigned to different possible drug condition orders of 0.1
mg/kg, 0.3 mg/kg and 0.5 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: 4.7 mg, 9.5 mg, 14.5 mg
Administration schedule: “administered twice daily, approximately 3.5 hours apart, 7
days a week”
Duration of each medication condition: 2 weeks
Washout before study initiation: not stated
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Abbreviated Teacher/Parent Rating Scale
2. IOWA Conners’ Teacher Rating Scale
3. Conners’ (48-item) Parent Rating Scale
4. Mothers’ Objective Method for Subgrouping
5. Parent and Teacher Versions of the Child Symptom Inventory
General behaviour
1. IOWA Conners’ Teacher Rating Scale (Oppositional Defiant subscale)
Non-serious adverse events
1. Stimulant Side Effects Checklist
2. Yale Global Tic Severity Scale, which includes 4 behaviourally anchored subscales:
Total Motor Tic score, Total Phonic Tic score, Overall Impairment Rating and Global
Severity score
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Notes Sample calculation: not stated
Ethics approval: yes; approved by a university Institutional Review Board (IRB)
Comments from study authors
1. No evidence suggested that immediate-release methylphenidate exacerbated tics
in children with anxiety
2. Teacher ratings actually indicated improvement in motor and vocal tic frequency
with medication (placebo > 0.5 mg/kg)
Key conclusions of study authors
1. Findings suggest that the co-occurrence of diagnosed chronic multiple tic
disorders and ADHD with anxiety represents a particularly troublesome clinical
phenotype, at least in the home setting
2. Comorbid anxiety disorder was not associated with a less favourable response to
immediate-release methylphenidate in children with ADHD and chronic multiple tic
disorder, but replication with larger samples is warranted before firm conclusions can
be drawn about potential group differences
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: May 2015. Emailed study authors requesting
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Dose schedules were counterbalanced and
were assigned on a random basis
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “...dispensed in dated, sealed envelopes at
two-week intervals”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk “In order to increase sample homogeneity,
an additional three childrenwith diagnosed
specific phobia (n = 2) or major depressive
episode without comorbid anxiety disorder
(n = 1) were excluded from data analyses”
Vested interest bias Low risk Study was funded by the National In-
stitute of Mental Health (NIMH) and
the Tourette Syndrome Association In-
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corporated. CIBA Pharmaceutical Com-
pany supplied methylphenidate place-
bos. Novartis supplied immediate-release
methylphenidate
Conflicts of interest: “Kenneth D. Gadow
is a shareholder in Checkmate Plus, pub-
lisher of the Child Symptom Inventory-4”
Garfinkel 1983
Methods Double-blind, randomised, placebo-controlled, cross-over experiment with 4 arms
1. Methylphenidate
2. Clomipramine
3. Desipramine
4. Placebo
Study lasted 20 weeks; first and last 2 weeks were baseline periods during which no
medication was given. Different interventions lasted 3 weeks each (Monday to Friday)
with a 7-day washout between changes in drugs
Participants Number of participants screened: not stated
Number of participants included: 12 (all boys). Participants were randomly assigned to
the different possible drug condition orders
Number of participants followed up: 12
Number of withdrawals: 0
Diagnosis: DSM-III of ADD. Eight participants were day hospital patients and 4 were
in-patients
Age: mean 7.3 years (range 5.9 to 11.6)
IQ: > 70
Methylphenidate naive: 50%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic and patient ward
Comorbidity: no
Comedication: no comedication during study period
Sociodemographics: not stated. Children presented with remarkably similar clinical,
family and educational histories. None of the children had localising neurological signs
or met criteria for other psychiatric diagnoses
Inclusion criterion
1. ADD according to DSM-III
Exclusion criteria
1. None mentioned directly
Interventions Participants were randomly assigned to the different possible drug condition orders of
methylphenidate, clomipramine, desipramine and placebo
Mean methylphenidate dosage: 18 mg/d
Administration schedule: b.i.d., morning and lunch
Duration of each medication condition: 3 weeks
Washout before study initiation: 2 weeks before study entry and 7 days between drug
conditions
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Titration period: first week of the drug condition after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale: rated daily by care workers (in settings away from
the classroom) and teachers (in classroom)
General behaviour
1. Werry-Weiss-Peters Activity Rating Scale: rated daily by parents for day patients
and by evening child care staff for fully hospitalised children
Non-serious adverse events
1. Diastolic and systolic blood pressure, measured by the nurse while participants
were sitting and standing at 09.00 AM and 12.00 PM
2. Apical pulse, morning and afternoon
Notes Sample calculation: no information
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusions of study authors
1. Methylphenidate was significantly better for improving classroom and behavioural
manifestations of ADD as compared with placebo, desipramine and clomipramine
2. Tricyclic antidepressants may have a significant therapeutic effect as indicated by
mood elevation and amelioration of non-classroom behaviour in the evenings
3. Results encourage further clinical and pharmacological investigation of ADD
using various alternative treatments
Comment from review authors
1. Only information and data extracted from the methylphenidate group and the
placebo group
Email correspondence with study authors. October 2013. We obtained supplemental
information regarding number of drop-outs and SD for Conners’ Rating Scale. We also
wanted other data but were not able to obtain these, as the study took place several years
ago and the data are no longer available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children
were randomly given methylphenidate, de-
sipramine, clomipramine, placebo
A Latin square was followed to control for
the order of presentation of drugs
Allocation concealment (selection bias) Low risk Children were randomly given MPH,
DMI, CMI, placebo. A Latin square was
followed to control for the order of presen-
tation of drugs
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, parents, attending physicians,
teachers, nursing staff and child care work-
ers did not know which medication the
child received, ensuring the double-blind
procedure. Medication was added to lac-
tose powder and was placed in identical ap-
pearing gelatin capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, parents, attending physicians,
teachers, nursing staff and child care work-
ers did not know which medication the
child received, ensuring the double-blind
procedure. Medication was added to lac-
tose powder and was placed in identical ap-
pearing gelatin capsules
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Low risk No reporting bias
Vested interest bias Low risk Study was funded by Ontario Mental
Health Foundation
Conflicts of interest: none
Gonzalez-Heydrich 2010
Methods Cross-over trial with 2 interventions
1. OROS methylphenidate
2. Placebo
Phases: Number of phases varied by dose group. For all dose groups, after completing
first phase, participants were on a 1-week washout period before cross-over. Participants
assigned to 1 of 3 maximum OROSmethylphenidate dose groups in randomly assigned
order
1. Group 1: 1 week low dose, 1 week placebo
2. Group 2: 1 week low dose, 1 week medium dose, 1 week placebo
3. Group 3: 1 week low dose, 1 week medium dose, 1 week high dose, placebo
Participants assigned to next group after 3 participants have successfully completed
preceding group with no side effects
Participants Number of participants screened: 40
Number of participants included: 33 (19 boys, 14 girls). Participants were randomly
assigned to different possible drug condition orders
Number of participants followed up: 33
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV-R (combined (51.1%), inattentive (48.5%))
Age: mean 10.5 years (SD 3.0, range 6.4 to 17.5)
IQ: mean 89.7 (SD 16.9, range 59 to 123)
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Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: hospital ward
Comorbidity: epilepsy (100%), others (not stated)
Comedication: yes
Sociodemographics: not stated
Inclusion criteria
1. Speaks English
2. IQ > 35 and score > 35 on Scales of Independent Behavior Revised (SIB-R) Broad
Independence Scale (both IQ and adaptive functioning at the moderate mental
retardation level or higher)
3. Diagnosis of epilepsy by International League Against Epilepsy (ILEA) criteria 26
(repeated, afebrile, unprovoked seizures with a seizure within the past 5 years)
4. Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R diagnosis of
ADHD
5. Score ≥ 4 on Conners’ Global Index (CGI) severity scale for ADHD
6. Score > 90% on ADHD Rating Scale, Parent Version; investigator scored for age
and sex on inattentive, hyperactive-impulsive or total score at first visit
7. Has not taken stimulants or alpha-adrenergic medications for longer than 2 weeks
before study entry
8. If taking antidepressants, neuroleptics or lithium, doses have been stable for
longer than 4 weeks
9. Currently on an antiepileptic drug regimen with stable doses for longer than 4
weeks before study entry
10. Seizure-free for longer than 1 month before study entry
11. Prescribing clinician for epilepsy anticipates the need for a stable antiepileptic
drug regimen for the duration of the study
12. Guardian gives permission for study personnel to communicate with prescribing
epilepsy clinician
13. Teacher agrees to fill out ADHD Rating Scale at baseline and at the end of each
arm of the study
Exclusion criteria
1. Has had a seizure within the month preceding study entry
2. Change in antiepileptic drug regimen or dose within 4 weeks of study entry
3. History of moderate or severe adverse event related to methylphenidate
4. History of any psychotic disorder
5. Current acute major depression or bipolar mania
6. Current psychiatric disorder requiring pharmacotherapy (other than ADHD)
7. Unstable significant medical condition other than epilepsy
8. Any known conditions that may make treatment with methylphenidate medically
inadvisable
9. Not currently working with a physician for epilepsy treatment
10. Previously participated in a trial that provided adequate treatment with extended-
release methylphenidate
11. Weighs < 9 kg
12. Pregnant
13. Unwilling to use an effective form of contraception
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14. Child has taken a stimulant (methylphenidate, an amphetamine preparation or
pemoline), an alpha-adrenergic (clonidine or guanfacine) or other ADHD medication
within 2 weeks of the screening telephone interview (children will not be withdrawn
from psychotropic medications to be enrolled in the study)
Interventions Participants were randomly assigned to different possible drug condition orders of
methylphenidate and placebo. Each patient was given 5 mg of immediate-release
methylphenidate in the morning and at noon for 1 day. If this dose was tolerated, 18 mg
of OROSmethylphenidate was administered in the morning for the remaining 6 days of
the first week. For group 1, maximum dose remained 18 mg, and methylphenidate and
placebo arms lasted 1 week. For group 2, a further 1 week of OROS methylphenidate at
a dose of 36 mg was given in the morning for 1 week; this group was also administered
placebo for 2 weeks. For group 3, maximum dose was 54 mg in the morning, and each
arm of the cross-over lasted 3 weeks
Mean methylphenidate dosage: 11 participants < 1 mg/kg/d, 13 participants 1 to 1.5
mg/kg/d, 9 participants 1.5 to 2 mg/kg/d
Administration schedule: 1 dose in the morning
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: yes; 1 week
Titration period: no
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition, Observer, Parent, Teacher Version;
Conners’ Global Index (CGI)-ADHD-Severity: clinician-rated at baseline and at end
of each cross-over week
Serious adverse events
1. Seizure Classification Interview: observer, baseline and during trial
Non-serious adverse events
1. Barkley Side Effects Checklist - Modified: observer, each study visit
Notes Sample calculation: no
Ethics approval: not stated
Comment from study authors
1. Considering exposure time, we observed increased daily risk of seizures with
increasing dose of OROS methylphenidate, suggesting that potential safety concerns
require further study
Key conclusions of study authors
1. No serious adverse events and no carry-over effects were noted in the cross-over
trial
2. A larger study is needed to assess the effect of OROS methylphenidate on seizure
risk
3. Cross-over design, including participants with frequent seizures, could maximise
power and address high participant heterogeneity and recruitment difficulties
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Email correspondence with study authors: April 2014. We obtained supplemental effi-
cacy data from study authors
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation lists for each maximum
dose group were prepared by a statistician
and maintained by the research pharmacist
Allocation concealment (selection bias) Low risk Randomisation lists for each maximum
dose group were prepared by a statistician
and maintained by the research pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participantswere randomly assigned to take
OROS methylphenidate or placebo. Prin-
cipal investigator was blind to medication
status. In cases of seizure worsening... Data
and SafetyMonitoring Board (DSMB) and
Institutional Review Board (IRB) were in-
formed of these seizures. Study person-
nel, the DSMB and the IRB were not un-
blinded through this process, as the partic-
ipant would not be exposed again to the
same condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Principal investigator was blinded to med-
ication status
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Five participants discontinued treatment
while taking placebo and 14 while taking
OROSmethylphenidate; however, all were
included in all analyses
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) High risk All outcomes reported referred to parent-
and teacher-rated versions of ADHD Rat-
ing Scale, Fourth Edition, and to clinician-
rated ADHD Severity measured weeks 1
to 4 in the protocol. Barkley Total scores
(although significantly different) were not
reported, although individual effects were
reported
Vested interest bias Unclear risk Supported by National Institute of Men-
tal Health (NIMH) Grant, Number K23
MH066835
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Conflicts of interest: Four study authors are
involved in the pharmaceutical sector
Gorman 2006
Methods Participants with ADHD took part in a randomly ordered, double-blind, cross-over
clinical drug trial comprising 21 consecutive days of
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 43
Number of participants followed up: 41 (21 boys, 20 girls)
Number of withdrawals: 2
Diagnosis of ADHD: DSM-IV (combined (n = 22), hyperactive-impulsive (n = 0),
inattentive (n = 19))
Age: mean 9.08 years (range 6.26 to 12.55)
IQ: mean 107.66
Methylphenidate naive: 37 (out of 41)
Ethnicity: Caucasian (92.67%)
Country: USA
Setting: out-patient clinic
Comorbidity: > 2 anxiety disorders (12.16%), lifetime affective disorder (2.46%), op-
positional defiant disorder or conduct disorder (49.28%)
Comedication: 0%
Sociodemographics: mean 50.43 (range 22 to 66) (Hollingsworth SES)
Inclusion criteria
1. 6 to 12 years of age
2. Diagnosis of ADHD according to DSM-IV, and based on a combination of the
Parent Interview for Child Symptoms-4 and a semi structured interview
3. IQ > 80
4. Normal or corrected vision and hearing
5. No current use of medicine
Exclusion criteria
1. Physical disabilities; history of neurological disorder, chronic medical illness,
bipolar disorder, schizophrenia or pervasive developmental disorder; and an episode of
major depressive disorder within at least 6 months
Interventions Participants were randomly assigned to 1 dose of methylphenidate and placebo
Mean methylphenidate dosage: final daily dose 33.12 mg ± 1.36 (SE), range 25 to 50
mg/d (0.94 ± 0.02 mg/kg)
Administration schedule: b.i.d.
Duration of each medication condition: 21 days
Washout before study initiation: not stated
Medication-free period between interventions: from lunch to the following morning
Titration period: 0.25 mg/kg b.i.d. (breakfast and lunch) on days 1 to 2; 0.25 mg/kg b.
i.d. plus 0.125 mg/kg at 4:00 PM on days 3 to 7; 0.3 mg/kg b.i.d. and 0.15 mg/kg at 4:
00 PM on days 8 to 14; and 0.4 mg/kg b.i.d. and 0.2 mg/kg at 4:00 PM on days 15 to
21. All dosages were administered to the nearest 2.5 mg
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Titration: took place after randomisation
Treatment compliance: not stated. Four participants with ADHD had undergone pre-
vious trials of stimulant therapy ranging from 2 weeks to 7 months
Outcomes ADHD symptoms
1. IOWA Conners’ Scale, teacher- and parent-rated: at the end of each treatment
period (around day 21)
Serious adverse events
1. Five participants with ‘serious side effects’ were referred to, but no further
information was given
Non-serious adverse events
1. Barkley and Murphy Side Effects Rating Scale, rated by an investigator, at the end
of each treatment
2. Weight, in street clothes and without shoes on a professional scale, at the end of
each treatment period
Notes Sample calculation: not described.
Ethics approval: yes
Comment from study authors
1. “The unusually high proportion of girls reflects increasing sensitivity by clinicians
to the identification of girls with ADHD as well as the awareness of our referring
sources that we were studying sex differences in ADHD”
Key conclusions of study authors
1. ADHD subtypes benefited comparably from methylphenidate treatment with
respect to inattention
2. Children with ADHD-combined subtype underwent greater reductions in
hyperactivity/impulsivity, but children with ADHD-inattentive subtype also benefited
in this respect
3. Only children with ADHD/C displayed a reduction in externalising problems
under methylphenidate. ADHD subtypes reacted comparably with stimulant
treatment with respect to arithmetic performance, valence of teacher and parent
comments and task-incompatible behaviours - all measures that do not distinguish
between inattention, hyperactivity/impulsivity or oppositionality
4. Somatic effects of treatment were comparable for subtypes
Comment from review authors
1. Chang et al. 2001 (in Gorman 2006) is a PhD thesis; the other 2 articles are based
on data from this. We have not had access to the full thesis
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: January 2014. We obtained supplemental
information from study authors. Study authors do not have the files anymore; therefore
we are not able to obtain all of the data requested
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Answer from study author: “Table of ran-
dom numbers were used to make the allo-
cation process, such that numbers ending
in an even digit corresponded to one or-
der and those ending in an odd digit to an-
other” (Krogh 2014c [pers comm]
Allocation concealment (selection bias) Low risk Answer from study author: “Table of ran-
dom numbers were used to make the allo-
cation process, such that numbers ending
in an even digit corresponded to one or-
der and those ending in an odd digit to an-
other” (Krogh 2014c [pers comm]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo capsules, identical in appear-
ance and taste to those containing
methylphenidate, and administered on the
same schedule
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Second author blinded. Placebo capsules,
identical in appearance and taste to those
containing methylphenidate, and adminis-
tered on the same schedule
Incomplete outcome data (attrition bias)
All outcomes
Low risk When parents reported serious side effects
(n = 5), their children’s dosages were re-
duced, or planned increments were omit-
ted. However, study authors noted “elim-
inating participants who could not toler-
ate their assigned dosage might potentially
skew the sample”
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No
Answer from study author: “Event related
potentials and performance measures on a
cognitive task were not reported (I didn’t
attempt to publish the ERP data because
the analyses I conducted did not yield sig-
nificant results) - And since we do not look
at this outcome, we see it as low” (Krogh
2014c [pers comm])
Vested interest bias Low risk National Institute of Mental Health
(NIMH)
Conflicts of interest: Study authors have no
financial relationships to declare
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Green 2011
Methods One-day, randomised, parallel trial with 2 arms
1. Immediate-release methylphenidate
2. Placebo
Six-month follow-up of study participants continuing methylphenidate treatment
Participants Number of participants screened: not stated
Number of participants included: 34 (20 boys, 14 girls)
Number of participants randomly assigned: methylphenidate 22, placebo 12
Number of participants followed up: methylphenidate 22, placebo 12
Number of patients continuing methylphenidate treatment beyond the 1-day trial: 16
Number of participants followed up: 15
Number of withdrawals from extension trial: 1
Regarding the group of patients participating in the 1-day trial
Diagnosis of ADHD: DSM-IV-TR (combined (33.3%), hyperactive-impulsive (not
stated), inattentive (50%), not otherwise specified (17.7%))
Age: mean 11.1 years (range 5 to 20)
IQ: mean: 81.4
Methylphenidate naive: 61.8%
Ethnicity: not stated
Country: Israel
Setting: hospital/out-patient clinic
Comorbidity in total sample: velocardiofacial syndrome (100%), oppositional defiant
disorder (23.5%), specific phobia (26.5%), generalised anxiety disorder (11.8%), social
phobia(11.8%), dysthymic disorder (8.8%) and separation anxiety (5.9%)
Comorbidity in methylphenidate group: congenital anomalies of the heart and great
vessels (54.5%)
Comedication: no
Sociodemographics: not stated. The 2 groups had similar baseline demographics
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions RCT: Participants were randomly assigned to methylphenidate or placebo
Mean methylphenidate dosage: 15.7 ± 5.6 mg (0.5 mg/kg)
Administration schedule: once
Duration of intervention: 1 day
Titration period: no mention, none
Washout before study initiation: 3 days
Treatment compliance: not stated
Follow-up: Some participants continued methylphenidate treatment beyond the RCT
Mean MPH dosage: not stated
Administration schedule: not stated
Duration of treatment: 6 months
Treatment compliance: 1 withdrew because of poor compliance
Outcomes Non-serious adverse events
1. Cardiologic evaluation (ECG, heart rate and blood pressure): immediately before
taking the pill (methylphenidate or placebo), and again after 90 minutes
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2. Barkley Side Effects Rating Scale (modified Hebrew Version), parent-rated: 24
hours after methylphenidate administration and at 6-month follow-up
Notes Sample calculation: not stated
Ethics approval: Study protocol was approved by the Institutional Review Board of the
Rabin Medical Center
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Comments from study authors
1. We found that all participants (100%) with velocardiofacial syndrome treated
with methylphenidate exhibited ≥ 1 side effect
2. Rate of all side effects immediately observed following initiation of treatment
remained similarly high after 6 months of treatment
3. According to our findings, it seems that children with velocardiofacial syndrome
did not develop tolerance to methylphenidate side effects
4. None of the children withdrew because of side effects
5. Limitations: short duration of parallel-group trial and relatively small sample size
Key conclusions of study authors
1. Use of methylphenidate in children with velocardiofacial syndrome appears to be
effective and relatively safe
2. Comprehensive cardiovascular evaluation for children with velocardiofacial
syndrome before and during stimulant treatment is recommended
Email correspondence with study authors: November 2013. We obtained supplemental
information regarding ADHD diagnostic criteria from study authors. Furthermore, we
received safety data from the study sample, excluding participants older than 18 years
or with IQ < 70 (or both), but we decided not to use these data in our analyses, as data
were missing for 60% of the control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomly assigned to
drug or placebo in a 2:1 ratio, according to
their order of recruitment
Allocation concealment (selection bias) High risk Participants were randomly assigned to
drug or placebo in a 2:1 ratio, according to
their order of recruitment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and their parents were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk Study authors have confirmed that planned
outcomes for the 1-day (randomised con-
trolled) trial were measured and reported
Vested interest bias Low risk This work was funded by the Basil
O’Connor Starter Scholar Research Award
of the March of Dimes, NARSAD (Na-
tional Alliance for Research in Schizophre-
nia and Affective Disorders) Young Inves-
tigator Award, the Marguerite Stolz Award
from the Sackler Faculty of Medicine and
the National Institute on Drug Abuse
(NIDA)
Conflicts of interest: Study authors have
had no institutional or corporate/commer-
cial relationships for the past 36 months
that might pose a conflict of interest&&
Greenhill 2002
Methods Three-week, randomised, double-blind, 32-site, parallel trial with 2 arms
1. Modified-release methylphenidate
2. Placebo
Participants Number of participants screened: 507
Number of participants included: 321
Number of participants randomly assigned: methylphenidate 158, placebo 163
Number of participants followed up: methylphenidate 141, placebo 135
Number of withdrawals: methylphenidate 17, placebo 28
Diagnosis of ADHD: DSM-IV (combined subtype or predominantly hyperactive-im-
pulsive subtype)
Sex: 257 boys, 57 girls
Age: mean 9 years (range 6 to 15)
IQ: > 80
ADHD treatment naive: 36%
Ethnicity: Caucasian (71%), African American (15%), Hispanic (10%), other (4%)
Country: USA
Setting: out-patient clinic
Comorbidity: none
Comedication: concomitant use of clonidine, anticonvulsant drugs and medications
known to affect blood pressure and heart rate was not allowed
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
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Inclusion criteria
1. 6 to 16 years of age
2. Primary diagnosis of ADHD, combined subtype or predominantly hyperactive-
impulsive subtype, as defined in DSM-IV
3. Did not respond to placebo with a reduction of ADHD symptoms during
washout period
4. First-grade or higher school setting in which a single teacher could assess
behaviour
5. Blood pressure, heart rate and oral temperature had to be within normal range
6. Did not respond to placebo with a reduction of ADHD symptoms during
washout period
7. First-grade or higher school setting in which a single teacher could assess
behaviour
8. Blood pressure, heart rate and oral temperature had to be within normal range
Exclusion criteria
1. Comorbid psychiatric diagnosis
2. History of seizure or tic disorder
3. Family history of Tourette’s syndrome
4. IQ < 80
5. Inability to follow or understand study instructions
6. Female who had undergone menarche
7. Use of amphetamines, pemoline or an investigational drug within 30 days of
study entry
8. Concomitant use of clonidine, anticonvulsant drugs or medications known to
affect blood pressure, heart rate or CNS function
9. Hyperthyroidism or glaucoma
10. Concurrent chronic or acute illness (e.g. allergic rhinitis, severe cold) or disability
that could confound study results
11. Failed a previous trial of stimulants for ADHD
12. Requiring a third daily dose in the afternoon or evening
13. Documented allergy or intolerance to methylphenidate
14. Living with anyone who currently had substance abuse disorder (excluding
dependency)
Interventions Participants were randomly assigned to modified-release methylphenidate or placebo
Mean methylphenidate dosage: 40.7 mg/d (1.28 mg/kg/d)
Administration schedule: once daily
Duration of intervention: 3 weeks
Titration period: none
Treatment compliance: Medication counts showed satisfactory adherence in both groups
Outcomes General behaviour
1. Conners’ Teacher Global Index: rated twice daily (morning and afternoon), 3
times a week
2. Conners’ Parent Global Index, 1 day of each weekend during the morning,
afternoon and evening
Non-serious adverse events
1. Pittsburgh (11-item) Side Effects Questionnaire: parent- and teacher-rated weekly
2. Teachers completed a similar side effect questionnaire
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Notes Sample calculation: no
Ethics approval: yes; probably approved by an institutional review board
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: yes; participants with
a documented allergy or intolerance to methylphenidate were excluded
Comments from study authors (limitations)
1. Because no dose-response curves were collected on children in the study, we could
not determine whether effects of modified-release methylphenidate were dose-related
2. Study inclusion and exclusion criteria were selected for milder cases of ADHD
3. Lower scores in this trial mean that findings may not be generalisable
4. Three-week duration of the trial did not allow investigators to determine whether
dual-phase effects of modified-release methylphenidate persist with long-term
treatment
5. Study design limited generalisability of the results because it excluded acute
placebo responders and those who had failed to respond to any methylphenidate
treatment before the start of the study
6. Parents were aware that researchers had the option of stepping up the “dose” of
placebo each week
Key conclusion of study authors
1. Modified-release methylphenidate administered once daily in the morning was
well tolerated and was significantly more effective in a double-blind comparison with
placebo in controlling ADHD symptoms throughout the school day
Email correspondence with study authors: November and December 2013: not possible
to get supplemental information regarding the study through personal email correspon-
dence with study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated “randomised”. Stratification based
on previous treatment before randomisa-
tion ensured equal distribution across the
2 treatment groups
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical appearing mod-
ified-release methylphenidate and placebo
capsules were packaged in blister cards
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated “double-blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 316 were included in the safety population,
and 314 in the ITT efficacy population.
All statistical summaries and analyses were
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conducted for the ITT population using
the LOCF approach for childrenwhowith-
drew prematurely
Selection bias (e.g. titration after randomi-
sation → exclusion): yes; exclusion of
placebo responders
Selective reporting (reporting bias) Unclear risk No protocol available. All pre-specified
outcomes of interest have been reported
Vested interest bias High risk This study was funded by Celltech Phar-
maceuticals Incorporated
Conflicts of interest: Dr. Greenhill is a con-
sultant for Celltech-Medeva and a member
of its medical advisory board. Drs. Findling
and Swanson are consultants for Celltech-
Medeva
Greenhill 2006
Methods Seven-week multi-centre, randomised, double-blind, placebo-controlled, parallel trial
with 2 arms
1. Extended-release dexmethylphenidate
2. Placebo
To compare the efficacy and safety of extended-release dexmethylphenidate vs placebo
in paediatric patients with ADHD
Pre-randomisation phase of up to 2 weeks followed by double-blind treatment phase for
7 weeks (5 weeks of dose titration followed by 1 week of optimal constant dose)
Participants Number of participants screened: not stated
Number of participants included: 103
Number of participants randomly assigned: methylphenidate 53, placebo 50
Number of participants followed up: methylphenidate 48, placebo 37 (ITT analyses:
methylphenidate 52, placebo 45)
Number of withdrawals: methylphenidate 5, placebo 13
Diagnosis of ADHD:DSM-IV, extended-release dexmethylphenidate (combined (83%)
, hyperactive-impulsive (1.9%), inattentive (15.1%))
Age: mean methylphenidate 9.6 years, placebo 10.4 years (range 6 to 17)
IQ: > 70 (age-appropriate functioning levels academically)
Sex: 66 boys, 37 girls
Methylphenidate naive: 40
Ethnicity: Caucasian (60%), African American (23.3%), other (16.5%)
Country: USA
Setting: classroom setting
Comorbidity: no psychiatric comorbidity
Comedication: not stated
Sociodemographics: not stated. No significant difference in baseline demographics was
noted between the 2 groups. See Tables 1 and 2
238Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Greenhill 2006 (Continued)
Inclusion criteria
1. ADHD diagnosis as per DSM-IV
2. Baseline age of 6 to 17 years
3. Conners’ ADHD/DSM-IV Scales - Teacher, for boys 6 to 8 years ≥ 27, 9 to 11
years ≥ 24, 12 to 14 years ≥ 19, 15 to 17 years ≥ 14
4. Conners’ ADHD/DSM-IV Scales - Teacher, for girls 6 to 8 years ≥ 16, 9 to 11
years ≥ 13, 12 to 14 years ≥ 12; 15 to 17 years ≥ 6
5. Age-appropriate functioning levels academically
6. Negative pregnancy test and adequate contraception
Exclusion criteria
1. Clinically significant abnormalities in vital signs, physical examination findings or
laboratory test results
2. History of seizures or use of anticonvulsant medication
3. Comorbid psychiatric conditions (obtained by clinical interview)
4. Any medical condition that could interfere with study participation or
assessments, or that may pose danger with administration of methylphenidate
5. Psychotropic medications
6. Initiation of psychotherapy within the past 3 months
7. Positive urine drug screen
8. History of poor response or intolerance to methylphenidate
9. Pregnant or nursing
10. Any other investigational drug within 30 days of study entry
Interventions Participants were randomly assigned to an extended-release formulation of
dexmethylphenidate or placebo. Permitted doses were 5 mg/d for the first week; 5 or 10
mg/d for the second week; 5 mg/d, 10 mg/d or 15 mg/d for the third week; 5 mg/d, 10
mg/d, 15 mg/d or 20 mg/d for the fourth week; and 5 mg/d, 10 mg/d, 15 mg/d, 20 mg/
d or 30 mg/d for the fifth through seventh weeks
Mean final methylphenidate dosage: 24.0 ± 7.1 mg/d
Administration schedule: once daily in the mornings
Duration of intervention: 5-week titration period plus 2 weeks at a constant dose
Titration period: initiated after randomisation
Treatment compliance: At each study visit, compliance was assessed by investigator and
study staff on the basis of pill count and participant report
Outcomes ADHD symptoms
1. Conners’ ADHD/DSM-IV Scales - Teacher: rated weekly by teachers
2. Conners’ ADHD/DSM-IV Scales - Parent: rated weekly by parents
Quality of life
1. Child Health Questionnaire, Parent Form 50: parent-rated at final visit
Serious adverse events
1. Spontaneous reporting recorded weekly: no deaths or serious adverse events
Non-serious adverse events
1. Vital signs were rated weekly
2. Spontaneously reported adverse events were recorded weekly
Notes Sample calculation: Assumptions for sample size andpower included treatment difference
of 9.0 and and SD of 13.5
Ethics approval: no information provided
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Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: yes; participants with
history of poor response or intolerance to methylphenidate were excluded
Withdrawals due to adverse events: methylphenidate 0, placebo 1
Comments from study authors
1. It is of interest that no participant who received extended-release
dexmethylphenidate discontinued the study because of an adverse event. This may
result in part from the fact that more than one-third of participants in each treatment
group had prior experience with ADHD medications (mainly methylphenidate and
dexmethylphenidate) and in part from the flexible-dose design of the study
2. Another possible limitation is that patients with previous methylphenidate or
dexmethylphenidate experience were enrolled only if they had not experienced
moderate to severe adverse reactions. By excluding patients who could not tolerate
methylphenidate or dexmethylphenidate, investigators may have inflated the apparent
safety and tolerability of extended-release dexmethylphenidate. However, only about
one-fourth of the participants in each treatment group had prior experience with
methylphenidate or dexmethylphenidate, so this factor probably had little impact on
adverse event rates during the study
Key conclusions of study authors
1. In conclusion, results of this trial indicate that extended-release
dexmethylphenidate administered once daily in doses of 5 mg to 30 mg is safe and
effective for treatment of paediatric patients with ADHD symptoms, as reflected by its
significant superiority over placebo on Conners’ ADHD/DSM-IV Scales - Teacher,
Conners’ ADHD/DSM-IV Scales - Parent, Clinical Global Impressions -
Improvement Scale and Clinical Global Impressions - Severity Scale, and in the Child
Health Questionnaire Psychosocial Component score
2. Extended-release dexmethylphenidate was well tolerated and had a safety profile
consistent with those of other methylphenidate and dexmethylphenidate formulations,
resulting in appetite reduction and reduced weight in some patients
Comments from review authors
1. Statistically significant treatment by centre interaction in primary efficacy analysis
2. Study authors defined baseline scores on Conners’ ADHD/DSM-IV Scales -
Teacher (to be included) as different scores for different age groups, but they informed
efficacy as the difference from baseline to endpoint in all medicated individuals
3. As precise information on dose (mg/kg/d) was lacking, it is difficult to evaluate
whether 24 mg/d was enough for participants in this age range (6 to 17 years)
Email correspondence: July 2014. Wrote to Novartis to request additional information
but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further description pro-
vided
Allocation concealment (selection bias) Unclear risk No description provided
240Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Greenhill 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further description pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further description pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study used an ITT analysis. LOCF analysis
was used to impute missing values for all
final visit analyses
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) High risk Study authors defined baseline scores
on Conners’ ADHD/DSM-IV Scales -
teacher-rated, as inclusion criteria (differ-
ent scores for age groups), but they in-
formed efficacy as the difference from base-
line to endpoint for all medicated individ-
uals
Vested interest bias High risk Study funded by Novartis
Conflicts of interest: Two study authors are
employed by Novartis. Only Roberta R.
Ball has no conflicts of interest
Grizenko 2012
Methods Double-blind, cross-over, placebo-controlled, 2-week trial of methylphenidate in chil-
dren diagnosed with ADHD
1. Methylphenidate (0.5 mg/kg, b.i.d.)
2. Placebo
Phases: 2
Participants Number of participants screened: not stated
Number of participants included: 430 (average IQ group). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 430 (334 boys, 96 girls)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined 96 (48.73%), hyperactive-impulsive not
stated for average IQ group alone, inattentive not stated for average IQ group alone)
Age: mean 9.45 years (range 6 to 12)
IQ: mean 96.68 ± 9.98 (range 80 to 120)
Methylphenidate naive: not stated for average IQ group alone
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
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Comorbidity: not stated
Comedication: not stated
Sociodemographics: income group 4.62 (SD 1.56). Income groups set at 1 (< Can$
6000), 2 (Can$ 6000 to 10,000), 3 (Can$ 10,000 to 20,000), 4 (Can$ 20,000 to 30,
000), 5 (Can$ 30,000 to 40,000) and 6 (> Can$ 40,000)
Inclusion criteria
1. Children 6 to 12 years of age
2. Diagnosed with ADHD by a psychiatrist or a paediatrician participating in a
double-blind, placebo-controlled trial. Children were recruited from the Disruptive
Behavior Disorders Program and from the general sector out-patient clinic at Douglas
Hospital in Montreal, a psychiatric university teaching hospital
Exclusion criteria
1. Children with IQ < 70 (as measured by the Wechsler Intelligence Scale for
Children)
2. Met DSM-IV criteria for psychosis, pervasive developmental disorder or
Tourette’s syndrome
3. Previous intolerance or allergic reaction to methylphenidate (Grizenko 2006 and
Grizenko 2012 - both in Grizenko 2012)
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 0.5 mg/kg/d
Administration schedule: b.i.d. morning and noon
Duration of each medication condition: methylphenidate 1 week, placebo 1 week (in-
cluding weekends)
Washout before study initiation: 1 week before the start of the trial
Medication-free period between interventions: not stated, appears to have been none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Global Index - Teacher Version: once a week + 1 week before
medication trial
2. Conners’ Global Index - Parent Version: once a week (1 week before medication
trial and on the Sunday after children were given their medication of the weekend
(Grizenko 2006 - in Grizenko 2012)
General behaviour
1. Parents completed a Child Behavior Checklist 1 week before the start of the
medication trial
Serious adverse events
1. No important adverse events or side effects were noted
Non-serious adverse events
1. Barkley Side Effects Rating Scale
Notes Sample calculation: not stated
Ethics approval: yes
Key conclusion of study authors
1. Grizenko 2012: All children with ADHD within normal and high levels of
intellectual functioning respond equally to psychostimulant treatment; proper
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medication management is necessary for all children with the disorder
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes (see summary of participants)
Any withdrawals due to adverse events: not stated
Email correspondence with study authors: October 2013. We received some data from
study authors. We sent another email to ask for additional information but have not
received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was completed by a re-
search psychologist who had no contact
with participants
Allocation concealment (selection bias) Low risk “The sealed envelope containing the in-
formation about the order of MPH and
placebo administration for the participant
was opened after the CCR rating was as-
signed and recorded”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both drug and placebo were prepared by
a pharmacist in identical coloured gelatine
capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk Estimated enrolment: 700
Study start date: November 1999
Estimated primary completion date:
March 2018 (final data collection date for
primary outcome measure)
Vested interest bias Unclear risk Study was supported by the Canadian In-
stitutes of Health
Conflicts of interest: Dr. Joober has re-
ceived consultation honoraria from Pfizer
Canada and Janssen Ortho. Dr. Zappitelli
receives research salary support and grant
funding from the Kidney Research Scien-
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tist Core Education and National Training
Programme, the Fondation de Recherche
en Sante du Quebec and the Research In-
stitute of the McGill University Health
Centre, for research not related to this
manuscript
Gruber 2007
Methods Fourteen-day, double-blind, placebo-controlled, cross-over study with 2 interventions
1. Placebo
2. Methylphenidate
Participants Number of participants screened: not stated
Number of participants included: 37 (31 boys, 6 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 37
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (70%), hyperactive-impulsive (11%), inat-
tentive (19%))
Age: mean 9.2 years (range 6 to 12)
IQ: mean 96.7
Methylphenidate naive: not stated
Ethnicity: Caucasian (94%), other (6%)
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (30%), conduct disorder (46%), major de-
pressive disorder (5%), general anxiety disorder (3%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. ADHD according to DSM-IV
2. Patient at the Disruptive Behavior Disorders Program and in the out-patient
department of Douglas Mental Health University Institute in Montreal
3. Between 6 and 12 years of age
Exclusion criteria
1. Score < 80 on the Wechsler Intelligence Scale for Children, Third Edition
2. Diagnosis of psychosis
3. Diagnosis of Tourette’s syndrome
4. Pervasive developmental disorder
5. Taking any medication other than methylphenidate
6. Previous intolerance/allergic reaction to any psychostimulant
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 0.5 mg/kg/d
Administration schedule: twice daily, morning and noon
Duration of each medication condition: 7 days
Washout before study initiation: no
244Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gruber 2007 (Continued)
Medication-free period between interventions: no
Titration period: none
Treatment compliance: not stated
Outcomes General behaviour
• Child Behavior Checklist, daily
Non-serious adverse events
• Sleep assessment using miniature antigraphs, measured daily
Notes Ethics approval: Study was approved by the Research Ethics Board of Douglas Mental
Health University Institute
Key conclusion of study authors
1. Findings of the present study support the hypothesis that sleep moderates
performance on the Continuous Performance Test in children with ADHD receiving
placebo or methylphenidate
Comment from review authors
1. Unfortunately, the data are not useable because of how the study is set up
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes (see exclusion
criteria)
Any withdrawals due to adverse events: no
Email correspondence with study authors: February and March 2014. Emailed study
author twice but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Order of administration (methylphenidate
or placebo) was determined by random as-
signment
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “MPH and placebo were prepared in iden-
tical coloured gelatin capsules by the hos-
pital’s clinical pharmacist, who was not in-
volved in the study in any other way. Cap-
sules were sealed in individual, daily-dose
envelopes to help control accurate admin-
istration”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): yes
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Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Low risk This was not an industry-supported study
Conflicts of interest: Study authors have in-
dicated no financial conflicts of interest
Hale 2011
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: baseline, placebo, low-dose methylphenidate and high-dose methylphenidate for
4 weeks per medication phase
Participants Number of participants screened: 65
Number of participants included: 56 (39 boys, 17 girls). Participants were randomly
assigned to 1 of 6 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV-TR (combined (58.9%), hyperactive-impulsive (7.1%)
, inattentive (33.9%))
Age: mean 120.84 months (SD 30.85 months, range 6 to 16 years)
IQ: mean 99.56 (SD 6.84, n = 41)
Methylphenidate naive: number not stated (“All participants were either medication
naive or received and appropriate wash-out period”)
Ethnicity: European American (82%), African American (18%)
Country: USA
Setting: out-patient clinic
Comorbidity: specific learning disability (n = 13), oppositional defiant disorder/conduct
disorder (n = 11), anxiety/depression (n = 6)
Comedication: not stated
Sociodemographics: middle class (n = 44), lower class (n = 12); urban (n = 36), suburban
(n = 13), rural (n = 7)
Inclusion criteria
1. Diagnosis based on DSM-IV-TR criteria by referring physician - independent
confirmation by licensed and/or certified psychologist
2. Demonstrated significant attention, hyperactivity and/or impulse control
problems interfering with major life function in both home and school settings
3. ≥ 1.5 SD above the mean on ≥ 1 of the attention problems on the Child
Behavior Checklist, Teacher Report Form; Inattention and/or Hyperactive-Impulsive
subscales of the Conners’ Parent Rating Scale - Revised and Long; or Conners’ Teacher
Rating Scale - Revised
Exclusion criteria
1. ≥ 1 comorbid secondary diagnosis
2. History of mental retardation
3. Seizure disorder - brain injury
4. Other medical condition affecting cognitive or neuropsychological performance -
missing or different instruments for measuring methylphenidate response (i.e. missing
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data)
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate (0.15 mg/kg, 0.30 mg/kg) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: twice daily
Duration of each medication condition: 4 weeks
Washout before study initiation: 2 days
Medication-free period between interventions: no
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale - Revised and Long: teacher-rated at baseline and
at treatment follow-up
General behaviour
1. Schools Situation Questionnaire - Revised: teacher-rated at baseline and at
treatment follow-up
Non-serious adverse events
1. Side Effects Rating Scale, unclear who rated: at baseline and at treatment follow-
up
Notes Sample calculation: no
Ethics approval: not stated
Comment from study authors
1. Several study limitations are worth noting. First. age limitations. Second,
neuropsychological tests that were not counterbalanced and analysed for order effects.
Third, inter-rater reliability during methylphenidate trials. Fourth, intelligence/
cognitive screening
Key conclusion of study authors
1. Robust cognitive and behavioural methylphenidate response was achieved for
children with significant baseline executive working memory/self regulation (EWM/
SR) impairment, yet response was poor for those with adequate EWM/SR baseline
performance. Even for strong methylphenidate responders, the best dose for
neuropsychological functioning was typically lower than the best dose for behaviour.
Findings offer 1 possible explanation for why long-term academic methylphenidate
treatment gains in ADHD have not been realised
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: June to August 2014. Emailed study authors
twice to request additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All medications and placebos were pre-
pared by the study pharmacist, who ran-
domly assigned children to 1 of 6 trial or-
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ders in placebo (P), low-dose (L) and high-
dose (H) conditions (P-L-H, P-H-L, L-P-
H, L-H-P, H-L-P, H-P-L)
Allocation concealment (selection bias) Low risk Research assistants, teacher, parents and
participants were blinded to the order
of conditions. Ground methylphenidate
tablet was placed in lactose-filled opaque
capsules for active drug conditions, with
lactose included only for the placebo con-
dition, and was administered twice per day
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research assistants, teacher, parents and
participants were blinded to the order of
conditions. All medications and placebos
were prepared by the study pharmacist.
Groundmethylphenidate tablet was placed
in lactose-filled opaque capsules for the ac-
tive drug condition, with lactose included
only for the placebo condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk After results were analysed, the order of
conditions was revealed
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants for whom data were miss-
ing or different instruments were used for
methylphenidate response were excluded
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk Research part funded by the Neuropsy-
chiatric Research Institute, Fargo, North
Dakota, USA
Conflicts of interest: Study authors disclose
no conflicts of interest
Heriot 2008
Methods Three-month, parallel trial with 4 arms
1. Methylphenidate and parent training programme
2. Methylphenidate and supportive non-training parent group
3. Placebo and parent training
4. Placebo and supportive non-training parent group
Participants Number of participants screened: 93
Number of participants included: 20 to 26 (NB: 6 withdrew, but unclear whether before
or after random assignment)
Number of participants randomly assigned: not stated
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Number of participants followed up: methylphenidate + parent training 4,
methylphenidate + no training 4, placebo + training 4, placebo + no training 4
Number of withdrawals: not stated
Sex: 13 boys, 3 girls
Diagnosis of ADHD: DSM-IV (combined (25%), hyperactive-impulsive (56%), inat-
tentive (19%))
Age: mean 4.78 years (range 3 to 6)
IQ: mean 97 (range 80 to 123)
Methylphenidate naive: 100%
Ethnicity: no information
Country: New Zealand
Setting: out-patient clinic
Comorbidity (type: ODD 5/31%)
Comedication: no
Sociodemographics: SES group 1: 1, group 2: 0, group 3: 3, group 4: 4, group 5: 3,
group 6: 5. No significant differences in baseline demographics were noted between the
2 groups
Inclusion criteria
1. Between 3.0 and 5.9 years of age
2. Resident with a primary caregiver for ≥ 6 months
3. Meet diagnostic criteria for ADHD as defined in DSM-IV
4. Features of ADHD had to be present for ≥ 12 months and to a degree that was
considered to be developmentally inappropriate and functionally inappropriate and
functionally impairing across settings
5. Above the 93rd percentile on the Global Index subscale of the Conners’ Rating
Scales
Exclusion criteria
1. Currently in hospital
2. Currently in another treatment study
3. Currently receiving treatment
4. Full scale IQ < 80
5. Pervasive developmental disorder or psychosis
6. Major neurological or medical illness that would interfere with participation or
require medications incompatible with methylphenidate
7. Chronic serious tics or Tourette’s disorder
8. History of child abuse
9. Inability of parent to understand English
Interventions Participants were randomly assigned to methylphenidate + parent training,
methylphenidate + no parent training, placebo + parent training or placebo + no parent
training
Mean methylphenidate dosage: 0.3 mg/kg
Administration schedule: twice a day - morning and lunchtime
Duration of intervention: 3 months
Titration period: Dosage was built up over the first week
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale-IV Parent and Teacher Versions: data not reported in an
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useable form - not possible to obtain data from study author
2. Conners’ Parent Rating Scale - Revised, Long Version: no data provided in the
article
3. Conners’ Teacher Rating Scale - Revised, Long Version: no data provided in the
article
Non-serious adverse events
1. Stimulant drug, Barkley Side Effects Rating Scale
Notes Sample calculation: no
Ethics approval: yes; obtained from theUniversity ofWaikato,Department of Psychology
Ethical Review Committee and the Waikato Ethics Committee for Waikato Hospital
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Seven of the 16 children no longer met DSM-IV (1994) diagnostic criteria for
ADHD at the end of the study
2. Ethnicity did not appear to affect outcomes, although it was unclear whether the
content of the programme was equally appropriate for all ethnic groups
3. Limitations
i) Small number of participants
ii) Of those willing to participate, only 43% met eligibility criteria for the study
iii) No follow-up data
Key conclusion of study authors
1. Children were more likely to improve when treatment involved ≥ 1 active
component (medication or parent training). However, variability in individual parental
and child participant responses to all treatment conditions was notable, indicating the
importance of interaction between treatment variables and other factors. Findings are
discussed within the framework of a transactional model, and inferences are drawn
about limitations of the idea that a “best treatment” exists that is universally applicable.
Although improvement among children receiving treatment with methylphenidate was
greater than for others, it is notable that all treatments were associated with
improvement in some children
Email correspondence with study authors: January, February and May 2014. Emailed
study author but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were allocated to conditions
sequentially, using RAND function (SPSS)
to generate the sequence. Each parent was
randomly assigned to attend the training
programme group or the support group
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Throughout the period of data collection,
participants and therapist were blinded to
medication status
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Throughout the period of data collection,
participants and therapist were blinded to
medication status. All parents and teachers
were blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Only data for completing participants were
reported
Selection bias (e.g. titration after randomi-
sation → exclusion): unclear. Four were
excluded after randomisation because of
“treatment integrity problems”
Selective reporting (reporting bias) Unclear risk We were unable to identify a protocol
Vested interest bias Low risk No funding to conduct the study was re-
ceived from any party
Conflicts of interest: None of the study
authors are affiliated with pharmaceutical
companies
Hicks 1985
Methods Double-blind, cross-over trial with 2 interventions
1. Methylphenidate, low and high doses
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 44. Participants were randomly assigned to different
low and high doses of methylphenidate and to placebo
Number of participants followed up: 44 (36 boys, 8 girls; 20 in-patients, 24 out-patients)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 8.4 years (SD 1.75, range not reported)
IQ: mean 98.31 (SD 12.96)
Methylphenidate naive: not stated
Ethnicity: Caucasian (68.2%), African American (31.8%)
Country: not stated
Setting: out-patient clinic and patient ward
Comorbidity: not stated
Comedication: not stated
Sociodemographics: mean 3.59 (SD 1.29) (Hollingshead 2-factor SES index)
Inclusion criteria
1. Diagnosis of ADHD according to DSM-III
Exclusion criteria
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1. None stated
Interventions Participants were randomly assigned to different orders of methylphenidate (low-dose
0.3 mg/kg, high-dose 0.6 mg/kg) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: b.i.d. morning and noon
Duration of each medication condition: 12 for in-patients, 19 for out-patients
Washout before study initiation: not stated
Medication-free period between interventions: 68 hours
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale: rated weekly
2. Conners’ Teachers Rating Scale: rated weekly
Non-serious adverse events
1. Pulse, measured once in each treatment condition, before and 1 hour after
treatment
2. Blood pressure, measured once in each treatment condition, before and 1 hour
after treatment
3. Blood samples, measured once in each treatment condition, before and 1 hour
after treatment, including growth hormone, prolactin, thyroid-stimulating hormone
Notes Sample calculation: not stated
Ethics approval: yes
Key conclusion of study authors
1. “MPH appears able to engage homeostatic mechanisms which take over and
operate to return functioning to a more normal level”
Comment from review authors
1. Study participants are both in-patients and out-patients; therefore the sample
group is highly heterogeneous
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: March 2014. We obtained from study authors
supplemental information regarding funding and ethics. Not able to obtain additional
data as they are no longer available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
252Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hicks 1985 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Low risk Funded by the National Institutes of
Health (NIH)
Conflicts of interest: not stated
Hoeppner 1997
Methods Double-blind, cross-over trial with 2 interventions
1. High-dose (H) methylphenidate
2. Low-dose (L) methylphenidate
3. Placebo (P)
Four orders
1. P, L, H
2. H, P , L
3. P, H, L
4. L, P, H
Participants Number of participants screened: 95
Number of participants included: 50. Participants were randomly assigned to different
orders of low-dose and high-dose methylphenidate and placebo
Number of participants followed up: 50 (39 boys, 11 girls)
Number of withdrawals: none
Diagnosis of ADHD: DSM-III-R
Age: mean 9.6 years (range 6 to 18.1)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Meeting DSM-III-R ADHD, DSM-III ADD or DSM-III-ADD/H criteria
2. Score ≥ 1½ SD above the norm on the Conners’ Parent Rating Scale or the
Conners’ Teacher Rating Scale
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Exclusion criteria
1. No information
Interventions Participants were randomly assigned to different possible orders of high-dose
methylphenidate (0.3 mg/kg), low-dose methylphenidate (0.15 mg/kg) and placebo
(doses rounded up to the nearest 2.5 mg)
Mean methylphenidate dosage: no information
Administration schedule: twice a day - 8:00 AM and 12:00 PM
Duration of each medication condition: 1 week
Washout before study initiation: “received an appropriate wash-out period”
Medication-free period between interventions: from lunchtime until next morning - 20
hours
Titration period: none
Treatment compliance: no information
Outcomes ADHD symptoms
1. Conners’ Parent/Teacher Rating Scale: completed daily
Notes Sample calculation: no
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Dependent measures in this study often failed to detect significant dose-response
effects when analysed individually, and placebo effect were found for 4 of the 9
measures. Although ratings from the Conners’ Parent and Teacher Rating Scales were
sensitive to dose-response effects, findings were not uniform across raters and did not
correspond with cognitive response
2. Small sample size
Key conclusion of study authors
1. According to cognitive rank order ratings, linear and quadratic methylphenidate
response patterns were identified, with the best dose for each group significantly
different from that obtained for all other conditions
Email correspondence with study authors:March 2014. Emailed study authors to request
additional information but have received no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Low risk Pharmacists randomly assigned partici-
pants to 1 of 4 trial sequences
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo consisted of an opaque capsule
filled with lactose; active drug consisted of
the same lactose-filled capsule, to which
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methylphenidate was added
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo consisted of an opaque capsule
filled with lactose; active drug consisted of
the same lactose-filled capsule, to which
methylphenidate was added
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No reporting bias
Vested interest bias Unclear risk No information
Horn 1991
Methods Twelve-week, double-blind, randomised, parallel trial with 6 arms
1. Placebo
2. Low-dose methylphenidate
3. High-dose methylphenidate
4. Placebo + behavioural parent training + child self control instruction
5. Low-dose methylphenidate + behavioural parent training + child self control
instruction
6. High-dose methylphenidate + behavioural parent training + child self control
instruction.
Nine-month follow-up
Participants Number of participants screened: 117
Number of participants included: 107 (83 boys, 24 girls)
Number of participants randomly assigned: 16 to each arm
Number of withdrawals after randomisation: 18
Number followed up: at end of study (12 weeks) 78, 9 months after termination of study
71
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 8.27 years (range 7 to 11)
IQ: > 70
Methylphenidate naive: not stated
Ethnicity: Caucasian (84.9%), African American (9.4%), Hispanic (3.8%), Asian Amer-
ican (1.9%)
Country: USA
Setting: out-patient clinic
Comorbidity: conduct disorder (7.5%), disruptive oppositional disorder (15%), oppo-
sitional defiant disorder (43%)
Comedication: not stated
Sociodemographics:mean yearly family incomeUSD$25,019.No significant differences
in baseline demographics were noted between treatment groups or between treatment
groups and treatment drop-outs in any of the following parameters: child’s age, grade,
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sex, IQ; parental marital status, annual family income and maternal education and age.
However, a significantly greater number of non-white children were included in the
placebo alone condition than in remaining treatment conditions or among treatments
drop-outs
Inclusion criteria
1. 7 to 11 years of age
2. Exact agreement between a licensed clinical psychologist and a board certified
paediatrician with respect to diagnosis of ADHD according to DSM-III-R criteria
3. Score on Hyperkinesis Index of the Conners’ Parent or Teacher Rating Scale ≥ 2
SD above published means
4. Current psychostimulant therapy required to be withdrawn for the course of the
study
Exclusion criteria
1. Comorbid anxiety, depressive disorder or both
2. Gross physical impairments, intellectual deficits or psychosis in child or parents
Interventions Washout before study initiation: 2 weeks before initial diagnostic evaluation
Participants were randomly assigned to 1 of 6 treatment conditions, including placebo,
low-dose methylphenidate (0.4 mg/kg) and high-dose methylphenidate (0.8 mg/kg)
Administration schedule: daily
Duration of intervention: 12 weeks
Titration period: no
Treatment compliance: 87.39% of parents in the non-placebo medication conditions
group reported anonymously that their child took the medications almost every day,
whereas the remainder of families reported usage an average of 3 to 4 days a week.
Stimulant medication was withdrawn immediately after post-test assessments
Follow-up: 9 months
Outcomes ADHD symptoms
All dependent measures were administered at pre-test, post-test (within 1 week or 2
weeks of the end of the treatment phase of the study) and follow-up
1. Child Behaviour Checklist
2. Swanson, Nolan and Pehlam Scale
3. Conners’ Parent Rating Scale
4. Conners’ Teacher Rating Scale
Adverse events
1. Medication side effects, monitored by a board certified paediatrician
Notes Sample calculation: no information
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: August 2013. Not possible to receive supple-
mental information or data through personal email correspondence with study authors.
They do not recommend inclusion of the study in this review because of problems with
the design and methods used at the time the study was carried out (Ramstad 2013a [pers
comm])
Risk of bias
256Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Horn 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Two of 12 families were randomly assigned
to each of the 6 treatment conditions. This
procedure was repeated 8 times, so that by
the end of the study, 16 families were ran-
domly assigned to each of the 6 treatment
conditions, for a total of 96 families
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Note that assessors were
blinded to treatment status at all times
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were conducted on 4 samples: (1)
participants completing the entire study
and followed up at 9 months (n = 71), (2)
participants completing the entire study (n
= 78), (3) participants completing the en-
tire study + participants completing ≥ 6
weeks (n = 90) and (4) all of the above
+ those who dropped out immediately af-
ter initiating treatment (n = 96). When no
post-test and/or follow-up data were avail-
able for drop-outs, pre-test values or post-
test values, or both, were substituted.Given
that analyses produced essentially the same
results, only the analyses that include com-
pleters are reported
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias Unclear risk No information
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Methods Fourteen-week, parallel trial with 3 arms
1. Placebo
2. Low-dose stimulant therapy
3. High-dose stimulant therapy
Participants Number of participants screened: not stated
Number of participants included: 48 (35 boys, 13 girls). 16 children randomly assigned
to each of the following 3 treatment conditions: (1) medication placebo alone, (2) low-
dose (0.4 mg/kg) stimulant therapy, or (3) high-dose (0.8 mg/kg) stimulant therapy. A
sample of 21 non-clinical controls (13 boys and 8 girls) was also included in the study
Number of withdrawals: Seven families dropped out from pre-test to post-test: high-
dose methylphenidate 3, placebo 4
Numper of participants followed up: low-dose methylphenidate 16, high-dose
methylphenidate 13, placebo 12
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 7.97 years (SD 1.4, range 7 to 11)
IQ: ≤ 70
Methylphenidate naive: 98%
Ethnicity: Caucasian (78.0%), African American (12.2%), Hispanic (9.8%)
Country: USA
Setting: out-patient clinic
Comorbidity: conduct disorder (n = 5), oppositional defiant disorder (n = 12)
Comedication: no
Sociodemographics: middle-income families. No significant differences between treat-
ment groups or between treatment groups and drop-outs in any participant and/or
demographic characteristics at pre-test, with the exception of ethnicity. A significantly
greater proportion of African American children were included in the placebo condition
than in the high-dose condition
Inclusion criteria
1. Diagnosis of ADHD according to DSM-III-R
2. Exact agreement between 2 assessors (paediatrician and psychologist) with respect
to ADHD diagnosis
3. Score on Hyperkinesis Indices of the Conners’ Parent and Teacher Rating Scale ≥
2 SD above published means
Exclusion criteria
1. Comorbid anxiety and/or depressive disorder
2. Gross physical impairment
3. Intellectual deficits
4. Psychosis in child or parents
5. IQ < 70 (measured with the Peabody Picture Vocabulary Test - Revised)
Interventions Participants were randomly assigned to 3 treatment conditions: (1) medication placebo
alone, (2) low-dose (0.4mg/kg) stimulant therapy or (3) high-dose (0.8mg/kg) stimulant
therapy
Duration of intervention: 14 weeks
Titration period: no
Treatment compliance: One check on medication compliance consisted of periodic dis-
pensing of medication over the course of the study during follow-up visits to staff paedi-
atricians. In addition, a medical compliance questionnaire was completed anonymously
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by parents 1 month after post-test assessments. 91.9% of parents in the medication
conditions indicated that their child took the stimulant medication almost every day
throughout the study, whereas nearly all remaining families reported average usage of 3
to 4 days a week
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale
2. Conners’ Teacher Rating Scale
General behaviour
1. Conners’ Teacher Rating Scale, Conduct problems
Notes Sample calculation: no information
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. In contrast to placebo, although methylphenidate resulted in significantly greater
amelioration of many of the core features of ADHD, we found no evidence of a
decrease in perceived competence, or of an increase in external or unknown
explanations of control or dysphoria at post-test (i.e. 14 weeks later)
Email correspondence with study authors: August 2013 and January 2014. We emailed
study authors to request a copy of the protocol and additional information on, for
example, the randomisation procedure and funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All medication was dispensed in a double-
blinded fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All medication was dispensed in a double-
blinded fashion
Incomplete outcome data (attrition bias)
All outcomes
High risk No description of imputation method
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Unclear risk No information
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Methods Single-day, randomised, controlled, parallel, double-blind study with 2 arms investigat-
ing postural stability in 24 children with ADHD
1. Methylphenidate
2. Placebo
Participants Number of participants screened: 80
Number of participants included: 24
Number randomly assigned: methylphenidate 12 (11 boys, 1 girl), placebo 12 (11 boys,
1 girl)
Number of participants followed up in each arm: methylphenidate 12, placebo 12
Number of withdrawals in each arm: methylphenidate 0, placebo 0
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age:methylphenidatemean 10.06 years (range 7 to 16), placebomean 10.88 years (range
7 to 16)
Methylphenidate naive: 0%
Ethnicity: Israeli
Country: Israel
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
IQ: > 70
Sociodemographics: not stated
Differences between groups
1. No significant difference in baseline demographics were noted between the 2
groups
Inclusion criteria
1. DSM-IV diagnosis
2. 7 to 16 years of age
3. Methylphenidate treatment on a daily basis for the past 3 months
4. Only methylphenidate responders (improvement in ADHD symptoms after
methylphenidate treatment according to parent and teacher reports on the ADHD
Rating Scale, Fourth Edition, and according to paediatric neurologist follow-up)
5. IQ > 70
6. ADHD symptoms had to be severe for ≥ 6 items on the DSM-IV ADHD Rating
Scale (ADHD RS-IV), Parent Version
Exclusion criteria
1. Neurological, orthopaedic or psychiatric diagnoses according to DSM-IV criteria
that can affect motor control and postural stability: cerebral palsy, neuropathic disease,
limb fracture or head trauma during the previous year
2. Use of any medication other than methylphenidate during the study period
Interventions Participants were randomly assigned to 5 mg of short-acting methylphenidate or 5 mg
placebo. They had been drug-free for 24 hours before the start of the trial
Administration schedule: 5 mg × 1 (single dose)
Duration of intervention: 1 day
Titration period: none
Treatment compliance: 100%
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Outcomes Serious adverse events
1. No serious adverse events of drug treatment were experienced
Non-serious adverse events
1. No non-serious adverse events of drug treatment were experienced
Notes Sample calculation: yes
Ethics approval: no information
Key conclusions of study authors
1. Methylphenidate improves postural stability in ADHD, especially when an
additional task is performed, probably through enhanced attention abilities, thus
contributing to improved balance control during performance of tasks that require
attention
2. Methylphenidate remains to be studied as a potential drug treatment to improve
balance control and physical functioning in other clinical populations
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; see ’Inclusion criteria’
Any withdrawals due to adverse events: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation using a table of random
numbers
Allocation concealment (selection bias) Low risk Placebo pill was identical in appearance to
the methylphenidate pill
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and tester administering the
examination were blinded to group assign-
ments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and tester administering the
examination were blinded to group assign-
ments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs in either group
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
Vested interest bias Unclear risk No information
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Methods Multimodal Treatment Study of Children With ADHD (MTA) (Jensen 1999 (MTA)):
14-month multi-centre, randomised, parallel clinical trial with 4 arms
1. Medication management
2. Behavioural treatment
3. Combined treatment (medication management + behavioural treatment)
4. Community care (control group)
Phases: For the 2 groups receiving medication, an initial 28-day titration period was
provided. This titration phase was carried out as a randomised, double-blind, placebo-
controlled, cross-over trial with daily switching of methylphenidate doses (placebo, low,
middle and high). Once delivery of randomly assigned treatments byMTA staff stopped
at 14months, theMTAbecame an observational study inwhich participants and families
were free to choose their own treatment, but in the context of availability and barriers
to care existing in their communities. The following follow-up assessments took place
after completion of the RCT at 10 months’ follow-up (24 months after randomisation)
, 3-year follow-up, 8-year follow-up and 10-year follow-up
In our review, we will compare combined behavioural treatment (RCT) according to our
protocol and will look at the medication treatment group as a cohort (observational)
Participants Titration period (Greenhill 2001) (Jensen 1999 (MTA))
28-day RCT (combined treatment + medication management group)
Number of participants included: 289 (medication management 144, combined treat-
ment 145)
Number of participants completed: 256
Number of participants not finishing titration: 33. Of the completers, 198 were assigned
to an individually best dose of methylphenidate for the 14-month trial, the rest to other
medication or no medication
Main study (Jensen 1999) (Jensen 1999 (MTA))
Number of participants screened: 4541
Number of participants included: 579
Number of participants randomly assigned to methylphenidate + behavioural treatment
(combined treatment): 145, MPH 144, behavioural treatment (BEH) 144
Number of participants followed up: combined treatment 142; medication 136; be-
havioural treatment 141
Number of withdrawals/drop-outs: combined treatment 3; medication 8; behavioural
treatment 3
Demographic data for combined treatment, behavioural treatment and medication
management
Diagnosis of ADHD: DSM-IV (combined (100%))
Age: mean 8.4 years (range 7 to 9.9)
IQ: mean 100.4
Sex: 346 boys, 87 girls
Methylphenidate naive: 177
Ethnicity: White (60.3%), African American (20.6%), Hispanic (8.8%), other (10.4%)
Country: USA and Canada
Setting: out-patient clinic
Comorbidity: anxiety disorder (35.1%), conduct disorder (14.1%), oppositional defiant
disorder (38.8%), affective disorder (3.5%), tic disorder (10.2%), mania/hypomania
(3%)
Comedication: not stated
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Sociodemographics: 130 families on welfare. Population ranges widely in socioeconomic
status. No significant differences in baseline demographics were noted between the 3
groups
10-Month follow-up (MTA Group 2004) (Jensen 1999 (MTA))
Number of participants followed up in each arm: MGT 128, COMB 138, BEH 139;
age (mean 8.4 years); sex (322 boys, 83 girls). No differences between demographic
characteristics of the originally randomly assigned579MTAparticipants andparticipants
assessed during 10-month follow-up. The only statistically significant difference among
treatment groups was a trivial difference in age (MHT was 0.3 years older than BEH)
3-Year follow-up (Jensen 2007) (Jensen 1999 (MTA))
Number of participants followed up: medication 115, combined treatment 127
Age: mean 11.7 years (range 10 to 13)
Sex: 291 boys, 78 girls
No significant differences in baseline characteristics were noted between participants in
the 36-month assessment and those unable to be followed
8-Year follow-up (Molina 2008) (Jensen 1999 (MTA))
Number of participants followed up: medication management 101, combined treatment
119. 32.5% of theMTA sample was medicated more than 50% of days the previous year
Age: mean 16.8 years (range 13 to 16). At 8-year assessment, 55 MTA participants had
turned 18 years of age. Only 30% of the sample still fulfilled an ADHD diagnosis.
Participants lost to 8-year follow-up, compared with those retained, more often were
male; had younger mothers, less educated parents and lower parent income; and were
more likely to have been on welfare at baseline
10-Year follow-up, blood pressure (Vitiello 2012) (Jensen 1999 (MTA))
Number of participants followed up: medication management 77, combined treatment
93. A comparison of participants retained through the year 10 (n = 346) vs those who
were not (n = 233) showed a smaller proportion of males in the retained group. Fur-
thermore, participants were divided into groups on the basis of the following criteria:
“never medicated”, currently medicated, previously medicated. For the currently medi-
cated group, numbers of participants were, respectively, 184, 184, 108, 50 and 12 for 24
months, 36 months, 72 months, 96 months and 120 months of follow-up, respectively.
Medication use during the previous 30 days was the criterion for positive medication
status
Growth studies, 24-month assessment (Jensen 2004) (Jensen 1999 (MTA))
For growth outcomes, data from both the originally randomly assigned treatment groups
and naturalistic subgroups were collected. Naturalistic subgroups consisted of those who
had been medicated at all assessment points up to 24 months (medication use during
previous 30 days was the criterion for positive medication status) and those who had not
been medicated at assessment points
Participants with consistent use of medication (med/med): 255
Participants with no use of medication (NoMed/NoMed) 139; combined treatment 135,
medication management 120
Growth studies, 36-month assessment (Swanson 2007) (Jensen 1999 (MTA))
Naturalistic subgroups were established on the basis of patterns of treatment with stim-
ulant medication. If medication was used within a 30-day period before assessment,
medication status was positive (Med); otherwise it was negative (NoMed). If an indi-
vidual’s medication status changed at any assessment point, he or she was placed in the
263Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jensen 1999 (MTA) (Continued)
inconsistently medicated group
Participants with Med (n = 70). At baseline and at 14-, 24- and 36-month assessment
points, respectively, percentages of medicated children taking methylphenidate were as
follows: 85.4%, 79.7%, 76.8%, 73.5%. Naturalistic subgroups did not differ in initial
size at birth (birth weight), age, parent or teacher ratings of ADHD symptoms, sex,
expected adult size (mid-parent size), welfare status or maternal smoking
Inclusion criteria
1. Boys and girls
2. 7 to 9. 9 years of age
3. Grades 1 through 4
4. In residence with the same primary caretaker(s) for the past 6 months or longer
5. Meeting DSM-IV criteria for ADHD, combined type.
Exclusion criteria
1. Child currently in hospital
2. Child currently in another study
3. < 80 on all Weschler Intelligence Scales for Children, Third Edition, and on
Severe Impairment Battery (SIB) (bipolar disorder, psychosis or personality disorder)
4. Chronic serious tics or Tourette’s syndrome
5. Obsessive-compulsive disorder serious enough to require separate treatment
6. Neuroleptic medication in previous 6 months
7. Major neurological or medical illness
8. History of intolerance to MTA medications
9. Ongoing or previously unreported abuse
10. Missed one-fourth of school days in previous 2 months
11. Same classroom as child already in MTA study
12. Parental stimulant abuse in previous 2 years
13. Non-English-speaking primary caretaker
14. Another child in same household in MTA study
15. No telephone
16. Suicidal or homicidal
Interventions Titration period (Greenhill 2001) (Jensen 1999 (MTA))
Mean methylphenidate dose during titration period: combined treatment 32.1 mg/d,
medication management 28.9 mg/d. Medication management started with a 4-day sin-
gle-blind, safety lead-in period, during which participants were exposed to 3 progres-
sively higher daily methylphenidate doses given 3 times daily. This was followed by a
28-day, double-blind, daily, switch titration of methylphenidate hydrochloride, with 5
randomly ordered repeats each of placebo, 5 mg, 10 mg and 15 mg or 20 mg. Cross-site
teams of experienced clinicians blindly reviewed graphs portraying parent and teacher
ratings of responses to each of the 4 doses and by consensus selected each child’s best
dose
Compliance: not stated. 29 of 32 placebo responders had to go back to taking
methylphenidate during the maintenance period
Main study (Jensen 1999) (Jensen 1999 (MTA))
Participants were randomly assigned to medication management, behavioural treatment
or combined treatment
Mean methylphenidate dosage during main study: combined treatment 31.2 mg/d,
medication management: 37.8 mg/d
Administration schedule: 3 times a day - breakfast, lunch and in the afternoon
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Duration of intervention: 14 months
Treatment compliance: monthly pill counts, intermittent saliva measurements to moni-
tor intake of methylphenidate and encouragement for families to make up missed visits.
“The study achieved a high degree of adherence to protocol.” NB! For participants not
attaining an adequate response to methylphenidate during titration, alternate medica-
tions were titrated openly in the following order until a satisfactory choice was found:
dextroamphetamine, pemoline, imipramine and others, if necessary approved by a cross-
site panel. Thus, 256 participants successfully completed titration; of these, 198 of 289
participants were assigned to an individually titrated best dose of methylphenidate, and
26 were titrated to dextroamphetamine. 32 were given no medication because of a robust
placebo response
10-Month follow-up (MTA Group 2004) (Jensen 1999 (MTA))
Duration of intervention: 24 months (10-month follow-up from 14-month RCT)
Treatment compliance: not stated. From end of treatment to first follow-up, percentage
of participants taking medication decreased for combined treatment (87% vs 70%) and
methylphenidate (93% vs 72%) but increased for behavioural intervention (23% to
38%)
3-Year follow-up (Jensen 2007) (Jensen 1999 (MTA))
Duration of intervention: 3 years (36-month follow-up from 14-month RCT)
Treatment compliance: not stated. At 36 months, percentage of participants taking
medication was 70% for the combined group, 72% for the methylphenidate group and
45% for the behavioural intervention group
8-Year follow-up (Molina 2009) (Jensen 1999 (MTA))
Duration of intervention: 8 years
Mean methylphenidate dosage: 44.93 mg
10-Year follow-up (Vitello 2012) (Jensen 1999 (MTA))
Duration of intervention: 10 years
Treatment compliance: not stated
Mean methylphenidate dosage: 54.3 mg
Outcomes Titration period (Greenhill 2001) (Jensen 1999 (MTA))
• Conners’ Lonely and Milich Questionnaire (with Inattention/Overactive (I/O))
• Aggressive/Defiant (A/D) and Mixed (I/O + A/D) subscales: assessed daily by
parents and teachers
• Swanson, Kotkin, Agler, M-Flynn and Pelham (with Attention and Deportment
subscales): rated daily by parents and teachers
Main study (Jensen 1999)
• SNAP Inattention and Hyperactivity-Impulsivity subscale, both parent and
teacher: assessed at baseline and at 3, 9 and 14 months
• SNAP Oppositional Defiant Disorder subscale, both parent- and teacher-rated:
assessed at baseline and at 3, 9 and 14 months.
• Abikoff Classroom Observational System (ADHD and oppositional/aggressive
symptoms): blind ratings by blind observers
Serious adverse events
Main study (Jensen 1999)
1. 6 of 11 reported severe side effects could have been due to non-medication factors
2. Three deaths were recorded among ADHD participants during 10 years of
observation: a suicide at age 14 (participant was taking methylphenidate), a fatal car
accident at age 17 (participant was the driver and was taking methylphenidate) and a
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sudden unexplained death at age 17 (participant was found dead in bed; no specific
cause of death could be determined; he had been treated previously with
methylphenidate and had been off medication for longer than 1 year when he died)
Non-serious adverse events
Main study (Jensen 1999)
Participants were provided up to 8 additional sessions when needed to address clinical
emergencies or instances of possible study attrition
1. Pittsburgh Side Effects Rating Scale: monitored monthly, reviewed by the
pharmacotherapist
2. Internalising symptoms (anxiety and depression): measured with an internalising
subscale from parent- and teacher-completed Social Skills Responsive Scale (SSRS),
measured at baseline and at 3, 9 and 14 months
3. Children’s self ratings on the Multidimensional Anxiety Scale for Children:
assessed at baseline and at 3, 9 and 14 months
Titration period (Greenhill 2001) (Jensen 1999 (MTA))
1. Pittsburgh Side Effects Rating Scale (10 adverse events commonly associated with
methylphenidate were rated)
3-Year follow-up (Molina 2007) (Jensen 1999 (MTA))
1. Substance abuse: assessed at 24 and 36 months by a child-reported substance use
questionnaire (Molina and Pelham, 2003) adapted for the MTA. The measure
included items for lifetime and current (past 6 months) use of licit substances (alcohol,
cigarettes, chewing tobacco) and illicit drugs (marijuana and other street drugs). Also
included were items for inappropriate or non-prescribed use of medications, including
stimulants
2. Delinquency: assessed by the Self-Reported Antisocial Behavior Questionnaire
through 24-month assessment and the Self-Reported Delinquency Questionnaire at
36-month assessment. Delinquency was coded along an ordinal scale on the basis of
the most serious act committed during the past 6 months: 0 = no delinquency; 1 =
minor delinquency only at home (e.g. theft of less than $5 or vandalism); 2 = minor
delinquency outside the home (e.g. vandalism, cheating someone, shoplifting less than
$5); 3 = moderately serious delinquency (e.g. vandalism, theft of $5 or more, weapon
carrying); 4 = serious delinquency (e.g. breaking and entering, drug selling, attacking
someone with the intent to seriously hurt or kill, rape); and 5 = engagement in 2 or
more different Level 4 offences. Because only a small number of MTA children were
coded 5 (n = 14 at baseline, n = 4 and 5 between 14 and 36 months), we grouped codes
4 and 5 for data analyses, making a 5-level ordinal scale of 0 to 4
8-Year follow-up (Molina 2009) (Jensen 1999 (MTA))
1. Delinquent behaviour coded on a 5-point ordinal scale using parent and youth
report across several measures
2. Number of contacts with police and arrests using the Services for Children and
Adolescents-Parent Interview, parent reported
3. Depression rated by the Children’s Depression Inventory, self rated
4. Anxiety rated with by Multidimensional Anxiety Scale for Children, self rated
5. Psychiatric hospitalisation by 8 years, parent reported
8-Year follow-up, substance abuse (Molina 2009) (Jensen 1999 (MTA))
1. Substance use: assessed by a child/adolescent-reported questionnaire adapted for
the MTA. Substance use outcomes were measured at all interviews beginning with 24-
month assessment
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For analysis of stimulant treatment duration in relation to substance use at 8-year follow-
up, the primary outcome was the number of substances used in the past 6 months,
to ensure that most stimulant treatment received would have preceded substance use.
Component variables included the following: “drunk” once or more or drank alcohol
3 to 4 or more times; 1 or more cigarettes per day in the past month (time frame
exception specific to tobacco); marijuana 2 or more times; and any other illicit drug use
or prescription medication misuse. Secondary analyses explored each class of substances
separately. For analysis of stimulant treatment exposure over time in relation to substance
use at 8-year follow-up, the primary outcome variable was substance use disorder in the
past year for any substance (excluding tobacco). Secondary analyses explored alcohol and
marijuana/other drug use disorders separately
10-Year follow-up (Vitello 2012) (Jensen 1999 (MTA))
1. Blood pressure and heart rate monitoring, measured after participants had been
sitting for 5 minutes, adjusted for age and sex
2. Height and weight
3. Hospitalisation measured at each assessment point
4. No symptomatic cardiovascular events leading to medical attention were reported
during the period of observation, and no stimulant treatment discontinuation
consequent to cardiovascular adverse effects occurred during the 10-year period
Growth (Jensen 2004, Swanson 2007) (Jensen 1999 (MTA))
1. Height in centimeters and weight in kilograms, assessed at baseline, 14 months,
24 months and 36 months
Notes Sample calculation: yes; power analysis, with 576 participants required
Ethics approval: yes; approved by both local institutional review boards and National
Institutes of Health Office for Protection From Research Risk
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any drop-outs due to adverse events: Four participants were removed during the lead-
in (titration period) because of prohibitive side effects: 1 child with buccal movements;
another with skin picking; a third with depression, crying, sleep delay and appetite loss;
and a fourth who was anorexic, listless and emotionally constricted
Comments from study authors
1. Main study (Jensen 1999)
i) Recruitment, screening and selection procedures aimed to collect a carefully
diagnosed sample of impaired children with ADHD and a wide range of comorbid
conditions and demographic characteristics representative of patients seen in clinical
practice
ii) The design did not include a no-treatment or placebo group
iii) More than three-fourths of participants given behavioural treatment were
successfully maintained without medication throughout the study. Consequently, it
should not be concluded that behavioural treatment interventions did not work
iv) Combined treatment and medication management were clinically and
statistically superior to behavioural treatment and community care in reducing
children’s ADHD symptoms. (...) For other areas of function (oppositional/aggressive
behaviours, internalising symptoms, social skills, parent-child relations and academic
achievement), few differences among our treatments were noted, and when found,
were generally of smaller magnitude
v) Significantly lower total daily dose of methylphenidate in the combined
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treatment arm is noteworthy but was not unforeseen. The importance of this finding is
unclear, and a rigorous test of the question would likely require a different design
2. Titration period (Greenhill 2001) (Jensen 1999 (MTA))
i) Short 28-day duration limited generalisability to long-term treatment
ii) Rates of response to methylphenidate ran between 70% and 80% within the
expected range
iii) MTA titration study showed a steeper dose-response curve for younger and
lighter children with ADHD
iv) When ratings were collected under placebo-controlled, double-blind
conditions, parents reported more adverse events than did teachers. For this reason,
clinicians would be wise to collect methylphenidate side effect ratings from parents in
the afternoons and evenings
3. 10-Month follow-up (MTA Group 2004) (Jensen 1999 (MTA))
i) At follow-up, dose levels of medication management participants (in
methylphenidate equivalents) were significantly higher than those of participants in the
combined treatment group. Interesting results suggest the possibility that early
combined treatment interventions might allow reduced overall medication
requirements during later periods, consistent with findings reported by others
4. 3-Year follow-up (Jensen 2007) (Jensen 1999 (MTA))
i) By 36 months, none of the randomly assigned treatment groups differed
significantly in any of the 5 clinical and functional outcomes. (..) However despite no
significant group differences at 36-month assessment, substantial improvement was
manifested by all groups. As no untreated control groups were included, and because
all treatment groups were improved in terms of relevant symptoms at 36 months
compared with baseline, it is possible that all treatments worked but at different rates
in different time periods
ii) It is interesting that both medication and educational services provided for
24 to 36 months were markers for poorer outcome at 36 months, suggesting that those
who are doing poorly are given additional treatment, yet still do not do as well as those
for whom treatment is not considered essential
5. Vitiello 2001 (Jensen 1999 (MTA))
i) Comorbid anxiety, oppositional defiant disorder or conduct disorder was not
associated with statistically significant differences in methylphenidate dose at the end of
titration or maintenance, the number of medication changes or the time to first change
ii) A short-term response to placebo occurred in 32 children (of 256 who
completed double-blind titration) but was maintained in only 3 patients over the long
term
6. Conners 2001 (Jensen 1999 (MTA))
i) It is clear that the treatment effect in this study depends on the choice of
endpoint measure. Results highlight the fact that no “one true outcome” can be found
for a randomised clinical trial, because different measures may be sensitive to different
forms of treatment
7. 8-Year follow-up (Molina 2008) (Jensen 1999 (MTA))
i) Across time (to 8-year follow-up), 17.2% of children were medicated at
every assessment, beginning with the 14-month report
8. 10-Year follow-up (Vitiello 2012) (Jensen 1999 (MTA))
i) This clinical trial was not specifically designed to evaluate cardiovascular
function
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ii) Blood pressure and heart measurements were not conducted under double-
blind conditions, and measurement methods varied across clinical sites
iii) Abnormal blood pressure values were not systematically confirmed over 3
separate assessments, as required for a diagnosis of pre-hypertension or hypertension
iv) Time of day when measurements were taken was variable
9. Implications and applications for primary care providers (Jensen 2001)
(Jensen 1999 (MTA))
i) Behavioural treatments may help families actively cope with their child’s
disorder while making necessary life accommodations to optimise family functioning,
even when such treatments are not as effective as medication in reducing symptoms of
children with ADHD
ii) Findings suggest that high-quality treatments may have considerable impact
on restoring children with ADHD to normal or near-normal functioning at home and
in the classroom. Because essentially none of the children with ADHD met the normal
criteria met by 88% of comparison children drawn from the same classrooms at study
outset, the notion that ADHD is just normal behaviour labelled by uninformed
parents or overwhelmed teachers appears not only implausible, but preposterous
10. W.E. Pelham 1999 (Jensen 1999 (MTA))
i) Two major treatment modalities - behavioural and pharmacological - were
assessed at different time points relative to the intensive phase of treatment. Specifically,
the effects of pharmacological treatments were assessed at post treatment, while
participants were actively medicated; in contrast, the effects of behavioural treatment
were assessed after therapist involvement diminished. The intensive period of
behavioural treatment ended in late December or early January, and endpoint measures
typically were taken 4 to 6 months later - usually several months after the last planned,
face-to-face therapeutic contact. This design aspect has numerous implications for
interpretation of study findings. For example, we cannot state that the medication
(methylphenidate for the vast majority) had long-term effects. Rather, results simply
demonstrate that effects of methylphenidate given steadily for 14 months are the same
at the end of that time as at the beginning (indeed the correlations between drug effects
at these 2 points of the study are very high). When differences in outcomes between
these groups (e.g. behavioural therapy, medication management) are analysed, data
suggest it is likely that combined treatment for children whose parents and teachers
continued the behavioural interventions they had been taught will have outcomes
superior to those of medication management, and outcomes with combined treatment
for those whose parents and teachers did not continue behavioural treatment will be
equivalent to those with medication management alone (which would not be
surprising, as functionally this is what they would be receiving)
11. Growth, 24-month outcomes (Jensen 2004) (Jensen 1999 (MTA))
i) Growth suppression effects could be related to a medication effect, with the
continuously treated subgroup showing slower growth than the untreated subgroup.
Alternatively, the “Continuously treated subgroup”, defined by unknown self selection
factors, could have had a slower growth rate before the start of the study, which
continued during treatment and follow-up phases of the MTA. Our data cannot permit
a determination of the validity of these alternative interpretations. At this first follow-
up, our observations were of children in the MTA when they were between the ages of
9 and 11 years, which is before the expected phase of accelerated growth in adolescence
and before the age when growth is expected to slow and final height is approximated.
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Rate of growth and length of the growth phase together determine ultimate (adult)
height, and it is possible that consistent treatment with medication may reduce the rate
but lengthen the duration of growth, so final height would be delayed but not reduced.
It is possible that the never-medicated group was pared down to good responders and
the medicated groups were enriched by poor behavioural responders. In the analysis of
14- to 24-month change scores, “Medication status” was significant for both height (X²
= 16.16, P value < 0.001) and weight (X² = 13.32, P value < 0.004)
12. Growth, 36-month assessment (Swanson 2007) (Jensen 1999 (MTA))
i) We did not document a decrease in relative size among the group of
participants with a history of treatment before entry into the MTA protocol during
subsequent treatment with stimulant medication over 3 years. However, this group (the
consistently medicated naturalistic subgroup) was smaller than the stimulant naive
group (the newly medicated naturalistic subgroup at entry), suggesting that early
treatment of children (before 7 to 9 years of age) with stimulant medication may have
produced a reduction in growth rate before entry into the MTA protocol
Key conclusions of study authors
1. Main study (Jensen 1999)
i) For ADHD symptoms, our carefully crafted medication management was
superior to behavioural treatment and to routine community care that included
medication. Our combined treatment did not yield significantly greater benefits than
medication management for core ADHD symptoms but may have provided modest
advantages for non-ADHD symptoms and positive functioning outcomes
2. Vitiello 2001 (Jensen 1999 (MTA))
i) For most children, initial titration found a dose of methylphenidate in the
general range of the effective maintenance dose but did not prevent the need for
subsequent maintenance adjustments. For optimal pharmacological treatment of
individuals with ADHD, both careful initial titration and ongoing medication
management are needed
3. Titration period (Greenhill 2001) (Jensen 1999 (MTA))
i) The MTA titration protocol validated the efficacy of weekend
methylphenidate dosing and established a total daily dose limit of 35 mg of
methylphenidate for children weighing < 25 kg. It replicated previously reported
methylphenidate response rates (77%), distribution of best doses (10 mg/d to 50 mg/
d) across participants, effect sizes on impairment and deportment and dose-related
adverse events. With t.i.d. dosing, the MTA titration trial showed that significant
stimulant medication effects on ADHD symptom reduction and drug-related adverse
events could be detected by parents and teachers by using daily ratings under
controlled conditions
4. 10-Month follow-up (MTA Group 2004) (Jensen 1999 (MTA))
i) The benefits of intensive medical intervention for ADHD extend 10 months
beyond the intensive treatment phase only in symptom domains and diminish over
time.
5. 3-Year follow-up (Jensen 2007) (Jensen 1999 (MTA))
i) By 36 months, the earlier advantage of having had 14 months of the
medication algorithm was no longer apparent, possibly because of age-related decline
in ADHD symptoms, changes in medication management intensity, starting or
stopping of medications altogether or other factors not yet evaluated. At 24 and 36
months, investigators assessed delinquency and substance abuse
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6. Molina 2007 (Jensen 1999 (MTA))
i) Cause-and-effect relationships between medication treatment and
delinquency are unclear; absence of associations between medication treatment and
substance use must be re-evaluated at older ages
ii) Findings underscore the need for continuous monitoring of these outcomes
as children with attention deficit hyperactivity disorder enter adolescence. No
statistically significant effects of randomly assigned treatment on individual rate of
change in delinquency were observed between baseline and 36 months at the P value <
.05 level. Results suggest that increasing delinquency between 24 and 36 months was
associated with an increase in substance use during the same time period. We found no
evidence of protective or adverse effects of medication treatment for ADHD in either
study
7. 8-Year follow-up (Molina 2009) (Jensen 1999 (MTA))
i) Type or intensity of 14 months of treatment for ADHD in childhood (at age
7 to 9.9 years) does not predict functioning 6 to 8 years later. Rather, an early ADHD
symptom trajectory regardless of treatment type is prognostic. This finding implies that
children with behavioural and sociodemographic advantages, with the best response to
any treatment, will have the best long-term prognosis. As a group, however, despite
initial symptom improvement during treatment that is largely maintained after
treatment, children with combined-type ADHD exhibit significant impairment in
adolescence. Innovative treatment approaches targeting specific areas of adolescent
impairment are needed
8. 10-Year follow-up, blood pressure (Vitiello 2012) (Jensen 1999 (MTA))
i) Stimulant treatment did not increase the risk for pre-hypertension or
hypertension over the 10-year period of observation. However, stimulants had a
persistent adrenergic effect on heart rate during treatment
9. Growth studies, 24-month follow-up (Jensen 2004) (Jensen 1999 (MTA))
i) In the MTA follow-up, exploratory naturalistic analyses suggest that
consistent use of stimulant medication was associated with maintenance of
effectiveness but continued mild growth suppression
10. Growth studies, 3-year follow up (Swanson 2007) (Jensen 1999 (MTA))
i) Combined-type attention-deficit hyperactivity disorders were, as a group,
greater than expected from norms before treatment but show stimulant-related
decreases in growth rate after initiation of treatment, which appeared to reach
asymptotes within 3 years without evidence of growth rebound
11. W.E. Pelham 1999 (Jensen 1999 (MTA))
i) Active medication for ADHD is better than withdrawn behavioural
treatment (on some but not most measures)
ii) Combined treatment adds modestly to active medication but is superior to
behaviour management alone
iii) Study treatments that include active medication are better than community
treatments that include medication, and behavioural treatment is comparable with
medication as delivered in the community
iv) Concurrent BT results ≥ 20% lower and increasing medication dosages
relative to treatment with medication alone
12. Comorbidity (Jensen 2001) (Jensen 1999 (MTA))
i) Our findings suggest that children with ADHD with and without
oppositional defiant disorder/conduct disorder and anxiety differed in many baseline
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characteristics, outcomes and response to treatment. Children with anxiety tended to
be more treatment-responsive than those with ADHD + oppositional defiant disorder/
conduct disorder, and even ADHD-only participants
13. Anxiety (March 2000) (Jensen 1999 (MTA))
i) Contravening earlier studies, no adverse effects of anxiety on medication
response for core ADHD or other outcomes in anxious or non-anxious ADHD
children was demonstrated. When ADHD is treated, it is important for practitioners
to search for comorbid anxiety and negative affectivity and to adjust treatment
strategies accordingly
14. Swanson 2007 (Jensen 1999 (MTA))
i) Long-term benefits of consistent treatment were not documented; selection
bias was not shown to account for loss of relative superiority of medication over time;
no evidence of “catch-up” growth was found; early treatment with medication did not
protect against later adverse outcomes. We expect that these challenges to views of
practitioners will contribute to future controversy about long-term outcomes of the
MTA
15. Molina 2012, substance use (Jensen 1999 (MTA))
i) Our findings provide no evidence that ADHD medication protects from, or
increases risk for, adolescent substance use, or SUD. This finding held for recent
medication and for days of cumulative treatment with stimulants. Unmeasured
confounders may have been operating because of the naturalistic follow-up study
design, and we did not statistically control for psychopathology and functioning at
follow-up assessment. Observed lack of association between stimulant exposure over
time and adolescent substance use/SUD does not eliminate the possibility that brain-
based changes in neural mechanisms underlying addiction vulnerability are occurring
as a function of prolonged stimulant treatment. Substance use/SUD outcomes for the
MTA should be considered in the context of several unique study features and
limitations. All children in the MTA were diagnosed with the combined type of DSM-
IV ADHD, and generalisation of study results generally should not extend beyond this
subtype. Our follow-up assessments, which relied on self report, often with 2-year
windows, might have missed episodes of substance use, and rates may be
underestimated
16. Pelham 2000 (Jensen 1999 (MTA))
i) The Diagnostic Interview Schedule for Children interview shows that 75%
of children in the behavioural treatment group were maintained without medication
for 14 months, and 64% did not meet diagnostic criteria for ADHD at 14 months
(MTA Cooperative Group, 1999, 1999a). Such findings highlight the fact that
intensive behavioural treatments are a viable alternative to medication for treatment of
individuals with ADHD
Comments from review authors
1. Authors from the MTA study have written more than 70 articles describing
different outcomes and challenges of the study. We have included only those found
through our comprehensive literature search and others that we found relevant to
include upon looking through article reference lists
2. We have discussed whether to include the MTA study, as not all participants
randomly assigned to medication (combined treatment and medication management
group) received methylphenidate. Those who did not have an adequate response to
methylphenidate were given other medication (e.g. dextroamphetamine, pemoline,
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imipramine) or no medication. Furthermore, some participants in the BEH group
were also medicated during the 14-month randomisation phase. From all other studies
in this review, we have included only receivers of pure methylphenidate. Furthermore,
lots of participants did not have an ADHD diagnosis at follow-up assessment. At 8-
year follow-up, only 30% of remaining participants still had a diagnosis of ADHD.
However, we have chosen to use the data from MTA, as it is such a large and well-
known study. All MTA analyses will be included in the review as sensitivity analyses
3. Regarding Molina 2012 (substance use): We have included/asked for additional
data from this study, even though the medicated group received medication for a mean
of only 2071.10 (SD 728.87) days of the 8 years the follow-up took place
4. The following articles from the MTA study have been assessed by only 1 review
author: Pelham 2000, Carey 2000, Swanson and Hinshaw 2007, Galanter 2003,
Hinshaw 1999, Molina 2013
Email correspondence with study authors: January 2014 to June 2014. We sent several
emails to the MTA group to request additional information. However, we were not able
to obtain additional data. We did receive an email from Dr. Hinshaw confirming that
the data on ADHD symptoms, parent-rated, were wrong - instead of a mean of 1.85,
the correct mean was 0.85 for combined treatment after 14 months. We also received an
email from Dr. Swanson in June 2014 stating that he would help with data collection.
We wanted to conduct a reanalysis of data excluding those few participants not receiving
methylphenidate. Dr. Swanson proved several helpful comments on this and enclosed
published articles, but we did not receive additional data, in part because of the time
frame of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done centrally by
the National Institute of Mental Health
(NIMH) Data Center, stratified by site in
blocks of 16 (4 to each group). Stratified by
6 sites. Sealed, ordered envelopes were sent
to sites for successive entries
Allocation concealment (selection bias) Low risk Sealed, ordered envelopes were sent to sites
for successive entries. Treatment assign-
ment was concealed until the family con-
firmed agreement to accept randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment assignment was concealed un-
til the family confirmed agreement to ac-
cept randomisation. After agreement on
best dose, the blind was broken, and the
agreed on dose (if not placebo) became the
participant’s initial maintenance dose
Blinding of outcome assessment (detection
bias)
High risk After agreement on best dose, the blind
was broken, and the agreed on dose (if
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All outcomes not placebo) became the participant’s ini-
tial maintenance dose. However, for some
outcome measures, 3 strategies were de-
vised to enlist blinded raters and objective
observations
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analyses. Despite high compliance,
we checked whether compliance with as-
sessments (i.e. missing data) could have
changed our findings. Random-effects re-
gression analyses were completed 2 ways:
once with inclusion of all participants, and
then including only participants who pro-
vided data over multiple time points dur-
ing the study. No differences emerged from
these 2 sets of analyses
Selective reporting (reporting bias) Low risk This study was supported by several grants
from the National Institute of Mental
Health (NIMH), Bethesda, Maryland
Vested interest bias Low risk This study was supported by several grants
from the National Institute of Mental
Health, Bethesda, Maryland
Conflicts of interest: Several study authors
have affiliations with medical companies
Johnston 1988
Methods Two-week cross-over trial with 3 interventions
1. Methylphenidate
2. Placebo
3. Sustained-release methylphenidate (we do not report on this group here)
Phases: to define rebound effects in 21 boys 4 to 10 years of age, with aDSM-III diagnosis
of ADD and treated with methylphenidate some days, and placebo other days
Participants Number of participants screened: not stated
Number of participants included: 21. Participants were assigned to different orders of
methylphenidate and placebo
Number of participants followed up: 21 (21 boys, 0 girls)
Number of withdrawals: 0
Diagnosis of ADD: DSM-III-R (subtype not stated)
Age: mean 7 years 7 months (range 4 to 10 years)
IQ: mean 101 (range 79 to 120)
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (summer treatment programme)
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Comorbidity: conduct disorder (n = 2), oppositional defiant disorder (n = 17), learning
disability (n = 9)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-III-R diagnosis of ADD
Exclusion criteria
1. Not stated
Interventions Random sequence allocation to
1. 0.3 mg/kg methylphenidate twice daily (at breakfast and just before lunch; n = 21)
2. 0.6 mg/kg methylphenidate twice daily (at breakfast and just before lunch; n = 16
of the same 21 participants)
3. 20 mg sustained-release methylphenidate (n = 8). Not reported here
4. Placebo
Within-participant random sequence, condition varied daily
Mean methylphenidate dosage: not stated
Duration of intervention: 2 weeks. Note: It is not clear for how many days each boy
received either of the methylphenidate doses or placebo
Treatment compliance: not stated
Outcomes ADHD symptoms
• Modified Conners’ Scale Parent, daily, and Teacher ACR, 2 to 3 ratings per
treatment condition. Daily reports of social and academic behaviour. Not stated who
did the rating for these reports
• Swanson, Nolan and Pelham Scale, teacher-rated
• Abbreviated Conners’ Rating Scale
• IOWA Conners’ Teacher Rating Scale
Non-serious adverse events
• Rebound/Modified Conners’ Scale, Parent, for rebound effect assessment
• Specific Behaviour Ratings by parent (5, specific individual problem behaviours,
rated every night)
Notes Sample calculation: none
Ethics approval: no information
Funding/vested interest: no information
Any withdrawals due to adverse events: no
Author affiliations: University. No conflicting interests stated
Comment from review authors
1. Non-validated endpoints used. No definition (defined cutoff score on scales) of
what the authors considered to be ‘rebound’
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
Email correspondence with study authors: Emailed study authors to request additional
information. Also asked whether this study includes the Pelham 1989 reference. No
answer from study author, so we extracted data as from 2 different studies
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Order of drug condition for each child was
randomly assigned over days
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Child, parent, teacher and programme
counsellors were blinded to the condition.
Active medication and placebo were dis-
guised in gelatin capsules and pre-packaged
in individually dated envelopes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Low risk Conflicts of interest: During the writing of
this report, C. Johnston was supported by
a Doctoral Fellowship from the Social Sci-
ences and Humanities Research Council of
Canada
Kaplan 1990
Methods Three open trials, then a placebo-controlled, double-blind, cross-over study with 2 in-
terventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: 6. Participants were randomly assigned to 1 of 2
possible drug condition orders
Number of participants followed up: 6 (all boys)
Number of withdrawals: 0. Three out-patients were studied in an open-label design
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 14.4 years (range 13 to 16)
IQ: mean 86 (range 76 to 97)
Methylphenidate naive: 5 (55%)
Ethnicity: not stated
Country: USA
Setting: out-patient clinic and in-patient ward
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Comorbidity: aggressive conduct disorder (100%)
Comedication: yes; diphenhydramine 50 mg
Sociodemographics: not stated
Inclusion criteria
1. Meeting DSM-III criteria for both ADHD and aggressive conduct disorder
Exclusion criteria
1. Consent from parent or custodial social service agency
2. Psychosis or drug abuse history
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.6 mg/
kg, with 30 mg as a ceiling for methylphenidate and placebo
Mean methylphenidate dosage: 0.47 mg/kg
Administration schedule: twice a day, 8:00 AM and noon
Duration of each medication condition: 3 weeks
Washout before study initiation: 1 week
Medication-free period between interventions: 20 hours
Titration period: 1 week after randomisation
Treatment compliance: no information
Outcomes ADHD symptoms
• Conners’ Teacher Rating Scale: completed weekly by classroom teachers
• In addition, for in-patients, Conners’ Rating Scale was completed weekly by the
unit nurse
Non-serious adverse events
• Treatment Emergent Side Effect Scale: completed weekly by treating psychiatrists
• Dizziness, appetite loss and headache were reported in 3 of the 9 youngsters
Notes Sample calculation: no
Ethics approval: no information
Comment from study authors
1. As the result of an oversight, assignment to methylphenidate-first or placebo-first
condition was made in the absence of a specific randomisation formula. Five of the 6
participants received placebo for the first condition and methylphenidate for the
second condition
Key conclusion of study authors
1. Findings provide preliminary evidence of the efficacy of methylphenidate in
reducing aggression among aggressive conduct-disordered adolescents also diagnosed
with ADHD
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Email correspondence with study authors: March 2014. Emailed study author twice to
request additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk As the result of an oversight, assignment to
methylphenidate or placebo as the first con-
dition was made in the absence of a specific
randomisation formula. Five of the 6 par-
ticipants received placebo for the first con-
dition and methylphenidate for the second
condition
Allocation concealment (selection bias) Low risk Assignment to order condition was deter-
mined with no knowledge of the particular
participants involved; thus participants did
not receive 1 condition or the other based
on symptoms or any other systematic bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In 2 cases, school vacation at the in-pa-
tient setting prevented teacher ratings from
being obtained during 1 condition of the
study. In those 2 instances, the decision
was made to use Conners’ ratings obtained
from the unit nurse for both the condition
for which no teacher ratings were provided
and the condition for which teacher ratings
were given; thus comparisons were consis-
tent in terms of rater
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Unclear risk No information
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Methods Double-blind, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Followed by long-term follow-up of 12 children out of 21 who continued to receive
methylphenidate. Follow-up for an average of 16 months
Phases
1. Baseline
2. Cross-over study
3. Follow-up
Participants Regarding the cross-over trial
Number of participants screened: not stated
Number of participants included: 26, but 5 children dropped out, 3 were removed by
parents and 2 were disqualified because of a death in the family in 1 and a protocol
procedural error in the other
Number of participants randomly assigned: 21 (18 boys, 3 girls)
Number of participants followed up: 21, plus 2 participants who had been withdrawn
but returned later for follow-up
Number of withdrawals to follow-up: 0, but data for a few variables were not obtained
for all participants
Diagnosis of ADHD: DSM-III
Age: mean 9.3 years (range 8 to 12)
IQ: mean 100.7
Methylphenidate naive: 100%
Ethnicity: White (62%), Hispanic/Oriental/Black (14%), mixed race (24%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional disorder (14%), enuresis (38%)
Comedication: not stated
Sociodemographics: 2-parent household (95%)
Inclusion criteria
1. ADHD diagnosis according to DSM-III
2. IQ > 80
3. Free of major health problems, neurological disorders or psychosis
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to methylphenidate or placebo
Methylphenidate dosage: between 0.3 and 0.6 mg/kg/d in the short-term phase
Administration schedule: 2 time points a day
Duration of each medication condition: not stated
Washout before study initiation: from noon to the following morning (i.e. the next day)
Titration period: no
Outcomes ADHD symptoms
1. Attention Deficit Disorder-Hyperactivity: Comprehensive Teacher Rating Scale:
rated before diagnosis, at cross-over, at the conclusion of the short-term protocol and
again during long-term follow-up
2. Conners’ Parent Questionnaire: rated before diagnosis, at cross-over, at the
conclusion of the short-term protocol and again during long-term follow-up
279Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kelly 1989 (Continued)
Notes Sample calculation: not stated
Ethics approval: yes
Key conclusion of study authors
1. Findings indicate that many pre-adolescents with ADHD exhibit low self esteem.
Despite clinical response to medication, short-term improvement in self esteem may
not occur; however, long-term, multi-modal management that includes medication
does appear to improve self esteem
Comment from review authors
1. The data that we used in the review were derived from the cross-over period
described
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: January 2014. Study authors not able to
provide us with further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Child assigned in a double-blind, cross-
over format to methylphenidate fol-
lowed by placebo or placebo followed by
methylphenidate
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Because data for a few variables were not
obtained for all participants, a procedure
for unbalanced analysis of variance was re-
quired and was accomplished by using the
general linear model (GLM) procedure in
the Statistical Analysis System (SAS)
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not stated
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Vested interest bias Unclear risk CIBA Geigy Pharmaceuticals provided
placebos
Conflicts of interest: no information
Kent 1995
Methods Double-blind, cross-over trial with 3 interventions
1. Methylphenidate 10 mg
2. Methylphenidate 15 mg
3. Placebo
Phases: The first 2 doses (7:00 AM and noon) were unchanged from the open trial,
whereas the 4:00 PM dose was 10 mg of methylphenidate, 15 mg of methylphenidate or
placebo. Each of these 3 4:00 PM medication conditions was administered in random
order during the 12-day period. Each medication condition was administered for a total
of 4 days
Participants Number of participants screened: not stated
Number of participants included: 12 (11 boys, 1 girl). Participants were randomly as-
signed to different possible drug condition orders of methylphenidate and placebo
Number of participants followed up: not stated (but all 12 seem to appear in the results)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 9.0 years (SD 2, range 5.5 to 11.25)
IQ: not stated
Methylphenidate naive: 60%
Ethnicity: not stated
Country: USA
Setting: in-patient ward
Comorbidity: oppositional defiant disorder (25%), learning disability and oppositional
defiant disorder (50%), conduct disorder (8%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. In addition to fulfilling ADHD diagnostic criteria, patients were considered for
the study only if they showed a beneficial response to an open trial of methylphenidate,
as discussed below
Exclusion criteria
1. Major depressive disorder
2. Separation anxiety disorder
3. Tics or history of tics
4. Glaucoma
5. Psychosis or history of psychosis
6. Known hypersensitivity to methylphenidate
Interventions Participants were randomly assigned to different possible drug condition orders of 10
mg or 15 mg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 7:00 AM, noon and 4:00 PM
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Duration of each medication condition: 4 days
Washout before study initiation: none stated
Medication-free period between interventions: none
Titration period: Open titration of methylphenidate was accomplished within 14 days
of the child’s admission
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Child Behavior Rating Form, rated by nursing staff: after each day shift and each
evening shift
Non-serious adverse events
1. Sleep latency, sleep adequacy, food intake and weight: recorded by nursing staff
Notes Ethics approval: Informed consent for study participation was obtained from each child’s
parent or guardian. All procedures were approved by the study site’s Human Subjects
Research Review Committee
Comment from study authors
1. Patient population studied was particularly disturbed, and data were obtained in
the context of in-patient treatment
Key conclusions of study authors
1. This study’s findings show that children with ADHD derive substantial symptom
reduction from methylphenidate administered in late afternoon, with no untoward
effects on sleep. Therefore, t.i.d. should be considered for those children who exhibit
ADHD symptoms in the evening
2. Adverse effects on sleep latency were not apparent in the sample overall
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; patients were
excluded from consideration for study participation if they had known hypersensitivity
to methylphenidate
Any withdrawals due to adverse events: none
Email correspondence with study authors: March 2014. Sent an email to study authors
to request additional information but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Each of the 3 4:00 PM medication con-
ditions was administered in random order
during the 12-day double-blind cross-over
period
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The identity of each day’s 4:00 PM dose
was known only to the hospital pharmacist,
until the child completed the 12-day pro-
tocol
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results are provided for all 12 children
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk This work was supported by the John and
Maxine Bendheim Fellowship and by the
Leon Lowenstein Foundation
Conflicts of interest: not stated
Kent 1999
Methods Cross-over trial with 3 interventions
1. Methylphenidate 0.3 mg/kg
2. Methylphenidate 0.6 mg/kg
3. Placebo
Phases: 3-week, double-blind, 2-way cross-over, long-term (≥ 12 months) follow-up
Participants Number of participants screened: not stated
Number of participants included: 50 (38 boys, 12 girls). Participants were randomly
assigned to different possible drug condition orders of methylphenidate and placebo
Number of participants followed up: 43
Number of withdrawals: 7
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean not reported (range 4 to 14 years)
IQ: “overall normal intelligence”
Methylphenidate naive: not stated
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: depression (37%), anxiety (37%), learning disability (51%), conduct dis-
order (5%), “psychiatric disorder” (2%), Tourette’s disorder (12%), “other” (23%)
Comedication: not stated
Sociodemographics: “Fifteen (30%) live in households that have a family income below
the Canadian poverty line ($20,000/y)”, 26 “rural”, 9 “suburban”, 14 “urban”. 21 live
with 1 biological parent, 24 live with both parents, 4 live with adoptive parents or
“guardians”
Inclusion criteria
1. ADHD diagnosis
2. 4 to 14 years of age
3. English or French speaking
4. Living with caretakers with whom they had lived for longer than 6 months
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5. Presence of a teacher who could evaluate the child in class
Exclusion criteria
1. History of significant developmental delay
2. Previous diagnosis of pervasive developmental disorder
3. Unwillingness of parents and/or school personnel to meet methylphenidate
treatment requirements
Interventions Participants were randomly assigned to different possible drug condition orders of 0.3
mg/kg methylphenidate and 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: Each new condition started on a Saturday morning (to allow
parents’ observation/evaluation on weekend). Capsules given at 8:00 AMand 12:00 PM.
Conners’ administered at baseline and on the last day of each week. A 30-minute semi
structured follow-up interview was conducted≥ 12 months after completion of the trial
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: 12:00 PM to 8:00 AM the following day
Titration period: none initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Questionnaire: baseline and on the last day of each week
2. Conners’ Teacher Questionnaire: baseline and on the last day of each week
Non-serious adverse events
1. Weekly reporting of side effects by parents and teachers. No use of standard side
effects questionnaire
Notes Sample calculation: not stated
Ethics approval: yes; the Research Ethics Board of the IWK Grace Health Centre ap-
proved the protocol
Comments from study authors
1. “We found the MPT to be helpful, practical, and definitive for families of
children with attention-deficit/hyperactivity disorder to making a decision about
medication use”
2. “Regardless of the outcome, it was important for families to complete the MPT to
understand, for their own child, the effect of methylphenidate on the child’s behaviour
and the presence of any side effects”
Key conclusion of study authors
1. “An ’N of 1’ MPT was easily performed and permitted families to decide whether
to use methylphenidate for long-term treatment of attention-deficit disorder or
attention-deficit/hyperactivity disorder. Regardless of methylphenidate use or lack of
use, the condition of all of these children was improved at follow-up”
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
Email correspondence with study authors: August 2013. We received additional infor-
mation from study authors, but they were not able to provide the additional data that
we requested
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Once enrolled in the MPT, the non-
blinded hospital pharmacist randomly as-
signed each child to a particular dosing
schedule”. “The capsules contained, in ran-
dom order: placebo of the prescribed dose
of methylphenidate (Ritalin) hydrochlo-
ride (0.3 mg/kg or 0.6 mg/kg)”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Families (n = 50) with a child eligible for
MPT were given 3 bottles of identical cap-
sules”. “The family, teacher, and physician
were blinded for the order of medication”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “At the end of each trial the code was bro-
ken. The physician evaluated this informa-
tion andmade a clinical inference about the
degree of response each week”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias High risk Not stated
Conflicts of interest: Study authors spon-
sored by Pharmaceutical Manufacturers’
Association of Canada Studentship
Klorman 1990
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 2
Participants Number of participants screened: not clear
Number of participants included: 48. Participants were randomly assigned to 1 of 1 dose
of methylphenidate and placebo
Number of participants followed up: appears to have been 48
Number of withdrawals: not clear
Diagnosis of ADHD: DSM-III
Age: mean not stated (range 12 to 18 years)
IQ: mean 108.62
Sex: 42 boys, 6 girls
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Methylphenidate naive: 46/48; 2 had brief trials in childhood
Ethnicity: Caucasian (n = 46)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional and conduct disorder (n = 24), oppositional not conduct
disorder (n = 12), anxiety (n = 5), drug or alcohol abuse (n = 2), depression (n = 1)
Comedication: no
Sociodemographics: double- or single-parent family, predominantly middle class (mean
Hollingshead socioeconomic status score of 48.8 (i.e. social class II))
Inclusion criteria
1. Participants 12 to 18 years of age without previous stimulant therapy referred for
evaluation of response to stimulants from 1984 to 1988
Exclusion criteria
1. CNS involvement
2. Childhood autism
3. Psychosis
4. Uncorrected visual or auditory problems
5. IQ < 80
Interventions Participants were randomly assigned to 3 weeks of methylphenidate hydrochloride and
placebo
Mean methylphenidate dosage: 35.21 mg (± 5.94 (SD)). Range 15 mg (2 daily doses)
to 40 mg (3 daily doses)
Administration schedule: Doses were gradually increased at the end of the first and
second weeks
Washout before study initiation: not described
Titration period: after randomisation
Treatment compliance: not described
Outcomes ADHD symptoms
1. Abbreviated Conners’ Hyperactivity Questionnaire: rated by teacher and parent,
weekly
2. IOWA Inattention/Overactivity and Aggression Scales: rated by teacher and
parent, weekly
Mean parent- and teacher-reported Conners’ hyperactivity and inattention scores were
graphed but SD values were not. Also, the paper did not refer to measures of impulsivity
or total scores. We could not use these data in our meta-analyses because values were
missing and study authors were not able to provide supplemental data on this outcome
Non-serious adverse events
1. Side effects reported in Table 3: appetite loss; increased thirst, dry mouth,
stomachaches, nausea, headaches, sleep problems, shakiness, crying, anger,
unhappiness, sadness
Notes Sample calculation: not described
Ethics approval: not described
Key conclusion of study authors
1. These results support the continued effectiveness of stimulant therapy for
attention deficit disorder in adolescence. However, the magnitude of clinical
effectiveness reported was smaller than was previously found in younger patients
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Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April 2014. We obtained supplemental in-
formation/data from study authors (Magnusson 2014a [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Received information from study author (
Magnusson 2014a [pers comm])
Allocation concealment (selection bias) Low risk Received information from study author (
Magnusson 2014a [pers comm])
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Substances were dispensed in capsules of
identical appearance” (p 703)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parent and teacher ratings were used and
participants were blinded to which capsule
they were receiving
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk National Institute of Mental Health
(NIMH) grant MH38118
Conflicts of interest: no corporate affilia-
tions declared
Kolko 1999
Methods Randomised, placebo-controlled, cross-over trial with 2 possible drug interventions and
placebo, as well as 2 possible psychological interventions
1. Methylphenidate at 0.3 mg/kg
2. Methylphenidate at 0.6 mg/kg
3. Placebo
and
1. Behaviour modification
2. No behavioural modification
Participants Number of participants screened: 70
Number of participants included: 22 (all boys). Participants were randomly assigned to
different possible drug condition orders
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Number of participants followed up: 16
Number of withdrawals: 6
Diagnosis of ADHD: DSM-III-R (subtypes not stated)
Age: mean 9.6 years (range 6.9 to 12.9)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: African American (75%)
Country: USA
Setting: “partial hospitalisation” summer treatment programme
Comorbidity: conduct disorder (44%), oppositional defiant disorder (56%), anxiety
disorder (18.8%), major depressive disorder (11.5%), dysthymia (6%), intermittent
explosive disorder (6%), developmental articulation disorder (6%), asthma (12.5%)
Comedication: not stated
Sociodemographics: Three lived with 1 or both parents, 6 lived with grandparents, 1
lived with an aunt, 4 lived with non-relatives, 2 lived with foster mother. 44% of families
received welfare
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to different possible drug condition orders of 0.3
mg/kg and 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 8:00 AM and 11:30 AM to 12.00 PM
Duration of each medication condition: 1 day. Each medication condition was admin-
istered once per week for a total of 6 days during the trial
Washout before study initiation: 2 weeks
Medication-free period between interventions: no
Titration period: none
Treatment compliance: not stated
Behavioural intervention: behaviour modification and no behaviour modification were
alternated on a weekly basis for a total of 3 weeks per condition
Outcomes ADHD symptoms
1. Abbreviated IOWA Conners’ Rating Scale, which includes an Inattentive/
Overactive subscale and an Oppositional Defiant subscale
Non-serious adverse events
1. Barkley Stimulant Side Effects Rating Scale. Adapted by changing the rating scale
to include only 4 points rather than 9 points
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusions of study authors
1. Methylphenidate and behaviour modification had certain unique, main and
incremental effects that extend findings supporting their combination and suggest that
integrated studies should evaluate multiple dimensions of functioning in novel settings
2. Incorporation of other intervention components in combined treatments may be
warranted to enhance clinical efficacy
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Comments from review authors
1. Barkley Stimulant Side Effects Rating Scale was adapted by changing the rating
scale to include only 4 points (rather than 9 points) after pilot-testing. Therefore, we
cannot be sure whether the scale is still valid
2. Limitations: The number of participants studied was small, and only 22 of 70
screened met study eligibility criteria
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study author: January 2014. We were unable to obtain
additional data (Nilausen 2014 [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Each methylphenidate condition was ad-
ministered once per week for a total of 6
days during the trial, and behaviour mod-
ification and no behaviour modification
were alternated on a weekly basis, for a to-
tal of 3 weeks per condition. Thus, daily
methylphenidate conditions were crossed
with 2 weekly behavioural intervention
conditions
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is stated: “MPH or placebo was placed in
identical opaque capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Not stated
Selection bias: exclusion of 2 participants
with challenging behaviour
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk Not stated
Conflicts of interest: no information
289Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kollins 2006 (PATS)
Methods Eight-phase, 70-week, multi-centre trial (phase III study) including
1. Screening: varying time
2. Uncontrolled parent training: 10 weeks
3. Baseline: 2 to 4 weeks
4. Open-label, safety lead-in: 1 week
5. Random-sequence, double-blind, placebo-controlled, cross-over titration: 5
weeks. Optional pharmacogenetics study simultaneously
6. Randomised, optimal dose, double-blind, placebo-controlled, parallel trial: 4
weeks
7. Open-label, uncontrolled maintenance: 10 months
8. Randomised, double-blind, placebo discontinuation: 6 weeks
If parents requested and clinicians agreed that participants were severely symptomatic,
children could be moved directly into the medication phase that was concurrent with
parent training. If participants did not tolerate the dosing in phase 4, they could enter
the open-label maintenance phase if they tolerated lower doses (e.g. 1.25 mg, 2.5 mg).
If they tolerated all doses except 7.5 mg, they were eligible to enter phase 5, the cross-
over titration, with the planned week on a 7.5-mg dose replaced by an additional 5-mg
week. After phase 5, cross-over: (1) If the child showed the greatest clinical benefit during
1 of the 5 weeks of the cross-over trial, with no room for improvement, the blind was
broken and the child was randomly assigned to that methylphenidate dose or placebo in
phase 6; (2) if the child was a placebo responder, phase 6 was skipped and the child was
allowed to enter phase 7 while taking no medication and with monthly monitoring by
the treating physician; (3) if a particular week was deemed best, with ongoing room for
improvement, a 2-week double-blind trial of 7.5 mg and 10 mg t.i.d., each for 1 week,
was implemented, and teacher and parent ratings and side effects data were subsequently
blindly reviewed to determine the best dose; or (4) participants with no clinical benefit
any week were not eligible to continue in phase 6 or 7 but were given 1-month follow-
up and then were referred for community treatment
Participants Number of participants screened: 1915
Number of participants included in the study: 303 (229 boys, 74 girls)
Number of participants who completed the last phase of the study: 8
Number of withdrawals during the study: 295
Diagnosis of ADHD: DSM-IV (combined (75%), hyperactive-impulsive (25%), inat-
tentive (0%))
Age: mean 4.41 years (range not reported)
IQ: > 70 (mean 99.06)
Methylphenidate naive: 100%
Ethnicity: Caucasian (63%), African American (19%), Asian (2%), Hispanic or Latino
(16%), American Indian or Alaskan Native (0.7%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (52%), communication disorder (22%),
eliminationdisorder (i.e. encopresis, enuresis; 8%), specific phobia (8%), anxiety disorder
(8%), developmental co-ordination disorder (3%), conduct disorder (2%), pica (2%)
, adjustment disorder (1%), reactive attachment disorder (1%), obsessive-compulsive
disorder (0.7%), sleepwalking disorder (0.3%)
Comedication: no
Sociodemographics: double-parent family (76%), single-parent family (18%), mean
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Hollingshead socioeconomic status 47.20 (SD 9.56)
Phase 4, open-label, safety lead-in
Number of participants included: 183
Numberof participants followed up: 169
Number of withdrawals: 12
Number of participants leaving the study phase and entering maintenance (phase 7): 2
Phase 5, cross-over
Number of participants included: 165 (122 boys, 43 girls)
Number of participants followed up: 147
Number of withdrawals: 14
Number of participants leaving the study phase and entering maintenance (phase 7): 4
Diagnosis of ADHD: DSM-IV (combined (76%), hyperactive-impulsive (24%), inat-
tentive (0%))
Age: mean 4.74 years (range 3 to 5.5)
IQ: > 70 (mean 97.93)
Methylphenidate naive: 100%
Ethnicity: Caucasian (63%), African American (18%), Asian (1%), Hispanic or Latino
(18%), American Indian or Alaskan Native (0.6%)
Country: USA
Comorbidity: oppositional defiant disorder (55%), communication disorder (20%),
eliminationdisorder (i.e. encopresis, enuresis; 8%), specific phobia (7%), anxiety disorder
(10%), developmental co-ordination disorder (4%), conduct disorder (3%), pica (2%)
, adjustment disorder (0.6%), reactive attachment disorder (2%), obsessive-compulsive
disorder (0.6%), sleepwalking disorder (0.6%)
Comedication: no
Sociodemographics: double-parent family (79%), single-parent family (21%), mean
Hollingshead socioeconomic status 47.01 (SD 9.58)
Phase 6, parallel
Number of participants included: 114 (85 boys, 29 girls)
Number of participants randomly assigned: methylphenidate 61, placebo 53
Number of participants followed up: 77
Number of withdrawals: 1
Number of participants leaving the study phase and entering maintenance (phase 7): 36
Diagnosis of ADHD: DSM-IV (combined (75%), hyperactive-impulsive (25%), inat-
tentive (0%))
Age: mean 4.76 years (range not reported)
IQ: > 70 (mean 97.45)
Methylphenidate naive: 100%
Ethnicity: Caucasian (65%), African American (17%), Asian (0.9%), Hispanic or Latino
(17%), American Indian or Alaskan Native (0.9%)
Country: USA
Comorbidity: oppositional defiant disorder (53%), communication disorder (22%),
eliminationdisorder (i.e. encopresis, enuresis; 7%), specific phobia (7%), anxiety disorder
(11%), developmental co-ordination disorder (5%), conduct disorder (3%), pica (0.9%)
, adjustment disorder (0.9%), reactive attachment disorder (2%), obsessive-compulsive
disorder (0.9%), sleepwalking disorder (0.9%)
Comedication: no
Sociodemographics: double-parent family (80%), single-parent family (19%), mean
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Hollingshead socioeconomic status 47.61 (SD 9.45)
Phase 7, open-label maintenance
Number of participants included: 140 (104 boys, 36 girls)
Number of participants followed up: 95
Number of withdrawals: 45
Diagnosis of ADHD: DSM-IV (combined (76.4%), hyperactive-impulsive (23.6%),
inattentive (0%))
Age: mean 4.4 years
IQ: > 70
Methylphenidate naive: 100%
Ethnicity: Caucasian (65.0%), African American (17.1%), Asian (1.4%), Hispanic (15.
7%), American Indian (0.7%)
Country: USA
Comorbidity: oppositional defiant disorder (52.9%), communication disorder (19.3%)
, anxiety disorder (11.4%)
Comedication: no
Sociodemographics: double-parent family (81.4%), single-parent family (18.6%), mean
Hollingshead socioeconomic status 47.2 (SD 9.5)
Inclusion criteria
1. 36 to 65 months (3 to 5.5 years)
2. DSM-IV criteria for ADHD, hyperactive/impulsive or combined subtype, on
Parent Diagnostic Interview Schedule for Children, Fourth Edition, and clinical
interview by experienced clinician; symptoms were required to be present for a
minimum of 9 months
3. Age- and sex-adjusted T score ≥ 65 on the Hyperactive-Impulsive subscale of
Conners’ Parent and Teacher Rating Scales
4. Score < 55 on the Children’s Global Assessment of Functioning Scale
5. IQ > 70 as on the Differential Abilities Scale; children scoring < 70 were
considered for inclusion if their composite score from the Vineland Adaptive Behavior
Scale was > 70
6. Enrolled in some type of day programme: day care, pre-school, nursery school,
kindergarten, for ≥ 2 half-days/wk. School-type programme, in which class included
≥ 8 same-age peers; if children had been expelled from an eligible programme in the 3
months before screening, they could be considered for enrolment
7. Teachers willing to complete rating scale
8. Residing with primary caretaker for ≥ 6 months before screening
9. Patients and parents willing to attend all visits required by the study
10. Otherwise generally healthy, and systolic and diastolic blood pressure below 95th
percentile for age and sex
11. Stimulant-naive
Additional inclusion criteria for phase 4, open-label lead-in
1. Not showing substantial ADHD improvement after parent training (phase 2)
(continued impairment, operationalised as < 30% reduction on Conners’ Parent
Rating Scale or Conners’ Teacher Rating Scale, or a rating of less than “improved” by at
least 2 of the 3 raters (parent, teacher, clinician) completing the Clinical Global
Impressions Scale
2. Parental consent to a medication trial
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Additional inclusion criteria for phase 5, cross-over
1. Tolerating the dosing in phase 4 (i.e. children with moderate to severe adverse
events at doses < 5 mg in phase 4 were not eligible to continue)
Exclusion criteria
1. Children or their parent(s) could not understand or follow instructions given in
the study
2. Evidence of moderate to severe adverse events or evidence of a much improved
response to any dose of methylphenidate or another stimulant
3. > 5 weeks of exposure to ≥ 30 mg/d of methylphenidate or equivalent doses of
other stimulants
4. Use of any other psychotropic medication or an investigational drug in the past
30 days; episodic use of sympathomimetic decongestants for the common cold under
the study physician’s supervision was allowed
5. History of motor or vocal tics or Tourette’s syndrome
6. Major medical conditions that would interfere with involvement in a long-term
study or could be affected negatively by methylphenidate
7. Current evidence of adjustment disorder, pervasive developmental disorders,
autism, psychosis, significant suicidality or other psychiatric disorder, in addition to
ADHD that requires treatment with additional medication
8. Evidence of current physical, sexual or emotional abuse
9. Living with anyone who currently abuses stimulants or cocaine
10. History of bipolar disorder in both biological parents
-------
All cases were presented to a cross-site panel of clinicians, and only patients for whom
consensus indicated that all inclusion (and no exclusion) criteria were met could be
enrolled
Interventions Phases 1 to 3
Enrolment, parent training; baseline: no medical intervention
Phases 4 to 8
Medical intervention (short-acting, immediate-release methylphenidate)
Phase 4, open-label, safety lead-in
Titration: starting dose of 1.25 mg twice daily; increased to 7.5 mg 3 times daily
Duration: 1 week
Treatment compliance: not stated
Phase 5, cross-over
Randomly assigned sequence of doses of 1.25 mg, 2.5 mg, 5.0 mg or 7.5 mg immediate-
release methylphenidate and placebo administered 3 times daily for a week
Medication-free period between interventions: none
Mean methylphenidate dose: not stated
Duration: 5 weeks
Phase 6, parallel
After a 24-hour medication washout, 4 weeks of randomly assigned treatment with a
participant’s optimal methylphenidate dose as determined in phase 5, or placebo
Mean methylphenidate dose: 14.22 mg/d, 0.7 mg/kg/d
Duration: 4 weeks
Treatment compliance: not stated
Phase 7, open-label, maintenance
Maintenance starting doses were based on the best dose decision from cross-over titration.
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Phase 5 placebo responders were maintained without medication for ≥ 4 weeks, unless
their condition deteriorated, in which case open-label treatment could be initiated. For
any participant whose condition deteriorated, the methylphenidate dose was gradually
titrated for optimal response. The dosing regimen was adjusted tominimise some adverse
events to 3 times daily (at breakfast, around noon after lunch and at 3:30 PM), 7 days a
week
Mean methylphenidate dose: increased from 14.04 mg/d (0.71 mg/kg/d) at month 1 to
19.94 mg/d (0.92 mg/kg/d) at month 10
Duration: 10 months
Treatment compliance: not stated
Phase 8, discontinuation
Randomised, double-blind, placebodiscontinuation trial, inwhich an abruptmedication
replacement consisted of placebo for half of the children, while others continued on
their best methylphenidate dose from the end of phase 7. Children returned to active
medication if they met relapse criteria, in other words, Conners’ Parent Rating Scale
or Conners’ Teacher Rating Scale scores on the Hyperactivity/Impulsivity Index > 1.5
SD above age- and sex-adjusted norms, or a clinician rating of 4 on the Clinical Global
Impressions - Severity Scale
Duration: 6 weeks
Treatment compliance: not stated. Those who opted out of the double-blind phases
would be allowed to continue on open-label maintenance therapy. This greatly reduced
incentive for families to remain in the double-blind phases, especially if there was reason
to suspect that a child had been randomly assigned to placebo
Outcomes ADHD symptoms
1. Conners’, Loney and Milich Rating Scale, and Swanson, Kotkin, Agler, M-Flynn
and Pelham Scale: teacher- and parent-rated weekly in phase 5
2. Swanson, Nolan and Pelham Scales, Fourth Edition, average of parent and teacher
ratings: at the end of the last week (fourth) of phase 6
3. Conners’ Parent Rating Scale, Conners’ Teacher Rating Scale: rated by parents
and teachers weekly in phase 8
General behaviour
1. Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder Symptoms
and Normal Behaviour Scale, Early Childhood Inventory: teacher- and parent-rated at
baseline and at the end of phase 6
2. Child Behavior Checklist (home functioning)
3. Hillside Behaviour Rating Scale (school functioning)
Quality of life
1. Child Global Assessment Scale: completed only during non-randomised phases
Serious adverse events
1. Medication-related serious adverse events
Non-serious adverse events
1. Height and weight were measured without shoes or heavy clothes at each study
visit. (Growth charts provided by the Centers for Disease Control and Prevention
(CDC) were used to transform absolute units of measurement into Z-scores.)
Laboratory tests were performed at each study visit
2. General clinician inquiry regarding the child’s health problems at each study visit.
Adverse events monitored by telephone, and parent- and teacher-rated in phase 4. Side
Effects Rating Scale, parent-rated, weekly in phases 5, 6 and 8; monthly in phase 7.
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Side Effects Rating Scale, teacher-rated, weekly in phases 5 and 8, and in the last week
of phase 6, as well as in first and tenth months of phase 7
3. Safety related to early and continued medication treatment evaluated at 6-year
follow-up
4. Adverse Events Checklist was based on the Pittsburgh Side Effects Rating Scale.
The 4-point (none, mild, moderate or severe) teacher-rated scale included the
following: buccal-lingual movements; picking at skin or finger; lip or cheek chewing;
other abnormal motor movements; worried, anxious appearance; dull, tired, listless
appearance; headaches; stomachaches; crabby, irritable behaviour; tearful, sad,
depressed behaviour; appetite loss; prone to crying; and uninterested in others with
social withdrawal. The Parent Adverse Events Checklist also included trouble sleeping.
Only adverse events rated as moderate or severe were counted as reportable in the open
lead-in, titration and parallel phases of the study, whereas adverse events rated as mild,
moderate or severe were reported from the maintenance phase
5. Blood pressure and pulse, at each study visit. Cardiovascular adverse events were
based on age-adjusted normative values. Tachycardia was defined as 2 measurements of
resting heart rate above 120 beats per minute (bpm) at the same visit. Hypertension
was defined as 2 blood pressure readings at the same visit that were above the 95th
percentile for age and sex (systolic or diastolic), ranging from 110/72 for 3-year-olds to
115/74 for 6-year-olds. Blood pressure was checked again within 7 to 14 days. If the
reading remained above the cutoff limit, an adverse event for hypertension was
reported. Hypertension was rated as mild if < 10 mmHg, moderate if 11 mmHg to 20
mmHg and severe if > 20 mmHg above the limit
Notes Sample calculation: yes. Target sample size stated in the online protocol 165. Sample to
be randomly assigned 120
Ethics approval: yes; by institutional review boards at each study site. The study was
monitored by the Data and Safety Monitoring Board of the National Institute of Mental
Health
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors (limitations)
1. Design: The study included only immediate-release methylphenidate, not an
extended-release preparation. The study may have included an order effect in the cross-
over phase, particularly for children who were randomly assigned to receive higher
doses first. The PATS protocol did not provide a stimulant-untreated clinical control
group in non-controlled phases. Comparisons of height and weight before and after
treatment were made against population norms (i.e. children without an ADHD
diagnosis and methylphenidate-exposure). The follow-up period was not sufficient for
evaluation of the critical issue of long-term effects of initial growth suppression
observed in the first year of treatment
2. Dose: Doses used in the PATS were relatively low and homogeneous, and the high
end of the proposed dose range was truncated. This may have masked dose-related
effects
3. Population: The rigorous procedures for diagnosis of ADHD enhanced the
validity of the diagnostic process at the expense of excluding some children likely to
have met the conventional criteria for ADHD in other settings. Children who showed
substantial ADHD improvement after parent training were not eligible for medication
phases. The sample was too small for the medication to be declared safe for this age
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group. Failure to meet remission criteria may be caused by severity of ADHD
symptoms, not by possible ineffectivity of methylphenidate in pre-schoolers with
ADHD. A high attrition rate and differential attrition rates in the allocated groups
were possibly due to a delayed study start, repeated consent procedures, an always
available option to skip directly into maintenance and greater nervousness among
parents about medication side effects in pre-schoolers. Parents’ experience during the
titration phase presumably heightened their awareness of behavioural differences
associated with active and placebo medication
4. Data: missing data in general. Adverse event data entry procedures may have
inflated adverse event rates. Parents were told when double-blind switches between the
drug took place. This may have contributed to confounding of negative expectancy
and reporting of adverse events
5. Exploratory moderator analyses of efficacy data from phase 5 (cross-over): No
adjustments were made for multiple comparisons. Findings should be considered
preliminary. The Diagnostic Interview Schedule for Children, Fourth Edition, Parent
Version, has not been validated in pre-school children. Sample sizes across different
moderator categories/subgroups were relatively small. Data on compliance were missing
Key conclusions of study authors
1. Phase 5 (cross-over): Immediate-release methylphenidate, delivered in 2.5-mg, 5-
mg and 7.5-mg doses t.i.d., produced significant reductions in ADHD symptom scale
scores in pre-schoolers compared with placebo, although effect sizes (0.4 to 0.8) were
smaller than those cited for school-aged children taking the same medication
2. Pharmacogenetics study in phase 5 (cross-over): Emerging evidence suggests the
potential for understanding individual variability of responses to and side effects of
ADHD medications through the study of genetics, although additional research is
required before these findings can be proven to have clinical utility
3. Exploratory moderator analyses of efficacy data from phase 5 (cross-over): Of the
14 variables examined as potential moderators, only 1 (number of concurrent
comorbid disorders) served as a moderator of methylphenidate dose response. In pre-
schoolers with ADHD, the presence of no or 1 comorbid disorder (primarily
oppositional defiant disorder) predicted a large treatment response at the same level as
has been found in school-aged children, and 2 comorbid disorders predicted moderate
treatment response; whereas the presence of ≥ 3 comorbid disorders predicted no
treatment response to methylphenidate
4. Phase 6 (parallel): Medication effects varied by informant and outcome measure.
Parent measures and teacher scores on the Strengths and Weaknesses of Attention-
Deficit/Hyperactivity Disorder Symptoms and Normal Behaviour Scale did not
differentially improve with methylphenidate. Parent-rated depression (P value < 0.02)
and dysthymia (P value < 0.001) on the Early Childhood Inventory worsened with
methylphenidate, but scores were not in the clinical range. Significant medication
effects were found on the clinician Clinical Global Impressions - Severity Scale (P value
< 0.0001) and in teacher ratings on the Social Competence Scale (P value < 0.03). Pre-
schoolers with ADHD treated with methylphenidate for 4 weeks improve in some
aspects of functioning. Additional improvements might require longer treatment,
higher doses and/or intensive behavioural treatment in combination with medication
5. Phase 7 (maintenance): With careful monitoring and a gradual medication dose
increase, most pre-schoolers with ADHD maintained improvement during long-term
immediate-release methylphenidate treatment. Variability in effective and tolerated
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dosing was substantial
6. Entire study duration
i) Adverse events during the study: 11% of pre-schoolers discontinued
treatment because of intolerable methylphenidate adverse events. Of the serious
adverse events reported, 1 occurred at baseline, 2 at lead-in, 3 in titration, 1 in parallel
and 1 in maintenance. Only 1 was possibly related to methylphenidate
ii) Growth during the study: Average relative size at baseline was significantly
greater than 0 for z height and z weight, indicating greater than expected height (by 2.
04 cm) and weight (by 1.78 kg) for participants. During treatment, slopes were
significantly less than 0 for z height and z weight, indicating reduction in growth rates.
For 95 children who remained on medication, annual growth rates were 20.3% less
than expected for height (-1.38 cm/y) and 55.2% less (-1.32 kg/y) for weight. Risks of
reduced growth rates should be balanced against expected benefits when pre-school-
aged children are treated with stimulant medication
Withdrawals due to adverse events: number of withdrawals due to adverse events during
medication phases: 21 (i.e. 11%)
Number of participants leaving study phase and entering maintenance (phase 7): 4
Email correspondence with study authors: June 2014. We obtained supplemental infor-
mation/data from the study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1. Phase 5 (cross-over): Randomisation
was done centrally at the co-ordinating
site, using a computerised stratified
randomisation, a 1:1:1:1 starting dose
allocation ratio and a randomised,
balanced, cross-over protocol designed to
avoid order effects
2. Phase 6 (parallel-group): A second
randomisation to active methylphenidate
or to placebo was performed before entry
into the parallel-design, placebo-
controlled phase
3. Phase 8 (discontinuation):
Centralized randomisation used a
computer programme; each child was
allocated 1:1 to continuing
methylphenidate or switching to placebo
under double-blind conditions
Allocation concealment (selection bias) Low risk 1. Phase 5 (cross-over): central
randomisation using a computer
programme
2. Phase 6 (parallel-group): central
randomisation using a computer
programme
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3. Phase 8 (discontinuation): central
randomisation using a computer
programme
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 1. Phase 5 (cross-over): double-blind.
Placebo pills were identical to pills
containing active medication capsules
2. Phase 6 (parallel-group): double-
blind. Placebo pills were identical to pills
containing active medication capsules
3. Phase 8 (discontinuation): double-
blind. Placebo pills were identical to pills
containing active medication capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 1. Phase 5 (cross-over): double-blind.
Except in emergencies, clinicians
remained blind to dose sequences.
Blinding was maintained for primary
dependent measures until after the best
dose was determined, or as needed. Parent
and teacher dose-response rating scale
graphs were prepared and were blindly
evaluated by 2 study clinicians
2. Phase 6 (parallel-group): double-
blind. Except in emergencies, clinicians
remained blind to dose sequences.
Blinding was maintained for primary
dependent measures until after the best
dose was determined, or as needed. Parent
and teacher dose-response rating scale
3. Phase 8 (discontinuation): double-
blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1. Phase 5 (cross-over): All analyses
were run using the ITT principle (i.e.
each observation obtained for the child
was used in the analysis, including those
from children who entered each of the 2
phases under consideration and did not
complete the phase)
2. Phase 6 (parallel-group): All analyses
were run using the ITT principle (i.e.
each observation obtained for the child
was used in the analysis, including those
from children who entered each of the 2
phases under consideration and did not
complete the phase)
3. Phase 8 (discontinuation): ITT
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Selective reporting (reporting bias) Low risk 1. Phase 5 (cross-over): outcome
measures reported in accordance with the
published protocol
2. Phase 6 (parallel-group): outcome
measures reported in accordance with the
published protocol
3. Phase 8 (discontinuation): not
relevant
Vested interest bias High risk 1. Phase 5 (cross-over): sponsored by
the National Institute of Mental Health,
Columbia/New York State Psychiatric
Institute, Johns Hopkins University,
Columbia University, University of
California Irvine, Duke University
Medical Center, New York University
Child Study Center and University of
California Los Angeles, Arizona Institute
of Mental Health Research to J.K.G.
Generic methylphenidate was purchased
by grant funds
2. Phase 6 (parallel-group): sponsored
by the National Institute of Mental
Health, Columbia/New York State
Psychiatric Institute, Johns Hopkins
University, Columbia University,
University of California Irvine, Duke
University Medical Center, New York
University Child Study Center and
University of California Los Angeles,
Arizona Institute of Mental Health
Research to J.K.G. Generic
methylphenidate was purchased by grant
funds.
3. Phase 8 (discontinuation): sponsored
by the National Institute of Mental
Health, Columbia/New York State
Psychiatric Institute, Johns Hopkins
University, Columbia University,
University of California Irvine, Duke
University Medical Center, New York
University Child Study Center and
University of California Los Angeles,
Arizona Institute of Mental Health
Research to J.K.G. Generic
methylphenidate was purchased by grant
funds
Conflicts of interest
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1. Phase 5 (cross-over): Multiple study
authors had relationships with several
pharmaceutical companies for the period
2000 to 2007
2. Phase 6 (parallel-group): Multiple
study authors had relationships with
several pharmaceutical companies for the
period 2000 to 2007. Placebo responders
in phase 5 were excluded from phase 6.
Participants with no clinical benefit any
week were excluded from phase 6
(methylphenidate non-responders)
3. Phase 8 (discontinuation): Multiple
study authors had relationships with
several pharmaceutical companies for the
period 2000 to 2007
Konrad 2004
Methods Double-blind, placebo-controlled, within-participant trial of cross-over design, lasting
6 days with 2 possible drug interventions and placebo
1. Methylphenidate 0.25 mg/kg (low dose)
2. Methylphenidate 0.5 mg/kg (high dose)
3. Placebo
The order of drug conditions was randomly assigned, with the restriction that higher
doses should never be administered after placebo
Participants Number of participants screened: not stated
Number of participants included: 60 (44 boys, 16 girls)
Number of participants randomly assigned: low-dose methylphenidate 60; high-dose
methylphenidate 60; placebo 60
Number of participants followed up: 60 in each arm
Number of withdrawals: not stated for each arm
Diagnosis of ADHD: DSM-IV (combined 47 (78%), inattentive 13 (22%))
Age: mean 10.8 years (SD 1.6, range 8 to 12)
IQ: mean 97.4 (SD 10.7, range not stated)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Germany
Setting: out-patient clinic and in-patient ward
Comorbidity: oppositional defiant disorder (n = 6; 10%), conduct disorder (n = 18;
30%), anxiety (n = 12; 18%), dyslexia (n = 19; 32%)
Comedication: no
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Only children without a prior history of stimulant treatment were included in the
study protocol
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Exclusion criteria
1. General IQ < 80 (Wechsler Intelligence Scale for Children, Third Edition)
2. Any potentially confounding diagnoses such as psychosis, mania, major
depression, substance abuse, pervasive developmental disorders, receptive language
disorders
3. Use of any kind of additional medication (including selective serotonin reuptake
inhibitors or anticonvulsants)
Interventions Participants were randomly assigned to “low-dose” methylphenidate (0.25 mg/kg),
“high-dose” methylphenidate (0.5 mg/kg) and placebo
Mean methylphenidate dosage: 9.2 mg (SD 2.2) for low-dose group (0.25 mg/kg), 18.
4 mg (SD 5.4) for high-dose group (0.5 mg/kg)
Administration schedule: Medication was given between 7:00 AM and 8:00 AM for
6 days. “Cognitive testing began 60 minutes after medication ingestion and lasted 80
minutes”. The order of drug conditions was randomly assigned, with the restriction that
higher doses should never be administered after placebo. Thus, 11 orders were possible
for the 6-day procedure as a whole, and 6 orders were possible for the sequence of the
3 neuropsychological assessments. Children were assigned in equal numbers to the 6
orders
Duration of intervention: 6-day intervention
Titration period: 1 week of 0.3mg/kg methylphenidate for each participant “to ascertain
tolerance”
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Primary outcomes
i) German Teacher’s and Parental Report on ADHD symptoms
(Fremdbeurteilungsbogen für Hyperkinetische Störungen)
ii) Parental questionnaire on ADHD symptoms (Diagnostiksystem für
Psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV)
iii) Child Behavior Checklist
2. Specific attentional outcome measures
i) Baseline speed: assessed with a simple reaction time task
ii) Sustained attention: involved the continuous and consecutive presentation
of 50 series of 12 different dot patterns (600 signals)
iii) Focused attention: Four letters were presented simultaneously, and the child
was instructed to respond with the “yes” key to 1 target letter, but only if this occurred
in 1 of the relevant diagonal positions
iv) Divided attention: dual task that combined optic and acoustic
discrimination tasks
v) Stop-Signal paradigm: The “go” task in our stop-signal task was a choice
reaction task in which an unidentified flying object (UFO) appeared to the left or right
of a fixation cross
vi) Visual set-shifting: Task consisted of 3 parts
Notes Sample calculation: not stated
Ethics approval: yes; “the study was approved by the Medical Ethical Committee of the
University Hospital of Aachen”
Comments from study authors
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1. The present study investigated effects of day-to-day medication on attentional
functions, which might differ from dose-dependent effects in the long run
2. Our study did not include a third methylphenidate dose, which would have
allowed additional study of dose-response curves for higher doses of methylphenidate
Key conclusions of study authors
1. Results indicate that attentional functions are influenced differentially by
methylphenidate; intensity-dimension functions are best influenced by higher doses,
executive functions by moderate doses and selectivity-dimension functions by variable
doses
2. Divergent results from behaviour rating scales and from attentional paradigms
emphasise that clinicians have to decide what constitutes an appropriate clinical
response
3. A more comprehensive assessment of attention may help to reveal an individually
optimal dose for the treatment of attentional dysfunction
Comment from review authors
1. This study focuses on aspects of attention in relation to methylphenidate
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: unclear; only children without a prior history
of stimulant treatment were included in the study protocol
Any withdrawals due to adverse events: not stated
Email correspondence with study authors: January 2014. We sent an email to the study
author to request additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Within the 6-day protocol, the order of
drug conditions was randomly assigned,
with the restriction that higher doses
should never be administered after placebo
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The active medication and placebo were
prepared by a study protocol physicianwho
was not involved in the assessment. All cap-
sules were identical opaque gelatin capsules
and were administered in a double-blinded
manner. Capsules containing placebo (lac-
tose) or 0.25 mg/kg or 0.5 mg/kg doses
of methylphenidate were prepared for each
participant”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
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Incomplete outcome data (attrition bias)
All outcomes
High risk “Due to computer problems, data for four
children in one task in one condition were
missing. As recommended by Tabachnik
and Fidell (1996), these data were replaced
by the average of the group per condition”
Selection bias: yes; before
testing, all children were given 0.3 mg/kg
methylphenidate each day for ≥ 1 week to
ascertain tolerance
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk This research was funded by the German
Society for the Advancement of Scientific
Research (DFG grant KFO112)
Conflicts of interest: none declared
Konrad 2005
Methods Cross-over trial with 2 interventions
1. Methylphenidate (low and high doses)
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 44 (37 boys (84%), 7 girls (16%))
Number of participants followed up: 44
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined type 100%)
Age: mean 10.3 years (SD 1.9, range 8 to 12)
IQ: mean 98.1
Methylphenidate naive: not stated
Ethnicity: not stated
Country: Germany
Setting: in-patient ward
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis using multiple measures and observation in playroom, etc.
2. Children were included only if they also met criteria for ADHD diagnosis on
teachers’ rating scale
Exclusion criteria
1. General IQ < 80 (Wechsler Intelligence Scale for Children, Third Edition)
2. Any pervasive developmental disorders, receptive language disorders, visual
impairments
3. Any kind of additional medication (including selective serotonin reuptake
inhibitors (SSRIs) or anticonvulsants)
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Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of 0.25
mg/kg (low dose) or 0.5 mg/kg (high dose) methylphenidate and placebo
Mean methylphenidate dosage: 9.4 mg (SD 2.3) for the 0.25-mg/kg dose; 18.6 mg (SD
5.3) for the 0.50-mg/kg dose
Administration schedule: not stated
Time points: not stated
Duration of each medication condition: 2 days
Washout before study initiation: not stated
Medication-free period between interventions: no
Titration period: Before testing, all children were given 0.30 mg/kg methylphenidate
each day for ≥ 1 week to ascertain tolerance
Treatment compliance: not stated. Within the 6-day protocol, the order of drug condi-
tions was randomly assigned, with the restriction that the high dose never occurred right
after placebo
Outcomes ADHD symptoms
1. Primary outcomes
i) German Teachers’ Report on ADHD Symptoms (Fremdbeurteilungsbogen
für Hyperkinetische Störungen) of the Parental Questionnaire of ADHD symptoms
(Diagnostiksystem für Psychische Störungen im Kindes und Jugendalter nach ICD-10
und DSM-IV). Sum scores were calculated separately for both symptom scales
(hyperactive-impulsive symptoms and inattentive symptoms)
Notes Sample calculation: not stated
Ethics approval: yes; informed parental consent was obtained for all participants, and
the study was approved by the Medical Ethical Committee of the University
Key conclusions of study authors
1. Trend tests revealed linear effects of methylphenidate dose on actigraph data in
the test session (P value = 0.02) and at school (P value = 0.001), as well as on sustained
attention (P value < 0.001); inhibitory control showed a quadratic dose-response curve
(P value < 0.001)
2. Multi-variate regression analyses revealed that changes in both hyperactive-
impulsive symptoms (28%) and inattentive symptoms (23%) could be explained by
objective changes in motor activity. Thus, for clinical practice, it should be taken into
account that behaviour ratings of ADHD symptoms seemed to be predominantly
influenced by changes in motor activity
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; before testing, all children were given 0.30
mg/kg methylphenidate each day for ≥ 1 week to ascertain tolerance
Any withdrawals due to adverse events: not stated
Email correspondence with study author: July 2015. Email sent to study author to ask
for additional information, but we have received no reply
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Within the 6-day protocol, the order of
drug conditions was randomly assigned,
with the restriction that the high dose never
was given immediately after placebo
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active medication and placebo were pre-
pared by a study protocol physician who
was not involved in the assessment. All cap-
sules were identical opaque gelatin capsules
and were administered in a double-blind
manner
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk Funding for this research was provided
through a grant from theGerman Research
Foundation (DFG grant: KFO112-TP5)
Conflicts of interest: none declared
Leddy 2009
Methods Nine-week, randomised, controlled trial (RCT), cross-over design, with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 1
Participants Number of participants screened: 154
Number of participants included: 58 (sex not stated). Participants were randomly as-
signed to 1 of 3 possible drug condition orders
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined (95%), hyperactive-impulsive (2%), inatten-
tive (3%))
Age: mean not stated (range 6 to 12 years)
IQ: > 80
Methylphenidate naive: 19%
Ethnicity: not stated
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Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: oppositional defiant disorder (52%), conduct disorder (10.5%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. 6 to 12 years of age
2. ADHD (DSM-IV)
3. IQ
>
= 80
4. Symptoms positive for both Disruptive Behavior Disorders Rating Scale and
Diagnostic Interview Schedule for Children
5. Impairment in 2 settings (Impairment Rating Scale)
Exclusion criteria
1. Seizures/serious neurological problem
2. Pervasive developmental disorder, schizophrenia or other psychotic disorder
3. Necessity of psychotropic medication for treatment of a comorbid disorder
Interventions Participants were randomly assigned to different possible drug condition orders of 0.15
mg/kg (t.i.d.) methylphenidate, 0.3 mg/kg (t.i.d.) methylphenidate, 0.6 mg/kg (t.i.d.)
methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 3 time points
Duration of each medication condition: 12 days for placebo, methylphenidate 0.15 mg
and methylphenidate 0.3 mg; 9 days for methylphenidate 0.6 mg
Washout before study initiation: not stated
Medication-free period between interventions: no
Titration period: not stated
Treatment compliance: not stated
Outcomes General behaviour
1. Disruptive Behavior Disorders Rating Scale
Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale
Notes Sample calculation: not stated
Ethics approval: yes
Key conclusion of study authors
1. “among children with ADHD, those with DA-related genotypes associated with
greater brain DA signalling, DAT SLC6A3 9/9, and DRD2 A2/A2, showed a greater
suppression of lunch meal intake as MPH dose increased in comparison to children
with DA genotypes associated with lower brain DA signaling”
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: not stated
Any withdrawals due to adverse events: not stated
Email correspondence with study author: June 2014. Emailed the study author to ask
for raw data regarding side effects, data from the Disruptive Behavior Disorders Rating
Scale and other data. Study author responded to say he did not have them (Holmskov
2014 [pers comm])
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Drug dose varied daily on a randomized
basis and included four conditions (...)”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias High risk Conflicts of interest: Dr. Waxmonsky has
served on the Speakers’ Board for Novartis,
received an honorarium from Shire and re-
ceived research support from Shire and Eli
Lilly. Dr. Erbe has received educational and
research support from Genzyme Corpora-
tion. Dr. Pelham was paid an honorarium
by Shire Pharmaceuticals
Lehmkuhl 2002
Methods Four-week, randomised, double-blind, parallel trial with 2 arms
1. Sustained-release methylphenidate 20 mg to 60 mg
2. Placebo
Participants Number of participants screened: 102
Number of participants included: 85 (75 boys, 10 girls)
Number of participants randomly assigned: methylphenidate 43, placebo 42
Number of participants followed up: methylphenidate 40, placebo 38
Number of withdrawals: methylphenidate 3, placebo 4
Diagnosis of ADHD: DSM-IV (combined (74.1%), hyperactive-impulsive (0%), inat-
tentive (24.7%), unspecified (1.2%))
Age: mean 9.8 years (range 6 to 15)
Mean IQ: methylphenidate 104.8, placebo 102.7 (range 85 to 146)
Methylphenidate naive: 25 (29.4%)
Ethnicity: German (82), other (3)
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Country: Germany
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (51.8%), conduct disorder (9.4%), unspec-
ified conduct disorder (3.5%), dysthymia (1.2%)
Comedication: yes (n = 4)
Sociodemographics: not stated. The 2 groups were homogeneous in terms of sex distri-
bution, school type, school class and nationality (At baseline, SERS-D ratings for dis-
turbed sleep, nightmares, sadness, weepiness, anxiety, drowsiness and nervous twitching
were far more pronounced in group 1 than in group 2. These initial differences - except
for sadness - levelled out during the 4-week trial period)
Additional conduct disorders are less frequent in the group treated with medication (25
vs 30 participants), but this slight difference is not significant (Fisher’s exact test, P value
= 0.26)
Inclusion criteria
1. DSM-IV diagnosis of ADHD, verified against the ADHD Diagnostic Checklist
from the Diagnostic System for Mental Disorders in Childhood and Adolescence, as
per ICD-10 and DSM-IV
2. According to the class teacher, occurrence of considerable ADHD symptoms over
the previous 3 school days (provided the mean score on the aggregate
Fremdbeurteilungsbogen für Hyper kinetische Störunge rating scale was > 1.0)
3. Patients between 6 and 16 years of age
4. Attendance at an elementary or secondary school
5. IQ > 85
6. Body weight > 20 kg
Exclusion criteria
1. Diagnosis of depression or anxiety
2. Tics or Tourette’s syndrome or family occurrence of tic disorder
3. Pervasive developmental disorder
4. Psychosis
5. History of seizures or evidence on the EEG of risk of seizures
6. Pre-treatment of patients with methylphenidate or other psychostimulants up to 3
weeks before the study
7. Lack of knowledge of the German language of the patient or legal guardian
Interventions Participants were randomly assigned to sustained-release methylphenidate or placebo
Mean methylphenidate dosage: not stated
Administration schedule: once daily after breakfast
Duration of intervention: 4 weeks
Titration period: weekly dose titration initiated after randomisation. Initially, two 5
mg methylphenidate/placebo tablets/d for 2 days, then 20 mg (1 sustained-release
methylphenidate capsule/placebo) dosage increased to 40 mg and 60 mg, depending
on weight and course of symptoms. Titration up to 40 mg and 60 mg modified-release
methylphenidate was possible in the second and third weeks of treatment, respectively
(20 kg to 30 kg, maximum 20 mg modified-release methylphenidate; 31 kg to 50 kg,
maximum 40 mg modified-release methylphenidate; < 50 kg, maximum 60 mg modi-
fied-release methylphenidate)
Treatment compliance: not stated
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Outcomes ADHD symptoms
1. Moderation of ADHD symptoms according to teacher rating on the basis of the
Fremdbeurteilungsbogen für Hyperkinetische Störungen (aggregate rating scale), an
ADHD response-symptom checklist for observers based on ICD-10 and DSM IV
2. Fremdbeurteilungsbogen für Hyper kinetische Störungen (aggregate rating scale)
rated by observers, parents and teachers: rated each week (teacher rated in the morning,
parents in the afternoon)
3. Conners’ abbreviated questionnaire, teacher and parent/guardian rated: rated each
week (teacher rated in the morning, parents in the afternoon)
Serious adverse events
1. One serious adverse event - appendicitis - occurred in the methylphenidate group.
A relationship between the adverse event and the medication product is considered
unlikely by the study authors
Non-serious adverse events
1. Adverse events, documented by the investigating physician each week
2. Vital parameters, assessed each week
3. Blood analyses, assessed each week
4. EEG, performed at screening and at the end of the study - no remarkable changes
were found during the study
5. Physical and neurological examinations, performed at screening and at the end of
the study - no remarkable changes were found during the study
6. Barkley Side Effect Rating Scale-D, rated by parents and participants, time point
not stated
7. Neurological psychiatric adverse events were classified as follows
i) Neurological disorders (e.g. headaches, disturbed sleep)
ii) Psychiatric disorders (e.g. sadness, aggressiveness)
Notes Sample calculation:yes
Ethics approval: approved by local university ethics committees
Comments from study authors
1. Participant and parent observations differ to some extent from investigating
physicians’ documentation of adverse events. Differences in disturbed sleep, sadness
and weepiness between the 2 medication groups during week 1 thus seem more likely
to be the result of initial differences and homogeneities before the start of the trial, as
they improve over the course of the trial under treatment with methylphenidate
2. No clinically relevant changes on laboratory measures before and after the study
Key conclusions of study authors
1. This trial demonstrated clinically relevant and statistically significant benefits of
medication over placebo during 4-week therapy
2. Lehmkuhl 2002: In both the confirmatory analysis (change in teacher-rated
aggregate Fremdbeurteilungsbogen für Hyper kinetische Störungen rating scale) and all
secondary hypotheses of efficacy, medication 1 (methylphenidate) always proved far
more effective than medication 2 (placebo). This effect is clinically relevant. Under
medication 1, however, adverse events were considerably more frequent and severe
3. Sinzig 2007 (in Lehmkuhl 2002): Long-acting methylphenidate is effective in the
treatment of oppositional defiant disorder and aggressive behaviour, especially with
milder symptoms. Expected correlation between impulsivity and aggressiveness could
be confirmed
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Comments from review authors
1. Lemkuhl 2002 and Döpfner 2003 (in Lehmkuhl 2002): Only one review author,
who knew German, has extracted data from these 2 articles. Two review authors
assessed the other 3 articles and extracted data
2. No one chose to withdraw, but because of administrative mistakes, comedication,
etc., participants were taken out per protocol
3. Unpublished data from this study were received from HB Pharma
Any withdrawals due to adverse events: yes; 2 (appendicitis and aggression)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April toMay 2014. We emailed study authors
twice but received no further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
methylphenidate or placebo by the follow-
ing 4 strata: age (6 to 8 years; 9 to 11
years; 12 to 16 years), sex, severity of the
problem according to the teachers’ evalu-
ation (Fremdbeurteilungsbogen für Hyper
kinetische Störungen; sum-score > 40 and
< 40) and study centre attended. Central
randomisation was performed
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drug (or placebo) was dispensed in
packages containing a weekly supply that
was blinded from medical personnel and
parents
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study drug (or placebo) was dispensed in
packages containing a weekly supply that
was blinded from medical personnel and
parents
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No
Vested interest bias High risk Financial support for this study was
provided by Medice Arzneimittel Pütter
GmbH&Co.KG,Kuhloweg37,D-58638
Iserlohn
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Conflicts of interest: Dr. Doepfner is a
consultant for Lilly, Medice, Novartis and
Union Chimique Belge; serves on the Ad-
visory Boards of Lilly, Medice, Shire, No-
vartis and Union Chimique Belge; partici-
pates as a member of the Speakers’ Bureaus
of Lilly, Medice, Janssen-Cilag and Union
Chimique Belge; and has research contracts
with Lilly, Medice, Novartis, Union Chim-
ique Belge, the German Research Founda-
tion and the Federal Ministry of Health.
Dr. Lehmkuhl is on the Advisory Boards of
Lilly and Medice. Dr. Sinzig has no finan-
cial relationships to disclose
Lijffijt 2006
Methods Three-week, randomised, double-blind, cross-over, within-participant study conducted
to test methylphenidate/placebo to assess correlations betweenmeasures of attention and
inhibition with dopamine and norepinephrine blood levels
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 15 (13 boys, 2 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 15
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (11%), hyperactive-impulsive (2%), inatten-
tive (2%))
Age: mean 10.74 years (range 7 to 13)
IQ: mean 97.60
Methylphenidate naive: 0%
Ethnicity: not stated
Country: the Netherlands
Setting: out-patient clinic
Comorbidity: anxiety (n = 6), oppositional defiant disorder (n = 5)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis according to DSM-IV
2. Participants familiar with intake of methylphenidate for at least a year
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to different possible drug condition orders of 0.5
mg/kg or 1.0 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: 22.67 mg
Administration schedule: not stated
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Duration of each medication condition: 1 day
Washout before study initiation: 24 hours before testing
Medication-free period between interventions: no
Titration period: none/duration
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale
2. Conners’ Teacher Rating Scale
General behaviour
1. Child Behaviour Checklist; Teachers’ Report Form
Non-serious adverse events
1. Paper mentioned only this: “Although side effects were minimal (a feeling of
sleepiness), four participants were too fatigued after placebo or the 1.0 mg/kg dose to
continue with the change task after they first completed the stop task”
Notes Sample calculation: no
Ethics approval: yes; “The study was approved by the national medical ethical committee
(CCMO)”
Key conclusion of study authors
1. In children with ADHD, methylphenidate could act primarily on inhibitory
control and is not influenced by task difficulty
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: “four participants were too fatigued after placebo
or the 1.0 mg/kg dose to continue with the change task after they first completed the
stop task”
Email correspondence with study authors: March 2014: We sent an email to the study
author to request additional information but have received no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs. “All participants were famil-
iar with the intake of MPH for at least 1
year”
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk Not stated
Conflicts of interest: none declared
Lin 2014
Methods Eight-week, multi-centre (31 sites in 5 countries), double-blind, placebo-controlled,
comparator (MPH-OROS), parallel study with 3 interventions
1. Edivoxetine
2. OROS methylphenidate
3. Placebo
Phases
1. Screening
2. Clinical treatment
3. Discontinuation
Participants Number of participants screened: 448
Number of participants included: 340 (70.6% boys, 29.4% girls). Participants were
randomly assigned to 1 of 5 possible drug condition orders
Number of participants followed up: 210
Number of withdrawals: 60
Diagnosis of ADHD: DSM-IV-TR (combined (70.9%), hyperactive-impulsive (4.1%)
, inattentive (25%))
Age: mean 11.6 years (range 6 to 17)
IQ: not stated
Methylphenidate naive: All participants treated with methylphenidate were medication-
naive. 44% of placebo-treated participants, 47% of edivoxetine-treated participants in
the 0.1 mg/kg/d arm and 49% of edivoxetine-treated participants in each of the 0.2 mg/
kg/d and 0.3 mg/kg/d arms had used stimulants previously
Ethnicity: Caucasian (72.6%), African American (not stated), Asian (not stated), His-
panic (not stated), other (not stated)
Country: USA, Canada, Taiwan, Mexico and Puerto Rico
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (“less than 20%”)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD DSM-IV-TR diagnosis
2. > 6 years and < 17 years and 9 months of age at the time of informed consent
3. Diagnosis confirmed with the Kiddie Schedule for Affective Disorders and
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Schizophrenia, Present and Lifetime Versions, and ADHD Rating Scale, Fourth
Edition, score > 1.5 SD above age/sex norms and Clinical Global Impressions - ADHD
- Severity Scale score > 4
Exclusion criteria
1. Body weight < 18 kg or > 75 kg
2. History of bipolar I or II disorder, or psychosis, seizure disorder or pervasive
developmental disorder; motor tics or a diagnosis of Tourette’s syndrome; marked
anxiety, tension or agitation sufficient to contraindicate treatment with OROS
methylphenidate
3. History of electroencephalographic abnormalities
4. Clinically significant abnormal ECG
5. Serious or unstable medical illness
6. Any medical condition that would markedly increase sympathetic nervous system
activity (e.g. catecholamine-secreting neural tumour)
7. Requiring daily use of medications with sympathomimetic activity (e.g. albuterol,
pseudoephedrine)
8. Any medical condition that would be exacerbated by an increase in
norepinephrine tone
9. Current or past history of clinically significant hypertension
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of 18 mg,
36 mg or 54 mg OROS methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 1 a day
Duration of each medication condition: 8 weeks
Washout before study initiation: all methylphenidate naive
Medication-free period between interventions: no
Titration period: none, initiated after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition, parent-rated, Investigator-administered and
-scored: weekly, parent-rated (administered and scored by qualified personnel at the
investigative site based on an interview with the parent and the participant)
2. Clinical Global Impressions - ADHD - Improvement Scale
3. Clinical Global Impressions - ADHD - Severity Scale
4. Swanson, Nolan and Pelham Scale, Fourth Edition
5. Conners’ Comprehensive Behavior Rating Scales
Non-serious adverse events
1. Adverse events, vital signs, clinical laboratory tests (e.g. chemistry, haematology,
urinalysis), physical examination and ECGs
2. Columbia Suicide Severity Rating Scale: occurrence, severity and frequency of
suicide-related thoughts and behaviours
Notes Sample calculation: not stated
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: yes (3 participants)
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Email correspondence with study authors: April 2015. We emailed study authors to ask
for supplemental information/data but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Interactive voice response system was used
for randomisation and to determine which
study drug should be dispensed
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusion of methylphenidate non-respon-
ders (after randomisation)
Selective reporting (reporting bias) High risk Yes
Vested interest bias High risk Study sponsored by Ely Lilly
Conflicts of interest: Five authors work for
Lilly
Lopez 2003
Methods Cross-over trial with 3 interventions
1. Methylphenidate (Ritalin)
2. Concerta
3. Placebo
Phases: 4
1. Placebo
2. Concerta 18 mg
3. Concerta 38 mg
4. Methylphenidate (Ritalin LA) 20 mg
Evaluated on day 0, randomly assigned to drug condition on days 7, 14, 21 and 28. One
practice visit for a study duration of 5 weeks in total
Participants Number of participants screened: not stated
Number of participants included: 36 (29 boys, 7 girls). Participants were randomly
assigned to 1 of 24 (4 × 3 × 2 × 1) possible drug condition orders
Number of participants followed up: 36
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Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9 years (range 6 to 12)
IQ: not stated
Methylphenidate-naive: no
Ethnicity: Caucasian (36%), African American (27%), Hispanic or other (36%)
Country: USA
Setting: out-patient clinic
Co-morbidity: not stated
Co-medication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Met ADHD criteria based on Diagnostic Interview Schedule for Children
2. Parents consented to participation
Exclusion criteria
1. Concurrent significant medical or psychiatric illness or substance use disorder
Interventions Participants were randomly assigned to 1 of 24 possible drug condition orders of
methylphenidate (20 mg), (18 mg) Concerta, (36 mg) Concerta and placebo
Mean methylphenidate dosage: not stated
Administration schedule: not stated
Duration of each medication condition: 1 day
Washout before study initiation: not stated
Medication-free period between interventions: On themorning following each study pe-
riod, participants resumed their regularly prescribed medication up to Thursday evening
before the next study period day on Saturday
Titration period: All participants had been stabilised on an equivalent dose of 10 mg
twice daily of methylphenidate before study entry
Treatment compliance: No participants discontinued the study prematurely
Outcomes ADHD symptoms
1. Swanson, Kotkit, Agler, M-Flynn and Pelham Scale: observer, during each study
period
Non-serious adverse events
1. Physical exam, vital signs, haematology, blood chemistries, urinalysis - screening
2. Adverse events: self reported, each study period
3. Vital signs: observer, measured every 2 hours at each study period
4. Adverse effects did occur in < 3% of participants exposed to each agent and dose,
and 1 participant from each treatment group experienced a single mild adverse event
that included abdominal pain, nausea and dyspnoea
Notes Sample calculation: yes
Ethics approval: yes
Comment from study authors
1. Although single blinding of raters added to the objectivity of the observations,
lack of medication blinding had both negative and positive implications. On the
negative side, participants may have noticed the difference in the appearance of agents
administered to them, thus producing bias …[...]... another issue to contemplate is
that all participants in the study had previously been stabilised on methylphenidate
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and, irrespective of blinding, may well have been able to identify when they were
receiving placebo
Key conclusion of study authors
1. Although both methylphenidate (Ritalin LA) and Concerta were shown to be
effective, the different release profile for each formulation can result in distinct
differences between effects on measures of attention and deportment
Comment from review authors
1. Not able to use reported data
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April 2014. We received supplemental infor-
mation from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Order of medication assignment was deter-
mined by random assignment by a com-
puter programme
Allocation concealment (selection bias) Unclear risk Participants were randomly assigned to 4
treatment periods. For purposes of this
study, with the exception of themedicating
nurse, all study personnel were blinded to
the medication administered to the child
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk For purposes of this study, with the excep-
tion of the medicating nurse, all study per-
sonnel were blinded to the medication ad-
ministered to the child
Incomplete outcome data (attrition bias)
All outcomes
Low risk None reported. No participants discontin-
ued the study prematurely
Selection bias: no, but all patients were sta-
bilised previously on methylphenidate
Selective reporting (reporting bias) Unclear risk Protocol not identified
Vested interest bias High risk The study was funded by Novartis
Conflicts of interest: Dr. Silva is a consul-
tant and a member of the Speakers’ Bureau
for Novartis. Dr. Lopez is a consultant for
Eli Lilly, Novartis and Shire. He is also a
member of the Speakers’ Bureaus for No-
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vartis and Shire
Lufi 1997
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: Participants randomly assigned to 3 weeks of methylphenidate, 3 weeks of
placebo. No washout. Assessment at baseline and by the end of each phase
Participants Number of participants screened: not stated
Number of participants included: 20 (18 boys, 2 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 20
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.23 years (± 1.62, range 7.17 to 12.42)
IQ: > 70
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Israel
Setting: out-patient clinic
Comorbidity: none
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. IQ > 70
2. Treatment-naive
Exclusion criteria
1. Implicitly stated: gross physical impairment, intellectual deficits, major disease or
serious psychological problems, and not receiving any psychological treatment prior to
taking part in the research
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 10 mg
methylphenidate and placebo
Mean methylphenidate dosage: 10 mg/d
Administration schedule: mornings
Duration of each medication condition: 3 weeks
Washout before study initiation: All participants were treatment-naive
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale
General behaviour
1. Global Teacher Ratings: rating scale from 1 to 10 constructed specifically for this
study (assessment before ingestion of medication, after 3 weeks of first medication
period, after 3 weeks of second medication period)
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Notes Sample calculation: not stated
Ethics approval: not stated
Comment from study authors
1. Strong placebo effect
Key conclusions of study authors
1. Methylphenidate improved classroom behaviour as compared with no treatment
2. Placebo influence had almost the same effect as medication
3. Neither of these treatments significantly improved cognitive functioning and
personality characteristics of the child with ADHD
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: September 2013. We obtained supplemental
information/data from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “everyone involved in the assessment phase
...was blind to the type of medication...”
All medications (both
placebo and methylphenidate) were given
in identical capsules to prevent recognition
of the true medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...the parents, the teacher, the child and
the psychologist who tested the child did
not know what kind of medication the
child was taking...”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Unclear risk No information
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Methods Six-week, randomised, double-blind, placebo-controlled, cross-over study conducted to
detect the effects of methylphenidate on co-ordination and handwriting
1. Methylphenidate
2. Placebo
Participants Number of participants screened: 19
Number of participants included: 19 (12 boys, 7 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 19
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.51 years (range 7.08 to 13.83)
IQ: > 70
Methylphenidate naive: 0%
Ethnicity: not stated
Country: Israel
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
Sociodemographics: “Participants were from a medium level social-economic status”
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 0.4 mg/kg
Administration schedule: not stated
Duration of each medication condition: 3 weeks
Washout before study initiation: no
Medication-free period between interventions: yes
Titration period: not stated
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Abbreviated Symptom Questionnaire (teacher): assessed at baseline,
weeks 3 and 6
General behaviour
1. Achenbach’s Teacher Report: assessed at baseline, weeks 3 and 6
Notes Sample calculation: not stated
Ethics approval: not stated
Comments from study authors (limitations)
1. Limited group of participants
2. Use of only 1 dosage level
Key conclusions of study authors
1. Results show that methylphenidate improved some cognitive functions of eye-
hand co-ordination slightly better than placebo
2. Behaviour variables assessed by teachers improved only under the influence of
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methylphenidate
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no drop-outs
Email correspondence with study authors: October 2013. We obtained additional in-
formation on IQ from the first study author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”
Allocation concealment (selection bias) Unclear risk “The study was designed as a double-
blind, randomized, crossover, placebo-con-
trol procedure”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Each participantwas given exactly 0.4mg/
kg ofMPH in special capsules of MPH and
a placebo to avoid recognition of the med-
ication”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk Not stated
Conflicts of interest: not stated
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Methods Four-week, double-blind titration, placebo-controlled protocol. Cross-over trial with 2
interventions in 4 doses
1. Methylphenidate 5 mg × 2 daily
2. Methylphenidate 10 mg × 2 daily
3. Methylphenidate 15 mg × 2 daily
4. Placebo × 2 daily
Phases
1. Cross-over trial with Adderall and methylphenidate. First phase was not blinded.
(The child’s paediatrician or family physician determined whether methylphenidate or
Adderall should be prescribed; criteria were the physician’s familiarity with the agent
and whether he or she wanted the participant to receive a single dose (Adderall) or a
twice-daily dose (methylphenidate) of medication treatment for ADHD.) Second
phase: A 1-of-3 medication dose sequence was randomly assigned. 15 mg
methylphenidate was always given after 10 mg methylphenidate
2. 42 of the 117 participants receiving methylphenidate were matched, with 42
receiving Adderall
3. Best dose was compared with placebo. Best dose was assigned by consensus of a
clinical child psychologist and a board-certified child and adolescent psychiatrist before
the medication blind was broken
Manos 1999: Seven youths given methylphenidate and 4 given Adderall did not receive
the 15 mg dose of medication. The decision to forego the 15 mg condition was based on
the paediatrician’s assessment that the child was too young or underweight for this high
dose and our assessment that the best dose had already been achieved at a lower dose
Participants Number of participants screened: 195
Number of participants included: 177. Participants were randomly assigned to different
possible drug condition orders
Number of participants followed up: 134
Number of withdrawals: 43
Diagnosis of ADHD: DSM-IV (combined (55%), inattentive (45%))
Age: mean 10.1 years (SD not stated, range 5 to 17)
IQ: > 70
Sex: 33 boys, 9 girls
Methylphenidate naive: not stated
Ethnicity: Caucasian (93%), African American (7%), Asian (0%), Hispanic (0%), others
(0%)
Country: USA
Setting: out-patient clinic
Comorbidity: no significant comorbid disorders. Although no formal comorbidity data
are available, it appears that psychiatric comorbidity was modest in this cohort
Comedication: not stated
Sociodemographics: predominantly well educated
Manos 1999 and Faraone 2002: 42 were participants matched to the Adderall group in
order of diagnostic category, age and sex.Only these 42 of 117 receivingmethylphenidate
were compared with the Adderall group
Findling 2001a: 195 youths entered the study. Data for a best dose were provided for
177 participants: 111 in the methylphenidate group, 66 in the mixed amphetamine salts
group
Diagnosis of ADHD: inattentive (47%), combined (53%). Inattentive subtype is over-
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represented in the older age group
Age group: 4 to 8 years (mean 6.35) 69 (57 boys); 8 to 11 years (mean 9.47) 56 (45
boys); 11 to 17.59 years (mean 13.64) 52 (41 boys)
Sociodemographics: No significant differences in baseline demographics were noted
between groups
Findling 2001b
Number of participants included: 195
Number of participants completed: 137: methylphenidate 82, Adderall 55
Diagnosis of ADHD: DSM-IV (combined (57%), inattentive (43%))
Age: mean 10 years (SD not stated, range 4 to 17)
IQ: > 70
Sex: 66 boys, 16 girls
Ethnicity: Caucasian (84%), African American (6%), other (10%)
Country: USA
Comorbidity: without significant comorbid disorders
Comedication: possible, but not recorded
Sociodemographics: predominantly well educated. No differences in sex, ethnicity or
ADHD subtype were found between methylphenidate and Adderall groups. No partic-
ipants had a history of hypertension, hypotension or clinically significant cardiovascular
disease
Inclusion criteria
1. All children diagnosed with ADHD met full DSM-IV diagnostic criteria for this
disorder. Criteria include (1) presence of ≥ 6 symptoms for inattention and/or ≥ 6
symptoms for hyperactivity/impulsivity; (2) symptoms significantly interfering with
functioning at home and at school as noted during structured or semi structured
clinical interviews with the Computerized Diagnostic Interview for Children; (3)
symptom severity on broad-band (i.e. Conners’ Abbreviated Symptoms Questionnaire
(Conners, 1969)) and narrow-band (e.g. ADHD Rating Scale (DuPaul, 1991)) rating
scales at threshold or above (i.e. rated 2 or 3); (4) multiple raters (e.g. parents, teachers)
who agreed to the presence of the symptoms; and (5) empirical comparison with norms
indicating ≥ 1/5 SD cutoff on ≥ 1 rating scale. It should be noted that in identifying
the presence of symptoms, behaviours across informants were not pooled observations.
Behaviours were considered significant only if 2 informants agreed to the presence of
the symptom on rating scales or in interviews
Exclusion criteria
1. No patients were excluded from the trial per se
Interventions Participants were randomly assigned to different orders of 5 mg, 10 mg or 15 mg
methylphenidate and placebo
Mean methylphenidate dosage: best dose 9.1 mg to 10.4 mg
Administration schedule: morning (at 8.00 AM) and noon
Duration of each medication condition: 1 week
Washout before study initiation: none
Titration period: none
Treatment compliance: 11 terminated because of adverse events
Outcomes ADHD symptoms
Findling 2001: compared treatment for children and adolescents and weight-adjusted
dosing of methylphenidate. Measurement instruments include the following
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1. ADHD Rating Scale
2. Abbreviated Symptoms Questionnaire (Conners)
3. Composite Rating and School Situations Questionnaire Revised, parent and
teacher. Composite Rating, also observer-rated. Rating every seventh day of each week’s
dose and baseline. Best dose evaluated and compared with placebo and Adderall
Best dose based only on Abbreviated Symptoms Questionnaire - Teacher. Does not
separate methylphenidate and mixed amphetamine salts in tables
Non-serious adverse events
1. Side Effects Behavior Monitoring Scale by parents every week (symptoms were
considered problematic if parents rated them as ≥ 5)
2. Blood pressure and pulse every week
Findling 2001b
1. Blood pressure and pulse
Notes Sample calculation: Not stated
Ethics approval: Not stated
Key conclusions of study authors
1. Manos 1999: Both methylphenidate and Adderall have been shown to be effective
treatments for children with ADHD
2. Farone 2002: The present report extends this prior work by applying drug-
placebo response curve methods to the data reported by Manos et al. (1999). Results
show that the efficacy of Adderall and methylphenidate in improving functioning is
seen throughout the full range of improvement scores. Both drugs prevent worsening
and, for most patients, lead to improvements that are well into the normal range
3. Findling 2001a: Data suggest that psychostimulants are equally effective in
treating children and adolescents with ADHD. Adolescents with ADHD may not
necessarily require more medication than younger children to achieve a similar
therapeutic response
4. Findling 2001b: Short-term cardiovascular effects of both Adderall and
methylphenidate were modest. No participants experienced any clinically significant
change in these cardiovascular measures during the course of this brief trial
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; 15 youths in the
Adderall sample had been tried on methylphenidate before enrolment in this medication
trial. Because of lack of response or serious side effects, these children discontinued use
of methylphenidate. A total of 37% of the Adderall sample subsequently was composed
of children who had unsuccessfully used methylphenidate but successfully responded to
Adderall
Any withdrawals due to adverse events: yes; Findling 2001a (11/195), due to multiple
adverse events
Email correspondence with study authors: April 2014. Emailed study authors twice to
request additional data but have received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk First phase not blinded. Methylphenidate
is a selected group
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Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clinician, teacher and parent were blinded
only to dose, not to medication
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Clinician, teacher and parent were blinded
only to dose, not to medication
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only best dose compared with placebo.
Findling (Abbreviated Symptoms Ques-
tionnaire) + 30 participants. Of 43 partic-
ipants with < 4 weeks of data, 30 had only
3 weeks of data because physicians consid-
ered them too young or too small to receive
15 mg before initiating protocol
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias High risk Study was supported in part by funding
from Shire Pharmaceutical Development
Incorporated to Dr. Faraone
Conflicts of interest: Study authors ac-
knowledge partial support to the second
author from theNational Institute onDrug
Abuse (NIDA) (grants R01-DA07957 and
MCJ-390592) and from the Maternal and
Child Health Program, Health Resources
and Service Administration, Department
of Health and Human Services (grant
390715), and to the third author from the
Stanley Foundation
Martins 2004
Methods Four-week-long, double-blind, randomised, parallel trial with 2 interventions
1. Methylphenidate group: methylphenidate, 7 days a week
2. Placebo group: methylphenidate Monday through Friday, and placebo on
weekends
Participants Number of participants screened: not stated
Number of participants included: 40 (all boys)
Number of participants randomly assigned: methylphenidate 21, placebo 19
Number of participants followed up: methylphenidate 19, placebo 19
Number of withdrawals: methylphenidate 2, placebo 0
Diagnosis of ADHD: DSM-IV (combined (92.5%))
Age: mean methylphenidate 9 years (SD 2.2, range 6 to 14), placebo 9.6 years (SD 2.8,
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range 6 to 14)
IQ: mean, methylphenidate 97.3, placebo 93.5
Methylphenidate naive: not stated
Ethnicity: European-Brazilian: methylphenidate 16 (76.2%), placebo 15 (78.9%)
Country: Brazil
Setting: out-patient clinic
Comorbidity: yes; conduct or oppositional defiant disorder (methylphenidate 57.2%,
placebo 57.9%)
Comedication: not stated, no psychiatric medication
Sociodemographics: Monthly family income was calculated according to the following
formula: total monthly income received by all members of the family (expressed in
number ofminimumwages) divided by the number of persons in the family. A value lower
than 0.7 (approximately US$ = 68 per family member per month) is usually an indicator
of poverty in Brazil. Methylphenidate 3.3, placebo 2.4. No significant differences in
baseline demographics were noted between the 2 groups
Inclusion criteria
1. ADHD diagnosis according to DSM-IV criteria
2. Between 6 and 14 years of age
3. Male
4. Education level between first and eighth elementary grades
Exclusion criteria
1. Presence of significant neurological or clinical disease
2. Presence of bipolar disorder or substance abuse/dependence disorder
3. Use of any psychiatric medication in the past 6 months, including
methylphenidate
4. Estimated IQ < 70
Interventions Participants were randomly assigned to methylphenidate 7 days a week or to
methylphenidate on weekdays and placebo on weekends
Mean methylphenidate dosage: Initial dose of methylphenidate was 0.3 mg/kg/d the
first week. Dose was raised to 0.5 mg/kg/d the second week and to 0.70 mg/kg/d the
third and fourth weeks
Administration schedule: twice a day: breakfast and lunch
Duration of intervention: 4 weeks
Titration period: none
Treatment compliance: Only 7 of 160 blister packs were returned with unused pills
Outcomes ADHD symptoms
1. 10-item Conners’ Abbreviated Rating Scale (Conners 1985). Rated every Monday
after school by both teachers and parents
Serious adverse events
1. Barkley Side Effect Rating Scale
i) Number of adverse effects reported
ii) Mean severity of reported adverse effects
(Completed only by parents for assessment of side effects on weekends)
Notes Sample calculation: no
Ethics approval: approved by the Ethical Committee of theHospital de Clínicas de Porto
Alegre (HCPA) (approved as an International Review Board (IRB) by the Office for
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Human Research Protections, United States of America)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Comments from study authors
1. Context established by the home setting on the weekend may have created
conditions in which the effects of methylphenidate were minimal or insignificant,
because children may have been involved in play activities much of the time
2. It is reasonable to suggest that during the weekend, when networks related to
ADHD neurobiology might be demanded less often, differences between drug and
placebo would be more difficult to detect
3. It is possible that parental tolerance of ADHD symptoms on weekends might be
greater than on weekdays. Our findings may not be generalisable to females
Key conclusion of study authors
1. Our findings suggest that weekend holidays during methylphenidate
administration reduce the side effects of insomnia and appetite suppression without
causing a significant increase in ADHD symptoms, on weekends or on the first day of
school after the weekend (Monday)
Email correspondence with study authors: We have contacted study authors several times
to ask for additional information about data, but we have received no data from this
study that we can use
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, double-blind, parallel-group
design was used. Participants were ran-
domly assigned to 1 of 2 groups, accord-
ing to a computer-derived algorithm (EPI-
INFO.06)
Allocation concealment (selection bias) Low risk Computer-derived algorithm
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Methylphenidate and placebo pills were of
the same shape and colour
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind. No other information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Measured adherence to protocol by assess-
ing returned, unopened blister packs.None
of the findings in the analyses was signifi-
cantly affected by the 2 participants (they
did not follow the protocol as stated by re-
searchers) from themethylphenidate group
who did not receive a few doses appropri-
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ately on weekends or on Monday. Some
teacher ratings (8.5%) were missed because
of the child’s absence from school on a spe-
cific day of evaluation or because of a school
holiday
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No reporting bias
Vested interest bias Unclear risk Methylphenidate and placebo pills were
supplied by Novartis Pharmaceuticals (São
Paulo, Brazil) at no cost and without re-
strictions. No additional funding was re-
quested or received from Novartis or any
other commercial entity
Conflicts of interest: Study authors have re-
ported no conflicts of interest
McBride 1988a
Methods Individual, double-blind, cross-over trial for 4 weeks with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 73. Participants were randomly assigned to 1 of 2
possible drug condition orders
Number of participants followed up: 70 (53 boys, 17 girls)
Number of withdrawals: 3
Diagnosis of ADHD: DSM-III (77% met the criteria for ADD with hyperactivity)
Mean age: methylphenidate responders 8.5 (SD not stated), methylphenidate non-re-
sponders 9.5 (SD not stated). Range 6 to 17 years
Mean IQ: methylphenidate responders 102 (SD 21), methylphenidate non-responders
89 (SD 23)
Methylphenidate naive: 71 (97%)
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: carbamazepine or phenytoin or valproic acid or mephobarbital (6.4 re-
ceiving a combination of these drugs). Clonidine (n = 1)
Sociodemographics: no information
Inclusion criteria
1. Referred because the child’s academic performance was below that expected on the
basis of his abilities, as documented by psychological testing, or because his behavioural
dysfunction was interfering with self-image and socialisation, or for both reasons
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2. 6 to 17 years of age
3. No child was excluded from the trial on the basis of low intelligence, history of
seizures or concurrent medication
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.3 mg/
kg methylphenidate and placebo. Methylphenidate was rounded to the nearest 1.25 mg
Mean methylphenidate dosage: no information, but mean dose during follow-up was 0.
36 mg/kg/dose
Administration schedule: morning and 4 hours later
Duration of each medication condition: 2 weeks
Washout before study initiation: none
Medication-free period between interventions: none
Titration period: none
Treatment compliance: no information
Outcomes ADHD symptoms
1. Abbreviated Conners’ Teacher and Parent Questionnaire
2. Parent Questionnaires was rated at the end of each weekend and at the end of
each school week. Teacher Questionnaires were filled out at the end of the week
Serious adverse events
1. No serious side effects during the trial
Non-serious adverse events
1. No information about how data on side effects were obtained
None of the parents of responders who had experienced side effects during the trial
thought the effects were significant enough that they should not treat their child with
methylphenidate, and no side effects other than appetite suppression continued during
regular therapy after the trial
Follow-up 6 months after: n = 33. 15 had no change in weight curves. 1 gained 7 kg
beyond his original percentile
Notes Sample calculation: no information
Ethics approval: no information
Comments from study authors
1. Participants in this study were not a randomly selected group of children with
ADD but, rather, a referral population already screened by their school psychologists
and primary care physicians
2. Individual children with differing absorption, metabolism or underlying
neurochemical abnormality may have different response thresholds, and potential
responders may have been overlooked because they did not consistently try a higher
dose
3. 15% of children with ADD in this study were adopted
4. The finding that non-responders were older may reflect the development of
secondary characteristics such as decreased motivation and poor study habits in long-
term ADD -symptoms not easily reversed during a short trial
5. A problem inherent in this trial, as in an open trial, is dependence on the
observations of teachers and parents who have variable observational skills, variable
tolerance for symptoms of ADD and different perspectives on medication
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6. Lower Conners’ scores may be explained by the fact that many characteristics
rated on Conners’ questionnaires reflect hyperactivity, and some of these children were
more inattentive than hyperactive
Key conclusions of study authors
1. 51 (of 70) children showed improvement during 1 of the 2-week periods, and
that period corresponded with methylphenidate therapy in 48
2. 6 of the 22 who did not respond to methylphenidate experienced worsening of
function while taking the drug. No serious side effects were reported during the trial
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The pharmacist labelled the 2 sets of cap-
sules as “Medicine A” and “Medicine B” in
either order by coin flip for the first 22 tri-
als, and then by using a random numbers
table
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The manner of labelling was sealed by the
pharmacist in an envelope that was not
opened until the trial had ended and find-
ings had been discussed with the parents
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objectivity was lessened for a few parents
because the decreased appetite associated
with methylphenidate led them to suspect
which capsules contained the drug
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the few trials for which 1 to 3 of 10
items on Conners’ questionnaire had not
been scores, the score was prorated based
on 30 points maximum
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk None
Vested interest bias Unclear risk No information
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Methods Phase II, randomised, double-blind, placebo-controlled, laboratory-classroom, cross-
over study with a lead-in open-label dose-optimisation phase
1. Mehtylphenidate transdermal system
2. Placebo
Participants Number of participants screened: 93
Number of participants included: 80
Number of participants randomly assigned: methylphenidate 80, placebo 80 (cross-over)
Number of withdrawals: 7 “adverse events”, 3 consent withdrawn, 2 lost to follow-up, 1
because of “lack of efficacy”. 1 participant discontinued because of “protocol violation”
Diagnosis of ADHD: DSM-IV-R (combined 62 (79%), hyperactive-impulsive 4 (5%),
inattentive 13 (17%))
Age: mean 9.1 years (SD 1.7, range 6 to 12)
IQ: > 70
Sex of baseline participants included in ITT: 57 boys (72%), 22 girls (28%)
Methylphenidate naive: 37%
Ethnicity: Caucasian 55 (70%), African American 8 (10%), Asian 2 (3%), other 14
(18%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. 6 to 12 years of age inclusive
2. ADHD DSM-IV diagnosis using Kiddie Schedule for Affective Disorders and
Schizophrenia and psychiatric assessment
3. ADHD Rating Scale score ≥ 26 at baseline/unmedicated
4. Normal laboratory parameters and vital signs including ECG
Exclusion criteria
1. Comorbid psychiatric diagnosis (apart from oppositional defiant disorder)
2. History of seizures
3. History of tic disorders
4. Mental retardation
5. Any illness or skin disorder that might jeopardise safety or compromise study
assessments
6. No clonidine, atomoxetine, antidepressants, investigational medications, hepatic
P450 enzyme-altering agents, medications with central nervous system effects,
sedatives, anxiolytics or antipsychotics within the 30 days before screening
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: “At the end of the dose optimization phase of the study,
the majority of patients (78%) were optimized to either the 16 mg or 20 mg dosage
strengths”
Administration schedule: once daily
Duration of each medication condition: 1 week
Washout before study initiation: “up to 28 days”
Medication-free period between interventions: 4:00 PM to 7:00 AM the next day (15
hours)
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Titration period: 5-week dose-optimisation phase
Treatment compliance: “During the laboratory classroom period, 97% and 96% of par-
ticipants were compliant with [methylphenidate transdermal system] MTS and placebo
treatments respectively”
Outcomes ADHD symptoms
1. Primary outcome
i) Swanson, Kotkit, Agler, M-Flynn and Pelham Scale at multiple time points:
pre-dose and 2, 3, 4, 5, 6, 7.5, 9. 10.5 and 12 hours post dose
ii) ADHD Rating Scale, Fourth Edition (administered at each visit)
iii) Conners’ Parent Rating Scale - Revised Short Version (Conners 1997a).
Completed at 11:00 AM and 3:00 PM on the Sunday before the first visit and
subsequently, before each visit to the centre
“The mean values of the CPRS-R over the 11:00 AM and 3:00 PM time points were
used in the analysis”
General behaviour
1. Clinical Global Impressions - Severity and - Improvement scales as well as the
Parent Global Assessment
Non-serious adverse outcomes
1. Vital signs, blood pressure, pulse, oral temperature, respiratory rate, height,
weight, laboratory measures, physical examination, dermal evaluation
Notes Sample calculation: yes
Ethics approval: yes
Key conclusions of study authors
1. Treatment with methylphenidate transdermal system resulted in statistically
significant improvement in all efficacy measures
2. Time course and therapeutic effects of methylphenidate transdermal system
suggest that this novel methylphenidate delivery system provides efficacious once-daily
treatment for ADHD
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; “Participants
were either known to be responsive to stimulants or naive to stimulant treatment”
Any withdrawals due to adverse events: yes; 7/93 participants were withdrawn because
of adverse effects during the dose-optimisation period (i.e. before randomisation)
Email correspondence with study authors: June 2014. We obtained supplemental infor-
mation regarding risk of bias. Additional data were not available (Ramstad 2013a [pers
comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participantswere randomized into either 1
week of [methylphenidate transdermal sys-
tem] MTS or 1 week of [placebo transder-
mal system] PTS (in their individually op-
timized dose) and were crossed over to the
opposite treatment the following week”
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From correspondence: “Participants were
randomized centrally for each of the study
conditions. Randomization codes were not
available to site study staffs, but were pro-
vided to research pharmacies at each site
which corresponded to a particular dose
pack” (Ramstad 2014 [pers comm])
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Phase-II randomized, double-
blind, placebo-controlled laboratory class-
room, crossover study with a lead-in open-
label dose optimization phase”
From correspondence: “Active and inac-
tive patches were identical in appearance”
(Ramstad 2014 [pers comm])
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
High risk Safety population according to Table Two
is n = 93. Table Six lists safety data for n =
80 participants only. Safety data for 13 par-
ticipants appear to be “missing” - includ-
ing those from participants withdrawn be-
fore randomisation as the result of adverse
events
Selective reporting (reporting bias) High risk Safety population according to Table Two
is n = 93. Table Six lists safety data for n =
80 participants only. Safety data for 13 par-
ticipants appear to be “missing” - includ-
ing those from participants withdrawn be-
fore randomisation as the result of adverse
events
Vested interest bias High risk “This studywas supported by funding from
Shire US Inc”
Conflicts of interest: Two medical writ-
ers acknowledged (Amy M. Horton &
Michelle Roberts) but were unclear about
where they came from or what their role
was in the publication
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Methods Cross-over trial with 2 interventions
1. Methylphenidate at low, medium and high doses
2. Placebo
Phases: 4
Participants Number of participants screened: 17
Number of participants included: 16 (12 boys, 4 girls). Participants were randomly
assigned to 1 of 12 possible drug condition orders
Number of participants followed up: 16
Number of withdrawals: 0
Diagnosis of ADHD:DSM-IV-TR (combined (63%), hyperactive-impulsive (6%), inat-
tentive (31%))
Age: mean 9.2 years (range 7 to 12)
IQ: mean 107.7 (range not reported)
Methylphenidate naive: ~ 80%
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (19%), conduct disorder (25%), generalised
anxiety disorder (31%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children 7 to 12 years of age with ADHD referred to an out-patient
neuropsychiatry clinic for evaluation of response to methylphenidate
Exclusion criteria
1. Children with low cognitive performance (IQ < 80)
Interventions Participants were randomly assigned to 1 of 12 possible drug condition orders of low,
medium and high methylphenidate and placebo
Mean methylphenidate dosage: low (mean 0.21 mg/kg to 0.33 mg/kg, SD 0.07 to 0.
02); medium (mean 0.31 mg/kg to 0.43 mg/kg, SD 0.09 to 0.03); and high (mean 0.
42 mg/kg to 0.65 mg/kg, SD 0.13 to 0.15) methylphenidate Administration schedule:
1 per day at 9:00 AM
Duration of each medication condition: 1 day
Washout before study initiation: 48 hours before study
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Inattention/overactivity symptoms based on 5/10 items from the Iowa Conners’
Rating Scale, rated by observer 90 to 120 minutes after ingestion of capsule
Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. With respect to the medication protocol, we cannot predict that similar results
would hold with longer-term treatment with methylphenidate, given that these
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findings were obtained under a single acute drug challenge
2. Our findings for a predominantly male group of children with ADHD may not
be generalisable to other groups of children with ADHD, for example, community
samples that involve more girls and different rates of occurrence of comorbid conditions
3. Small sample size places limitations on conclusions that can be drawn from our
findings
Key conclusions of study authors
1. Findings provide preliminary evidence that methylphenidate affects higher-level
language comprehension skills, which require sustained attention and mental effort
2. If generalisable to classroom listening skills, these findings have implications for
clinicians and teachers involved with children with ADHD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Multiple blind procedures’, capsules iden-
tically packaged by pharmacists
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Examiner, who was kept blind to child’s
medication status’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No LTFU
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) High risk Symptom data not reported
Vested interest bias High risk Supported by funds from The Psychiatric
Endowment Fund
Conflicts of interest: Study authors had re-
ceived funding from Eli Lilly, Shire Phar-
maceuticals, Janssen-Ortho and McNeil
Pharmaceuticals
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Methods Two-week, randomised, double-blind, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: 78
Number of participants included: 57 (all boys). Participants were randomly assigned to
1 of 2 possible drug condition orders
Number of participants followed up: 57
Number of withdrawals: 0
Diagnosis of ADHD:DSM-IV (combined and hyperactive-impulsive (53%), inattentive
(47%))
Age: mean 9.5 years (range 7 to 12)
IQ: normal
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Israel
Setting: out-patient clinic
Comorbidity: no
Comedication: no
Sociodemographics: representing all socioeconomic strata
Inclusion criteria
1. Male
2. 7 to 12 years
3. ADHD, DSM-IV
4. Drug-naive and with no other intervention
5. Suitable candidate for methylphenidate treatment
6. Attention disorder was associated with a significant effect on daily life, and scores
on 1 of the Attention subscales of both parent and teacher questionnaires were 1.5 SD
or above the mean as suggested in clinical guidelines
Exclusion criteria
1. Chronic psychiatric and neurological disorders, for example, obsessive-compulsive
disorder
2. Tourette’s syndrome
3. Seizure disorder
4. Severe learning disability (defined by special education enrolment)
5. Definitive primary diagnosis of an anxiety disorder (DSM-IV) or sensory
impairment
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.3 mg/
kg immediate-release methylphenidate and placebo
Methylphenidate dose range: 6 mg to 12 mg
Administration schedule: once daily
Duration of each medication condition: 1 week
Washout before study initiation: no (drug-naive)
Titration period: no
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale, revised: weekly (after each intervention period)
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Notes Sample calculation: yes
Ethics approval: yes
Comments from study authors
1. Results of the present study should be interpreted with caution
2. As only boys were included, the results might not be valid for girls
3. Children were clinic referrals and therefore might not be representative of the
population of children with ADHD at large
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April to October 2013. We received supple-
mental data from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned with a table of random
numbers
Allocation concealment (selection bias) Low risk Placebo (prepared as look-alike capsules by
the hospital pharmacy)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk According to study authors, all planned
outcomes were assessed and analysed
Vested interest bias Low risk Not funded
Conflicts of interest: none declared
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Methods Randomised, multi-centre, double-blind, 5-period, cross-over trial in a laboratory class-
room setting with 3 interventions
1. Extended-release dexmethylphenidate
2. Extended-release racemic methylphenidate hydrochloride
3. Placebo
Phases: extended-release dexmethylphenidate 20 mg/d, extended-release
dexmethylphenidate 30 mg/d, extended-release racemic methylphenidate hydrochloride
36mg/d, extended-release racemicmethylphenidate hydrochloride 54mg/d and placebo
Participants Number of participants screened: 84
Number of participants included: 84 (55 boys, 29 girls). Participants were randomly
assigned to 1 of 5 possible drug condition orders
Number of participants followed up: 81
Number of withdrawals: 3
Diagnosis of ADHD: DSM-IV (combined (89.3%), inattentive (10.7%))
Age: mean 9.5 years (SD 1.7, range 6 to 12)
IQ: not stated
Methylphenidate naive: 0%
Ethnicity: Caucasian (42.9%), African American (27.4%), Hispanic (28.6%), other (1.
2%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD using Diagnostic Interview Schedule for Children
2. On stabilised total daily dose or nearest equivalent dose of 40 mg to 60 mg of
extended-release racemic methylphenidate hydrochloride or 20 mg to 30 mg extended-
release dexmethylphenidate for ≥ 2 weeks before screening visit
Exclusion criteria
1. Tic disorder or Tourette’s syndrome
2. History of a seizure disorder
3. Psychiatric illness
4. Substance abuse disorder
5. Taking prohibited concomitant medications or ADHD medication other than
methylphenidate
6. Taking antidepressant or psychotropic medications
7. Had begun psychotherapy within 3 months before randomisation
8. Home-schooled children
9. Females of child-bearing potential with positive urine pregnancy test before
enrolment (or, if sexually active, not using adequate and reliable contraception)
Interventions Participants were randomly assigned to 1 of 5 possible drug condition orders of extended-
release dexmethylphenidate 20 mg/d, 30 mg/d, 36 mg/d, 54 mg/d and placebo
Mean methylphenidate dosage: not stated
Administration schedule: once daily.Morning dosing as 2 capsules Sunday to Saturday. 6
doses were administered at home (Sunday to Friday), and the Saturday dose was admin-
istered by research staff. This was repeated until all 5 treatments had been administered.
Mean duration of exposure to study medication was 7 days for all 5 treatments
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Washout before study initiation: 6 days medication-free
Titration period: “On stabilized total daily dose or the nearest equivalent dose of 40 to
60 mg of d,l-MPH or 20 to 30 mg d-MPH for at least 2 weeks prior to the screening
visit” initiated before randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Primary efficacy variable
i) Change from pre-dose Swanson, Kotkit, Agler, M-Flynn and Pelham
(SKAMP) Rating Scale-Combined score at 2 hours post dose with extended-release
dexmethylphenidate 20 mg/d compared with extended-release racemic
methylphenidate hydrochloride 36 mg. This change was calculated by subtracting the
pre-dose value (hour 0 score) from the post-dose value
2. Secondary outcome measures
i) Change from pre-dose (0 hour) on Combined, Attention and Deportment
subscores of the Swanson, Kotkit, Agler, M-Flynn and Pelham Scale, at specified
intervals post dose (0.5, 1, 2, 3, 4, 6, 8, 10, 11 and 12 hours), and area under the score
vs time curve (AUC) of the change from pre-dose in Combined score from hour 0 to
hour 4 (AUC 0 to 4), and from hour 0 to hour 12 (AUC 0 to 12)
General behaviour
1. “The Conners’ Parent Rating Scale (CPRS), a 27-item questionnaire designed to
evaluate children’s behaviour (Conners 1998a), was completed by parents on the
Practice Day to assess behaviour without medication and at each subsequent
assessment day to rate the child’s behaviour during the previous week”
Serious adverse events
1. Safety assessments consisted of monitoring and recording of all adverse events
Non-serious adverse events
1. Safety assessments consisted of monitoring and recording all adverse events and
recording vital signs and body weight at each visit
2. Laboratory parameters (including haematology, blood chemistry and urinalysis),
ECGs and results of physical examinations were assessed for abnormalities at screening
and final visits (no final visit assessments were carried out for ECGs and physical
examinations)
Notes Sample calculation: yes; “It was determined that approximately 90 patients were required
to detect a 0.05-level treatment difference at 84% power assuming a difference and
standard deviation of 3.5 and 11 for SKAMP-Combined score, at 2 hours post-dose
using a paired t-test”
Ethics approval: no information
Key conclusions of study authors
1. “The results of this study demonstrated that all active treatments generally
provided significant improvement in ADHD symptoms over placebo over 11 to 12
hours postdose in children 6-12 years old”
2. “The primary efficacy variable, adjusted mean change in SKAMP-Combined
score from pre-dose to 2 hours post-dose, was significantly greater during treatment
with d-MPH-ER 20 mg/day than d,l-MPH-ER 36 mg/day (adjusted mean change 10.
65 and 5.94, respectively; p 0.001). Similar results at two hours post-dose were noted
for the secondary measure of SKAMP-Combined score comparing d-MPH-ER 30 mg/
day with d,l-MPH-ER 54 mg/day (adjusted mean change 11.17 and 7.52, respectively;
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p0.001).”
Comment from review authors
1. We did not include the Swanson pencil and paper math test of “academic
productivity” among ADHD outcome measures. This may be seen as an ADHD
outcome measure, but it does not specifically measure the 3 key ADHD core signs of
inattention, hyperactivity and impulsivity
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; “Children re-
cruited for this study had been stabilized on a total daily dose or the nearest equivalent
dose of 40 to 60 mg of d,l-MPH or 20 to 30 mg d-MPH for at least 2 weeks prior
to the screening visit” - so presumably non-responders to methylphenidate and those
experiencing intolerable adverse events while taking methylphenidate were not included
Email correspondence with study authors: July 2014. Emailed study authors to ask for
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A total of 84 subjects were randomized to
receive treatment and were included in the
efficacy and safety analyses”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “After the Practice Day, the first assigned
treatment was dispensed to the parents as
blinded capsules according to their child’s
randomized sequence. To maintain blind-
ing, all treatments were over-encapsulated
and the same number of capsules were
given once daily for each sequence”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The ratings were based on the frequency
and quality of behaviours as observed by
three independent, blinded raters in each
class. To maintain consistency throughout
the study, the blinded observers were re-
sponsible for observing and rating the same
6 children at specified intervals throughout
the 12-hour testing period at each center”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The intent-to-treat population included
all randomized patients who took at least 1
dose of study medication and had at least
1 post-dose efficacy measurement”
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
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Selective reporting (reporting bias) Low risk No selective outcome reporting
Vested interest bias High risk “This study was funded by Novartis Phar-
maceuticals Corporation and reports the
following involvement: design and con-
duct of the study; collection, manage-
ment, analysis, and interpretation of data;
preparation, review, and approval of the
manuscript”
Conflicts of interest: Dr. Muniz is an em-
ployee of Novartis Pharmaceuticals Cor-
poration. He has no other relationships to
disclose. Dr. Brams reports the following
relationships: serves as speaker, consultant
and Advisory Board member for Novar-
tis and Shire; receives grant research sup-
port from Novartis, Shire and Eli Lilly. Dr.
Mao reports the following relationships:
speaker for Novartis, Eli Lilly, Bristol-My-
ers Squibb, AstraZeneca and Shire; con-
sultant for Eli Lilly, Novartis and Shire;
receives grant research support from No-
vartis. Mr. McCague is an employee of
Novartis Pharmaceuticals Corporation. He
has no other relationships to disclose.
Ms. Pestreich is an employee of Novartis
Pharmaceuticals Corporation. She has no
other relationships to disclose. Dr. Silva
reports the following relationships: none
since 15 December 2006; before that, she
was a speaker for Novartis, AstraZeneca
and Janssen; received grant/research sup-
port from Novartis and Celgene
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Murray 2011
Methods Phase IV, double-blind, randomised, cross-over, analogue classroom trials with 2 inter-
ventions
1. OROS methylphenidate
2. Placebo
Phases
1. Screening/washout phase: up to 28 days
2. Titration: up to 6 weeks
3. Double-blind assessment period, with the following subperiods
i) Open-label OROS methylphenidate: school day 1, OROS methylphenidate
or placebo
ii) Open-label OROS methylphenidate: ≥ 7 days
iii) School day 2: OROS methylphenidate or placebo
Participants Number of participants screened: not stated
Number of participants included: 89. Participants randomly assigned to 1 of 2 possible
drug condition orders: 68
Number of withdrawals before randomisation: 21
Number of withdrawals after randomisation: 2
Diagnosis of ADHD:DSM-IV-TR (combined (59%), hyperactive-impulsive (4%), inat-
tentive (37%))
Age: mean 10.75 years (range 5 to 15)
IQ: > 80
Sex: 45 boys, 23 girls
Methylphenidate naive: 65%
Ethnicity: Caucasian (62%), African American (28%), Asian (not stated), Hispanic (not
stated), other (10%)
Country: USA
Setting: out-patient clinic
Comorbidity: anxiety (9%), depressive disorders (1%), learning disability (38%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. 9 to 12 years of age
2. DSM-IV-TR diagnosis of ADHD
3. Parent-completed ADHD-RS-IV total or subscale scores ≥ 90th percentile for
their age and sex
4. Attendance at a public or private school
5. Ability to read and understand English
6. Patients currently receiving ADHD medication must be inadequately managed
on their current stimulant dose
7. To be eligible for the double-blind, randomised assessment period, participants
had to reach their individualised OROS methylphenidate dose, defined as
i) ADHD Rating Scale, Fourth Edition (as scored by parent or guardian): ≤
75th percentile for age and sex
ii) ADHD Rating Scales, Fourth Edition (as scored by parent or guardian):
between 75th and 85th percentiles for age and sex after either (1) a dose decrease for
tolerability (1 dose decrease by 18 mg to a minimum of 18 mg/d was allowed), or (2)
having reached a dosage of 54 mg/d
Exclusion criteria
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1. Estimated full-scale IQ score ≤ 80, as determined by the 4-subtest version of the
Wechsler Abbreviated Scale of Intelligence
2. Severe learning disability, defined as≥ 2 SD below the mean score for their age on
Gray Oral Reading Test, Test of Phonological Processing or Wechsler Individual
Achievement Test, Second Edition
3. History or current diagnosis of a neurological or psychiatric disorder that might
compromise the participant’s welfare or ability to comply with study requirements
4. Inability to take or tolerate OROS methylphenidate
5. History of or current primary diagnosis of severe anxiety disorder, conduct
disorder, psychotic disorders, pervasive developmental disorder, eating disorder,
obsessive-compulsive disorder, sleep disorder, major depressive disorder, bipolar
disorder, substance use disorder, chronic tic disorder, personal or family history of
Tourette’s syndrome
6. Weight < 3rd percentile for age
7. History of hospitalisation for treatment of a mood, anxiety or psychotic disorder
8. History of failed response to methylphenidate
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of OROS
methylphenidate and placebo
Mean OROS methylphenidate daily dosage: 47.6 mg
Administration schedule: once daily, morning
Average duration of OROS methylphenidate treatment: not stated
Duration of placebo intervention: 1 day
Washout before study initiation: up to 28 days
Medication-free period between interventions: no
Titration period: before randomisation, up to 6 weeks
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkit, Agler, M-Flynn and Pelham Scale, observer-rated: 4 hours post
dose (at the 2 laboratory days)
Serious adverse events
1. Serious adverse effects assessed at the 2 laboratory days and during open-label
periods
Non-serious adverse events
1. Adverse effects, vital signs and body weight, at the 2 laboratory days
2. Adverse effects were collected during the open-label phase
Notes Sample calculation: yes
Ethics approval: yes
Key conclusion of study authors
1. OROS methylphenidate improves performance on measures of attention and
vigilance, behaviour and working memory in a laboratory school setting in 9- to 12-
year-olds with ADHD
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while tak-
ing methylphenidate before randomisation: yes; a history of failed response to
methylphenidate was an exclusion criterion
Any withdrawals due to adverse events: 2
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Email correspondence with study authors: June 2013 to June 2014. We have attempted
to obtain supplemental efficacy data (Swanson, Kotkit, Agler, M-Flynn and Pelham
Scale) and safety data from study authors. We are awaiting data from the Yale OpenData
Access Project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind.
Placebo and OROS methylphenidate were
matched in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 participants
received OROS methylphenidate on both
laboratory school days in error; therefore,
only data for their first laboratory school
assessment were included in the analyses
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
Vested interest bias High risk Supported by Ortho-McNeil Janssen Sci-
entific Affairs, LLC
Conflicts of interest: Several study authors
had affiliations with pharmaceutical com-
panies producing methylphenidate
Musten 1997
Methods Double-blind, randomised, placebo-controlled, cross-over trial with 3 interventions
1. Low dose of methylphenidate
2. High dose of methylphenidate
3. Placebo
Participants Number of participants screened: 109
Number of participants included: 54 met inclusion criteria; of these, the parents of
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13 children refused methylphenidate treatment. In the final sample, 41 children were
included. Participants were randomly assigned to 1 of the possible drug condition orders
Number of participants followed up: 31
Number of withdrawals: 10
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Regarding participants completing the study
Age: mean 58.07 months (range 48 to 70)
IQ: mean 99.26
Sex: 26 boys, 5 girls
Methylphenidate naive: 93.5%
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (84%), conduct disorder (19%), mood dis-
order (0%), obsessive-compulsive disorder (0%), overanxious disorder (0%), somatisa-
tion disorder (0%), psychotic symptoms (0%)
Comedication: not stated
Sociodemographics: combined parental income Canadian $42,000: 2-parent home
(74%), single-parent home (26%). Significant differences were observed between the
treatment refused group (n = 13) and the treatment completed group (n = 31) on baseline
symptoms assessed by Diagnostic Interview for Children and Adults-Parents; Swanson,
Nolan and Pelham scale; and Conners’ hyperactivity ratings
Inclusion criteria
1. 4 to 6 years of age
2. DSM-III-R diagnosis of ADHD (assessed by parent reports in the Diagnostic
Interview for Children and Adults-Parents and a score > 1 of 8 on the 14 DSM-III-R
items on the parent-rated Swanson, Nolan and Pelham Scale)
3. Standard score 80 on the Peabody Picture Vocabulary Test if unilingual English,
72 if bilingual
4. Mean score equal to 1.5 SD above age and sex means on the Hyperkinesis Index
of Conners’ Parent Rating Scale-Revised, as completed by the parent. Reports from day
care providers or pre-schools were also required to indicate problem behaviours
5. Attention score < 88 seconds on the parent-supervised attention task. This
criterion is 1.5 SD above the mean for attention on the task as performed by normal
pre-school children
6. Parents and children fluent in English
Exclusion criteria
1. Attending or entering first grade at the time of assessment or for the duration of
the study
2. Sensory or physical handicaps, developmental disorders (e.g. autism), neurological
disease or obvious CNS dysfunction as assessed by a paediatrician
3. Had been receiving methylphenidate longer than 6 months, or daily dose was
above dose specified in the research protocol
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of low-
dose (0.3 mg/kg) and higher-dose (0.5 mg/kg) methylphenidate and placebo
Administration schedule: twice daily, morning and lunch
Duration of each medication condition: 7 to 10 days
Washout before study initiation: 48 hours before screening assessment
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Titration period: none
Treatment compliance: Treatment compliance was determined by counting the number
of pills returned to the researcher at the end of each assessment week
Data on compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale - Revised
Non-serious adverse events
1. Side Effects Rating Scale (Barkley 1990) rated by parent at the end of each
treatment period
Notes Sample calculation: no
Ethics approval: no information
Comment from study authors
1. Data on side effects are limited because of the age group of the population under
investigation (4 to 6 years) - pre-schoolers cannot always articulate medication-related
sensations, and this may have interfered with parents’ ability to detect medication side
effects
Key conclusions of study authors
1. Musten 1997 (Musten 1997): Results suggest that methylphenidate can be used
to improve the functioning of pre-school-aged children with ADHD, in a manner
similar to their school-age counterparts
2. Firestone 1998 (Musten 1997): Results indicate that methylphenidate has
relatively low toxicity in pre-school children (over the first 7 to 10 days), that some
behavioural changes that might be viewed as side effects of methylphenidate are
actually normal behaviours or ADHD behaviours in pre-school children (e.g.
sociability), that these “side-effect” behaviours are more common in pre-school than
school-aged children, that some “side effects” of methylphenidate are associated with
improvements in behaviour and that pre-school and school-aged children may
experience different side effects of methylphenidate (e.g. mood changes, anxiety)
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Email correspondence with study authors: June 2013. Personal email correspondence
with study author did not provide supplemental data and information as requested
because of author’s retirement, and because he has no access to the data because the study
took place 15 years ago
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was presented in a fully ran-
domised order as prepared by the hospital’s
pharmacy department
Allocation concealment (selection bias) Low risk Methylphenidate and placebo were placed
in orange gelatin capsules to disguise taste
differences
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants, research personnel and
medical personnel were unaware of the or-
der of medication conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants, research personnel and
medical personnel were unaware of the or-
der of medication conditions
Incomplete outcome data (attrition bias)
All outcomes
High risk Only data for children completing the en-
tire study were analysed
Selective reporting (reporting bias) Unclear risk Not possible to get a copy of the protocol
Vested interest bias Low risk Supported by Health Canada grant
Conflicts of interest: none declared
Newcorn 2008
Methods Twenty-site, randomised, placebo-controlled, double-blind, 6-week, parallel trial with 3
arms
1. Extended-release methylphenidate
2. Placebo
3. Atomoxetine
Participants Number of participants screened: 635
Number of participants included: 516
Number of participants randomly assigned: methylphenidate 220, placebo 74
Number of participants followed up: methylphenidate 180, placebo 57
Number of withdrawals: methylphenidate 40, placebo 17
DSM-IV diagnosis of ADHD (combined (67%), hyperactive-impulsive (1%), inatten-
tive (32%))
Age: MPH mean 10.2, P mean 10.1 (range 6 to 16)
IQ: not stated
Sex: 211 boys, 83 girls
MPH-naive: 41%/121
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (36%)
Comedication: not stated
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Children 6 to 16 years of age
2. Meeting DSM-IV criteria for ADHD, any subtype
3. Symptom severity at entry was required to be ≥ 1.5 SD above US age and sex
norms, as assessed by the ADHD Rating Scale, Fourth Edition - Parent Version
4. ADHD as the primary diagnosis
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Exclusion criteria
1. Seizures, bipolar disorder, psychotic illness or pervasive developmental disorder
2. Taking concomitant psychoactive medications.
3. Anxiety or tic disorders or both
4. Previously treated with an adequate trial of methylphenidate or amphetamine and
either did not experience at least some improvement in ADHD signs and symptoms
(non-responders) or did experience intolerable adverse events
Interventions Participants were randomly assigned to OROS methylphenidate or placebo
Mean methylphenidate dosage: 39.9 mg/d (SD 14.6) or 1.26 mg/kg/d (SD 0.55)
Administration schedule: single morning dose
Duration of intervention: 6 weeks
Titration period: none
Treatment compliance: not stated. Patientswere required to discontinue any psychoactive
medication for ≥ 5 days before entering the study
Outcomes ADHD symptoms
1. ADHD Rating Scale: observer-rated at baseline and at weeks 1, 3 and 6
2. Conners’ Parent Rating Scale, ADHD Index: rated at baseline and at weeks 1, 3
and 6
3. General behaviour
Quality of life
1. Child Health Questionnaire: parent/teacher/observer-rated at baseline and at
weeks 3 and 6
2. Serious adverse events
Non-serious adverse events
1. Open-ended questioning for adverse events and vital signs: observer-rated at
baseline and at weeks 1, 3 and 6
2. No differences were observed in mean change in systolic blood pressure between
placebo and methylphenidate
3. Weight loss was significantly greater with methylphenidate than with placebo
Notes Sample calculation: no
Ethics approval: yes; approved by each site’s ethical review board
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Comments from study authors (limitations)
1. It is likely that the methylphenidate dose was suboptimal for some adolescent
participants
2. Restricting the dose of methylphenidate to 54 mg could also have limited
response in some younger participants, as OROS methylphenidate sometimes is
prescribed at doses higher than the FDA-recommended maximum for children
Key conclusion of study authors
1. Both treatments produced robust improvement, with a statistically significant
difference in response favouring OROS methylphenidate
Email correspondence with study authors: November 2013 and January 2014. We re-
quested additional data from study authors but never received them
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were administered according
to a double-dummy design. Identically ap-
pearing capsules were used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study drugs were administered according
to a double-dummy design. Identically ap-
pearing capsules were used
Incomplete outcome data (attrition bias)
All outcomes
Low risk NNTB was calculated for each treatment
in relation to placebo and for atomoxetine
in relation to methylphenidate. The num-
ber of participants was chosen to have 90%
power to declare non-inferiority on the ba-
sis of a comparison of response rates, with
a non-inferiority margin of 15%
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk All pre-specified outcomes of interest have
been reported
Vested interest bias High risk Supported by Eli Lilly and Company
Conflicts of interest: Dr. Newcorn receives
grant support from Eli Lilly and McNeil;
is a consultant and/or advisor for Eli Lilly,
McNeil, Shire, Novartis and Sanofi-Aven-
tis; and is a member of Speakers’ Bu-
reaus for Eli Lilly and Novartis. Dr. Kra-
tochvil receives grant support fromAbbott,
Cephalon, Eli Lilly, McNeil, Pfizer, Shire
and Somerset; receives from Eli Lilly study
medication for an NIMH (National In-
stitute of Mental Health)-funded study; is
a consultant for Abbott, AstraZeneca, Eli
Lilly and Pfizer; and is a member of the
Eli Lilly Speakers’ Bureau. Dr. Casat re-
ceives research funding from Eli Lilly, No-
vartis andAbbott, and serves on an advisory
board for Eli Lilly. Dr. Allen and Dr. Ruff
are employees and shareholders of Eli Lilly.
Dr. Michelson and Dr. Moore are former
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employees of Eli Lilly
Nikles 2006
Methods Cross-over trial with 2 interventions
1. Short-acting stimulants (methylphenidate and dexamphetamine)
2. Placebo
Phases: Each trial included 3 pairs of treatment periods (n-of-1). Each pair contained the
stimulant and the comparator stimulant or placebo. The child’s doctor individualised the
dosing, and the order of drugs was randomly assigned within each pair. Two treatment
periods were included in a school week, and 2 days per treatment period (not including
Wednesdays and weekends)
Participants Number of participants screened: 108 (85 boys, 21 girls). Two boys repeated n-of-1
trials; 22 (20%) trials were not completed
Number of participants included: 86. Participants were randomly assigned to 1 of 3
possible drug condition orders
Number of participants followed up: 86
Number of withdrawals: 10 (12%) trials were not completed
Diagnosis of ADHD: DSM-IV (subgroups not stated)
Age: median 10 years (range 5 to 16)
IQ: not stated
Sex: 66 boys, 18 girls
Methylphendaite-naive: 36 were taking methylphenidate, 47 dexamphetamine, 3 un-
known pre-trial medication
Ethnicity: All were Caucasian (Nikles 2007 in Nikles 2006)
Country: Australia
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: caregiver’s occupation: full-timework 21%, part-time or casual work
33%, unemployed or retired 5%, unpaid homemakers 25%, other 10%, unknown 5%
Inclusion criteria
1. Clinical diagnosis of ADHD according to DSM-IV criteria
2. Stable on an apparently optimal dose of stimulant
3. Informed consent from parent and school teacher (children 12 years of age
provided assent)
4. 5 to 16 years of age
5. Uncertainty about treatment effectiveness
Exclusion criteria
1. No teachers available and willing to provide observations
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of individual
doses of methylphenidate, dexamphetamine and placebo
Mean methylphenidate dosage: not stated
Administration schedule and time points: different for different individuals, as this is a
series of n-of-1 trials
Duration of each medication condition: 2 days each of methylphenidate and placebo
per week
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Washout before study initiation: 40 hours (from4:00PMTuesday to 8:00AMThursday)
and 64 hours (4:00 PM Friday to 8:00 AM Monday)
Titration period: not stated, but all were stabilised on an “optimal” dose of stimulant,
initiated before randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
First 41 participants used at the end of each treatment period
1. Conners’ Teacher and Parent Self Reported - Revised, short form
2. Conners-Wells Adolescent Rating Scales
From 42nd participant onwards used at the end of each treatment period
1. Changed to ADHD du Paul Rating Scale IV parent and teacher questionnaires,
“because they were less expensive but adequately reliable and valid for monitoring
response to treatment”
2. Conners-Wells Adolescent Rating Scales
Non-serious adverse events
1. Assessment of adverse effects by parent and teacher during and at the end of each
treatment period
Notes Sample calculation: irrelevant
Ethics approval: yes
Key conclusion of study authors
1. Attention deficit hyperactivity disorder n-of-1 trials can be implemented
successfully by mail and telephone communication. This type of trial can be valuable
in clarifying treatment effect when it is uncertain, and in this series, treatments had a
noticeable impact on short-term management
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: yes (n = 1, insomnia and depression)
Comments from review authors
1. This study was more about the use of n-of-1 trials in determining optimal drug
treatment in cases for which this was uncertain
2. Nikles 2007 (in Nikles 2006) does not add any relevant outcome data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The order of drugs was randomly assigned
within each pair”; “There were three pairs
of treatment periods, with the order of
drugs randomly assigned by a computer-
generated randomisation schedule within
each”
Allocation concealment (selection bias) Low risk See above
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients, parents, doctors, and the research
assistant were all blinded to medication or-
der”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A hospital pharmacy encapsulated the
medication (crushing of tablets and pro-
duction of identical capsules containing
either medication or placebo)”; “Active
medication was encapsulated and identical
placebo capsules were produced by a hos-
pital pharmacy”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All outcomes are reported
Vested interest bias Unclear risk No information
Conflicts of interest: Study authors have in-
dicated that they have no financial relation-
ships relevant to this article to disclose
Oesterheld 1998
Methods Cross-over trial with 3 interventions
1. Methylphenidate
2. Lactose placebo
3. Vitamin C placebo
Phases: Five-day trial lasting for 3 consecutiveweeks, with 2medication-free days between
phases
Participants Number of participants screened: 30
Number of participants included: 4. Participantswere randomly assigned todifferent pos-
sible drug condition orders of methylphenidate, lactose placebo and vitamin C placebo
Number followed up: 4 (2 boys, 2 girls)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (66.7%), hyperactive-impulsive (0%), inat-
tentive (33.3%))
Age: mean 8.25 years (range 5 to 11)
IQ: mean 72.5 (range 63 to 79)
Methylphenidate naive: 100%
Ethnicity: Native American (100%)
Country: USA
Setting: out-patient clinic (residential school)
Comorbidity: not stated
Comedication: no
Sociodemographics: not living with family
Inclusion criteria
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1. Native Americans
2. 5 to 12 years of age
3. Residing at the residential school within 6 months
4. DSM-IV ADHD diagnosis
5. Diagnosis of foetal alcohol syndrome, partial foetal alcohol syndrome or alcohol-
related birth defects according to criteria from the Fetal Alcohol Study Group of the
Research Society of Alcoholism (1989)
Exclusion criteria
1. Pregnancy
2. Lactose intolerance
3. Prior psychotropic medication use
4. Bipolar disorder
5. Acute and chronic medical or neurological disorders
6. Current history of seizures
7. Lead levels > 9 mcg/dL
8. Height and weight at or below 3rd percentile
9. IQ < 60
Interventions Participants were randomly assigned to different possible drug condition orders of
methylphenidate (0.6 mg/kg), lactose placebo and vitamin C placebo
Mean methylphenidate dosage: not stated (range 10 mg/d to 17.5 mg/d)
Administration schedule: 7:30 AM, 11:00 AM and 2:00 PM
Duration of each medication condition: 5 days for 3 consecutive weeks
Washout before study initiation: not stated
Medication-free period between interventions: 2 days
Titration period: none. Fixed dose. Initiated before/after randomisation
Treatment compliance: medication given by nurse (directly observed treatment)
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale (48 items) and Conners’ Teacher Rating Scale (39
items): both completed daily in each trial period by caretakers and teachers, respectively
Non-serious adverse events
1. Barkley Side Effects Questionnaire was completed by both teacher and caretaker
before treatment
Notes Sample calculation: no
Ethics approval: yes; Human Subjects Committee of the University of South Dakota’s
School of Medicine and the Research Committee of the Black Hills Children’s Home
Society
Key conclusion of study authors
1. When fetal alcohol syndrome and ADHD co-exist, ADHD symptoms of native
children may respond to standard treatment with methylphenidate without major side
effects
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from review authors
1. Methylphenidate was prepared to the nearest 2.5 mg using regular 5 mg and 10
mg methylphenidate tablets that had been crushed and placed within gelatin capsules,
which may result in uncertainty of actual dose administered
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Email correspondence with study authors: not able to find email addresses for study
authors because information is missing from the paper. Not possible to find on the
Internet, etc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The order of the trials was randomly deter-
mined
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk School caretakers, nurses, teachers and re-
searchers were blinded as to whether treat-
ment consisted of placebo or active agent.
All agents were placed in identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk On each day of each trial, a teacher, blinded
to evaluation data, rated the child’s be-
haviour in school using Conners’ Teacher
Rating Scale (39 items). The caregiver,
blinded to evaluation data, completed
Conners’ Parent Rating Scale (48 items)
on a daily basis. School caretakers, nurses,
teachers and researchers were blinded as to
whether treatment consisted of placebo or
active agent. All agents were placed in iden-
tical capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk Research was supported by a University of
South Dakota/USF-Mini Grant
Conflicts of interest: none declared
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Methods Double-blind, randomised, cross-over trial with 4 interventions
1. Methylphenidate
2. Desipramine
3. L-dopa
4. Placebo
Participants Number of participants screened: not stated
Number of participants included: 16. Participants were randomly assigned to 1 of the
possible drug condition orders
Number of participants followed up: 16 (all boys)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (combined (100%))
Age: mean 10.4 years (range 7 to 12)
IQ: 95.4
Methylphenidate naive: 0 (0%)
Ethnicity: not stated
Country: the Netherlands
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 6), comorbid anxiety disorder (n = 1),
specific developmental disorders (n = 3)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Diagnosis of ADHD according to DSM-III-R criteria
2. Scored in the clinical range on both the Child Behavior Checklist Inattention
factor (t scores > 70, i.e. 98th percentile) and Conners’ Teacher Rating Scale
Hyperactivity factor (mean factor score > 2.2)
Exclusion criteria
1. Diagnosis of tic disorder or pervasive developmental disorder
2. Abnormal values (1 week before medication study) of ECG and blood measures
that contraindicate desipramine medication
3. Family history of severe heart problems
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of
methylphenidate, desipramine, L-dopa and placebo
Mean methylphenidate dosage: 15 mg
Administration schedule: once, in the afternoon
Duration of each medication condition: 1 day
Washout before study initiation: 3 days before for methylphenidate users
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: 100%
Outcomes Non-serious adverse events
1. Sleepiness reported by 1 participant
Notes Sample calculation: no
Ethics approval: yes
Key conclusions of study authors
1. Inhibition of performance improved under desipramine but not under
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methylphenidate or L-dopa. Response time to the stop signal was marginally shortened
after intake of desipramine
2. Methylphenidate decreases omission and choice errors and causes faster reaction
times in trials without the stop tone
3. No effects of L-dopa whatsoever were noted
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; all participants were already stable on
methylphenidate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “A double-blind randomised design was
used”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Low risk Research supported by Netherlands Or-
ganisation for Scientific Research (NWO)
Grant 575-63-082
Conflicts of interest: not declared
Palumbo 2008
Methods Multi-centre, randomised, double-blind, 16-week, parallel trial with 2 × 2 factorial design
1. Methylphenidate alone
2. Methylphenidate and clonidine
3. Clonidine alone
4. Placebo
Two successive 4-week titration periods followed by an 8-week maintenance period
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Participants Number of participants screened: 205
Number of participants included: 122 (98 boys, 24 girls)
Number randomly assigned: methylphenidate 29, placebo 30, methylphenidate + cloni-
dine 32, clonidine 31
Number followed up: methylphenidate 18, placebo 10, methylphenidate + clonidine
24, clonidine 31
Number of withdrawals: methylphenidate 11, placebo 20, methylphenidate + clonidine
8, clonidine 5
DSM-IV diagnosis of ADHD (combined (76%), hyperactive-impulsive (4%), inatten-
tive (20%))
Age: mean 9.5 (range not reported)
IQ: > 70
Methylphenidate-naive: 57 (46.7%)
Ethnicity: Caucasian (77.9%), African American (10.7%), Hispanic (6.6%), other (4.
9%)
Country: USA
Setting: out-patient clinic
Co-morbidity: oppositional defiant disorder (47%), conduct disorder (9%)
Co-medication: no. Protocol-based behavioural interventions
Sociodemographics: not stated. Participant groups were similar except for a higher per-
centage of whites in the clonidine group and some minor differences with regard to
family history of ADHD and tics
Inclusion criteria
1. Children 7 through 12 years of age in school
2. DSM-IV ADHD, any subtype: indication of a sufficient number of ADHD
symptoms on the Disruptive Behavior Disorders Rating Scale as rated by a teacher
3. Rating of ADHD symptoms above specified cutoff scores (boys: grade 2 to 3 =
10; grade ≥ 4 = 9; girls: grade 2 to 3 = 7, grade ≥ 4 = 6) on the Iowa Conners’ Teacher
Rating Scale
4. Indication of the presence of sufficient ADHD symptoms at home on the Iowa
Conners’ Parent Rating Scale
5. Investigators rating of global functioning on the Child Global Assessment Scale
(CGAS) ≤ 70, with difficulty evident in ≥ 2 areas, such as school and home
6. ADHD must be viewed as worthy of treatment with medications, as judged by
the parent and the site investigator
7. Informed consent/assent signed
8. Designated school for each participant agrees to participate in the study by
completing all required questionnaires and following all specified procedures
9. Child must be able to swallow the tablets and capsules used in this study
Exclusion criteria
1. Evidence of a tic disorder
2. Major depression
3. Pervasive developmental disorder
4. Autism
5. Psychosis
6. Mental retardation
7. Anorexia nervosa
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8. Bulimia
9. Serious cardiovascular (e.g. significant hypotension, congenital heart disease) or
other medical disorder that would preclude safe use of methylphenidate or clonidine
10. Impaired renal function or pregnancy
11. Family history of long QT syndrome, cardiomyopathy or premature (age 45
years) sudden death
12. Prolonged QTc interval (> 440 milliseconds), high-grade ventricular ectopy,
atrioventricular block beyond first degree, bundle branch block, intraventricular
conduction block (> 100 milliseconds), pacemaker rhythm or HR < 60 bpm on the
ECG, significant hypotension, cardiomyopathy, congenital heart disease, aortic or
pulmonary stenosis, history of syncope
13. Blood pressure ≥ 2 SD above or below the age- and sex-adjusted mean
14. Stimulants had to be discontinued ≥ 2 weeks before enrolment
15. Any other psychotropic medications, anxiolytics or hypnotics had to be
discontinued ≥ 6 weeks before enrolment
Previous use of methylphenidate or clonidine was permitted
Interventions Participants were randomly assigned to immediate-release methylphenidate or placebo
Mean methylphenidate dosage: 0.76 ± 0.54 mg/kg/d (30.2 ± 18.9 mg/d
(methylphenidate-only group) and 25.4 ± 18.2 mg/d (methylphenidate + clonidine))
Administration schedule: 1 to 3 times daily (morning, noon and afternoon)
Duration of intervention: 12 to 16 weeks
Washout before study initiation: 2 weeks
Titration period: 8-week flexible-dose titration period (4 weeks for clonidine, then 4
weeks for methylphenidate) initiated after randomisation
Maintenance period of optimal dose: 8 weeks
Treatment compliance: monitored using pill counts (results of monitoring not stated)
Outcomes ADHD symptoms
1. ADHD Rating Scale (ADHD RS-IV, 18-item): child psychiatrist-rated at baseline
and at 16 weeks
2. ASQ: teacher-rated at baseline and at 4, 8, 12 and 16 weeks
3. ASQ: parent-rated at baseline and at 4, 8, 12 and 16 weeks
4. IOWA Conners’ Rating Scale: teacher-rated at baseline and at 4, 8, 12 and 16
weeks
Quality of life
1. Child Global Assessment Scale: rated at baseline and at 4, 8, 12 and 16 weeks
Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale (20 items, modified from the original 13
items to include potential clonidine side effects): parent- and teacher-rated at baseline
and at 4, 8, 12 and 16 weeks.
2. Spontaneous self reports of adverse events: parent- and participant-rated at
baseline and at 4, 8, 12 and 16 weeks, or by telephone calls conducted between visits
3. Weight, ECG, supine and standing blood pressures and pulse at visits 4, 8, 12 and
16
Notes Sample calculation: yes; sample size of 140 participants (35 per treatment group) was
determined to provide between 80% and 90% power to detect a group difference (effects
of clonidine)
358Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Palumbo 2008 (Continued)
Ethics approval: yes; approved by the institutional review board at each site
Comments from study authors
1. Overall, findings should be viewed cautiously in the light of the relatively small
sample size and differential rates of attrition across groups
2. Findings are limited by the exclusion of children with certain co-morbid disorders
such as mood and anxiety disorders, known cardiac problems or abnormal ECGs
3. Also, given that all participants received psychoeducational and behavioural
interventions as part of the protocol, these results may be limited to settings in which
such behavioural interventions are applied
4. Study relied largely on parent and teacher questionnaires to identify possible side
effects of medications. However, such rating scales may overestimate rates of
medication side effects because sometimes such complaints reflect other factors, such as
underlying conditions or co-morbid psychopathology
Key conclusions of study authors
1. Based on Conners’ Teachers Abbreviated Symptom Questionnaire;
methylphenidate offers best combination of efficacy and tolerability for ADHD
2. Clonidine, used alone or with methylphenidate, appears safe and well tolerated in
childhood ADHD
3. Study provides evidence that measures of quality of life for the family are sensitive
to pharmacological treatment for ADHD
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: Moderate to severe adverse events were cited as
a reason for withdrawal in 8 participants: methylphenidate + clonidine 5, clonidine 2,
methylphenidate 1
Methylphenidate + clonidine: irritability (n = 1), tearfulness and irritability (n = 1),
headaches (n = 1), itching (n = 1), asymptomatic ECG abnormalities (prolonged QTc)
(n = 1) Methylphenidate: tachycardia and palpitations (n = 1)
Email correspondence with study authors: March 204 to June 2014. We attempted to
obtain supplemental efficacy data from the study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation plan
included stratification by centre (investiga-
tor) and by sexual maturity status (Prepu-
bertal: Tanner I-II, Pubertal: Tanner III-V)
Allocation concealment (selection bias) Low risk Only the programmer in the Biostatistics
Centre and the pharmacist knew the allo-
cation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Methylphenidate (or matching placebo)
powder packaged in gelatin capsules
359Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Palumbo 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All investigators, study co-ordinators,
teachers, parents and children were blinded
to treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Statistical analyses were performed accord-
ing to the ITT principle, and last available
observations were carried forward and im-
puted when needed for both efficacy and
safety measures. However, only data from
the ADHD Rating Scale for children who
completed the titration period were anal-
ysed
Selective reporting (reporting bias) Low risk Protocol published. All pre-specified out-
comes of interest have been reported
Vested interest bias High risk This project was supported by NIH (Na-
tional Institutes of Health) and NINDS
(National Institute of Neurological Disor-
ders and Stroke)
Conflicts of interest: Some study authors
are on the ADHD Advisory Board and the
Speakers’ Bureau of; are scientific consul-
tants or principal or site investigators for;
and/or have received educational or fund-
ing support from several pharmaceutical
companies
Pearson 2013
Methods Four-week, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases
1. 1-week placebo
2. 1-week low-dose methylphenidate
3. 1-week medium-dose methylphenidate
4. 1-week high-dose methylphenidate
Participants Number of participants screened: 94
Number of participants included: 24 (19 boys, 5 girls). Participants were randomly
assigned to 1 of 4 possible drug condition orders
Number of participants followed up: 24
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined 19, inattentive 5)
Age: mean 8.8 years (range 7.1 to 12.7)
IQ: mean 85 (range 46 to 112)
Methylphenidate naive: 13
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Ethnicity: Caucasian (n = 13), African American (n = 4), Asian (n = 1), Hispanic (n =
5), other (n = 1)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 5), obsessive-compulsive disorder (n =
2), separation anxiety disorder (n = 1)
Comedication: yes
Sociodemographics: Hollingshead 4 Factor Social Class 1.7 (0.9); Hollingshead 4 Factor
SES Score 52.3 (10.8)
Inclusion criteria
1. Not clearly stated
Exclusion criteria
1. Serious neurological disorders (e.g. stroke, seizures)
2. Down syndrome
3. Fragile X syndrome
4. Tourette’s syndrome
5. Psychosis
6. Mood disorders
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of (low,
medium and high) methylphenidate and placebo
Mean methylphenidate dosage: low = 0.21 mg/kg; medium = 0.35 mg/kg; high = 0.48
mg/kg
Administration schedule: b.i.d.
Duration of each medication condition: 1 week
Washout before study initiation: yes
Medication-free period between interventions: not stated
Titration period: 1 week before randomisation
Treatment compliance: “Parents completed a medication administration form, were
asked about missing or late doses at weekly interviews and teachers were asked as well.
Forms were verified by number of pills in returned vials. Families were asked again in
case of discrepancy. Parents and teachers were also asked about unanswered items om
questionnaires”
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale - Revised
2. Conners’ Teacher Rating Scale - Revised
3. Swanson, Nolan and Pelham Scale, Fourth Edition
4. ADD/H Comprehensive Teacher Rating Scale (ACTeRS), Parent and Teacher
Forms
Non-serious adverse events
1. Nine of 24 parents (38%) reported insomnia at the high dose, compared with 5
(21%) while taking placebo
2. Nine parents reported loss of appetite at the high dose, compared with only 1
during placebo
Notes Sample calculation: no
Ethics approval: yes
Key conclusions of study authors
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1. It is ideal for clinicians to assess behavioural response in both home and school
settings when titrating methylphenidate treatment for children with ASD and
significant ADHD symptoms
2. It is important to monitor each child for side effects (e.g. increases in stereotypies
or irritability)
3. Methylphenidate formulations are efficacious and well tolerated in children with
ASD and significant ADHD symptoms
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk We used the Digram balanced randomisa-
tion method that Dr. David Lane (a pro-
fessor of both psychology and statistics at
nearby Rice University) used to create the
8 balanced drug dose orders to which our
24 participants were assigned
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk One-week, single-blind, “lead-in-dosing”;
all study personnel with participant contact
were blind with respect to dosages given
during the drug trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The study medication was prepared by
the University of Texas Psychiatry Research
Pharmacy: theRitalinLAbeadsweremixed
with (inert) placebo beads and placed in
two opaque gelatin capsules, and the white
generic IR-MPH was crushed and mixed
with cornstarch and placed in two size 1
gelatin capsules”
Incomplete outcome data (attrition bias)
All outcomes
High risk Blank was left for missing data
Selection bias: yes; exclusion of placebo
responder during single-blind placebo
washout week
Selective reporting (reporting bias) Low risk All outcomes are reported
Vested interest bias Low risk Funded by grant number MH072263
from National Institute of Mental Health
(NIMH)
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Conflicts of interest: none declared&&
Pelham 1989
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases
1. No clear method description: “The procedure was double-blind placebo-
controlled in which each child received, in random order with condition varied daily,
placebo b.i.d. and 0.3 mg MPH/kg b.i.d.” - “5 to 9 days of data were gathered”
Participants Number of participants screened: not stated
Number of participants included: 24. Participants were randomly assigned to 1 of 2
possible drug condition orders; condition varied daily: placebo b.i.d. and 0.3 mg MPH/
kg b.i.d
Number followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III (combined (not stated), hyperactive-impulsive (19/24),
inattentive (2/24))
Age: mean not reported (range: boys 5 years 6 months to 11 years; girls 5 years 8 months
to 11 years 3 months)
IQ: boys 100.8 (SD 14.23), girls 104.0 (SD16.52)
Sex: 12 boys, 12 girls
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: attention deficit disorder (1/24), conduct disorder (5/24), oppositional
defiant disorder (15/24), learning disability (6/25)
Comedication: yes; other doses of stimulants reported but not on study days
Sociodemographics: not stated
Inclusion criteria
1. None stated
Exclusion criteria
1. Children who were mentally retarded and those who had gross neurological
disorders were not included in the study
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.3 mg/
kg methylphenidate and placebo. “Each child received, in random order with condition
varied daily, placebo b.i.d. and 0.3 mg MPH/kg b.i.d.”
Mean methylphenidate dosage: boys 9.8 mg (range 5.3 to 16.9), girls 9.5 mg (range 5.
2 to 13.1)
Administration schedule: at breakfast and at lunchtime
Duration of each medication condition: not stated
Washout before study initiation: not stated
Medication-free period between interventions: no
Titration period: none
Treatment compliance: no information
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Outcomes ADHD symptoms
1. Abbreviated Conners’ Teacher Rating Scale (CTRS): 1 to 3 times per condition
2. Revised Behaviour Problem Checklist: counsellor-rated, 1 to 3 times per condition
3. IOWA Conners’ Teacher Rating Scale (IOWA CTRS)
General behaviour
1. Daily frequencies (following rules, non-compliance, positive peer behaviours,
conduct problems, negative verbalisations, numbers of time-outs per day): daily
2. Time-out: daily
3. Classroom measures, teacher recorded: daily
4. Daily report card
5. Observed peer interaction using modification of RECESS code: daily
Notes Sample calculation: no
Ethics approval: no information.
Comment from study authors
1. Study involved only 12 boys and 12 girls; 1 dose of methylphenidate in the
context of a highly structured summer programme: results must be considered
preliminary
Key conclusions of study authors
1. Results revealed equivalent and beneficial effects of methylphenidate for both
boys and girls
2. Methylphenidate therefore would appear to be a treatment that is as useful for
girls with ADD as for boys with ADD
Comments from review authors
1. Data reported from this study cannot be considered robust
2. No information on ethics committee approval, on randomisation, on primary
endpoint (multiple endpoints), on sample size calculation, on safety, etc. Concomitant
behavioural treatment was provided, but no details are given in the Methods section
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no information
Any withdrawals due to adverse events: no information
Email correspondence with study authors: October 2014. We received no supplemental
information/data from study authors. We asked authors whether this article was part of
the Johnston 1988 study but received no response, so we extracted the data as from 2
separate studies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Each child received, in random order
with condition varied daily, placebo and
methylphenidate
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
Low risk Active medication and placebo were dis-
guised in gelatin capsules and were pre-
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All outcomes packaged in individual, dated envelopes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Unclear risk Not stated
Pelham 1990a
Methods Double-blind, placebo-controlled, cross-over trial
1. Immediate-release methylphenidate
2. Sustained-release methylphenidate
3. Sustained-release dextroamphetamine
4. Pemoline
5. Placebo
Participants Number of participants screened: not stated
Number of participants included: 22 (all boys). Participants were randomly assigned to
1 of the possible drug condition orders
Number of participants followed up: 22
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 10.39 years (range 8.08 to 13.17)
IQ: mean 105.68
Methlyphenidate-naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (summer treatment programme)
Comorbidity: oppositional/defiant disorder (n = 9), conduct disorder (n = 4), “suggesting
the presence of a learning disability”, but IQ > 80 (n = 13)
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. Participating in the Summer Treatment Program of the 1988 Western Psychiatric
Institute and Clinic Attention Deficit Disorder Program
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned different possible drug condition orders of
methylphenidate (10 mg b.i.d., SR-20 q.a.m.) and placebo
Mean methylphenidate dosage: immediate-release methylphenidate 10 mg = 0.29 mg/
kg
Administration schedule: twice daily: immediate-release methylphenidate twice daily:
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morning and lunchtime; sustained-release methylphenidate once daily: morning
Duration of each medication condition: 1 day, but in total 3 to 6 days
Washout before study initiation: none
Medication-free period between interventions: not stated
Titration period: no
Treatment compliance: none
All completed study: not stated
Outcomes ADHD symptoms
1. Teacher ratings on the Abbreviated Conners’ Teacher Rating Scale: 2 to 4 times in
each medication condition
2. Counsellor ratings on the Abbreviated Conners’ Teacher Rating Scale: 2 to 4
times in each medication condition
Non-serious adverse events
1. Parent, teacher and counsellor side effect checklist: at least once per condition
Notes Sample calculation: no
Ethics approval: not stated
Comments from study authors
1. It should be noted that the results we have presented apply to the short-term
effects of these medications
2. Results of this study might not predict long-term response to the initial dose
Key conclusions of study authors
1. The 3 long-acting stimulants and immediate-release methylphenidate were
superior to placebo
2. All 4 had similar time courses with effects from 1 to 9 hours after ingestion
3. Individual differences in drug responsivity were noted
Comments from review authors
1. The article states that comorbidity is diagnosed according to DSM-III-R, but
study authors do not mention whether the ADHD diagnosis is based on DSM-III-R
2. We have chosen in our data extraction to assume that this is so
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: January 2014. No contact made through
author correspondence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active medication and placebo were dis-
guised in gelatin capsules and were pre-
packaged in individual daily pill reminders
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk Not stated
Conflicts of interest: not stated
Pelham 1993a
Methods Cross-over trial with 2 interventions
1. Methylphenidate 0.3 mg/kg and 0.6 mg/kg
2. Placebo
Phases: 3
Participants Number of participants screened: not stated
Number of participants included: 31. Participants were randomly assigned to 1 of 3
possible drug condition orders
Number of participants followed up: 31 (all boys)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (therefore no subtype)
Age: mean 98.8 months (range 5.42 to 9.92)
IQ: mean 110.7 (range not stated)
Methylphenidate naive: not stated
Ethnicity: Caucasian (93.5%), African American (6.5%)
Country: USA
Setting: hospital (Summer Treatment Program)
Comorbidity: oppositional defiant disorder (32%), conduct disorder (48%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criterion
1. Boys with ADHD attending a Psychiatric Institute and Clinic Summer Treatment
Program
Exclusion criteria
1. None described
Interventions Participants were randomly assigned to 1 (of not stated) possible drug condition order
of 0.3 mg/kg and 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage (SD): low 8.1 mg (range 5 to 15); high 16.0 mg (range
10 to 22.5)
Administration schedule: twice a day morning and midday; conditions were changed
daily over 6 weeks
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Duration of each medication condition: 2 weeks overall (individual treatment condition
1 day)
Washout before study initiation: not described
Titration period: none
Treatment compliance: not reported
Outcomes ADHD symptoms
1. Teachers rated inattention/overactivity daily with the IOWA Conners’ Teacher
Rating Scale
Notes Sample calculation: no
Ethics approval: not stated
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Key conclusion of study authors
1. Relatively small incremental value was gained by the higher dose of medication or
by the addition of behaviour modification compared with the effects of the low dose of
methylphenidate
Email correspondence with study author: June 2014. Emailed study author to ask for
additional information but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Referred to as a randomised study but se-
quence generation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules were identically packaged
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Referred to as double-blind but not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to be 100% follow-up
Selective reporting (reporting bias) Unclear risk Protocol not identified
Vested interest bias Unclear risk None reported
Conflicts of interest: no information
368Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pelham 1999
Methods Six-week, within-participant, double-blind, placebo-controlled, cross-over design
1. Methylphenidate
2. Placebo
3. D- and L-AMPH
Phases: 5
Participants Number of participants screened: 26
Number of participants included: 25 (21 boys, 4 girls). Participants were randomly
assigned to 1 of 4 possible drug condition orders
Number of participants followed up: 23
Number of withdrawals: 2
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.6 years (range 5.8 to 12.7)
IQ: average intelligence
Methylphenidate naive: not stated
Ethnicity: Caucasian (88%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 13), conduct disorder (n = 8)
Comedication: not stated
Sociodemographics: “Median family income was US $40 000, with incomes ranging
widely (from US $10 000 per year to US $100 000 per year)”
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 10 mg
or 17.5 mg methylphenidate and placebo
Administration schedule: 2 time points
Duration of each medication condition: 5-day period
Washout before study initiation: not stated
Medication-free period between interventions: no
Titration period: none initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale (parent)
2. IOWA Conners’ Rating Scale (teacher)
Non-serious adverse events
1. Tics
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusions of study authors
1. “Both drugs were routinely superior to placebo and produced dramatic
improvements in rates of negative behaviour, academic productivity, and staff/parent
ratings of behaviour”
2. DEX-AMPH AMPH produced greater improvement than methylphenidate.
Doses of DEX-AMPH AMPH used were more potent than those of methylphenidate
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3. Both drugs produced low levels of side effects. 25% of study participants were
judged by the clinical team to be non-responders
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: yes; 1 (exacerbation of tic disorder)
Email correspondence with study authors: April 2014. We requested additional infor-
mation from study authors but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The clinical team was not blind to med-
ication condition when making their rec-
ommendations. Therefore, as a reliability
check of the clinical team’s recommenda-
tions, one of the authors (J.W.)whowas not
involved in the clinical teammeetingsmade
independent recommendations based on
the same data given to the clinical team.
This rater was blind to drug condition ex-
cept placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The clinical team was not blind to med-
ication condition when making their rec-
ommendations. Therefore, as a reliability
check of the clinical team’s recommenda-
tions, one of the authors (J.W.)whowas not
involved in the clinical teammeetingsmade
independent recommendations based on
the same data given to the clinical team.
This rater was blind to drug condition ex-
cept placebo”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias High risk Grants from the Shire Richwood Phar-
maceutical Company and National Insti-
tute of Mental Health (Grants MH53554,
MH45576 and MH50467)
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Methods Cross-over trial with 3 interventions
1. Concerta
2. Immediate-release methylphenidate
3. Placebo
Phases: 3
Participants Number of participants screened: 70
Number of participants included: 68. Participants were randomly assigned to 1 possible
drug condition order
Number of participants followed up: 68 (66 for ADHD symptoms)
Number of withdrawals: 2
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.1 years (range 6 to 12)
IQ: mean 104.8
Sex: 89% boys, 11% girls
Methylphenidate naive: 0%
Ethnicity: Caucasian (94%), other (6%)
Country: USA
Setting: out-patient clinic (Summer Treatment Program)
Comorbidity: oppositional defiant disorder (43%), conduct disorder (37%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. Children 6 to 12 years of age with ADHD were recruited via several sources,
including advertisement; physician, agency and school referral; and parent referral
2. All participants were required to be medicated with methylphenidate and to
receive a stable dose for ≥ 4 weeks before the start of the study
Exclusion criteria
1. Medical condition that would contraindicate the use of stimulants
2. Physical condition or severe learning difficulty that would interfere with
participation in study, including IQ < 80
3. Receiving additional medication for ADHD
4. Any medication with CNS effects, anticonvulsants or investigational medications
5. Reached menarche
6. Blood pressure at or above the 95th age and height percentile
Interventions Participants were randomly assigned to different possible drug condition orders of im-
mediate-release methylphenidate 3 times a day (t.i.d.); Concerta methylphenidate once
a day (qd); and placebo
Mean methylphenidate dosage: 0.75 mg/kg (SD 0.34) (Three dosing levels were used:
5 mg immediate-release methylphenidate t.i.d./18 mg Concerta q.d.; 10 mg immedi-
ate-release methylphenidate t.i.d./36 mg Concerta q.d.; and 15 mg immediate-release
methylphenidate t.i.d./54 mg Concerta q.d. The dose level used for each child was based
on that child’s methylphenidate dosing before the start of the study
Administration schedule: immediate-release methylphenidate 3 times a day; Concerta
once daily
Duration of each medication condition: 7 days
Washout before study initiation: not described
Titration period: none
Treatment compliance: “virtually 100%”
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Outcomes ADHD symptoms
1. Teachers and parents completed weekly symptom ratings using the IOWA
Conners’ Rating Scale
2. Teachers and parents rated oppositional defiant behaviour weekly using the
Abbreviated Conners’ Rating Scale
3. Teacher ratings on the Swanson, Kotkin, Agler, M-Flynn and Pelham Scale, daily
Non-serious adverse events
1. Reports of adverse events were collected via spontaneous reports over the course of
the study. Additionally, each week, parents provided responses to questions on adverse
events, sleep quality, appetite and tics
Notes Sample calculation: no
Ethics approval: yes
Comment from study authors
1. All participants also received a behavioural intervention
Key conclusion of study authors
1. This investigation clearly supports the efficacy of the Concerta long-acting
formulation of methylphenidate for parents who wish to have medication benefits for
their child throughout the day and early evening
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; all participants
were required to be medicated with methylphenidate and were receiving a stable dose
for ≥ 4 weeks before the start of the study
Email correspondence with study author: June 2014. Emailed study author to ask for
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Referred to as double-blind; capsules were
identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Referred to as double-blind; capsules were
identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported for 66/70 for ADHD and
behaviour
Selective reporting (reporting bias) Unclear risk No protocol available
372Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pelham 2001a (Continued)
Vested interest bias High risk Research was supported by ALZA Corpo-
ration, the manufacturers of Concerta
Conflicts of interest: Dr. Pelham is a mem-
ber of the ALZA advisory committee on
Concerta and its development. Drs. Hoff-
man and Lock are members of the ALZA
paediatric advisory board
Pelham 2002
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 136 (all boys) (110 for 30-day follow-up). Participants
were randomly assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 136 (106 for 30-day follow-up)
Number of withdrawals: 0 (4 for 30-day follow-up)
Diagnosis of ADHD: DSM-III-R (therefore no subtype)
Age: mean 9.7 years (range 7.6 to 12.7)
IQ: mean 104.5
Methylphenidate naive: not stated
Ethnicity: Caucasian (81%), African American (15%)
Country: USA
Setting: Summer Treatment Program
Comorbidity: oppositional defiant disorder (53%), conduct disorder (24%)
Comedication: not stated
Sociodemographics: median family income: US $25,000, (range US $10,000 to > $100,
000)
Inclusion criterion
1. Boys attending a psychiatric institute and clinic intensive Summer Treatment
Program over 8 weeks
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 possible drug condition order of 0.3 mg/kg
methylphenidate and placebo
Mean methylphenidate dosage: 10 mg (SD 2.7)
Administration schedule: twice daily at 7:45 AM and 11:45 AM
Duration of each medication condition programme: 12 days (order randomly assigned
daily over 6 weeks, doses administered over weekdays, except on Fridays); follow-up: 30
days
Washout before study initiation: 2 weeksmedication free baseline in programme, unclear
for follow-up
Titration period: none
Treatment compliance: not reported
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Outcomes ADHD symptoms
1. Programme: daily ratings of inattention/hyperactivity using IOWA Conners’
Rating Scale completed by counsellor
2. Follow-up: daily ratings of inattention/hyperactivity using IOWA Conners’
Rating Scale completed by teacher
General behaviour
1. Programme: daily ratings of oppositional defiant behaviour using IOWA Conners’
Rating Scale completed by counsellor
2. Follow-up: daily ratings of oppositional defiant behaviour using IOWA Conners’
Rating Scale, completed by teacher
Notes Sample calculation: no
Ethics approval: yes
Comment from study authors
1. Boys were told 50% of the time whether they were receiving placebo or
medication and incorrectly 50% of the time; all boys received behavioural
interventions over the course of the programme
Key conclusion of study authors
1. Expectancy (of treatment effectiveness) did not improve behaviour; only active
medication improved behaviour
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: June 2014. Emailed study authors to ask for
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters were blinded to medication condi-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up apparent during pro-
gramme but data reported for 106/110 fol-
lowed up in the community
Selective reporting (reporting bias) Unclear risk Although measures were rated daily, how
data were aggregated/reported as a single
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result per phase is not clear
Vested interest bias High risk Supported by NIMH (Grant MH48157)
Conflicts of interest: Pelham served as an
advisor for ALZACorporation (see Pelham
2001a)
Pelham 2005
Methods Eight-day, multi-centre, double-blind, randomised, dose-ranging, cross-over trial with 2
interventions
1. Methylphenidate transdermal system
2. Placebo
From a Summer Treatment Program
Participants Number of participants screened: 36
Number of participants included: 36 (33 boys, 3 girls). Participants were randomly
assigned to 1 of 8 possible drug conditions
Number of participants followed up: 36
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.6 years (range 6 to 13)
IQ: mean 105.3 (SD 18)
Stimulant-naive: 15 (42%)
Ethnicity: Caucasian (75%), African American (19%), Hispanic (3%), mixed African
American/White (3%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no; antidepressants were withdrawn from 2 participants before study
enrolment
Sociodemographics: Parents were manual workers (6%), clerical/sales workers (32%),
technicians/semi professionals (23%) and executives/major professionals (32%)
Inclusion criteria
1. Not stated
Exclusion criteria
1. Medical history prohibiting patients from taking stimulants or participating
2. Involvement in Summer Treatment Program activities
3. Skin problems or allergies to ingredients in the patches
Interventions Participants were randomly assigned to 1 of 8 possible drug conditions of
methylphenidate transdermal system and placebo
Methylphenidate transdermal system dosage: 6.25 cm² (0.45 mg/h), 12.5 cm² (0.9 mg/
h), 25 cm² (1.8 mg/h)
Administration schedule: 1×/d (at 6:00 AM and 7:00 AM). Application sites were alter-
nated each day between left and right hips
Duration of each medication condition (crossed with time of application): 1-day; patch
worn for ≥ 12 hours/d
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Duration of study: 8 days
Washout before study initiation: no
Medication-free period between interventions: no
Titration period: none
Treatment compliance: 100%. Parents returned patches and dosing records to the study
site
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale and Abbreviated Conners’ Rating Scale were rated
daily by parents, counsellors and teachers
Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale completed daily by parents, counsellors and
teachers
2. Any other adverse events that the child experienced were recorded
3. Skin irritation at application sites rated each day by parents for skin reactions or
irritations before application, before removal and the following morning. Presence of
erythema: none (0), very slight (1), well defined (2), moderate (3) or severe (4).
Presence of discomfort: none (0), mild (1), moderate but tolerable (2) or severe (3)
Notes Sample calculation: yes (36 to 48)
Ethics approval: yes; institutional review board at each site approved the study
Comments from study authors
1. No children experienced a skin reaction severe enough that the study physician
recommended discontinuing the patch
2. Limitations: short study duration, no controlled time-course evaluation
Key conclusions of study authors
1. Methyphenidate transdermal system produced significant effects that were similar
to those previously reported with comparable methylphenidate doses
2. Substantial effect of application time on total daily functioning not apparent in
this setting; additional controlled time-course studies will be necessary to fully evaluate
the question of morning onset
3. Further study will be necessary to establish long-term efficacy and safety of the
methylphenidate transdermal system
Comment from review authors
1. Families received monetary compensation to participate
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: February to March 2014. We attempted
to obtain supplemental information regarding randomisation, allocation concealment,
washout period and efficacy and safety data from study authors but without success
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study sponsor produced random orders
and prepared medication kits in numbered
containers for each participant
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Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment sequences were concealed until
completion of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treatment sequences were concealed until
completion of the study
Incomplete outcome data (attrition bias)
All outcomes
High risk Evaluable participant data were analysed.
As the result of record-keeping difficulties
at 1 site, efficacy data were excluded for 5
participants
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias High risk Study was supported by Noven Pharma-
ceuticals. Furthermore, Dr. Pelham was
supported by grants from NIAAA, NIDA,
NIMH and NINDS
Conflicts of interest: Several study authors
have received consulting fees and research
funding and have been consultants and/or
served on the Speakers’ Bureaus of several
pharmaceutical companies in the past year
Pelham 2011
Methods Three-week, randomised, double-blind, double-dummy, cross-over trial with 3 inter-
ventions
1. Immediate-release methylphenidate
2. Methylphenidate transdermal system
3. Placebo
Parents and children spent Friday evening to Sunday morning in a laboratory setting,
where data collection took place
Participants Number of participants screened: not stated
Number of participants included: 10 (all boys). Participants were randomly assigned to
different drug orders of immediate-release methylphenidate, methylphenidate transder-
mal system and placebo
Number of participants followed up: 9
Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV (combined (80%), hyperactive-impulsive (0%), inatten-
tive (20%))
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Age: mean 8.6 years (range 6.4 to 9.7)
IQ: mean 95.3 (range 83 to 109)
Methylphenidate naive: none; all receiving a stable dose of immediate-release
methylphenidate before enrolment
Ethnicity: Caucasian (50%), African American (20%), Asian (0%), Hispanic (0%),
Native American (10%), other (20%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder/conduct disorder (80%)
Comedication: no other psychotropics
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis according to DSM-IV
2. IQ > 80
Exclusion criteria
1. Skin sensitivity or any significant dermatological disease
2. Atypical electrocardiogram results or hypertension
3. Atypical blood and urine test results or evidence of other medical condition that
could be worsened by stimulant usage
4. Participants taking other psychotropics besides methylphenidate
5. Participants with psychopathology other than ADHD or oppositional defiant
disorder or conduct disorder severe enough to merit additional treatment
Interventions Participants were randomly assigned to immediate-release methylphenidate,
methylphenidate transdermal system or placebo
Immediate-release methylphenidate
Mean dosage: 30 mg/24 h
Administration schedule: 10 mg t.i.d. morning, lunch, afternoon
Methylphenidate transdermal system
Mean dosage: 33 mg/24 h
Administration schedule: two 10 cm²methylphenidate transdermal system patches worn
for 24 hours at the buttock, with sides alternated daily
Time point: applied in the morning
Duration of each medication condition: 1 week
Washout before study initiation: 48 hours before study (no washout between treatment
periods)
Titration period: none
Treatment compliance: Dosing and adhesion records were collected each week, but no
data were available in the article
Outcomes ADHD symptoms
1. Iowa Conners’ Scale, rated by the laboratory classroom teacher at each treatment
condition
Non-serious adverse events
1. Vital signs (temperature, weight, blood pressure, pulse) were measured Friday
night by staff. Furthermore, vital signs were taken at 0, 4, 8 and 24 hours after the first
dose on Saturdays
2. Adverse events were measured Friday night by staff and during weekdays by
parents, and were reported spontaneously on Saturday evening and Sunday morning
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3. Skin was examined Friday night by staff. Furthermore, nurses assessed each
methylphenidate transdermal system application for skin irritation during the
laboratory day before application and at 0.5, 12 and 24 hours after removal
4. Sleep: Parents rated the child’s sleep during weekdays. On Friday and Saturday
nights in the laboratory setting, nursing staff monitored children hourly between 9:00
PM and midnight and recorded sleep onset
5. Appetite: Parents rated this during weekdays
Notes Sample calculation: no
Ethics approval: yes
Key conclusion of study authors
1. Methylphenidate transdermal system demonstrates efficacy and tolerability
comparable with t.i.d. immediate-release methylphenidate
Comments from study authors
1. All participants had been receiving methylphenidate previously, and this may
explain the small number of side effects
2. Furthermore, tolerability findings cannot be generalised to stimulant-naive
children
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no; however, all
participants had been receiving methylphenidate previously, and this may explain the
small number of side effects
Email correspondence with study authors: July 2014. Emailed study authors to request
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment; no information
about how
Allocation concealment (selection bias) Low risk Double-dummyprocedure: All children re-
ceived patches and capsules each day, with
applicable placebos
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant discontinued the study
during the first week because of worsening
behaviourwhile takingplacebo andwas not
included in the analyses: all other partici-
pants completed the study
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Adverse events: All participants receiving≥
1 dose of medication were included in the
safety analysis
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk Not possible to find the protocol
Vested interest bias High risk Sponsored by a grant fromNoven Pharma-
ceuticals (manufacturer of the MTS)
Conflicts of interest: Dr. Pelham has served
as a consultant for Shire, McNeil, Noven,
Celltech/Medeva, Novartis and Abbott
Laboratories; has received honoraria from
Shire and Janssen and research support
from Shire, Alza, Eli Lilly, Noven and
Cephalon; and holds common stock in
Abbott Laboratories. Dr. Waxmonsky has
served on the Speakers’ Bureau for Novartis
and has received research support from Eli
Lilly and Shire Incorporated. Dr. Hoffman
has served on the advisory board andSpeak-
ers’ Bureau for Shire Pharmaceuticals and
on the Speakers’ Bureau for McNeil. Dr.
Ballow has received research support from
GlaxoSmithKline, Panacos, Boehringer In-
gelheim, Pharmasset, Jacobus and Phar-
mena. Dr. Schentag has served as a consul-
tant for or received support from Noven,
Wyeth,Daiichi, TargantaTherapeutics and
Astellas. Dr. Gonzalez is a full-time em-
ployee of P’Kinetics International Incor-
porated. No other conflicts of interest are
known
Pelham 2014
Methods Three-week, randomised, controlled, cross-over trial with 2 factors - medication and
behavioural intervention - with daily medication changes
1. Methylphenidate
2. Placebo
3. Behavioural treatment
Participants Number of participants screened: not stated
Number of participants included: 48 (44 boys, 4 girls). Participants were randomly
assigned to 1 of 3 different doses of drug condition orders
Number of participants followed up: 47
Number of withdrawals: 1
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Diagnosis of ADHD: DSM-VI (subtypes not stated)
Age: mean 9.35 years (range 5 to 12)
IQ: mean 106.33 (SD 14.61; range not stated)
Methylphenidate naive: not stated
Ethnicity: Caucasian (79%), African American (12.5%)
Country: USA
Setting: Summer Treatment Program
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV ADHD
2. IQ ≥ 80
3. No documented adverse response to, or medical conditions that would
contraindicate use of, methylphenidate
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of 0.15
mg/kg/dose methylphenidate t.i.d.; 0.3 mg/kg/dose methylphenidate t.i.d.; 0.6 mg/kg/
dose methylphenidate t.i.d. and placebo
Mean methylphenidate dosage: not clearly stated: “average doses were 5.4 mg (range =
2.5 - 10), 11 mg (range = 6.25 - 20), and 21 mg (range = 11.25 - 30), respectively”
Administration schedule: 3 time points
Duration of each medication condition: 0.15 mg dose for 4 days, 0.30 mg dose for 4
days and 0.6 mg dose for 3 days, switched daily
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: not stated.
Treatment compliance: “One child’s parents withdrew from the study after 2 days because
of their concerns about possible side effects of the medication”
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale: rated by counsellors, daily
General behaviour
1. IOWA Conners’ Rating Scale O/D: rated by counsellors, daily
Non-serious adverse events
1. Counsellors completed the Pittsburgh Side Effects Rating Scale, daily
2. Study staff monitored ratings for clinically significant adverse events, daily
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors
1. The prototypic child with ADHD could be treated with the equivalent of 0.15
mg/kg methylphenidate (5 mg per dose in the current sample) twice daily-a dose lower
than that used in studies of stimulant treatment in the past 30 years-if he or she is
receiving moderate- to high-intensity behavioural treatment
2. Our data show that stimulant doses can be reduced dramatically if a child is
treated with behaviour modification
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Key conclusion of study authors
1. “Results illustrate the importance of taking dosage/intensity into account when
evaluating combined treatments; there were no benefits of combined treatments when
the dosage of either treatment was high but combination of the low-dose treatments
produced substantial incremental improvement over unimodal treatment”
Comment from review authors
1. Very difficult to understand the real effect of medication because of daily
oscillation of the dose
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; only participants not having any docu-
mented adverse response to methylphenidate were included
Any withdrawals due to adverse events: yes (n = 1)
Email correspondence with study authors: April 2015. We emailed study authors to
request supplemental information but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The children, their parents, and clinical
staff members were uninformed of medi-
cation condition and only the research co-
ordinator, pharmacist and medical direc-
tor had access to the medication order. The
medical director could reveal medication
conditions in cases of severe side-effect re-
ports”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Observers were independent staff mem-
bers whowere not involved in the children’s
treatment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No access to protocol. No description in
clinicaltrials.gov
Vested interest bias Low risk Funded by a grant from the National In-
stitute of Mental Health (MH62946). Dr.
Pelham was funded by grants from the
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National Institutes of Health (MH62946,
MH69614, MH53554, MH69434,
MH65899, MH78051, MH062946,
NS39087, AA11873, DA12414,
HD42080) and the Institute of Education
Sciences (L03000665A). Dr. Fabiano was
supported in part by a Ruth S. Kirschstein
National Research Service Award Predoc-
toral Fellowship (1F31MH064243-01A1)
andby theDepartment of Education, Insti-
tute of Education Sciences (R324J06024,
R324B06045)
Conflicts of interest: not declared
Perez-Alvarez 2009
Methods Twelve-month, randomised, controlled, parallel study with 2 different treatment strate-
gies
A) Participants with a score
>
= 2.5/1.8 on the Swanson, Nolan and Pelham Scale, Fourth
Edition (teacher/parents), were randomly assigned to
1. Concerta
2. Humanistic psychology
3. Concerta + psychology
B) Participants with score < 2.5/1.8 on the Swanson, Nolan and Pelham Scale, Fourth
Edition, were randomly assigned to
1. Humanistic psychology
2. Concerta + psychology
Participants Number of participants screened: not stated
Number of participants included: 150
Number randomly assigned: Concerta + psychology 59, humanistic psychology 59
Number followed up: Concerta + psychology 59, humanistic psychology 59
Number of withdrawals: Concerta + psychology 0, humanistic psychology 0
Diagnosis of ADHD:DSM-IV-TR (combined (67%), hyperactive-impulsive (0%), inat-
tentive 33%))
Age: mean 10 years (range 7 to 14)
Sex: boy:girl 4:1 for those with combined type; 1:3 for those with inattentive type
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Spain
Setting: out-patient clinic
Comorbidity: no
Comedication: no
IQ: > 70
Sociodemographics: not stated
Inclusion criteria
1. ADHD DSM-IV-TR, combined or inattentive type
2. 7 to 15 years
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3. IQ > 70
Exclusion criteria
1. Previous medication or therapy
2. Comorbidity
Interventions Participants were randomly assigned to Concerta + psychology or humanistic psychology
OROS methylphenidate dose: not stated
Administration schedule: not stated
Duration of intervention: 12 months
Titration period: not stated
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanons, Nolan and Pelham, Fourth Edition (18-item): rated at baseline, 6
months and 12 months by teachers and parents
Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Key conclusion of study authors
1. In summary, while further confirmation is awaited, the cognitive PASS assessment
may be a useful tool for better diagnostic and prognostic classification in comparison
with behavioural phenotyping
Comment from review authors
1. In study methods and data extraction, all participants receiving Concerta +
psychology (3A + 2B) were analysed together, as were all participants receiving
humanistic psychology (2A + 1B)
Email correspondence with study authors: June 2014. We received supplemental infor-
mation regarding funding, ethics approval and protocol from the study authors, although
they were not able to send data from the Swanson, Nolan and Pelham Scale, Fourth
Edition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned, but
no information was given to explain how
assignment was done
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No; all planned analyses are described in
the paper
Vested interest bias Low risk Study was not funded. Research was part
of the workday, participants were voluntary
and no funding was needed to implement
the study
Conflicts of interest: none. Investigators are
staff members at institutions (affiliations)
reported in the paper
Pliszka 1990
Methods Four-week, double-blind, cross-over trial, in which children were randomly assigned to
the following
1. Two doses of methylphenidate (low: 0.25 mg/kg to 0.40 mg/kg; and high: 0.45
mg/kg to 0.70 mg/kg)
2. Placebo
Participants Number of participants screened: 79
Number of participants included: 46
Number of participants followed up: 43 (30 without anxiety, 13 with anxiety)
Number of withdrawals: 3. Participants were randomly assigned to different orders of
methylphenidate low dose, methylphenidate high dose or placebo
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 9 years (range not reported)
IQ: > 70
Sex: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: anxiety (30%), oppositional defiant disorder (56.0%), conduct disorder
(23.3%) (Participants who expressed transient anxiety or depression about consequences
of punishment for misbehaviour were considered to not meet the criteria for an over-
anxious disorder)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
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1. DSM-III-R criteria for ADHD
2. Candidate for a stimulant trial
Exclusion criteria
1. None stated
No patients met the criteria for any psychotic or depressive disorder. Participants were
free of medication, as well as any other medical disorder
Interventions A total of 4 weeks of medication. First week always placebo; remaining 3 weeks, partic-
ipant were randomly assigned to different orders of placebo and low- (0.25 mg/kg to 0.
40 mg/kg) and high-dose (0.45 mg/kg to 0.70 mg/kg) methylphenidate. Doses were as
follows: 5 mg and 10 mg for weight < 25 kg; for those overweight, the 2 dose conditions
were 10 mg and 20 mg
Administration schedule: b.i.d., 7:00 AM and 12 noon. Saturday, the dose was adjusted
so that it was given 90 minutes before measurements were taken
Duration of each medication condition: 1 week
Washout before study initiation: not relevant; did not take methylphenidate before
Medication-free period between interventions: 17 hours
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA Conners’ Teacher Rating Scale (both Inattention/Overactivity and
Aggressive subscales): rated weekly by teachers at the end of each week
Notes Sample calculation: no information
Ethics approval: no information
Comments from study authors
1. Data strongly suggest that children who met criteria for ADHD and anxiety are
not children who simply have become “demoralised” by frequent conflicts with parents
and teachers. They represent a distinct subgroup
2. It is unclear from these data whether children with comorbid ADHD and anxiety
form a separate subtype of ADHD, similar to the DSM-III diagnosis of ADD without
hyperactivity, or whether this is a group of children with primary anxiety that may lead
to oppositional behaviour and temper tantrums, and the presence of these symptoms
may lead parents and teachers to report inattention and overactivity when the
symptoms may not be objectively present
3. This study strongly suggests that it is important to control for the presence of
anxiety disorders in research on ADHD
4. Analyses were made on the basis of whether anxiety was present with ADHD. To
meet criteria for anxiety, children had to report the symptoms themselves
Key conclusions of study authors
1. A total of 43 participants completed a double-blind trial of methylphenidate;
participants with comorbid anxiety had a significantly poorer response
2. Results suggest that ADHD with comorbid anxiety may characterise children
with primary anxiety who develop secondary inattentiveness, or may represent a
different subtype of ADHD, perhaps similar to the condition of attention deficit
disorder without hyperactivity, as under DSM-III
3. ADHD participants with anxiety were rated significantly lower on the IOWA
Conners’ Teacher Rating Scale, Inattention/Overactivity subscale, than those without
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anxiety, although the mean score for both groups was well into the disturbed range
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: November 2013. We received from the study
authors supplemental information regarding participants’ intellectual function and fund-
ing and additional data. The raw data no longer exist; therefore we cannot analyse data
from different periods in the cross-over trial, only endpoint data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to placebo and low-
dose and high-dose methylphenidate
Allocation concealment (selection bias) Unclear risk Randomly assigned to placebo and low-
dose and high-dose methylphenidate. Not
stated how investigators allocated partici-
pants to the intervention
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The child, his or her parents, teachers and
research assistants were all blinded to drug
status
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The child, his or her parents, teachers and
research assistants were all blinded to drug
status
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only 3 drop-outs. All other participants
were included in the final analysis
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk The entire outcome as stated in the meth-
ods was reported in the results
Vested interest bias Low risk National Institute of Mental Health
(NIMH)
Conflicts of interest: not declared
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Methods Three-week, randomised, double-blind, placebo-controlled, parallel trial with 3 arms
1. Adderall
2. Methylphenidate
3. Placebo
Participants Number of participants screened: 73
Number of participants included: 58
Number randomly assigned: methylphenidate 20, placebo 18
Number followed up: methylphenidate 19, placebo 16
Number of withdrawals: methylphenidate 1, placebo 2
Diagnosis of ADHD: DSM-IV. Diagnostic Interview Schedule for Children diagnosis
of ADHD (subtype not stated)
Age: mean 9 years (range not reported)
IQ: > 75
Sex: not stated
Methylphenidate naive: methylphenidate 5 (25%), placebo 1 (6%)
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (methylphenidate 14%, placebo 10%), con-
duct disorder (methylphenidate 1%, placebo 2%), anxiety disorder (methylphenidate
20%, placebo 5%)
Comedication: not stated
Sociodemographics: not stated. No significant difference in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Children in grades 1 to 5
2. ADHD according to Diagnostic Interview Schedule for Children
3. IQ > 75
4. ≥ 1.5 SD above the mean for his/her age and sex on the IOWA Conners’ Teacher
Rating Scale, Inattention/Overactivity factor
Exclusion criteria
1. Other medical illness
2. Meeting Diagnostic Interview Schedule for Children criteria for major depression
episode, manic episode or tic disorder
3. History of psychosis or signs of psychosis or significantly depressed mood on the
mental status examination
4. Current treatment consists of non-stimulant psychotropic medication
Interventions Participants were randomly assigned to immediate-release methylphenidate or placebo
Mean methylphenidate dosage: total dose 25.2 mg/d
Administration schedule: 17 (85%) received 2 or more doses
Time points: 1 to 3 times a day: morning, after school and additional noon if needed
Duration of intervention: 3 weeks
Titration period: none
Treatment compliance: not stated. Dosage was adjusted at the end of weeks 1 and 2 via
an algorithm based on teacher and parent ratings
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Outcomes ADHD symptoms
1. IOWA Conners’ Teacher Rating Scale: rated twice daily (morning and afternoon)
Mondays through Thursdays
General behaviour
1. Conners’ Global Index: parent-rated
Non-serious adverse events
1. Multi-Modality Treatment of ADHD (MTA) side effects scale: parent-rated
weekly (Thursday evenings)
Notes Sample calculation: no
Ethics approval: no
Comment from study authors
1. Mean mg/kg dose for methylphenidate non-responders was 0.43, which is less
than the 0.3 mg/kg to 0.8 mg/kg dose known to be required for adequate response in
some children with ADHD
Key conclusion of study authors
1. Both medications were superior to placebo for reducing inattentive and
oppositional symptoms in the classroom and on the Conners’ Global Index
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: January 2014. Supplemental information
received from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned: “We used a random
number generator to determine which of
the 3 groups the child was assigned to”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, children, teachers and treating
physicians were blind to medication status.
Medication was crushed,mixed with a blue
food powder and placed in opaque capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo participants were randomly as-
signed to follow methylphenidate or
Adderall treatment algorithm. The blinded
psychiatrist could not determine the child’s
medication status simply by knowing
which algorithm was being followed. Prin-
cipal Investigator knew the medication sta-
tus of participants
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Incomplete outcome data (attrition bias)
All outcomes
High risk Morning and afternoon IOWA scores were
averaged at the end of the week
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Vested interest bias High risk Research funded by Shire Richwood Incor-
porated
Conflicts of interest: Dr. Browne is
currently with Watson Pharmaceuticals,
Corona, California
Pliszka 2007
Methods Five-week double-blind, cross-over, placebo-controlled trial, conducted to examine elec-
trophysiological effects of methylphenidate on inhibitory control in children with
ADHD
1. Methylphenidate
2. Placebo
Participants Number of participants screened: 12
Number of participants included: 12 (8 boys, 4 girls). Participants were randomly as-
signed to 1 of (not stated) possible drug condition orders
Number of participants followed up: 12
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (100%))
Age: mean 12.3 years (range 9 to 15)
IQ: not stated
Methylphenidate naive: 10
Ethnicity: Caucasian (67%), African American (8%), Hispanic (25%)
Country: USA
Setting: not stated
Comorbidity: oppositional defiant disorder (45%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD, combined type
2. Conners’ Global Index: restless/impulsive ratings ≥ 1.5 SD above the mean for
child’s age and sex on both parent and teacher ratings
Exclusion criteria
1. General Cognitive Ability on DIfferential Abilities Scale > 85
2. Any substance abuse/dependence
3. Any neurological disease
4. Long-term use of any medicine
5. Learning disability
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Interventions Participants were randomly assigned to different possible drug condition orders of 5 mg,
10 mg, 15 mg, 20 mg methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 3 time points
Duration of each medication condition: 7 days
Washout before study initiation: not stated
Medication-free period between interventions: 0
Titration period: none initiated before/after randomisation
Outcomes General behaviour
1. Parents and Teacher Conners’ Global Index (CGI)
Notes Sample calculation: no
Ethics approval: yes; study approved by the Institutional Review Board of the University
Comments from study authors
1. Several limitations of the study should be noted
2. Our sample was relatively small and was composed entirely of children with
ADHD, combined type alone, and no other significant comorbidity other than
oppositional defiant disorder
3. All participants were positive responders to methylphenidate
4. Our sample was too small to examine for effects of sex and ethnicity, and results
should be replicated in a larger sample
Key conclusions of study authors
1. Methylphenidate may improve inhibitory control by enhancing brain
mechanisms that trigger the inhibitory process and make stopping a motor act more
probable (reflected by increased N200) and by increasing attentional resources to the
task when unsuccessful inhibitions occur (as reflected by increased NoGo-P3)
2. These results are consistent with functional imaging studies, suggesting a role for
the right frontal inferior cortex and the cingulate cortex in the pathophysiology of
ADHD
Comment from review authors
1. Although this study includes only good responders to methylphenidate, this
occurred by chance and not by design, as 10 out of 12 were treatment naive
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: May 2014. Study authors could not give us
the necessary data (e.g. separate data for each intervention period); therefore we could
not use Conners’ Global Index data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Double-blind, crossover, placebo-con-
trolled”
Allocation concealment (selection bias) Low risk From email: One investigator was assigned
on the basis of chance; the other remained
blinded
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind. One investigator assigned
on the basis of chance; the other remained
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk One investigator assigned on the basis of
chance; the other remained blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias Low risk Funded by theNational Institute ofMental
Health Grant R01 MH63986
Conflicts of interest: Pliszka received hon-
oraria and research support from Shire and
MacNeil and research support from Ely
Lilly and Cephalon
Quinn 2004
Methods Cross-over trial with 3 interventions
1. Dex,l-methylphenidate
2. Dexmethylphenidate
3. Placebo
Participants Number of participants screened: not stated
Number of participants included: 32. Participants were randomly assigned to possible
drug condition orders
Number of participants followed up: 31 (all boys)
Number of withdrawals: 1
Diagnosis of ADHD:DSM-IV (combined (87.1%), hyperactive-impulsive (9.7%), inat-
tentive (3.2%))
Age: not stated (range 9 to 12 years)
IQ: > 80
Methylphenidate naive: 0%
Ethnicity: not stated
Country: USA and Canada
Setting: out-patient clinic
Comorbidity: (0%)
Comedication: 0% for other medications for ADHD
Sociodemographics: not stated
Inclusion criteria
1. Male, between 9 and 12 years of age
2. Meet DSM-IV criteria for ADHD, as confirmed by the Diagnostic Interview
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Schedule for Children
3. Clinical history of positive response to treatment with ≥ 20 mg/d of dex,l-MPH
for ≥ 1 month
4. Rating > 90th percentile on Parent and Teacher Versions of the Swanson, Nolan
and Pelham ADHD Rating Scale
5. IQ ≥ 80 as assessed by a validated intelligence test
Exclusion criteria
1. Any associated CNS, cardiovascular, renal or respiratory disorder
2. Known sensitivity to methylphenidate or receiving other medication for ADHD
3. Comorbid clinical disorders reported during clinical interview or identified
during administration of the Diagnostic Interview Schedule for Children
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of dex,
MPH, dex,I-MPH and placebo. Both the order of drugs and the dose sequence were
randomly assigned
Mean methylphenidate dosage: d-MPH 2.5 mg, 5 mg or 10 mg; dex,l-MPH 5 mg, 10
mg or 20 mg
Administration schedule: once at 8.30 AM
Duration of each medication condition: 1 day. Interventions were separated by≥ 6 days
Washout before study initiation: 24 hours
Medication-free period between interventions: ≥ 24 hours
Titration period: none
Treatment compliance: administered at the laboratory
Outcomes ADHD symptoms
1. Conners, Loney and Milich (CLAM) Scale: teacher-rated, at 2 hours, 3.5 hours
and 6 hours (CLAM aggressive/defiant, CLAM inattention/overactivity)
2. Conners’ Hyperactivity Index: teacher-rated, at 2 hours, 3.5 hours and 6 hours
Non-serious adverse events
1. Adverse events
2. Average pulse rate also measured
Notes Sample calculation: no
Ethics approval: approved by each centre’s institutional review board
Comments from study authors (limitations)
1. Study was conducted in a laboratory school setting (no healthy participants, high
level of staffing, short and repetitive classroom period compared with a regular
classroom setting)
2. Relatively small sample size
3. Narrow age range
Key conclusions of study authors
1. Efficacy of methylphenidate resides in the d-isomer. Elimination of the i-isomer
does not diminish the efficacy of an acute dose of methylphenidate
2. This study demonstrates that single low (2.5 mg), medium (5 mg) and high (10
mg) doses of dexmethylphenidate match the efficacy of equimolar single low (5 mg),
medium (10 mg) and high (20 mg) doses of dex,l-methylphenidate over a 6-hour
period, based on repeated measurements of a surrogate measure of academic
performance
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
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adverse events while taking methylphenidate before randomisation: yes; included only
children stable on methylphenidate
Email correspondence with study authors: July to August 2014. We contacted study
authors to obtain safety data and supplemental information regarding randomisation,
allocation concealment, blinding, handling of incomplete outcome data and outcomes,
but we were not successful
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised. Both the order of drugs and
the dose sequence were randomly assigned
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Except for first practice day, on which only
participants were blinded, administration
of doses was double-blinded throughout
the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind. Blinded observers rated be-
haviour
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study authors report only 1 respondent
(LTFU), not related to side effects
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk All outcomes reported. No protocol avail-
able
Vested interest bias High risk Study was funded by Celgene
Conflicts of interest: All study authors dis-
closed that they have past and present affil-
iations with the pharmaceutical industry
Ramtvedt 2013
Methods Six-week, cross-over trial with 3 interventions
1. Methylphenidate
2. Placebo
3. Dextroamphetamine
Phases: 3
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Participants Number of participants screened: not stated
Number of participants included: 36. Participants were randomly assigned to 1 of 6
possible drug condition orders
Number of participants followed up: 36 (29 boys, 7 girls) (n = 34 for adverse event data)
Number of withdrawals: 0
Diagnosis of ADHD:DSM-IV-TR (combined (69%), hyperactive-impulsive (3%), inat-
tentive (28%))
Age: mean 11.4 years (range 9 to 14)
IQ: mean 90.9
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Norway
Setting: out-patient clinic
Comorbidity: anxiety/depressive disorder (n = 9, 25%), oppositional defiant disorder (n
= 20, 55%), learning disability (n = 22, 61%) and Asperger syndrome (n = 1, 3%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis rated as > 2 SD above the mean on the Conners’ Rating Scale,
DSM-IV Inattention and/or DSM-IV Hyperactivity-Impulsivity subscales
2. Between 9 and 14 years of age
3. No prior treatment with stimulants
4. Stimulant treatment that has been approved by a paediatrician or psychiatrist
Exclusion criteria
1. Moderate to severe mental retardation
2. Psychosis
3. Brain injury
4. Sensory deficits, motor impairment or both
5. Epilepsy
6. Factors that would substantially reduce the possibility of obtaining reliable
observations from a parent or teacher
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate (30 mg/d to 40 mg/d), dextroamphetamine (10 mg/d to 20 mg/d) and
placebo
Mean methylphenidate dosage: not stated
Administration schedule: methylphenidate, 3 time points (morning, lunch and after-
noon); dextroamphetamine, 2 time points (morning and afternoon)
Duration of each medication condition: 2 weeks (first week: low dose (30 mg/d), second
week: high dose (40 mg/d))
Washout before study initiation: no; all were stimulant-naive
Medication-free period between interventions: yes; Saturday and Sunday (48 hours)
Titration period: 2 weeks initiated after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. DSM-IV Inattention and Hyperactive-Impulsive subscales from Conners’ Rating
Scale - Revised, Long Version, Parent and Teacher Forms
2. 21-item ADHD questionnaire was developed for this study (8 items reflecting
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inattention, 6 items reflecting hyperactive-impulsive behaviour and 4 items reflecting
oppositional defiant behaviour), completed daily from Monday to Friday, every week
by parents and teachers (Ramtvedt 2013)
3. Children’s self-report scale - developed for this study: 8 items, rated weekly by the
children themselves
General behaviour
1. Child Behavior Checklist
2. Teacher Rating Form
3. ADHD questionnaire - Inattentive subscale, teacher-rated
Non-serious adverse events
1. Barkley Side Effect Rating Scale: Parents were instructed to rate side effects in co-
operation with their child at the end of each week during the trial
Notes Sample calculation: not stated
Ethics approval: yes
Comments from study authors
1. Drugs were not camouflaged in identical capsules, increasing the risk for
identification of drug order
2. In only 1 case, a parent identified the drug order with certainty. That particular
child was removed from the study
3. ADHD questionnaire, used to rate ADHD symptoms during the stimulant trial,
was developed for this study and cannot be considered equivalent to well-established
ADHD Rating Scales
4. Sample size might not have been sufficient to detect subtle differences between
stimulants at the group level
Key conclusions of study authors
1. Methylphenidate and dextroamphetamine were significantly effective. No
significant superiority of 1 stimulant over the other was detected at the group level
2. Adverse events associated with dextroamphetamine vs methylphenidate appear
similar at the group level but may differ substantially in individual children
3. Overall, insomnia and decreased appetite were significantly associated with
stimulants
Comments from review authors
1. This does not seem to be a particularly useful paper because the main point (not
explicitly stated) was to obtain an equivalence for the QbTest (measures the 3 core
signs of ADHD). As a result of this, the medication regimen was dedicated to find the
best effects of both medications
2. Study authors stated that the primary outcome measure was developed for the
study and cannot be considered equivalent to known ADHD Rating Scales. Therefore,
we have not used the data on ADHD symptoms in our analyses
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: April 2015. We obtained supplemental in-
formation or data regarding comedication, randomisation and blinding
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly and evenly as-
signed to each of 6 possible drug orders.
“The children were assigned to the six pos-
sible drug condition orders by drawing
numbers”
Allocation concealment (selection bias) Unclear risk Not clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants, parents, teachers and test ad-
ministrators were blinded to drug order.
One parent identified the drug order.
Tablets of similar colours, shapes and tex-
tures were administered, but the drugswere
not camouflaged in identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk No access to protocol
Vested interest bias High risk First phase was conducted as part of ordi-
nary clinical practice at Neuropsychiatric
Unit, Østfold Hospital Trust. Second and
third phases, data analysis and preparation
of manuscript were sponsored by South-
Eastern Norway Regional Health Author-
ity, and also by Østfold Hospital Trust
and National Resource Centre for ADHD,
both under the umbrella of South-Eastern
Norway Regional Health Authority
Conflicts of interest: Henning Aabech is a
member of the Strattera Advisory Board,
Eli Lilly Norway
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Methods Triple-blind, randomised, cross-over trial with 4 interventions
1. Placebo
2. 5 mg methylphenidate
3. 10 mg methylphenidate
4. 15 mg methylphenidate
Phases
1. Week 1: baseline assessment
2. Weeks 2 to 5: cross-over trial
Participants Number of participants screened: 22
Number of participants included: 14 (12 boys, 2 girls)
Number of participants followed up: 11
Number of withdrawals: 1
Number of participants excluded during the study: 2
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: 8.3/7.75 years (range 6 to 10)
IQ: > 100
Methylphenidate naive: not stated
Ethnicity: Caucasian (86%), not stated (14%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
Sociodemographics: Low to middle socioeconomic status
Inclusion criteria
1. DSM-III diagnosis of ADHD by the child’s paediatrician and the clinic’s directing
clinical psychologist
2. Maternal report of a developmental history consistent with ADD-H (Barkley
1981)
3. Maternal rating of ≥ 2 SD above the mean for the child’s age on the Werry-Weiss-
Peters Activity Scale
4. Teacher rating > 15 on the Abbreviated Conners’ Teacher Rating Scale
5. Children showing a favourable response to methylphenidate (≥ 25% mean
increase in classroom on-task behaviour and decrease ≥ 2 SD on the Abbreviated
Conners’ Teacher Rating Scale (compared with baseline levels) during any of the active
medication weeks)
6. Performance on the Matching Familiar Figures Test characteristic of a “fast-
inaccurate or impulsive” responder (i.e. faster than average responses and higher than
average error rates for the child‘s age)
Exclusion criteria
1. Any gross neurological, sensory or motor impairment
2. Those currently taking medication
3. Those classified as non-responders, defined as neither improved
(methylphenidate-induced facilitation ≥ 25%) on the Paired Associates Learning test
nor declined in relation to baseline and placebo
Interventions Participants were randomly assigned to 1 of 24 possible drug condition orders of fixed
doses of methylphenidate (5 mg, 10 mg, 15 mg) and placebo. As a result of the small
sample size, not all drug orders were used. Post hoc comparison showed that doses were
distributed approximately equally across different positions in the sequence
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Administration schedule: once daily, in the morning
Duration of each medication condition: 7 days
Washout before study initiation: none, but all weekly dosage changes occurred on Sat-
urdays to control for potential rebound effects
Titration period: none
Treatment compliance: Both used and unused envelopes with capsules were returned to
control for medication compliance. No results regarding compliance were reported
Outcomes ADHD symptoms
1. Abbreviated Conners; Teacher Rating Scale: Teacher rated symptoms each Friday,
in the morning, or at the end of each treatment condition
2. Dosage changes occurred on Saturdays
No useable data
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusion of study authors
1. Results of the present investigation demonstrate a functional relationship between
psychoactive medication and impulsivity, attention and behaviour of children with
ADD in classroom settings
Comment from review authors
1. Although study authors refer in 1 of the articles to the other 2 articles as a recent
study and a past investigation, it seems to us that these articles discuss the exact same
study
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; included only methylphenidate-favourable
responders
Any withdrawals due to adverse events:no
Email correspondence with study authors: July 2013. Study authors informed us that
original records were shredded after 20 years, and that they could not provide the re-
quested data (Ramstad 2013c [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Order of drug administration was deter-
mined by randomly assigning each child to
1 of 24 possible drug disorders
Allocation concealment (selection bias) Low risk Methylphenidate was packaged by the
pharmacist in coloured gelatin capsules to
avoid detection of dose and taste. Capsules
were placed in individually dated envelopes
to ensure accurate dose administration
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple-blind design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Teachers and observers were blind to when
medicationwas administered andwhat spe-
cific doses were given
Incomplete outcome data (attrition bias)
All outcomes
High risk Data from 2 of 12 children in the present
investigation were not included in the sta-
tistical analyses because they were classified
as non-responders according to results of
the Paired Associates Learning test
Selective reporting (reporting bias) Unclear risk Not possible to receive a copy of the proto-
col
Vested interest bias Unclear risk No information regarding funding
Conflicts of interest: not declared
Rapport 1987
Methods Double-blind, placebo-controlled, cross-over trial with 2 interventions
1. Methylphenidate (5 doses)
2. Placebo
Phases: Five methylphenidate doses were given in a randomly assigned, counterbalanced
sequence. Children received each dose for 6 consecutive days
Participants Number of participants screened: 134. Childrenwere screened for inclusion after referrals
from paediatricians, psychiatrists and school personnel over a 5-year period. Different
publications reported different numbers of included children, ranging from 22 to 76
children. Study authors stated: “this is a sample of children who were recruited across
several years with publications presenting findings over that time period. Thus, there
were slight differences in sample composition as more participants were added. But
essentially these studies included the same sample”. Participants were randomly assigned
to 1 of 4 possible drug condition orders. Different publications reported different figures
for missing data, number of withdrawals and other important information. This was
included in our ’Risk of bias’ assessment and is reported in the ’Risk of bias’ table. One-
day washout (Saturdays) was described in each publication
Age: 10 to 12 years. Reported ages varied across publications but, in most publications,
ranged from 6 to 11 years
DSM-III diagnosis of ADHD (subtype not stated)
IQ: mean 101. DuPaul 1993 stated that children were of average or above average
intelligence
Sex: 37 boys and 5 girls (Rapport 1987)
Methylphenidate naive: 100% (in both Rapport 1987 + DuPaul 1993). In Rapport
1987, 8 had experienced brief trials of stimulants within the previous 4 years
Ethnicity: not stated
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Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: No children were taking medication before participating in the study
(DuPaul 1993 in Rapport 1987)
Sociodemographics: low to middle socioeconomic status (Hollingshead) (Rapport 1987
and DuPaul 1993 in Rapport 1987)
Inclusion criteria
1. Independent diagnosis by the child’s paediatrician and the Rhode Island
Construction Leadership Council (CLC), directing clinical psychologists using DSM-
III criteria for ADHD
2. Maternal report of a developmental history consistent with ADHD and problems
in ≥ 50% of situations on the Home Situations Questionnaire
3. Maternal rating ≥ 2 SD above the mean for the child’s age on the Werry-Weis-
Peters Activity Scale
4. Teacher rating on the Abbreviated Conners’ Teacher Rating Scale > 15 - the
designated cutoff score for hyperactivity
5. Performance on the Matching Familiar Figures Test characteristic of a “fast
inaccurate or impulsive” responder (i.e. faster than average responses and higher than
average error rates for the child’s age)
6. Absence of any gross neurological, sensory or motor impairment as determined by
paediatric examination
We believe that this study consists of 13 articles. When study authors were asked about
that, Dr.DuPaul answered thatmany of the publications based on the Rhode IslandCon-
struction Leadership Council (CLC) Clinic “were fairly the same study”. Even though
some publications describe 6 inclusion criteria and others describe 5, we believe that the
publications are based on the same study (Ramstad 2013b [pers comm])
Interventions Participants were randomly assigned to 1 of 5 possible drug condition orders of
methylphenidate and placebo. Methylphenidate was described by each child’s paediatri-
cian in the following doses: placebo, 5 mg, 10 mg, 15 mg and 20 mg. Fixed doses were
prescribed (rather than mg/kg)
Administration schedule: Children were seen once a week at the Rhode Island Con-
struction Leadership Council (CLC) Clinic. Baseline measures were obtained during the
child’s second clinic visit to allow familiarisation with clinic personnel and testing pro-
cedures. On subsequent testing days, children were administered a capsule of the active
agent (methylphenidate) or placebo. This procedure continued until each child received
each dose for 6 consecutive days. All weekly dosage changes occurred on Sundays, and
no medication was administrated on Saturdays, to allow for needed washout due to
inter-individual variation in serum and blood plasma levels following acute administra-
tion of methylphenidate. All children described in the present study were classified as
favourable responders, whereas those whose performance did not improve to this extent
were classified as non-responders. These criteria were established a priori. All children
described in the present study were favourable responders based on the given criteria.
(Children showing drug-induced facilitation of performance≥ 25% (i.e. a 25% drop in
error rate) compared with baseline or placebo were classified as favourable responders,
whereas those whose performance did not improve to this extent were classified as non-
responders)
Treatment compliance: Rapport 1987 and DuPaul 1993 (in Rapport 1987): Both used
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and unused envelopes were returned to the Rhode IslandConstruction LeadershipCoun-
cil (CLC) on a weekly basis to assess medication compliance. DuPaul 1993 and Denney
1999 (in Rapport 1987): Medication was properly administered nearly 100% of the
time, with “make-up” observation days scheduled after rare occasions when compliance
was not obtained
Outcomes ADHD symptoms
1. Abbreviated Conners’ Teacher Rating Scale: once each week (1.5 to 2 hours after
morning medication)
Non-serious adverse events
1. Data from the Subjective Treatment Emergent Symptom Scale (no data reported
on this scale. Additional data cannot be obtained from study authors)
2. Kelly 1988 (in Rapport 1987) measured heart rate. Each child’s resting heart rate
(average beats per minute) was measured for 5-minute periods at 3 intervals
(immediately before oral ingestion of methylphenidate or placebo (IV), 120 minutes
post ingestion and 180 minutes post ingestion). Each of these measurements was taken
at the same relative time of day (between 2:00 PM and 6:00 PM) and on the same day
of each week throughout the 6-week course of the study
Notes Sample calculation: no
Ethics approval: not stated. From Kelly 1988 in Rapport 1987: believe the study was
approved by the Institutional Review Board IRB at the University of Rhode Island (the
site of the study), but Dr. Rapport could confirm this (Ramstad 2013c [pers comm])
Key conclusions of study authors
1. Group results showed significant medication effects on classroom percentage of
on-task behaviour, academic efficiency, teacher ratings of attention and continuous
performance task omission errors
2. Results indicate that higher dosages are linearly related to increasing levels of rate,
and that these effects are dependent upon both the initial heart rate value and the time
course of medication
3. Methylphenidate had a significant effect on classroom measures of attention and
academic efficiency, which were similar to those of normal control children. Still 25%
of the sample failed to show normalised levels of classroom performance
4. Results of the present investigation show that methylphenidate effects were
generally rate-dependent in the classical fashion (i.e. negative linear relationship
between control response rate and output ratio) for responding that was controlled by
schedules, which engendered both low and high response rates
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; excluded methylphenidate non-responders
Any withdrawals due to adverse events: not stated
Email correspondence with study author: We contacted Dr. Rapport by email (Ramstad
2013c [pers comm]). He has stated that he does not have any supplementary data except
those provided in these articles. We also contacted Dr. DuPaul (Ramstad 2013b [pers
comm])
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Rapport 1987: All children received each of
the 5 methylphenidate doses in a randomly
assigned counterbalanced sequence
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk All methylphenidate and placebo doses
were packaged in coloured gelatin capsules
by the clinic’s pharmacist. Capsules were
sealed in individual daily-dated envelopes.
All teachers were blinded as to time of ad-
ministration and specific dose
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): yes
(4 participants)
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Unclear risk Study was not supported by any funding,
either external or internal. This project was
supported in part by a Biomedical Research
Support Grant (no. S07 RR05712), which
was awarded to the first study author by the
Biomedical Research Support Grant Pro-
gram, Division of Research Resources, Na-
tional Institutes of Health
Conflicts of interest: no information
Rapport 2008
Methods Double-blind, placebo-controlled, 5-week, cross-over trial with 2 interventions
1. Methylphenidate (5 mg, 10 mg, 15 mg and 20 mg)
2. Placebo
Phases: baseline (1 week) and 5 cross-over phases (1 week placebo and 1 week
methylphenidate each)
Participants Number of participants screened: not stated
Number of participants included: 65. Participants were randomly assigned to 1 (of not
stated) possible drug condition order
Number of participants followed up: 65 (58 boys, 7 girls)
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV (all were of the combined subtype)
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Age: mean 8.56 years (SD 1.25; range 6 to 11)
IQ: mean 102.8 (SD 10.0; range not stated)
Methylphenidate naive: Eight had experienced brief trials of stimulant therapy within
the previous 4 years. None were prescribed psychostimulants immediately before the
start of the current study
Ethnicity: Caucasian (100%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: low to middle
Inclusion criteria
1. ADHD diagnosis confirmed by the Kiddie Schedule for Affective Disorders and
Schizophrenia
2. Problems in ≥ 50% of the situations on the Barkley Home Situations
Questionnaire
3. Maternal rating ≥ 2 SD above the mean on the Werry-Weiss-Peters Activity Scale
4. Teacher rating on the ADD/H Comprehensive Teacher Rating Scale ≥ 2 SD
above the mean
Exclusion criteria
1. Conduct disorder; gross neurological, sensory or motor impairment
Interventions Participants were randomly assigned to different possible drug condition orders of im-
mediate-release methylphenidate (5 mg/d, 10 mg/d, 15 mg/d, 20 mg/d) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: once daily, in the morning
Duration of each medication condition: 1 week
Washout before study initiation: None were prescribed psychostimulants immediately
before the start of the current study
Medication-free period between interventions: 1 day
Titration period: none
Treatment compliance: “nearly 100%; envelopes were returned on a weekly basis”
Outcomes Non-serious adverse events
1. Subject’s Treatment Emergent Symptoms Scale of National Institute of Mental
Health (NIMH) (adjusted to children for the children): rated weekly by observer
interviewing parent and child
Notes Sample calculation: not stated
Ethics approval: yes
Comments from study authors
1. Increased frequency and/or severity of emergent symptoms reported by or
observed in children receiving psychostimulant therapy are probable to the extent that
dosing regimens differ from the parameters reported herein, particularly for symptoms
highly specific to methylphenidate, that is, children receiving multiple doses per day,
single doses exceeding 20 mg, different methylphenidate formulations and
methylphenidate over a longer duration of time are likely to experience greater
frequency and/or severity of emergent symptoms
2. Immediate-release methylphenidate formulary is currently used less frequently
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than that of newer formulations, and the generalisability of present findings to long-
duration, sustained-release and other variants is unknown
Key conclusion of study authors
1. Collectively, our findings point to a clear need to develop psychometrically sound
treatment-emergent symptom rating scales for the purposes of monitoring physical and
behavioural complaints of children treated with psychostimulants
Comment from review authors
1. Study authors used a design with a once-daily, immediate-release preparation of
methylphenidate. This seems to be exceptional compared with other studies
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: April 2014. Obtained supplemental informa-
tion regarding data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By email: We used a computer-generated
random assignment (without replacement)
procedure with an additional stipulation
that a nearly equal number of children
had to be assigned to each of the possi-
ble drug condition orders. Children were
entered onto the list as they entered the
study and followed that particular order (of
which coders, parents, teachers and evalu-
ators were unaware throughout the study)
(Magnusson 2014b [pers comm])
Allocation concealment (selection bias) Low risk Same as above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Methylphenidate and placebo dosages were
packaged in coloured gelatin capsules by
the clinic’s pharmacist to avoid detection of
dose and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Rater was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information received by email: no drop-
outs (Magnusson 2014b [pers comm])
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
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Selective reporting (reporting bias) Low risk All outcomes are reported
Vested interest bias Low risk None
Conflicts of interest: nofinancial, corporate
or commercial relationships to disclose
Riggs 2011
Methods Sixteen-week, randomised, 11-centre, parallel-group trial with 2 arms
1. OROS methylphenidate
2. Placebo
Participants in both medication groups received manual-standardised, individual cog-
nitive-behavioural therapy through motivational enhancement approaches throughout
the 16-week medication trial
Participants Number of participants screened: 1334
Number of participants included: 303 (239 boys, 64 girls)
Number of participants randomly assigned: methylphenidate 151, placebo 152
Number of participants followed up in each arm: methylphenidate 151, placebo 152
Number of withdrawals in each arm: methylphenidate 33, placebo 43
Diagnosis of ADHD:DSM-IV (combined (68.6%), hyperactive-impulsive (2.6%), inat-
tentive (28.1%))
Age: mean 16.5 years (SD 1.3; range 13 to 18)
IQ: All participants were cognitively normal
Methylphenidate naive: not stated
Ethnicity: Hispanic (15.2%)
Race: Caucasian (61.7%), African American (23.2%), Asian (1.3%), Native American/
Alaskan (1.0%), other (12.7%)
Country: USA
Setting: out-patient clinic
Comorbidity: major depressive disorder (12.5%), conduct disorder (32.3%), non-nico-
tine substance use disorder (100%)
Comedication: drug/alcohol use
Sociodemographics: not stated
Differences between groups
1. No statistically significant differences in baseline demographics were noted
between the 2 groups
Inclusion criteria
1. Meets DSM-IV diagnostic criteria for ADHD
2. Meets DSM-IV diagnostic criteria for ≥ 1 non-nicotine substance use disorder
3. DSM-IV ADHD Symptom Checklist score ≥ 22 derived from the adolescent-
completed checklist
Exclusion criteria
1. Serious medical illness or cardiac illness
2. History of tic disorder*
3. Pregnant or breastfeeding
4. Meets DSM-IV criteria for current or lifetime psychotic disorder
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5. Meets DSM-IV criteria for current or lifetime bipolar disorder
6. Requires/or prescribed other concurrent psychotropic medication
7. Taking any medications that may produce interactions with OROS
methylphenidate
Opiate dependence
1. Methamphetamine abuse, dependence or past month use
2. Suicidal risk
3. Enrolled in an in-patient, residential, day treatment or out-patient substance
abuse programme within 28 days before signing consent
4. Participation in other substance or mental health treatment
Exploratory analyses of treatment response (ADHD-RS)
1. ADHD subtypes
i) Defined according to DSM-IV criteria (i.e. inattentive subtype with ≥ 6
inattentive symptoms and not ≥ 6 hyperactive-impulsive symptoms)
a) Number of participants excluded: 13 because they did not meet criteria
for a subtype, 14 because they did not meet criteria for hyperactive-impulsive subtype
b) Number of participants included: inattentive subtype 103, combined
subtype 173. Subtypes did not differ with regard to age or ethnicity but did differ with
regard to sex, comorbid conduct disorder, inattentive and hyperactive-impulsive
symptoms and dependence diagnoses
ii) More strictly defined subtypes (i.e. strict inattentive subtype with ≥ 6
inattentive symptoms and ≤ 3 hyperactive-impulsive symptoms; strict combined type
with ≥ 6 inattentive symptoms and ≥ 8 hyperactive-impulsive symptoms)
a) Number of participants included: inattentive subtype 52, combined
subtype 97
2. Major depressive disorder comorbidity
i) 38 participants with major depressive disorder, 265 without major depressive
disorder
ii) Number of participants randomly assigned
a) Methylphenidate: 19 with major depressive disorder, 133 without
major depressive disorder
b) Placebo: 19 with major depressive disorder, 132 without major
depressive disorder
iii) No significant differences between groups were noted with regard to ADHD
symptom severity, comorbid conduct disorder or substance abuse or dependence
diagnoses. Differences between groups were noted with regard to age, sex, court
mandate to substance treatment and days of past-month non-nicotine substance use
3. Comorbid conduct disorder
i) 299 participants included in this analysis. Four were excluded because they
did not have a non-tobacco substance use disorder or did not meet inclusion criteria
for ADHD
ii) Number of participants randomly assigned: methylphenidate 48 with
conduct disorder, placebo 49 with conduct disorder
Interventions Participants were randomly assigned to OROS methylphenidate or placebo
Mean methylphenidate dosage at the end of treatment: 68 mg
Administration schedule: single dose in the morning
Duration of intervention: 16 weeks
Titration period: 2 weeks post randomisation
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Treatment compliance: 79% (pill counts), 82.3% (self reports)
Outcomes ADHD symptoms
1. ADHD Rating Scale, clinician-administered, adolescent informant: rated at
baseline and weekly for 16 weeks
2. ADHD Rating Scale, clinician-administered, parent informant: rated at weeks 8
and 16
Serious adverse events
1. Systematically assessed by medical clinicians during weekly visits
Non-serious adverse events
1. Systematically assessed by medical clinicians during weekly visits
2. Laboratory assessments ascertained at baseline and at 16 weeks included liver
function testing, complete blood count with differential and urinalysis
3. Massachusetts General Hospital Abuse and Diversion Questionnaire, self
administered and completed monthly
4. Massachusetts General Hospital Liking Scale completed at study weeks 4, 8, 12
and 16. Relevant subscales: feeling high, feeling depressed, craving medication, craving
substances
Notes Sample calculation: yes; sample size of 300 participants was calculated for ADHDRating
Scale
Ethics approval: yes; Institutional Review Boards approved the protocol before partici-
pant enrolment
Comments from study authors
1. One participant did not meet diagnostic criteria for ADHD, and 1 did not have a
score ≥ 22 on the ADHD Rating Scale, but both were included in analyses
2. Two participants did not meet diagnostic criteria for a non-tobacco substance use
disorder but were included in analyses
3. Results of this study add to the growing suspicion that CBT (for SUD) may
contribute to ADHD treatment response and warrants further investigation
4. Limitations: This study was not powered to address safety, and no current
consensus exists regarding the most valid outcome measures for ADHD in adolescents
with or without substance use disorder
Key conclusions of study authors
1. OROS methylphenidate did not show greater efficacy than placebo for ADHD or
greater reduction in substance use among adolescents concurrently receiving individual
cognitive-behavioural therapy for co-occurring substance use disorders
2. OROS methylphenidate was relatively well tolerated and was associated with
modestly greater clinical improvement on some secondary ADHD and substance
outcome measures
3. With good monitoring, and in the context of substance abuse treatment, OROS
methylphenidate can be used safely in adolescents with a substance use disorder despite
non-abstinence
4. Higher baseline use of alcohol and cannabis was associated with increased risk of
experiencing a treatment-related adverse event with OROS methylphenidate, but
baseline use did not increase the risk of serious adverse events or of any particular
category of adverse events
5. For adolescent misuse/diversion of OROS methylphenidate, results suggest that
OROS methylphenidate was not misused/diverted to a greater extent than placebo and
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was not impacted by baseline substance use severity
6. Despite baseline differences, both inattentive and combined subtypes responded
equally to treatment, suggesting limited relevance for subtype designation in treatment
planning
7. ADHD symptom severity (based on DSM-IV ADHD Rating Scale) followed a
slightly different course of improvement, although with no differences between the
group with comorbid major depressive disorder and the group without major
depressive disorder in baseline or 16-week symptom severity, or in 16-week reduction:
Presence of major depressive disorder was not associated with ADHD treatment
response in this sample
8. Interaction effects showed that OROS methylphenidate improved substance use
disorder outcomes among adolescents with comorbid conduct disorder compared with
placebo
9. Although severe substance use disorder may require more intensive psychosocial
treatment, OROS methylphenidate may improve substance treatment outcomes
among adolescents with comorbid attention and conduct problems
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Comment from review authors
1. Data are influenced by drug abuse, especially data on adverse events, but no
statistically significant differences between OROS methylphenidate and placebo in self
reported medication abuse were noted
Email correspondence with study authors: December 2013. We obtained supplemental
information (IQ, allocation concealment and detailed description of 1 of the serious
adverse events)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to OROS
methylphenidate or matching placebo in a
1:1 ratio, stratified by site and completed
by computer at a centralised location
Allocation concealment (selection bias) Low risk Product was supplied in pre-randomly as-
signed kits containing individual bottles.
Kits and bottles were labelled with the pro-
tocol number and treatment/randomisa-
tion number. Labeling protected the study,
ensuring that it remained blinded, and in-
dicated that the medication was investiga-
tional
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Sites were provided blinded medication
bottles for each randomly assigned partici-
pant
Masking: double-blinded (participant,
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caregiver, investigator, outcomes assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking: double-blinded (participant,
caregiver, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analyses were ITT, including all
randomly assigned study participants
Completers (N = 227) were not different
from non-completers (N = 76) in baseline
demographic or clinical characteristics, and
the proportion of completers did not differ
by treatment assignment
Selective reporting (reporting bias) Low risk Nomajor violation compared with CT.gov
All pre-specified outcomes of interest have
been reported
Vested interest bias Unclear risk OROS methylphenidate and matching
placebo were supplied to the Clinical Trials
Network contract pharmacy (EMINENT
Services Corporation) by McNeil Con-
sumer and Specialty Pharmaceuticals (dis-
tributor for Concerta), at no cost
Principal investigators are NOT employed
by the organisation sponsoring the study.
NO agreement between principal investi-
gators and study sponsor (or its agents) re-
stricts the principal investigator’s rights to
discuss or publish trial results after the trial
is complete
Conflicts of interest: Some study authors
have received research support from, served
on Speakers’ Bureaus of or acted as consul-
tants for pharmaceutical companies
Rubinsten 2008
Methods Five-day, randomised, double-blind, placebo-controlled, cross-over trial with 4 interven-
tions and 11 possible orders
1. Methylphenidate, in 3 different dosages
2. Placebo
Participants Number of participants screened: 170
Number of participants included: 18. Participants were randomly assigned to 1 of 11
possible drug condition orders
Number of participants followed up: 18 (15 boys, 3 girls)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-IV (combined (28%), hyperactive-impulsive (0%), inatten-
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tive (72%))
Age: mean 9.73 years (range not reported)
IQ: mean 104.44
Methylphenidate naive: 0%
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: not stated
Comedication: no
Sociodemographics: no information
Inclusion criteria
1. Completed the same research protocol in an acute, randomised placebo-
controlled, cross-over trial
2. IQ ≥ 82
3. No current evidence on or history of neurological dysfunction, poor physical
health, uncorrected sensory impairments or history of psychosis
4. At least average reading scores
5. ADHD according to DSM-IV
6. One group of patients needed to have a score < 79 (n = 6)
i) One group had a score between 80 and 89 on the Wide Range Achievement
Test (n = 6 of 9 meeting criterion)
ii) One group had a score ≥ 90 on the Wide Range Achievement Test (n = 6 of
83 meeting criterion)
7. Free of medication for minimum of 24 hours before diagnostic assessment and
participation in the medical trial
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 11 possible drug condition orders of
methylphenidate (10 mg, 15 mg and 20 mg) and placebo
Mean methylphenidate dosage: 0.27 mg/kg, 0.42 mg/kg and 0.58 mg/kg, respectively
Administration schedule: not stated
Duration of each medication condition: 1 day
Washout before study initiation: 24 hours
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Examiner observed the child for possible side effects of medication
Notes Sample calculation: no
Ethics approval: not stated
Comment from study authors
1. This was a sample of small children, so we do not know whether the same results
would hold for adolescents or adults
Key conclusion of study authors
1. We found clear dissociation of methylphenidate functions: Methylphenidate
improved working memory functions but did not improve specific cognitive functions
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such as quantity manipulation. Moreover, methylphenidate showed decreased efficacy
for arithmetic performance in ADHD + developmental dyscalculia, highlighting the
need for additional intervention in this subgroup
Comment from review authors
1. Study authors selected 12 patients from a larger population but did not describe
how this was done
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Master randomisation tables were prepared
by the research support pharmacist at the
hospital using simple randomisation with
restrictions. A balanced block 22designwas
used
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Examiner, psychiatrist, child and child’s
family were not informed about the child’s
randomisation order or daily medication
status until trial completion. Placebo and
activemedicationwere prepared by the hos-
pital pharmacist as powdered and packaged
in an opaque gelatin capsule to prevent
identification of content by colour, taste or
volume. Each child’smedicationwas placed
in an individually named and dated enve-
lope to ensure accurate administration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examiner, psychiatrist, child and child’s
family were not informed about the child’s
randomisation order or daily medication
status until trial completion
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Low risk Research was completed while Dr. Rubin-
sten was a post-doctoral fellow at the Hos-
pital for Sick Children (HSC), in Toronto,
Canada, and was supported by the Roth-
schild Fellowship from Israel. It was un-
dertaken, in part, through funding received
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from the Canadian Institutes of Health
(CIHR: Grant #MOP 64312), a CIHR
post-doctoral fellowship (A-CB), and the
Canada Research Chairs Program (RT)
Samuels 2006
Methods Double-blind, randomised, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 2
Participants Number of participants screened: not stated
Number of participants included: 6. Participantswere randomly assigned to 1 (not stated)
possible drug condition order
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean (not stated)
IQ: mean (not stated)
Sex: not stated
Methylphenidate naive: not stated
Ethnicity: Caucasian (100%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children 5 to 15 years of age
2. Long-term stable dose of stimulant medicine for treatment of ADHD
3. Recruited from local private paediatrician and psychiatric offices
Exclusion criteria
1. Receiving concomitant medication that might increase blood pressure
2. Documented hypertension requiring antihypertensive therapy
Interventions Participants were randomly assigned to 1 (not stated) possible drug condition order of
(not stated) methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: Each childwas kept on his or her previous regimen of treatment
and a corresponding placebo
Duration of each medication condition: 24 hours
Washout before study initiation: 3-day run-in
Titration period: Children were kept on stable medication doses and schedules
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. 24-hour ambulatory blood pressure monitoring (ABPM) was performed on and
off medication
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No separate data were available for methylphenidate
Notes Sample calculation: no
Ethics approval: not stated
Key conclusion of study authors
1. This study provides evidence of a possible negative cardiovascular effect of
stimulant medications in children with ADHD. This potential cardiovascular risk
should be balanced against the beneficial behavioural effects of this class of medication
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: July 2014. Emailed study authors to ask for
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described; “randomized in double-
blind fashion”
Allocation concealment (selection bias) Unclear risk “Randomized in double-blind fashion”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as “double-blind”. All medica-
tions andplacebowere identically packaged
by the research pharmacy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Only participants who successfully under-
went an ambulatory blood pressure moni-
toring study at the end of each phase were
included in the primary analyses
Selective reporting (reporting bias) Unclear risk Protocol not found
Vested interest bias Unclear risk Not stated
Conflicts of interest: not declared
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Methods Twelve-month, parallel RCT with 4 arms
1. Methylphenidate + parent training
2. Methylphenidate + parent support
3. Placebo + parent training
4. Placebo + parent support
Follow-up at baseline (before treatment), at end of titration (3 to 4 weeks) and after 4,
8 and 12 months of treatment
Follow-up study of cohort completing the 12-month RCT: Participants were evaluated
annually for 5 years
Participants Number of participants screened: 302
Number of participants included: 91 included in the RCT (methylphenidate: 37 boys,
9 girls; placebo: 37 boys, 8 girls)
Number of participants randomly assigned: methylphenidate 46, placebo 45
Number of participants followed up: methylphenidate 45, placebo 18
Number of withdrawals: methylphenidate 1, placebo 27
Diagnosis of ADHD: DSM-III-R diagnosis of ADHD (subtype not stated)
Mean age: methylphenidate 8.4 years, placebo 8.3 years (range 6 to 12)
IQ: mean (methylphenidate 110.3; placebo 107.6)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Canada
Setting: research unit at hospital.
Comorbidity: oppositional defiant disorder (methylphenidate 56.5%, placebo 44.4%)
, conduct disorder (methylphenidate 6.5%, placebo 20.0%), anxiety (methylphenidate
21.7%, placebo 24.4%)
Comedication: no
Sociodemographics: Placebo group had a higher score at baseline for psychosocial ad-
versity than those assigned to the methylphenidate group
Psychosocial risk index: methylphenidate 1.5%, placebo 2.7%
Inclusion criteria
Screening
1. Age between 6 and 12 years
2. ≥ 6 of 14 ADHD symptoms on the ADHD Rating Scale (DuPaul 1991a)
3. Parental report of some ADHD symptoms at school
4. No previous treatment with methylphenidate
5. Willingness to participate in a study that involved random assignment to
treatments for ADHD (both pharmacological and non-pharmacological)
6. ≥ 1 parent able to communicate in English.
Diagnostic evaluation
1. Exhibit pervasive ADHD, defined as ≥ 8 of the 14 DSM-III-R criteria for
ADHD, in 1 setting (at home on the PICS, or at school on the Teacher Telephone
Interview (prepared by study authors)) and ≥ 5 ADHD criteria in the other setting
2. History of ADHD symptoms of ≥ 6 months’ duration before the age of 7 years
Final inclusion criteria
1. Exhibit pervasive ADHD, defined as ≥ 8 of the 14 DSM-III-R criteria for
ADHD in 1 setting and ≥ 5 ADHD criteria in the other setting
2. History of ADHD symptoms of ≥ 6 months’ duration before the age of 7 years
3. Estimated full-scale IQ > 80
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4. No primary anxiety or affective disorder
Exclusion criteria
1. Attending a full-time residential or day treatment programme
2. Has received regular medication for a medical problem
3. Chronic medical condition including a severe motor or vocal tic disorder and
Tourette’s syndrome
4. Prior treatment for tics
Interventions Randomly assigned to 1 of the 4 treatment groups after stratification based on comorbid,
conduct or oppositional disorder: methylphenidate + parent training/parent support,
placebo + parent training/parent support
Titration period: 3 to 4 weeks (depending on child’s weight) after randomisation
Mean methylphenidate dosage: target dose 0.7 mg/kg body weight, twice daily
Administration schedule: breakfast and lunch
Duration of intervention: 12 months
Treatment compliance: methylphenidate 80%, placebo 64%
Outcomes ADHD symptoms
1. Parent- and teacher-rated IOWA Conners’ Rating Scale at baseline, at end of
titration and at 4 months
General behaviour
1. Parent- and teacher-rated telephone interview probe (TIP) (Corkum, personal
communication, 1992) questionnaire at baseline and at 4 months. Grouped into 4
factors: inattention, hyperactivity-impulsivity, oppositional behaviour, difficulty
experienced by rater in dealing with typical daily problem situations
Non-serious adverse effects
1. Parent- and teacher-rated questionnaire with 14 common side effects (modified
from Barkley 1990) administered by telephone at baseline, at end of titration and at 4
months. Grouped into 4 factors: affective, overfocusing, physiological and tics. Parent-
rated questionnaire with 16 possible adverse effects (also modified from Barkley 1990)
at annual evaluations (telephone interviews)
2. Height and weight were measured at baseline, at week 3 to 4 and at 4 months in
the RCT, and annually in the follow-up study. Standing height was measured in
centimeters without shoes from floor to vertex of head. Weight in indoor clothing,
without shoes, was measured in kilograms. Baseline and annual measures of height and
weight were ascertained with the same stadiometer
3. Presence and severity of tics were rated at baseline, end of titration, 4 months, 8
months and 12 months by research assistants interviewing parents and teachers.
Moderate and severe Tourette’s-like symptoms were assessed and diagnosed by the
supervising psychiatrist
Notes Sample calculation: yes
Ethics approval: yes
Comments from study authors
1. Current RCT is limited by sample size and by medium statistical power
2. This cannot be generalised to situations in which higher doses of methylphenidate
may be used, or to children with more than moderate tics
3. Instrument used to measure adverse effects was originally designed for short-term
pharmacological studies and could fail to identify potentially long-term health
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concerns in the follow-up study
4. Sample in the follow-up study of previous participants in an RCT would be
biased in favour of adherence relative to a cohort chosen and followed from the time of
identification
5. Infrequent contact with participants and lack of an untreated control group are
additional limitations of the follow-up study
6. Study did not include pubertal staging
Key conclusions of study authors
RCT
1. Positive effects of methylphenidate on behaviour are evident in the classroom, but
with methylphenidate given twice daily, parents did not report that methylphenidate
improved behaviour at home
2. Comorbid anxiety did not appear to influence development of side effects or
behavioural response to methylphenidate when dose was titrated as in standard clinical
practice
3. Doses of methylphenidate based on the typical clinical titration procedure did not
produce significantly more tics than placebo in children with or without pre-existing
(mild to moderate) tics
Follow-up study
1. Psychostimulants improve ADHD symptoms for up to 5 years, but adverse effects
persist
2. Long-term use of high doses of stimulants during a period of 1 to 5 years is likely
to have measurable effects on rate of growth in school-aged children with attention
deficit hyperactivity disorder
Comments from review authors
1. Thiruchelvam 2001 reported no relevant outcome measures for our review; the
article was therefore excluded during the full-text reading process
2. Corkum 1999 was excluded during the abstract reading process
3. Data in both Schachar 1997 and Diamond 1999 are preliminary (interim results
of first 4 months of treatment). Data from the 2 placebo groups (cointervention:
parent training and parent support) and the 2 methylphenidate groups (same 2
cointerventions) are combined (placebo vs methylphenidate). No final report focuses
on ADHD symptoms
4. As participants are allowed to switch from the allocated intervention group during
the study, we can use only data regarding adverse effects
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: September to October 2013. Unfortunately,
they were not able to provide supplemental data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned after stratification
based on the presence of comorbid conduct
or oppositional disorder and assigned to 1
of the 4 treatment groups. Randomly as-
signed based on a random number table
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Allocation concealment (selection bias) Low risk Concealed from the physician and par-
ticipants before randomisation and main-
tained throughout the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants (child, research staff, par-
ents and teachers) were blinded to themed-
ication assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants (child, research staff, par-
ents and teachers) were blinded to themed-
ication assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk No imputationmethod: The effect of treat-
ment was analysed among participants who
adhered to their originalmedication assign-
ment. At the 4-month point, children not
taking any medication were grouped with
those taking placebo. When a participant
switched from placebo to methylphenidate
treatment, they were counted within the
methylphenidate group
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not possible to find protocol
Vested interest bias Unclear risk Medical Research Council of Canada, Na-
tional Health Research Development Pro-
gram of Canada and the Department of
Psychiatry, TheHospital for Sick Children,
Toronto. Placebo pills were provided by
Ciba Geigy, Canada, Ltd
Conflicts of interest: Two study authors
have reported working as consultants for
pharmaceutical companies, and 1 has fur-
thermore received industry-sponsored re-
search grants
Schachar 2008
Methods Single-centre, randomised, double-blind, 3-way cross-over trial with 2 interventions
1. Methylphenidate (immediate-release or extended-release)
2. Placebo
Phases: immediate-release and multi-layer-release
Participants Number of participants screened: not stated
Number of participants included: 18
Number of participants followed up: 17 (15 boys, 2 girls)
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Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV diagnosis of ADHD (combined (100%))
Age: mean 11.3 years (range 6.8 to 15.3)
IQ: ≥ 85
Methylphenidate naive: 5 (29.4)
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: no
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. 6 to 15 years of age
2. IQ ≥ 85 within previous 12 months
3. Mentally and physically competent to provide written informed consent
4. Ability to read, speak and understand English
5. Otherwise able to comply with study protocol
Exclusion criteria
1. Allergic to methylphenidate or amphetamines, or had a history of serious adverse
reactions to methylphenidate or lack of response to methylphenidate
2. Serious or unstable medical illness, comorbid psychiatric illness of sufficient
severity to require treatment or currently receiving psychotropic medications or herbal
treatments
3. Disorders of the sensory organs (particularly deafness), autism, psychosis or any
unstable psychiatric conditions
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of imme-
diate-release and extended-release methylphenidate and placebo
Mean methylphenidate dosage: 31.2 mg/d (SD 11.7 mg/d; range 20 to 60 mg/d), 1.2
mg/kg
Administration schedule: twice daily, in the morning and at noon (4 hours apart)
Duration of each medication condition: 6 days
Washout before study initiation: 1 day
Titration period: none. Participants who were receiving methylphenidate at the time of
study entry received the dose of methylphenidate that they were taking before entry into
the study/duration initiated before/after randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA: parent-rated weekly (8 times in 1 day)
2. Conners’ Continous Performance Task: rated weekly (8 times in 1 day)
Non-serious adverse events
1. Clinical Assessment of Side Effects Scale: parents and teachers separately, rated
weekly 1 day before other assessments
2. Spontaneously reported adverse events: investigator, collected weekly
Notes Sample calculation: no
Ethics approval: yes
Key conclusion of study authors
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1. Both MLR methylphenidate and immediate-release methylphenidate compared
with placebo demonstrated significant improvement on IOWA-C average total score,
with onset of action observable by 1 hour
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Email correspondence with study authors: May 2014. Emailed study authors to ask for
supplementary information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to a treatment se-
quence according to a Latin square
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind; not further described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind; not further described
Incomplete outcome data (attrition bias)
All outcomes
High risk All enrolled participants with data from all
3 treatment phases who did not havemajor
protocol violations were considered evalu-
able for efficacy; all participants were eval-
uated for safety
Selective reporting (reporting bias) Low risk No protocol was published. All pre-spec-
ified outcomes of interest have been re-
ported
Vested interest bias High risk Study was funded by Purdue Pharma
(Canada)
Conflicts of interest: Some study authors
are working for Purdue Pharma
Schulz 2010
Methods Double-blind, randomised, multi-centre, triple cross-over design with 3 interventions
1. Methylphenidate - Ritalin LA 20 mg once daily
2. Methylphenidate - Medikinet Retard 20 mg once daily
3. Placebo
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Participants Number of patients screened: 147
Number of participants included: 147
Number of participants randomly assigned: not stated
Number of participants followed up: 139
Number of withdrawals: 1
Diagnosis of ADHD:DSM-IV diagnosis (combined (55%), hyperactive-impulsive (8%)
, inattentive (37%))
Age: mean 10.2 years (range 6 to 14)
IQ: not stated
Sex: 119 boys, 28 girls
Methylphenidate naive: 0%
Ethnicity: not stated
Country: Germany
Setting: out-patient clinic
Comorbidity: 6.8% (disturbance in social behaviour (2.7%), initial insomnia (0.7%),
oppositional defiant disorder (1.36%), dysphemia (0.68%), encopresis (0.68%))
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD confirmed by Kiddie Schedule for Affective
Disorders and Schizophrenia in the German Version (Delmo et al. 2000)
2. All children had to be on a stable and well-tolerated dose of 20 mg-equivalent
methylphenidate for ≥ 1 month before screening
Exclusion criteria
1. Patients with known previous non-response to methylphenidate
2. Children with relevant somatic or psychiatric comorbidity requiring
pharmacological treatment (e.g. psychosis, major depression)
3. Patients with warnings as described in the prescribing information for Ritalin LA,
including tic disorders
Interventions Pre-randomisation phase and 3 treatment periods of 7 days each. Participants were
randomly assigned to 1 of 6 possible drug condition orders of 20 mg Ritalin LA
methylphenidate, 20 mg Medikinet Retard methylphenidate and placebo
Mean methylphenidate dosage: 20 mg daily
Administration schedule: once daily, morning
Time points: 9:00 AM
Duration of each medication condition: 7 days
Washout before study initiation: none
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) Scale (Wigal 1998) by 3
treatment-blinded observers: rated at 1.5, 3.0, 4.5, 6.0 and 7.5 hours after drug intake
at the end of each treatment week
General behaviour
1. Nisonger Child Behavior Rating Form (NCBRF-TIQ) to assess behaviour in
children (Aman 2002): applied once at the end of each treatment period
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Serious adverse events
1. One serious adverse event was reported: a case of acute appendicitis during
treatment with Ritalin LA. This was judged to be not treatment related
2. Four events were reported as “severe” and drug-related: placebo: 2× aggressive
behaviour; placebo: 1× lack of attention; Medikinet: 1× aggressive behaviour
Non-serious adverse events
1. Monitoring and recording of all adverse events (AEs) by
i) “Non-directive questioning” at every visit
ii) “Regular monitoring of vital signs”
iii) Participant were called by phone every midweek and were asked about
adverse events
iv) Clinical abnormality in blood pressure defined as increase or decrease ≥ 20
mmHg from age-dependent normal values (ages 6 to 9: systolic blood pressure (SBP)
90 mmHg, diastolic blood pressure (DBP) 60 mmHg; age > 10 years: SBP 110
mmHg, DBP 75 mmHg)
Clinically notable increased values for SBPwere recorded under all 3 treatments: 15% on
placebo, 17% on Ritalin LA and 18% on Medikinet. Abnormal increases in DBP were
noted in 5%of patients takingplacebo andRitalin and in3%of patients givenMedikinet.
Abnormal values in SBP among participants who had normal values at screening and at
baseline were recorded in only 7 participants (3 given placebo, 3 taking Medikinet and
2 taking Ritalin LA - as reported in the article). Changes in vital signs were attributed to
sympathomimetic effects of methylphenidate and were not considered clinically relevant
Notes Sample calculation: yes
Ethics approval: yes
Comments from study authors
1. Another factor to be considered a limitation is that all participants were known
methylphenidate responders. This decision was made to ensure that study objectives
regarding efficacy were met. However, it might have led to overestimation of treatment
effect and tolerability in the overall population, as no treatment-naive participants were
included in this trial
2. Individual dose titration as a standard approach in everyday practice was not
allowed during this trial; therefore treatment response might not have been optimal for
all children
3. Inclusion of many other children, all with ADHD, as well as other experimental
factors might have influenced the behaviour of the individual child
4. Encapsulation might have altered the pharmacokinetics of active substances
Key conclusions of study authors
1. Compared with placebo, both Ritalin LA and Medikinet Retard demonstrated
robust treatment effects on core inattentive and hyperactive symptoms for up to 7.5
hours in children with ADHD in a laboratory classroom
2. Treatment with Ritalin LA and Medikinet Retard was generally well tolerated
3. No participant had to discontinue participation in the trial because of adverse
events
4. Although almost every third participant was affected by ≥ 1 adverse event, almost
all adverse events were of mild intensity
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; efficacy trial to
prove non-inferiority of Ritalin LA vs Medikinet Retard. Highly restrictive inclusion
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criterion - responders only. Study authors acknowledge “it might overestimate the treat-
ment effect and the tolerability in the overall population, as no treatment naive patients
have been included in this trial”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was centrally generated
with a validated system that automated the
random assignment of treatment sequences
to randomization numbers in a specified
ratio”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All treating physicians, other site staff, and
patients, as well as data analysts andNovar-
tis in-house personnel, remained blinded
from the time of randomization until
database lock. The raters also did not have
access to information about adverse events
to maintain the blind”; “To ensure blind-
ing of the study, all capsules were overen-
capsulated in an identical optical design”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The scale was rated by three treatment-
blinded observers in the classroom who
were specifically trained on the SKAMP
scale”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomly assigned participants were
included in the intention-to-treat (ITT)
population. Missing values for the primary
endpoint were replaced by the worst value
observed in another participant under the
same treatment at the same assessment
time. For non-inferiority comparisons, the
per-protocol (PP) population consisting of
participants without major protocol viola-
tions was considered primary
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No information
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Vested interest bias High risk Trial aimed at showing efficacy of Ritalin
LA with purpose of obtaining marketing
authorisation
Conflicts of interest: Almost all study au-
thors have received grants, research support
or other kinds of financial support from the
medical industry
Schwartz 2004
Methods Two-week, double-blind, placebo-controlled, cross-over, randomised clinical trial with
2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 44 (37 boys, 7 girls)
Number of participants followed up: 44
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.2 years (range 6 to 12)
IQ: > 70
Methylphenidate naive: 16
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: conduct disorder (39%), oppositional defiant disorder (32%), separation
anxiety disorder (16%), major depression (7%)
Comedication: no
Sociodemographics: income level category, mean 3.7
Inclusion criteria
1. ADHD diagnosis
Exclusion criteria
1. IQ < 70
2. Tourette’s syndrome
3. Pervasive developmental disorder
4. Psychosis.
5. Taking any medication other than methylphenidate
6. Previous intolerance or allergic reaction to any psychostimulant
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of (0.5 mg/
kg) methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: twice per day: morning/noon time points
Duration of each medication condition: 7 days
Washout before study initiation: yes (2 weeks)
Medication-free period between interventions: not stated
Titration period: none stated
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Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Rating Scales - both teacher- and parent-rated
2. Restricted Academic Situation Scale
Non-serious adverse events
1. Actigraphic monitoring of sleep
Notes Sample calculation: post hoc power calculation
Ethics approval: yes
Comment from study authors
1. Good responder participants showed improvement in behaviour when taking
methylphenidate but no difference in sleep-onset latency compared with those given
placebo (average 49 minutes). However, this latency was rather long, and this was an
open trial with no comparison group with poor or no response to methylphenidate
Key conclusions of study authors
1. Methylphenidate induces a 4% reduction in actigraph (slight but significant sleep
disturbance)
2. Children who responded well to methylphenidate did not exhibit increased motor
activity in sleep compared with those who did not respond or who responded poorly
3. Therapeutic efficiency does not come with more sleep side effects
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; exclusion of
children with history of intolerance
Email correspondence with study authors: March to April 2014. We emailed study
authors twice to ask for supplemental information regarding data on ADHD symptoms
but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “After baseline assessments, children ran-
domly received either placebo or (...)”
Allocation concealment (selection bias) Unclear risk Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No protocol identified
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Vested interest bias High risk Grants from Le Fonds de la Recherche en
Santé du Québec and the Canadian Insti-
tutes of Health Research
Conflicts of interest: Yes. Dr. Joober is
a principal investigator on a clinical trial
not related to this study that is sponsored
by AstraZeneca Canada Incorporated, and
receives no direct compensation for this
trial. Dr. Boivin has the following indus-
try financial ties: The Litebook Company
Ltd., Medicine Hat, Alberta, Canada; and
Pulsar Informatics Inc., Vancouver, British
Columbia, Canada
Sharp 1999
Methods Cross-over trial with 3 interventions
1. Methylphenidate
2. Dextroamphetamine
3. Placebo
Phases
1. Three-week medical-free baseline, randomised administration of
methylphenidate, dextroamphetamine and placebo followed by breakfast and lunch
daily
2. Stepwise increase in stimulant dose each week
3. Each phase lasted 3 weeks
4. Dosage range: methylphenidate 10 mg/d to 70 mg/d, dextroamphetamine 5 mg/d
to 30 mg/d
Participants Number of participants screened: 150 (girls)
Number of participants included: 42 girls and 56 comparison boys
Number of participants followed up: 42
Number of withdrawals: 1 girl given placebo at each phase
Diagnosis of ADHD: DSM-IV (subtype not stated)
Mean age: 9.1 years (range 6.0 to 12.7)
Mean IQ: boys 109.3, girls 105.2
Sex: 56 boys, 42 girls
Methylphenidate naive: Elia 1991: 18 out of 48 had no previous stimulant drug treat-
ment; Castellanos 1996: 80% had been previously treated with stimulants
Ethnicity: girls: Caucasian (67%), African American (19%), Hispanic (14%); boys:
Caucasian (73%), African American (21%), Hispanic (4%), Asian (2%)
Country: USA
Setting: out-patient clinic
Comorbidity: 71% boys, 69% girls; oppositional defiant disorder (33% boys, 50% girls)
, conduct disorder (7% boys, 2% girls), major depression (0% boys, 7% girls), separation
anxiety (0% boys, 2% girls), specific phobias (0% boys, 7% girls), trichotillomania (2%
boys, 0% girls), tic disorders not otherwise specified (13% boys, 2% girls), enuresis (18%
boys, 12% girls), reading disorder (5% boys, 8% girls)
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Comedication: not stated
Sociodemographics: SES mean score 48.0 ± 25.8 (girls), 52.4 ± 26.9 (boys)
Inclusion criteria
1. Girls with a history of severe hyperactivity, impulsivity and inattentiveness that
interfered with home and school functioning
2. Symptoms of ADHD present in ≥ 2 settings
3. Conners’ Hyperactivity factor scores from home teachers were ≥ 2 SD greater
than age and sex norms
Exclusion criteria
1. Full-scale IQ < 80 on Wechsler Intelligence Scale for Children - Revised
2. Chronic medical or neurological disease, including Tourette’s disorder and
chronic tic disorders
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of
methylphenidate, dextroamphetamine and placebo
Sharp 1999
Mean methylphenidate dosage: week 1 mean dose 0.45 mg/kg, week 2 mean dose 0.85
mg/kg and week 3 mean dose 1.28 mg/kg
Administration schedule: breakfast and lunch - 5 days per week administered by nurse;
administered by parent on weekends
Elia 1991
Mean methylphenidate dosage: week one 0.9 mg/kg, week two 1.5 mg/kg and week
three 2.5 mg/kg
Administration schedule: 9:00 AM and 1:00 PM throughout the entire week (7 days)
Duration of each medication condition: 3 weeks
Washout before study initiation: 3-week medication-free period before study
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Hyperactivity and Conduct factors score: teacher-rated
2. Wender Utah Rating Scale (WURS): parent-rated
3. Conners’ Abbreviated Teacher Rating Scale (ABTRS): completed weekly
4. Conners’ Teacher Rating Scale (CTRS): completed weekly
General behaviour
1. Child Behavior Checklist (CBCL): parent-rated
2. Woodstock-Johnson Achivement Battery: observer (psychologist)-rated
3. Teachers Report Form (TRF): teacher-rated
4. Conners’ Parent Questionnaire (CPQ): completed weekly by parents
5. Children’s Psychiatric Rating Scale (CPRS): completed weekly by psychiatric staff
6. Activity monitor (measuring truncal motor activity): from 9:00 AM to 4:00 PM
Serious adverse events
Mean beneficial and adverse effects of dextroamphetamine and methylphenidate were
nearly identical for all ratings, including ratings of appetite problems. However, objec-
tively verified significant decreases in body weight (drug main effect, F 10.27; P value =
0.0002) were significantly greater for dextroamphetamine (mean change -1.1 ± 1.0 kg
from baseline; P value = 0.02) than for methylphenidate (-0.4 ± 1.1 kg; not significant)
Stimulant-related adverse effects and body weight
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Non-serious adverse events
1. Subject Treatment Emergent Symptom Scale (STESS): physicians and parents
2. Some items on the CPRS, such as nervous mannerisms and obsessive thinking:
rated as adverse effects (Elia 1991)
3. 24-hour urine and blood studies: at baseline and at third week for each treatment
Notes Sample calculation: no
Ethics approval: no information available
Key conclusion of study authors
1. Sharp 1999
i) Our primary conclusion is that our sample of girls demonstrated very similar
patterns of comorbidity and impairment and identical patterns of drug response
Comment from review authors
1. We need a lot of information on the girls
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: June 2014. We received supplemental infor-
mation from Dr. Castellanos
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Order of medication (methylphenidate,
placebo or dextroamphetamine) was ran-
domly assigned on the basis of a table ad-
ministered by the research pharmacy. Dose
escalationwas fixed, with 2 ranges, depend-
ing on body weight (> or < 30 kg). Three
weeks (1 dose per week) in each phase. For
most children, this was followed by ran-
dom assignment to pemoline vs placebo af-
ter another washout period
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Methylphenidate, dextroam-
phetamine and placebo were packaged in
identical capsules by the NIH pharmacy
and were administered by NH nurses in
double-blinded randomly assigned order
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All ratings were performed blind to treat-
ment assignment
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Did not describe what they did with the
missing data
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol published. All outcomes dis-
cussed were reported
Vested interest bias Unclear risk None mentioned
Conflicts of interest: not declared
Shiels 2009
Methods “3-day, double-blind, placebo-controlled medication assessment”
Participants Number of participants screened: not stated
Number of participants included: 49
Number of participants randomly assigned: not stated
Number of participants followed up: not stated
Number of withdrawals: methylphenidate 0, placebo 0
Diagnosis of ADHD: DSM-IV (combined 35 (71%), hyperactive-impulsive 3 (6%),
inattentive 11 (23%))
Age: mean 10.5 years (range 9 to 12)
IQ: mean 104 (range not stated)
Sex: 80% boys, 20% girls
Methylphenidate naive: not stated
Ethnicity: Caucasian (76%), African American (14%), other (10%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (43%), conduct disorder (22%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV ADHD diagnosis
2. Attending ADHD summer research programme
Exclusion criteria
1. Full-scale IQ < 80
2. History of seizures or other neurological problems or medication to prevent
seizures
3. History of other medical problems for which psychostimulant treatment may
involve considerable risk
4. Current use of psychotropic medications other than for ADHD (i.e.
antipsychotics, mood stabilisers, antidepressants and anxiolytics)
5. History or concurrent diagnosis of pervasive developmental disorder,
schizophrenia or other psychotic disorders
6. Absence of functional impairment
7. Vision or hearing problems that would make it difficult to complete discounting
tasks (or other tasks; data not reported)
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Interventions Participants were assigned to extended-release methylphenidate in “high” or “low” dose
(range 18 to 90 mg/d)
Mean methylphenidate: low dose 39 mg Concerta, high dose 73 mg Concerta
Administration schedule: once daily
Time points: in the morning, 90 minutes before cognitive task
Duration of intervention: 7:30 AM to 5:00 PM, Monday through Thursday
Titration period: not stated
Treatment compliance: not stated
Washout before study initiation: methylphenidate 1 week if taking atomoxetine, 24
hours if taking methylphenidate
Outcomes General behaviour
Impairment Rating Scale (IRS; Fabiano 2006)
Non-serious adverse events
Pittsburgh Side Effects Rating Scale, blood pressure and heart rate assessed daily during
times of peak medication effects
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: none
Key conclusions of study authors
1. These findings provide initial evidence that stimulant medication reduces delayed
discounting among those with the disorder
2. Methylphenidate, an effective pharmacological treatment for ADHD, reduced the
preference for smaller immediate rewards over larger delayed rewards when delays and
rewards were actually experienced by the child. This raises the possibility that stimulant
medication improves real-world behaviour of children with ADHD by altering delay-
related impulsivity
Comment from review authors
1. This study focused on effects of methylphenidate on “delay discounting”, a
function of impulsivity. However, no data are available on the effects of
methylphenidate on ADHD symptoms more generally, nor are data available regarding
side effects or changes in blood pressure and pulse.
Email correspondence with study authors: July 2014. Emailed study authors to request
additional information but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To maintain blinding, participants were
given the same number of opaque capsules
per day regardless of actual MPH dose”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not described
Vested interest bias High risk Not described
Conflicts of interest: “In the past 3 years,
James G. Waxmonsky has served on the
Speakers Bureau for Novartis, received
honoraria from Scepter, and received re-
search support from Eli Lilly”
Silva 2005a
Methods Six-week, randomised, single-blind, placebo-controlled, cross-over trial with 5 interven-
tions
1. Extended-release methylphenidate 20 mg
2. Extended-release methylphenidate 40 mg
3. OROS methylphenidate 18 mg
4. OROS methylphenidate 36 mg
5. Placebo
Participants Number of participants screened: not stated
Number of participants included: 54 (34 boys, 20 girls)
Number of participants followed up: 53
Number of withdrawals: 1
Diagnosis of ADHD:DSM-IV (combined (70.4%), hyperactive-impulsive (1.9%), inat-
tentive (27.8%))
Age: mean 9.4 years (range 6 to 12)
IQ: > 80
Methylphenidate naive: 0%
Ethnicity: Caucasian (63.0%), African American (14.8%), Asian (0%), other (22.2%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children 6 to 12 years old
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2. Meeting DSM-IV criteria for primary diagnosis of ADHD
3. Written consent from parents
4. Treated and stabilised on total daily dose of 20 mg to 40 mg methylphenidate for
≥ 2 weeks before enrolment
5. Females are required to be pre-menarchal, sexually abstinent or using an approved
method of contraception
6. Females of childbearing potential are required to have a negative pregnancy test
before enrolment
Exclusion criteria
1. IQ level ≤ 80
2. Diagnosed with Tourette’s syndrome or a tic disorder
3. Deemed by investigator to be unable to comply with study instructions
4. Significant concurrent medical or psychiatric illness or substance abuse disorder
5. History of sensitivity to methylphenidate
6. History of substance abuse
7. Currently taking atomoxetine
8. Have taken, or is currently taking or planning to take, any investigational drug
within 30 days of study start date
Interventions Participants were randomly assigned to 1 of 10 possible drug condition orders of 20
mg extended-release methylphenidate, 40 mg extended-release methylphenidate, 18 mg
OROS methylphenidate, 36 mg OROS methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: once
Duration of each medication condition: 1 day
Washout before study initiation: 1 day
Medication-free period between interventions: Participants were instructed to continue
to take their regularly prescribed medication Sundays through Thursdays between study
days; no medication was administered on Fridays to avoid possible carry-over effects
during the Saturday treatment period
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale: by blinded raters, -0.5, 0.5,
1, 2, 3, 4, 6, 8, 10 and 12 hours post dose. Primary analysis time point was 2 hours
post dose
Non-serious adverse events
1. Adverse events were assessed throughout the classroom period day
Only 1 adverse event was considered to be drug-related
Notes Sample calculation: yes; 46
Ethics approval: approved by an independent investigational review board
Comments from study authors
1. As available formulations of extended-release methylphenidate contain 11% more
methylphenidate than their OROS methylphenidate counterparts, outcomes might
appear to be biased toward extended-release methylphenidate
2. OROS methylphenidate releases a third bolus of active drug between 8 and 12
hours after dosing, whereas extended-release methylphenidate releases its last bolus at 4
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hours post dose. Hence, outcomes during the last 4 hours of the day might,
theoretically, be biased towards OROS methylphenidate
3. Study was conducted in a controlled laboratory classroom
4. These results are representative of participants who are known responders to
methylphenidate
5. All participants had been previously stabilised on ADHD medication, so they
may have been able to detect a difference between active treatment and placebo
Key conclusions of study authors
1. Efficacy of extended-release methylphenidate 20 mg is similar to that of OROS
methylphenidate 18 mg and 36 mg during the first 8 hours post dose
2. Statistically greater benefits are observed with extended-release methylphenidate
40 mg than with OROS methylphenidate 36 mg and persist through hour 8
3. Active treatments show comparable efficacy from 8 to 12 hours post dose
4. Both doses of each methylphenidate formulation are well tolerated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Email correspondence with study authors: April 2014. Sent an email to study authors
to ask for additional data but have not receive a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel, with the exception of
the nurse, pharmacist or physician dispens-
ing medication, were blinded
Study medications were administered in an
opaque container with a small aperture, so
participants could not see them during ad-
ministration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The Swanson, Kotkin, Agler,M-Flynn and
Pelham Scale was completed by blinded
raters
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol found
Vested interest bias High risk Funding from Novartis Pharmaceuticals
Corporation
Conflicts of interest: All study authors have
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been consultants, have received honoraria
or have worked for Novartis
Silva 2006
Methods Cross-over trial with 2 interventions
1. D-MPH-ER 20 mg once daily
2. Placebo
Phases: 2 cross-over phases
Participants Number of participants screened: not stated
Number of participants included: 54 (38 boys, 16 girls)
Number of participants followed up: 53
Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV (combined (90.7%), hyperactive-impulsive (0%), inat-
tentive (9.3%))
Age: mean 9.4 years (range 6 to 12)
IQ: not stated
Methylphenidate naive: none
Ethnicity: predominantly Caucasian
Country: USA
Setting: laboratory classroom
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Boys and girls
2. Age 6 to 12 years
3. Diagnosed with ADHD
4. Must have been stabilised on methylphenidate 20 mg/d to 40 mg/d for≥ 1 month
5. For girls: pre-menarchal, sexually abstinent or using reliable contraceptive and
have negative urine pregnancy test
Exclusion criteria
1. Investigator deemed IQ below average or evidence of IQ < 80; home-schooled
2. Tourette’s syndrome
3. Tic disorder
4. Significant medical illness
5. Significant psychiatric illness (schizophrenia, bipolar disorder, autism)
6. Parents or guardians unable to understand or follow instructions
7. Taking antidepressants
8. Initiated psychotherapy 3 months before screening
9. Positive urine drug screening
10. Poor response to methylphenidate
11. Currently taking other medications for ADHD
12. Taking or planning to take another investigational drug within 30 days of study
start; previously participated in d-MPH-ER study
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Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 20 mg/
d d-MPH-ER and placebo
Mean methylphenidate dosage: 20 mg/d
Administration schedule: once daily; morning
Duration of each medication condition: 1 week
Washout before study initiation: 1 day
Medication-free period between interventions: 1 day
Titration period: none
Treatment compliance: 100% in laboratory classroom sessions
Outcomes ADHD symptoms
1. SKAMP: once weekly, observer-rated
Non-serious adverse events
1. Recorded adverse events described by parents and children, as well as in
laboratory school setting, 1 day each week
Notes Sample calculation: yes
Ethics approval: not stated
Comments from study authors
1. One of the inclusion criteria in this study was that participants were known to be
currently stable on another methylphenidate preparation
2. We listed all side effects, irrespective of whether they were reported by parent or
child. These were gathered both during the week preceding laboratory observation days
and during the laboratory classroom day
3. We did not systematically analyse compliance data during the week preceding the
laboratory classroom
Key conclusion of study authors
1. In this study, once-daily d-MPH-ER 20 mg was a safe and effective treatment for
paediatric participants with ADHD symptoms
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes
Any withdrawals due to adverse events: yes; 1 (during placebo)
Email correspondence with study authors: June 2014. Sent twice to study author to ask
for additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned by
computerised random number assignment
Allocation concealment (selection bias) Low risk Study medication comprised 1 bottle of 5
capsules of blinded study medication or 1
bottle of 5 matching placebo capsules
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Study medication com-
prised 1 bottle of 5 capsules of blinded
study medication or 1 bottle of 5 matching
placebo capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Three independent blinded raters
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety population consisted of all partici-
pants who received≥ 1 dose of study med-
ication. Efficacy population comprised all
randomly assigned participants who pro-
vided valid efficacy measurements for both
treatment periods
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias High risk Financed by Novartis
Conflicts of interest: Some study authors
have affiliations with medical companies
Silva 2008
Methods Randomised, multi-centre, double-blind, placebo-controlled, cross-over design with 2
interventions
1. d-MPH-ER
2. Placebo
Participants Number of participants screened: 68 (45 boys, 23 girls)
Number of participants included: 68
Number of participants followed up: 67
Number of withdrawals: 1 (from the placebo group)
Diagnosis of ADHD: DSM-IV (combined (82.4%), hyperactive-impulsive (0%), inat-
tentive (17.6 %))
Age: mean 9.5 years (range 6 to 12)
IQ: > 70
Methylphenidate naive: none
Ethnicity: Caucasian (50%), African American (22.1%), Asian (0%), Hispanic (19.1%)
, other (8.8%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
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1. 6 to 12 years of age
2. DSM-IV diagnosis of ADHD
3. Participants had to be clinically and behaviourally stable in the opinion of the
referring physician and the site’s principal investigator
4. Have taken their current dose of medication without adjustment for ≥ 2 weeks
(this was required to be a total daily dose or nearest equivalent of methylphenidate 40
mg or immediate-release d-MPG 20 mg (Concerta 36 mg was allowed))
5. Parents and/or guardians had to provide informed consent
6. Female participants were required to be pre-menarcheal or sexually abstinent, or
had to be using an adequate and reliable contraceptive method (e.g. double-barrier
method), which was documented in the medical record. Girls who were sexually active
were required to have a negative result on a urine pregnancy screening test
Exclusion criteria
1. Children were excluded if they or their parents/guardians were unable to
understand or follow instructions necessary to participate in the study
2. If they were deemed by the investigator to have below-normal cognitive capacity,
or if they were home schooled
3. Diagnosed with Tourette’s disorder or a tic disorder, or had a history of, or
concurrent, significant medical or psychiatric illness or substance abuse disorder
4. Children taking an antidepressant medication, those who initiated psychotherapy
within the 3 months preceding screening and those with a positive urine drug screen
5. Also excluded were children with poor response or intolerance to
methylphenidate, who were currently taking other medications for ADHD or were
taking or planning to take any other investigational drug within 30 days of study start
or who had previously participated in d-MPH-ER studies
Interventions Participants were randomly assigned to d-ER-MPH or placebo
Mean methylphenidate dosage: 20 mg/d
Administration schedule: once daily, in the morning
Duration of each medication condition: 7 days
Washout before study initiation: 2 days
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Combined score on the Swanson, Kotkit, Agler, M-Flynn and Pelham Scale:
measured at time points 1, 3, 4, 5, 7, 9, 10, 11 and 12 hours post dose by independent
blinded raters. Rated at practice day (0), period 1 (visit day 7) and period 2 (visit day
14), and at final visit (visit day 15)
2. Attention and deportment scores on the Swanson, Kotkit, Agler, M-Flynn and
Pelham Scale, obtained from 0.5 hours up to 12 hours by independent blinded raters.
Rated at practice day (0), period 1 (visit day 7) and period 2 (visit day 14), and at final
visit (visit day 15)
3. Combined score on the Swanson, Kotkit, Agler, M-Flynn and Pelham Scale,
measured at time point 0.5 by independent raters. Rated at practice day (0), period 1
(visit day 7) and period 2 (visit day 14), and at final visit (15)
Non-serious adverse events
1. Vital signs obtained at practice day (0), period 1 (visit day 7) and period 2 (visit
day 14), and at final visit (15)
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2. Recording of spontaneously reported adverse events
Notes Sample calculation: no
Ethics approval: yes
Comment from study authors
1. Unequal carry-over effects: As a result of the design used in this study, a test for
carry-over effects could not be performed. Instead, tests of sequence effects in the
analysis of the co-variance model were examined. If tests on sequence factors among
time points were statistically significant (P value = 0.05), analyses were performed by
each period
Limitations
1. Each participant took d-MPH-ER for only 1 week
2. Only 1 dose (20 mg/d) was used, meaning that results may not be generalisable to
other doses
3. Study was confined to school-aged children, so applicability of results to pre-
school children, adolescents or adults is unknown
4. All participants in this study had been previously shown to respond to and
tolerate methylphenidate or D-MPH
5. Children who received placebo during the week before the laboratory classroom
day showed statistically better pre-dose performance than children who received active
medication on all measures except the Swanson, Kotkit, Agler, M-Flynn and Pelham
Scale
Key conclusions of study authors
1. In this study, once-daily d-MPH-ER 20 mg was effective in treating both
inattentive and behavioural symptoms in paediatric patients over a 12-hour laboratory
classroom day
2. Primary efficacy variable - combined score on the Swanson, Kotkit, Agler, M-
Flynn and Pelham Scale - showed significant superiority over placebo at all time points
from 1 to 12 hours
3. Secondary efficacy variables indicated that onset of effect was rapid (0.5 hours)
and duration of effect was relatively long (12 hours post dose)
4. In this sample, the drug was safe and well tolerated
5. Changes in vital signs were comparable with those of placebo
Inclusion of methylphenidate responders only/exclusion of MPH non-responders/chil-
dren who have previously experienced adverse events while taking methylphenidate be-
fore randomisation: yes
Email correspondence with study authors: October 2013. We received supplemental
information from study authors regarding ethics approval and data. We were not able to
obtain first period data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment
Allocation concealment (selection bias) Unclear risk No information
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study medications were identical in ap-
pearance for blinding purposes; double-
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety population consisted of all partici-
pants who took ≥ 1 dose of study medica-
tion. Efficacy population included all ran-
domly assigned participants who provided
valid efficacy measurements for both treat-
ment periods
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Outcomes according to protocol
Vested interest bias High risk Funded by Novartis Pharmaceuticals Cor-
poration
Conflicts of interest: Some study authors
have affiliations with medical companies
Smith 1998
Methods Main study
Eight-week intensive Summer Treatment Program, including a 6-week, double-blind,
cross-over trial with 4 interventions
1. Three different doses of methylphenidate
2. Placebo
Follow-up study
Retrospective follow-up study of 16 individuals who completed double-blind, placebo-
controlled, cross-over studies during 2 separate Summer Treatment Programs
Participants Main study
Number of participants screened: not stated
Number of participants included: 49
Number of participants followed up: 46 (41 boys, 5 girls)
Number of withdrawals: 3
Diagnosis of ADHD: DSM-III-R
Age: mean 13.8 years (range 12 to 17)
IQ: mean 101 (range 65 to 129)
Methylphenidate naive: 28%
Ethnicity: Caucasian (85%), African American (15%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (50%), conduct disorder (15%)
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Comedication: no
Sociodemographics: median family income US $38,500
Inclusion criteria
1. Meeting DSM-III-R diagnostic criteria for ADHD
2. 12th birthday before the protocol began
3. Verbal IQ > 80
4. No conditions that precluded a trial of stimulant medication or full participation
in Summer Treatment Program academic and athletic activities
Exclusion criteria
1. No information
Follow-up study
Number of participants included: 16 (all boys)
Number of participants followed up: 16
Number of withdrawals: none
Diagnosis of ADHD: DSM-III-R
Age: mean (children) 10.2 years (range 8 to 11); mean (adolescents) 12.7 years (range
12 to 14.5)
IQ: mean (children) 109; mean (adolescents) 107
Methylphenidate naive: 4 (25%)
Ethnicity: Caucasian (100%)
Country: USA
Comorbidity: not stated
Comedication: not stated
Sociodemographics: family income (children US $37,943; adolescents US $49,650)
Inclusion criteria
1. Meeting DSM-III-R diagnostic criteria for ADHD
2. Younger than 12 years old when they participated in the children’s Summer
Treatment Program
3. Older than 12 years old when they participated in the adolescent Summer
Treatment Program
4. Full-scale IQ > 80
5. No learning disabilities or physical condition that precluded full participation in
Summer Treatment Program classroom activities, athletic activities or a trial of
stimulant medication
Exclusion criteria
1. No information
Interventions Main study
Participants were randomly assigned to 1 of the possible drug condition orders of 25
mg/d, 50 mg/d or 75 mg/d methylphenidate and placebo
Mean methylphenidate dosage: 0.17 mg/kg
Administration schedule: 3 times a day: 7:45 AM, 11:45 AM, 3:45 PM
Duration of each medication condition: 6 days
Washout before study initiation: 2 weeks
Medication-free period between interventions: 16 hours
Titration period: none
Treatment compliance: not stated
Follow-up study
Participants were randomly assigned to 1 of the possible drug condition orders of 0.3
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mg/kg methylphenidate and placebo
Mean methylphenidate dosage: 0.3 mg/kg
Administration schedule: twice a day: 8:00 AM and 12:00 PM
Duration of each medication condition: 1 day
Washout before study initiation: 2 weeks
Medication-free period between interventions: 20 hours
Titration period: none
Treatment compliance: not stated. Adolescentswere evaluated on aprotocol that included
placebo and 3 doses of methylphenidate. To facilitate comparison, doses for adolescents
were converted to milligrams per kilogram, and the dose closest to 0.3 mg/kg was used
in this study
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale (subscale: Inattention/Overactivity): completed
every day by counsellors and classroom teachers
General behaviour
1. IOWA Conners’ Rating Scale (subscale: Oppositional Defiant): completed every
day by counsellors and classroom teachers
Non-serious adverse events
1. Smith 1998: Side effects rating form (rating 12 potential side effects associated
with stimulant medication on a 4-point scale. A side effect rating of 3 (severe) was
defined as troubling enough to contraindicate that dose of medication): completed
every day by counsellors and parents during medication assessment
2. Evans 1997: Ratings on major side effects associated with MPH: completed each
day by classroom teachers
Notes Sample calculation: no
Ethics approval: not stated
Comments from study authors
Main study
1. One participant had a full-scale IQ of 65 but was judged to be sufficiently
intelligent to understand the behavioural contingencies, activity rules and social skills
training provided in the programme
2. Comment on high response rate in this study compared with other studies of
adolescents with ADHD
i) Higher response rate in this study may be due to greater statistical and
methodological power to detect medication effects compared with previous studies,
including (1) a larger sample, (2) a broader range of doses, (3) measurement in a well-
controlled, naturalistic setting, (4) repeated replications of medication conditions and
(5) a statistical cutoff of 0.5 to define a positive response to medication
Follow-up study
1. For data compared in this study, randomisation and medication administration
procedures were identical for children and adolescents, except that adolescents were
evaluated on a protocol that included placebo and 3 doses of methylphenidate. To
facilitate comparison, doses for adolescents were converted to milligrams per kilogram,
and the dose closest to 0.3 mg/kg was used in this study
2. Sample included only Caucasian males
3. Only one third of participants in the adolescent programme had completed the
summer treatment programme for children
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4. Students exhibited a much higher than expected positive response to stimulant
medication
Key conclusions of study authors
Main study
1. Results show that the shape of the dose-response curve is influenced by the
measurement method; most adolescents exhibited improved social behaviour when
treated with methylphenidate, most positive effects of methylphenidate were achieved
at the lowest dose and diminishing positive effects and increasing risk of negative
effects were noted with successively higher doses
Follow-up study
1. Stimulant medication is equally effective with children and adolescents with
ADHD who are engaged in similar activities
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study authors: September 2014. We contacted study authors
twice to ask for supplemental information/data but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Medication conditions were randomly as-
signed daily, with each condition occurring
once a week. Thus, adolescents received a
mode of 6 replications of each medication
condition
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind; no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind; no further information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Somemissing data was caused by holidays
or absences from the program”
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias Low risk Supported by grants from the National In-
stitute on Drug Abuse, the National Insti-
tute of Mental Health, the National Insti-
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tute on Alcohol Abuse and Alcoholism and
the National Institute of Child Health and
Human Development
Conflicts of interest: not declared
Smith 2004
Methods n-of-1 randomised, double-blind, cross-over trial investigating the effects of Ritalin on
the disruptive behaviour of a child diagnosed with ADHD. One-day antecedent anal-
ysis in the clinic followed by an extended school-based trial, during which participants
received methylphenidate or placebo before evaluation
Duration: 15 days
Participants Number of participants screened: not stated
Number of participants included: 1 boy
Number of participants followed up: 1
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV (subtype: not stated)
Age: 11 years
IQ: 124
Methylphenidate naive: no
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participant was randomly assigned to 1 of 2 possible drug condition orders of (20 mg/
d) immediate-release methylphenidate and placebo
Out-patient clinic setting, duration1day: ingestion of 20mgmethylphenidate or placebo
45 minutes before evaluation (randomised)
Cross-over 4 hours later followed by second evaluation
School setting: 15 days (3 school weeks)
Administration schedule: once daily, mornings, 45 minutes before first evaluation
Medication-free periods: on weekends; a total of 9 days with medication and 6 days
without, randomly assigned throughout the trial period
Titration period: no
Washout period before study initiation: none other than weekends
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition - School Version (18 items): completed by
the teacher and an independent observer in the classroom. Classroom assessments were
conducted within normal classroom activities in the morning (first 4 hours of school).
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Mean inter-rater reliability 79% (range 56% to 100%)
Notes Sample calculation: no
Ethics approval:not stated
Comments from study authors
1. A major problem with single data point analyses is the difficulty involved in
generalising outcomes to other settings and times
2. Another difficulty involved inclusion of only 1 participant. However, the
objectivity of clinic data in combination with checklist outcomes provides generalisable
results, which reduces some of these limitations
Key conclusion of study authors
1. The investigation suggests that the 1-day antecedent analysis procedure could be
used as an initial evaluation of the use of Ritalin
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondencewith study authors:October 2013.We received from study authors
supplemental information regarding diagnostic criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A third party, who was not involved in the
clinical procedure, determined the selec-
tion of actual medication packs
Allocation concealment (selection bias) Low risk A third party, who was not involved in the
clinical procedure, determined the selec-
tion of actual medication packs
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk A third party, not involved in the clin-
ical procedures, determined the selection
of actual medication packs. Thus, per-
sons conducting the direct evaluation were
blinded to all medication manipulations (i.
e. the child, parents, therapists and data
collectors). However, no description was
provided about whether medication and
placebo pills were identical. “Prior to clin-
ical assessment, two packets of medication
were provided to the participant’s parent.
One package contained 20 mg of Ritalin
and the other package contained a placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A third party, who was not involved in the
clinical procedure, determined the selec-
tion of actual medication packs. Thus, per-
sons conducting the direct evaluation were
blinded to all medication manipulations (i.
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e. the child, parents, therapists anddata col-
lectors)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol identified and no email from
study author
Vested interest bias Unclear risk Not stated
Smithee 1998
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 26 (20 boys, 6 girls)
Number of participants followed up: not stated
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-IV (combined (77% ), inattentive (23%))
Age: mean 9.63 years (range 6.5 to 12)
IQ: mean 99.71
Methylphenidate naive: 24
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant/conduct disorder (n = 13a), anxiety disorders (n =
13), nocturnal enuresis (n = 4), vocal tics (n = 4), motor tics (n = 3)
Comedication: not stated
Sociodemographics: middle class status; mean social class of 2.12
Inclusion criteria
1. 6.5 to 12 years of age
2. Full-scale, verbal or performance IQ
>
= 85
3. Normal or corrected vision and hearing
4. No physical handicaps
5. No history of psychotic or neurological disorder
6. No previous psychotropic treatment except for brief interventions of at most a
couple of months (n = 2)
Exclusion criteria
1. None stated
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 0.78 mg/kg/d
Administration schedule: 3 times daily for 14 days per medication conditions
Time points: morning, noon and 4:00 PM
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Duration of each medication condition: 14 days
Washout before study initiation: not stated
Medication-free period between interventions: no
Titration period: on days 1 to 3, participants received a dose 2.5 mg below their target
dose of 0.3 mg/kg b.i.d. On days 4 to 7, dose was raised to 0.3 mg/kg b.i.d., and on day
8, the 4:00 PM dose was added
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Abbreviated Conners’ Hyperactivity Questionnaire, parent and teacher: before
trial and at each phase of 14 days
2. IOWA, parent and teacher: before trial and at each phase of 14 days
3. Hyperactivity Attention and Aggression Scales of the TOTS, parent and teacher:
before trial and at each phase of 14 days
Non-serious adverse events
1. Weight with clothes but without shoes: observer, before and last day of each phase
2. Interview to assess the presence of side effects: 11 somatic side effects and 3 mood
problems
3. Appetite decrease, increased thirst, dry mouth, stomachaches, nausea, headaches,
dizziness, tremors, drowsiness, sleep problems, tics, crying, anger and sadness, EEG
Relatively few side effects were reported, probably in part because of adjustment in
dosages in response to emergent symptoms
Notes Sample calculation: no
Ethics approval: not stated
Comment from study authors
1. Teachers tended to detect greater improvement with medication than did parents.
Nevertheless, both parents and teachers detected significant improvement with
treatment
Key conclusion of study authors
1. Stimulant treatment increased accuracy and speed among younger children and
curtailed variability of reaction time for the sample as a whole. However,
methylphenidate did not affect ERPs. In combination, results imply that enhancement
of performance by methylphenidate does not involve the demands of response selection
examined in this trial
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with trial authors: March 2014. We received supplemental data
from trial authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Medications were administered in random
order
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medications were administered in random
order, under double-blind conditions; cap-
sules of identical appearance and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At the end of each phase, an investigator
blind to pharmacological conditions ad-
ministered a structured interview to the
child’s parent concerning emergent side ef-
fects in the preceding period
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reports of side effects led to bind
reduction of dosages or omission of
planned increments for 3 participants un-
der methylphenidate
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Table with numbers of reported somatic ef-
fects not given
Vested interest bias Low risk Research supported by National Institute
of Mental Health (NIMH) Grant MH
38228; Rafael Klorman
Conflicts of interest: not declared
Solanto 2009
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: week-long exposure to placebo and to each of 3 different dosage regimens of
immediate-release methylphenidate
Participants Number of participants screened: not stated
Number of participants included: 30
Number of participants followed up: 25
Number of withdrawals: 5
Diagnosis of ADHD: DSM-IV (combined (60%), inattentive (40%))
Age: not stated
IQ: not stated
Sex: not stated
Methylphenidate naive: All but 1 were stimulant-naive
Ethnicity: not stated
Country: USA
Setting: hospital
Comorbidity: oppositional defiant disorder (combined 13%, predominantly inattentive
20%); learning disability (combined 40%, predominantly inattentive 20%); anxiety
(combined 0%, predominantly inattentive 10%)
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Comedication: no
Sociodemographics: minority representation (combined 53%, predominantly inatten-
tive 20%)
Inclusion criteria
1. Between 7 and 12 years of age
2. Concordant reports: Conners’ Parent Rating Scale and Conners’ Teacher Rating
Scale - Combined group T scores
>
= 65 on both DSM-IV Inattentive and DSM-IV
Hyperactive-Impulsive Scales
3. Predominantly Inattentive group T scores
>
= 65 on the DSM-IV Inattentive Scale
and < 65 on the DSM-IV Hyperactive-Impulsive scale
4. Diagnosis of ADHD, combined or predominantly inattentive according to a
structured diagnostic interview of the parent: Diagnostic Interview Schedule for
Children and Adolescents
5. Expert clinical diagnosis of ADHD based on review of all information collected
Exclusion criteria
1. Currently receiving psychotropic medication
2. Wechsler Intelligence Scale for Children, Third Edition: < 80
3. Mood disorder, Tourette’s disorder or psychotic disorder
4. Sensory impairment or chronic medical or neurological condition including
asthma that required systemic medication
5. Colour blindness
Interventions Participants were randomly assigned to 1 of 24 possible drug condition orders of low-
dose, medium-dose and high-dose methylphenidate and placebo
Mean methylphenidate dosage (Combined vs predominantly Inattentive): low dose 0.
50 ± 0.12 vs 0.44 ± 0.13; medium dose 0.83 ± 0.20 vs 0.73 ±-0.21; high dose 1.54 ± 0.
31 vs 1.40 ± 0.38
Administration schedule: 3 times daily: morning, midday and 3:00 PM
Duration of each medication condition: 1 week
Washout before study initiation: not required
Medication-free period between interventions: no
Titration period: open-label lead-in week, not specified whether before or after randomi-
sation of treatment
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale, parent and teacher: baseline and end of each
medication phase
2. Conners’ Teacher Rating Scale, parent and teacher: baseline and end of each
medication phase
3. ADHD Rating Scale, Fourth Edition: observer, weekly
Non-serious adverse events
1. Height, weight and vital signs: observer, weekly
2. Side Effects Rating Scale: observer, weekly
Notes Sample calculation: no
Ethics approval: not stated
Key conclusion of study authors
1. Results support the clinical utility of methylphenidate in the treatment of
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predominantly inattentive subtype and provide no evidence of differences in response
between subtypes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: April 2014. We received supplemental infor-
mation from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Double-blind, cross-over with week-long
exposure to placebo and each of 3 differ-
ent dosage regimens of immediate-release
methylphenidate in randomly assigned or-
der
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, cross-over with week-long
exposure to placebo and each of 3 differ-
ent dosage regimens of immediate-release
methylphenidate in randomly assigned or-
der. Study medications were prepared and
coded by the hospital pharmacy using iden-
tical gelatin capsules for active medication
and placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Across the 4 placebo and drug conditions,
data points were missing as follows: Parent
Conners’ 1%,TeacherConners’ 6%, Parent
SKAMP 1%, Teacher SKAMP 4%, Side
Effects 0%. Missing scores were replaced
by the mean of scores for that group in that
condition
Selection bias: titration conducted but un-
clear whether before or after randomisa-
tion. No participants were excluded after
the 1-week titration period
Selective reporting (reporting bias) Low risk Protocol identified; all outcomes reported
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Vested interest bias High risk No information
Conflicts of interest: Three study authors
have served or received grants from phar-
maceutical companies in the past
Stein 1996
Methods Five-week, triple-blind, placebo-controlled, cross-over trial with 4 interventions
1. Methylphenidate twice daily
2. Methylphenidate 3 times daily
3. Methylphenidate titration
4. Placebo
Participants Number of participants screened: not stated
Number of participants included: 25 (all boys)
Number of participants followed up: 24
Number of withdrawals: 1
Diagnosis of ADHD: DSM-III-R (combined (88%), inattentive (12 %))
Age: mean 8.0 years (range 6 to 12)
IQ: not stated
Methylphenidate naive: 44%
Ethnicity: Caucasian (96%), Hispanic (4%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (28%), conduct disorder (12%)
Comedication: no
Sociodemographics: Hollingshead SES category I: 8 (33%), II: 8 (33%), III: 3 (12.5%)
, IV: 5 (20.8%)
Inclusion criteria
1. DSM-III-R ADHD diagnosis from parent interview using Disruptive Behavior
Disorders module of the NIMH Diagnostic Interview Schedule for Children - Parent-
rated (DISC-P)
2. Clinically significant ratings on Conners’ Parent Rating Scale for Impulsivity/
Hyperactivity factor (T > 65) or on Child Behavior Checklist (parent form)
3. Attention factor (T > 65)
4. Teacher ratings below 20th percentile for attention or hyperactivity problems on
the ADD-H Teacher Rating Scale (ACTeRS)
Exclusion criteria
1. History of significant developmental delay (indicated by IQ testing or special
educational services)
2. Diagnosis of pervasive developmental disorder
3. Unwillingness of parents or school personnel to meet study requirements
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 8.8 mg, 0.3 mg/kg/dose
Administration schedule: twice/3 times daily: 8:00 AM, 12:00 PM (and 2:00 PM)
Duration of each medication condition: 1 week
450Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stein 1996 (Continued)
Washout before study initiation: ≥ 5 days
Medication-free period between interventions: none
Titration period: initiated after randomisation
Treatment compliance: “there was generally good compliance, with a mean of 1.5missed
doses per child over the 5-week course of the study”
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale (CPRS), 48 items; factors include Conduct Problem,
Learning Problem, Psychosomatic Problems, Impulsivity/Hyperactivity and Anxiety.
Collected on a weekly basis for 5 consecutive weeks, including baseline assessment
2. ADD-H Comprehensive Teacher Rating Scale (ACTeRS): collected on a weekly
basis for 5 consecutive weeks, including baseline assessment
Serious adverse events
1. None observed
Non-serious adverse events
1. Stimulant Side Effects Rating Scale (SSERS): collected on a weekly basis for 5
consecutive weeks, including baseline assessment
2. Sleep log: Parents completed a sleep log to record the time when the child was
sent to bed and fell asleep, as well as total sleep duration
3. Actigraph: For 2 consecutive 18-hour periods during each week, children wore an
actigraph wrist monitor from 4:00 PM to 8:00 AM to record activity level, latency to
sleep onset (time sent to bed to first minute of sleep), duration of sleep and number
and duration of awakenings
Notes Sample calculation: no
Ethics approval: approved by the Institutional Review Board of theUniversity of Chicago
Comments from study authors
1. Analysis revealed no significant effects of order on any of the measures of ADHD
symptoms, sleep variables and side effects
2. Our sample size and resultant statistical power were moderate, limiting our ability
to detect mild or subtle effects
Key conclusions of study authors
1. For many children with ADHD, t.i.d. dosing may be optimal
2. Few differences in acute side effects have been noted between b.i.d. and t.i.d.
methylphenidate dosing
3. Dosing schedule should be selected according to severity and time course of
ADHD symptoms, rather than in anticipation of dosing schedule-related side effects
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: July 2014. Supplemental information regard-
ing randomisation and whether all planned outcomes were measured and reported was
received from study authors. Unfortunately, study authors no longer had access to the
dataset; therefore it has not been possible to receive supplemental data
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to 1
of 4 different orders of drug administra-
tion. The research pharmacist used a ran-
dom numbers table to assign participants
to different orders of administration
Allocation concealment (selection bias) Low risk “All medication and placebos were pre-
pared by the study pharmacist and placed
in opaque gelatin capsules” In addition to
the pharmacist, 1 investigator had access to
the dosage code in the event of a medical
emergency that necessitated breaking the
blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple-blinded: Participants always took 3
capsules daily during the study. “Active
drug phase (b.i.d. or three t.i.d.) was always
preceded by a titration phase. The purpose
of the titration phase was to introduce a
typical dose of MPH gradually, so that any
observation of side effects during the b.i.
d. and t.i.d. dosing phases could not be at-
tributed to rapid introduction of MPH”;
“All medication and placebos were pre-
pared by the study pharmacist and placed
in opaque gelatin capsules”; “In addition to
the pharmacist, one investigator had access
to the dosage code in the event of a med-
ical emergency that necessitated breaking
the blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Triple-blinded: In addition to the phar-
macist, one investigator had access to the
dosage code in the event of a medical emer-
gency that necessitated breaking the blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk One drop-out. Data collected on this par-
ticipant were used in the descriptive in-
formation for baseline, t.i.d. and titration
phases
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk All planned outcomes were measured and
reported
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Vested interest bias Low risk None declared. Theworkwas supported by
the Smart Family Foundation
Conflicts of interest: no affiliations with
pharmaceutical companies stated
Stein 2003
Methods Four-week, double-blind, placebo-controlled, cross-over trial in which participants were
randomly assigned to
1. Three doses of methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 47 (33 boys, 14 girls)
Number of participants followed up: 39
Number of withdrawals: 8
Diagnosis of ADHD: DSM-IV (combined (68%), hyperactive-impulsive (0%), inatten-
tive (32%))
Age: mean 9.02 years (range 5 years 11 months to 16 years)
IQ: mean 106.8
Stimulant-naive: 70%
Ethnicity: Caucasian (89.4%), African American (4.3%), Hispanic (2.1%), other (4.
3%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (17%), encopresis/enuresis (10.6%), tic dis-
order (2.1%)
Comedication: no
Sociodemographics: predominantly mid to upper socioeconomic status referral base of
the clinic
Inclusion criteria
1. DSM-IV criteria for ADHD
Exclusion criteria:
1. Mental retardation
2. Severe mood disorders (requiring antidepressant or concurrent psychotropic
medications)
3. Tourette’s syndrome, seizure disorders or other medical disorders associated with
symptoms that may mimic ADHD (e.g. thyroid disorder)
4. Children taking systemic medications
Interventions Participants were randomly assigned to different orders of OROS methylphenidate (18
mg, 36 mg, 54 mg) and placebo. No child could start with the 54-mg dose, and 1 child
who weighed < 40 kg did not receive the 54-mg dose to minimise potential side effects
in smaller children
Administration schedule: once daily
Duration of each medication condition: 7 days
Washout before study initiation: 2-week washout period for children who took stimulant
medication before study start
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Medication-free period between interventions: no
Titration period: none
Treatment compliance: 92% of all study medications were given
Outcomes ADHD symptoms
1. ADHD Rating Scale, Fourth Edition: parent-rated, at baseline and weekly during
interventions
2. ACTeRS: teacher-rated at baseline and weekly during interventions
Non-serious adverse events
1. Side Effect Rating Scale (SERS; Barkley 1990): parent-rated at baseline and
weekly during interventions
2. Vital signs (weight, height, blood pressure, pulse and temperature): obtained
weekly by clinical staff
3. Children’s Sleep Questionnaire
Notes Sample calculation: no
Ethics approval: approved by the Institutional Review Boards of The University of
Chicago, Children’s National Medical Center and the General Clinical Research Center
Advisory Council
Comments from study authors
1. Forced titration procedure deserves some comment
2. The advantage of this procedure is increased potential to determine optimal
response. However, this procedure is likely to result in increased reports of stimulant
side effects compared with a more gradual titration procedure
In interpreting the results, several limitations should be kept in mind
1. Potential expectancy biases or placebo effects need to be considered because each
medication differed in appearance, size and colour, and, in the case of the 54-mg
condition, number of capsules
2. Other limitations include the short-term nature of the study, the relatively small
number of participants with ADHD predominantly inattentive subtype and the
measures of ADHD symptoms used that were rating scales rather than behavioural
observations or laboratory measures of attention
Key conclusions of study authors
1. In children with ADHD combined subtype - the most common subtype of
ADHD - increasing doses of stimulant medication were associated with increased
improvement in inattention and hyperactivity symptoms
2. In children with ADHD predominantly inattentive subtype, symptom
improvement occurred at lower doses and less benefit was derived from higher doses
3. In both ADHD subtypes, higher doses were associated with parent ratings of
increased insomnia and decreased appetite
4. Children who were homozygous for the less common, 9-repeat DAT1 30-UTR
genotype displayed a distinct dose-response curve from that of other genotype groups,
with absence of typical linear improvement when the dose was increased from 18 mg to
36 mg and 54 mg
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Correspondence with study authors: August 2014.We contacted study authors to request
additional data. Study authors no longer have access to the data
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Dosing schedules were assigned from a ran-
domly ordered list of all dosing schedules
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Each medication differed in appearance,
size and colour and, in the case of the 54-
mg condition, number of capsules. The
placebo capsule was slightly larger than the
methylphenidate preparations. Study au-
thors conducted several analyses to investi-
gate the impact of these differences in ap-
pearance on the findings of the study (al-
most no impact on the results) but still con-
sidered risk of bias to be high. Parents and
clinicians who were blinded to genotype
and medication status rated ADHD symp-
toms, impairment and stimulant side ef-
fects each week
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and clinicians who were blinded
to genotype and medication status rated
ADHD symptoms, impairment and stim-
ulant side effects each week
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Any child who could not complete a treat-
ment phase was classified as a premature
discontinuation. Their data were included
for all phases that were completed. No de-
scription on how many participants the
analyses were based on
Selective reporting (reporting bias) High risk Data were included for all phases that were
completed. There is no description that re-
veals how many people the analyses were
based on. In the abstract belonging to the
study (Stein et al. 2004), researchers write
that theywill “prospectively evaluate the ef-
fects of different doses of stimulant medi-
cation on these and other sleep problems”.
This is not provided in any of the articles
included in the Stein 2003 study
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Vested interest bias High risk This study was supported by the National
Institute of Mental Health, the General
Clinical Research Center Program of the
National Center for Research Resources
and the National Institutes of Health, De-
partment of Health and Human Services
Conflicts of interest: Drs. Stein, Robb,
Conlon and Newcorn participate in the
Speakers’ Bureau for McNeil Consumer
and Specialty Pharmaceuticals, and Drs.
Stein and Newcorn are members of the
Concerta National Advisory Committee
Stein 2011
Methods Eight-week, double-blind, cross-over trial comparing the following
1. Extended-release d-MPH (10 mg, 20 mg, 25 to 30 mg)
2. Extended-release MAS (10 mg ,20 mg, 25 to 30 mg)
with a week of randomly assigned placebo within each drug period
Participants Number of participants screened: 77
Number of participants included: 65
Number of participants followed up: 56
Number of withdrawals: 9
Demographic data on the 56 participants
Diagnosis of ADHD: DSM-IV (combined (67%), hyperactive-impulsive (0%), inatten-
tive (33%))
Age: mean 11.78 years (range 9 to 17)
IQ: > 70
Sex: 41 boys, 15 girls
MPH-naive: 35.7%
Ethnicity: Caucasian (41.0%), African American (41.0%), Asian (2%), Hispanic (7%),
Bi-racial/mixed (9%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD, any subtype
2. Signed informed consent and assent
3. Clincal Global Impressions - Severity for ADHD (CGI-S-ADHD) rating ≥ 4
4. Findings on physical exam, laboratory studies, vital signs and ECG are judged to
be normal for age
5. Pulse and blood pressure are within 95% of age and sex means
6. Able to complete study instruments and swallow capsules
7. Willing to commit to the entire visit schedule for the study, including ≥ 1 visit to
UIC Medical Center
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Exclusion criteria
1. Mental retardation, autism, severe mood disorders, Tourette’s disorder, seizure
disorders or other medical disorders that were contraindications of stimulant treatment
that mimic ADHD (e.g. thyroid disorder)
2. Non-responder to either medication at doses offered in the study in an adequate
trial. Must not have experienced disabling adverse effects with either medication
3. Concomitant psychotropic medications or medications that might have a CNS
effect are required
4. Any other medical condition that represents a contraindication for either
treatment
5. History of alcohol or drug abuse in the past 3 months, or a positive urinary toxic
screen on initial evaluation that is not explained by a time-limited medical circumstance
6. Females of childbearing age who are sexually active, do not use acceptable birth
control (double protection method) and, after counselling, are unwilling to do so
7. History of allergic reactions to multiple medications
8. History of psychosis
9. Diagnosis of bipolar disorder
Interventions Participants were randomly assigned to 3 dose conditions of ER d-MPH and ER MAS
administered sequentially from lowest to highest dose with a randomly assigned week of
placebo during each period
Methylphenidate dosage: 10 mg, 20 mg and 25 to 30 mg. Maximum dose was 25 mg
in smaller children (i.e. < 35 kg) to minimise potential side effects
Administration schedule: once daily
Duration of each medication condition: 1 week
Washout before study initiation: 2-day washout period before beginning of the trial. No
washout period between treatment periods
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. ADHD Parent Rating Scale, Fourth Edition, rated weekly
Non-serious adverse events
1. Stimulant Side Effects Rating Scale (Barkley 1990): rated weekly by parents
2. Vital signs (weight, height, blood pressure, pulse and temperature): obtained
weekly
3. ECG before and after study
4. Sleep measured by actigraphy and questionnaires (from abstract)
Notes Sample calculation: no
Ethics approval: approved by the Institutional Review Board of University of Illinois at
Chicago
Comment from study authors
1. Short duration of time children were maintained on each dose and fixed dose
titration
Key conclusions of study authors
1. Both ER d-MPH and ER MAS were associated with significant, dose-dependent
reductions in ADHD symptoms
2. Decreased appetite and insomnia were more common and were seen at higher
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dose levels for both stimulants
3. Dose level, rather than stimulant class, was strongly related to medication response
4. Although most children responded similarly to both stimulants, 14.3% of total
samples were responders to ER d-MPH only, and 12.5% responded only to ER MAS
5. Future comparative effectiveness studies with multiple informants and larger
samples over longer time periods are necessary to develop a data-driven, personalised
approach to ADHD treatment
Comment from review authors
1. Protocol states that an exclusion criterion was “Non-responder to either
medication at the doses offered in the study in an adequate trial”. This is not written in
the full text of the study. Asked study author about this issue, who replied, “Although
non response was an exclusion [criterion] a priori, in fact this did not come up and no
cases were excluded from participation based upon this”. Even though this means that
children in the trial were not only responders, we still choose to analyse this study as
part of the studies that included only responders
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; see comments
above
Email correspondence with study authors: November and December 2013. We received
supplemental data from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Order of drug was randomly assigned so
that 50%startedwithERd-MPHand50%
started with ER MAS; also a randomly as-
signed week of placebo during each period
Allocation concealment (selection bias) Low risk Weekly blister packs containing capsules of
study drug, which were indistinguishable
from each other
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant, caregivers, outcome assessors
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participant, caregivers, outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants who received ≥ 2
weeks of study drug to ensure that all par-
ticipants had been exposed to ≥ 1 week of
active drug were analysed
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
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Selective reporting (reporting bias) Low risk No. Regarding the Wiebe et al. abstract, a
paper is almost ready for submission
Vested interest bias High risk Investigator-initiated study sponsored by
Novartis Pharmaceuticals, with additional
support provided by the University of Illi-
nois at Chicago (UIC) Center for Clinical
and Translational Science (CCTS)
Conflicts of interest: Some study authors
are affiliated with pharmaceutical compa-
nies
Stoner 1994
Methods Two n-of-1, double-blind, placebo-controlled, cross-over, randomised controlled trial.
Both cases received 4 levels of the following
1. Methylphenidate 5 mg, 10 mg and 15 mg
2. Placebo
After the double-blind trial, the code was broken, and the best dose was administered
to the participant. Follow-up data on the best dose were also measured. Follow-up data
were recorded anecdotally for the first case (Dan) and systematically for the second case
(Bill)
Participants Number of participants screened: 2 boys
Number of participants included: 2
Number of participants followed up: 2
Number of withdrawals: none
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: Dan 9 years, Bill 13 years
IQ: not stated
Methylphenidate naive: 100%
Ethnicity: not stated
Country: USA
Setting: not stated
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to different orders of 3 doses of methylphenidate
and placebo
Mean methylphenidate dosage: not relevant
Administration schedule: once daily at breakfast
Duration of each medication condition: Dan received placebo for 3 days, and 5 days
of treatment with 5 mg, 10 mg or 15 mg methylphenidate consecutively. Bill received
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placebo for 3 days, and 3 days of treatment with 5 mg, 10 mg or 15 mgmethylphenidate
consecutively
Washout before study initiation: treatment-naive
Medication-free period between interventions: 24 hours between doses
Titration period: none
Treatment compliance: Parents were instructed to initial a monitoring form each time
they gave a dose to their child after breakfast. No further description of this was provided
Regarding the follow-up trial: Dan 15 mg; Bill 10 mg (5 mg twice daily)
Outcomes General behaviour
1. Child Attention Problems Scale (CAP, 12-items; Barkley 1990): teacher-rated, at
the end of each medication trial
Non-serious adverse events
1. Stimulants Drug Side Effect Rating Scale: rated by participants, parents and Bill’s
teacher at the end of each medication trial
No relevant outcomes measured in the follow-up phase
Notes Sample calculation: not relevant
Ethics approval: not stated
Comments from study authors
1. Although results from both studies are promising, they must be interpreted with
great caution because various methodological and design features introduced threats to
internal validity. For example, inclusion of a no-medication day between trial phases
would be more in keeping with standard practice of clinical research trials of medication
2. Even though methylphenidate has a relative low half-life (4 to 6 hours), it is
thought to be completely eliminated from the body within 24 hours of ingestion; a
carry-over of effect from one trial to another may have occurred
Key conclusion of study authors
1. Curriculum-based measurement data collected during short medication trials can
be used to select a dose of methylphenidate that is likely to be beneficial for a student’s
ongoing academic growth
Comments from review authors
1. As we do not know whether any of the children were intellectually disabled, we
can use the study results only in sensitivity analyses
2. The article reports some side effects, but we could not obtain more information
on this from the study authors; therefore, these data are not used in the review
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: no
Email correspondence with study author: January 2014.Wrote to study author to request
additional information regarding ethics approval, intellectual disability, etc., but have
not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The order of medication levels was deter-
mined randomly. In packing the envelopes,
1 of the study authors arranged the coded
envelopes according to the randomly deter-
mined order of trials
Allocation concealment (selection bias) Low risk Each medication level was prepared and
packed in separate envelopes by a pharma-
cist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Each dose of methylphenidate and placebo
was grounded into a powder,mixedwith an
inert compound, and was sealed in a small
coloured drug capsule, so that doses were
identical in appearance and taste. Thus, the
pharmacist, the data collectors, the partic-
ipants and their families did not know the
order of drug administration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Each dose of methylphenidate and placebo
was grounded into a powder,mixedwith an
inert compound, and was sealed in a small
coloured drug capsule, so that doses were
identical in appearance and taste. Thus, the
pharmacist, the data collectors, the partic-
ipants and their families did not know the
order of drug administration
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data were provided
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol was identified, and no answer
was received from the study author
Vested interest bias Low risk National Association of School Psycholo-
gists
Conflicts of interest: not declared
Sumner 2010
Methods Three-week, triple-blind, randomised, cross-over trial with 2 interventions
1. Methylphenidate or atomoxetine
2. placebo
461Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sumner 2010 (Continued)
Participants Number of participants screened: not stated
Number of participants included: 31
Number of participants followed up: not stated
Number of withdrawals: 1
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean not stated (range 6 to 14 years)
IQ: not stated
Sex: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: none
Comedication: none
Sociodemographics: not stated
Inclusion criteria
1. 6 to 14 years
2. ADHD, any subtype, according to DSM-IV criteria
3. ADHD symptoms of sufficient severity to warrant pharmacotherapy, but patient
had never received the active medications evaluated in this study or had not exhibited
significant treatment-limiting adverse effects while using them
Exclusion criteria
1. Enrolment in self contained special education classes
2. Females with prior onset of menses: positive urine pregnancy tests at enrolment
3. Structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias or
other serious cardiac abnormalities
4. Considered by the investigator to be medically inappropriate for inclusion in a
study using placebo
5. Prior or present use of alcohol or illicit drugs
6. Major medical or neurological disorders that could affect motor activity,
attention, school attendance or ability to follow the study protocol
7. Diagnosis of a current anxiety disorder, tics, Tourette’s syndrome, major
depressive disorder
8. History of bipolar disorder, dysthymia or psychosis, or a family history of
Tourette’s syndrome
9. Treatment with a monoamine oxidase inhibitor within 14 days before screening
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders: placebo,
low, medium doses of OROS methylphenidate; or low, medium doses of OROS
methylphenidate, placebo
Doses: low (18 mg), medium (participants < 50 kg: 27 mg; participants > 50 kg: 36 mg)
Administration schedule: not stated
Duration of each medication condition: 1 week
Washout before study initiation: 1 week
Titration period: no
Treatment compliance: not stated
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Outcomes ADHD symptoms
1. ADHD Rating Scale: clinician-rated, weekly
2. Conners’ Parent Rating Scale - Revised: short form, parent-rated, weekly
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors (limitations)
1. Small participant sample size
2. Short medication washout
3. Lack of information about prior ADHD medication use
4. Absence of a true placebo arm in a parallel design
Key conclusions of study authors
1. Use of an objective measure, coupled with more stringent treatment response
thresholds, may better inform treatment decisions by clinicians and may reduce costs
and enhance assay sensitivity in ADHD clinical trials
2. Longer-term, multi-centre, prospective, parallel-group studies incorporating true
placebo arms and more heterogeneous participant populations are warranted to
confirm these preliminary findings
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; exclusion of par-
ticipants who have exhibited significant treatment-limiting adverse effects while treated
with methylphenidate
Any withdrawals due to adverse events: not stated
Email correspondence with study authors: August to September 2013. We attempted to
obtain supplemental information regarding characteristics of participants, withdrawals,
funding and efficacy data from study authors but without success
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to 1 of 2 treatment se-
quence groups
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple-blinded: Study participants, their
parents/guardians and clinicians were
blinded to study assignment in terms of
medications and dosing sequences. An un-
blinded prescribing physician and an un-
blinded study co-ordinator did not par-
ticipate in clinical ratings. Placebo was
matched to blindedmedication, so that the
2 were indistinguishable
Blinding of outcome assessment (detection
bias)
Low risk See above
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One participant withdrew before the
placebo visit and was not included in these
analyses
Selective reporting (reporting bias) Unclear risk No protocol was available
Vested interest bias Unclear risk It was not clear who sponsored the study,
but someone did (see authors’ affiliations)
Conflicts of interest: Calvin R. Sumner is
an employee of and an equity holder for the
study sponsor. Virginia S. Haynes, PhD, is
an employee of 3i Global (Basking Ridge,
NJ) and a paid consultant for the study
sponsor. Martin H. Teicher, MD, PhD,
served as paid consultant and clinical in-
vestigator for the sponsor. Jeffrey H. New-
corn, MD, serves as advisor and consultant
for Lilly, Ortho-McNeil Janssen, Schering-
Plough and Shire.He receives research sup-
port from Lilly, Ortho-McNeil Janssen and
Shire
Sunohara 1999
Methods Cross-over trial with 3 arms
1. Methylphenidate: low dose
2. Methylphenidate: high dose
3. Placebo
Phases: 3
Participants Number of participants screened: not stated
Number of participants included: 20 (16 boys, 4 girls)
Number of participants followed up: 20
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 10.5 years (range 10 to 12)
IQ: < 80
Methylphenidate naive: none
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 4), learning disability (n = 8)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children 10 to 12 years of age meeting DSM-II-R criteria for ADHD recruited
from Child Development Centre at Hospital for Sick Children, Canada
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Exclusion criteria
1. Conduct disorder, externalising disorder, anxiety
2. IQ < 80
Interventions Participants were randomly assigned to low- (mean 0.28 mg/kg) and high-dose (mean
0.56 mg/kg) methylphenidate and placebo in the morning and afternoon
Duration of each medication condition: 2 days
Washout before study initiation: no
Titration period: no
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Reported as adverse effects. There were 0 adverse effects at the higher dose for all
children
Notes Sample calculation:not stated
Ethics approval:no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: unclear
Key conclusion of study authors
1. No adverse effects of the higher dose were reported for any children
Email correspondence with study authors: April 2014. Wrote to study authors to ask for
additional data but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) High risk Not clear
Vested interest bias High risk Research was supported by a RESTRA-
COM graduate studentship for The Hos-
pital for Sick Children Research Institute
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and Novartis Pharmaceuticals
Swanson 1998
Methods Randomized, double-blind, cross-over study with 6 interventions
1. Methylphenidate
2. Placebo
Adderall in 4 different doses
1. 5 mg
2. 10 mg
3. 15 mg
4. 20 mg
Participants Number of participants screened: 36.
Number of participants included: 33
Number of participants followed up: 29
Number of withdrawals: 4
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 10.58 years (range 7 to 14)
IQ: > 80
Sex: 26 boys, 7 girls
Methylphenidate naive: 0%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (laboratory classroom)
Comorbidity: none
Comedication: none
Sociodemographics: not stated
Inclusion criteria
1. Age between 7 and 14 years
2. Diagnosis of ADHD by DSM-IV
3. History of clinically significant response to typical doses of methylphenidate (5
mg to 20 mg, b.i.d. or t.i.d.)
Exclusion criteria
1. Blood pressure outside 95th percentiles for age and sex
2. Wechsler Intelligence Scale for Children - Second Edition: score < 80
3. Abnormalities noted upon physical examination
4. Current treatment with a non-stimulant medication for ADHD
5. Comorbid disorder
6. History of aggressive behaviour serious enough to preclude participation in
regular classroom activities
Interventions Participants were randomly assigned to 1 of 36 possible drug condition orders of un-
known dose of methylphenidate, placebo and 4 doses of Adderall
Mean methylphenidate dosage: not stated
Administration schedule: once, morning
Duration of each medication condition: 7 days
Washout before study initiation: not stated
Medication-free period between interventions: none
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Titration period: none
Treatment compliance: 30 of 33 participants completed the 7-week trial
Outcomes ADHD symptoms
1. SKAMP Teacher Rating Scale, as modified by Greenhill into 2 domains of
Attention and Deportment (i.e. positive behaviour): completed by 1 of the teachers
after each 45-minute class period (i.e. every 1.5 hours on the Saturday of each week,
the teacher monitoring behaviour rated each student on each item)
Serious adverse events
1. No unusual or serious side effects were noted in this study
Non-serious adverse events
1. After each classroom period (6 times per day), teachers assessed each student on
the MTA 10-Item Stimulant Side Effects (SSE) rating scale
2. Parents completed a side effects rating scale that included SSE items plus an
additional item (trouble sleeping) 3 times per day, on Monday, Wednesday and Friday
of each week
Notes Sample calculation: no
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; only known
methylphenidate responders were included
Comments from study authors
1. Laboratory classroom experience may represent a novel experience for
participants, and this could alter response to medication
2. Group interactions in a classroom with 16 or 17 students with ADHD may be
different from those in the typical classroom of 20 to 30 students including 1 to 2
children with ADHD
3. Behaviour of 16 to 17 students with ADHD in a classroom with a student:teacher
ratio of about 8:1 may be different from that in a classroom with the typical ratio of
20:1 to 30:1
Key conclusions of study authors
1. This documentation of efficacy in a controlled study supports the addition of
Adderall to the armamentarium of psychotropic medications for treatment of ADHD
2. Differences in time-response patterns of Adderall and methylphenidate may help
tailor treatment to meet specific clinical needs of different children with ADHD
Email correspondence with study authors: January 2014. No reply has been received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Latin-square design (with provisions for 36
participants) was used to determine the
within-participant order of administration
of the 6 medication conditions, so that for
each of the first 6 weeks, approximately one
sixth of participants would be assigned to
each of the 6 conditions. Separate randomi-
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sation was used to determine assignment
of conditions across participants for week
7, to provide an opportunity to make up
missed weeks
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk For each condition, a pharmacist prepared
a set of 7 identical capsules, all containing
placebo (lactose), 1 of the 4 doses of Adder-
all or methylphenidate
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 of 33 participants completed the 7-week
trial; 98%of datawere collected as planned.
For each individual, missing data (1.1%
for SKAMP, 0% for Stimulant Side Effects)
were replaced by the average of values from
adjacent time points (or adjacent values for
session 1 or 6)
Selective reporting (reporting bias) Low risk No information
Vested interest bias High risk Supported by a grant fromRichwoodPhar-
maceutical Company
Swanson 1999
Methods Four-period, double-blind, randomised, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases
1. b.i.d.: 2 doses of immediate-release methylphenidate 4,5 hours apart
2. Flat: morning dose of 80% of b.i.d. morning dose and the rest at 30-minute
intervals over 6 hours, starting 1.5 hours after first dose
3. Ascending: morning dose of 40% of b.i.d. morning dose and that rest as
increasing doses at 30-minute intervals over 5 hours, starting 1.5 hours after first dose
Participants Number of participants screened: not stated
Number of participants included: 38 (33 boys, 5 girls)
Number of participants randomly assigned: 34. Participants were randomly assigned to
1 of 4 possible drug condition orders
Number of participants followed up: 31
Number of withdrawals: 3
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 9.2 years (range 7 to 12)
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IQ: not stated
Methylphenidate naive: 0%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (laboratory classroom)
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Diagnosis of ADHD
2. Onset by 7 years of age
3. Receiving current treatment with methylphenidate doses of 5 to 15 mg
administered 2 or 3 times per day
4. 7 to 12 years of age
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of
methylphenidate and placebo
Mean MPH dosage: not stated. Nominal dose: 20 mg/d
Administration schedule: 30-minute intervals from 7:30 AM to 3:00 PM
Duration of each medication condition: 1 day
Washout before study initiation: none
Titration period: none (participants were kept on current standard treatment in-between
trial days)
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale (SKAMP): teacher-rated, 4
times during the day
2. Conners, Loney and Milich Scale (CLAM): teacher-rated, 4 times during the day
Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Of the 38 children recruited for this trial, only 34 entered
Key conclusion of study authors
1. Acute tolerance to methylphenidate appears to exist
Comment from review authors
1. Publication includes 2 studies: In study I, relative efficacy was determined for 3
dosing patterns of methylphenidate vs placebo. In study II, tolerance was assessed by
comparison of 3-times-a-day regimens of methylphenidate only. The latter is not part
of the data extraction
Email correspondence with study authors: May 2014. Emailed study authors to ask for
additional information. No reply has been received
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk On subsequent Saturdays, each child re-
ceived (in random order) 1 of 3 possible
drug condition orders of methylphenidate
and placebo
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All treatments were administered in iden-
tical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Only completers were followed up
Selective reporting (reporting bias) Low risk No protocol was published. All pre-spec-
ified outcomes of interest have been re-
ported
Vested interest bias High risk Supported by ALZA Corporation, Palo
Alto, California
Swanson 2002a
Methods Randomised, double-blind, cross-over design
1. Immediate-release methylphenidate t.i.d. or methylphenidate experimental
administration
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 32 (28 boys, 4 girls)
Number of participants followed up: 30
Number of withdrawals: 2
Diagnosis of ADHD:DSM-IV (combined (93.8%), hyperactive-impulsive (6.2%), inat-
tentive (0%))
Age: mean 9.9 years (range 7 to 13)
IQ: not stated
Methylphenidate naive: 0%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic (laboratory classroom)
Comorbidity: 0%
Comedication: not stated
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Sociodemographics: not stated
Inclusion criteria
1. ADHD
2. Normal blood pressure
3. Not physically ill
4. Able to understand that they could withdraw from the study at any time
Exclusion criteria
1. Oppositional defiant disorder
2. Conduct disorder
3. Mood disorders
4. Anxiety disorders
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of 5 mg,
10 mg or 15 mg t.i.d., or 18 mg/d, 36 mg/d or 54 mg/d administered in bolus at 7:30
AM and once every 30 minutes for 8 hours of methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 3 time points
Duration of each medication condition: 1 day
Washout before study initiation: not stated
Medication-free period between interventions: none
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale (SKAMP)
General behaviour
1. Actigraph activity measurements
Non-serious adverse events
1. Proof of Concept Study (n = 32)
2. Teachers: appetite loss (t.i.d., n = 6; ascending, n = 7)
3. Parent reports of somatic complaints (primarily headache or stomachache): t.i.d.
methylphenidate (n = 9), ascending (n = 5)
4. Sleep onset was delayed slightly in the medication conditions (ascending, 0.65 h;
t.i.d., 0.55 h)
Notes Sample calculation: not stated
Ethics approval: yes
Comments from study authors (limitations)
1. Lack of normal control participants
2. Use of subjective rating measures
3. Use of different actigraph modes of operation
4. Lack of a systematic evaluation of whether baseline levels of behaviour were
predictive of medication effects
Key conclusions of study authors
1. Combination of an initial bolus of methylphenidate and an ascending pattern of
small doses significantly decreased hyperactivity and reduced inappropriate behaviour
2. Studies showed acute tolerance to clinical doses of methylphenidate and
application of this: creation of an ascending drug delivery pattern (OROS) of rapid
onset and with long duration of effect
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Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Anywithdrawals due to adverse events: All children in the trial were undergoing treatment
with methylphenidate when they were enrolled
Email correspondence with study authors: Study authors were contacted twice by email
and were asked for much supplemental information regarding data, but we have received
no data; therefore, most of the data from this study cannot be used in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized, 3-way, crossover trial in
which a double-blind, double-dummypro-
cedure was used”
Allocation concealment (selection bias) Unclear risk Not enough information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not enough information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no,
but all children in the trial were undergo-
ing treatment with methylphenidate when
they were enrolled
Selective reporting (reporting bias) Low risk “Two additional items developed (from
SKAMP) for the NIMH Collaborative
Multisite Multimodal Treatment Study of
Children With ADHD (MTA) (Greenhill
et al., 2001) were included in the classroom
ratings but were not included in the analy-
ses of this study”
Vested interest bias High risk “Supported by the ALZA Corporation”
472Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Swanson 2002b
Methods Randomized, 3-way, cross-over trial with 2 interventions
1. Methylphenidate (t.i.d. or OROS extended release)
2. Placebo
Phases: 3
Participants Number of participants screened: not stated
Number of participants included: 64
Number of participants followed up: 59
Number of withdrawals: 3
Diagnosis of ADHD: DSM-IV (combined (82.8%), hyperactive-impulsive (not stated)
, inattentive (not stated))
Age: mean 9.2 years (range 6 to 12)
IQ: not stated
Sex: 81.3% boys
Methylphenidate naive: none
Ethnicity: Caucasian (82.8%), African American (not stated), Asian (not stated), His-
panic (not stated)
Country: USA
Setting: out-patient clinic (laboratory classroom)
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV criteria for ADHD diagnosis, treated with immediate-release
methylphenidate 5 mg to 15 mg b.i.d. or t.i.d.
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of 5 mg,
10 mg or 15 mg t.i.d., or 18 mg, 36 mg or 54 mg OROS methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: t.i.d. 7:30 AM, 11:30 AM and 3:30 PM; OROS 7:30 AM
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: no measure
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale (SKAMP): rated by
laboratory school teacher on attendance on Saturdays
2. Conners, Loney and Milich Scale (CLAM): rated by parent and community
teacher on Fridays
3. Swanson, Nolan and Pelham (SNAP): rated by community teacher and parent at
the end of each week
Non-serious adverse events
1. “In addition to the effectiveness and efficacy measures, adverse effects were
actively solicited and assessed and information about sleep, appetite, and tics was
collected using a parent questionnaire”
2. Vital signs (blood pressure, pulse) after each classroom session on Saturdays in the
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laboratory school setting
3. Sleep: activity monitoring and parental assessment
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusion of study authors
1. Pharmacokinetic/Pharmacodynamic modelling provided the target for a novel
drug delivery pattern to overcome these shortcomings: an initial bolus to elicit a rapid
response and an ascending pattern of drug delivery to maintain constant effects
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; “The children
with ADHD in the proof-of-concept and proof-of-product studies were selected based
on a history of clinical response to stimulant medication, and this limits the extrapolation
of the findings to the drug-naive population”
Any withdrawals due to adverse events: no
Email correspondence with study authors: March 2014. We contacted study authors
twice by email and asked for supplemental information regarding data, but we have
received no data; therefore most of the data from this study cannot be used in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Double-blind proce-
dures were implemented by administration
of methylphenidate or placebo in capsules
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, double-dummy procedure
was used to disguise the 3 treatments
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Children with ADHD in proof-of-concept
and proof-of-product studies were selected
on the basis of a history of clinical response
to stimulant medication; this limits extrap-
olation of findings to the drug-naive pop-
ulation
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias High risk Supported by ALZA Corporation
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Methods Multi-centre, double-blind, double-dummy, placebo-controlled, cross-over study in an
analogue classroom setting comparing 3 treatment conditions
1. Metadate CD
2. Concerta
3. Placebo
Each treatment intervention lasted a week
Participants Number of participants screened: 214
Number of participants included: 184
Number of participants followed up: 157/184 ITT
Number of withdrawals: 27
Diagnosis of ADHD:DSM-IV (combined (82.2%), hyperactive-impulsive (4.8%), inat-
tentive (13.0 %))
Age: mean 9.6 years (range 6 to 12)
IQ: > 80
Sex: 131 boys, 48 girls
Methylphenidate naive: none
Ethnicity: Caucasian (70%), African American (11.5%), Asian (1.7%), Hispanic (12.
5%), other (5.3%)
Country: USA
Setting: out-patient clinic
Comorbidity: Approximately 25% had a comorbid condition; anxiety and oppositional
defiant disorder were most frequent. Females had a greater rate of comorbid anxiety
disorder (from Sonuga-Barke 2007). Anxiety: 20.8 girls, 5.9 boys. Oppositional defiant
disorder: 12.5 girls, 8.8 boys. Insomnia: 2.1 girls, 5.1 boys
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children (6 to 12 years old) who had clinical diagnoses of a DSM-IV subtype of
ADHD (inattentive type, hyperactive-impulsive type or combined type) were recruited
2. Treatment with methylphenidate in doses of 10 mg/d to 60 mg/d (5 mg to 20 mg
per administration, 1 to 3 times a day)
3. Children were deemed otherwise healthy by means of a medical history, physical
examination, vital signs measurement (blood pressure, heart rate, respiration and
temperature) and clinical laboratory assessments (haematology and urinalysis)
4. In addition, children had to demonstrate the ability to swallow placebo study
treatment capsules whole and without difficulty
5. Receiving an approved form of methylphenidate with demonstrated clinical
improvement during this treatment
Exclusion criteria
1. Intelligence quotient < 80 or inability to follow or understand study instructions
2. Pregnancy
3. History of seizure or tic disorder
4. Family history of seizure or Gilles de La Tourette’s syndrome
5. Congenital cardiac abnormality
6. History of cardiac disease including myocardial infarction within 3 months of
study entry
7. Glaucoma
8. Hyperthyroidism
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9. History of substance abuse or caretaker with history of substance abuse
10. Concurrent chronic or acute illness or other condition that might confound study
rating measures
11. Documented allergy or intolerance to methylphenidate
12. Use of an investigational drug within 30 days of study entry
13. Use of concomitant medication that could interfere with assessment of efficacy
and safety of study treatments
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of Metadate
CD, Concerta and placebo
Dose: Children treated with low doses (20 mg/d) of methylphenidate were randomly
assigned to receiveMetadate CD 20, Concerta 18 or placebo; those treated with medium
doses (20 to 40 mg/d) were randomly assigned to receive Metadate CD 40, Concerta
36 or placebo; children treated with high doses (40 mg/d) were randomly assigned to
receive Metadate CD 60, Concerta 54 or placebo
Administration schedule: once daily in the morning
Duration of each medication condition: 7 days
Washout before study initiation: no
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: Regarding the medicine, not stated. 157 received all 3 levels of
treatment and participated in all 7 classroom sessions
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale (SKAMP): tested on day 7 in
the laboratory school by 2 trained observers. Time points for the test (after ingestion of
medication/placebo): h = 0, h = 1.5, h = 3.0, h = 4.5, h = 6, h = 7, h = 12.0
2. Swanson, Nolan and Pelham (SNAP): parent-rated, administered twice during
each treatment week on days 3 and 6
Non-serious adverse events
1. Adverse events reported by participant or parent (guardian). Reported adverse
events were characterised (by the investigator at each site) as mild, moderate or severe
2. Barkley Side Effects Rating Scale: rated symptoms during past week and
completed weekly by parent (guardian) on day 6
3. Heart rate: measured before doses were taken and at the following time points
after ingestion: h = 1.5, h = 3.0, h = 4.5, h = 6, h = 7, h = 12.0
4. Blood pressure: measured before doses were taken and at the following time
points after ingestion: h = 1.5, h = 3.0, h = 4.5, h = 6, h = 7, h = 12.0
Notes Sample calculation: yes
Ethics approval: yes
Comments from study authors
1. In ANOVA of measures of blood pressure and heart rate, only 2 statistically
significant differences related to treatment emerged: systolic blood pressure at hour 7.5,
and pulse rate at hour 1.5
2. Site differences in this study deserve some comment because this is a common
finding in multi-site studies. Site difference was most prominent for subjective
outcome measures on the SKAMP Rating Scale, which depends on the training of
observers (difficult to equate across sites) and the context of the classroom (controlled
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but still may vary across sites because of class size, physical space and other factors that
may not be standardised)
3. Regarding analysis of sex (Sonuga-Barke 2007): Despite the relatively large
number of females in the sample, power was insufficient to include dose level as a
factor in the analysis
4. Given the manner in which sex effects appeared to vary across the day, present
results may be consistent with pharmacokinetic or pharmacodynamic explanations, or
a combination of the 2. Early and late sex-related differences in clinical effect may be
independent of one another or linked. Several possible explanations seem worth
testing. The superior methylphenidate response shown by females in the early part of
the day may result from greater sensitivity to methylphenidate or from higher
methylphenidate plasma concentrations due to increased rates or efficiency of
absorption of immediate-release components. The steeper decline in methylphenidate
response shown by females may be a consequence of earlier but normative clearance of
methylphenidate following more rapid absorption, or may be indicative of more rapid
clearance in females than in males
Limitations
1. Laboratory setting lacks many features of the natural environment of the home
and school. Thus, it is not certain whether the patterns reported here would be
observed in school settings in which an ADHD student would be in a classroom in
which most students not affected by this disorder
2. Study was designed to contrast total absorbed daily doses that were approximately
equal, although this resulted in differences in initial bolus doses of the 2 active
treatments (Metadate CD and Concerta). In this study, doses were not evaluated that
were equal to the initial bolus doses of immediate-release methylphenidate, which
would provide another test of the PK/PD model
3. Effects of both Metadate CD and Concerta in the low-dose subgroup were
smaller than in the high-dose subgroup, but we do not know whether a higher dose in
the low-dose subgroup would have increased the ES. Lack of tailoring to achieve
rigorous experimental control may be another limitation of this study
4. This study included only patients who already were being treated successfully
with methylphenidate. This means that severe and marked adverse events are unlikely
to be seen in this study, and it is possible that lack of effect on side effects rating scale
factors other than sleep/appetite may occur more readily in medication-naive patients.
Furthermore, it is important to recognise that this was a secondary analysis of a study
powered to show non-equivalence between the 2 methylphenidate formulations in
terms of efficacy, not in terms of adverse events
5. Sonuga-Barke 2009: This study included only patients who already were being
treated successfully with methylphenidate. This means that severe and marked adverse
events are unlikely to be seen in this study
6. Trial was also underpowered for detecting rare events that could be severe.
Measures of adverse events were derived only from parent ratings, not from direct
observations of behaviour
7. Significant side effects not measured by the Barkley Side Effects Rating Scale may
have occurred
Key conclusions of study authors
1. Once-daily doses of Metadate CD and Concerta produced statistically
significantly different PD effects on surrogate measures of behaviour and performance
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among children with attention deficit hyperactivity disorder in the laboratory school
setting
2. As predicted by the PK/PD model, superiority at any point in time was achieved
by the formulation with the highest expected plasma methylphenidate concentration
Regarding sex differences
1. Dose titration of once-daily formulations of methylphenidate ideally should be
based on systematic evidence of response at different periods across the day
2. Responses of female patients may require additional assessments later in the day
to determine optimal dose
Comment from review authors
1. Compared ratings on sex from SKAMP. However only compared the 2
medication conditions vs each other, not medication conditions vs placebo; therefore
we cannot use these analyses
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation:yes
Any withdrawals due to adverse events: Three study participants discontinued because of
adverse events that were judged to be unrelated to medications (gastroenteritis: Concerta
(n = 1); fever: placebo (n = 1); sunburn: placebo (n = 1))
Email correspondencewith study authors: June 2014.We emailed study authors to obtain
supplemental data. Unfortunately, data in the correct format are no longer accessible
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy. Treatments
were packaged according to a double-
dummy design. Each treatment pack con-
tained a 1-week supply of study treatment,
with each day’s supply consisting of 1 large
capsule to accommodate the size of any
dose level of Concerta (containing Con-
certa or placebo) and, depending on dose
level, between 1 and 3 smaller Metadate
CD-sized capsules (containing Metadate
CD or placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from participants finishing the whole
study (n = 157) and from the ITT popula-
tion (n = 184)
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Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias High risk Study was funded by Celltech Pharmaceu-
ticals Incorporated
Conflicts of interest: Some study authors
are consultants for pharmaceutical compa-
nies
Symons 2007
Methods Prospective, randomised, double-blind, placebo-controlled, cross-over, single-case de-
signs were used to evaluate methylphenidate administration for 3 school-aged children
with cerebral palsy and comorbid ADHD symptoms
1. Low-dose methylphenidate
2. High-dose methylphenidate
3. Placebo
Phases: 4 (including baseline)
Participants Number of participants screened: not stated
Number of participants included: 2 (1 boy, 1 girl)
Number of participants followed up: 2
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV (combined (100%), hyperactive-impulsive (0%), inat-
tentive (0%))
Age: mean 10.4 years (range 9 to 11)
IQ: > 70. Participant 2 = 92 non-verbal and 96 performance non-verbal (range not
stated)
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: cerebral palsy (100%), mild cognitive impairment (100%), autism spec-
trumdisorder (50%), physical impairment (50%), learningdisability (50%), other health
impairment (50%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD
2. Cerebral palsy
3. Attending public elementary schools
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of
methylphenidate (low or high dose) and placebo
Mean methylphenidate dosage: 2 doses of methylphenidate administered: low (0.3 mg/
479Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Symons 2007 (Continued)
kg) and high (0.5 mg/kg)
Administration schedule: once daily, mornings, before the child’s school arrival
Duration of each medication condition: Order of drug/placebo administration was ran-
domly assigned, and administration was provided for 5 consecutive school days in each
condition. Drug treatment was not administered on weekends
For participant 2, the order of administration was as follows: baseline, low dose, placebo,
high dose
For participant 3, the order of administration was as follows: baseline, placebo, low dose,
high dose
Washout before study initiation: not stated
Medication-free period between interventions: weekends
Titration period: not stated
Treatment compliance: not stated
Outcomes General behaviour
1. Direct observation protocol based on a 10-second partial interval (1/0) for
stereotyped and disruptive behaviours and time sampling for task-related behaviour
was used to code data collected directly from each child’s classroom for two 30-minute
sessions on 2 separate days for each week of the trial. Student and teaching staff
behaviours were recorded using handheld digital cameras. An observer designated as
the primary observer coded all videotaped sessions for that target student. A secondary
observer independently coded 20% of randomly selected videotaped sessions for each
student
Non-serious adverse events
1. No parent or teacher reports described significant side effects associated with
either dose level (e.g. changes in sleep, eating, etc.)
Notes Sample calculation: no
Ethics approval: not stated
Key conclusions of study authors
1. Low-dose but not high-dose methylphenidate administration resulted in clinically
significant reductions in directly observed stereotyped and disruptive behaviours for 3
elementary school-aged children with cerebral palsy
2. For 2 of the children, stereotyped behaviour was exacerbated during high-dose
administration
3. Finally, no change in attending, as measured by direct observation of task-related
behaviour, was noted
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: May 2014. Emailed study author to request
additional information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Order of drug/placebo administration was
randomly assigned
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Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, school personnel (i.e. teachers,
teacher assistants) and research assistants
responsible for observational data collec-
tion and coding were kept blind to drug/
placebo conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias Unclear risk Not stated
Conflicts of interest: This work was sup-
ported, in part, by aMcKnight Land-Grant
Professorship to Frank Symons
Szobot 2004
Methods Four-day, double-blind, placebo-controlled, randomised, fixed dose-escalating of
methylphenidate, parallel-group trial
Participants Number of participants screened: not stated
Number of participants included: 36 (all boys)
Number of participants randomly assigned: methylphenidate 19, placebo 17
Number of participants followed up: methylphenidate 19, placebo 17
Number of withdrawals: none
Diagnosis of ADHD: DSM-IV, combined (methylphenidate 84.6%, placebo 76.5%)
Age: mean 11.6 years
IQ: mean 94.7
Methylphenidate naive: no psychiatric medication for the past 6 months
Ethnicity: European-Brazilian (89%)
Country: Brazil
Setting: out-patient clinic
Comorbidity: Conduct disorder and oppositional defiant disorder (methylphenidate 58.
8%, placebo 68.4%), depressive disorder (methylphenidate 5.2%, placebo 5.9%), multi-
ple anxiety disorder (methylphenidate 5.2%, placebo 0%), tic disorder (methylphenidate
0%, placebo 5.9%)
Comedication: not stated
Sociodemographics: low- to middle-income families
Inclusion criteria
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1. Diagnosis of ADHD according to DSM-IV criteria (American Psychiatric
Association, 1994)
2. Between 8 and 17 years old
3. Male sex
Exclusion criteria
1. Presence of any neurological or significant clinical disease
2. Presence of bipolar disorder or any substance abuse/dependence disorder
3. Use of any psychiatric medication in the previous 6 months
4. Estimated IQ < 70
Interventions Participants were randomly assigned to methylphenidate or placebo
Mean methylphenidate dosage: 0.72 mg/kg/d
Administration schedule: twice a day: morning and lunchtime
Duration of intervention: 4 days
Titration period: first day 0.35 mg/kg
Treatment compliance: good
Outcomes ADHD symptoms
1. Conners’ Abbreviated Rating Scale (ABRS)
Quality of life
1. Children’s Global Assessment Scale (CGAS). CGAS was scored by a child
psychiatrist
Non-serious adverse events
1. A research assistant called each family to check side effects. No participants had to
interrupt the protocol because of side effects
Notes Sample calculation: no
Ethics approval: approved by the Ethical Committee of the HCPA (approved as an IRB
by the Office for Human Research Protections, USA)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Our results extend the efficacy of methylphenidate for ADHD core symptoms as
extensively demonstrated in clinical trials with samples from developed countries to
samples from developing countries, for whom a diverse culture may modulate clinical
presentation of the disorder
2. This study’s rate of robust response with methylphenidate might reflect the short
duration (4 days) of the clinical trial
3. Results may not generalise to other different sociocultural groups or to patients
from the community
4. Side effects were not objectively registered
Key conclusion of study authors
1. Methylphenidate group had a significantly greater decrease in ABRS scores and a
significantly greater increase in CGAS scores when compared with the placebo group
(P value < 0.01)
Email correspondence with study authors: October 2013. We received from the study
authors supplemental information regarding blinding and allocation concealment
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned on
the basis of a computer-derived algorithm
(EPIINFO6)
Allocation concealment (selection bias) Low risk Only the doctor performing the randomi-
sation knew the allocation, and he had
nothing to do with data collection
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: Participants, parents and all
research team members who had contact
with participants. Both methylphenidate
and placebo pills were manufactured by a
single pharmaceutical company; they had
the same format and colour and were given
to participants in 4 different blisters
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All research team members who had con-
tact with participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo-responders): no
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias High risk This work was supported by research funds
from Hospital de Clínicas de Porto Alegre,
FAPERGS and NOVARTIS
Szobot 2008
Methods Cross-over trial with 2 interventions
1. SODAS methylphenidate
2. Placebo
Phases: 2- or 3-week phases, with each group receiving placebo or SODAS
methylphenidate
Participants Number of participants screened: 25 from a previous ADHD/substance misuse study
and 15 through advertising
Number of participants included: 16
Number of participants followed up: 16
Number of withdrawals: 2 (both from group A; withdrawal rate 12.5%)
Diagnosis of ADHD: DSM-IV (combined 12 (75%), inattentive 3 (18.75%), hyperac-
tive/impulsive (n = 1))
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Mean age: group A 17.5 years (SD 2.33), group B 17.38 (SD 2.2)
IQ: group A 79.43 (SD 16.66), group B 84.75 (SD 21.16)
Sex: all boys (100%)
Methylphenidate naive: 100%
Ethnicity: European-Brazilian (group A 3 (37.5%), group B 7 (87.5%))
Country: Brazil
Setting: out-patient clinic
Comorbidity: conduct disorder (group A 100%, group B 75%); oppositional defiant
disorder (group A 25%, group B 37.5%); depression (group A 12.5%, group B 25%)
Comedication: yes (marijuana and cocaine); group A: marijuana (100%) and cocaine
(50%); group B: marijuana (87.5%) and cocaine (37.5%)
Sociodemographics: divorced parents (group A 37.5%, group B 50%); socioeconomic
group A + B + C (group A 50%, group B 87.5%); group D + E (group A 50%, group
B 12.5%)
Inclusion criteria
1. 15 to 21 years of age
2. Male
3. Current diagnosis of abuse of marijuana or cocaine (K-SADS-E and MINI)
4. Current diagnosis of ADHD: Kiddie Schedule for Affective Disorders and
Schizophrenia for School-Age Children, Epidemiological Version (K-SADS-E)
5. Stimulant naive
Exclusion criteria
1. Absence of responsible adult - to inform on childhood psychopathology and to
take responsibility for medication and/or the need for in-patient care for substance
misuse or psychiatric comorbidity
2. Primary psychiatric condition requiring immediate treatment (e.g. moderate/
severe depression)
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean SODAS methylphenidate dosage: 0.3, 0.7 and 1.2 mg/kg/d for weeks 1, 2 and 3
for group A, and for weeks 4, 5 and 6 for group B
Administration schedule: morning dose time points
Duration of each medication condition: 3 weeks
Washout before study initiation: no
Medication-free period between interventions: 24 hours
Titration period: none
Treatment compliance: “Study compliance was assessed by self-report, mother’s report
and pill counting”
Outcomes ADHD symptoms
1. Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age
Children, Epidemiological Version (K-SADS-E), for diagnosis
2. Swanson, Nolan and Pelham scale, Fourth Edition (SNAP-IV)
General behaviour
1. Clinical Global Impression (CGI) Scale
Serious adverse events
1. Barkley Side Effect Rating Scale (SERS)
Non-serious adverse events
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1. Barkley Side Effect Rating Scale (SERS)
Notes Sample calculation: not stated
Ethics approval:“The project was approved by the Institutional Review Board (IRB) of
Hospital de Clinicas de Porto Alegre (approved as an IRB by the Office for Human
Research Protections, United States of America, IRB 00000921”
Comments from study authors
1. In the present study, SODAS methylphenidate was significantly superior to
placebo in reducing ADHD symptoms and improving global functioning for all main
outcome measures (SNAP-IV and CGI scores)
2. No treatment effect on illicit substance use disorders was noted, and
methylphenidate-SODAS was well tolerated, despite causing greater appetite reduction
than was seen with placebo
Key conclusions of study authors
1. SODAS methylphenidate was more effective than placebo in reducing ADHD
symptoms in a non-abstinent out-patient sample of adolescents with comorbid
substance use disorders
2. Randomised clinical trials, with larger samples and substance use disorder
interventions, are recommended
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: One withdrawal resulted from a participant
feeling “worse”, “more restless”
Email correspondence with study authors: May 2014. We received supplemental infor-
mation from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “One of the investigators (LAR) random-
ized the 16 subjects into groups A or B and
prepared weekly blisters of medications for
each participant”
Allocation concealment (selection bias) High risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A pharmacist packaged mPH-SODAS
and matching placebo in capsules so that
the MPH-SODAS and placebo could not
be visually differentiated”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk From author correspondence: All persons
who evaluated outcome measures were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
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non-responders or placebo responders):
unclear
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias High risk “The ADHD outpatient program re-
ceives research support from Bristol-Myers
Squibb, Eli-Lilly, Janssen-Cilag andNovar-
tis”
Conflicts of interest: Study authors are con-
sultants and speakers for various companies
Tannock 1989
Methods Within-participant, cross-over trial with 3 interventions
1. Methylphenidate 0.3 mg/kg
2. Methylphenidate 1 mg/kg
3. Placebo
Two different drug conditions each day
Participants Number of participants screened: 16
Number of participants included: 19
Number of participants followed up: 12 (10 boys, 2 girls)
Number of withdrawals: none
Diagnosis of ADHD:DSM-IIIADD-H (equivalent to ’combined’ in later classifications)
Age: mean 8.4 years (range 6 to 11)
IQ: mean 105
Methylphenidate naive: Five received methylphenidate previously. Three were taking
methylphenidate at the time of referral and had a 48-hour pre-trial washout
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (n = 4), learning difficulties (n = 8; according
to school record and defined as < 25th percentile on 1 or more subtests within the Wide
Range Achievement Test (WRAT-R))
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Thought by referring physician to have ADHD
2. Confirmed through assessment by 2 child psychiatrists using the Parent Interview
Child Symptoms Questionnaire
3. Confirmed by teacher information on Conners’ Teacher Questionnaire, Rutter B
Questionnaire and the Swanson, Nolan and Pelham Questionnaire
Exclusion criteria
1. Full-scale WISC-R < 80
2. Exclusive diagnosis of emotional or conduct disorder; major neurological,
physical or sensory impairment; and/or any contraindication for use of
methylphenidate (e.g. tics, seizures, heart disease)
486Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tannock 1989 (Continued)
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of 0.3 mg/
kg or 0.6 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: not stated.
Administration schedule: Interval of 4 hours separated morning and afternoon doses
Duration of each medication condition: not stated
Washout before study initiation: 4 hours
Titration period: none
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Treatment-emergent side effects (e.g. stomach distress, pallor, mood swings, tics)
2. Pulse and blood pressure readings taken in sitting position immediately before
medication and again 1 hour after administration of dose
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
Key conclusions of study authors
1. Behavioural and academic improvements produced by a dose of 0.3 mg/kg in the
morning were no longer evident in the afternoon
2. 1 mg/kg methylphenidate produced behavioural improvements that were
clinically and statistically discernible in the afternoon, although academic
improvements had dissipated
3. Carryover effects of methylphenidate into the afternoon were discernible with 1.0
mg/kg but not with 0.3 mg/kg
Comment from review authors
1. Outcomes for ADHD symptoms were not appropriate for this study, so only
adverse effects were examined
Email correspondencewith study authors: sent email to study authors to ask for additional
information but have not received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The order of medication condition was
randomized with the restrictions that each
child receive two different medication con-
ditions each day (e.g. high, low) occur with
equal frequency in the morning and after-
noon” “The order of these six combinations
was randomized for each child”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The methylphenidate and placebo were
packaged in coloured gelatin capsules by
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the hospital pharmacist to avoid detection
of dose and taste, packaged in individual
envelopes and dispensed by project staff 1
hour before testing”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk Jointly funded by Ontario Mental Health
Foundation (Grant No. 963-86/88) and
Health and Welfare Canada (Grant No.
6606-3166-42)
Conflict of interest: Study authors’ affilia-
tions were not declared
Tannock 1992
Methods Cross-over trial with 2 interventions
1. Methylphenidate low dose
2. Methylphenidate high dose
3. Placebo
Phases: 3 separate drug conditions: placebo, low-dose (0.3 mg/kg) and high-dose (1.0
mg/kg) medication, with 2 test sessions each. Drug conditions changed on a daily basis:
6 test sessions plus baseline practice session
Participants Number of participants included: 26
Participants were randomly assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 23
Number of withdrawals: 3
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 9.2 years (range not stated)
IQ: mean 105.9 (SD 10.5)
Sex: 24 boys, 2 girls
Methylphenidate naive (not clear; “9 children receiving stimulant medication prior to
the present study”)
Ethnicity: not stated
Country: Canada
Setting: hospital/out-patient department
Comorbidity: 12
Comedication: not clear
Sociodemographics: not stated
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Inclusion criteria
1. Diagnosis of ADHD confirmed
2. Child had to be scheduled to receive a trial with methylphenidate independent of
the present investigation
Exclusion criteria
1. Wechsler Intelligence Scale for Children - Revised: < 80
2. Exclusive DSM-III diagnosis of Conduct disorder or an Emotional disorder
3. Major neurological, physical or sensory impairment
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: N/A (modal dose at 0.3 mg/kg = 7.5 mg (range 5.0 mg
to 15 mg), modal dose at 1.0 mg/kg = 27.5 mg (range 17.5 mg to 47.5 mg))
Administration schedule: daily single dose
Duration of each medication condition: 1 day
Washout before study initiation: 48 hours before study initiation
Medication-free periods between interventions: no
Titration period: none
Treatment compliance: capsules administered by project staff
Outcomes General behaviour
1. Wisconsin Card Sorting Test: observer, daily, 90 minutes after treatment
Non-serious adverse events
1. Decreased cognitive flexibility (repetitive actions with obsessive quality)
2. Movement stereotypes
3. Facial motor tics
4. Topic perseveration
5. Excessive pre-occupation with the task at hand and persistent talkativeness:
observer, during test session
6. Treatment-emergent side effects conducted routinely during medication trial in
our laboratory
7. Monitored throughout sessions
Three children exhibited unusual side effects leading to trial termination. One exhib-
ited hypersensitivity (skin rash, urticaria and throat clearing), and 2 became somewhat
disoriented and confused and complained of odd sensations in their limbs
Notes Sample calculation: no
Ethics approval: not stated
Key conclusion of study authors
1. Results indicate that methylphenidate increased perseverative errors on the first
assessment but decreased them on the second; clinical symptoms of perseveration
occurred at both assessments. Findings suggest that methylphenidate may reduce
cognitive flexibility temporarily in some children with ADHD
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Any withdrawals due to adverse events: yes; 3
Email correspondence with study authors: April 2014. We emailed study authors twice
to ask for supplemental information/data but have not received a response
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not clear
Allocation concealment (selection bias) Low risk Double-blind, placebo-controlled design.
Drug order for the first 3 test sessions was
randomly assigned, and each child retained
the same order for the remaining 3 sessions
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled design.
Medication packaged in coloured gelatin
capsules to avoid detection of dose and
taste. Each child followed the same routine
for every test session
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk Incomplete outcome data for 3 respon-
dents with unusual side effects
Selective reporting (reporting bias) Unclear risk No information presented on numbers of
participants with side effects or outcomes
for data on nausea, blood pressure, etc
Vested interest bias Low risk Research supported in part by a grant from
the Canadian Psychiatric Research Foun-
dation and a Post-Doctoral Fellowship by
the Ontario Mental Health Foundation
Conflicts of interest: not declared
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Methods Cross-over trial with 2/3 interventions
1. Methylphenidate low dose
2. Methylphenidate high dose
3. Placebo
Phases
1. Each child in ADHD group participated in a 6-day medication trial, consisting of
six 3-hour test sessions
2. Each child was tested on 2 separate occasions when given placebo, low-dose
methylphenidate (0.3 mg/kg) and high-dose methylphenidate (1.0 mg/kg) in a
randomly assigned counterbalanced sequence
Participants Number of participants screened: not stated
Number of participants included: methylphenidate 22, control 16. Participants were
randomly assigned to 1 of 6 possible drug condition orders
Number of participants followed up: 22 (21 boys, 1 girl)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 9.4 years (range not stated)
IQ: mean 105.5 (SD 11.3)
Methylphenidate naive: not clear: “Thus all these children would have received a trial
with psychostimulants independently of this study”; “8 children had been receiving
stimulant medication prior to this study”)
Ethnicity: not stated
Country: Canada
Setting: out-patient clinic
Comorbidity: 55%; oppositional disorder (n = 5), conduct disorder (n = 3), emotional
disorder as well as oppositional or conduct disorder (n = 4), major depression (n = 2),
avoidant disorder (n = 1), separation anxiety disorder (n = 1) and learning disorder (n =
6)
Comedication: not clear
Sociodemographics: not stated
Inclusion criteria
1. Confirmed diagnosis of ADHD: Child demonstrated ≥ 3 symptoms of
inattentiveness, 3 of impulsiveness and 2 of hyperactivity, with a history of these
symptoms before 6 years of age, based on diagnostic interview
2. Diagnosis was made if the child received a Rutter B total score ≥ 9 and fulfilled
any 2 of the following criteria: score ≥ 15 on the Conners’ Abbreviated Teacher
Questionnaire; ≥ 4 inattentive, 4 impulsive and 3 hyperactivity symptoms on the
Swanson, Nolan and Pelham Scale; or score of 5 or 6 on the Rutter-B hyperactivity
factor
Exclusion criteria
1. Wechsler Intelligence Scale for Children - Revised: score < 80 with psychosis, or
with any major neurological, physical or sensory impairment
Interventions Participants were randomly assigned to 1 of 6 possible drug condition orders of (dose
not stated) methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: 6 separate medication administrations: 2 placebo, 2 low dose
(0.3 mg/kg) and 2 high dose (1.0 mg/kg). First 3 test sessions were ordered randomly,
than were ordered repeatedly for last 3 sessions: daily for 6 days
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Duration of each medication condition: 3 hours
Washout before study initiation: 48 hours
Medication-free period between interventions: not clear
Titration period: none
Treatment compliance: “Medication was administered by project staff ”
Outcomes Non-serious adverse events
1. Blood pressure and pulse readings: before and 1 hour after ingestion
2. Reduced social responsivity: during each test session, observer
3. Intense concentration: during each test session, observer
4. Stereotypy: during each test session, observer
Notes Sample calculation: no
Ethics approval: not stated
Key conclusions of study authors
1. Results indicate that only high-dose treatment had a specific effect on focused
attention, and this effect was delayed relative to the more salient but non-specific
effects on overall efficiency of information processing
2. Task performance at high dose was related to concurrent clinical manifestations of
intense concentration, but no evidence suggested that methylphenidate produced
overfocusing
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
Email correspondence with study authors: April 2014. Emailed study authors twice for
supplemental information/data but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Double-blind, placebo-controlled, within-
participant design was used ...randomly as-
signed, counterbalanced sequence. Medi-
cations were prepared individually for each
child andwere packaged in coloured gelatin
capsules to avoid detectionof dose and taste
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled, within-
participant design was used ...randomly as-
signed, counterbalanced sequence. Medi-
cations were prepared individually for each
child andwere packaged in coloured gelatin
capsules to avoid detectionof dose and taste
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals were noted
Selection bias (e.g. titration before ran-
domisation→ exclusion): no
Selective reporting (reporting bias) Low risk All outcomes reported
Vested interest bias Low risk Study funded by the Canadian Psychiatric
Research Foundation and the Medical Re-
search Council of Canada
Conflicts of interest: not declared
Tannock 1995a
Methods Four-day, randomised, double-blind, placebo-controlled, cross-over trial with
1. Three doses of methylphenidate (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)
2. Placebo
With initial 1-day open-label trial
Participants Number of participants screened: 28
Number of participants included: 28 (25 boys, 3 girls). Participants were randomly
assigned to 3 doses of methylphenidate and placebo
Number of participants followed up: 28
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 8.9 years (range 7 to 11)
IQ: mean 106.5 (15.6)
Methylphenidate naive: 80%
Ethnicity: Caucasian (90%), other (10%)
Country: Canada
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder or conduct disorder (35%), learning disabil-
ities (39%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD, DSM-III-R
Exclusion criteria
1. IQ: Wechsler Intelligence Scale for Children - Revised: score < 80
2. Anxiety disorder (DSM-III-R)
3. Major neurological, physical or sensory impairment
Interventions Participants were randomly assigned to 3 doses of methylphenidate (0.3 mg/kg, 0.6 mg/
kg, 0.9 mg/kg) and placebo
Mean methylphenidate dosage: not stated
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Administration schedule: once daily
Duration of each medication condition: 1 day
Washout before study initiation: For children receiving methylphenidate before trial,
washout period ≥ 48 hours before trial, with no washout between periods
Titration period: All children participated in an initial 1-day open trial with a 0.3 mg/
kg dose of methylphenidate to ascertain tolerance, before proceeding with the double-
blind, placebo-controlled trial
Treatment compliance: not stated
Outcomes Non-serious adverse events
1. Cardiovascular function (heart rate). Radial pulse, taken for 1 minute. with the
child seated, was measured 3 times during each session: immediately before medication
(time 0) and again at 1 hour (time 1) and 2 hours (time 2) following administration of
the oral dose. From time 0 to time 1, children were seated at a table, colouring or
playing quietly with puzzles or board games: Children completed the cognitive task
from time 1 to time 2
Notes Sample calculation: yes
Ethics approval: yes; Institutional Research Ethics Board
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; 1-day open-
label trial to ascertain tolerance towards medication, but all participants were analysed
Key conclusions of study authors
1. Results indicate that methylphenidate enhanced cognitive flexibility, although the
high dose was less effective than lower doses in enhancing response inhibition
2. Dissociations of dose effects on cognitive function and behaviour were
demonstrated: Dose-response functions for changes in behaviour were linear, whereas
the function for response inhibition was U-shaped
Email correspondence with study authors: August 2013. We received from the first study
authors supplemental information regarding drop-outs, screening and ethics approval
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Low risk All medication was prepared by the hospi-
tal pharmacy and was packaged in opaque
gelatin capsules to avoid detection of dose
and taste
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Children, parents, teachers and research
staff were all blinded to medication condi-
tions
Blinding of outcome assessment (detection
bias)
Low risk Children, parents, teachers and research
staff were all blinded to medication condi-
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All outcomes tions
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from all 28 participants were analysed
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No
Vested interest bias Low risk Medical Research Council of Canada and
Health and Welfare Canada
Conflicts of interest: nothing to declare
Tannock 1995b
Methods Cross-over trial with 1 interventions
1. Methylphenidate (0.3 mg/kg, 0.6 mg/kg, 0.9 mg/kg)
2. Placebo
Phases: washout (if applicable), baseline, trial
Two groups - ADHD and ADHD + anxiety - were subjected to the same trial
Participants Number of participants screened: 50
Number of participants included: 40 (34 boys, 6 girls). Participants were randomly
assigned to 1 of 12 possible drug condition orders
Number of participants followed up: 40
Number of withdrawals: none
Diagnosis of ADHD: DSM-III-R (no subtype)
Age: mean not stated (range 7 to 11 years); ADHD mean 9.4; ADHD + anxiety mean
9.1
IQ: > 80
Methylphenidate naive: not stated
Ethnicity: Caucasian (90%), African American or Asian (10%)
Country: Canada
Setting: out-patient clinic
Comorbidity (type: overanxious 27.5%, separation anxiety 5%, overanxiety and separa-
tion anxiety 10%, avoidant disorder with overanxious traits 2.5%, ODD 55%, conduct
disorder 10%)
Comedication: not stated
Sociodemographics: predominantly from middle-class families
Inclusion criteria
1. Meeting DSM-III-R criteria
2. At least 2 of the following
i) ≥ 15 on the Conners’ Abbreviated Symptom Questionnaire
ii) ≥ 4 inattentive, 4 impulsive and 3 hyperactive symptoms rated as “pretty
much” or “very much” on Swanson, Nolan and Pelham Questionnaire
iii) Score of 5 or 6 on the Hyperactivity factor of the Rutter Child Scales
Exclusion criteria
1. Full scale IQ < 80
2. Evidence of major neurological, physical or sensory impairment
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3. Medical or neurological contraindications for stimulant medication
4. Not knowing the number facts of 10. Needing to use concrete materials (i.e.
fingers) to add numbers
Inclusion criteria for the ADHD + anxiety group
One or more of the following
1. DSM-III-R criteria for overanxious, separation anxiety or avoidant disorder based
on parent interview
2. Score > 1 SD above the mean for age and sex on the Revised Children’s Manifest
Anxiety Scale
3. Score > 1 SD for age and sex on the Trait Scale-C2 of the State-Trait Anxiety
Inventory for Children
Children in the ADHD group did not meet any of these criteria for anxiety
Interventions Participants were randomly assigned to 1 of 12 possible drug condition orders of 0.3
mg/kg, 0.6 mg/kg or 0.9 mg/kg methylphenidate and placebo
Mean methylphenidate dosage: 0.3 mg/kg = 8.75 (± 2.2); 0.6 mg/kg = 17.75 (± 4.2); 0.
9 mg/kg = 27.25 (± 5.6)
Administration schedule: once per day
Duration of each medication condition: 1 day
Washout before study initiation: 48 hours when applicable
Medication-free period between interventions: not stated
Titration period: 1-day open trial on 0.3 mg/kg before proceeding to ascertain tolerance.
Not stated whether initiated before/after randomisation
Treatment compliance: Medication was administered at the laboratory
Outcomes Non-serious adverse events
1. Heart rate and radial pulse, once at baseline and 3 times during each session
Notes Sample calculation: not stated
Ethics approval: not stated
Key conclusion of study authors
1. High levels of trait anxiety in children with ADHD predict poor (but not adverse)
response to methylphenidate in terms of working memory, and add to growing
evidence that ADHD with anxiety constitutes a distinct and clinically meaningful
subtype of ADHD
Comment from review authors
1. Main trial was preceded by a 1-day trial of the lowest dose to assess tolerance to
methylphenidate
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; see above
Any withdrawals due to adverse events: no
Email correspondence with study authors: June 2014. Emailed study authors twice to
request supplemental information/data but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
496Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tannock 1995b (Continued)
Random sequence generation (selection
bias)
Low risk Drugorderwas counterbalanced and deter-
mined by random assignment, such that an
approximately equal numbers of children
were assigned to each of 12 possible orders
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active medication and placebo were pre-
pared by the hospital pharmacy, packaged
in identical opaque gelatin capsules and ad-
ministered in a double-blind manner
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): 1-
day open trial to assess tolerance before
main trial, but no children were excluded
Selective reporting (reporting bias) Low risk All outcomes are reported
Vested interest bias Low risk Research was supported in part by the On-
tario Mental Health Foundation and the
National Health Research and Develop-
ment Program, Health Canada
Taylor 1987
Methods Double-blind, randomised, placebo-controlled, cross-over trial with 2 arms
1. Methylphenidate
2. Placebo
Each treatment period lasted for 3 weeks with a washout period of 1 week planned
between treatments and up-titration to optimum dosage during the 3 weeks
Participants Number of participants screened: 64
Number of participants included: 39. Of these, 26 had an ADHD diagnosis according to
DSM-III. Participants were randomly assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 38
Number of withdrawals: 1
Diagnosis of ADHD: DSM-III (n = 26; type not stated)
The following data reflect the whole trial (n = 38)
Age: mean 8.6 years (range 6 to 10)
IQ: all > 65; mean 93.4
Sex: all boys
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Methylphenidate naive: 100%
Ethnicity: not stated
Country: England
Setting: out-patient clinic
Comorbidity: no attentive or restless behaviour, but antisocial, disruptive or aggressive in
conduct (n = 6), hyperactive but not antisocial or aggressive (n = 9), with both hyperactive
and disruptive behaviour (n = 23), conduct disorder (n = 7), relationship problems (n =
2) and disturbance of emotions specific to childhood (n = 3)
Comedication: not stated
Sociodemographics: 40% from broken homes
Inclusion criteria
1. IQ > 65
2. Free of autistic features
3. Lives in a family home, not an institution
4. Attending primary school
5. Problems assessed at the clinic as severe enough to warrant psychiatric treatment
6. Free of contraindications to stimulant medication
7. No treatment with stimulant drugs
8. No psychotropic drugs given for ≥ 6 months previously
Exclusion criteria
1. Children with severe intellectual retardation or neurological disease
2. Autistic and psychotic children
3. Pre-school children
4. Adolescents
5. Female
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Mean methylphenidate dosage: 9 received doses from 0.2 mg/kg to 0.5 mg/kg, 21 from
0.5 mg/kg to 0.9 mg/kg and 8 from 0.9 mg/kg to 1.4 mg/kg
Administration schedule: time points not stated
Duration of each medication condition: 3 weeks
Washout before study initiation: All were stimulant-naive
Medication-free period between interventions: 1 week
Titration period: A flexible dosage regimen was used after randomisation. Each child
began with 5 mg daily, with dosage adjustments made at 2- to 3-day intervals. The
optimum dosage was assessed for each child, in the light of clinical response and the
occurrence of side effects, to a maximum of 30 mg daily
Treatment compliance: Compliance with medication was rated as good or very good in
89%
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale: rated at the end of each treatment period, that is,
day 21
2. Parental Account of Childhood symptoms (PACS), hyperactivity scale: rated at
the end of each treatment period, that is, day 21
Serious adverse events
1. No serious physical effects of medication were encountered
Non-serious adverse events
1. Unwanted effects of medication were assessed by using the physician’s ratings of
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26 possible symptoms with full physical examination, rated at the end of each
treatment period, that is, day 21
Notes Sample calculation: no
Ethics approval: not stated
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: no; all methylphenidate treatment-naive
Comment from study authors (limitation)
1. Long-term treatment with stimulant drugs could not be assessed in this short-
term trial
Key conclusion of study authors
1. A good response to methylphenidate was predicted by higher levels of inattentive
and restless behaviour, impaired performance on tests of attention, clumsiness, younger
age and absence of symptoms of overt emotional disorder. DSM-III and ICD-9
diagnoses of “hyperactivity” were not good predictors
Comments from review authors
1. Long-term treatment with stimulant drugs could not be assessed in this short-
term trial
2. Children with tics or cardiovascular disease were excluded
3. Demographic characteristics and mean dose include the whole sample (n = 38).
However, upon receipt of correspondence from the trial author, outcomes measured
included the 26 individuals diagnosed with ADHD (DSM-III)
4. Invetigators tested both for methylphenidate vs placebo (effects of treatment) and
for end of first treatment period vs end of second treatment period (effects of occasion),
as well as the interaction between treatment and occasion. “The two order groups were
combined together for those measures that had shown no significant effects of test
occasion or interaction of occasion with treatment. For measures which did show main
or interactive effects of occasion, the two order groups were considered separately”
Email correspondence with trial authors: October 2013. We received from trial authors
no supplemental information regarding data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Children were randomly allocated to re-
ceive drug first or placebo first. This was
carried out by pharmacy staff, who knew
only the name and identifying number of
each case
Allocation concealment (selection bias) Low risk Allocation was carried out by pharmacy
staff, who knew only the name and identi-
fying number of each case
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablets were dispensed to a trial member,
who did not knowwhat they contained and
handed them to parents
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Psychiatrist supervising treatment also as-
sessed and recorded side effects, physical
findings and parents’ general impressions
at the end of each treatment; other asses-
sors of outcomes were blinded to the treat-
ment given but also to possible clues aris-
ing from physical effects of the drug. Be-
havioural measures were carried out inde-
pendently of one another by investigators
blind to results of the other tests and to
teacher ratings
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dataweremissing for 3 children:One child
had missing data on the Parental Account
of Childhood Symptoms because he had
been taken into care, and two children had
missing data on the Conners’ Teacher Rat-
ing Scale hyperactivity factor because they
had been excluded from school. Method of
imputation not described
Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias High risk Partially funded by grant from CIBA Ltd.,
which provided medicine and placebo
Conflicts of interest: Dr. Schachar was sup-
ported during this period by a fellow-
ship from the Medical Research Council of
Canada&&
Taylor 1993
Methods Four-week, double-blind, cross-over trial with 3 interventions
1. Two different doses of methylphenidate
2. Placebo
Each medication dose/placebo was given for 1 week
Participants Number of participants screened: 57
Number of participants included: 32 (27 boys, 5 girls) were randomly assigned to possible
drug condition orders
Number of participants followed up: 32
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R
Age: mean 10.26 years (range 7.0 to 12.9)
IQ: mean 107 (SD 16.2; range 78 to 139)
Methylphenidate naive: 12 (37.5%)
Ethnicity: no information
Country: Canada
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Setting: out-patient clinic
Comorbidity: no information
Comedication: no information
Sociodemographics: no information
Inclusion criteria
1. 7 to 12 years of age
2. Verbal or performance IQ ≥ 85
Exclusion criteria
1. No information
Interventions Participants were randomly assigned to possible drug condition orders of, respectively,
mean 6.72 mg (5 mg to 10 mg) and mean 11.88 mg (10 mg to 15 mg) methylphenidate
and placebo
Administration schedule: morning and noon
Duration of each medication condition: 1 week
Washout before study initiation: none
Titration period: none
Treatment compliance: no information
Outcomes Non-serious adverse events
1. Decreased appetite, trouble falling asleep, stomachache, headache, dysphoria;
withdrawn, tearful, anxious, licking lips, picking at skin; facial grimacing, repetitive
movements
Notes Sample calculation: no information
Ethics approval: no information
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes
Key conclusion of study authors
1. Only ERPs (event-related potentials) reflected slowed processing in children with
ADHD that normalised with appropriate medication
Email correspondence with study authors: January 2014. No supplemental information
was received. We therefore have no more information on numbers of participants with
non-serious adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised. All medication and placebo
testing was conducted under double-blind
conditions with randomly assigned testing
order
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active medication and placebo substances
were placed in identical red and white cap-
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Taylor 1993 (Continued)
sules in powder form. Matched on both
taste and appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk All medication and placebo testing was
conducted under double-blind conditions
with randomly assigned testing order, but
how blinding was done was not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Selection bias: This series of 32 children
withADHDdoes not include an additional
group of 12 children with ADHD, who af-
ter drug trials were deemed “non-respon-
ders”
Selective reporting (reporting bias) High risk Did not report adverse event data
Vested interest bias Unclear risk Not stated
Tervo 2002
Methods Triple-blind, 3-way, cross-over trial with 2 interventions
1. Methylphenidate at high and low doses
2. Placebo
Phases
1. High: 0.3 mg/kg b.i.d.
2. Low: 0.05 mg/kg b.i.d.
Participants Number of participants screened: not stated
Number of participants included: 63 (49 boys, 14 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 49
Number of withdrawals: 14
Diagnosis of ADHD: DSM-IV (combined (70%), hyperactive-impulsive (16%), inat-
tentive (5%), other (9%))
Age: mean 9 years 10 months (SD 2 years 10 months; range not stated)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: motor dysfunction (35%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
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Interventions Participants were randomly assigned to 1 of 2 possible dose levels of immediate-release
methylphenidate and placebo
Mean methylphenidate dosage: not stated
Administration schedule: twice daily; time points not stated
Duration of each medication condition: 6 days
Washout before study initiation: 1 day
Titration period: not stated
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ Parent Rating Scale: parent-rated at baseline and at end of period
2. Conners’ Teacher Rating Scale: teacher-rated at baseline and at end of period
General behaviour
1. Child Behavior Checklist (CBCL): parent-rated at baseline and at end of period
2. Home Situations Questionnaire: parent-rated at baseline and at end of period
3. Teacher report form (similar to CBCL): teacher-rated at baseline and at end of
period
4. School Situations Questionnaire: teacher-rated at baseline and at end of period
Non-serious adverse events
1. Side Effects Rating Scale: parent, at baseline and at end of period
Notes Sample calculation: no
Ethics approval: no
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. A limitation of this study is that neuropsychological functioning (e.g. intellect,
ability, memory, visual perceptual functioning) was not measured in all children
2. All children with MD had substantially impaired motor skills and “soft
neurological signs” such as mixed laterality, mirror or overflow movements or
choreiform movements
Key conclusions of study authors
1. Children with ADHD-MD were more likely to have severe ADHD combined
type and other neurodevelopmental and behavioural problems
2. Both groups of children had a linear dose response to medication (placebo, low,
high), and no evidence was found of a group-by-dose interaction or an overall group
effect at home or at school
Comments from review authors
1. IQ not reported
2. Four children withdrew from the study as the result of adverse reactions - all
taking high dose
Email correspondence with study authors: April 2013. We received from study authors
the full dataset in SPSS
Risk of bias
Bias Authors’ judgement Support for judgement
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Tervo 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Low risk Only the clinical pharmacist knew the se-
quence of phases
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules of medication and placebo were
made and dispensed as described by
Barkley (1988). Tablets were crushed and
placed within orange opaque gelatin cap-
sules. Capsules disguised the taste of
methylphenidate and lactose placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Triple-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 14 of the 63 trials were excluded from the
analysis because of inadequately completed
outcome measures. Four of the 14 children
did not complete the trial because of ad-
verse reactions to medication (e.g. irritabil-
ity, headache, stomachache). These chil-
dren received high-dose medication in the
first trial interval
Selective reporting (reporting bias) Low risk No protocol was published. All pre-spec-
ified outcomes of interest have been re-
ported
Vested interest bias Unclear risk No conflicts of interest have been disclosed
Tirosh 1993a
Methods 16-day, double-blind, cross-over, counterbalanced study with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 20 (16 boys, 4 girls). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 20
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (ADD 30%, ADHD 70%)
Age: mean 9.3 years (range 7 to 12)
IQ: mean 102 (SD 11)
Methylphenidate naive: 100%
Ethnicity: not stated
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Tirosh 1993a (Continued)
Country: Israel
Setting: out-patient clinic
Comorbidity: no
Comedication: no
Sociodemographics: middle (12), upper-middle (5) and low (3) socioeconomic status of
parents
Inclusion criteria
1. DSM-III diagnosis of ADHD
2. 7 to 12 years old
Exclusion criteria
1. Methylphenidate before study
2. Neurological, sensory or physical health problems
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo
Methylphenidate dose range: 0.3 mg/kg to 0.5 mg/kg
Administration schedule: twice daily
Duration of each medication condition: 8 days
Washout before study initiation: no (participants were methylphenidate naive)
Titration period: no
Treatment compliance: Parents were asked to bring their packages of tablets back for pill
count; no data
Outcomes ADHD symptoms
1. Abbreviated Parent Rating Scale (APRS), weekly
2. Teacher Rating Scale (TRS), weekly
Notes Sample calculation: no
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Funding: no funding
Key conclusions of study authors
1. Teacher Rating Scale: Placebo-drug difference correlated more significantly with
outcome measures than did the baseline drug difference
2. Study underlines the validity of a multi-measure placebo/drug trial in evaluating
the efficacy of methylphenidate for children with attention deficit disorder
Email correspondence with study authors: August 2013. Study author stated that data
were discarded (Ramstad 2013d [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation with a table of random
numbers
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Tirosh 1993a (Continued)
Allocation concealment (selection bias) Low risk Look-alike placebo tablets were supplied by
the hospital pharmacy and were similarly
administered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk No information
Tirosh 1993b
Methods Double-blind, controlled, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: unknown
Number of participants included: 11 (8 boys, 3 girls). Participants were randomly as-
signed to 1 of 2 possible drug condition orders
Number of participants followed up: 10
Number of withdrawals: 1
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: median 9 years 8 months (range 6.9 to 12.3 years)
IQ: median 106 (range 92 to 118)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Israel
Setting: out-patient clinic
Comorbidity: none
Comedication: none
Sociodemographics: low middle class (n = 2), middle class (n = 8)
Inclusion criteria
1. Healthy; no neurological deficit
2. Living with their natural parents
3. Medication-naive
Exclusion criteria
1. Not stated
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Tirosh 1993b (Continued)
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of 0.3
mg/kg to 0.4 mg/kg methylphenidate hydrochloride (total dose 10 mg to 15 mg) and
placebo
Mean methylphenidate dosage: 0.3 mg/kg to 0.4 mg/kg
Administration schedule: once daily at 7:30 AM on 6 of the 8 days. During the other 2
days, a second dose was administered at 2:00 PM
Duration of each medication condition: 8 days
Washout before study initiation: not stated
Medication-free period between interventions: 3 days
Titration period: none
Treatment compliance: As measured by returned package pill counts, this was rated as
full compliance for the 10 children remaining in the study
Outcomes ADHD symptoms
1. Conners’ Teacher and Parent Rating Scale: before therapy and after each
intervention
Non-serious adverse events
1. Sleep measurements, 10 minutes before “lights out” until morning awakening for
4 successive nights during each of the 3 respective periods
Notes Sample calculation: no
Ethics approval: not stated
Key conclusions of study authors
1. Results support the notion that ADHD is a centrally generated disorder
attributable to hypoarousal, which subsequently stimulates motor overactivity
2. Methylphenidate does not appear to affect sleep patterns adversely and possibly
normalises them in individuals with ADHD
Comment from review authors
1. No useful data
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: December 2013. We were unable to receive
supplemental data from study authors because the study is 20 years old (Ramstad 2013d
[pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk A drug-placebo sequence was used for chil-
dren assigned odd numbers in the study
and vice versa
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Look-alike placebo tablets were supplied
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Tirosh 1993b (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator who analysed the data was un-
aware of the drug-placebo sequence
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol available
Vested interest bias Unclear risk No information
Tourette’s Syndrome Study Group 2002
Methods Sixteen-week, multi-centre, randomised, double-blind, placebo-controlled, parallel trial
to assess the efficacy of clonidine and methylphenidate for children and adolescents with
ADHD and chronic tic disorder
Weeks 1 to 4: clonidine/placebo dose titration; week 5 to 8: addition ofmethylphenidate/
placebo dose titration; week 9 to 16: maintenance therapy
Participants Number of participants screened: not stated
Number of participants included: 136
Number of participants randomly assigned: methylphenidate 37, placebo 32, clonidine
34, methylphenidate + clonidine 33
Number of participants followed up: methylphenidate 33, placebo 25, clonidine 30,
methylphenidate + clonidine 33
Number of withdrawals: methylphenidate 4, placebo 7, clonidine 4, clonidine +
methylphenidate 4
Diagnosis of ADHD: DSM-IV: methylphenidate: combined 32%, hyperactive-impul-
sive 3%, inattentive 65%; placebo: combined 19%, hyperactive-impulsive 0%, inatten-
tive 81%; clonidine: combined 21%, hyperactive-impulsive 3%, inattentive 76%; cloni-
dine + methylphenidate: combined 33%, hyperactive-impulsive 3%, inattentive 64%
Mean age: methylphenidate 10.7 years (SD 2.0); placebo 9.7 years (SD 1.8); clonidine
9.7 years (SD 1.8); clonidine + methylphenidate 10.6 years (SD 1.9). Total age range 7
to 14
Sex: methylphenidate 34 boys, 3 girls; placebo 29 boys, 3 girls; clonidine 29 boys, 5 girls;
clonidine + methylphenidate 24 boys, 9 girls
Stimulant-naive: 42%
Ethnicity: methylphenidate 81% Caucasian; placebo 94% Caucasian; clonidine 94%
Caucasian; clonidine + methylphenidate 85% Caucasian
Country: USA
Setting: out-patient clinic
Comorbidity: tic disorder diagnosis 100%; primarily obsessive-compulsive disorder
(OCD) and oppositional defiant disorder (ODD). Furthermore, conduct disorder, gen-
eralised anxiety disorder andmajor depressive disorder.Methylphenidate: obsessive-com-
pulsive disorder (11%), oppositional defiant disorder (33%). Placebo: obsessive-compul-
sive disorder (22%), oppositional defiant disorder (41%). Clonidine: obsessive-compul-
sive disorder (15%), oppositional defiant disorder (48%). Clonidine + methylphenidate:
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Tourette’s Syndrome Study Group 2002 (Continued)
obsessive-compulsive disorder (16%), oppositional defiant disorder (31%)
Comedication: not stated
IQ: > 70
Sociodemographics: not stated. Participant groups were similar, except that participants
assigned tomethylphenidate (alone or in combination with clonidine) are approximately
1 year older, present a higher proportion of pubertal cases, show underrepresentation
of the inattentive subtype of ADHD (and overrepresentation of the combined subtype)
and have lower baseline Conners’ Abbreviated Symptom Questionnaire (ASQ)-Teacher
scores. A higher proportion of girls was found in the combined treatment group
Inclusion criteria
1. DSM-IV for ADHD
2. Designated teacher in daily direct contact with the participant had to indicate the
presence of a sufficient number of ADHD symptoms (rated as “pretty much” or “very
much”) in the classroom setting using the Disruptive Behavior Disorders Rating Scale
(updated to DSM-IV) to meet DSM-IV criteria; and had to rate the severity of ADHD
symptoms above specified cutoff scores (boys: grade 2 to 3 = 10, grade ≥ 4 = 9; girls:
grade 2 to 3 = 7, grade ≥ 4 = 6) on the Iowa Conners’ Teacher Rating Scale
3. Investigator’s rating of global functioning on the Child-Global Assessment Scale
(C-GAS) had to be 70 (indicating difficulty in ≥ 1 area, such as school)
4. DSM-IV for Tourette’s disorder, chronic motor tic disorder or chronic vocal tic
disorder
Exclusion criteria
1. Secondary tic disorder (tardive tics, neuroacanthocytosis, Huntington disease)
2. Major depression, pervasive developmental disorder, autism, psychosis, anorexia
nervosa, bulimia, serious cardiovascular or other medical disorder that would preclude
the safe use of methylphenidate or clonidine, impaired renal function, pregnancy
3. Mental retardation
4. The following cardiac conditions: prolonged QTc interval (> 440 milliseconds),
high-grade ventricular ectopy, AV block > 1 degree, bundle branch block,
intraventricular conduction block (100 milliseconds), pacemaker rhythm or heart rate
< 60 on the electrocardiogram, cardiomyopathy, complex heart disease, aortic or
pulmonary stenosis, family history of long QT syndrome, cardiomyopathy or
premature sudden death (age 45 years), history of syncope and blood pressure < 2 SD
from age- and sex-adjusted mean
5. Other medications for treatment of ADHD, tics or other associated behavioural
symptoms. Any such treatment had to be discontinued ≥ 6 weeks (2 weeks for
methylphenidate) before enrolment
Interventions Participants were randomly assigned tomethylphenidate (Ritalin; Novartis) alone, cloni-
dine alone, clonidine + methylphenidate or placebo
Methylphenidate dosage: methylphenidate alone 25.7 mg/d, methylphenidate + cloni-
dine 26.1 mg/d
Administration schedule: 2 to 3 times daily
Duration of intervention: 12 weeks (4-week titration of methylphenidate, 8-week main-
tenance phase)
Titration period: 4-week initial dose titration period for clonidine, after which came
4-week dose titration for methylphenidate. Both titration periods took place after ran-
domisation
Treatment compliance: Pill count monitored compliance
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Tourette’s Syndrome Study Group 2002 (Continued)
Outcomes ADHD symptoms
1. ADHD Conners’ Abbreviated Symptom Questionnaire for Teachers (ASQ-
Teacher): rated at baseline and at week 16
2. Iowa Conners’ Teacher Rating Scale: rated at baseline and at week 16
3. Conners’ Abbreviated Symptom Questionnaire for Parents (ASQ-Parent): rated at
baseline and at weeks 8, 12 and 16
General behaviour
1. Iowa Conners’ Teacher Rating Scale: rated at baseline and at week 16
Quality of life
1. Children’s Global Assessment Scale: rated by site investigator at baseline and at
weeks 8, 12 and 16
Non-serious adverse events
1. Yale Global Tic Severity Scale (YGTSS): rated by site investigator at weeks 8, 12
and 16
2. Tic Symptom Self-Report Scale (TSSR): parent/participant- and teacher-rated at
weeks 8, 12 and 16 (teacher ratings only at week 16)
3. Global Tic Rating Scale: parent/participant- and teacher-rated at weeks 8, 12 and
16 (teacher ratings only at week 16)
4. Vital signs, ECG: rated at weeks 8, 12 and 16
5. Side Effects Rating Scale: rated at weeks 8, 12 and 16 (teacher ratings only at
week 16)
6. Independent safety monitoring committee, consisting of child psychiatrist,
paediatric cardiologist, paediatrician and statistician; reviewed data regarding adverse
events throughout the study
Notes Sample calculation: yes; 120 participants
Ethics approval: yes; the protocol was approved by the institutional review board at each
site
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Our study did exclude participants with known cardiac problems, so the safety of
combined clonidine and methylphenidate in this group was not addressed
Key conclusions of study authors
1. Our study indicates that prior concerns that methylphenidate worsens tics and
that the drug should be avoided in patients with tics may be unwarranted
2. The most effective treatment for ADHD in our trial was the combination of
clonidine and methylphenidate, although the incremental benefit of adding clonidine
to methylphenidate came at the expense of additional side effects, particularly sedation
Comments from review authors
1. Data extracted from week 4 to week 16 (from when methylphenidate was
introduced to participants)
2. Not able to use study data in our analyses
Risk of bias
Bias Authors’ judgement Support for judgement
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Tourette’s Syndrome Study Group 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-gener-
ated randomisation. Stratification by cen-
tre (investigator) and sexual maturity status
(prepubertal: Tanner stage I to II; pubertal:
Tanner stage III to V) Blocking was used to
ensure approximate balance among treat-
ment groups within each stratum
Allocation concealment (selection bias) Low risk Sealed envelopes that contained partici-
pants’ treatment assignments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded: participants, clinicians, data col-
lectors, outcome assessors, data analysts,
data safety and monitoring committee,
manuscript writers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only the programmer in the Biostatistics
Center who generated the plan and the
pharmacist in the Pharmacy Center who
packaged and labeled the drug were aware
of treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary statistical analyses were performed
according to the ITT principle and were
based on all randomly assigned partici-
pants, as randomised. For analysis of out-
come variables for efficacy, if a participant
was missing a response at a particular visit,
the last available observation for that par-
ticipant was carried forward and imputed
for that visit
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): no
Selective reporting (reporting bias) Low risk No
Vested interest bias Unclear risk Vested interest: the National Institute of
Neurological Disorders and Stroke, the
General Clinical Research Center, the Na-
tional Center for Research Resources, the
Tourette Syndrome Association
Boeringer Ingelheim Inc. (particularly Dr.
Virgil Dias), for supplying clonidine and
matching placebo; Bausch and Lomb, Inc.,
for supplying small gifts for our study par-
ticipants
Conflicts of interest: none declared
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Tucker 2009
Methods Multi-centre, open-label RCT including behaviour treatment as cointervention with 2
arms
1. Extended-release methylphenidate and behavioural treatment
2. Behavioural treatment
Participants Number of participants screened: 142
Number of participants included: 109
Number of participants followed up: 104 (66 boys, 38 girls)
Number of withdrawals: 5
Diagnosis of ADHD: DSM-IV (subtypes not described)
Age: mean 8.4 years (range 6 to 12)
IQ: not stated; all age-appropriate cognitive functioning
Methylphenidate naive: 100%
Ethnicity: Caucasian (73.1%), African American (24.0%), other (2.9%)
Country: USA
Setting: out-patient clinic
Comorbidity: none
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. DSM-IV diagnosis of ADHD
2. Age-appropriate cognitive functioning
Exclusion criteria
1. Previous exposure to methylphenidate or any amphetamine-based medication
2. Positive urine drug screen
3. Clinically significant abnormality in the screening assessment (physical exam, vital
signs, laboratory tests)
4. Cardiac abnormality
5. History of seizures or schizophrenia; current diagnosis of mood disorder or
anxiety disorder
Interventions Participants were randomly assigned to extended-release methylphenidate plus be-
havioural treatment or to behavioural treatment alone
Mean methylphenidate dosage: not stated
Administration schedule: once daily
Duration of intervention: 3 months
Titration period: initiated after randomisation. Methylphenidate was started at 10 mg/
d and could be increased weekly in intervals of 10 mg/d to a maximum of 60 mg/d.
Methylphenidate was administered to achieve the desired clinical effect with minimum
or no side effects
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Conners’ ADHD/DSM-IV Scales for Parents: measured at baseline and at end of
treatment
Non-serious adverse events
1. Investigating for potential genotoxic effects: No significant differences were found
2. Chromosomal aberrations (CAs), including micronuclei (MN) and sister
chromatid exchanges (SCEs), in cultured peripheral blood lymphocytes. Blood samples
were obtained from all participating patients for evaluation of cytogenetic status at
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Tucker 2009 (Continued)
baseline and after 3 months of treatment. These data are not used in the review
Notes Sample calculation: yes
Ethics approval: yes; approved by the ethics committees for all 17 study centres
Key conclusion of study authors
1. These findings support the notion that methylphenidate does not induce
chromosomal alterations nor other types of genetic damage in children treated for
ADHD
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no; all participants
were Methylphenidate naive
Email correspondence with study authors: December 2013 and January 2014. Not able
to contact study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further description
Allocation concealment (selection bias) Unclear risk Randomisation was stratified by age group
(6 to 8 years and9 to12 years) andby centre
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evaluation of cytogenetic damage by
blinded slide readers
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome data reported for 68 of 109 ran-
domly assigned participants
Selective reporting (reporting bias) Unclear risk No protocol identified
Vested interest bias High risk This work was funded by Novartis Phar-
maceuticals Corporation
Conflicts of interest: Some study authors
were employed by Novartis (5 of 8 had a
Novartis email address)
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Ullmann 1985
Methods Eight-week, cross-over trial
1. Three doses of methylphenidate (0.3 mg/kg, 0.5 mg/kg, 0.8 mg/kg)
2. Placebo
Two phases
1. Phase 1: 4-week fixed increase in methylphenidate dose
2. Phase 2: 4-week randomised, cross-over trial
The trial was conducted over 3 years
Participants Number of participants screened: not stated
Number of participants included: 86. Participants were randomly assigned to 3 doses of
methylphenidate and placebo
Number of participants followed up: 86 (67 boys, 19 girls)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (ADD (15.1%), ADD-H (70.9%), other (14.0%))
Age: mean 8.6 years (SD 1.8; range not stated)
IQ: > 70
Methylphenidate naive: not stated
Ethnicity: African American (17.4%), other (82.6%)
Country: USA
Setting: not stated
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis according to DSM-III
Exclusion criteria
1. Not described
Interventions Participants were randomly assigned to different doses of methylphenidate (0.3 mg/kg,
0.5 mg/kg and 0.8 mg/kg) and placebo
Administration schedule: once daily, before school
Duration of each medication condition: 1 week
Washout before study initiation: dose taken in the morning to the next day’s dose
Titration period: 4 weeks
Treatment compliance: “compliance were probably high”
Outcomes ADHD symptoms
1. ADD/H Comprehensive Teacher Rating Scale: completed by teachers on a weekly
basis, on the last day before treatment switching
Notes Sample calculation:no information
Ethics approval:no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comment from study authors
1. Order effects were non-significant, that is, ratings were similar for the first and
second weeks on each dose, regardless of the order in which doses were given
Key conclusion of study authors
1. Results from the study show that methylphenidate has a major effect in
improving attention and is helpful in decreasing activity levels but often has only a
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minor effect on deficient social skills and oppositional (aggressive) behaviour
Email correspondence with study authors: not able to find first or second study author’s
contact information; therefore not able to request supplemental data necessary for meta-
analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment
Allocation concealment (selection bias) High risk No description; only “methylphenidate in
opaque capsules”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Teacher rating under blinded conditions
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were pooled for a total of 86 partici-
pants
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Unable to obtain protocol
Vested interest bias Unclear risk National Institutes of Mental Health
(NIMH). Ciba-Geigy provided medica-
tion and placebo
Conflicts of interest: no information
Ullmann 1986
Methods Double-blind, cross-over trial in which participants were randomly assigned to the fol-
lowing conditions
1. Three different doses of methylphenidate (0.3 mg/kg, 0.5 mg/kg and 0.8 mg/kg)
2. Placebo
Participants Number of participants screened: not stated
Number of participants included: 118. Participants were randomly assigned to 3 different
doses of methylphenidate and placebo
Number of participants followed up: 118 (92 boys, 26 girls)
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 8.6 years (range 6 to 14)
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IQ: > 70
Methylphenidate naive: not stated
Ethnicity: Caucasian (81.4%), African American (18.6%)
Country: USA
Setting: school setting and out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Diagnosis of ADHD
Exclusion criteria
1. None mentioned
Interventions Participants were randomly assigned to 3 different doses of methylphenidate (0.3 mg/
kg, 0.5 mg/kg and 0.8 mg/kg) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: not stated
Duration of each medication condition: 1 week
Washout before study initiation: no information
Titration period: none
Treatment compliance: excellent compliance in all but a few children
Outcomes ADHD symptoms
1. ADD/H Comprehensive Teacher Rating Scale: rated by teachers at the end of
each school week
Non-serious adverse events
1. Teacher Checklist: rated by teachers at the end of each school week
Unable to obtain data on adverse events, as could not locate contact details of the first
or second study author (see notes)
Notes Sample calculation: no
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Double-blind placebo evaluation of children with ADD can and should be done
by practitioners to avoid medicating children who are responding to non-specific
effects of drugs
Comment from study authors (on side effects)
1. Very few children were reported completely free of adverse effects; however, these
were, on the whole, mild effects. In fact, a slightly higher proportion of children were
reported to show adverse psychological effects at baseline (0.60) and on baseline (0.53)
than on medication (0.46), but these differences were not significant
Comment from review authors
1. Used data from MPH responders in our analyses, which yielded a highly biased
result
Email correspondence with study authors: not able to find first or second study author’s
contact information; therefore not able to obtain additional data (e.g. data (table) on
adverse effects) from study authors
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Low risk Daily doses of methylphenidate or placebo
were placed in gelatin capsules to disguise
taste and dose differences; medication for
eachweekwas packaged in a dated envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Children, parents and teachers were
blinded to dose order, as was the assistant
who recorded data sent in by the teachers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Children, parents and teachers were
blinded to dose order, as was the assistant
who recorded data sent in by the teachers
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk No protocol
Vested interest bias Unclear risk Supported in part by aNational Institute of
Mental Health (NIMH) grant. Ciba-Geigy
provided medication and placebo
Conflicts of interest: not declared
Urman 1995
Methods Double-blind, placebo-controlled, within-participant (cross-over) trial looking at car-
diovascular effects of methylphenidate (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg) doses at
baseline and after 60 and 120 minutes post methylphenidate challenge in 2 groups of
participants with ADHD
1. ADHD without anxiety
2. ADHD with anxiety
Participants Number of participants screened: not stated
Number of participants included: 63 (58 boys, 5 girls)
Number of participants followed up: 63 (ADHD without anxiety 34, ADHD with
anxiety 29)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R (but “82% of the ADHD and 93% of the ADHD/
ANX group” would meet theDSM-IV criteria for a diagnosis of ADHD combined type)
Age: ADHD without anxiety, mean 9.1 years (SD 1.3; range 6 to 12); ADHD with
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anxiety, mean 8.7 years (SD 1.4) (overall range 6 to 12)
IQ: not stated
Methylphenidate naive: 63 (100%)
Ethnicity: Caucasian (90%), “African or Asian descent” (10%)
Country: Canada
Setting: not stated
Comorbidity: ADHD group: oppositional defiant disorder (14; 42%), conduct disorder
(5; 15%); ADHD with anxiety group: oppositional defiant disorder (11; 38%), conduct
disorder (8; 28%). Also, in the ADHD with anxiety group, 3 met the DSM-III criteria
for overanxious disorder, 2 met criteria for separation anxiety disorder and 5 met criteria
for both overanxious and separation anxiety disorders)
Sociodemographics: “The children tended to come from middle-class families”
Inclusion criteria
ADHD with anxiety group
1. T score ≤ 1 SD above the mean for age and sex on both the RCMAS and the
Trait Scale of the STAIC
ADHD without anxiety group
1. T score > 1 SD above the mean for age and sex on the RCMAS and/or the Trait
Scale of the STAIC
2. “The children could also meet diagnostic criteria for any anxiety disorder based
on the parent interview”
Exclusion criteria
ADHD without anxiety group
1. “Any child who scored within this range but met diagnostic criteria for any anxiety
disorder on the basis of parent diagnostic interview was excluded from the analysis”
Interventions Participants were randomly assigned to 1 of 4 possible drug condition orders of placebo
and methylphenidate (0.3 mg/kg, 0.6 mg/kg or 0.9 mg/kg), given once daily over a 4-
day period. Dosage was based on a child’s body weight to the nearest 2.5 mg. Chil-
dren followed the same routine for every test session with pre-methylphenidate mea-
surements and with measurements at 60 minutes and again at 120 minutes after taking
methylphenidate
Mean methylphenidate dosage: not stated
Duration of each medication condition: once daily, administered over a 4-day period -
each medication condition given once to each child
Washout before study initiation: All were methylphenidate naive
Medication-free period between interventions: not stated
Treatment compliance: “Any child with missing data for a particular measure was ex-
cluded from the analysis of that measure”, but study authors did not indicate the overall
quantity of missing data. “Medication was administered by a research nurse”
Outcomes Non-serious adverse events
1. Blood pressure (systolic and diastolic)
2. Heart rate (radial pulse measured for 60 seconds)
Notes Sample calculation: no information
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: not stated
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Comment from study authors
1. From a clinical perspective, stimulant-related increases in heart rate and blood
pressure in both groups of children with ADHD were modest and generally of little
clinical concern. Nonetheless, the present findings of an exaggerated cardiovascular
response to methylphenidate in the ADHD with anxiety group should alert clinicians
to the possibility of a differential medication response in anxious ADHD children
Key conclusions of study authors
1. This study yielded 2 major findings. First, it demonstrated that baseline
cardiovascular function did not differ between children with ADHD and children with
ADHD and anxiety. Second, it revealed the presence of an exaggerated diastolic blood
pressure response to methylphenidate in children with ADHD and anxiety
2. Data from the present study add to growing evidence that children with ADHD
and anxiety constitute a distinct subgroup of children with ADHD. Moreover, the
exaggerated response of children with ADHD and anxiety to methylphenidate suggests
the presence of abnormal regulation of norepinephrine (NE) function in this group,
compared with that observed in the anxiety disorder population
Comments from review authors
1. Inadequate description of method for blood pressure and heart rate measurement
2. Measurement of heart rate was presumably carried out by palpating radial pulse -
pulse oximetry or ECG would produce more reliable results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The order of medications was counter-
balanced and determined by random as-
signment such that an approximately equal
number of children received each dose on
a given day in the trial”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All medication was prepared by the hos-
pital pharmacy and packaged in opaque
gelatin capsules, to avoid detection of dose
and taste”; “Children, parents and research
staff were blind to the medication condi-
tions”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Medication was administered by a re-
search nurse who was blind to children’s
medication condition and classification of
anxiety”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
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Selective reporting (reporting bias) Unclear risk Not stated
Vested interest bias Low risk This work was supported in part by funds
from the Medical Research Council of
Canada and the Research Institute of the
Hospital for Sick Children
Conflicts of interest: not declared
Van der Meere 1999a
Methods Seven-week, randomised, double-blind, placebo-controlled, parallel-group trial with 3
arms
1. Methylphenidate
2. Placebo
3. Clonidine
Participants Number of participants screened: not stated
Number of participants included: 72 (62 boys, 10 girls)
Number of participants randomly assigned: methylphenidate 24, placebo 24, clonidine
24
Number of participants followed up in each arm: methylphenidate 23, placebo 24
Number of withdrawals in each arm: methylphenidate 1, placebo 0
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 8.8 years (range 7 to 12)
IQ: > 70
Methylphenidate naive: 100%
Ethnicity: mainly Caucasian
Country: the Netherlands
Setting: out-patient clinic
Comorbidity: conduct disorder (11%), oppositional defiant disorder (33%), depressive
disorder (3%), overanxious disorder (1%), dysthymia (3%), generalized tonic-clonic
seizures (1%), ventricular septal defect (1%), congenital hypothyroidism (1%), preco-
cious puberty (1%), deaf in right ear (1%), atresia in 1 ear (1%)
Comedication: yes; for participants who had diseases that required it, for example, hy-
pothyroidism
Sociodemographics: 44% from lower socioeconomic families
Differences between groups
1. No significant differences in age and IQ were noted between the 2 groups
Inclusion criteria
1. Boys and girls
2. 6 to 15 years of age
3. IQ > 70
4. Living in a family home and attending school
5. DSM-III-R diagnosis of ADHD, ADHD symptoms impeding development and
psychological/educational treatments with insufficient effect
6. No earlier use of stimulant drugs or clonidine and no psychoactive medications of
any kind in the last 6 months
7. No medical contraindications
520Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Van der Meere 1999a (Continued)
8. No important changes expected for the course of the trial
9. Iit was considered clinically meaningful by both parents and the attending
physician to try “hyperactivity medication”
Exclusion criteria
1. Additional psychoactive drugs during the trial
2. Pervasive developmental disorder or tic disorder. These participants were included
in other trial groups
Interventions Participants were randomly assigned to methylphenidate, placebo or clonidine
Total oral daily methylphenidate dosage: 0.06 mg/kg
Mean of the absolute methylphenidate dose: 9.85 mg (2.26)
Administration schedule: breakfast and lunchtime
Duration of intervention: 7 weeks
Titration: no, but dosage adjustments were made/allowed during first weeks
Titration period: none
Treatment compliance: maintained and checked by instructions (both oral and written)
to both parents and child, and by counting tablets remaining at the end of treatment.
Only 1 participant in the methylphenidate group showed poor compliance
Outcomes ADHD symptoms
1. Conners’ Teacher Rating Scale: baseline and at week 7
General behaviour
1. Parent and Teacher Versions of the abbreviated Groninger Behaviour Observation
Scale (GOO and GBO, respectively): baseline and at weeks 3, 5 and 7
2. Parent and Teacher Versions of the abbreviated Groninger Behaviour Checklists
(GGGS and GGBS, respectively): baseline and at week 7
3. GPO rating: baseline and at week 7
Non-serious adverse events
1. Parent ratings of drowsiness, insomnia, decreased appetite, nausea, headache,
nervousness, motor restlessness, feelings of dizziness, dry mouth, nightmares, apathy,
irritability and “other complaints”
2. Child and parents were asked about all kinds of physical and behavioural
complaints or changes at study visits
Notes Sample calculation: yes (≥ 15 participants in each group)
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. We concluded that the state regulation problem in ADHD is resistant to
methylphenidate and clonidine
Email correspondence with study authors: September 2013. We obtained supplemental
information regarding a publication with information about randomisation and supple-
mental data
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The statistician sent the randomisation
list to the pharmacist. Participants were
then randomly assigned by a research
pharmacist. To ensure blinding, pharma-
cists applied randomisation blocks at ran-
dom at a length of 2 or 4 participants.
Methylphenidate and matching placebos
were used
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Teacher, parent, clinician, child and experi-
menter were blind to treatment conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Teacher, parent, clinician, child and experi-
menter were blind to treatment conditions
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selection bias: no, but dosage adjustments
were made for several participants because
of annoying adverse events
Selective reporting (reporting bias) Low risk No
Vested interest bias High risk This study was supported by grants from
the Sophia Foundation for Medical Re-
search and Boehringer Ingelheim BV, the
Netherlands
Wallace 1994
Methods Double-blind, single-participant, randomised, cross-over trial
1. Methylphenidate
2. Placebo
Conducted in 11 hospitalised children with ADHD
Participants Number of participants screened: not stated
Number of participants included: 11. Participants were randomly assigned to 1 of 2
conditions: methylphenidate and placebo
Number followed up: 11
Sex: not reported
Number of withdrawals: 0
Diagnosis of ADHD: DSM-III-R (subtype not described)
Age: mean 9 years 5 months (range 4 to 13 years)
IQ: not stated
Methylphenidate naive: not stated
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Ethnicity: not stated
Country: USA
Setting: hospital/out-patient clinic
Comorbidity type: not stated
Sociodemographics: not stated
Inclusion criteria
1. Children diagnosed with ADHD who were hospitalised at a psychiatric hospital
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to methylphenidate and placebo on a daily basis
Mean methylphenidate dosage: not stated
Administration schedule: daily
Duration of each medication condition: methylphenidate 2 to 7 days, placebo 3 to 6
days
Washout before study initiation: not described
Medication-free period between interventions: none
Titration period: Optimal dose was based on maximal effectiveness and minimal side
effects, but this appears to reflect daily response to methylphenidate
Treatment compliance: not described
Outcomes ADHD symptoms
1. Abbreviated Conners’ Teacher Rating Scale (15-item): rated by teachers and by
day and night nursing staff
Serious adverse events
1. Side effects mentioned but not reported
Non-serious adverse events
1. Side effects mentioned but not reported
Notes Sample calculation: not stated
Ethics approval: not stated
Comment from study authors
1. Assigning highly consistent rates would reduce variance in measurements
Key conclusions of study authors
1. n-of-1 trial is useful for evaluating the effectiveness of methylphenidate in
individual patients with ADHD
2. Short duration of MPH action allows for multiple cross-over trials over a brief
time
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Comment from review authors
1. Data are not reported in a suitable form for meta-analysis; therefore we could use
no data from this study
Email correspondence with study authors: We could find no contact information; there-
fore, we could not get additional data through personal email correspondence with study
authors
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence was determined by “coin toss
method”
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “After completion of each trial, the treat-
ment code was broken”, but it was not
clear whether the psychiatry physician and
the fellow who made the decision to cease
methylphenidate were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk All data appear to have been reported, but
methylphenidate was discontinued on the
basis of results; therefore, data collection
did not continue for some participants
Selective reporting (reporting bias) Unclear risk Protocol not identified
Vested interest bias Unclear risk Veterans Administration Medical Center,
Vermont
Conflicts of interest: not declared
Wallander 1987
Methods Double-blind, placebo-controlled, cross-over trial with 3 interventions
1. Methylphenidate 0.3 mg/kg
2. Methylphenidate 0.6 mg/kg
3. Placebo
Participants Number of participants screened: 28 (20 boys, 8 girls)
Number of participants included: not clear. Participants were randomly assigned to 1 of
possible drug condition orders
Number of participants followed up: unclear
Number of withdrawals: unclear
Diagnosis of ADHD: DSM-III (subtype not stated)
Age: mean 8.4 years (range 6 to 12)
IQ: mean 79.64
Methylphenidate naive: 28 (100%)
Ethnicity: not stated
Country: USA
Setting: out-patient clinic and in-patient ward
Comorbidity: not stated
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Comedication: not stated
Sociodemographics: 3.52 (Hollingshead-Redlich Index)
Inclusion criteria
1. Meeting DSM-III criteria for the diagnosis of ADHD, as assessed by an
experienced psychiatrist and paediatrician
2. Scoring 2 SD above the mean for age and sex on both hyperactivity and
distractibility factors of the Conners’ Teacher Rating Scale
3. Naive to stimulant medication
Exclusion criteria
1. No information
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of
methylphenidate (0.3 mg/kg and 0.6 mg/kg) and placebo
Mean methylphenidate dosage: no information
Administration schedule: twice a day, 8:30 AM and noon
Duration of each medication condition: 12 days for in-patients and 19 days for out-
patients (mean 15.25 days)
Washout before study initiation: none
Medication-free period between interventions: 68 hours
Titration period: none
Treatment compliance: no information
Outcomes General behaviour
1. Oppositional behaviour
Notes Sample calculation: none
Ethics approval: no information
Key conclusions of study authors
1. Results indicate no change in social behaviours, as participants decreased their
display of problem behaviours as a function of stimulants
2. Peers and teachers responded and attendees less to them, however, when they
received stimulants as compared with placebo
Comment from review authors
1. Data could not be used in meta-analyses because some were missing
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: December 2013. No supplemental informa-
tion available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Receiving interventions in counterbal-
anced orders
Allocation concealment (selection bias) Unclear risk No information
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Agreement of 90% across all categories had
to be reached with this validity observer
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Protocol not identified
Vested interest bias Low risk Funded in part by Eunice Kennedy Shriver
National Institute of ChildHealth andHu-
man Development (NICHD) grants and
the University of Southern California Fac-
ulty Research and Innovation Fund
Conflicts of interest: not declared
Waxmonsky 2008
Methods Nine-week therapeutic summer camp consisting of a cross-over trial with 4 interventions
1. Placebo
2. Methylphenidate 0.15 mg/kg t.i.d.
3. Methylphenidate 0.3 mg/kg t.i.d.
4. Methylphenidate 0.6 mg/kg t.i.d.
Varied daily within a cross-over design of 3 intensities of behaviour modification therapy
1. No
2. Low
3. High
Each lasted 3 weeks
Participants Number of participants screened: 106 participants in the 2003 and 2004 Summer Treat-
ment Program (University of Buffalo)
Number of participants included: 101. ADHD subgroup 33, ADHD + severe mood
dysregulation (SMD) subgroup 68
Number of participants followed up: 99
Number of withdrawals: 2
Diagnosis of ADHD: DSM-IV (combined (92%), hyperactive-impulsive (not stated),
inattentive (not stated))
Age: mean 8.5 years (range 5 to 12)
IQ: mean105
Sex: 82 boys, 19 girls
Methylphenidate naive: not stated
Ethnicity: predominantly Caucasian
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Country: USA
Setting: out-patient clinic (Summer Treatment Program)
Comorbidity: oppositional defiant disorder (54%), conduct disorder (12%)
Comedication: not stated
Sociodemographics: predominantly middle class
Inclusion criteria
1. 5 to 12 years of age
2. Participants were required to stop all psychotropic medication 1 week before
intake
3. DSM-IV diagnosis of ADHD
4. ADHD-related impairment in ≥ 2 realms according to Parent and Teacher
Versions of the Impairment Rating Scale (IRS)
5. IQ > 80
6. Subgroups
i) ADHD: not meeting National Institutes of Mental Health criteria for severe
mood dysregulation
ii) ADHD plus severe mood dysregulation: meeting National Institutes of
Mental Health criteria for severe mood dysregulation, and having Young Mania Rating
Scale (YMRS) score ≥ 12 based on the last month’s behaviour and Conners’ Global
Index (CGI) mania severity score ≥ 3
Exclusion criteria
1. History of seizures or other neurological problems
2. Medical history that would involve considerable risk in taking stimulant
medication
3. History or concurrent diagnosis of any of the following disorders: pervasive
developmental disorder, schizophrenia or other psychotic disorders, sexual disorder,
organic mental disorder or eating disorder
4. Documented serious adverse reaction to methylphenidate
5. Significant developmental delays or autistic spectrum illness
6. Active use of psychotropic medication for disorders besides ADHD, including use
of antidepressants or mood-stabilising medications
7. Meeting full criteria for the narrow-phenotype criteria of bipolar disorder or in
need of urgent psychiatric treatment (active suicidal ideation). Participants newly
identified with major depressive disorder or bipolar disorder on the Diagnostic
Interview Schedule for Children were directly assessed by an M.D.- or Ph.D.-level
clinician
Interventions Participants attended a Summer Treatment Program each Monday through Friday for 9
weeks. Participants were randomly assigned possible drug condition orders of 0.15 mg/
kg t.i.d., 0.3 mg/kg t.i.d. and 0.6 mg/kg t.i.d. and placebo
Average methylphenidate dosages: 5 mg, 10 mg and 18 mg for 0.15 mg/kg, 0.3 mg/kg
and 0.6 mg/kg doses, respectively
Administration schedule: 7:45 AM, 11:45 AM and 3:45 PM
Duration of each medication condition: Each dose varied daily and was repeated 3 or 4
times within each behavioural treatment condition
Study duration: Monday through Friday for 9 weeks, totalling 45 days
Washout before study initiation: 1 week
Medication-free period between interventions: 0 to 2 days
Titration period: none
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Treatment compliance: not stated
Cointervention: Three behavioural conditions (no behaviour modification, low-inten-
sity behaviour modification and high-intensity behaviour modification) are delivered in
random order, with each condition lasting 3 weeks. Parents attended training sessions
and implemented behaviour programmes at home
Outcomes Non-serious adverse events
1. Pittsburgh Side Effects Rating Scale: completed daily by camp staff and parents
Notes Sample calculation: not stated
Ethics approval: yes; by the Health Sciences Institutional Review Board (IRB) of the
University of Buffalo
Comment from study authors
1. Limitations: Trial duration of only 9 weeks, lack of daily completion of mood
assessments and limited generalisation potential due to a population of predominantly
Caucasian and middle-class participants
Key conclusion of study authors
1. Methylphenidate and behaviour modification therapy are tolerable and effective
treatments for children with ADHD and severe mood dysregulation, but additional
treatments may be needed to optimise their functioning
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
MPH before randomisation: yes; excluded patients with prior serious reactions to
methylphenidate
Any withdrawals due to adverse events: 1 withdrew because of tic-like movements
Email correspondence with study authors: August 2014. Obtained supplemental infor-
mation regarding randomisation, allocation concealment and handling of missing data.
Not possible to retrieve safety data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random orders were generated by com-
puter with the restrictions that each con-
dition occurred at least once in each week.
Children were assigned to previously gen-
erated codes at enrolment
Allocation concealment (selection bias) Low risk Because thiswas a cross-over study inwhich
all children received all conditions multi-
ple times, each child’s entire 9-week sched-
ule was assigned at once. Treatment orders
were concealed in an opaque envelope and
were stored in a locked cabinet in the med-
ication lab. Only authorised staff members
had access to this cabinet
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Children, parents and staff
were blinded to medication conditions.
Placebo and methylphenidate were pack-
aged in identical opaque capsules to main-
tain blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Parents and staff were
blinded to medication conditions
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
Vested interest bias High risk This study was funded by National In-
stitute of Mental Health (NIMH) Grant
MH62946 and a Klingenstein Third Gen-
eration Foundation Fellowship in Child
and Adolescent Depression Research
Conflicts of interest: Several authors have
affiliations with pharmaceutical companies
Whalen 1990
Methods Two cross-over trials with 3 interventions conducted 3 years apart
1. Methylphenidate 0.3 mg/kg
2. Methylphenidate 0.6 mg/kg (maximum 25 mg)
3. Placebo
Participants Number of participants screened: unknown
Number of participants included: study one 24, study two25. Participantswere randomly
assigned to 1 of the possible drug condition orders
Number of participants followed up: study one 24 (22 boys, 2 girls), study two 25 (25
boys)
Number of withdrawals: study one 0, study two 0
ADHD diagnosis: study 1 DSM-III-R, study 2 DSM-III
Age: study one mean 9 years 8 months (range 6.4 to 13.2 years), study two mean 9 years
1 month (range 6.4 to 12.5 years)
IQ: no mental retardation (both studies)
Methylphenidate naive: 0 % (both studies)
Ethnicity: study one: Caucasian (92%), African American (4%), Hispanic (4%); study
2: Caucasian (72%), African American (12%), Asian (8%), Hispanic (8%)
Country: USA
Setting: out-patient clinic (Summer Treatment Program)
Comorbidity: study one not stated, study two no gross neurological dysfunction
Comedication: not stated
529Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Whalen 1990 (Continued)
Sociodemographics: All were from middle- or low middle-income backgrounds (both
studies)
Inclusion criteria
1. Study one
i) Primary diagnosis of ADDH
ii) Taking methylphenidate on a regular basis before the programme
iii) Conners’ ADHD Stigma Questionnaire: ratings from parents > 15
2. Study two
i) Diagnosis of hyperactivity, ADD or ADDH
Exclusion criteria
1. No information
Interventions Participants were randomly assigned to 1 of the possible drug condition orders of 0.3
mg/kg (study one) or 0.6 mg/kg (study two) of methylphenidate and placebo. As regards
study two, a single dose of 25 mg was set as the upper limit
Mean methylphenidate dosage: 8.75 mg
Administration schedule: twice a day, morning and lunchtime
Duration of each medication condition: 1 week
Washout before study initiation: unknown
Medication-free period between interventions: 20 hours
Titration period: none
Treatment compliance: good (2 staff dispensed the medication for ingestion)
Outcomes General behaviour
1. UC-Conners’ Child Behavior Scale (UC-CCBS): rated once by staff and twice by
naive university undergraduates
Notes Sample calculation: no
Ethics approval: no information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: yes; only participants
taking maintenance dosage of methylphenidate or well titrated
Comment from study authors
1. Studies used similar procedures, with a few exceptions. The 2 sessions (i.e. study
two) occurred between 1 and 2 weeks apart, rather than on consecutive days. Thus, the
opportunity for medication washout was greater. Study two teams consisted of 3 rather
than 4 players. In study two, 2 boys received scores below the hyperactivity cutoff on
the maternal ratings, and paternal ratings yielded scores below the cutoff for 2 different
boys
Key conclusions of study authors
1. In both studies, double-blind ratings done by naive and staff observers
demonstrated nearly identical medication effects, that is, placebo-related increases in
behaviour problems and methylphenidate-related increases in dysphoria
2. Ratings of medication effects proved remarkably resilient, showing an
invulnerability to biasing influences introduced by general knowledge about research
design, diagnostic status or treatment effects; or by specific knowledge about and
experience with participating children
Email correspondence with study authors: January 2014. No supplemental information
has been received
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Study one: no information (unclear risk of
bias)
Study two: Two thirds of the boys received
medication first, and the remaining third
received placebo first. (This unequal split
resulted from the boys’ simultaneous par-
ticipation in a randomised 3-week dose-re-
sponse assessment that was not pertinent to
the present study) (high risk of bias)
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Both active medication and placebo were
placed in opaque gelatin capsules. Two
staff, blinded to medication status, dis-
pensed medication (low risk of bias)
Study 2: All staff were familiar with the
boys, and some knew which boys had been
diagnosed with ADHD, but none knew
medication dosage or status (high risk of
bias)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study 2: All staff were familiar with the
boys, and some knew which boys had been
diagnosed with ADHD, but none knew
medication dosage or status
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk None
Vested interest bias Unclear risk No information
531Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wigal 2003
Methods Double-blind, 2-stage, cross-over, pharmacokinetic and pharmacodynamic trial with 4
interventions
1. Ritalin 10 mg
2. Immediate-release or extended-release methylphenidate 40:60 (treatment C)
3. Immediate-release or extended-release methylphenidate 30:70 (treatment D)
4. Placebo
Phases: initial screening week, stage 1 cross-over of Ritalin vs placebo, stage 2 cross-over
of treatment C and treatment D. Four weeks, with each study period lasting 1 week
Participants Number of participants screened: not stated
Number of participants included: 27. Participants were randomly assigned to 1 of 4
possible drug condition orders
Number of participants followed up: 25 (21 boys, 4 girls)
Number of withdrawals: 4
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 10 ± 1.4 years (range 7 to 12)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: Caucasian (88%), African American (8%), Asian (4%), Hispanic (0%), other
(0%)
Country: USA
Setting: out-patient clinic (laboratory and community)
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. One of 3 DSM-IV ADHD diagnostic criteria as specified in the Diagnostic
Interview Schedule for Children or the Swanson, Nolan and Pelham, or both
2. 7 to 12 years of age
3. In need of methylphenidate treatment
4. Positive methylphenidate response
5. Prior successful treatment of ADHD symptoms with a methylphenidate product
without adverse events
6. Methylphenidate products restricted to immediate-release methylphenidate twice
daily, with the first daily dose required to be between 7.5 and 15 mg, and the second
daily dose required to be between 5 and 15 mg, yielding a total daily dose of between
12.5 and 30 mg; or a sustained-release methylphenidate product taken once daily, with
the single daily dose required to be 20 mg
7. Oral or written consent by both children and parents
8. Normal blood pressure, pulse rate and temperature
9. Girls had to be premenarchal
Exclusion criteria
1. Participation in another drug study during the preceding 30 days
2. Concurrent illness or condition with symptoms that could affect performance of
any of the tests performed
3. Family history of drug abuse
4. Unable to follow instructions given in the study
5. Individuals who were severely depressed, psychotic, anxious, tense or agitated; or
who had seizures or a family history of Tourette’s syndrome, with primary diagnosis of
532Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wigal 2003 (Continued)
oppositional defiant disorder or conduct disorder
6. Participants taking a medication in addition to methylphenidate for ADHD
7. Documented allergy or intolerance to methylphenidate
8. Individuals who were diagnosed with hyperthyroidism, were lactose-intolerant or
had glaucoma
9. Participants unable to comply with blood drawing procedures during initial
screening
10. Use of any of the following medications: amphetamines, pemoline, tricyclic
antidepressants, MAO (monoamine oxidase) inhibitors, serotonin reuptake inhibitors,
neuroleptics, benzodiazepines or benzodiazepine derivatives, clonidine, anticonvulsant
medications, cough/cold preparations containing stimulants or sedatives
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate and placebo in each of the 2 stages, 1 and 2, with each treatment period
lasting 1 week
Stage 1
1. Treatment A
i) Participants were given 1 encapsulated tablet of Ritalin (10 mg) and 1
capsule of placebo after breakfast, and 1 encapsulated tablet of Ritalin (10 mg) after
lunch for 7 days
2. Treatment B
i) Participants were given 2 placebo capsules after breakfast and 1 placebo
capsule after lunch for 7 days
Stage 2
Half of the participants in each treatment group were randomly assigned to 20 mg/d
dosage of methylphenidate, the other half to 40 mg/d dosage
1. Treatment C
i) Participants were given a daily morning dose (after breakfast) of two 20 mg
capsules of the 40:60 prototype formulation or one 20 mg capsule of the 40:60
prototype formulation and 1 capsule of placebo; and a midday dose (after lunch) of 1
capsule of placebo for 7 days
2. Treatment D
i) Participants were given a daily morning dose (after breakfast) of two 20 mg
capsules of the 30:70 prototype formulation or one 20 mg capsule of the 30:70
prototype formulation and 1 capsule of placebo; and a midday dose (after lunch) of 1
capsule of placebo for 7 days
ii) Blood samples (3 mL) were collected pre-dose and at 0.5, 1.5, 2, 3, 4.5, 6, 7.
5 and 9 hours after the morning dose on the last day (Saturday) of each treatment week
Mean methylphenidate dosage: 20 mg/d or 40 mg/d
Administration schedule: once daily or twice daily
Time points: mornings and after lunch
Duration of each medication condition: 1 week
Washout before study initiation: not stated
Medication-free period between interventions: 1 day (Sundays)
Titration period: none
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham (10-item) Scale: deportment and
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attention ratings performed every 1.5 hours (0 to 9 hours) at the end of each treatment
week, by laboratory classroom teachers
2. Swanon, Kotkin, Agler, M-Flynn and Pelham (10-item) Scale: rated on weekdays
by community classroom teachers
3. Conners, Loney and Milich (16-item): rated Monday, Wednesday and Friday by
community classroom teachers and parents
General behaviour
1. Conners, Loney and Milich (16-item) Scale: ratings performed once every
Monday, Wednesday and Friday of each treatment week by the regular community
classroom teacher and the parents
Non-serious adverse events
1. Side Effects Rating form completed during all treatments by the children’s regular
community classroom teacher on Monday, Wednesday and Friday of each treatment
week, daily by parents and each Saturday by the University of California at Irvine
Child Developmental School (UCI-CDC) classroom teacher
2. All adverse events occurring during the study were reviewed by the investigator to
assess their relationship to drug treatment (unrelated, unlikely, possibly, probably,
almost certainly)
3. In addition, each sign or symptom reported was graded on a 3-point scale (mild,
moderate or severe), and date and time of onset, time relationship to drug dosing,
duration and outcome were noted
4. Clinical laboratory tests were performed at the local laboratory at baseline and at
the end of the trial, and included blood count with differential, biochemistry (Na
(sodium), K (potassium), Ca (calcium), PO4 (phosphate), total protein, glucose,
alkaline phosphatase, AST (aspartate aminotransferase), ALT (alanine
aminotransferase), total bilirubin, creatinine, albumin) and urinalysis (osmolality, pH
(power of hydrogen) level, glucose, protein, white blood cells and casts)
5. Vital signs, including blood pressure and heart rate, were measured at each visit to
the laboratory classroom
6. Body weight: 36.9 ± 7.6 kg
7. Height: 142 ± 8.4 cm
Notes Sample calculation: not stated
Ethics approval: yes; study protocol and participant’s informed consent form were ap-
proved by the Institutional Review Board (Office of the Vice Chancellor for Research,
University of California at Irvine)
Key conclusion of study authors
1. Both methylphenidate formulations, given once in the morning, were superior to
placebo and comparable with Ritalin b.i.d. treatment on all primary efficacy measures
Comments from review authors
1. Prototype formulation used - this may not be bioequivalent to the marketed
formulation
2. Selective reporting of safety findings - omission of data obtained by adverse events
rating form. Pre-specified primary outcome measure for efficacy (of prototype
formulations versus placebo) - regular community classroom teacher. Conners’ Global
Index scores from Collegiate Learning Assessment (CLA) results presented only in
Figure 4; no mean (SD) values provided in publication
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse eventswhile takingmethylphenidate before randomisation: yes;methylphenidate
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tolerability was an inclusion criterion. Serious adverse events were an exclusion criterion
Email correspondence with study authors: July 2014. Emailed study authors twice for
supplemental information but have received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Qualified participants were randomly as-
signed to a 2-stage, double-blind study se-
quence consisting of 4 study treatments,
each lasting for a period of 1 week
Allocation concealment (selection bias) Low risk Ritalin (10 mg) tablets were placed into
capsule shells by Eurand Americas Incor-
porated. Resulting capsules were tested
according to US Pharmacopeial Con-
vention (USP) dissolution conditions for
methylphenidate tablets and showed a dis-
solution profile comparable with intact Ri-
talin tablets. All medications were supplied
in white, opaque, size 3, hard gelatin cap-
sule shells, and were packaged in blister
cards to enhance compliance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Ritalin (10 mg) tablets were placed into
capsule shells by Eurand Americas Incor-
porated. Resulting capsules were tested
according to US Pharmacopeial Con-
vention (USP) dissolution conditions for
methylphenidate tablets and showed a dis-
solution profile comparable with intact Ri-
talin tablets. All medications were supplied
in white, opaque, size 3, hard gelatin cap-
sule shells, and were packaged in blister
cards to enhance compliance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): yes
Selective reporting (reporting bias) Unclear risk “Because the administration of the Side Ef-
fects Rating Form involved queries about
specific adverse events, the frequency of
adverse events reported in the parents’
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and teachers’ Side Effect Rating Form was
higher than that obtained from the reports
elicited by general inquire (data not shown)
”
Vested interest bias High risk Funding for this study was provided by
Celltech Americas Incorporated
Conflicts of interest: Some study authors
are working for Celltech Americas Incor-
porated
Wigal 2004
Methods Four-week, randomised, double-blind, placebo-controlled, ITT, parallel trial conducted
at 12 US centres with 3 arms
1. Dexmethylphenidate
2. Dex,I-methylphenidate
3. Placebo
Participants Number of participants screened: 174
Number of participants included: 132 (116 boys, 16 girls)
Number of participants randomly assigned: dexmethylphenidate 44, dex,l-
methylphenidate 46, placebo 42
Number of participants followed up: dexmethylphenidate 42, dex,l-methylphenidate
40, placebo 37
Number of withdrawals: dexmethylphenidate 2, dex,l-methylphenidate 6, placebo 5
Diagnosis of ADHD: DSM-IV (combined (64%), hyperactive-impulsive (1%), inatten-
tive (35%))
Age: mean 9.8 years (range 6 to 17)
IQ: not stated. No mental retardation
Methylphenidate naive: 95 (72%)
Ethnicity: Caucasian (78%), African American (14%), other (8%)
Country: USA
Setting: out-patient clinic
Comorbidity: no
Comedication: no
Sociodemographics: not stated. No significant differences in baseline demographics were
noted between the 2 groups
Inclusion criteria
1. Enrolled in elementary school
2. Within 30% of normal body weight
3. Anticipated as available for the entire length of the study
4. Female participants were required to be pre-menarche
Exclusion criteria
1. History or evidence of cardiovascular, renal, respiratory (other than asthma/
allergy), endocrine or immune system disease
2. History of substance abuse
3. Hypersensitivity to dex,l-methylphenidate or other stimulants
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4. Treatment with any investigational drug within 30 days of screening
5. Any other significant central nervous system disorders such as mental retardation,
Tourette’s or chronic tic disorder, psychosis, pervasive developmental disorder, eating
disorders, obsessive-compulsive disorder, impulse control disorder or sleep disorders
requiring medication, major depressive disorder or generalised anxiety disorder
6. Treatment with antidepressants (tricyclic antidepressants, serotonin reuptake
inhibitors and monoamine oxidase inhibitors), sedative/hypnotics (e.g. barbiturates,
benzodiazepine), neuroleptic/antipsychotics, mood stabilisers; anticonvulsants, beta-
blockers, α2-agonists, thyroid medications and long-term oral steroids
Interventions Participants were randomly assigned to immediate-release methylphenidate (dex- or d,
l- racemats) or placebo
Meanmethylphenidate dosage: dexmethylphenidate 18.25mg/d, dex,i-methylphenidate
32.14 mg/d
Administration schedule: twice daily in the morning (7:00 AM to 8:00 AM) and at noon
(11:30 AM to 2:30 PM)
Duration of intervention: 4 weeks
Titration period: maximum 3 weeks initiated after randomisation, included in the 4
weeks of intervention
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Nolan and Pelham ADHD Rating Scale - Teacher Version: teacher-
rated, at baseline and twice weekly for 4 weeks, in the afternoon
2. Swanson, Nolan and Pelhan ADHD Rating scale - Parent Version: parent-rated,
at baseline and daily on the weekend for 4 weeks, at 3:00 PM and 6:00 PM
Non-serious adverse events
1. Occurrence and severity, monitored by investigator, at weekly visits
2. Laboratory tests, physical examination findings and vital signs
Notes Sample calculation: yes
Ethics approval: yes; approved by the institutional review board at each centre
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Comments from study authors
1. Post hoc contrasts of small differences between dexmethylphenidate and dex,l-
methylphenidate conditions were not statistically significant in this between-
participant design
2. Three participants who did not meet the criteria set for a placebo response during
the lead-in period were inadvertently entered into the double-blind phase (2 randomly
assigned to dex,l-methylphenidate, 1 to placebo), which was a violation of the protocol
Key conclusions of study authors
1. For treatment of ADHD, an average titrated dose of 18.25 mg/d of
dexmethylphenidate is as efficacious and safe as an average titrated dose of 32.14 mg/d
of dex,l-methylphenidate
2. Both active treatments have large effect sizes. Thus, dexmethylphenidate and dex,
l-methylphenidate appear to provide similar efficacy
Comment from review authors
1. We have not used these data, as reported data could not be used in our meta-
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analyses
Email correspondence with study authors: January 2014. Not possible to obtain data
from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Drug (dexmethylphenidate and dex,l-
methylphenidate) and placebo were iden-
tical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Sample size calculations were based on a
clinically meaningful effect size of 0.75
in the change in score over 4 weeks on
the teacher-rated Swanson, Nolan and Pel-
ham Scale between dexmethylphenidate
and placebo groups. Efficacy parameters
were performed on the ITT sample, which
included participants who received medi-
cation, had a baseline efficacy evaluation
and had ≥ 1 post-baseline efficacy evalua-
tion
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No protocol published
All pre-specified outcomes of interest have
been reported
Vested interest bias High risk This study was supported by Celgene Cor-
poration
Conflicts of interest: Dr. Wigal reports ex-
tensive disclosure
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Methods Four- to six-week, open-label treatment (dose optimisation), cross-over, 2-week double-
blind trial with 2 interventions
1. Methylphenidate (NWP06 - liquid formulation of extended-release
methylphenidate)
2. Placebo
Phases: 2
Participants Number of participants screened: 45 (32 boys, 12 girls)
Number of participants included: 44. Participants were randomly assigned to 1 of the
possible drug condition orders
Number of participants followed up: 39
Number of withdrawals: 6
Diagnosis of ADHD:DSM-IV (combined (70.5%), hyperactive-impulsive (2.3%), inat-
tentive (27.3%))
Age: mean 8.8 years (range 6 to 12)
IQ: not stated
Methylphenidate naive: 0 (0%)
Ethnicity: White 35 (79.5%), Black/African American 4 (9.1%), Asian 3 (6.8%), other
2 (4.5%)
Country: USA
Setting: out-patient clinic
Comorbidity: elimination disorder (4; 9.1%), oppositional defiant disorder (8; 18.2%)
, specific phobias (2; 4.5%)
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. ADHD diagnosis by psychiatrist, psychologist, developmental paediatrician or
paediatrician
2. Pharmacological treatment for ADHD and has experienced suboptimal efficacy
or a safety or tolerability issue with current regimen, or has been in need of a long-
acting liquid formulation
3. Conners’ Global Index Scale score > 3
4. ADHD Rating Scale score (Hyperactive-Impulsive or Inattentive subscale) > 90th
percentile for age and sex
Exclusion criteria
1. Comorbidity (DSM-IV Axis I), with the exceptions of specific phobia, motor
skills disorders, oppositional defiant disorder, sleep disorders, elimination disorders,
adjustment disorders, learning disorders or communication disorders
2. IQ < 80
3. Chronic disease: seizure disorder, thyroid disease, Tourette’s disorder or family
history of Tourette’s disorder or tics, serious cardiac conditions, cardiomyopathy,
serious arrhythmias, structural cardiac disorders, glaucoma or severe hypertension
4. Any investigational medication 15 days before screening
5. Atomeoxetine (ATX) inhibitor 30 days before screening
Interventions Participants were randomly assigned to different sequences of methylphenidate and
placebo
Mean methylphenidate dosage: 32.8 mg/d
Administration schedule: q.i.d.
Duration of each medication condition: 1 week
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Washout before study initiation: yes (1 day for stimulants)
Medication-free period between interventions: no
Titration period: 3 weeks before randomisation
Treatment compliance: 2 withdrawals of assent/consent, 2 adverse events, 1 lack of
efficacy, 1 LTFU
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham Scale, ADHD Rating Scale (open-
label phase)
Non-serious adverse events
42 participants (93.3%) experienced a treatment-emergent adverse event. Three (6.
7%) participants experienced severe adverse effects (affect lability, aggression and initial
insomnia), and 2 (4.4%) participants had to discontinue medication (affect lability and
aggression)
1. Open-label phase: Participants experienced decreased appetite (55.6%),
abdominal pain upper (42.2%), affect lability (26.7%), initial insomnia (22.2%),
insomnia (17.8%) and headache (17.8%). Other adverse events reported in more than
5% of participants included vomiting, diarrhoea, logorrhoea, aggression, dizziness,
irritability, fatigue, upper respiratory tract infection, cough and flushing
2. Double-blind phase: 11 (24.4%) participants had an adverse event while receiving
NWP06, and 5 (11.1%) participants had an adverse event while receiving placebo
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors
1. “This study of NWP06 allowed inclusion of patients who were either treatment
naive or had previously been treated with stimulants (...)”; “Subjects were required to
have been in need of pharmacological treatment for ADHD (...)”
2. “Our population more closely reflects a real-world population and provides a
more rigorous test of the study drug”
Key conclusion of study authors
1. NWP06 resulted in significant improvement in the Swanson, Kotkin, Agler, M-
Flynn and Pelham-combined score at 4 hours post dose as compared with placebo
among completers. This study shows that NWP06 significantly improved ADHD
symptoms in school-aged children and was well tolerated
Comments from review authors
1. Laboratory school environment and lack of the ADHD Rating Scale
2. Race/ethnicity does not reflect a real-world population
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: not clear
Any withdrawals due to adverse events: yes (n = 2)
Email correspondence with study authors: emailed study authors to request additional
information but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Results from open-label phase
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Results from open-label phase
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants had to be in treatment
with suboptimal efficacy (no inclusion of
placebo responders)
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders): Six
participants were LTFU during the open-
label titration phase, 2 as a result of adverse
events. These participants are not included
in our analyses
Selective reporting (reporting bias) Low risk ADHD Rating Scale not reported (used
only in the open phase)
Vested interest bias High risk Study received funds fromNextWave Phar-
maceutics (Belden and Berry are with
NextWave)
Conflicts of interest: All study authors are
affiliated with NextWave Pharmaceuticals
Wigal 2014
Methods Cross-over trial with 2 interventions
1. Methylphenidate-MLR
2. Placebo
Phases: 4
1. Screening/washout period (< 4 weeks)
2. Open-label dose-optimisation period
3. Randomised, double-blind, placebo-controlled, cross-over design
4. 30-day safety follow-up period
Participants Number of participants screened: 32
Number of participants included: 26 (in open-label phase). Participants were randomly
assigned to 1 of 2 possible drug condition orders
Number of participants followed up: 20
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Number of withdrawals: 6
Diagnosis of ADHD: DSM-IV-TR (combined (n = 11), hyperactive-impulsive (n = 3),
inattentive (n = 12))
Age: mean 8.7 years (range 6 to 12)
IQ: mean not stated (range 86 to 133)
Sex: 12 boys, 10 girls
Methylphenidate naive: none
Ethnicity:White (82%), Black (9%), Asian (5%), Hispanic or Latino (23%), other (5%)
Country: USA
Setting: out-patient clinic
Comorbidity: 11; generalised anxiety disorder, enuresis, oppositional defiant disorder,
chronic motor or vocal tic disorder, transient tic disorder
Comedication: no
Sociodemographics: not stated
Inclusion criteria
1. Children (male or female) 6 to 12 years of age
2. Any of the 3 subtypes of ADHD as defined by DSM-IV-TR, ADHD-RS-IV total
or subscale score > 90th percentile relative to the general population of children by age
and sex
3. Naive to treatment for ADHD or inadequately managed on current treatment
regimen
4. Negative illicit drug and alcohol test results at screening and at each visit to the
research site
Exclusion criteria
1. IQ > 80
2. Any severe psychiatric or significant comorbid condition
3. Use of a monoamine oxidase inhibitor or any psychotropic medication with
central nervous system effects < 14 days of screening, or any experimental drug or
medical device > 30 days of screening
4. Clinically significant electrocardiogram (ECG), or any laboratory abnormality
5. Any participant unable or unwilling to follow directions and complete study
assessments or take oral capsules
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate (15 mg, 20 mg, 30 mg or 40 mg) and placebo
Mean methylphenidate dosage: 32 mg
Administration schedule: once a day
Time points: in the morning
Duration of each medication condition: 1 week
Washout before study initiation: 2 days
Medication-free period between interventions: not stated
Titration period: yes; 2 to 4 weeks before randomisation
Treatment compliance: yes; verified at scheduled study visits by study personnel who
examined documentation of drug dispensed, drug consumed and remaining drug, and
recorded the information on the drug reconciliation form
Compliance was calculated to be > 82% throughout the study
Outcomes ADHD symptoms
1. Swanson, Kotkin, Agler, M-Flynn and Pelham: total scores, trained observers,
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post dose over time points 1.0, 2.0, 3.0, 4.5, 6.0, 7.5, 9.0, 10.5 and 12.0 hours
2. Swanson, Kotkin, Agler, M-Flynn, and Pelham: attention and deportment scores
averaged over all post-dose time points
3. ADHD Rating Scale, Fourth Edition: clinician-rated, 3.0 hours post dose each
laboratory day
Non-serious adverse events
1. Safety and tolerability assessments
Notes Sample calculation: yes
Ethics approval: yes
Comment from study authors
1. Limitations of this study: Study was slightly underpowered and produced a study
population that may not be reflective of the general population of children and
adolescents with ADHD
Key conclusions of study authors
1. In this study, methylphenidate-MLR administered to children 6 to 12 years of age
demonstrated a significant decrease in scores on the Swanson, Kotkit, Agler, M-Flynn
and Pelham Scale compared with placebo
2. Onset of action in this population is 1 hour, and duration of efficacy is sustained
to 12 hours post dose
3. Future studies that include measurement of efficacy earlier than hour 1.0 and
extend beyond hour 12.0 would add clarity to the precise onset and duration of clinical
efficacy
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; 2 withdrew during the open-label phase as
the result of lack of efficacy
Any withdrawals due to adverse events: yes (n = 1)
Email correspondence with study authors: April 2015. Obtained supplemental informa-
tion from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation was determined by using
a table of random numbers. Randomi-
sation tables were provided to the ran-
domisation monitor, who created unblind-
ing envelopes and packaged the drug with
blinded labels
Allocation concealment (selection bias) High risk One participant received placebo at 2 peri-
ods - the method was not efficacious
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All sponsor representatives, investigators,
participants and independent raters re-
mained blinded until after datawere locked
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Yes; this has been done
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT were used
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo-responders):
no; no exclusion of methylphenidate non-
responders after randomisation
Selective reporting (reporting bias) Low risk No selective reporting bias
Vested interest bias High risk Study was funded by Rhodes Pharmaceu-
ticals L.P.
Conflicts of interest: Several study authors
work for, or have received grant and re-
search support or both from pharmaceuti-
cal companies
Wilens 2006b
Methods Two-week, randomised, double-blind, 15-centre, parallel trial with 2 arms
1. OROS methylphenidate
2. Placebo
Phases: preceded by a 4-week, open-label, dose-titration phase, and followed by an 8-
week, open-label, follow-up phase
Participants Number of participants screened: not stated
Number of participants included: 220 in the 4-week dose-titration phase
Number of participants randomly assigned: 177 (142 boys, 35 girls); methylphenidate
87, placebo 90
Number of withdrawals: methylphenidate 16, placebo 28
Number of participants followed up: 171; number completing follow-up: 135
Diagnosis of ADHD: DSM-IV (subtype not stated)
Age: mean 14.6 years (range 13 to 18)
IQ: not stated
Methylphenidate naive: not stated
ADHD treatment-naive: 24
Ethnicity: Caucasian (75.1%), African American (13.6%), other (11.3%)
Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated. The 2 groups were similar demographically, but the
placebo group had a greater ratio of males (P value < 0.04)
Inclusion criteria
1. Diagnosis of attention deficit hyperactivity disorder (ADHD), as defined by the
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Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
2. Children’s Global Assessment Scale rating of 41 to 70 at baseline (screening phase)
3. Between 8 and 13 years of age
Exclusion criteria
1. Participants who are known to not respond to methylphenidate
2. Adverse experiences from methylphenidate or hypersensitivity to Concerta or its
components
3. Marked anxiety, tension or agitation
4. Psychiatric comorbidity requiring additional or different medication
5. Glaucoma, ongoing seizure disorder, psychotic disorder, Tourette’s disorder or
family history of Tourette’s disorder, bipolar disorder, an eating disorder
6. Treatment with theophylline, coumarin, anticonvulsants
7. Severe gastrointestinal narrowing
8. Systolic or diastolic blood pressure at the 95th percentile or greater for age, sex
and height at screening
Interventions Participants were randomly assigned to OROS methylphenidate or placebo
Mean methylphenidate dosage: 0.84 mg/kg
Administration schedule: once daily
Duration of intervention: 2 weeks
Titration period: 4 weeks initiated before randomisation. All participants initiated ther-
apy at 18 mg/d, and clinical response was measured after 1 week. If response to treatment
was inadequate, as per the a priori study definition, the dose was titrated upward (in 18-
mg increments) at 1-week intervals for up to 4 weeks, with maximum dose of 72 mg/d
Treatment compliance: not stated; 8-week, open-label follow-up on individualised dosage
Outcomes ADHD symptoms
1. ADHD Rating Scale, clinician- and parent-rated: completed at baseline and
weekly during double-blind phase
Serious adverse events
1. Reported in only 1 participant during the open-label dose-titration phase of the
study. While being treated with OROS methylphenidate 18 mg/d, a 16-year-old
female participant with a history of depression and suicidal ideation threatened suicide
on the third day of medication use after an argument with her mother. Decision was
made to discontinue study medication, and symptoms resolved
2. No serious adverse events were reported during the double-blind phase
Non-serious adverse events
1. Heart rate and blood pressure, recorded by a clinician weekly throughout the
whole study
2. ECG at screening and at end of double-blind phase of the study
3. Spontaneous reports to the investigator of adverse events recorded at weekly visits
4. Safety assessments made at monthly visit and every 2 weeks between monthly
visits during follow-up
5. Height and weight assessed at baseline and at weeks 4 and 8 in the follow-up study
No participants experienced clinically important effects on ECG indexes, heart rate or
blood pressure during the study
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Notes Sample calculation: yes
Ethics approval: yes; study was approved by the institutional review boards for all par-
ticipating centres before the start of the study
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-
responders/children who have previously experienced adverse events while taking
methylphenidate before randomisation: yes; criteria of response, defined as ≥ 30% im-
provement from baseline on the investigator-scored ADHD Rating Scale. Participants
who successfully completed the open-label dose-titration phase were assigned a randomi-
sation number
Comments from study authors
1. Exclusion criteria were significant and possibly limited the generalisability of
results
2. Participants may have had improved ADHD symptoms or psychosocial carry-
over effects as a consequence of participation in the study, medication titration and
regular meeting with study personnel
3. Our study was conducted partially during the summer, and this may have resulted
in less stress on adolescents and overall improvement in both study groups. More
sensitive measures of attention may be needed for adolescents with ADHD than for
children
4. Participants were titrated to their individualised dosage before the double-blind
phase of the study. This may have biased the results toward a positive response in the
double-blind phase
The short duration of the double-blind phase may have decreased the likelihood of
detecting potential rare adverse events. Rates of adverse events reported for OROS
methylphenidate have been underestimated because participants entering this study
phase were already stabilised on an affective tolerated dosage of medication
Key conclusions of study authors
1. In adolescents, once-daily OROS methylphenidate significantly reduced ADHD
symptoms and was well tolerated at dosages up to 72 mg/d
2. Adolescents required, on average, a higher absolute dose but a lower weight-
adjusted dose (mg/kg) of OROS methylphenidate than was previously reported in
children
3. The incidence of adverse events was not related to dose
Email correspondence with study authors: December 2013 and Janurary 2014. Not able
to make contact with study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but method was not de-
scribed
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators were supplied with packages
containing medication for each partici-
pant, as identified by randomisation num-
ber. Therefore, investigators and partici-
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pants were blinded towhether a participant
was receiving active medication or placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators were supplied with packages
containing medication for each partici-
pant, as identified by randomisation num-
ber. Therefore, investigators and partici-
pants were blinded towhether a participant
was receiving active medication or placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk Non-responders not included. LOCF tech-
nique was used for all assessments in the
double-blind phase. Of 182 (83%) partic-
ipants who successfully achieved the crite-
ria for improvement at the dose-titration
phase, only 177 were randomly assigned to
the double-blind phase, because 5 reached
the criteria after the double-blindphasewas
closed. Of 177 randomly assigned partic-
ipants, 1 did not enter the double-blind
phase, and efficacy data were not collected
for another participant. Therefore, 175
participants were included in the efficacy
analysis of the double-blind phase, but 177
were included in the dosage and safety anal-
ysis
Selective reporting (reporting bias) Low risk No major violation compared with what is
reported in ClinicalTrials.gov
All pre-specified outcomes of interest have
been reported
Vested interest bias High risk Funded by McNeil Consumer and Spe-
cialty Pharmaceuticals
Conflicts of interest: Several study authors
have had commitments (e.g. speakers, con-
sultants, advisors) with various pharmaceu-
tical companies
Wilens 2008
Methods Open-label, 5-week, dose-optimisation period. This dose was maintained during the
subsequent 3 weeks of the trial, except for 1 day per week of 3-way cross-over assessment
Randomised, double-blind, 8-centre, 3-way, 3-week, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
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Participants Number of participants screened: 148
Number of participants included: 128 in open-label, dose-titration; 120 randomly as-
signed to 1 of 3 possible drug orders
Number followed up: 127 for safety and 117 for efficacy
Number of withdrawals: 2
Characteristics of the 127 followed up for safety
Sex: 84 boys, 42 girls
Diagnosis of ADHD:DSM-IV (combined or hyperactive-impulsive (92.1%) inattentive
(not stated))
Age: mean 8.8 years (SD 1.84; range 6 to 12)
IQ: > 80
Methylphenidate naive: not stated
Ethnicity: Caucasian (63.2%), African American (15.4%), Asian (not stated)
Country: USA
Comorbidity: not allowed
Comedication: not stated
Sociodemographics: not stated
Characteristics of the 117 followed up for efficacy
Sex: 75 boys, 42 girls
Diagnosis of ADHD: DSM-IV (type not stated)
Age: mean 8.8 years (range 6 to 12)
IQ: > 80
MPH-naive: not stated
Ethnicity: Caucasian (63.2%), African American (15.4%), Asian (0%), other (21.4%)
Country: USA
Setting: out-patient clinic
Comorbidity: not allowed
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Diagnosed with ADHD according to DSM-IV-T
2. Minimum IQ score of 80
Exclusion criteria
1. Conduct disorder or comorbid illnesses that contraindicated or could confound
methylphenidate transdermal system treatment
2. History of failing to respond to psychostimulant treatment
3. Taken another investigational product within 30 days of screening or participated
in other research trials involving drug treatment during the course of the study
4. Safety population consisted of 127 participants, who received ≥ 1 dose of study
medication
11 participants discontinued before the double-blind randomisation phase, resulting in
an ITT population of 117 participants
Seven participants discontinued before the double-blind randomisation phase, 3 were
randomly assigned but did not undergo methylphenidate transdermal system (MTS)
treatment
Two participants did not complete the analogue classroom phase of the study: 1 because
of an application site reaction, and 1because of an adverse event (conjunctivitis), resulting
in a total of 115 study completers
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Interventions Participants were randomly assigned to 1 of 3 possible drug orders of methylphenidate
(4 and 6 hours) and placebo
Mean methylphenidate dosage: 10 mg patch (n = 15), 15 mg patch (n = 34), 20 mg
patch (n = 32) and 30 mg patch (n = 36)
Administration schedule: once daily in the morning; patch worn for 9 hours daily, and
for 4 or 6 hours for cross-over assessments
Duration of each medication condition: 1 day
Washout before study initiation: none; in-between treatment with optimal dose of
methylphenidate
Titration period: 5 weeks before randomisation
Treatment compliance: not stated
Outcomes ADHD symptoms
1. Swanson, Kotkit, Agler, M-Flynn and Pelham: teacher-rated at randomisation
(week 5) and 2 hours after patch application at end of treatment (week 6, 7, 8)
Quality of life
1. ADHD Impact Module-Child - Child Impact Scale and Family Impact Scale:
rated at baseline, at randomisation (week 5) and at end of study (week 8)
Non-serious adverse events
1. Vital signs were evaluated at screening, at baseline and at weeks 1 to 8
2. Erythema, edema, papules and vesicles, discomfort, haematology, urinalysis and
electrocardiographic measures were completed at screening, at baseline and at weeks 5
and 8
No clinicallymeaningful changes frombaseline were observed in vital signs, ECG, urinal-
ysis and haematological results or physical examinations. Adverse events were recorded
from the time informed consent was signed until 30 days (week 12) after the last drug
treatment
Notes Sample calculation: yes; assuming amean difference in Swanson, Kotkit, Agler,M-Flynn
and Pelham deportment score of 2.0 between active treatment and placebo, an SD of 5.
0, a between correlation of 0.2, 90% power and a probability level of .05 (2-sided), it
was estimated that approximately 102 participants were needed to complete the double-
blind, cross-over phase of the study
Ethics approval: yes; institutional review board at each site approved the study
Comments from study authors
1. Important to note that participants who failed to respond to psychostimulants in
the past and those with conduct disorder were excluded from the study. Therefore,
results of this study should not be extrapolated to these patient populations
2. From Manos in Wilens 2008: Lack of placebo comparison has the potential to
confound the findings of this study. The relatively short study duration (about 2
months) may not be sufficient to capture some emerging changes in health-related
quality of life
Key conclusion of study authors
1. All efficacy measures indicated that 4- and 6-hour wear times improved ADHD
symptoms
Comments from review authors
1. Treatment period is 1 day, 1 week apart for the 3 phases, and all participants are
treated with methylphenidate at optimal titrated dose in-between
2. Quality of life assessments are aggregated for all (not possible to assess
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methylphenidate vs placebo)
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: yes; participants with
a history of failing to respond to psychostimulant treatment were also excluded
Any withdrawals due to adverse events: yes; 1 (conjunctivitis)
Email correspondence with study authors in April to June 2014. Emailed study authors
twice to ask for additional data but never received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Single randomisation schedule prepared by
an independent statistician using computer
software that generated random numbers
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Each participant wore 2 patches prepared
by an unblinded pharmacist to maintain
treatment blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT population (more than 1 application
of a study drug and pre-dose efficacy as-
sessment at week 6). Participants who did
not reach an optimal dose by week 5 were
discontinued from the study
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders):
yes; participants who did not reach an opti-
mal dose byweek 5were discontinued from
the study
Selective reporting (reporting bias) Unclear risk Protocol published. All pre-specified out-
comes of interest have been reported
Vested interest bias High risk This study was funded by Shire Develop-
ment Incorporated
Conflicts of interest: Several study authors
have affiliations with medical companies
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Methods Blind, randomised, 4-week, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Participants Number of participants screened: unknown
Number of participants included: 36. Participants were randomly assigned to 1 of 2
possible drug condition orders
Number of participants followed up: 30 (25 boys, 5 girls)
Number of withdrawals: 4
Diagnosis of ADHD: DSM-IV (combined (53%), hyperactive-impulsive (3%), inatten-
tive (43%))
Age: mean 9.17 years (SD 1.84; range 6 to 12)
IQ: > 70
Methylphenidate naive: 14 (47%)
Ethnicity: Caucasian (90%), African American (not stated), Asian (3%), Hispanic (not
stated), other (7%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional disorder (70%), conduct disorder (7%), major depressive
disorder (3%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Male and female out-patients
2. 6 to 12 years of age
3. Diagnosis of ADHD by DSM-IV, as manifested in clinical evaluation and
confirmed by structured interview
4. Participation in structured morning routine (e.g. school, camp, other organized
activities)
Exclusion criteria
1. Mental retardation (IQ < 75)
2. Participants with a medical condition, or treatment that will jeopardise
participant safety or affect the scientific merit of the study
3. Participants with moderate to severe dermatological atopy
4. Participants with known structural cardiac abnormalities
5. Organic brain disorders
6. Seizure disorder
7. Participants with Tourette’s syndrome or a history of psychosis or bipolar disorder
8. Participants with current comorbid psychopathology that, in the investigator’s
opinion, will warrant immediate treatment or will interfere with safe execution of the
protocol (i.e. anxiety or major depressive disorder rated as moderate on Conners’
Global Index)
9. Participants with a history of intolerable adverse effects or non-response to
methylphenidate
10. Pregnant or nursing females
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate (20 mg) and placebo
Mean methylphenidate dosage: not stated
Administration schedule: patch applied in morning and worn for 9 hours
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Duration of each medication condition: 2 weeks
Washout before study initiation: none
Titration period: 1 week after randomisation
Treatment compliance: > 80% for all participants
Outcomes ADHD symptoms
1. ADHD Rating Scale: clinician-rated at baseline and weekly for 4 weeks
2. Conners’ Global Index: parent-rated at baseline and weekly for 4 weeks (no data)
Non-serious adverse events
1. Adverse events and vital signs: clinician-rated at baseline and weekly for 4 weeks
2. ECG: clinician-rated at baseline and at end of study
Notes Sample calculation: no
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while takingmethylphenidate before randomisation: yes; participants with
a history of no response or intolerability to methylphenidate were excluded for ethical
reasons
Comment from study authors
1. Doses used are lower than US FDA-approved dose of 30 mg. It is unclear whether
results of this study represent optimal response
Key conclusion of study authors
1. Early administration of methylphenidate transdermal system was associated with
improved ADHD symptoms and before-school functioning in children with ADHD
Email correspondence with study authors: March/April 2014. We contacted the first
study author twice to ask for supplemental data but have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Low risk Prescriptions filled by hospital pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No additional information from study au-
thor
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind (participant, caregiver, inves-
tigator)
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT: participants who completed 1 week
of treatment; LOCF
Selection bias: yes. Excluded participants
not following 1 week of treatment
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Selective reporting (reporting bias) Low risk Protocol published. All pre-specified out-
comes of interest have been reported
Vested interest bias High risk This study and medication/placebo were
funded by a grant through Shire Pharma-
ceuticals. Shire had no role in design, col-
lection, analysis, interpretation, writing or
decision to submit
Conflicts of interest: Some study authors
have received research support from medi-
cal companies
Wilkison 1995
Methods Double-blind, placebo-controlled, cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 2
Participants Number of participants screened: not stated
Number of participants included: 16. Participants were randomly assigned to 1 possible
drug condition order
Number of participants followed up: 16 implied (16 boys, 0 girls)
Number of withdrawals: not stated
Diagnosis of ADHD: DSM-III-R (subtype not stated)
Age: mean 10.2 years (range 8 to 13)
IQ: mean 112.6
Methylphenidate naive: 0%
Ethnicity: not stated
Country: USA
Setting: out-patient clinic
Comorbidity: no
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Boys
2. 8 to 13 years of age
3. ADHD
4. Recruited from an out-patient clinic at a large metropolitan children’s hospital in
the USA
5. Conners’ Hyperactivity Index score 1.5 SD above the norm on parent ratings
6. ≥ 6 months of treatment with methylphenidate
7. Confirmed DSM-III-R diagnosis
8. History of > 6 months of methylphenidate treatment
Exclusion criteria
1. No physical or psychiatric diagnosis other than ADHD
2. Evidence of learning disability
3. “Each parent and prescribing physician reported that the subject responded
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positively to MPH”
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate (normal dose) and placebo
Mean methylphenidate dosage: 0.030 mg/kg (range 0.08 to 1.10 mg/kg/d)
Administration schedule: not stated
Duration of each medication condition: 36 hours
Washout before study initiation: not stated
Titration period: not stated
Treatment compliance: not stated
Outcomes General behaviour
1. Behaviour problems - Child Behavior Checklist, parent ratings. Data not reported
Notes Sample calculation: not described
Ethics approval: not described
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Key conclusion of study authors
1. Stimulant effects on child’s motivation to perform a task may compensate for
deficits in other areas
Comment from review authors
1. All participants had been treated previously with methylphenidate for longer than
6 months; each parent and physician reported good response
Email correspondence with study authors: May 2014. We obtained supplemental infor-
mation from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk From correspondence: generated by phar-
macist (Magnusson 2014c [pers comm])
Allocation concealment (selection bias) Low risk From correspondence: Recruiter had no in-
volvement in and was blinded to allocation
sequence (Magnusson 2014c [pers comm])
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk From correspondence: Pharmacist in-
structed parents (via instructions on pill
bottle) regarding which pills should be ad-
ministered and at what time (Magnusson
2014c [pers comm])
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
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Incomplete outcome data (attrition bias)
All outcomes
Low risk From correspondence: Approximately 2%
of skin conductance and heart rate data
were affected by participant movement
and were replaced with interpolated values
Physiological data were lost for 2 partici-
pants with ADHD and for 2 participants
without ADHD. For 3 of the remaining 28
participants, 1 of the 4 repeated measure-
ments of interbeat intervals was replaced
with the mean of the participant’s diag-
nostic group because his ECG recordings
were inadequate (Magnusson 2014c [pers
comm])
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk No reporting bias
Vested interest bias Low risk Research was supported by University of
Utah Biomedical Sciences Research Grant
and a grant from the University Research
Committee
Conflicts of interest: no corporate affilia-
tions described
Wodrich 1998
Methods Three-week cross-over trial with 3 interventions
1. Methylphenidate 5 mg, twice daily
2. Methlphenidate 15 mg, twice daily
3. Placebo
Phases
1. Each drug condition lasted 7 days (Thursday through Wednesday)
2. “No washout period was deemed necessary, given the brief half-life and absence of
carry-over effects of MPH [methylphenidate]”
Participants Number of participants screened: 123 (“treated in the clinic”)
Number of participants included: 57 (47 boys, 10 girls)
Number of participants followed up: 57
Number of withdrawals: 66. Away on summer vacation (n = 30), teacher failed to com-
plete all rating forms (n = 29), teacher marked 2 values indicated on a single dimension
(n = 3), adverse medication side effect (n = 2), dropped out before child’s medication
trial was completed (n = 2)
Diagnosis of ADHD: DSM-III-R
Age: mean 8.5 years (SD 2.1; range 6 to 14)
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: Caucasian “Anglo” 54 (95%), Hispanic 3 (5%)
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Country: USA
Setting: out-patient clinic
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. DSM-III-R Diagnosis of ADHD, confirmed by a clinical psychologist
Exclusion criteria
1. No primary disorder “better explained the child’s presenting symptoms” (e.g.
mood disorder, anxiety disorder, adjustment disorder, pervasive developmental
disorder)
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders (5 mg
methylphenidate or 15 mg methylphenidate) and placebo, given at 8:00 AM and 12:00
PM
Mean methylphenidate dosage: 10 mg/d, 30 mg/d and placebo
Administration schedule: 3-week, triple-blind, cross-over medication trial consisting of
placebo, 5 mg of methylphenidate and 15 mg of methylphenidate, twice a day. Each
drug condition lasted 7 days (Thursday through Wednesday)
Duration of each medication condition: 3 weeks
Washout before study initiation: approximately 20 hours (lunchtime until “immediately
before school” the next day)
Titration period: not stated
Treatment compliance: not stated
Number of withdrawals: 2. Parents dropped out of the study before their child’s medi-
cation trial was completed
Outcomes ADHD symptoms
1. Abbreviated Conners’ Rating Form
2. School Situations Questionnaire: “As our research concern was to locate tools
helpful to school psychologists, we chose to address only the utility of using SSQ. For
statistical analysis, scores from zero (no problem) to 9 (severe problem) were entered
for each situation” (p 84)
General behaviour
1. Personality Inventory for Children
Serious adverse events
1. Side Effects Questionnaire
Non-serious adverse events
1. Side Effects Questionnaire
Notes Sample calculation: not stated
Ethics approval: not stated
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes
Key conclusions of study authors
1. School Situation Questionnaire ratings improved with methylphenidate
treatment in all situations related to task performance (i.e. arriving at school; during
individual seatwork, small group activities and lectures) but less so in non-task or
unstructured situations
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2. Many change scores were large enough to be clinically meaningful
3. Use of School Situations Questionnaire by school psychologists was discussed as a
means of efficiently providing contextual information not available from ADHD
dimensional rating scales
Email correspondence with study authors: June 2014. We obtained supplemental infor-
mation from study authors. We contacted study author to ask for missing data, but s/he
was not able to supply the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects then underwent a three-week,
triple-blinded, cross-over medication trial
consisting of placebo, 5 mg, and 15 mg of
MPH dose twice a day (immediately be-
fore school and at lunchtime)” (p 83); “Or-
der of administration was counterbalanced
so that equivalent numbers of children re-
ceived each sequence” (p 83)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects then underwent a three-week,
triple-blinded, cross-over medication trial
consisting of placebo, 5 mg, and 15 mg of
MPHdose twice a day (immediately before
school and at lunchtime). Each drug con-
dition lasted seven days (Thursday through
Wednesday)” (p 83); “Doses were prepared
and packaged for the three week trial by a
licensed pharmacist who split MPH tablets
and placed them with lactose into re-seal-
able capsules. The placebo dose consisted
of lactose-filled capsules only. Equivalent
numbers of capsules (three) were dispensed
at each dosing time to maintain uniformity
and disguise presence/amount of
medication, as three capsules were required
to encompass the largest dose (15 mg)” (p
83)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “This procedure was followed for three
weeks, with themedication code being bro-
ken the final week anddetermination about
medication efficacy and decision to con-
tinue addressed at that time” (p 84)
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No information
Vested interest bias Unclear risk No information
Wolraich 2001
Methods Twenty-eight-day, randomised, parallel, double-blind clinical trial with 3 arms
1. OROS methylphenidate
2. Immediate-release methylphenidate
3. Placebo
Participants Number of participants screened: 405
Number of participants included: 312; OROS methylphenidate 94, immediate-release
methylphenidate 94, placebo 89
Number of participants followed up: OROS methylphenidate 79, immediate-release
methylphenidate 81, placebo 46
Number of withdrawals: OROS methylphenidate 15, immediate-release
methylphenidate 13, placebo 43
Diagnosis of ADHD:DSM-IV (combined (73.4%), hyperactive-impulsive (7.1%), inat-
tentive (19.5%))
Age: mean 9.0 years (range 6 to 12)
IQ: > 70
Sex: 233 boys, 49 girls
Methylphenidate naive: 20.2%
Ethnicity: Caucasian (84.4%), African American (7.4%), Asian (0.4%), Hispanic (3.
5%), other (4.3%)
Country: USA
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (41.8%), conduct disorder (11.3%), tic dis-
order (5.3%), anxiety disorder (1.4%), depression (0.7%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. 6 to 12 years of age
2. Clinical diagnosis of any subtype of ADHD - had to be confirmed by the
Diagnostic Interview Schedule for Children (Version 4), administrated by a trained
interviewer
3. Patients who were taking methylphenidate or had taken it in the past had to have
been on a total daily dose of methylphenidate (immediate-release or a combination of
immediate-release/extended-release) of ≥ 10 mg but ≤ 60 mg
4. Patients had to agree to take the supplied study drug as the only medication for
ADHD during the 4-week study period
5. IQ > 70
Exclusion criteria
1. Acute or serious chronic disease
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2. Hypersensitivity to methylphenidate
3. Significant adverse experiences from methylphenidate
4. Taking a medication that would interfere with safe administration of
methylphenidate
5. Glaucoma, Tourette’s syndrome, ongoing seizure disorder or psychotic disorder
6. Girls who had reached menarche
During the course of the study, participants were allowed to receive behavioural inter-
ventions as long as the interventions had been initiated before the start of the study and
did not change during the study. New behavioural therapy was not allowed during the
course of the study
Interventions Average total daily dose: immediate-release methylphenidate 29.5 mg per day (0.90.4
mg/kg/d), OROS methylphenidate 34.3 mg per day (1.1 to 0.5 mg/kg/d)
Administration schedule: 3 times a day
Duration of intervention: 4 weeks
Titration period: 4-week titration period before randomisation (open-label) for study
participants who had not received methylphenidate for ADHD from their own practi-
tioner in the 4 weeks before study entry. Participants who had taken methylphenidate
during the 4 weeks before study entry were assigned to a dose level based on their pre-
study therapeutic dose and regimen
Treatment compliance: not stated
Outcomes ADHD symptoms
1. IOWA Conners’ Rating Scale: teacher- and parent-rated on day 27
2. Swanson, Nolan and Pelham Scale, Fourth Edition: teacher- and parent-rated,
week 4
Quality of life
1. Child Global Assessment Scale
Notes Sample size calculation: yes
Ethics approval: yes
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: yes; 111 who had
not receivedmethylphenidate before the study initially were enrolled into a dose-titration
study. One of these did not enrol in the randomised study because the 54-mg dose was
found to be ineffective
Key conclusion of study authors
1. Results of this study show that OROS methylphenidate administered once a day
and immediate-release methylphenidate administered 3 times a day were significantly
better than placebo and were not significantly different from each other for the primary
efficacy measure, teacher IOWA Conners’ Rating Scale, Inattention-Impulsivity-
Overactivity subscale score, which evaluated attention and behaviour at school.
Furthermore, significant improvement in attention and behaviour was seen in the first
week for participants who were taking OROSmethylphenidate qd or immediate-release
methylphenidate t.i.d. compared with placebo, and this improvement was maintained
throughout the 4 weeks of the study. These results were consistent across settings
(home and school), raters (parents, teachers, clinical investigators) and measures
(IOWA Conners’ Rating Scale; Swanson, Nolan and Pelham, Fourth Edition; Peer
Interaction; Global Assessments; Parent Satisfaction) and were statistically significant
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Comments from review authors in July 2013:corresponded with first study author, Wol-
raich, who answered all of our questions (Krogh 2013c [pers comm])
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Within each dose level, participants were
randomly assigned equally to OROS
methylphenidate qd, immediate-release
methylphenidate (overencapsulated Ri-
talin) t.i.d. or placebo in a 3-group parallel
design. Stratified randomisation was con-
ducted centrally at ALZA Corporation
Allocation concealment (selection bias) Low risk Double-dummy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind; double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Unclear risk Not able to get study protocol
Vested interest bias High risk Funded by ALZA Corporation (medical
company)
Conflicts of interest: Study authors are part
of the Concerta Study Group
Zeiner 1999
Methods Cross-over trial with 2 interventions
1. Methylphenidate
2. Placebo
Phases: 7 weeks (3 weeks of medication, 1 week washout, 3 weeks of placebo)
Zeiner 1995 (in Zeiner 1999): extended treatment (mean duration 634 ± 130 days)
Participants Number of participants screened: 46
Number of participants included: 38. Participants were randomly assigned to 1 of 2
possible drug condition orders
Number of participants followed up: 36 (36 boys, 0 girls)
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Number of withdrawals: 2
Diagnosis of ADHD: DSM-III-R or DSM-IV (combined type (> 75%), hyperactive-
impulsive and inattentive types not stated)
Age: mean 8,7 years (range 7 to 11)
IQ: mean 102 (range 79 to 139)
Methylphenidate naive: 100%
Ethnicity: not stated
Country: Norway
Setting: out-patient clinic
Comorbidity: oppositional defiant disorder (23; 64%)
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Male
2. Between 7 and 12 years of age
3. Fulfilled diagnostic criteria for ADHD
4. IQ ≥ 70
Exclusion criteria
1. Pervasive developmental disorder
2. Psychosis or mood disorder
3. Any acute or chronic medical or neurological disease
4. Used stimulants or any other psychotropic drug
Interventions Participants were randomly assigned to 1 of 2 possible drug condition orders of
methylphenidate (0.5 mg/kg) and placebo. Thirty-one children received a morning dose
of 10 mg or 15 mg (and 5 young boys received 7.5 mg)
Mean methylphenidate dosage: not stated; 0.55 mg/kg to 0.56 mg/kg daily across the
entire duration of the extended treatment period (Zeiner 1995 in Zeiner 1999)
Administration schedule: Capsules were given in 2 doses (at 8 AM and 11.30 AM)
Duration of each medication condition: 3 weeks
Washout before study initiation: not relevant
Methylphenidate naive: all
Medication-free period between interventions: 1 week
Titration period: none
Treatment compliance: no information
Outcomes ADHD symptoms
1. Parent Account of Childhood Symptoms, at home
2. Conners’ Teacher Rating, in classroom
Assessments of the child were made during the last week of each trial period
Non-serious adverse events
1. Height, weight, heart rate, systolic blood pressure, diastolic blood pressure
Notes Sample calculation: no
Ethics approval: no information
Comment from study authors
1. This study has obvious limitations. Sample size was limited, and heterogeneity
was noted with regard to behavioural characteristics and test performance. This
heterogeneity may conceal associations found in subgroups of children with ADHD.
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Boys between 7 and 11 years of age were chosen. They represent the majority of
children admitted with hyperactivity and inattention, but boys of other age groups may
show a different clinical picture
Key conclusions of study authors
1. Response to methylphenidate was examined in 36 boys, 7 to 11 years of age, with
ADHD in a double-blind, placebo-controlled trial of cross-over design
2. Hyperactivity and conduct problems were significantly reduced during
methylphenidate treatment
3. Stimulant medication was associated with improvement on tests of sustained
attention, working memory and motor steadiness
4. When individual changes were studied, it was found that 83% showed significant
improvement in their hyperactivity at home or at school, and for 60%, levels of
hyperactive behaviour were within the normal range
5. High levels of hyperactivity at school at a relatively low age was a significant
predictor of normalisation of hyperactivity in ≥ 1 setting. However, these predictors
could classify correctly only 71% of children
6. In clinical practice, a trial with stimulants is indicated for children with ADHD
who show symptoms that are sufficiently severe to cause impairment at home and at
school
Comments from review authors
1. Generation of allocation sequence is unclear
2. No sample size calculation was performed
3. Number of screened patients is unclear
4. In Zeiner 1995 (in Zeiner 1999), this was written: No sociodemographic
information
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: no
Email correspondence with study authors: May to June 2014. We emailed Dr. Zeiner
on 05 May 2014 and 02 June 2014 but never received a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children were randomly allocated to re-
ceive methylphenidate first or placebo first
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A randomized crossover, double-blind de-
sign with methylphenidate and placebo”.
Placebo andmethylphenidate capsules that
were used were identical, to ensure blind-
ness to the drug condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All raters were blind to the drug condi-
tion”
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Incomplete outcome data (attrition bias)
All outcomes
High risk “The report from a teacher during one of
the periods was missing for one child. Ow-
ing to technical problems or unwillingness
to participate data were missing on some
of the test measures [which measured side
effects] for a few children” (Zeiner 1995 in
Zeiner 1999)
Selection bias: yes; only responders from
the 7-week trial were included in the ex-
tended-treatment methylphenidate group
Selective reporting (reporting bias) Low risk No selective outcome reporting
Vested interest bias Low risk This researchwas supported by theNorwe-
gian Medical Research Council, the Nor-
wegian Public Health Association and the
Legacy of Haldis and Josef Andresen
Conflicts of interest: not declared
Zeni 2009
Methods Randomised, cross-over trial with 2 interventions
1. Methylphenidate and aripiprazole
2. Placebo and aripiprazole
Phases: 2; randomisation, cross-over
Participants Number of participants screened: 30
Number of participants included: 16 (9 boys, 7 girls). Participants were randomly as-
signed to 1 of 2 possible drug condition orders
Number of participants followed up: 14
Number of withdrawals: 1
Diagnosis of ADHD:DSM-IV (inattentive (7.1%), hyperactive (14.3%), combined (78.
6%), out of n = 14)
Age: mean 10.71 years (SD 1.86; range 8 to 17)
IQ: > 70
Methylphenidate-naive: not stated
Ethnicity: European-Brazilian (71.4%), other (28.6%)
Country: Brazil
Setting: out-patient clinic
Co-morbidity: bipolar disorder (71.4%), borderline personality disorder (28.6%), anxi-
ety disorder (57.1%), conduct disorder (57.1%), oppositional defiant disorder (78.6%)
, psychosis (50%), out of n = 14
Co-medication: aripiprazole (100%)
Sociodemographics: divorced parents (57.1%); socioeconomic level A + B + C: 92.9%;
D + E: 7.1%
Inclusion criteria
1. 8 to 17 years of age
2. Diagnosis of borderline personality disorder, Axis I or II, co-morbid with ADHD
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(DSM-IV)
3. ADHD symptom onset preceding mood symptoms
4. ≥ 30% improvement in mood symptoms in previous trial of aripiprazole
5. Residual attention hyperactivity and opposition symptoms defined as score > 1.5
on the Swanson, Nolan and Pelham Scale, Fourth Edition
Exclusion criteria
1. IQ < 70
2. Use of any medication other than aripiprazole 10 weeks before the study
3. Diagnoses of pervasive developmental disorder
4. Schizophrenia
5. Substance abuse or dependence
6. Severe suicide/homicide risk counterindicating out-patient treatment
7. History of hypersensitivity to aripiprazole or methylphenidate
8. Any other acute or chronic disease that may interfere with the study
9. Pregnancy
Interventions Participants were randomly assigned to different possible drug condition orders of
methylphenidate (0.3 mg/kg for the first week, 0.7 mg/kg for the second week) and
placebo, both alongside aripiprazole
Mean methylphenidate dosage: 15 mg in the first week (10 mg in the morning and 5
mg in the afternoon), 35 mg in the second week (20 mg in the morning and 15 mg in
the afternoon)
Administration schedule: b.i.d. (morning and afternoon)
Duration of each medication condition: 2 weeks
Washout before study initiation: none (but recruited from 6-week aripiprazole study)
Medication-free period between interventions: not stated
Titration period: none
Treatment compliance: self report, mother’s report, pill counting in returned blister packs
Outcomes ADHD symptoms
1. Swanson, Nolan and Pelham Scale, Fourth Edition (Brazilian Version): rated
weekly by parents
General behaviour
1. Oppositional index of the Swanson, Nolan and Pelham Scale, Fourth Edition
(Brazilian Version): rated weekly by parents
Non-serious adverse events
1. Serious Adverse Event Rating Scale (SAERS)
2. Open question
Notes Sample calculation: no
Ethics approval: yes
Comments from study authors
1. The small sample size may not have allowed us to detect significant differences
between placebo and methylphenidate
2. The short-term duration of this trial may be an important limitation for the
observation of significant differences in adverse events between therapeutic agents
Key conclusions of study authors
1. Methylphenidate was not more effective than placebo in reducing attention or
hyperactivity symptoms in this short-term trial
564Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zeni 2009 (Continued)
2. Secondary finding suggests that depressive symptoms can be ameliorated by the
addition of methylphenidate to aripiprazole
3. Although methylphenidate was found to not de-stabilise borderline personality
disorder, its use should be considered with caution because 1 participant presented a
severe mixed episode needing hospitalisation during methylphenidate treatment
Exclusion ofmethylphenidate non-responders/childrenwho have previously experienced
adverse events while taking methylphenidate before randomisation: Only participants
who reported improved borderline personality disorder in the previous aripiprazole trial
were included. However, participants who reported that ADHD improved too much (as
indicated by a score < 1.5 on the Swanson, Nolan, and Pelham Scale, Fourth Edition)
in the previous aripiprazole trial were excluded (see ’Exclusion criteria’)
Any withdrawals due to adverse events: 1; exacerbation of borderline personality disorder
and ADHD requiring hospitalisation
Email correspondence with study authors: May 2014. We obtained supplemental infor-
mation regarding data. Study authors provided us with data from the first period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent third party randomly as-
signed participants to groups A and B
Allocation concealment (selection bias) Low risk A pharmacist packaged methylphenidate
and matching placebo in capsules, so
they could not be differentiated by shape,
colour, smell, weight or taste
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A pharmacist packaged methylphenidate
and matching placebo in capsules, so
they could not be differentiated by shape,
colour, smell, weight or taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk After all 4 assessments were completed,
study blinding was broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses of primary and secondary out-
come measures were performed using a
mixed-effects model (MEM) approach,
which provides a flexible framework for
analysis of repeated measures, while ac-
counting for missing data (i.e. lost to fol-
low-up)
Selection bias (e.g. titration after randomi-
sation→ exclusion): no
Selective reporting (reporting bias) Low risk Outcomes reported according to protocol
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Vested interest bias Unclear risk This work was fully supported by re-
search grants from Conselho Nacional
de Desenvolvimento Cientifico e Tecno-
logico (CNPq, Brazil) (Grant 471761=03-
6) and Hospital de Clinicas de Porto Ale-
gre (GPPG 03-325). Aripiprazole was pro-
vided by Bristol-Myers Squibb without re-
striction
Conflicts of interest: stated, “this is an inde-
pendent investigator trial”. However some
study authors have affiliations with medi-
cal companies
ADD: attention deficit disorder.
ADD-H: attention deficit disorder with hyperactivity.
ADHD: attention deficit hyperactivity disorder.
b.i.d.: twice a day.
CNS: central nervous system.
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised.
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
ECG: electrocardiogram.
EEG: electroencephalogram.
EKG: electrocardiogram.
FDA: Food and Drug Administration.
ITT: intention-to-treat.
LLC: limited liability company.
LOCF: last observation carried forward.
LTFU: loss to follow-up.
MedDRA: Medical Dictionary for Regulatory Activities.
MPH: methylphenidate.
MPT: methylphenidate trial.
MTA: Multimodal Treatment Study of Children With ADHD.
MTS: methylphenidate transdermal system.
NNTB: number needed to treat for an additional beneficial outcome.
OROS: Osmotic Release Oral System.
PTS: placebo transdermal system.
q.a.m.: every morning.
qd: once a day.
RCT: randomised controlled trial.
SD: standard deviation.
SODAS: spheroidal oral drug absorption system.
t.i.d.: three times a day.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
An 2013 N = No information
Likely no relevant outcome for our review
Outcomes reported: Resting state brain function
Anderson 2002 N = 10 boys
Likely no relevant outcome for our review
Outcomes reported: Functional magnetic resonance relaxometry
Barkley 1988a N = 28
Likely no relevant outcome for our review
Outcomes reported: Home Situations Questionnaire; Parenting Stress Index; Beck Depression Inventory
Barkley 1997 N = No information
Likely no relevant outcome for our review
Outcomes reported: “2 questionnaires”; “Electronic apparatus”
Bart 2013 N = 24
Likely no relevant outcome for our review
Outcomes reported: Movement Assessment Battery for Children - Second edition; Online Continuous
Performance Test
Bedard 2002 N = 31
Likely no relevant outcome for our review
Outcomes reported: Response interference; Stroop Naming Speed
Bedard 2003 N = 59
Likely no relevant outcome for our review
Outcomes reported: Parent Interview for Child Symptoms; Teacher Telephone Interview-IV; Selective Stop-
Signal Task
Bedard 2004 N = 26
Likely no relevant outcome for our review
Outcomes reported: Parent Interview for Child Symptoms; Teacher Telephone Interview-IV; Reading
subtest/Wide Range Achievement Test - 3; Word Attack andWord Identification subtests of theWoodcock
Reading Mastery; Test-Revised Cambridge Neuropsychological Testing Automated Battery
Bedard 2007 N = 40
Likely no relevant outcome for our review
Outcomes reported: Working memory; Test of Word and Language Efficiency; Wide Range Achievement
Test - 3;Woodcock-Johnson Tests of Achievement; Cambridge Neuropsychological Test Automated Battery
(CANTAB) Spatial Span
Beery 1994 N = 70
Likely no relevant outcome for our review
Outcomes reported: Behavioural management, behavioural disinhibition
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Ben-Pazi 2006 N = 55
Likely no relevant outcome for our review
Outcomes reported: Hastening phenomena
Bental 2008 N = 25
Likely no relevant outcome for our review
Outcomes reported: Reading measures
Brown 1984b N = 20
Likely no relevant outcome for our review
Outcomes reported: Children’s Checking Task
Buhrmester 1992 N = 19
Likely no relevant outcome for our review
Outcomes reported: Prosocial behavior
Campbell 1996 N = 30
Likely no relevant outcome for our review
Outcomes reported: Reactions time on Tachistoscopic Task
Carlson 1991 N = 13
Likely no relevant outcome for our review
Outcomes reported: Reaction times; cognitive tasks
Carlson 1992 N = 24
Likely no relevant outcome for our review
Outcomes reported: On task and disruptive behaviour; academic work completion and accuracy
Cox 2004b N = 6
Likely no relevant outcome for our review
Outcomes reported: Driving performance - measured by computer
Dawson 1998 N = 13
Likely no relevant outcome for our review
Outcomes reported: Mirsky’s proposed factors of attention: sustained attention, focus/execute, encode, and
stability of attention
De Sonneville 1991 N = 17
Likely no relevant outcome for our review
Outcomes reported: Specific attention function: sustained attention, information processing, response or-
ganization
DeVito 2008 N = 21
Likely no relevant outcome for our review
Outcomes reported: Cambridge Gamble Task; measures of response inhibition and reflection-impulsivity
on the Information Sampling Task
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Evans 1986 N = No information
Likely no relevant outcome for our review
Outcomes reported: Verbal memory and learning
Fox 2014 N = 14
Likely no relevant outcome for our review
Outcomes reported: Memory tasks
Francis 2001 N = 50
Likely no relevant outcome for our review
Outcomes reported: Story telling and story grammar analysis
Gan 1982 N = 20
Likely no relevant outcome for our review
Outcomes reported: Performance on paired-associate learning task
Granger 1996 N = 26
Likely no relevant outcome for our review
Outcomes reported: Social behaviour
Grizenko 2010 N = 371
Likely no relevant outcome for our review
Outcomes reported: Academic behaviour; sustained attention; impulse inhibition control
Günther 2010 N = 54
Likely no relevant outcome for our review
Outcomes reported: Sustained attention measured by computer attention tests
Halliday 1983 N = No information
Likely no relevant outcome for our review
Outcomes reported: Event-related potentials
Hanisch 2004 N = 45
Likely no relevant outcome for our review
Outcomes reported: Computerized attention tasks
Hazel-Fernandez 2006 N = 19
Likely no relevant outcome for our review
Outcomes reported: Paired Associates Learning Task; Tower of Hanoi
Hinshaw 1989 N = 25
Likely no relevant outcome for our review
Outcomes reported: Prosocial behavior
Hinshaw 1993 N = 22
Likely no relevant outcome for our review
Outcomes reported: Antisocial behaviour
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Humphries 1979 N = 24
Likely no relevant outcome for our review
Outcomes reported: Maze-tracking performance
King 2009a N = 75
Likely no relevant outcome for our review
Outcomes reported: Social information processing
King 2009b N = 32
Likely no relevant outcome for our review
Outcomes reported: Laboratory provocation task: measuring hostile, instrumental, reactive, and proactive
aggression
Lange 2007 N = 58
Likely no relevant outcome for our review
Outcomes reported: Reaction time; alertness; vigilance; divided attention
Leitner 2007b N = 16
Likely no relevant outcome for our review
Outcomes reported: Gait; stride to stride variability, memory, visual-spatial, verbal, and attention domains
Malone 1988 N = 31
Likely no relevant outcome for our review
Outcomes reported: Word processing; reaction time; cognitive decision task
Malone 1993 N = 26
Likely no relevant outcome for our review
Outcomes reported: Impulsive responding
Malone 1994 N = 17
Likely no relevant outcome for our review
Outcomes reported: Right hemisphere dysfunction
Martin 2007 N = 24
Likely no relevant outcome for our review
Outcomes reported:Depression; addiction rate;ContinuousPerformanceTask; heart rate andbloodpressure
Mehta 2004 N = 14
Likely no relevant outcome for our review
Outcomes reported: Working memory
Milich 1989 N = 26
Likely no relevant outcome for our review
Outcomes reported: Continuous Performance Task
Milich 1991 N = 21
Likely no relevant outcome for our review
Outcomes reported: Task persistence
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Novak 1995 N = 16
Likely no relevant outcome for our review
Outcomes reported: Reaction time; visuospatial attention
O’Toole 1997 N = 23
Likely no relevant outcome for our review
Outcomes reported: Non-verbal learning
Peeke 1984 N = 9
Likely no relevant outcome for our review
Outcomes reported: Verbal information processing
Pelham 1985 N = 29
Likely no relevant outcome for our review
Outcomes reported: Classroom academic and social behaviour
Pelham 1990b N = 17
Likely no relevant outcome for our review
Outcomes reported: Attention during baseball game; on task behaviour; ability to answer question about
the status of the game
Pelham 1992 N = 28
Likely no relevant outcome for our review
Outcomes reported: Self-reported attribution and evaluation of behaviour
Pelham 1997 N = 60
Likely no relevant outcome for our review
Outcomes reported: Performance, self-evaluation, persistence, and attributions on cognitive task
Pelham 2001b N = 68
Likely no relevant outcome for our review
Outcomes reported: A large number of different measures of behaviour
Rapport 1995 N = 45
Likely no relevant outcome for our review
Outcomes reported: Paired Associates Learning Task
Richardson 1988 N = 42
Likely no relevant outcome for our review
Outcomes reported: Reading achievement
Rubia 2003 N = 13
Likely no relevant outcome for our review
Outcomes reported: Motor timing
Sangal 2006 N = 58
Likely no relevant outcome for our review
Outcomes reported: Auditory amplitude
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Sengupta 2008 N = 188
Likely no relevant outcome for our review
Outcomes reported: Task oriented behaviour
Silk 2012 N = No information
Likely no relevant outcome for our review
Outcomes reported: Neural substrates
Smith 2013 N = 20
Likely no relevant outcome for our review
Outcomes reported: Functional magnetic resonance imaging
Solanto 1986 N = 12
Likely no relevant outcome for our review
Outcomes reported: Attention during play measured by locomotor activity; Children’s Checking Test; and
fine motor control
Solanto 1997 N = 22
Likely no relevant outcome for our review
Outcomes reported: Continuous Performance Test
Srinivas 1992 N = 9
Likely no relevant outcome for our review
Outcomes reported: Sustained attention measured by computer attention tests
Strand 2012 N = 17
Likely no relevant outcome for our review
Outcomes reported: Working memory
Stray 2009 N = 25
Likely no relevant outcome for our review
Outcomes reported: Motor functions
Swanson 1993 N = 26
Likely no relevant outcome for our review
Outcomes reported: Impulsive responding
Szobot 2003 N = 36
Likely no relevant outcome for our review
Outcomes reported: Cerebral blood flow
Tannock 2000 N = 47
Likely no relevant outcome for our review
Outcomes reported: Naming speed and academic measures
Teicher 2003 N = 19
Likely no relevant outcome for our review
Outcomes reported: Computerized Contiuous Performance Test and functional magnetic resonance imag-
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(Continued)
ing
Teicher 2006 N = 14
Likely no relevant outcome for our review
Outcomes reported: Rate-dependent behavioural effects
Teicher 2007 N = 11
Likely no relevant outcome for our review
Outcomes reported: McLean Motion Attention Test
Tillery 2000 N = 32
Likely no relevant outcome for our review
Outcomes reported: Auditory performance
Trommer 1991 N = 44
Likely no relevant outcome for our review
Outcomes reported: Go-No-GO performance
Tsang 2012 N = 134
Likely no relevant outcome for our review
Outcomes reported: Cognitive tasks; emotional functions
Tucha 2006 N = 58
Likely no relevant outcome for our review
Outcomes reported: Reaction time tasks
Verbaten 1994 N = 12
Likely no relevant outcome for our review
Outcomes reported: Continuous Performance Test
Waschbusch 2007 N = 61
Likely no relevant outcome for our review
Outcomes reported: Academic oriented tasks
Whalen 1987 N = 24
Likely no relevant outcome for our review
Outcomes reported: Social behaviour
Characteristics of studies awaiting assessment [ordered by study ID]
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Drtilkova 1997
Methods RCT
14 days
Studied all aspects of methylphenidate, amphetaminil, mesocarb and placebo in a group of 118 children
Participants
Interventions
Outcomes
Notes Article is written in Czech. We have not yet been able to have the article translated
Short 2004
Methods The purpose of this trial was to examine the efficacy of psychostimulant medication in a naturalistic sample of pre-
school children. Researchers examined the benefits and side effects of methylphenidate and mixed amphetamine salts
(Adderall)
Participants
Interventions
Outcomes
Notes
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Bottelier 2014
Trial name or title
Methods 16-week, placebo-controlled RCT with methylphenidate in 100 medication-naive participants with ADHD
Participants
Interventions
Outcomes
Starting date
Contact information
574Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bottelier 2014 (Continued)
Notes This article describes methods and design. We are awaiting additional publications
Gendron 2012
Trial name or title
Methods Placebo-controlled trial of methylphenidate involving 30 medication-naive children with ADHD
Participants
Interventions
Outcomes
Starting date
Contact information
Notes Correspondence with trial authors in August 2013. Trial will be submitted for review over the next fewmonths
NCT00483106
Trial name or title Clinical and pharmacogenetic study of attention deficit hyperactivity disorder (ADHD)
Methods RCT
Participants Children with ADHD, aged 6 to 12 years
Interventions Ritalin and placebo
Outcomes Conners’ Global Index (CGI)
Starting date
Contact information Ridha Jobber, McGill University
Notes
NCT02039908
Trial name or title Examining tolerance to CNS stimulants in ADHD
Methods RCT
Participants Children with ADHD, aged 6 to 12 years
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NCT02039908 (Continued)
Interventions Methylphenidate
Outcomes
Starting date
Contact information
Notes
Nurmi 2013
Trial name or title Pharmacogenetics of growth effects complicating ADHD treatment (Neuropsychopharmacology)
Methods 8-week RCT: double-blind, randomised, placebo-controlled trial with 4 interventions and 16-month exten-
sion
1. Guanfacine
2. Dexmethylphenidate
3. Combination guanfacine + dexmethylphenidate (16-month)
4. Placebo
Phases: 8-week, double-blind; 16 months open
Participants Number of participants screened: not stated
Number of participants included: 209 (sex not stated). Participants were randomly assigned to 1 of 4 possible
drug condition orders
Number of participants followed up: 99
Number of withdrawals: not stated
Diagnosis of ADHD: not stated
Age: not stated
IQ: not stated
Methylphenidate naive: not stated
Ethnicity: not stated
Country: USA
Comorbidity: not stated
Comedication: not stated
Sociodemographics: not stated
Inclusion criteria
1. Not stated
Exclusion criteria
1. Not stated
Interventions Participants were randomly assigned to 1 of 3 possible drug condition orders of dexmethylphenidate and
placebo
Administration schedule: not stated
Duration of each medication condition: not stated
Washout before trial initiation: not stated
Medication-free period between interventions: not stated
Titration period: not stated
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Nurmi 2013 (Continued)
Treatment compliance: not stated
Outcomes Outcomes: adverse events
Both dexmethylphenidate monotherapy (Z-score decrease of -0.12 for height and -0.84 for BMI) and com-
bination treatment (Z-score decrease of -0.19 for height and -0.83 for BMI) were associated with slowing of
growth. In the methylphenidate-only condition, DRD3 rs3732790 minor allele homozygotes showed a 2.0
greater Z-score weight loss than was seen with common allele carriers (P value = 1.09 × 10−8)
Starting date 2012 (date on which conference abstract published). Study end date unknown
Contact information Erika L Nurmi: erika.nurmi@vanderbit.edu
James T McCracken: jmcracken@mednet.ucla.edu. Department of Psychiatry and Biobehavioral Sciences,
UCLA NPI-Semel Institute, 760 Westwood Plaza, Los Angeles, CA 90024-1759, USA
Notes Sample calculation: no
Ethics approval: not stated
Results of this trial have not yet been published. Trial authors expect to publish their findings within the year
ADHD: Attention deficit hyperactivity disorder.
BMI: Body mass index.
CNS: Central nervous system.
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Teacher-rated ADHD symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All parallel-group trials and
first-period cross-over trials
19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
1.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 High risk of bias 19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
2 Subgroup analysis: types of scales 19 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Conners’ Teacher Rating
Scale (CTRS)
8 518 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.82, -0.47]
2.2 Abbreviated Conners’
Rating Scale (ACRS) - Teacher
2 105 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.79, 0.29]
2.3 Conners’ Abbreviated
Symptom Questionnaire for
Teachers (ASQ-Teacher)
1 59 Std. Mean Difference (IV, Random, 95% CI) -0.28 [-0.79, 0.23]
2.4 IOWA Conners’ Teacher
Rating Scale (IOWA CTRS) -
hyperactivity
2 193 Std. Mean Difference (IV, Random, 95% CI) -1.08 [-1.39, -0.77]
2.5 Schedule for Non-adaptive
and Adaptive Personality
(SNAP) - Teacher
2 328 Std. Mean Difference (IV, Random, 95% CI) -0.61 [-0.96, -0.25]
2.6 Teacher ratings of
attention
1 20 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.45, 0.35]
2.7 Teacher ratings of
impulsivity
1 20 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.83, 0.92]
2.8 IOWA Conners’
Teacher Rating Scale -
Inattention/Overactivity
(IOWA-I/O)
2 197 Std. Mean Difference (IV, Random, 95% CI) -1.03 [-1.36, -0.69]
2.9 Fremdbeurteilungsbogen
für Hyperkinetische Störungen
(FBB-HKS)
1 85 Std. Mean Difference (IV, Random, 95% CI) -1.06 [-1.52, -0.61]
2.10 Conners’
ADHD/DSM-IV Scales -
Teacher (CADS-T)
2 254 Std. Mean Difference (IV, Random, 95% CI) -1.05 [-1.31, -0.78]
2.11 Strengths and
Weaknesses of ADHD
Symptoms and Normal
Behaviour (SWAN) Scale
1 64 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.82, 0.17]
3 Medication status: medication
naive versus not medication
naive
6 717 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-1.08, -0.50]
3.1 Medication naive 4 431 Std. Mean Difference (IV, Random, 95% CI) -0.63 [-0.94, -0.31]
3.2 Not medication naive 2 286 Std. Mean Difference (IV, Random, 95% CI) -1.06 [-1.33, -0.79]
4 Subgroup analysis: duration of
treatment
19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
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4.1 Short term (up to 6
months)
18 1445 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-0.94, -0.68]
4.2 Long term (over 6
months)
1 253 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.72, -0.22]
5 Subgroup analysis: dose 19 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Low dose 8 493 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.82, -0.46]
5.2 High dose 7 688 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-1.08, -0.54]
5.3 Unknown dose 6 669 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.06, -0.68]
6 Subgroup analysis: parallel-group
trials compared with
first-period cross-over trials
19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
6.1 Parallel-group trials 17 1506 Std. Mean Difference (IV, Random, 95% CI) -0.80 [-0.95, -0.65]
6.2 First-period cross-over
trials
2 192 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.87, -0.29]
7 Subgroup analysis: trials with
cohort selection bias of all
participants compared with
trials without cohort selection
bias of all participants
19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
7.1 Trials with cohort
selection bias of all participants
7 994 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-1.01, -0.57]
7.2 Trials without cohort
selection bias of all participants
12 704 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-0.93, -0.59]
8 ADHD symptoms, cross-over
trial (endpoint data)
59 5145 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.06, -0.80]
8.1 Low risk of bias 4 204 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.97, -0.30]
8.2 High risk of bias 55 4941 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.09, -0.82]
9 ADHD symptoms, cross-over
trials (endpoint data), subgroup
analysis: dose
59 6821 Std. Mean Difference (IV, Random, 95% CI) -0.85 [-0.96, -0.74]
9.1 Low dose 42 3408 Std. Mean Difference (IV, Random, 95% CI) -0.73 [-0.89, -0.57]
9.2 High dose 36 3413 Std. Mean Difference (IV, Random, 95% CI) -0.98 [-1.13, -0.84]
10 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
compared with cross-over trials
(endpoint data)
75 6344 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.01, -0.80]
10.1 All parallel-group trials
and first-period cross-over trials
19 1698 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
10.2 Cross-over trials
(endpoint data)
56 4646 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.09, -0.82]
11 All parallel-group trials and
cross-over trials: risk of bias
75 6344 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.01, -0.80]
11.1 Low risk of bias 4 204 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.97, -0.30]
11.2 High risk of bias 71 6140 Std. Mean Difference (IV, Random, 95% CI) -0.92 [-1.03, -0.81]
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Comparison 2. Independent assessor-rated ADHD symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All parallel-group trials and
first-period cross-over trials
10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
1.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 High risk of bias 10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
2 Subgroup analysis: types of scales 10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Swanson, Kotkin,
Agler, M-Glynn and Pelham
(SKAMP) Scale
1 164 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.04, -0.41]
2.2 ADHD Rating Scale
(ADHD-RS )
7 1442 Std. Mean Difference (IV, Random, 95% CI) -0.71 [-1.09, -0.32]
2.3 Swanson, Nolan and
Pelham (SNAP) Scale
1 221 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.61, -0.08]
2.4 Unknown 1 78 Std. Mean Difference (IV, Random, 95% CI) -0.94 [-1.41, -0.47]
3 Subgroup analysis: duration of
treatment
10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
3.1 Short term (up to 6
months)
9 1686 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-0.95, -0.40]
3.2 Long term (over 6
months)
1 221 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.61, -0.08]
4 Subgroup analysis: parallel-group
trials compared with
first-period cross-over trials
10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
4.1 Parallel-group trials 7 1609 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.91, -0.28]
4.2 First-period cross-over
trials
3 298 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-0.99, -0.52]
5 Subgroup analysis: trials with
cohort selection bias of all
participants compared with
trials without cohort selection
bias of all participants
10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
5.1 Trials with cohort
selection bias of all participants
4 630 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-0.73, -0.29]
5.2 Trials without cohort
selection bias of all participants
6 1277 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.11, -0.33]
6 Subgroup analysis: dose 10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
6.1 Low dose 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 High dose 6 1380 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-0.91, -0.20]
6.3 Unknown dose 4 527 Std. Mean Difference (IV, Random, 95% CI) -0.80 [-0.98, -0.61]
7 ADHD symptoms, cross-over
trials (endpoint data), subgroup
analysis: risk of bias
19 2471 Std. Mean Difference (IV, Random, 95% CI) 1.00 [-1.16, -0.84]
7.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 High risk of bias 19 2471 Std. Mean Difference (IV, Random, 95% CI) 1.00 [-1.16, -0.84]
8 ADHD symptoms, cross-over
trials (endpoint data), subgroup
analysis: dose
19 3874 Std. Mean Difference (IV, Random, 95% CI) -0.89 [-1.02, -0.75]
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8.1 Low dose 16 2021 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.82, -0.55]
8.2 High dose 12 1853 Std. Mean Difference (IV, Random, 95% CI) -1.13 [-1.31, -0.95]
9 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
compared with cross-over trials
(endpoint data)
28 4215 Std. Mean Difference (IV, Random, 95% CI) -0.83 [-0.98, -0.67]
9.1 All parallel-group trials
and first-period cross-over trials
10 1907 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.89, -0.39]
9.2 Cross-over trials (endpoint
data)
18 2308 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.13, -0.77]
Comparison 3. Parent-rated ADHD symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All parallel-group trials and
first-period cross-over trials
21 2187 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
1.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 High risk of bias 21 2187 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
2 Subgroup analysis: types of scales 21 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Conners’ Parent Rating
Scale (CPRS)
7 751 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.87, -0.30]
2.2 ADHD Rating
Scale - Fourth Edition
(ADHD-RS-IV)
2 194 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.58, -0.02]
2.3 Fremdbeurteilungsbogen
für Hyperkinetische Störungen
(FBB-HKS)
1 85 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.36, -0.46]
2.4 Conners’
ADHD/DSM-IV Scales -
Parent (CADS-P)
1 120 Std. Mean Difference (IV, Random, 95% CI) -1.26 [-1.65, -0.86]
2.5 CADS-P Inattentive
subscale
1 109 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-1.17, -0.39]
2.6 CADS-P Hyperactivity
subscale
1 109 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.32, -0.53]
2.7 Clinican’s Manual for
the Assesment of Disruptive
Behavior Disorders Rating
Scale for Parents (Barkley)
1 41 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.82, 0.41]
2.8 Abbreviated Conners’
Rating Scale (ACRS) - Parent
2 121 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-0.99, -0.25]
2.9 Swanson, Nolan, and
Pelham, Fourth Edition -
Parent (SNAP-IV-Parent) Scale
4 430 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.79, -0.40]
581Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.10 Strengths and
Weaknesses of ADHD
Symptoms and Normal
Behavior (SWAN) Scale
1 86 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.86, 0.00]
2.11 IOWA Conners’ Rating
Scale - Inattention/Overactivity
(IOWA-I/O)
3 352 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-1.35, -0.21]
3 Subgroup analysis: duration of
treatment
21 2187 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
3.1 Short term (up to 6
months)
20 1925 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-0.84, -0.50]
3.2 Long term (over 6
months)
1 262 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.82, -0.33]
4 Subgroup analysis: dose 21 2335 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.79, -0.48]
4.1 Low dose 5 329 Std. Mean Difference (IV, Random, 95% CI) -0.53 [1.00, -0.07]
4.2 High dose 10 1132 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.86, -0.33]
4.3 Unknown dose 8 874 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-0.92, -0.52]
5 Medication status: medication
naive versus not medication
naive
7 795 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-1.05, -0.48]
5.1 Medication naive 4 492 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-1.03, -0.35]
5.2 Not medication naive 3 303 Std. Mean Difference (IV, Random, 95% CI) -0.88 [-1.33, -0.42]
6 Subgroup analysis: trials with
cohort selection bias of all
participants compared with
trials without cohort selection
bias of all participants
21 2187 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
6.1 Trials with selection bias
of all participants
10 1559 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-0.86, -0.51]
6.2 Trials without cohort
selection bias of all participants
11 628 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-0.90, -0.33]
7 Subgroup analysis: parallel-group
trials compared with
first-period cross-over trials
21 2187 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
7.1 Parallel-group trials 19 2094 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.83, -0.50]
7.2 First-period cross-over
trials
2 93 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-1.07, -0.23]
8 ADHD symptoms, cross-over
trials (endpoint data)
41 3734 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-0.90, -0.67]
8.1 Low risk of bias 4 204 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-0.96, -0.13]
8.2 High risk of bias 37 3530 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-0.92, -0.69]
9 ADHD symptoms, cross-over
trials (endpoint data), subgroup
analysis: dose
41 4918 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.79, -0.58]
9.1 Low dose 26 2272 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-0.82, -0.48]
9.2 High dose 28 2646 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-0.84, -0.60]
10 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
compared with cross-over trials
(endpoint data)
59 5861 Std. Mean Difference (IV, Random, 95% CI) -0.74 [-0.83, -0.65]
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10.1 All parallel-group trials
and first-period cross-over trials
21 2215 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.82, -0.51]
10.2 Cross-over trials
(endpoint data)
39 3646 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-0.90, -0.67]
Comparison 4. Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-
over trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparision of raters 31 5697 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.79, -0.59]
1.1 Teacher-rated 19 1689 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-0.93, -0.63]
1.2 Independent assessor-rated 9 1829 Std. Mean Difference (IV, Random, 95% CI) -0.61 [-0.87, -0.35]
1.3 Parent-rated 21 2179 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-0.81, -0.50]
2 Age 6 1039 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.74, -0.14]
2.1 2 to 6 years 1 64 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.82, 0.17]
2.2 7 to 11 years 2 278 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-1.03, -0.15]
2.3 12 to 18 years 3 697 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.88, 0.12]
3 Comorbidity versus no
comorbidity
20 2310 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-0.91, -0.53]
3.1 ADHD with comorbidity 18 1981 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-0.94, -0.51]
3.2 ADHD without
comorbidity
2 329 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.92, -0.46]
4 Subtypes ADHD: ADHD
Rating Scale (parent-, teacher-
or independent assessor-rated)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Combined ADHD 2 559 Std. Mean Difference (IV, Random, 95% CI) 0.65 [-1.30, 2.60]
4.2 Inattentive ADHD 1 204 Std. Mean Difference (IV, Random, 95% CI) -1.31 [-1.61, -1.01]
5 Cross-over trials: first-period
data versus endpoint data
(parent-, independent assessor-
and teacher-rated)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 First-period data 4 372 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.85, -0.44]
5.2 Endpoint data 4 372 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.18, -0.65]
Comparison 5. Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of serious adverse events
(SAE)
9 1532 Risk Ratio (IV, Random, 95% CI) 0.98 [0.44, 2.22]
2 Nervous system 6 2280 Risk Ratio (IV, Random, 95% CI) 0.87 [0.30, 2.53]
2.1 Aggression 1 303 Risk Ratio (IV, Random, 95% CI) 0.50 [0.05, 5.49]
2.2 Concussion 1 303 Risk Ratio (IV, Random, 95% CI) 0.34 [0.01, 8.17]
2.3 Loss of consciousness 1 221 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.02]
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2.4 Psychosis 4 712 Risk Ratio (IV, Random, 95% CI) 1.78 [0.19, 16.96]
2.5 Syncope 3 741 Risk Ratio (IV, Random, 95% CI) 1.39 [0.23, 8.47]
3 Digestive system: gastrointestinal
disorders
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
4 Urinary system: kidney infection 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
5 Circulatory and respiratory
systems: asthma
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
6 Immune system: cyst rupture 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
7 Other: drug toxicity 1 303 Risk Ratio (IV, Random, 95% CI) 0.34 [0.01, 8.17]
Comparison 6. Number of serious adverse events: cross-over trials (endpoint data)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of serious adverse events
(SAE)
8 1721 Risk Ratio (IV, Random, 95% CI) 1.62 [0.34, 7.71]
2 Hallucinations/psychosis 4 187 Risk Ratio (IV, Random, 95% CI) 1.10 [0.18, 6.72]
Comparison 7. Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total number of non-serious
adverse events
21 3132 Risk Ratio (IV, Random, 95% CI) 1.29 [1.10, 1.51]
2 Subgroup analysis: total number
of non-serious adverse events
according to dose
21 3135 Risk Ratio (IV, Random, 95% CI) 1.28 [1.11, 1.49]
2.1 Low dose 2 151 Risk Ratio (IV, Random, 95% CI) 1.09 [0.82, 1.46]
2.2 High dose 10 1761 Risk Ratio (IV, Random, 95% CI) 1.22 [1.10, 1.35]
2.3 Unknown dose 10 1223 Risk Ratio (IV, Random, 95% CI) 1.37 [1.01, 1.87]
3 Nervous system 21 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Affective 4 390 Risk Ratio (Random, 95% CI) 2.39 [0.48, 11.96]
3.2 Aggression 2 417 Risk Ratio (Random, 95% CI) 1.16 [0.17, 7.80]
3.3 Apathy 1 59 Risk Ratio (Random, 95% CI) 0.80 [0.19, 3.33]
3.4 Confusion 2 548 Risk Ratio (Random, 95% CI) 1.01 [0.22, 4.73]
3.5 Depression 1 59 Risk Ratio (Random, 95% CI) 0.83 [0.22, 3.10]
3.6 Dizziness 3 683 Risk Ratio (Random, 95% CI) 2.50 [0.70, 8.99]
3.7 Drowsiness 4 811 Risk Ratio (Random, 95% CI) 1.27 [0.82, 1.98]
3.8 Emotional lability 1 132 Risk Ratio (Random, 95% CI) 2.41 [0.27, 21.32]
3.9 Fatigue 7 858 Risk Ratio (Random, 95% CI) 0.76 [0.36, 1.63]
3.10 Headache 17 2724 Risk Ratio (Random, 95% CI) 1.22 [0.90, 1.64]
3.11 Insomnia 3 349 Risk Ratio (Random, 95% CI) 1.31 [0.35, 4.93]
3.12 Irritability 11 1721 Risk Ratio (Random, 95% CI) 1.11 [0.77, 1.60]
3.13 Nervousness 2 362 Risk Ratio (Random, 95% CI) 2.52 [0.82, 7.76]
3.14 Pain 1 132 Risk Ratio (Random, 95% CI) 1.91 [0.21, 17.60]
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3.15 Picking at skin or
fingers, nail biting, lip or cheek
chewing
1 316 Risk Ratio (Random, 95% CI) 1.01 [0.60, 1.70]
3.16 Sad, tearful or depressed 4 707 Risk Ratio (Random, 95% CI) 1.41 [0.86, 2.29]
3.17 Somnolence 2 173 Risk Ratio (Random, 95% CI) 0.59 [0.11, 3.11]
3.18 Trouble sleeping or sleep
problems
13 2416 Risk Ratio (Random, 95% CI) 1.60 [1.15, 2.23]
3.19 Tics or nervous
movements
8 1231 Risk Ratio (Random, 95% CI) 0.85 [0.26, 2.79]
3.20 Worried or anxious 3 596 Risk Ratio (Random, 95% CI) 1.37 [0.84, 2.25]
4 Digestive system 18 Risk Ratio (IV, Random, 95% CI) Subtotals only
4.1 Decreased appetite 16 2962 Risk Ratio (IV, Random, 95% CI) 3.66 [2.56, 5.23]
4.2 Decreased weight 6 859 Risk Ratio (IV, Random, 95% CI) 3.89 [1.43, 10.59]
4.3 Diarrhoea 5 857 Risk Ratio (IV, Random, 95% CI) 1.07 [0.41, 2.74]
4.4 Dyspepsia 2 159 Risk Ratio (IV, Random, 95% CI) 1.80 [0.71, 4.54]
4.5 Increased appetite 1 179 Risk Ratio (IV, Random, 95% CI) 0.07 [0.00, 1.43]
4.6 Nausea 11 1995 Risk Ratio (IV, Random, 95% CI) 1.30 [0.85, 1.99]
4.7 Stomachache 13 2341 Risk Ratio (IV, Random, 95% CI) 1.30 [1.00, 1.69]
4.8 Vomiting 11 1916 Risk Ratio (IV, Random, 95% CI) 1.17 [0.76, 1.79]
5 Circulatory and respiratory
systems
8 Risk Ratio (Random, 95% CI) Subtotals only
5.1 ECG: prolonged
QT-interval
2 466 Risk Ratio (Random, 95% CI) 0.81 [0.13, 5.00]
5.2 ECG: tachycardia 1 245 Risk Ratio (Random, 95% CI) 1.04 [0.11, 10.18]
5.3 Cough 4 996 Risk Ratio (Random, 95% CI) 0.95 [0.41, 2.18]
5.4 Nasal congestion 2 479 Risk Ratio (Random, 95% CI) 1.19 [0.59, 2.41]
5.5 Pharyngolaryngeal pain 1 303 Risk Ratio (Random, 95% CI) 1.12 [0.59, 2.13]
5.6 Supraventricular
extrasystoles
1 17 Risk Ratio (Random, 95% CI) 3.00 [0.11, 84.55]
5.7 Upper respiratory tract
infection
1 217 Risk Ratio (Random, 95% CI) 1.07 [0.42, 2.76]
6 Skeletal and muscular systems 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
6.1 Arthralgia 1 303 Risk Ratio (IV, Random, 95% CI) 0.67 [0.24, 1.84]
6.2 Asthenia 1 177 Risk Ratio (IV, Random, 95% CI) 0.21 [0.01, 4.25]
6.3 Back pain 1 303 Risk Ratio (IV, Random, 95% CI) 0.81 [0.39, 1.66]
6.4 Myalgia 1 303 Risk Ratio (IV, Random, 95% CI) 0.60 [0.23, 1.62]
6.5 Toothache 1 303 Risk Ratio (IV, Random, 95% CI) 1.01 [0.43, 2.35]
7 Immune system 7 Risk Ratio (IV, Random, 95% CI) Subtotals only
7.1 Gastroenteritis 3 435 Risk Ratio (IV, Random, 95% CI) 4.63 [0.99, 21.72]
7.2 Influenza 3 624 Risk Ratio (IV, Random, 95% CI) 0.65 [0.20, 2.10]
7.3 Nasopharyngitis 5 979 Risk Ratio (IV, Random, 95% CI) 1.15 [0.70, 1.87]
7.4 Otitis media 1 100 Risk Ratio (IV, Random, 95% CI) 1.77 [0.17, 18.94]
7.5 Pharyngitis 2 293 Risk Ratio (IV, Random, 95% CI) 2.43 [0.49, 12.05]
7.6 Pyrexia 2 400 Risk Ratio (IV, Random, 95% CI) 1.02 [0.01, 87.72]
7.7 Rhinitis 1 132 Risk Ratio (IV, Random, 95% CI) 1.28 [0.43, 3.79]
7.8 Upper respiratory tract
infection - not otherwise
specified (NOS)
5 917 Risk Ratio (IV, Random, 95% CI) 1.19 [0.68, 2.06]
7.9 Viral infection NOS 3 614 Risk Ratio (IV, Random, 95% CI) 0.70 [0.23, 2.15]
8 Height 1 Mean Difference (IV, Random, 95% CI) Totals not selected
9 Weight 5 805 Std. Mean Difference (IV, Random, 95% CI) -1.12 [-1.55, -0.70]
10 BMI 1 Mean Difference (IV, Random, 95% CI) Totals not selected
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11 Vital signs 9 3374 Mean Difference (IV, Random, 95% CI) 1.41 [0.30, 2.52]
11.1 Diastolic blood pressure
(mmHg)
8 1067 Mean Difference (IV, Random, 95% CI) 0.94 [-0.12, 2.01]
11.2 Systolic blood pressure
(mmHg)
8 1067 Mean Difference (IV, Random, 95% CI) -0.05 [-1.25, 1.16]
11.3 Pulse or heart rate (bpm) 8 1240 Mean Difference (IV, Random, 95% CI) 3.41 [0.87, 5.94]
12 Other 5 1815 Risk Ratio (IV, Random, 95% CI) 1.20 [0.56, 2.57]
12.1 Accidental injury 3 656 Risk Ratio (IV, Random, 95% CI) 0.99 [0.48, 2.07]
12.2 Epistasis 1 132 Risk Ratio (IV, Random, 95% CI) 4.25 [0.23, 77.22]
12.3 Excoriation 1 303 Risk Ratio (IV, Random, 95% CI) 3.52 [1.19, 10.46]
12.4 Overdose 1 221 Risk Ratio (IV, Random, 95% CI) 2.97 [0.12, 72.20]
12.5 Skin disorder (rash) 2 200 Risk Ratio (IV, Random, 95% CI) 0.52 [0.01, 26.44]
12.6 Skin laceration 1 303 Risk Ratio (IV, Random, 95% CI) 0.42 [0.15, 1.16]
Comparison 8. Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total number of non-serious
adverse events
21 2072 Risk Ratio (Random, 95% CI) 1.33 [1.11, 1.58]
2 Subgroup analysis: total number
of non-serious adverse events
according to dose
21 2859 Risk Ratio (Random, 95% CI) 1.26 [1.11, 1.44]
2.1 Low dose 16 1539 Risk Ratio (Random, 95% CI) 1.11 [0.94, 1.31]
2.2 High dose 12 1080 Risk Ratio (Random, 95% CI) 1.57 [1.22, 2.01]
2.3 Unknown dose 2 240 Risk Ratio (Random, 95% CI) 0.98 [0.51, 1.86]
3 Nervous system 50 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Aggression 2 589 Risk Ratio (Random, 95% CI) 0.52 [0.17, 1.60]
3.2 Agitation 1 62 Risk Ratio (Random, 95% CI) 1.18 [0.38, 3.60]
3.3 Anger 3 264 Risk Ratio (Random, 95% CI) 0.45 [0.26, 0.77]
3.4 Behavioural complaints 1 82 Risk Ratio (Random, 95% CI) 0.55 [0.35, 0.86]
3.5 Buccal or lingual
movements
4 302 Risk Ratio (Random, 95% CI) 1.06 [0.62, 1.79]
3.6 Compulsive acts 1 90 Risk Ratio (Random, 95% CI) 2.57 [1.45, 4.56]
3.7 Daydreaming 3 222 Risk Ratio (Random, 95% CI) 0.66 [0.44, 0.98]
3.8 Dizziness 9 746 Risk Ratio (Random, 95% CI) 1.17 [0.89, 1.55]
3.9 Drowsiness: dull, tired,
listless or sleepy
21 1350 Risk Ratio (Random, 95% CI) 0.97 [0.73, 1.28]
3.10 Euphoria 6 405 Risk Ratio (Random, 95% CI) 1.06 [0.72, 1.57]
3.11 Headache 37 3752 Risk Ratio (Random, 95% CI) 1.21 [1.01, 1.45]
3.12 Insomnia or sleep
problems
31 3270 Risk Ratio (Random, 95% CI) 1.57 [1.20, 2.06]
3.13 Irritability 23 2238 Risk Ratio (Random, 95% CI) 0.92 [0.66, 1.27]
3.14 Nightmares 10 686 Risk Ratio (Random, 95% CI) 0.97 [0.66, 1.42]
3.15 Overly meticulous 1 96 Risk Ratio (Random, 95% CI) 40.77 [2.35, 706.72]
3.16 Obsessive thinking 1 90 Risk Ratio (Random, 95% CI) 2.35 [1.53, 3.62]
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3.17 Picking at skin or
fingers, nail biting, lip or cheek
chewing
15 888 Risk Ratio (Random, 95% CI) 1.12 [0.88, 1.41]
3.18 Repetitive language 1 48 Risk Ratio (Random, 95% CI) 1.0 [0.32, 3.10]
3.19 Sad, tearful or depressed 23 1849 Risk Ratio (Random, 95% CI) 1.15 [0.94, 1.41]
3.20 Socially withdrawn -
decreased interaction with
others
12 771 Risk Ratio (Random, 95% CI) 1.24 [0.82, 1.87]
3.21 Sleep efficiency (SEF) 2 108 Risk Ratio (Random, 95% CI) 0.48 [0.02, 14.28]
3.22 Stares a lot 9 904 Risk Ratio (Random, 95% CI) 1.03 [0.75, 1.40]
3.23 Tics or nervous
movements
19 1403 Risk Ratio (Random, 95% CI) 1.33 [1.03, 1.72]
3.24 Unusual blinking 1 48 Risk Ratio (Random, 95% CI) 3.13 [0.12, 80.68]
3.25 Worried or anxious 20 1673 Risk Ratio (Random, 95% CI) 0.82 [0.60, 1.12]
4 Digestive system 42 Risk Ratio (Random, 95% CI) Subtotals only
4.1 Decreased appetite or loss
of appetite
35 3862 Risk Ratio (Random, 95% CI) 3.04 [2.35, 3.94]
4.2 Diarrhoea 3 402 Risk Ratio (Random, 95% CI) 0.58 [0.19, 1.74]
4.3 Dry mouth 5 342 Risk Ratio (Random, 95% CI) 1.25 [0.54, 2.90]
4.4 Dyspepsia 1 62 Risk Ratio (Random, 95% CI) 0.22 [0.02, 2.14]
4.5 Nausea 9 768 Risk Ratio (Random, 95% CI) 1.52 [1.00, 2.30]
4.6 Increased appetite 1 136 Risk Ratio (Random, 95% CI) 0.20 [0.08, 0.50]
4.7 Stomachache 33 3777 Risk Ratio (Random, 95% CI) 1.61 [1.27, 2.04]
4.8 Vomiting 4 710 Risk Ratio (Random, 95% CI) 0.90 [0.26, 3.11]
5 Urinary system: urinary
incontinence
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
6 Skeletal and muscular system:
somatic complaints
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Immune system 7 Risk Ratio (IV, Random, 95% CI) Subtotals only
7.1 Allergic rhinitis 4 475 Risk Ratio (IV, Random, 95% CI) 1.38 [0.35, 5.51]
7.2 Fever 2 91 Risk Ratio (IV, Random, 95% CI) 1.39 [0.09, 20.56]
7.3 Lymphadenitis 2 296 Risk Ratio (IV, Random, 95% CI) 3.93 [0.44, 35.11]
7.4 Pharyngolaryngeal pain 1 160 Risk Ratio (IV, Random, 95% CI) 2.0 [0.19, 21.62]
7.5 Pharyngitis 4 754 Risk Ratio (IV, Random, 95% CI) 0.71 [0.19, 2.62]
7.6 Upper respiratory tract
infection
5 888 Risk Ratio (IV, Random, 95% CI) 0.61 [0.27, 1.37]
8 Skin 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
8.1 Rash 2 208 Risk Ratio (IV, Random, 95% CI) 0.96 [0.14, 6.41]
8.2 Skin laceration 1 167 Risk Ratio (IV, Random, 95% CI) 2.96 [0.12, 71.75]
9 Vital signs 14 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Diastolic blood pressure
(mmHg)
11 755 Mean Difference (IV, Random, 95% CI) 1.23 [-0.39, 2.86]
9.2 Systolic blood pressure
(mmHg)
11 755 Mean Difference (IV, Random, 95% CI) 0.53 [-1.30, 2.36]
9.3 Pulse or heart rate (bpm) 14 939 Mean Difference (IV, Random, 95% CI) 5.06 [2.88, 7.24]
10 Height (cm) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
11 Weight 6 530 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.23, 0.11]
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Comparison 9. Teacher-rated general behaviour
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All parallel-group trials and
first-period cross-over trials:
risk of bias
5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
1.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 High risk of bias 5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
2 Subgroup analysis: types of scales 5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
2.1 Conners’ Global Index -
Teacher (CGI-T)
1 314 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.14, -0.68]
2.2 Groninger Behaviour
Observation Scale (GBOS)
1 43 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.46, -0.21]
2.3 Conners’ Teacher Rating
Scale - Conduct problems
1 25 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.48, 0.14]
2.4 IOWA Conners’ Rating
Scale - Oppositional/Defiant
(IOWA-O/D)
2 286 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.12, -0.59]
3 Subgroup analysis: dose 5 696 Std. Mean Difference (IV, Random, 95% CI) -0.85 [-1.02, -0.69]
3.1 Low dose 2 71 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.16, -0.19]
3.2 High dose 3 466 Std. Mean Difference (IV, Random, 95% CI) -0.89 [-1.08, -0.70]
3.3 Unknown dose 1 159 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.21, -0.46]
4 Subgroup analysis: duration of
treatment
5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
4.1 Short term (up to 6
months)
5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
4.2 Long term (over 6
months)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Subgroup analysis: parallel-group
trials versus first-period
cross-over trials
5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
5.1 Parallel-group trials 5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
5.2 First-period cross-over
trials
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 General behaviour, cross-over
trials (endpoint data)
16 2014 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.78, -0.60]
6.1 Low dose 13 1110 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.72, -0.48]
6.2 High dose 12 904 Std. Mean Difference (IV, Random, 95% CI) -0.82 [-0.95, -0.68]
7 Subgroup analysis: general
behaviour, cross-over trials
(endpoint data): risk of bias
16 1308 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-0.87, -0.63]
7.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 High risk of bias 16 1308 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-0.87, -0.63]
8 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
(teacher-rated) versus cross-over
trials (endpoint data)
21 1976 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-0.88, -0.70]
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8.1 All parallel-group trials
and first-period cross-over trials
5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
8.2 Cross-over trials (endpoint
data)
16 1308 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-0.87, -0.63]
Comparison 10. Independent assessor-rated general behaviour
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 General behaviour, cross-over
trials (endpoint data)
8 1241 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.75, -0.46]
1.1 Low dose 7 903 Std. Mean Difference (IV, Random, 95% CI) -0.56 [-0.76, -0.36]
1.2 High dose 5 338 Std. Mean Difference (IV, Random, 95% CI) -0.71 [-0.93, -0.49]
2 Subgroup analysis: general
behaviour, cross-over trials
(endpoint data): risk of bias
8 951 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.88, -0.49]
2.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 High risk of bias 8 951 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.88, -0.49]
3 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
(independent assessor-rated)
compared with cross-over trials
(endpoint data)
8 951 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.88, -0.49]
3.1 Parallel-group trials and
first-period cross-over trials
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Cross-over trials (endpoint
data)
8 951 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.88, -0.49]
Comparison 11. Parent-rated general behaviour
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All parallel-group trials and
first-period cross-over trials
6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
2 Subgroup analysis: risk of bias 6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
2.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 High risk of bias 6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
3 Subgroup analysis: types of scales 6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
3.1 TheWeekly Parent Ratings
of Evening and Morning
Behaviour (WPREMB) -
Revised
1 17 Std. Mean Difference (IV, Random, 95% CI) 0.50 [-0.47, 1.47]
3.2 Conners’ Global Index
(CGI) - Parent
2 352 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-0.63, -0.20]
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3.3 Swanson, Nolan
and Pelham, Fourth
Edition - Oppositional
(SNAP-IV-Oppositional)
1 15 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.95, 0.23]
3.4 IOWA Conners’ Rating
Scale - Oppositional/Defiant
(IOWA-I/O)
2 286 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.01, -0.49]
4 Subgroup analysis: parallel-group
trials compared with
first-period cross-over trials
6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
4.1 Parallel-group trials 5 655 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-0.78, -0.23]
4.2 First-period cross-over
trials
1 15 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.95, 0.23]
5 Subgroup analysis: duration of
treatment
6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
5.1 Short term (up to 6
months)
6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
5.2 Long term (over 6
months)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Subgroup analysis: dose 6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
6.1 Low dose 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 High dose 4 496 Std. Mean Difference (IV, Random, 95% CI) -0.42 [-0.77, -0.08]
6.3 Unknown dose 2 174 Std. Mean Difference (IV, Random, 95% CI) -0.73 [-1.08, -0.38]
7 General behaviour, cross-over
trials (endpoint data)
6 550 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-0.93, -0.56]
7.1 Low dose 5 248 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-0.93, -0.38]
7.2 High dose 4 302 Std. Mean Difference (IV, Random, 95% CI) -0.83 [-1.07, -0.60]
8 Subgroup analysis: general
behaviour, cross-over trials
(endpoint data): risk of bias
6 384 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.05, -0.63]
8.1 Low risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 High risk of bias 6 384 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.05, -0.63]
9 Subgroup analysis: all
parallel-group trials and
first-period cross-over trials
(parent-rated) compared with
cross-over trials (endpoint data)
12 1054 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-0.86, -0.50]
9.1 All parallel-group trials
and first-period cross-over trials
6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
9.2 Cross-over trials (endpoint
data)
6 384 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.05, -0.63]
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Comparison 12. Additional subgroup analyses of general behaviour: parallel-group trials and first-period cross-
over trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparisions of raters 8 1338 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.86, -0.52]
1.1 Teacher-rated 5 668 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.04, -0.71]
1.2 Independent assessor-
rated
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Parent-rated 6 670 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.27]
2 Comorbidity versus no
comorbidity
7 579 Std. Mean Difference (IV, Random, 95% CI) -0.70 [-0.98, -0.43]
2.1 ADHD with comorbidity 6 265 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-0.95, -0.23]
2.2 ADHD without
comorbidity
1 314 Std. Mean Difference (IV, Random, 95% CI) -0.91 [-1.14, -0.68]
3 Cross-over trials: first-period data
versus endpoint data (teacher-,
parent-, and independent
assessor-rated)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 First-period data 1 16 Mean Difference (IV, Random, 95% CI) -0.81 [-1.75, 0.13]
3.2 Endpoint data 1 14 Mean Difference (IV, Random, 95% CI) 0.14 [-0.71, 1.00]
Comparison 13. Quality of life: parallel-group trials and first-period cross-over trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subgroup analysis: types of scales 3 514 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.42, 0.80]
1.1 Child Health
Questionnaire (CHQ)
1 257 Std. Mean Difference (IV, Random, 95% CI) 0.54 [0.25, 0.83]
1.2 Children´ s Global
Assessment Scale (CGAS)
1 36 Std. Mean Difference (IV, Random, 95% CI) 0.79 [0.10, 1.47]
1.3 Child Health and Illness
Profile, Child Edition: Parent
Report Form (CHIP-CE:PRF)
1 221 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.37, 0.91]
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Analysis 1.1. Comparison 1 Teacher-rated ADHD symptoms, Outcome 1 All parallel-group trials and first-
period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 1 All parallel-group trials and first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 5.3 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 7.2 % -1.07 [ -1.43, -0.71 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 2.0 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 1.9 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.1) 6.8 % -1.02 [ -1.40, -0.64 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 6.9 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 8.7 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 2.8 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 2.2 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 10.0 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 5.0 % -0.33 [ -0.82, 0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 5.5 % -1.06 [ -1.52, -0.61 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 7.0 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 4.7 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 3.2 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 4.6 % -1.13 [ -1.65, -0.60 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 5.6 % -0.57 [ -1.03, -0.12 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 3.9 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 6.8 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 916 782 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.78, df = 18 (P = 0.05); I2 =37%
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 11.23 (P < 0.00001)
Total (95% CI) 916 782 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.78, df = 18 (P = 0.05); I2 =37%
Test for overall effect: Z = 11.23 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Teacher-rated ADHD symptoms, Outcome 2 Subgroup analysis: types of scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 2 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Conners’ Teacher Rating Scale (CTRS)
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 4.1 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 3.8 % -0.74 [ -1.65, 0.17 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 35.0 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 5.9 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 4.4 % -1.02 [ -1.86, -0.17 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 22.4 % -0.58 [ -0.96, -0.21 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 15.3 % -0.57 [ -1.03, -0.12 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 9.2 % -0.73 [ -1.32, -0.15 ]
Subtotal (95% CI) 265 253 100.0 % -0.64 [ -0.82, -0.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 7 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.12 (P < 0.00001)
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Abbreviated Conners’ Rating Scale (ACRS) - Teacher
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 43.6 % -0.15 [ -1.03, 0.73 ]
Lehmkuhl 2002 43 7 (6.5574) 42 15 (6.4807) 56.4 % -1.22 [ -1.68, -0.75 ]
Subtotal (95% CI) 53 52 100.0 % -0.75 [ -1.79, 0.29 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 4.43, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 1.42 (P = 0.16)
3 Conners’ Abbreviated Symptom Questionnaire for Teachers (ASQ-Teacher)
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 100.0 % -0.28 [ -0.79, 0.23 ]
Subtotal (95% CI) 29 30 100.0 % -0.28 [ -0.79, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
4 IOWA Conners’ Teacher Rating Scale (IOWA CTRS) - hyperactivity
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 35.0 % -1.13 [ -1.65, -0.60 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 65.0 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 118 75 100.0 % -1.08 [ -1.39, -0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 6.82 (P < 0.00001)
5 Schedule for Non-adaptive and Adaptive Personality (SNAP) - Teacher
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 35.3 % -0.85 [ -1.33, -0.38 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 64.7 % -0.47 [ -0.72, -0.22 ]
Subtotal (95% CI) 169 159 100.0 % -0.61 [ -0.96, -0.25 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.92, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 3.34 (P = 0.00084)
6 Teacher ratings of attention
Brown 1985 10 46.6 (7.5) 10 51.4 (9.1) 100.0 % -0.55 [ -1.45, 0.35 ]
Subtotal (95% CI) 10 10 100.0 % -0.55 [ -1.45, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
7 Teacher ratings of impulsivity
Brown 1985 10 61.6 (8.1) 10 61.2 (9) 100.0 % 0.04 [ -0.83, 0.92 ]
Subtotal (95% CI) 10 10 100.0 % 0.04 [ -0.83, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
8 IOWA Conners’ Teacher Rating Scale - Inattention/Overactivity (IOWA-I/O)
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 75.7 % -1.07 [ -1.45, -0.69 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 24.3 % -0.89 [ -1.56, -0.22 ]
Subtotal (95% CI) 140 57 100.0 % -1.03 [ -1.36, -0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 6.08 (P < 0.00001)
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
9 Fremdbeurteilungsbogen fu¨r Hyperkinetische Sto¨rungen (FBB-HKS)
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 100.0 % -1.06 [ -1.52, -0.61 ]
Subtotal (95% CI) 43 42 100.0 % -1.06 [ -1.52, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.58 (P < 0.00001)
10 Conners ADHD/DSM-IV Scales - Teacher (CADS-T)
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 52.4 % -1.07 [ -1.43, -0.71 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.1) 47.6 % -1.02 [ -1.40, -0.64 ]
Subtotal (95% CI) 120 134 100.0 % -1.05 [ -1.31, -0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 7.79 (P < 0.00001)
11 Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour (SWAN) Scale
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 100.0 % -0.33 [ -0.82, 0.17 ]
Subtotal (95% CI) 32 32 100.0 % -0.33 [ -0.82, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 24.81, df = 10 (P = 0.01), I2 =60%
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Analysis 1.3. Comparison 1 Teacher-rated ADHD symptoms, Outcome 3 Medication status: medication
naive versus not medication naive.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 3 Medication status: medication naive versus not medication naive
Study or subgroup
Favours
methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medication naive
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 22.1 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 14.9 % -0.33 [ -0.82, 0.17 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 14.1 % -1.13 [ -1.65, -0.60 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 12.7 % -0.73 [ -1.32, -0.15 ]
Subtotal (95% CI) 227 204 63.8 % -0.63 [ -0.94, -0.31 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 6.18, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 3.86 (P = 0.00011)
2 Not medication naive
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 18.2 % -1.07 [ -1.45, -0.69 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 18.0 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 201 85 36.2 % -1.06 [ -1.33, -0.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 7.69 (P < 0.00001)
Total (95% CI) 428 289 100.0 % -0.79 [ -1.08, -0.50 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 14.63, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 5.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.18, df = 1 (P = 0.04), I2 =76%
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Analysis 1.4. Comparison 1 Teacher-rated ADHD symptoms, Outcome 4 Subgroup analysis: duration of
treatment.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 4 Subgroup analysis: duration of treatment
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short term (up to 6 months)
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 5.3 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 7.2 % -1.07 [ -1.43, -0.71 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 2.0 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 1.9 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 6.8 % -1.02 [ -1.40, -0.64 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 6.9 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 8.7 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 2.8 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 2.2 % -1.02 [ -1.86, -0.17 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 5.0 % -0.33 [ -0.82, 0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 5.5 % -1.06 [ -1.52, -0.61 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 7.0 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 4.7 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 3.2 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 4.6 % -1.13 [ -1.65, -0.60 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 5.6 % -0.57 [ -1.03, -0.12 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 3.9 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 6.8 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 782 663 90.0 % -0.81 [ -0.94, -0.68 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 22.81, df = 17 (P = 0.16); I2 =25%
Test for overall effect: Z = 12.02 (P < 0.00001)
2 Long term (over 6 months)
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 10.0 % -0.47 [ -0.72, -0.22 ]
Subtotal (95% CI) 134 119 10.0 % -0.47 [ -0.72, -0.22 ]
Heterogeneity: not applicable
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 3.70 (P = 0.00022)
Total (95% CI) 916 782 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.82, df = 18 (P = 0.05); I2 =38%
Test for overall effect: Z = 11.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.37, df = 1 (P = 0.02), I2 =81%
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Analysis 1.5. Comparison 1 Teacher-rated ADHD symptoms, Outcome 5 Subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 5 Subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 14.7 % -0.85 [ -1.33, -0.38 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 4.3 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 4.0 % -0.74 [ -1.65, 0.17 ]
Childress 2009 61 18.3 (13.12) 63 30 (13.01) 24.3 % -0.89 [ -1.26, -0.52 ]
Ialongo 1994 16 13.87 (7.71) 12 15.25 (7.27) 5.9 % -0.18 [ -0.93, 0.57 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 13.6 % -0.33 [ -0.82, 0.17 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 23.6 % -0.58 [ -0.96, -0.21 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 9.6 % -0.73 [ -1.32, -0.15 ]
Subtotal (95% CI) 245 248 100.0 % -0.64 [ -0.82, -0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.97, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 6.89 (P < 0.00001)
-2 -1 0 1 2
Favours methylphenidate Favours control
(Continued . . . )
598Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 High dose
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 17.2 % -1.02 [ -1.40, -0.64 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 7.4 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 21.4 % -0.47 [ -0.72, -0.22 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 13.5 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 10.1 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 13.2 % -1.13 [ -1.65, -0.60 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 17.1 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 371 317 100.0 % -0.81 [ -1.08, -0.54 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 14.85, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 5.84 (P < 0.00001)
3 Unknown dose
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 20.2 % -1.07 [ -1.43, -0.71 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 18.8 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 26.4 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 6.2 % -0.57 [ -1.30, 0.16 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 14.2 % -1.06 [ -1.52, -0.61 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 14.3 % -0.57 [ -1.03, -0.12 ]
Subtotal (95% CI) 377 292 100.0 % -0.87 [ -1.06, -0.68 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.37, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 9.01 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.11, df = 2 (P = 0.21), I2 =36%
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Analysis 1.6. Comparison 1 Teacher-rated ADHD symptoms, Outcome 6 Subgroup analysis: parallel-group
trials compared with first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 6 Subgroup analysis: parallel-group trials compared with first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 5.3 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 7.2 % -1.07 [ -1.43, -0.71 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 2.0 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 1.9 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 6.8 % -1.02 [ -1.40, -0.64 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 6.9 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 8.7 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 2.8 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 2.2 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 10.0 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 5.0 % -0.33 [ -0.82, 0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 5.5 % -1.06 [ -1.52, -0.61 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 4.7 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 3.2 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 4.6 % -1.13 [ -1.65, -0.60 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 3.9 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 6.8 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 820 686 87.4 % -0.80 [ -0.95, -0.65 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 27.09, df = 16 (P = 0.04); I2 =41%
Test for overall effect: Z = 10.49 (P < 0.00001)
2 First-period cross-over trials
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 7.0 % -0.58 [ -0.96, -0.21 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 5.6 % -0.57 [ -1.03, -0.12 ]
Subtotal (95% CI) 96 96 12.6 % -0.58 [ -0.87, -0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 3.92 (P = 0.000090)
Total (95% CI) 916 782 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.82, df = 18 (P = 0.05); I2 =38%
Test for overall effect: Z = 11.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.77, df = 1 (P = 0.18), I2 =43%
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Analysis 1.7. Comparison 1 Teacher-rated ADHD symptoms, Outcome 7 Subgroup analysis: trials with
cohort selection bias of all participants compared with trials without cohort selection bias of all participants.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 7 Subgroup analysis: trials with cohort selection bias of all participants compared with trials without cohort selection bias of all participants
Study or subgroup
Favours
methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Trials with cohort selection bias of all participants
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 5.3 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 7.2 % -1.07 [ -1.43, -0.71 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 6.9 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 8.7 % -0.71 [ -1.01, -0.41 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 10.0 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 5.0 % -0.33 [ -0.82, 0.17 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 6.8 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 559 435 49.8 % -0.79 [ -1.01, -0.57 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 15.88, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 6.93 (P < 0.00001)
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Study or subgroup
Favours
methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Trials without cohort selection bias of all participants
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 2.0 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 1.9 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 6.8 % -1.02 [ -1.40, -0.64 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 2.8 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 2.2 % -1.02 [ -1.86, -0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 5.5 % -1.06 [ -1.52, -0.61 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 7.0 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 4.7 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 3.2 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 4.6 % -1.13 [ -1.65, -0.60 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 5.6 % -0.57 [ -1.03, -0.12 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 3.9 % -0.73 [ -1.32, -0.15 ]
Subtotal (95% CI) 357 347 50.2 % -0.76 [ -0.93, -0.59 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 12.94, df = 11 (P = 0.30); I2 =15%
Test for overall effect: Z = 8.66 (P < 0.00001)
Total (95% CI) 916 782 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.82, df = 18 (P = 0.05); I2 =38%
Test for overall effect: Z = 11.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.8. Comparison 1 Teacher-rated ADHD symptoms, Outcome 8 ADHD symptoms, cross-over
trial (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 8 ADHD symptoms, cross-over trial (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
DuPaul 1996 24 15.17 (9.19) 24 23 (9.35) 1.6 % -0.83 [ -1.42, -0.24 ]
Flapper 2008 12 12.5 (9.445) 12 19.17 (10.143) 1.2 % -0.66 [ -1.48, 0.17 ]
Gorman 2006 41 0.66 (0.8964) 41 1.52 (1.0885) 1.9 % -0.85 [ -1.31, -0.40 ]
Stein 1996 25 15.5 (4.8) 25 16.3 (4.6) 1.7 % -0.17 [ -0.72, 0.39 ]
Subtotal (95% CI) 102 102 6.5 % -0.64 [ -0.97, -0.30 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 3.72 (P = 0.00020)
2 High risk of bias
Abikoff 2009 19 1.13 (0.46) 19 1.5 (0.55) 1.5 % -0.71 [ -1.37, -0.06 ]
Barkley 2000 15 14 (12.3) 15 17.7 (13.8) 1.4 % -0.28 [ -0.99, 0.44 ]
Blum 2011 24 58.1 (22.1) 24 75.2 (19.8) 1.6 % -0.80 [ -1.39, -0.21 ]
Brown 1984a 11 7.45 (3.72) 11 16.73 (7.58) 1.0 % -1.50 [ -2.46, -0.53 ]
Brown 1988 11 10 (6.69) 11 8 (0.63) 1.2 % 0.40 [ -0.44, 1.25 ]
Bukstein 1998 18 3.59 (2.64) 18 5.49 (3.32) 1.5 % -0.62 [ -1.29, 0.05 ]
Chronis 2003 21 0.9 (0.8) 21 3.9 (2.8) 1.5 % -1.43 [ -2.11, -0.74 ]
Coghill 2007 75 58.5 (12.8) 75 73 (11.3) 2.1 % -1.19 [ -1.54, -0.85 ]
Cook 1993 15 0.6 (0.137) 15 0.69 (0.143) 1.4 % -0.63 [ -1.36, 0.11 ]
Corkum 2008 21 59.65 (11.46) 21 67.4 (10.49) 1.6 % -0.69 [ -1.32, -0.07 ]
Douglas 1986 16 0.56 (0.6) 16 1.07 (0.6) 1.4 % -0.83 [ -1.55, -0.10 ]
Epstein 2011 93 17.5 (10.87) 93 26.67 (12.04) 2.2 % -0.80 [ -1.10, -0.50 ]
Fabiano 2007 48 1.4 (2.46) 48 5.86 (4.68) 1.9 % -1.18 [ -1.62, -0.75 ]
Fitzpatrick 1992a 19 0.73 (0.65) 19 1.36 (0.8) 1.5 % -0.85 [ -1.51, -0.18 ]
Gadow 1990 11 6 (6.68) 11 14 (7.87) 1.1 % -1.05 [ -1.96, -0.15 ]
Gadow 1995 34 7.1 (5.4) 34 14.2 (4.6) 1.7 % -1.40 [ -1.93, -0.87 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gadow 2007 71 5.7 (5.1) 71 11.6 (6.9) 2.1 % -0.97 [ -1.32, -0.62 ]
Gadow 2011 54 5.9 (5.3) 54 10.9 (8.1) 2.0 % -0.73 [ -1.12, -0.34 ]
Garfinkel 1983 12 4.887 (4.8416) 12 6.37 (6.3118) 1.3 % -0.25 [ -1.06, 0.55 ]
Grizenko 2012 198 54.38 (11.13) 198 63.76 (14.38) 2.4 % -0.73 [ -0.93, -0.52 ]
Hoeppner 1997 50 8.2 (6.85) 50 14.23 (8.31) 2.0 % -0.79 [ -1.19, -0.38 ]
Kaplan 1990 6 0.9 (0.8) 6 1.7 (0.9) 0.8 % -0.87 [ -2.08, 0.34 ]
Kolko 1999 22 3.3 (2.9) 22 9.9 (3.8) 1.4 % -1.92 [ -2.64, -1.19 ]
Kollins 2006 (PATS) 142 1 (0.74) 165 1.31 (0.79) 2.3 % -0.40 [ -0.63, -0.18 ]
Konrad 2004 60 26.3 (5.2) 60 42.5 (6.1) 1.8 % -2.84 [ -3.35, -2.33 ]
Konrad 2005 44 14.3 (10.1) 44 22.2 (13.8) 2.0 % -0.65 [ -1.08, -0.22 ]
Lufi 1997 20 30.85 (15.19) 20 32.6 (12.75) 1.6 % -0.12 [ -0.74, 0.50 ]
Lufi 2007 19 6.97 (3.8) 19 12.56 (6.69) 1.5 % -1.01 [ -1.69, -0.33 ]
Manos 1999 117 56.12 (11.81) 117 64.38 (15.41) 2.3 % -0.60 [ -0.86, -0.34 ]
McBride 1988a 46 7.5 (4.5) 46 17 (6.5) 1.9 % -1.69 [ -2.16, -1.21 ]
McGough 2006 80 3.2 (5.1877) 80 8 (5.1877) 2.2 % -0.92 [ -1.25, -0.59 ]
Moshe 2012 57 55.5 (9.5) 57 62.1 (7.9) 2.1 % -0.75 [ -1.13, -0.37 ]
Pearson 2013 24 59.3 (12.7) 24 75.6 (11.5) 1.6 % -1.32 [ -1.95, -0.69 ]
Pelham 1989 24 2.45 (3.8669) 24 4.2 (6.624) 1.7 % -0.32 [ -0.89, 0.25 ]
Pelham 1990a 22 2.3 (2) 22 3.8 (4.6) 1.6 % -0.42 [ -1.01, 0.18 ]
Pelham 1993a 31 2 (2.1) 31 6 (4.3) 1.7 % -1.17 [ -1.71, -0.63 ]
Pelham 1999 25 1.1 (1.2) 25 3.7 (2.6) 1.6 % -1.26 [ -1.88, -0.65 ]
Pelham 2001a 68 7.94 (5.83) 68 16.4 (7.74) 2.1 % -1.23 [ -1.60, -0.86 ]
Pelham 2002 136 1.8 (1.7) 136 3.5 (2.9) 2.3 % -0.71 [ -0.96, -0.47 ]
Pelham 2005 29 2.3 (2.7) 29 5.7 (5.9) 1.7 % -0.73 [ -1.26, -0.20 ]
Pelham 2011 10 6 (4.3) 10 9.7 (51) 1.2 % -0.10 [ -0.98, 0.78 ]
Pliszka 1990 30 13.8 (8.8) 30 25.2 (15.3) 1.7 % -0.90 [ -1.43, -0.37 ]
Quinn 2004 32 1.58 (3.85) 32 6.39 (6.81) 1.8 % -0.86 [ -1.37, -0.35 ]
Rapport 1987 31 7.16 (5) 31 15.84 (5.06) 1.6 % -1.70 [ -2.29, -1.12 ]
Silva 2008 68 1.4 (2.46) 68 5.86 (4.68) 2.1 % -1.19 [ -1.55, -0.82 ]
Smith 1998 45 1.2 (1.5) 45 4.4 (3.5) 1.9 % -1.18 [ -1.63, -0.73 ]
Smith 2004 1 10.3 (0.2108) 1 15.3 (0.1031) Not estimable
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Smithee 1998 25 0.647 (0.51) 25 1.12 (0.5766) 1.7 % -0.86 [ -1.45, -0.28 ]
Solanto 2009 30 60.04 (10.57) 30 63.28 (10.55) 1.8 % -0.30 [ -0.81, 0.21 ]
Taylor 1987 39 0.85 (1) 39 1.59 (1.04) 1.9 % -0.72 [ -1.18, -0.26 ]
Tirosh 1993a 20 17.6 (6.3) 20 32 (9.2) 1.4 % -1.79 [ -2.53, -1.05 ]
Ullmann 1986 118 -45.6 (19.2) 118 -11.3 (15.1) 2.2 % -1.98 [ -2.29, -1.67 ]
Wigal 2013 44 7.1 (5.64) 44 19.3 (8.38) 1.8 % -1.69 [ -2.18, -1.20 ]
Wilens 2008 120 15.4 (10.7354) 120 24.5 (10.7354) 2.3 % -0.84 [ -1.11, -0.58 ]
Zeiner 1999 38 8.83 (6.49) 38 14.69 (6.17) 1.9 % -0.92 [ -1.39, -0.44 ]
Subtotal (95% CI) 2459 2482 93.5 % -0.95 [ -1.09, -0.82 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 235.24, df = 53 (P<0.00001); I2 =77%
Test for overall effect: Z = 14.00 (P < 0.00001)
Total (95% CI) 2561 2584 100.0 % -0.93 [ -1.06, -0.80 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 242.57, df = 57 (P<0.00001); I2 =77%
Test for overall effect: Z = 14.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.91, df = 1 (P = 0.09), I2 =66%
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Analysis 1.9. Comparison 1 Teacher-rated ADHD symptoms, Outcome 9 ADHD symptoms, cross-over
trials (endpoint data), subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 9 ADHD symptoms, cross-over trials (endpoint data), subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Barkley 2000 15 14 (12.3) 15 17.7 (13.8) 1.0 % -0.28 [ -0.99, 0.44 ]
Brown 1984a 11 7.45 (3.72) 11 16.73 (7.58) 0.8 % -1.50 [ -2.46, -0.53 ]
Brown 1988 11 9.5 (5.04) 11 8 (0.63) 0.9 % 0.40 [ -0.44, 1.25 ]
Chronis 2003 21 2 (2) 21 3.9 (2.8) 1.2 % -0.77 [ -1.40, -0.14 ]
Coghill 2007 75 65 (14.1) 75 73 (11.3) 1.6 % -0.62 [ -0.95, -0.30 ]
Cook 1993 15 0.6 (0.137) 15 0.69 (0.143) 1.0 % -0.63 [ -1.36, 0.11 ]
DuPaul 1996 24 19.46 (9.28) 24 23 (9.35) 1.2 % -0.37 [ -0.94, 0.20 ]
Fabiano 2007 48 3.17 (3.54) 48 5.86 (4.68) 1.5 % -0.64 [ -1.05, -0.23 ]
Fitzpatrick 1992a 19 0.73 (0.65) 19 1.36 (0.8) 1.1 % -0.85 [ -1.51, -0.18 ]
Flapper 2008 12 17.435 (10.48) 12 19.17 (10.143) 0.9 % -0.16 [ -0.96, 0.64 ]
Gadow 1990 11 9 (6.15) 11 14 (7.87) 0.9 % -0.68 [ -1.55, 0.18 ]
Gadow 1995 34 9.3 (6.4) 34 14.2 (4.6) 1.4 % -0.87 [ -1.37, -0.37 ]
Gadow 2007 71 7.3 (5.8) 71 11.6 (6.9) 1.6 % -0.67 [ -1.01, -0.33 ]
Gadow 2011 54 9.2 (5.9) 54 10.9 (8.1) 1.5 % -0.24 [ -0.62, 0.14 ]
Garfinkel 1983 12 4.887 (4.8416) 12 6.37 (6.3118) 0.9 % -0.25 [ -1.06, 0.55 ]
Hoeppner 1997 50 8.2 (6.85) 50 13.54 (8.66) 1.5 % -0.68 [ -1.08, -0.28 ]
Kolko 1999 22 4.1 (4.4) 22 9.9 (3.8) 1.1 % -1.39 [ -2.05, -0.72 ]
Kollins 2006 (PATS) 165 1.25 (0.84) 165 1.31 (0.79) 1.7 % -0.07 [ -0.29, 0.14 ]
Konrad 2004 60 26.3 (5.2) 60 42.5 (6.1) 1.3 % -2.84 [ -3.35, -2.33 ]
Konrad 2005 44 17.9 (13.3) 44 22.2 (13.8) 1.5 % -0.31 [ -0.74, 0.11 ]
Lufi 1997 20 30.85 (15.19) 20 32.6 (12.75) 1.2 % -0.12 [ -0.74, 0.50 ]
Lufi 2007 19 6.97 (3.8) 19 12.56 (6.69) 1.1 % -1.01 [ -1.69, -0.33 ]
Manos 1999 117 56.12 (11.81) 117 64.38 (15.41) 1.7 % -0.60 [ -0.86, -0.34 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McBride 1988a 46 7.5 (4.5) 46 17 (6.5) 1.4 % -1.69 [ -2.16, -1.21 ]
McGough 2006 80 3.2 (5.1877) 80 8 (5.1877) 1.6 % -0.92 [ -1.25, -0.59 ]
Moshe 2012 57 55.5 (9.5) 57 62.1 (7.9) 1.5 % -0.75 [ -1.13, -0.37 ]
Pearson 2013 24 63.4 (12.8) 24 75.6 (11.5) 1.2 % -0.99 [ -1.59, -0.38 ]
Pelham 1989 24 2.45 (3.8669) 24 4.2 (6.624) 1.2 % -0.32 [ -0.89, 0.25 ]
Pelham 1990a 22 2.3 (2) 22 3.8 (4.6) 1.2 % -0.42 [ -1.01, 0.18 ]
Pelham 1993a 31 2 (2.1) 31 6 (4.3) 1.3 % -1.17 [ -1.71, -0.63 ]
Pelham 1999 25 1.1 (1.2) 25 3.7 (2.6) 1.2 % -1.26 [ -1.88, -0.65 ]
Pelham 2002 136 1.8 (1.7) 136 3.5 (2.9) 1.7 % -0.71 [ -0.96, -0.47 ]
Pelham 2005 29 2.3 (2.7) 29 5.7 (5.9) 1.3 % -0.73 [ -1.26, -0.20 ]
Pliszka 1990 30 14.5 (12.5) 30 25.2 (15.3) 1.3 % -0.76 [ -1.28, -0.23 ]
Quinn 2004 32 1.47 (2.37) 32 6.39 (6.81) 1.3 % -0.95 [ -1.47, -0.43 ]
Rapport 1987 31 7.16 (5) 31 15.84 (5.06) 1.2 % -1.70 [ -2.29, -1.12 ]
Silva 2008 68 3.17 (3.54) 68 5.86 (4.68) 1.6 % -0.64 [ -0.99, -0.30 ]
Smith 1998 45 2.7 (2.7) 45 4.4 (3.5) 1.5 % -0.54 [ -0.96, -0.12 ]
Smith 2004 1 10.3 (0.2108) 1 15.3 (0.1031) Not estimable
Solanto 2009 30 61.52 (7.98) 30 63.28 (10.55) 1.3 % -0.19 [ -0.69, 0.32 ]
Stein 1996 25 15.5 (4.8) 25 16.3 (4.6) 1.3 % -0.17 [ -0.72, 0.39 ]
Zeiner 1999 38 8.83 (6.49) 38 14.69 (6.17) 1.4 % -0.92 [ -1.39, -0.44 ]
Subtotal (95% CI) 1704 1704 53.2 % -0.73 [ -0.89, -0.57 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 180.96, df = 40 (P<0.00001); I2 =78%
Test for overall effect: Z = 9.11 (P < 0.00001)
2 High dose
Abikoff 2009 19 1.13 (0.46) 19 1.5 (0.55) 1.1 % -0.71 [ -1.37, -0.06 ]
Blum 2011 24 58.1 (22.1) 24 75.2 (19.8) 1.2 % -0.80 [ -1.39, -0.21 ]
Bukstein 1998 18 3.59 (2.64) 18 5.49 (3.32) 1.1 % -0.62 [ -1.29, 0.05 ]
Chronis 2003 21 0.9 (0.8) 21 3.9 (2.8) 1.1 % -1.43 [ -2.11, -0.74 ]
Coghill 2007 75 58.5 (12.8) 75 73 (11.3) 1.6 % -1.19 [ -1.54, -0.85 ]
Corkum 2008 21 59.65 (11.46) 21 67.4 (10.49) 1.2 % -0.69 [ -1.32, -0.07 ]
Douglas 1986 16 0.56 (0.6) 16 1.07 (0.6) 1.0 % -0.83 [ -1.55, -0.10 ]
DuPaul 1996 24 15.17 (9.19) 24 23 (9.35) 1.2 % -0.83 [ -1.42, -0.24 ]
Epstein 2011 93 17.5 (10.87) 93 26.67 (12.04) 1.6 % -0.80 [ -1.10, -0.50 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fabiano 2007 48 1.4 (2.46) 48 5.86 (4.68) 1.4 % -1.18 [ -1.62, -0.75 ]
Flapper 2008 12 12.5 (9.445) 12 19.17 (10.143) 0.9 % -0.66 [ -1.48, 0.17 ]
Gadow 1990 11 6 (6.68) 11 14 (7.87) 0.8 % -1.05 [ -1.96, -0.15 ]
Gadow 1995 34 7.1 (5.4) 34 14.2 (4.6) 1.3 % -1.40 [ -1.93, -0.87 ]
Gadow 2007 71 5.7 (5.1) 71 11.6 (6.9) 1.6 % -0.97 [ -1.32, -0.62 ]
Gadow 2011 54 5.9 (5.3) 54 10.9 (8.1) 1.5 % -0.73 [ -1.12, -0.34 ]
Gorman 2006 41 0.66 (0.8964) 41 1.52 (1.0885) 1.4 % -0.85 [ -1.31, -0.40 ]
Grizenko 2012 198 54.38 (11.13) 198 63.76 (14.38) 1.7 % -0.73 [ -0.93, -0.52 ]
Kaplan 1990 6 0.9 (0.8) 6 1.7 (0.9) 0.6 % -0.87 [ -2.08, 0.34 ]
Kolko 1999 22 3.3 (2.9) 22 9.9 (3.8) 1.0 % -1.92 [ -2.64, -1.19 ]
Kollins 2006 (PATS) 142 1 (0.74) 165 1.31 (0.79) 1.7 % -0.40 [ -0.63, -0.18 ]
Konrad 2005 44 14.3 (10.1) 44 22.2 (13.8) 1.5 % -0.65 [ -1.08, -0.22 ]
Pearson 2013 24 59.3 (12.7) 24 75.6 (11.5) 1.2 % -1.32 [ -1.95, -0.69 ]
Pelham 1993a 31 1.7 (2.1) 31 6 (4.3) 1.3 % -1.25 [ -1.80, -0.71 ]
Pelham 2001a 68 7.94 (5.83) 68 16.4 (7.74) 1.5 % -1.23 [ -1.60, -0.86 ]
Pelham 2005 29 2.8 (3.2) 29 5.7 (5.9) 1.3 % -0.60 [ -1.13, -0.08 ]
Pelham 2011 10 6 (4.3) 10 9.7 (51) 0.9 % -0.10 [ -0.98, 0.78 ]
Pliszka 1990 30 13.8 (8.8) 30 25.2 (15.3) 1.3 % -0.90 [ -1.43, -0.37 ]
Silva 2008 68 1.4 (2.46) 68 5.86 (4.68) 1.5 % -1.19 [ -1.55, -0.82 ]
Smith 1998 45 1.2 (1.5) 45 4.4 (3.5) 1.4 % -1.18 [ -1.63, -0.73 ]
Smithee 1998 25 0.647 (0.51) 25 1.12 (0.5766) 1.2 % -0.86 [ -1.45, -0.28 ]
Solanto 2009 30 60.04 (10.57) 30 63.28 (10.55) 1.3 % -0.30 [ -0.81, 0.21 ]
Taylor 1987 39 0.85 (1) 39 1.59 (1.04) 1.4 % -0.72 [ -1.18, -0.26 ]
Tirosh 1993a 20 17.6 (6.3) 20 32 (9.2) 1.0 % -1.79 [ -2.53, -1.05 ]
Ullmann 1986 118 -45.6 (19.2) 118 -11.3 (15.1) 1.6 % -1.98 [ -2.29, -1.67 ]
Wigal 2013 44 7.1 (5.64) 44 19.3 (8.38) 1.4 % -1.69 [ -2.18, -1.20 ]
Wilens 2008 120 15.4 (10.7354) 120 24.5 (10.7354) 1.7 % -0.84 [ -1.11, -0.58 ]
Subtotal (95% CI) 1695 1718 46.8 % -0.98 [ -1.13, -0.84 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 124.79, df = 35 (P<0.00001); I2 =72%
Test for overall effect: Z = 13.24 (P < 0.00001)
Total (95% CI) 3399 3422 100.0 % -0.85 [ -0.96, -0.74 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 333.89, df = 76 (P<0.00001); I2 =77%
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 14.98 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.30, df = 1 (P = 0.02), I2 =81%
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Analysis 1.10. Comparison 1 Teacher-rated ADHD symptoms, Outcome 10 Subgroup analysis: all parallel-
group trials and first-period cross-over trials compared with cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 10 Subgroup analysis: all parallel-group trials and first-period cross-over trials compared with cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All parallel-group trials and first-period cross-over trials
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 1.5 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 1.7 % -1.07 [ -1.43, -0.71 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 0.9 % -0.15 [ -1.03, 0.73 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 0.8 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 1.6 % -1.02 [ -1.40, -0.64 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 1.6 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 1.8 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 1.0 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 0.9 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 1.9 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 1.4 % -0.33 [ -0.82, 0.17 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 1.5 % -1.06 [ -1.52, -0.61 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 1.7 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 1.4 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 1.1 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 1.4 % -1.13 [ -1.65, -0.60 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 1.5 % -0.57 [ -1.03, -0.12 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 1.3 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 1.6 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 916 782 26.6 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 28.82, df = 18 (P = 0.05); I2 =38%
Test for overall effect: Z = 11.22 (P < 0.00001)
2 Cross-over trials (endpoint data)
Abikoff 2009 19 1.13 (0.46) 19 1.5 (0.55) 1.2 % -0.71 [ -1.37, -0.06 ]
Barkley 2000 15 14 (12.3) 15 17.7 (13.8) 1.1 % -0.28 [ -0.99, 0.44 ]
Blum 2011 24 58.1 (22.1) 24 75.2 (19.8) 1.3 % -0.80 [ -1.39, -0.21 ]
Brown 1984a 11 7.45 (3.72) 11 16.73 (7.58) 0.8 % -1.50 [ -2.46, -0.53 ]
Brown 1988 11 9.5 (5.04) 11 8 (0.63) 0.9 % 0.40 [ -0.44, 1.25 ]
Bukstein 1998 18 3.59 (2.64) 18 5.49 (3.32) 1.1 % -0.62 [ -1.29, 0.05 ]
Chronis 2003 21 0.9 (0.8) 21 3.9 (2.8) 1.1 % -1.43 [ -2.11, -0.74 ]
Coghill 2007 75 58.5 (12.8) 75 73 (11.3) 1.7 % -1.19 [ -1.54, -0.85 ]
Cook 1993 15 0.6 (0.137) 15 0.69 (0.143) 1.0 % -0.63 [ -1.36, 0.11 ]
Corkum 2008 21 59.65 (11.46) 21 67.4 (10.49) 1.2 % -0.69 [ -1.32, -0.07 ]
Douglas 1986 16 0.56 (0.6) 16 1.07 (0.6) 1.1 % -0.83 [ -1.55, -0.10 ]
DuPaul 1996 24 15.17 (9.19) 24 23 (9.35) 1.3 % -0.83 [ -1.42, -0.24 ]
Epstein 2011 93 17.5 (10.87) 93 26.67 (12.04) 1.8 % -0.80 [ -1.10, -0.50 ]
Fabiano 2007 48 1.4 (2.46) 48 5.86 (4.68) 1.5 % -1.18 [ -1.62, -0.75 ]
Fitzpatrick 1992a 19 0.73 (0.65) 19 1.36 (0.8) 1.1 % -0.85 [ -1.51, -0.18 ]
Flapper 2008 12 12.5 (9.445) 12 19.17 (10.143) 0.9 % -0.66 [ -1.48, 0.17 ]
Gadow 1990 11 6 (6.68) 11 14 (7.87) 0.8 % -1.05 [ -1.96, -0.15 ]
Gadow 1995 34 7.1 (5.4) 34 14.2 (4.6) 1.4 % -1.40 [ -1.93, -0.87 ]
Gadow 2007 71 5.7 (5.1) 71 11.6 (6.9) 1.7 % -0.97 [ -1.32, -0.62 ]
Gadow 2011 54 5.9 (5.3) 54 10.9 (8.1) 1.6 % -0.73 [ -1.12, -0.34 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Garfinkel 1983 12 4.887 (4.8416) 12 6.37 (6.3118) 0.9 % -0.25 [ -1.06, 0.55 ]
Gorman 2006 41 0.66 (0.8964) 41 1.52 (1.0885) 1.5 % -0.85 [ -1.31, -0.40 ]
Grizenko 2012 198 54.38 (11.13) 198 63.76 (14.38) 1.9 % -0.73 [ -0.93, -0.52 ]
Hoeppner 1997 50 8.2 (6.85) 50 14.23 (8.31) 1.6 % -0.79 [ -1.19, -0.38 ]
Kaplan 1990 6 0.9 (0.8) 6 1.7 (0.9) 0.6 % -0.87 [ -2.08, 0.34 ]
Kolko 1999 22 3.3 (2.9) 22 9.9 (3.8) 1.1 % -1.92 [ -2.64, -1.19 ]
Konrad 2004 60 26.3 (5.2) 60 42.5 (6.1) 1.4 % -2.84 [ -3.35, -2.33 ]
Konrad 2005 44 14.3 (10.1) 44 22.2 (13.8) 1.6 % -0.65 [ -1.08, -0.22 ]
Lufi 1997 20 30.85 (15.19) 20 32.6 (12.75) 1.2 % -0.12 [ -0.74, 0.50 ]
Lufi 2007 19 6.97 (3.8) 19 12.56 (6.69) 1.1 % -1.01 [ -1.69, -0.33 ]
Manos 1999 117 56.12 (11.81) 117 64.38 (15.41) 1.9 % -0.60 [ -0.86, -0.34 ]
McBride 1988a 46 7.5 (4.5) 46 17 (6.5) 1.5 % -1.69 [ -2.16, -1.21 ]
McGough 2006 80 3.2 (5.1877) 80 8 (5.1877) 1.7 % -0.92 [ -1.25, -0.59 ]
Pearson 2013 24 59.3 (12.7) 24 75.6 (11.5) 1.2 % -1.32 [ -1.95, -0.69 ]
Pelham 1989 24 2.45 (3.8669) 24 4.2 (6.624) 1.3 % -0.32 [ -0.89, 0.25 ]
Pelham 1990a 22 2.3 (2) 22 3.8 (4.6) 1.3 % -0.42 [ -1.01, 0.18 ]
Pelham 1993a 31 1.7 (2.1) 31 6 (4.3) 1.3 % -1.25 [ -1.80, -0.71 ]
Pelham 1999 25 1.1 (1.2) 25 3.7 (2.6) 1.2 % -1.26 [ -1.88, -0.65 ]
Pelham 2001a 68 7.94 (5.83) 68 16.4 (7.74) 1.7 % -1.23 [ -1.60, -0.86 ]
Pelham 2002 136 1.8 (1.7) 136 3.5 (2.9) 1.9 % -0.71 [ -0.96, -0.47 ]
Pelham 2005 29 2.8 (3.2) 29 5.7 (5.9) 1.4 % -0.60 [ -1.13, -0.08 ]
Pelham 2011 10 6 (4.3) 10 9.7 (51) 0.9 % -0.10 [ -0.98, 0.78 ]
Pliszka 1990 30 13.8 (8.8) 30 25.2 (15.3) 1.4 % -0.90 [ -1.43, -0.37 ]
Quinn 2004 32 1.47 (2.37) 32 6.39 (6.81) 1.4 % -0.95 [ -1.47, -0.43 ]
Rapport 1987 31 7.16 (5) 31 15.84 (5.06) 1.3 % -1.70 [ -2.29, -1.12 ]
Silva 2008 68 1.4 (2.46) 68 5.86 (4.68) 1.7 % -1.19 [ -1.55, -0.82 ]
Smith 1998 45 1.2 (1.5) 45 4.4 (3.5) 1.5 % -1.18 [ -1.63, -0.73 ]
Smith 2004 1 10.3 (0.2108) 1 15.3 (0.1031) Not estimable
Smithee 1998 25 0.647 (0.51) 25 1.12 (0.5766) 1.3 % -0.86 [ -1.45, -0.28 ]
Solanto 2009 30 60.04 (10.57) 30 63.28 (10.55) 1.4 % -0.30 [ -0.81, 0.21 ]
Stein 1996 25 15.5 (4.8) 25 16.3 (4.6) 1.3 % -0.17 [ -0.72, 0.39 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tirosh 1993a 20 17.6 (6.3) 20 32 (9.2) 1.0 % -1.79 [ -2.53, -1.05 ]
Ullmann 1986 118 -45.6 (19.2) 118 -11.3 (15.1) 1.8 % -1.98 [ -2.29, -1.67 ]
Wigal 2013 44 7.1 (5.64) 44 19.3 (8.38) 1.4 % -1.69 [ -2.18, -1.20 ]
Wilens 2008 120 15.4 (10.7354) 120 24.5 (10.7354) 1.9 % -0.84 [ -1.11, -0.58 ]
Zeiner 1999 38 8.83 (6.49) 38 14.69 (6.17) 1.5 % -0.92 [ -1.39, -0.44 ]
Subtotal (95% CI) 2323 2323 73.4 % -0.95 [ -1.09, -0.82 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 222.00, df = 54 (P<0.00001); I2 =76%
Test for overall effect: Z = 14.11 (P < 0.00001)
Total (95% CI) 3239 3105 100.0 % -0.91 [ -1.01, -0.80 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 260.75, df = 73 (P<0.00001); I2 =72%
Test for overall effect: Z = 16.84 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.67, df = 1 (P = 0.06), I2 =73%
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cross-over trials: risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 1 Teacher-rated ADHD symptoms
Outcome: 11 All parallel-group trials and cross-over trials: risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
DuPaul 1996 24 15.17 (9.19) 24 23 (9.35) 1.3 % -0.83 [ -1.42, -0.24 ]
Flapper 2008 12 12.5 (9.445) 12 19.17 (10.143) 0.9 % -0.66 [ -1.48, 0.17 ]
Gorman 2006 41 0.66 (0.8964) 41 1.52 (1.0885) 1.5 % -0.85 [ -1.31, -0.40 ]
Stein 1996 25 15.5 (4.8) 25 16.3 (4.6) 1.3 % -0.17 [ -0.72, 0.39 ]
Subtotal (95% CI) 102 102 5.0 % -0.64 [ -0.97, -0.30 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 3.72 (P = 0.00020)
2 High risk of bias
Abikoff 2009 19 1.13 (0.46) 19 1.5 (0.55) 1.2 % -0.71 [ -1.37, -0.06 ]
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 1.5 % -0.85 [ -1.33, -0.38 ]
Barkley 2000 15 14 (12.3) 15 17.7 (13.8) 1.1 % -0.28 [ -0.99, 0.44 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 1.7 % -1.07 [ -1.43, -0.71 ]
Blum 2011 24 58.1 (22.1) 24 75.2 (19.8) 1.3 % -0.80 [ -1.39, -0.21 ]
Brown 1984a 11 7.45 (3.72) 11 16.73 (7.58) 0.8 % -1.50 [ -2.46, -0.53 ]
Brown 1985 10 15.1 (4.6) 10 15.7 (2.9) 0.9 % -0.15 [ -1.03, 0.73 ]
Brown 1988 11 10 (6.69) 11 8 (0.63) 0.9 % 0.40 [ -0.44, 1.25 ]
Bukstein 1998 18 3.59 (2.64) 18 5.49 (3.32) 1.1 % -0.62 [ -1.29, 0.05 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 0.8 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 1.6 % -1.02 [ -1.40, -0.64 ]
Chronis 2003 21 0.9 (0.8) 21 3.9 (2.8) 1.1 % -1.43 [ -2.11, -0.74 ]
Coghill 2007 75 58.5 (12.8) 75 73 (11.3) 1.7 % -1.19 [ -1.54, -0.85 ]
Cook 1993 15 0.6 (0.137) 15 0.69 (0.143) 1.0 % -0.63 [ -1.36, 0.11 ]
Corkum 2008 21 59.65 (11.46) 21 67.4 (10.49) 1.2 % -0.69 [ -1.32, -0.07 ]
Douglas 1986 16 0.56 (0.6) 16 1.07 (0.6) 1.0 % -0.83 [ -1.55, -0.10 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Epstein 2011 93 17.5 (10.87) 93 26.67 (12.04) 1.8 % -0.80 [ -1.10, -0.50 ]
Fabiano 2007 48 1.4 (2.46) 48 5.86 (4.68) 1.5 % -1.18 [ -1.62, -0.75 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 1.6 % -1.07 [ -1.45, -0.69 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 1.8 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 1.0 % -0.57 [ -1.30, 0.16 ]
Fitzpatrick 1992a 19 0.73 (0.65) 19 1.36 (0.8) 1.1 % -0.85 [ -1.51, -0.18 ]
Gadow 1990 11 6 (6.68) 11 14 (7.87) 0.8 % -1.05 [ -1.96, -0.15 ]
Gadow 1995 34 7.1 (5.4) 34 14.2 (4.6) 1.4 % -1.40 [ -1.93, -0.87 ]
Gadow 2007 71 5.7 (5.1) 71 11.6 (6.9) 1.7 % -0.97 [ -1.32, -0.62 ]
Gadow 2011 54 5.9 (5.3) 54 10.9 (8.1) 1.6 % -0.73 [ -1.12, -0.34 ]
Garfinkel 1983 12 4.887 (4.8416) 12 6.37 (6.3118) 0.9 % -0.25 [ -1.06, 0.55 ]
Grizenko 2012 198 54.38 (11.13) 198 63.76 (14.38) 1.9 % -0.73 [ -0.93, -0.52 ]
Hoeppner 1997 50 8.2 (6.85) 50 14.23 (8.31) 1.6 % -0.79 [ -1.19, -0.38 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 0.9 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 1.9 % -0.47 [ -0.72, -0.22 ]
Kaplan 1990 6 0.9 (0.8) 6 1.7 (0.9) 0.6 % -0.87 [ -2.08, 0.34 ]
Kolko 1999 22 3.3 (2.9) 22 9.9 (3.8) 1.1 % -1.92 [ -2.64, -1.19 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 1.4 % -0.33 [ -0.82, 0.17 ]
Konrad 2004 60 26.3 (5.2) 60 42.5 (6.1) 1.4 % -2.84 [ -3.35, -2.33 ]
Konrad 2005 44 14.3 (10.1) 44 22.2 (13.8) 1.6 % -0.65 [ -1.08, -0.22 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 1.5 % -1.06 [ -1.52, -0.61 ]
Lufi 1997 20 30.85 (15.19) 20 32.6 (12.75) 1.2 % -0.12 [ -0.74, 0.50 ]
Lufi 2007 19 6.97 (3.8) 19 12.56 (6.69) 1.1 % -1.01 [ -1.69, -0.33 ]
Manos 1999 117 56.12 (11.81) 117 64.38 (15.41) 1.9 % -0.60 [ -0.86, -0.34 ]
McBride 1988a 46 7.5 (4.5) 46 17 (6.5) 1.5 % -1.69 [ -2.16, -1.21 ]
McGough 2006 80 3.2 (5.1877) 80 8 (5.1877) 1.7 % -0.92 [ -1.25, -0.59 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 1.7 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 1.4 % -0.28 [ -0.79, 0.23 ]
Pearson 2013 24 59.3 (12.7) 24 75.6 (11.5) 1.2 % -1.32 [ -1.95, -0.69 ]
Pelham 1989 24 2.45 (3.8669) 24 4.2 (6.624) 1.3 % -0.32 [ -0.89, 0.25 ]
Pelham 1990a 22 2.3 (2) 22 3.8 (4.6) 1.3 % -0.42 [ -1.01, 0.18 ]
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(. . . Continued)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 1993a 31 2 (2.1) 31 6 (4.3) 1.3 % -1.17 [ -1.71, -0.63 ]
Pelham 1999 25 1.1 (1.2) 25 3.7 (2.6) 1.2 % -1.26 [ -1.88, -0.65 ]
Pelham 2001a 68 7.94 (5.83) 68 16.4 (7.74) 1.7 % -1.23 [ -1.60, -0.86 ]
Pelham 2002 136 1.8 (1.7) 136 3.5 (2.9) 1.9 % -0.71 [ -0.96, -0.47 ]
Pelham 2005 29 2.3 (2.7) 29 5.7 (5.9) 1.4 % -0.73 [ -1.26, -0.20 ]
Pelham 2011 10 6 (4.3) 10 9.7 (51) 0.9 % -0.10 [ -0.98, 0.78 ]
Pliszka 1990 30 13.8 (8.8) 30 25.2 (15.3) 1.4 % -0.90 [ -1.43, -0.37 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 1.1 % -0.89 [ -1.56, -0.22 ]
Quinn 2004 32 1.58 (3.85) 32 6.39 (6.81) 1.4 % -0.86 [ -1.37, -0.35 ]
Rapport 1987 31 7.16 (5) 31 15.84 (5.06) 1.3 % -1.70 [ -2.29, -1.12 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 1.4 % -1.13 [ -1.65, -0.60 ]
Silva 2008 68 1.4 (2.46) 68 5.86 (4.68) 1.7 % -1.19 [ -1.55, -0.82 ]
Smith 1998 45 1.2 (1.5) 45 4.4 (3.5) 1.5 % -1.18 [ -1.63, -0.73 ]
Smith 2004 1 10.3 (0.2108) 1 15.3 (0.1031) Not estimable
Smithee 1998 25 0.647 (0.51) 25 1.12 (0.5766) 1.3 % -0.86 [ -1.45, -0.28 ]
Solanto 2009 30 60.06 (10.57) 30 63.28 (10.55) 1.4 % -0.30 [ -0.81, 0.21 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 1.5 % -0.57 [ -1.03, -0.12 ]
Tirosh 1993a 20 17.6 (6.3) 20 32 (9.2) 1.0 % -1.79 [ -2.53, -1.05 ]
Ullmann 1986 118 -45.6 (19.2) 118 -11.3 (15.1) 1.8 % -1.98 [ -2.29, -1.67 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 1.3 % -0.73 [ -1.32, -0.15 ]
Wigal 2013 44 7.1 (5.64) 44 19.3 (8.38) 1.4 % -1.69 [ -2.18, -1.20 ]
Wilens 2008 120 15.4 (10.7354) 120 24.5 (10.7354) 1.9 % -0.84 [ -1.11, -0.58 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 1.6 % -1.05 [ -1.44, -0.67 ]
Zeiner 1999 38 8.83 (6.49) 38 14.69 (6.17) 1.5 % -0.92 [ -1.39, -0.44 ]
Subtotal (95% CI) 3137 3003 95.0 % -0.92 [ -1.03, -0.81 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 252.17, df = 69 (P<0.00001); I2 =73%
Test for overall effect: Z = 16.60 (P < 0.00001)
Total (95% CI) 3239 3105 100.0 % -0.91 [ -1.01, -0.80 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 259.30, df = 73 (P<0.00001); I2 =72%
Test for overall effect: Z = 16.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.43, df = 1 (P = 0.12), I2 =59%
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Analysis 2.1. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 1 All parallel-group
trials and first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 1 All parallel-group trials and first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 10.4 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 10.1 % -0.72 [ -1.04, -0.41 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 10.2 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 10.4 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 7.7 % -0.62 [ -1.16, -0.09 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 10.6 % -0.35 [ -0.61, -0.08 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 10.6 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 11.0 % 0.04 [ -0.18, 0.27 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 8.5 % -0.94 [ -1.41, -0.47 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 10.3 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Total (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 2 Subgroup analysis:
types of scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 2 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Swanson, Kotkin, Agler, M-Glynn and Pelham (SKAMP) Scale
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 100.0 % -0.72 [ -1.04, -0.41 ]
Subtotal (95% CI) 82 82 100.0 % -0.72 [ -1.04, -0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.49 (P < 0.00001)
2 ADHD Rating Scale (ADHD-RS )
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 14.6 % -1.18 [ -1.46, -0.89 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 14.4 % -0.78 [ -1.09, -0.48 ]
Findling 2010 143 17.7 (12.2) 72 27.7 (12.75) 14.6 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 12.1 % -0.62 [ -1.16, -0.09 ]
Newcorn 2008 220 23.1 (9.70618) 74 34.4 (7.7459) 14.7 % -1.22 [ -1.50, -0.94 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 15.1 % 0.04 [ -0.18, 0.27 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 14.5 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 831 611 100.0 % -0.71 [ -1.09, -0.32 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 69.77, df = 6 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.59 (P = 0.00033)
3 Swanson, Nolan and Pelham (SNAP) Scale
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 100.0 % -0.35 [ -0.61, -0.08 ]
Subtotal (95% CI) 114 107 100.0 % -0.35 [ -0.61, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
4 Unknown
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 100.0 % -0.94 [ -1.41, -0.47 ]
Subtotal (95% CI) 39 39 100.0 % -0.94 [ -1.41, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000089)
Test for subgroup differences: Chi2 = 6.41, df = 3 (P = 0.09), I2 =53%
-2 -1 0 1 2
Favours methylphenidate Favours control
617Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 3 Subgroup analysis:
duration of treatment.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 3 Subgroup analysis: duration of treatment
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short term (up to 6 months)
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 10.4 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 10.1 % -0.72 [ -1.04, -0.41 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 10.2 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 10.4 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 7.7 % -0.62 [ -1.16, -0.09 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 10.6 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 11.0 % 0.04 [ -0.18, 0.27 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 8.5 % -0.94 [ -1.41, -0.47 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 10.3 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 954 732 89.4 % -0.68 [ -0.95, -0.40 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 55.84, df = 8 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.82 (P < 0.00001)
2 Long term (over 6 months)
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 10.6 % -0.35 [ -0.61, -0.08 ]
Subtotal (95% CI) 114 107 10.6 % -0.35 [ -0.61, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
Total (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.87, df = 1 (P = 0.09), I2 =65%
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Analysis 2.4. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 4 Subgroup analysis:
parallel-group trials compared with first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 4 Subgroup analysis: parallel-group trials compared with first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 10.4 % -1.18 [ -1.46, -0.89 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 10.2 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 10.4 % -0.80 [ -1.10, -0.51 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 10.6 % -0.35 [ -0.61, -0.08 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 10.6 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 11.0 % 0.04 [ -0.18, 0.27 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 10.3 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 919 690 73.7 % -0.60 [ -0.91, -0.28 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 55.74, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.69 (P = 0.00023)
2 First-period cross-over trials
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 10.1 % -0.72 [ -1.04, -0.41 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 7.7 % -0.62 [ -1.16, -0.09 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 8.5 % -0.94 [ -1.41, -0.47 ]
Subtotal (95% CI) 149 149 26.3 % -0.76 [ -0.99, -0.52 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.31 (P < 0.00001)
Total (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 2.5. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 5 Subgroup analysis:
trials with cohort selection bias of all participants compared with trials without cohort selection bias of all
participants.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 5 Subgroup analysis: trials with cohort selection bias of all participants compared with trials without cohort selection bias of all participants
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Trials with cohort selection bias of all participants
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 10.2 % -0.78 [ -1.09, -0.48 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 7.7 % -0.62 [ -1.16, -0.09 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 10.6 % -0.35 [ -0.61, -0.08 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 10.3 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 320 310 38.9 % -0.51 [ -0.73, -0.29 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.32, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Trials without cohort selection bias of all participants
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 10.4 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 10.1 % -0.72 [ -1.04, -0.41 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 10.4 % -0.80 [ -1.10, -0.51 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 10.6 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 11.0 % 0.04 [ -0.18, 0.27 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 8.5 % -0.94 [ -1.41, -0.47 ]
Subtotal (95% CI) 748 529 61.1 % -0.72 [ -1.11, -0.33 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 52.42, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.60 (P = 0.00032)
Total (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 2.6. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 6 Subgroup analysis:
dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 6 Subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High dose
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 10.4 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 10.1 % -0.72 [ -1.04, -0.41 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 10.6 % -0.35 [ -0.61, -0.08 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 10.6 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 11.0 % 0.04 [ -0.18, 0.27 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 10.3 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 765 615 63.2 % -0.55 [ -0.91, -0.20 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 50.96, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.03 (P = 0.0024)
3 Unknown dose
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 10.2 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 10.4 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 7.7 % -0.62 [ -1.16, -0.09 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 8.5 % -0.94 [ -1.41, -0.47 ]
Subtotal (95% CI) 303 224 36.8 % -0.80 [ -0.98, -0.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 8.59 (P < 0.00001)
Total (95% CI) 1068 839 100.0 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =30%
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Analysis 2.7. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 7 ADHD symptoms,
cross-over trials (endpoint data), subgroup analysis: risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 7 ADHD symptoms, cross-over trials (endpoint data), subgroup analysis: risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Armstrong 2012 78 9.8 (7.7719) 78 20.8 (7.7719) 6.1 % -1.41 [ -1.76, -1.06 ]
Bedard 2008 130 2.22 (2.17) 130 6.51 (3.54) 6.9 % -1.46 [ -1.73, -1.18 ]
Brams 2012 158 -4.47 (9.1005) 158 4.5 (9.088) 7.3 % -0.98 [ -1.22, -0.75 ]
Chronis 2003 21 3.3 (1.7) 21 5.8 (3.3) 3.7 % -0.93 [ -1.57, -0.29 ]
Douglas 1986 16 0.47 (0.42) 16 1.07 (0.64) 3.0 % -1.08 [ -1.83, -0.33 ]
Do¨pfner 2004 82 0.374 (0.366) 82 1.08 (0.751) 6.3 % -1.19 [ -1.52, -0.86 ]
Fabiano 2007 48 2.3 (1.5) 48 6 (3.6) 5.2 % -1.33 [ -1.77, -0.89 ]
Kent 1995 12 2.7 (2.3) 12 2.8 (1.9) 2.8 % -0.05 [ -0.85, 0.75 ]
Murray 2011 67 8.7 (7.7761) 64 18.1 (7.76) 5.9 % -1.20 [ -1.58, -0.83 ]
Pelham 1990a 22 4.81 (3.2) 22 6.3 (4.8) 4.0 % -0.36 [ -0.95, 0.24 ]
Pelham 1999 25 2.6 (1.4) 25 5.6 (2.9) 3.9 % -1.30 [ -1.91, -0.68 ]
Pelham 2002 136 3 (1.4) 136 4.4 (2.3) 7.2 % -0.73 [ -0.98, -0.49 ]
Pelham 2005 29 5.1 (3.8) 29 6.9 (4.8) 4.6 % -0.41 [ -0.93, 0.11 ]
Pelham 2014 47 2.3 (1.5) 47 6 (3.6) 5.2 % -1.33 [ -1.78, -0.88 ]
Silva 2005a 54 0.67 (0.58) 54 1.94 (1.18) 5.5 % -1.36 [ -1.78, -0.94 ]
Silva 2008 68 2.24 (9.8542) 68 7.77 (9.7965) 6.2 % -0.56 [ -0.90, -0.22 ]
Solanto 2009 30 15.21 (9.21) 30 26.58 (11.39) 4.4 % -1.08 [ -1.63, -0.54 ]
Swanson 2004b 184 12.62 (11) 184 22.11 (14.1) 7.5 % -0.75 [ -0.96, -0.54 ]
Wilens 2010 30 14.76 (14.48) 30 28.33 (15.75) 4.5 % -0.89 [ -1.42, -0.35 ]
Subtotal (95% CI) 1237 1234 100.0 % -1.00 [ -1.16, -0.84 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 57.64, df = 18 (P<0.00001); I2 =69%
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 12.05 (P < 0.00001)
Total (95% CI) 1237 1234 100.0 % -1.00 [ -1.16, -0.84 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 57.64, df = 18 (P<0.00001); I2 =69%
Test for overall effect: Z = 12.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 8 ADHD symptoms,
cross-over trials (endpoint data), subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 8 ADHD symptoms, cross-over trials (endpoint data), subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Bedard 2008 130 3.39 (2.65) 130 6.51 (3.54) 4.6 % -0.99 [ -1.25, -0.74 ]
Brams 2012 159 -2.02 (9.041) 158 4.5 (9.088) 4.8 % -0.72 [ -0.94, -0.49 ]
Chronis 2003 21 4.3 (2.2) 21 5.8 (3.3) 2.6 % -0.52 [ -1.14, 0.09 ]
Douglas 1986 16 0.47 (0.42) 16 1.07 (0.64) 2.1 % -1.08 [ -1.83, -0.33 ]
Fabiano 2007 48 4 (2.7) 48 6 (3.6) 3.7 % -0.62 [ -1.03, -0.21 ]
Kent 1995 12 2.7 (2.3) 12 2.8 (1.9) 1.9 % -0.05 [ -0.85, 0.75 ]
Pelham 1990a 22 4.81 (3.2) 22 6.3 (4.8) 2.7 % -0.36 [ -0.95, 0.24 ]
Pelham 1999 25 2.6 (1.4) 25 5.6 (2.9) 2.6 % -1.30 [ -1.91, -0.68 ]
Pelham 2002 136 3 (1.4) 136 4.4 (2.3) 4.7 % -0.73 [ -0.98, -0.49 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 2005 29 5.2 (3.8) 29 6.9 (4.8) 3.0 % -0.39 [ -0.91, 0.13 ]
Pelham 2014 47 4 (2.7) 47 6 (3.6) 3.6 % -0.62 [ -1.04, -0.21 ]
Silva 2005a 54 0.99 (0.71) 54 1.94 (1.18) 3.7 % -0.97 [ -1.37, -0.57 ]
Silva 2008 68 2.24 (9.8542) 68 7.77 (9.7965) 4.1 % -0.56 [ -0.90, -0.22 ]
Solanto 2009 30 18.63 (10.45) 30 26.58 (11.39) 3.0 % -0.72 [ -1.24, -0.19 ]
Swanson 2004b 184 16.44 (12.43) 184 21.47 (14.61) 4.9 % -0.37 [ -0.58, -0.16 ]
Wilens 2010 30 14.76 (14.48) 30 28.33 (15.75) 3.0 % -0.89 [ -1.42, -0.35 ]
Subtotal (95% CI) 1011 1010 54.9 % -0.69 [ -0.82, -0.55 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 27.84, df = 15 (P = 0.02); I2 =46%
Test for overall effect: Z = 9.94 (P < 0.00001)
2 High dose
Armstrong 2012 78 9.8 (7.7719) 78 20.8 (7.7719) 4.0 % -1.41 [ -1.76, -1.06 ]
Bedard 2008 130 2.22 (2.17) 130 6.51 (3.54) 4.5 % -1.46 [ -1.73, -1.18 ]
Brams 2012 158 -4.47 (9.1005) 158 4.5 (9.088) 4.7 % -0.98 [ -1.22, -0.75 ]
Chronis 2003 21 3.3 (1.7) 21 5.8 (3.3) 2.5 % -0.93 [ -1.57, -0.29 ]
Do¨pfner 2004 82 0.374 (0.366) 82 1.08 (0.751) 4.1 % -1.19 [ -1.52, -0.86 ]
Fabiano 2007 48 2.3 (1.5) 48 6 (3.6) 3.5 % -1.33 [ -1.77, -0.89 ]
Murray 2011 67 8.7 (7.7761) 64 18.1 (7.76) 3.9 % -1.20 [ -1.58, -0.83 ]
Pelham 2005 29 5.1 (3.8) 29 6.9 (4.8) 3.0 % -0.41 [ -0.93, 0.11 ]
Pelham 2014 47 2.3 (1.5) 47 6 (3.6) 3.4 % -1.33 [ -1.78, -0.88 ]
Silva 2005a 54 0.67 (0.58) 54 1.94 (1.18) 3.6 % -1.36 [ -1.78, -0.94 ]
Solanto 2009 30 15.21 (9.21) 30 26.58 (11.39) 2.9 % -1.08 [ -1.63, -0.54 ]
Swanson 2004b 184 12.62 (11) 184 22.11 (14.1) 4.9 % -0.75 [ -0.96, -0.54 ]
Subtotal (95% CI) 928 925 45.1 % -1.13 [ -1.31, -0.95 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 32.09, df = 11 (P = 0.00074); I2 =66%
Test for overall effect: Z = 12.39 (P < 0.00001)
Total (95% CI) 1939 1935 100.0 % -0.89 [ -1.02, -0.75 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 98.88, df = 27 (P<0.00001); I2 =73%
Test for overall effect: Z = 12.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.11, df = 1 (P = 0.00), I2 =93%
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Analysis 2.9. Comparison 2 Independent assessor-rated ADHD symptoms, Outcome 9 Subgroup analysis:
all parallel-group trials and first-period cross-over trials compared with cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 2 Independent assessor-rated ADHD symptoms
Outcome: 9 Subgroup analysis: all parallel-group trials and first-period cross-over trials compared with cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All parallel-group trials and first-period cross-over trials
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 4.1 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 4.0 % -0.72 [ -1.04, -0.41 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 4.0 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 4.1 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 3.1 % -0.62 [ -1.16, -0.09 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 4.2 % -0.35 [ -0.61, -0.08 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 4.1 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 4.3 % 0.04 [ -0.18, 0.27 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 3.3 % -0.94 [ -1.41, -0.47 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 4.0 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 1068 839 39.2 % -0.64 [ -0.89, -0.39 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 59.25, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.04 (P < 0.00001)
2 Cross-over trials (endpoint data)
Armstrong 2012 78 9.8 (7.7719) 78 20.8 (7.7719) 3.8 % -1.41 [ -1.76, -1.06 ]
Bedard 2008 130 2.22 (2.17) 130 6.51 (3.54) 4.1 % -1.46 [ -1.73, -1.18 ]
Brams 2012 159 -2.02 (9.041) 158 4.5 (9.088) 4.3 % -0.72 [ -0.94, -0.49 ]
Chronis 2003 21 3.3 (1.7) 21 5.8 (3.3) 2.7 % -0.93 [ -1.57, -0.29 ]
Douglas 1986 16 0.47 (0.42) 16 1.07 (0.64) 2.3 % -1.08 [ -1.83, -0.33 ]
Fabiano 2007 48 2.3 (1.5) 48 6 (3.6) 3.4 % -1.33 [ -1.77, -0.89 ]
Kent 1995 12 2.7 (2.3) 12 2.8 (1.9) 2.1 % -0.05 [ -0.85, 0.75 ]
Murray 2011 67 8.7 (7.7761) 64 18.1 (7.76) 3.7 % -1.20 [ -1.58, -0.83 ]
Pelham 1990a 22 4.81 (3.2) 22 6.3 (4.8) 2.8 % -0.36 [ -0.95, 0.24 ]
Pelham 1999 25 2.6 (1.4) 25 5.6 (2.9) 2.8 % -1.30 [ -1.91, -0.68 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 2002 136 3 (1.4) 136 4.4 (2.3) 4.2 % -0.73 [ -0.98, -0.49 ]
Pelham 2005 29 5.2 (3.8) 29 6.9 (4.8) 3.1 % -0.39 [ -0.91, 0.13 ]
Pelham 2014 47 2.3 (1.5) 47 6 (3.6) 3.4 % -1.33 [ -1.78, -0.88 ]
Silva 2005a 54 0.67 (0.58) 54 1.94 (1.18) 3.5 % -1.36 [ -1.78, -0.94 ]
Silva 2008 68 2.24 (9.8542) 68 7.77 (9.7965) 3.9 % -0.56 [ -0.90, -0.22 ]
Solanto 2009 30 18.21 (10.34) 30 26.58 (11.39) 3.1 % -0.76 [ -1.28, -0.23 ]
Swanson 2004b 184 12.04 (11.62) 184 22.15 (13.91) 4.4 % -0.79 [ -1.00, -0.58 ]
Wilens 2010 30 14.76 (14.48) 30 28.33 (15.75) 3.1 % -0.89 [ -1.42, -0.35 ]
Subtotal (95% CI) 1156 1152 60.8 % -0.95 [ -1.13, -0.77 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 59.92, df = 17 (P<0.00001); I2 =72%
Test for overall effect: Z = 10.59 (P < 0.00001)
Total (95% CI) 2224 1991 100.0 % -0.83 [ -0.98, -0.67 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 149.20, df = 27 (P<0.00001); I2 =82%
Test for overall effect: Z = 10.26 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.00, df = 1 (P = 0.05), I2 =75%
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Analysis 3.1. Comparison 3 Parent-rated ADHD symptoms, Outcome 1 All parallel-group trials and first-
period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 1 All parallel-group trials and first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 4.9 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 1.8 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.0 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 5.6 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 3.7 % -0.21 [ -0.82, 0.41 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 5.8 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 6.8 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.8 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 3.0 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 2.7 % -0.03 [ -0.81, 0.76 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 7.3 % -0.58 [ -0.82, -0.33 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 5.3 % -0.43 [ -0.86, 0.00 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 5.1 % -0.91 [ -1.36, -0.46 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 6.8 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 4.7 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.3 % -0.72 [ -1.39, -0.04 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 5.0 % -0.59 [ -1.04, -0.13 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 5.6 % -0.93 [ -1.32, -0.53 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 6.7 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 5.7 % -1.17 [ -1.56, -0.78 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 1.6 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 1265 922 100.0 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.14, df = 20 (P = 0.00021); I2 =60%
Test for overall effect: Z = 8.51 (P < 0.00001)
Total (95% CI) 1265 922 100.0 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.14, df = 20 (P = 0.00021); I2 =60%
Test for overall effect: Z = 8.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Parent-rated ADHD symptoms, Outcome 2 Subgroup analysis: types of scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 2 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Conners’ Parent Rating Scale (CPRS)
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 6.1 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -4.7 (24.5) 8 -2.9 (5.6) 6.9 % -0.09 [ -1.05, 0.86 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 22.5 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 22.5 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 10.3 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 9.1 % -0.03 [ -0.81, 0.76 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 22.6 % -0.88 [ -1.17, -0.59 ]
Subtotal (95% CI) 482 269 100.0 % -0.58 [ -0.87, -0.30 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.07; Chi2 = 14.42, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 4.00 (P = 0.000064)
2 ADHD Rating Scale - Fourth Edition (ADHD-RS-IV)
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 8.8 % 0.06 [ -0.89, 1.01 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 91.2 % -0.34 [ -0.63, -0.04 ]
Subtotal (95% CI) 96 98 100.0 % -0.30 [ -0.58, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
3 Fremdbeurteilungsbogen fu¨r Hyperkinetische Sto¨rungen (FBB-HKS)
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 100.0 % -0.91 [ -1.36, -0.46 ]
Subtotal (95% CI) 43 42 100.0 % -0.91 [ -1.36, -0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.99 (P = 0.000066)
4 Conners ADHD/DSM-IV Scales - Parent (CADS-P)
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 100.0 % -1.26 [ -1.65, -0.86 ]
Subtotal (95% CI) 57 63 100.0 % -1.26 [ -1.65, -0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.27 (P < 0.00001)
5 CADS-P Inattentive subscale
Tucker 2009 53 -8.8 (6.38) 56 -3.8 (6.32) 100.0 % -0.78 [ -1.17, -0.39 ]
Subtotal (95% CI) 53 56 100.0 % -0.78 [ -1.17, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000086)
6 CADS-P Hyperactivity subscale
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 100.0 % -0.93 [ -1.32, -0.53 ]
Subtotal (95% CI) 53 56 100.0 % -0.93 [ -1.32, -0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.59 (P < 0.00001)
7 Clinican’s Manual for the Assesment of Disruptive Behavior Disorders Rating Scale for Parents (Barkley)
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 100.0 % -0.21 [ -0.82, 0.41 ]
Subtotal (95% CI) 22 19 100.0 % -0.21 [ -0.82, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
8 Abbreviated Conners’ Rating Scale (ACRS) - Parent
Lehmkuhl 2002 43 10 (6.5574) 42 16 (12.9615) 70.8 % -0.58 [ -1.02, -0.15 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 29.2 % -0.72 [ -1.39, -0.04 ]
Subtotal (95% CI) 62 59 100.0 % -0.62 [ -0.99, -0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
9 Swanson, Nolan, and Pelham, Fourth Edition - Parent (SNAP-IV-Parent) Scale
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 17.4 % -0.61 [ -1.07, -0.14 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 61.4 % -0.58 [ -0.82, -0.33 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 18.2 % -0.59 [ -1.04, -0.13 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 3.0 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 216 214 100.0 % -0.60 [ -0.79, -0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 6.03 (P < 0.00001)
10 Strengths and Weaknesses of ADHD Symptoms and Normal Behavior (SWAN) Scale
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 100.0 % -0.43 [ -0.86, 0.00 ]
Subtotal (95% CI) 48 38 100.0 % -0.43 [ -0.86, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
11 IOWA Conners’ Rating Scale - Inattention/Overactivity (IOWA-I/O)
Findling 2006 120 5.1 (3.0672) 39 8.1 (3.06) 34.5 % -0.97 [ -1.35, -0.60 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 31.3 % -0.14 [ -0.63, 0.35 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 34.2 % -1.17 [ -1.56, -0.78 ]
Subtotal (95% CI) 238 114 100.0 % -0.78 [ -1.35, -0.21 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 11.15, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Chi2 = 22.34, df = 10 (P = 0.01), I2 =55%
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Analysis 3.3. Comparison 3 Parent-rated ADHD symptoms, Outcome 3 Subgroup analysis: duration of
treatment.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 3 Subgroup analysis: duration of treatment
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short term (up to 6 months)
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 4.9 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 1.8 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.0 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 5.6 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 3.7 % -0.21 [ -0.82, 0.41 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 5.8 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 6.8 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.8 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 3.0 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 2.7 % -0.03 [ -0.81, 0.76 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 5.3 % -0.43 [ -0.86, 0.00 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 5.1 % -0.91 [ -1.36, -0.46 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 6.8 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 4.7 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.3 % -0.72 [ -1.39, -0.04 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 5.0 % -0.59 [ -1.04, -0.13 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 5.6 % -0.93 [ -1.32, -0.53 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 6.7 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 5.7 % -1.17 [ -1.56, -0.78 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 1.6 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 1132 793 92.7 % -0.67 [ -0.84, -0.50 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 49.47, df = 19 (P = 0.00016); I2 =62%
Test for overall effect: Z = 7.89 (P < 0.00001)
2 Long term (over 6 months)
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 7.3 % -0.58 [ -0.82, -0.33 ]
Subtotal (95% CI) 133 129 7.3 % -0.58 [ -0.82, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.56 (P < 0.00001)
Total (95% CI) 1265 922 100.0 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.14, df = 20 (P = 0.00021); I2 =60%
Test for overall effect: Z = 8.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 3.4. Comparison 3 Parent-rated ADHD symptoms, Outcome 4 Subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 4 Subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 4.6 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 1.8 % -1.56 [ -2.59, -0.53 ]
Childress 2009 60 24.9 (14.18) 63 35.9 (13.03) 5.4 % -0.80 [ -1.17, -0.44 ]
Ialongo 1994 13 12.81 (4.35) 12 9.9 (4.28) 2.5 % 0.65 [ -0.16, 1.46 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 4.8 % -0.43 [ -0.86, 0.00 ]
Subtotal (95% CI) 166 163 19.1 % -0.53 [ -1.00, -0.07 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 14.32, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.25 (P = 0.024)
2 High dose
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.0 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.03) 5.2 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 3.5 % -0.21 [ -0.82, 0.41 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 2.6 % -0.03 [ -0.81, 0.76 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 6.5 % -0.58 [ -0.82, -0.33 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 6.1 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 4.4 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.1 % -0.72 [ -1.39, -0.04 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 6.0 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 5.2 % -1.17 [ -1.56, -0.78 ]
Subtotal (95% CI) 653 479 44.5 % -0.60 [ -0.86, -0.33 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 33.84, df = 9 (P = 0.00010); I2 =73%
Test for overall effect: Z = 4.43 (P < 0.00001)
3 Unknown dose
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 5.3 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 6.1 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.1 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 2.9 % -0.20 [ -0.91, 0.52 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 4.7 % -0.91 [ -1.36, -0.46 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 4.7 % -0.59 [ -1.04, -0.13 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 5.1 % -0.93 [ -1.32, -0.53 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 1.5 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 519 355 36.4 % -0.72 [ -0.92, -0.52 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 11.75, df = 7 (P = 0.11); I2 =40%
Test for overall effect: Z = 7.20 (P < 0.00001)
Total (95% CI) 1338 997 100.0 % -0.64 [ -0.79, -0.48 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 60.86, df = 22 (P = 0.00002); I2 =64%
Test for overall effect: Z = 8.05 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.86, df = 2 (P = 0.65), I2 =0.0%
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Analysis 3.5. Comparison 3 Parent-rated ADHD symptoms, Outcome 5 Medication status: medication
naive versus not medication naive.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 5 Medication status: medication naive versus not medication naive
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medication naive
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 19.4 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 13.5 % -0.33 [ -0.82, 0.17 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 12.8 % -1.13 [ -1.65, -0.60 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 15.8 % -0.93 [ -1.32, -0.53 ]
Subtotal (95% CI) 256 236 61.4 % -0.69 [ -1.03, -0.35 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 8.61, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 3.99 (P = 0.000065)
2 Not medication naive
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 6.3 % 0.06 [ -0.89, 1.01 ]
Findling 2006 120 4.3 (3.1768) 39 7.7 (3.1225) 16.2 % -1.07 [ -1.45, -0.69 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 16.1 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 210 93 38.6 % -0.88 [ -1.33, -0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.94, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 3.77 (P = 0.00016)
Total (95% CI) 466 329 100.0 % -0.76 [ -1.05, -0.48 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 18.21, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 5.33 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 3.6. Comparison 3 Parent-rated ADHD symptoms, Outcome 6 Subgroup analysis: trials with
cohort selection bias of all participants compared with trials without cohort selection bias of all participants.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 6 Subgroup analysis: trials with cohort selection bias of all participants compared with trials without cohort selection bias of all participants
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Trials with selection bias of all participants
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 4.9 % -0.61 [ -1.07, -0.14 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 5.8 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 6.8 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.8 % -0.76 [ -1.05, -0.47 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 7.3 % -0.58 [ -0.82, -0.33 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 5.3 % -0.43 [ -0.86, 0.00 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 6.8 % -0.88 [ -1.17, -0.59 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 6.7 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 5.7 % -1.17 [ -1.56, -0.78 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 1.6 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 945 614 57.5 % -0.68 [ -0.86, -0.51 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 22.53, df = 9 (P = 0.01); I2 =60%
Test for overall effect: Z = 7.53 (P < 0.00001)
2 Trials without cohort selection bias of all participants
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 1.8 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.0 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 5.6 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 3.7 % -0.21 [ -0.82, 0.41 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 3.0 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 2.7 % -0.03 [ -0.81, 0.76 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 5.1 % -0.91 [ -1.36, -0.46 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 4.7 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.3 % -0.72 [ -1.39, -0.04 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 5.0 % -0.59 [ -1.04, -0.13 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 5.6 % -0.93 [ -1.32, -0.53 ]
Subtotal (95% CI) 320 308 42.5 % -0.62 [ -0.90, -0.33 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 27.50, df = 10 (P = 0.002); I2 =64%
Test for overall effect: Z = 4.21 (P = 0.000026)
Total (95% CI) 1265 922 100.0 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.14, df = 20 (P = 0.00021); I2 =60%
Test for overall effect: Z = 8.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 3.7. Comparison 3 Parent-rated ADHD symptoms, Outcome 7 Subgroup analysis: parallel-group
trials compared with first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 7 Subgroup analysis: parallel-group trials compared with first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 4.9 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 1.8 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.0 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 5.6 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 3.7 % -0.21 [ -0.82, 0.41 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 5.8 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 6.8 % -0.39 [ -0.68, -0.09 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.8 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 3.0 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 2.7 % -0.03 [ -0.81, 0.76 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 7.3 % -0.58 [ -0.82, -0.33 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 5.3 % -0.43 [ -0.86, 0.00 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 5.1 % -0.91 [ -1.36, -0.46 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 6.8 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 4.7 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.3 % -0.72 [ -1.39, -0.04 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 5.6 % -0.93 [ -1.32, -0.53 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 6.7 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 5.7 % -1.17 [ -1.56, -0.78 ]
Subtotal (95% CI) 1217 877 93.4 % -0.66 [ -0.83, -0.50 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 49.63, df = 18 (P = 0.00009); I2 =64%
Test for overall effect: Z = 7.94 (P < 0.00001)
2 First-period cross-over trials
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 5.0 % -0.59 [ -1.04, -0.13 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 1.6 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 48 45 6.6 % -0.65 [ -1.07, -0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0026)
Total (95% CI) 1265 922 100.0 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.14, df = 20 (P = 0.00021); I2 =60%
Test for overall effect: Z = 8.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 3.8. Comparison 3 Parent-rated ADHD symptoms, Outcome 8 ADHD symptoms, cross-over trials
(endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 8 ADHD symptoms, cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
DuPaul 1996 24 15.75 (9.76) 24 21 (9.28) 2.1 % -0.54 [ -1.12, 0.03 ]
Flapper 2008 12 13 (11.707) 12 14.86 (10.669) 1.4 % -0.16 [ -0.96, 0.64 ]
Gorman 2006 41 0.72 (0.8324) 41 1.61 (0.8964) 2.7 % -1.02 [ -1.48, -0.56 ]
Stein 1996 25 5.5 (3.1) 25 6.3 (3.5) 2.2 % -0.24 [ -0.79, 0.32 ]
Subtotal (95% CI) 102 102 8.5 % -0.54 [ -0.96, -0.13 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 5.99, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 2.59 (P = 0.0096)
2 High risk of bias
Abikoff 2009 19 0.99 (0.55) 19 1.4 (0.63) 1.8 % -0.68 [ -1.33, -0.02 ]
Barkley 1991 40 14.53 (8.2) 40 24.88 (11.26) 2.6 % -1.04 [ -1.51, -0.57 ]
Barkley 2000 31 16.8 (9.7) 31 21.9 (12.5) 2.5 % -0.45 [ -0.95, 0.05 ]
Blum 2011 30 64.8 (26.5) 30 89.6 (13.1) 2.3 % -1.17 [ -1.72, -0.62 ]
Brams 2008 86 -16.382 (14.0495) 86 -4.62 (14.0495) 3.5 % -0.83 [ -1.15, -0.52 ]
Brown 1984a 11 11 (3.49) 11 19.55 (4.08) 0.9 % -2.17 [ -3.26, -1.07 ]
Brown 1988 11 31.5 (5.85) 11 39.66 (3.61) 1.0 % -1.61 [ -2.60, -0.63 ]
Chronis 2003 21 1.8 (1.5) 21 3.1 (1.9) 1.9 % -0.75 [ -1.37, -0.12 ]
Coghill 2007 75 67 (14.8) 75 77.2 (11.1) 3.4 % -0.78 [ -1.11, -0.44 ]
Cook 1993 15 0.41 (0.175) 15 0.59 (0.166) 1.5 % -1.03 [ -1.79, -0.26 ]
Corkum 2008 10 62.14 (14.11) 11 69.38 (10.23) 1.2 % -0.57 [ -1.45, 0.31 ]
Epstein 2011 93 19.6 (10.09) 93 28.26 (11.12) 3.6 % -0.81 [ -1.11, -0.51 ]
Findling 2007 20 20.81 (9.79) 20 32.19 (14.61) 1.9 % -0.90 [ -1.55, -0.24 ]
Fitzpatrick 1992a 19 0.96 (0.5) 19 1.75 (0.67) 1.7 % -1.31 [ -2.02, -0.60 ]
Gadow 1990 11 8.3 (6.19) 11 11 (8.24) 1.3 % -0.36 [ -1.20, 0.49 ]
Gadow 1995 34 7.8 (4.6) 34 11.8 (7.3) 2.5 % -0.65 [ -1.14, -0.16 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gadow 2007 71 7.8 (4.7) 71 11 (7) 3.4 % -0.53 [ -0.87, -0.20 ]
Gadow 2011 54 8.6 (5.6) 54 11.5 (7.7) 3.1 % -0.43 [ -0.81, -0.05 ]
Grizenko 2012 198 56.76 (11.87) 198 61.64 (14.19) 4.2 % -0.37 [ -0.57, -0.17 ]
Hoeppner 1997 50 7.13 (6.37) 50 12.16 (6.78) 3.0 % -0.76 [ -1.17, -0.35 ]
Kollins 2006 (PATS) 142 1.09 (0.69) 165 1.47 (0.7) 4.0 % -0.55 [ -0.77, -0.32 ]
Manos 1999 117 10.1 (6.71) 117 18.61 (11.86) 3.8 % -0.88 [ -1.15, -0.61 ]
McBride 1988a 41 6.5 (3.9) 41 17.4 (6.4) 2.3 % -2.04 [ -2.58, -1.50 ]
McGough 2006 93 20.2 (20.3481) 93 35.3 (21.3125) 3.6 % -0.72 [ -1.02, -0.42 ]
Musten 1997 41 63.29 (13.44) 41 77.23 (14.1) 2.7 % -1.00 [ -1.46, -0.54 ]
Pearson 2013 24 55.8 (9.3) 24 66.8 (12.7) 2.0 % -0.97 [ -1.57, -0.37 ]
Pelham 1999 25 1.7 (1.5) 25 3 (2.7) 2.2 % -0.59 [ -1.15, -0.02 ]
Pelham 2001a 68 11.41 (6.23) 68 19.91 (6.02) 3.2 % -1.38 [ -1.75, -1.00 ]
Pelham 2005 30 2.3 (2.2) 30 5.5 (3.8) 2.3 % -1.02 [ -1.56, -0.48 ]
Schachar 2008 18 -0.98 (2.14) 18 3.2 (2.82) 1.5 % -1.63 [ -2.40, -0.87 ]
Smithee 1998 26 0.8639 (0.4415) 26 1.14 (0.61022) 2.2 % -0.51 [ -1.07, 0.04 ]
Solanto 2009 30 56.96 (12.41) 30 65.8 (13.98) 2.4 % -0.66 [ -1.18, -0.14 ]
Stein 2011 93 20.27 (13.557) 101 29.12 (15.077) 3.7 % -0.61 [ -0.90, -0.33 ]
Taylor 1987 37 0.38 (0.46) 37 0.81 (0.76) 2.6 % -0.68 [ -1.15, -0.21 ]
Tirosh 1993a 20 10.75 (2.9) 20 14 (4.8) 1.9 % -0.80 [ -1.45, -0.16 ]
Zeiner 1999 38 3.08 (3.7) 38 5.25 (5.01) 2.7 % -0.49 [ -0.94, -0.03 ]
Zeni 2009 6 1.6267 (0.6894) 8 1.26 (0.77765) 0.9 % 0.46 [ -0.62, 1.54 ]
Subtotal (95% CI) 1748 1782 91.5 % -0.81 [ -0.92, -0.69 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 90.11, df = 36 (P<0.00001); I2 =60%
Test for overall effect: Z = 13.27 (P < 0.00001)
Total (95% CI) 1850 1884 100.0 % -0.78 [ -0.90, -0.67 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 97.00, df = 40 (P<0.00001); I2 =59%
Test for overall effect: Z = 13.53 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
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Analysis 3.9. Comparison 3 Parent-rated ADHD symptoms, Outcome 9 ADHD symptoms, cross-over trials
(endpoint data), subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 9 ADHD symptoms, cross-over trials (endpoint data), subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Barkley 2000 31 16.8 (9.7) 31 21.9 (12.5) 1.9 % -0.45 [ -0.95, 0.05 ]
Brams 2008 86 -16.382 (14.0495) 86 -4.62 (14.0495) 2.6 % -0.83 [ -1.15, -0.52 ]
Brown 1984a 11 11 (3.49) 11 19.55 (4.08) 0.7 % -2.17 [ -3.26, -1.07 ]
Brown 1988 11 31.5 (5.85) 11 39.66 (3.61) 0.8 % -1.61 [ -2.60, -0.63 ]
Chronis 2003 21 2.6 (2) 21 3.1 (1.9) 1.5 % -0.25 [ -0.86, 0.36 ]
Coghill 2007 75 67.2 (13.5) 75 77.2 (11.1) 2.5 % -0.81 [ -1.14, -0.47 ]
Cook 1993 15 0.41 (0.175) 15 0.59 (0.166) 1.2 % -1.03 [ -1.79, -0.26 ]
DuPaul 1996 24 19.42 (9.58) 24 21 (9.28) 1.7 % -0.16 [ -0.73, 0.40 ]
Findling 2007 20 20.81 (9.79) 20 32.19 (14.61) 1.4 % -0.90 [ -1.55, -0.24 ]
Fitzpatrick 1992a 19 0.96 (0.5) 19 1.75 (0.67) 1.3 % -1.31 [ -2.02, -0.60 ]
Flapper 2008 12 15.75 (10.391) 12 14.86 (10.669) 1.1 % 0.08 [ -0.72, 0.88 ]
Gadow 1990 11 9.8 (4.51) 11 11 (8.24) 1.0 % -0.17 [ -1.01, 0.66 ]
Gadow 1995 34 10.2 (5.4) 34 11.8 (7.3) 2.0 % -0.25 [ -0.72, 0.23 ]
Gadow 2007 71 10 (5.5) 71 11 (7) 2.5 % -0.16 [ -0.49, 0.17 ]
Gadow 2011 54 8.6 (5.2) 54 11.5 (7.7) 2.3 % -0.44 [ -0.82, -0.06 ]
Hoeppner 1997 50 7.13 (6.37) 50 12.16 (6.78) 2.2 % -0.76 [ -1.17, -0.35 ]
Kollins 2006 (PATS) 165 1.28 (0.73) 165 1.47 (0.7) 3.0 % -0.27 [ -0.48, -0.05 ]
Manos 1999 117 10.1 (6.71) 117 18.61 (11.86) 2.8 % -0.88 [ -1.15, -0.61 ]
McBride 1988a 41 6.5 (3.9) 41 17.4 (6.4) 1.8 % -2.04 [ -2.58, -1.50 ]
McGough 2006 93 20.2 (20.3481) 93 35.3 (21.3125) 2.7 % -0.72 [ -1.02, -0.42 ]
Musten 1997 41 67.03 (15.39) 41 77.23 (14.1) 2.1 % -0.68 [ -1.13, -0.24 ]
Pearson 2013 24 61.9 (11.7) 24 66.8 (12.7) 1.6 % -0.39 [ -0.97, 0.18 ]
Pelham 1999 25 1.7 (1.5) 25 3 (2.7) 1.7 % -0.59 [ -1.15, -0.02 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 2005 30 2.7 (2.2) 30 5.5 (3.8) 1.8 % -0.89 [ -1.42, -0.36 ]
Solanto 2009 30 61.64 (10.39) 30 65.8 (13.98) 1.8 % -0.33 [ -0.84, 0.18 ]
Stein 1996 25 5.5 (3.1) 25 6.3 (3.5) 1.7 % -0.24 [ -0.79, 0.32 ]
Subtotal (95% CI) 1136 1136 47.6 % -0.65 [ -0.82, -0.48 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 85.16, df = 25 (P<0.00001); I2 =71%
Test for overall effect: Z = 7.55 (P < 0.00001)
2 High dose
Abikoff 2009 19 0.99 (0.55) 19 1.4 (0.63) 1.4 % -0.68 [ -1.33, -0.02 ]
Barkley 1991 40 14.53 (8.2) 40 24.88 (11.26) 2.0 % -1.04 [ -1.51, -0.57 ]
Blum 2011 30 64.8 (26.5) 30 89.6 (13.1) 1.7 % -1.17 [ -1.72, -0.62 ]
Chronis 2003 21 1.8 (1.5) 21 3.1 (1.9) 1.5 % -0.75 [ -1.37, -0.12 ]
Coghill 2007 75 67 (14.8) 75 77.2 (11.1) 2.5 % -0.78 [ -1.11, -0.44 ]
Corkum 2008 10 62.14 (14.11) 11 69.38 (10.23) 1.0 % -0.57 [ -1.45, 0.31 ]
DuPaul 1996 24 15.75 (9.76) 24 21 (9.28) 1.6 % -0.54 [ -1.12, 0.03 ]
Epstein 2011 93 19.6 (10.09) 93 28.26 (11.12) 2.7 % -0.81 [ -1.11, -0.51 ]
Flapper 2008 12 13 (11.707) 12 14.86 (10.669) 1.1 % -0.16 [ -0.96, 0.64 ]
Gadow 1990 11 8.3 (6.19) 11 11 (8.24) 1.0 % -0.36 [ -1.20, 0.49 ]
Gadow 1995 34 7.8 (4.6) 34 11.8 (7.3) 1.9 % -0.65 [ -1.14, -0.16 ]
Gadow 2007 71 7.8 (4.7) 71 11 (7) 2.5 % -0.53 [ -0.87, -0.20 ]
Gadow 2011 54 8.6 (5.6) 54 11.5 (7.7) 2.3 % -0.43 [ -0.81, -0.05 ]
Gorman 2006 41 0.72 (0.8324) 41 1.61 (0.8964) 2.0 % -1.02 [ -1.48, -0.56 ]
Grizenko 2012 198 56.76 (11.87) 198 61.64 (14.19) 3.0 % -0.37 [ -0.57, -0.17 ]
Kollins 2006 (PATS) 142 1.09 (0.69) 165 1.47 (0.7) 2.9 % -0.55 [ -0.77, -0.32 ]
Musten 1997 41 63.29 (13.44) 41 77.23 (14.1) 2.0 % -1.00 [ -1.46, -0.54 ]
Pearson 2013 24 55.8 (9.3) 24 66.8 (12.7) 1.6 % -0.97 [ -1.57, -0.37 ]
Pelham 2001a 68 11.41 (6.23) 68 19.91 (6.02) 2.3 % -1.38 [ -1.75, -1.00 ]
Pelham 2005 30 2.3 (2.2) 30 5.5 (3.8) 1.7 % -1.02 [ -1.56, -0.48 ]
Schachar 2008 18 -0.98 (2.14) 18 3.2 (2.82) 1.2 % -1.63 [ -2.40, -0.87 ]
Smithee 1998 26 0.8639 (0.4415) 26 1.14 (0.61022) 1.7 % -0.51 [ -1.07, 0.04 ]
Solanto 2009 30 56.96 (12.41) 30 65.8 (13.98) 1.8 % -0.66 [ -1.18, -0.14 ]
Stein 2011 93 20.27 (13.557) 101 29.12 (15.077) 2.7 % -0.61 [ -0.90, -0.33 ]
Taylor 1987 37 0.38 (0.46) 37 0.81 (0.76) 2.0 % -0.68 [ -1.15, -0.21 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tirosh 1993a 20 10.75 (2.9) 20 14 (4.8) 1.4 % -0.80 [ -1.45, -0.16 ]
Zeiner 1999 38 3.08 (3.7) 38 5.25 (5.01) 2.0 % -0.49 [ -0.94, -0.03 ]
Zeni 2009 6 1.6267 (0.6894) 8 1.26 (0.77765) 0.7 % 0.46 [ -0.62, 1.54 ]
Subtotal (95% CI) 1306 1340 52.4 % -0.72 [ -0.84, -0.60 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 53.22, df = 27 (P = 0.002); I2 =49%
Test for overall effect: Z = 11.65 (P < 0.00001)
Total (95% CI) 2442 2476 100.0 % -0.69 [ -0.79, -0.58 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 139.72, df = 53 (P<0.00001); I2 =62%
Test for overall effect: Z = 13.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 3.10. Comparison 3 Parent-rated ADHD symptoms, Outcome 10 Subgroup analysis: all parallel-
group trials and first-period cross-over trials compared with cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 3 Parent-rated ADHD symptoms
Outcome: 10 Subgroup analysis: all parallel-group trials and first-period cross-over trials compared with cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All parallel-group trials and first-period cross-over trials
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 1.8 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 0.6 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 0.7 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 2.0 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 1.3 % -0.21 [ -0.82, 0.41 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 2.1 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 2.5 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 2.5 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 1.1 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 0.9 % -0.03 [ -0.81, 0.76 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 2.7 % -0.58 [ -0.82, -0.33 ]
Kollins 2006 (PATS) 61 1.09 (0.72) 53 1.41 (0.77) 2.1 % -0.43 [ -0.80, -0.06 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 1.8 % -0.91 [ -1.36, -0.46 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 2.5 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 1.7 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 1.1 % -0.72 [ -1.39, -0.04 ]
Taylor 1987 39 0.36 (0.42) 39 0.68 (0.64) 1.8 % -0.59 [ -1.04, -0.13 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 2.0 % -0.93 [ -1.32, -0.53 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 2.4 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 2.0 % -1.17 [ -1.56, -0.78 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 0.5 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 1278 937 36.1 % -0.66 [ -0.82, -0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.55, df = 20 (P = 0.00018); I2 =60%
Test for overall effect: Z = 8.52 (P < 0.00001)
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Cross-over trials (endpoint data)
Abikoff 2009 19 0.99 (0.55) 19 1.4 (0.63) 1.2 % -0.68 [ -1.33, -0.02 ]
Barkley 1991 40 14.53 (8.2) 40 24.88 (11.26) 1.7 % -1.04 [ -1.51, -0.57 ]
Barkley 2000 31 16.8 (9.7) 31 21.9 (12.5) 1.6 % -0.45 [ -0.95, 0.05 ]
Blum 2011 30 64.8 (26.5) 30 89.6 (13.1) 1.5 % -1.17 [ -1.72, -0.62 ]
Brams 2008 86 -16.382 (14.0495) 86 -4.62 (14.0495) 2.4 % -0.83 [ -1.15, -0.52 ]
Brown 1984a 11 11 (3.49) 11 19.55 (4.08) 0.6 % -2.17 [ -3.26, -1.07 ]
Brown 1988 11 36.5 (3.2) 11 39.66 (3.61) 0.8 % -0.89 [ -1.78, -0.01 ]
Chronis 2003 21 1.8 (1.5) 21 3.1 (1.9) 1.3 % -0.75 [ -1.37, -0.12 ]
Coghill 2007 75 67 (14.8) 75 77.2 (11.1) 2.3 % -0.78 [ -1.11, -0.44 ]
Cook 1993 15 0.41 (0.175) 15 0.59 (0.166) 1.0 % -1.03 [ -1.79, -0.26 ]
Corkum 2008 10 63.05 (13.89) 11 69.38 (10.23) 0.8 % -0.50 [ -1.37, 0.37 ]
DuPaul 1996 24 15.75 (9.76) 24 21 (9.28) 1.4 % -0.54 [ -1.12, 0.03 ]
Epstein 2011 93 19.6 (10.09) 93 28.26 (11.12) 2.4 % -0.81 [ -1.11, -0.51 ]
Findling 2007 20 20.81 (9.79) 20 32.19 (14.61) 1.2 % -0.90 [ -1.55, -0.24 ]
Fitzpatrick 1992a 19 0.96 (0.5) 19 1.75 (0.67) 1.1 % -1.31 [ -2.02, -0.60 ]
Flapper 2008 12 13 (11.707) 12 14.86 (10.669) 0.9 % -0.16 [ -0.96, 0.64 ]
Gadow 1990 11 8.3 (6.1) 11 11 (8.24) 0.8 % -0.36 [ -1.20, 0.49 ]
Gadow 1995 34 7.8 (4.6) 34 11.8 (7.3) 1.7 % -0.65 [ -1.14, -0.16 ]
Gadow 2007 71 7.8 (4.7) 71 11 (7) 2.3 % -0.53 [ -0.87, -0.20 ]
Gadow 2011 54 8.6 (5.6) 54 11.5 (7.7) 2.1 % -0.43 [ -0.81, -0.05 ]
Gorman 2006 41 0.72 (0.8324) 41 1.61 (0.8964) 1.8 % -1.02 [ -1.48, -0.56 ]
Grizenko 2012 198 56.76 (11.87) 198 61.64 (14.19) 2.9 % -0.37 [ -0.57, -0.17 ]
Hoeppner 1997 50 7.13 (6.37) 50 12.16 (6.78) 2.0 % -0.76 [ -1.17, -0.35 ]
Kollins 2006 (PATS) 142 1.09 (0.69) 165 1.47 (0.7) 2.7 % -0.55 [ -0.77, -0.32 ]
Manos 1999 117 10.1 (6.71) 117 18.61 (11.86) 2.6 % -0.88 [ -1.15, -0.61 ]
McBride 1988a 41 6.5 (3.9) 41 17.4 (6.4) 1.5 % -2.04 [ -2.58, -1.50 ]
McGough 2006 93 20.2 (20.3481) 93 35.3 (21.3125) 2.4 % -0.72 [ -1.02, -0.42 ]
Musten 1997 41 63.29 (13.44) 41 77.23 (14.1) 1.8 % -1.00 [ -1.46, -0.54 ]
Pearson 2013 24 55.8 (9.3) 24 66.8 (12.7) 1.3 % -0.97 [ -1.57, -0.37 ]
Pelham 1999 25 1.7 (1.5) 25 3 (2.7) 1.4 % -0.59 [ -1.15, -0.02 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 2001a 68 11.41 (6.23) 68 19.91 (6.02) 2.1 % -1.38 [ -1.75, -1.00 ]
Pelham 2005 30 2.7 (2.2) 30 5.5 (3.8) 1.5 % -0.89 [ -1.42, -0.36 ]
Schachar 2008 18 -0.98 (2.14) 18 3.2 (2.82) 1.0 % -1.63 [ -2.40, -0.87 ]
Smithee 1998 26 0.8639 (0.4415) 26 1.14 (0.61022) 1.5 % -0.51 [ -1.07, 0.04 ]
Solanto 2009 30 56.96 (10.57) 30 65.8 (13.98) 1.6 % -0.70 [ -1.23, -0.18 ]
Stein 1996 25 5.5 (3.1) 25 6.3 (3.5) 1.5 % -0.24 [ -0.79, 0.32 ]
Stein 2011 93 20.27 (13.557) 101 29.12 (15.077) 2.5 % -0.61 [ -0.90, -0.33 ]
Tirosh 1993a 20 10.75 (2.9) 20 14 (4.8) 1.2 % -0.80 [ -1.45, -0.16 ]
Zeiner 1999 38 3.08 (3.7) 38 5.25 (5.01) 1.8 % -0.49 [ -0.94, -0.03 ]
Subtotal (95% CI) 1807 1839 63.9 % -0.79 [ -0.90, -0.67 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 88.64, df = 38 (P<0.00001); I2 =57%
Test for overall effect: Z = 13.71 (P < 0.00001)
Total (95% CI) 3085 2776 100.0 % -0.74 [ -0.83, -0.65 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 140.36, df = 59 (P<0.00001); I2 =58%
Test for overall effect: Z = 16.20 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.61, df = 1 (P = 0.20), I2 =38%
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Analysis 4.1. Comparison 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and
first-period cross-over trials, Outcome 1 Comparision of raters.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-over trials
Outcome: 1 Comparision of raters
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Teacher-rated
Arnold 2004 35 0.7 (0.7) 40 1.4 (0.9) 2.0 % -0.85 [ -1.33, -0.38 ]
Biederman 2003 63 16.3 (12.12) 71 31.3 (15.37) 2.4 % -1.07 [ -1.43, -0.71 ]
Brown 1985 (1) 10 15 (3.1) 10 20.6 (2.6) 0.7 % -1.87 [ -2.96, -0.78 ]
Butter 1983 10 30.47 (17.3) 10 42.7 (14.2) 0.9 % -0.74 [ -1.65, 0.17 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 2.3 % -1.02 [ -1.40, -0.64 ]
Findling 2006 120 4.3 (3.264) 39 7.7 (3.1157) 2.3 % -1.05 [ -1.43, -0.67 ]
Findling 2008 94 18.3 (17.44) 88 31.6 (20.07) 2.6 % -0.71 [ -1.01, -0.41 ]
Firestone 1981 18 8.9 (4.93) 13 11.77 (4.83) 1.3 % -0.57 [ -1.30, 0.16 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 1.0 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 2.8 % -0.47 [ -0.72, -0.22 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 1.9 % -0.33 [ -0.82, 0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 2.1 % -1.06 [ -1.52, -0.61 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 2.4 % -0.58 [ -0.96, -0.21 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 1.9 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 1.4 % -0.89 [ -1.56, -0.22 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 1.8 % -1.13 [ -1.65, -0.60 ]
Tourette’s Syndrome Study Group 2002 37 1.315 (6.13) 32 2.82 (6.13) 2.0 % -0.24 [ -0.72, 0.23 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 1.6 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 2.3 % -1.05 [ -1.44, -0.67 ]
Subtotal (95% CI) 914 775 35.8 % -0.78 [ -0.93, -0.63 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 34.54, df = 18 (P = 0.01); I2 =48%
Test for overall effect: Z = 10.30 (P < 0.00001)
2 Independent assessor-rated
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 2.7 % -1.18 [ -1.46, -0.89 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 2.6 % -0.72 [ -1.04, -0.41 ]
Findling 2008 91 -21.619 (14.409) 85 -10.3 (14.409) 2.6 % -0.78 [ -1.09, -0.48 ]
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 2.7 % -0.80 [ -1.10, -0.51 ]
Gonzalez-Heydrich 2010 28 23 (12) 28 30 (10) 1.8 % -0.62 [ -1.16, -0.09 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 2.8 % -0.35 [ -0.61, -0.08 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 2.8 % -0.75 [ -1.02, -0.48 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 2.9 % 0.04 [ -0.18, 0.27 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 2.7 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 1029 800 23.5 % -0.61 [ -0.87, -0.35 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 56.91, df = 8 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.57 (P < 0.00001)
3 Parent-rated
Arnold 2004 35 0.8 (0.7) 40 1.3 (0.9) 2.0 % -0.61 [ -1.07, -0.14 ]
Brown 1985 10 7.5 (2.6) 10 13.1 (4.1) 0.8 % -1.56 [ -2.59, -0.53 ]
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 0.9 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 19.6 (12.75) 63 35.9 (13.01) 2.3 % -1.26 [ -1.65, -0.86 ]
Duric 2012 22 23.7 (15.153) 19 26.7 (13.02) 1.5 % -0.21 [ -0.82, 0.41 ]
Findling 2006 120 5.1 (2.9321) 39 8.1 (3.0232) 2.3 % -1.01 [ -1.39, -0.63 ]
Findling 2008 94 28.4 (21.07) 88 37 (23.39) 2.7 % -0.39 [ -0.68, -0.09 ]
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 2.7 % -0.76 [ -1.05, -0.47 ]
Firestone 1981 18 13.5 (7.26) 13 14.9 (6.58) 1.3 % -0.20 [ -0.91, 0.52 ]
Ialongo 1994 13 9.76 (5.94) 12 9.9 (4.28) 1.2 % -0.03 [ -0.81, 0.76 ]
Jensen 1999 (MTA) 133 0.85 (0.63) 129 1.24 (0.72) 2.8 % -0.58 [ -0.82, -0.33 ]
Kollins 2006 (PATS) 48 1.09 (0.72) 38 1.41 (0.77) 2.1 % -0.43 [ -0.86, 0.00 ]
Lehmkuhl 2002 43 1.1 (0.6557) 42 1.7 (0.6481) 2.1 % -0.91 [ -1.36, -0.46 ]
Newcorn 2008 195 -10.2 (9.1) 66 -2.3 (8.4) 2.7 % -0.88 [ -1.17, -0.59 ]
Schachar 1997a 37 1.2 (0.7) 29 1.3 (0.7) 1.9 % -0.14 [ -0.63, 0.35 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 1.4 % -0.72 [ -1.39, -0.04 ]
Tourette’s Syndrome Study Group 2002 37 2.85 (7.08) 32 6 (7.01) 2.0 % -0.44 [ -0.92, 0.04 ]
Tucker 2009 53 -8.2 (6.05) 56 -3.2 (4.6) 2.3 % -0.93 [ -1.32, -0.53 ]
Wilens 2006b 87 16.65 (11.07) 90 20.84 (13.58) 2.7 % -0.34 [ -0.63, -0.04 ]
Wolraich 2001 81 5.44 (3.22) 46 9.48 (3.78) 2.3 % -1.17 [ -1.56, -0.78 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zeni 2009 9 1.2789 (0.45518) 7 1.75 (0.90373) 0.8 % -0.65 [ -1.68, 0.37 ]
Subtotal (95% CI) 1263 916 40.7 % -0.65 [ -0.81, -0.50 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 50.49, df = 20 (P = 0.00019); I2 =60%
Test for overall effect: Z = 8.31 (P < 0.00001)
Total (95% CI) 3206 2491 100.0 % -0.69 [ -0.79, -0.59 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 149.62, df = 48 (P<0.00001); I2 =68%
Test for overall effect: Z = 13.01 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.00, df = 2 (P = 0.37), I2 =0%
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Analysis 4.2. Comparison 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and
first-period cross-over trials, Outcome 2 Age.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-over trials
Outcome: 2 Age
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 2 to 6 years
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 14.1 % -0.33 [ -0.82, 0.17 ]
Subtotal (95% CI) 32 32 14.1 % -0.33 [ -0.82, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 7 to 11 years
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 8.1 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 134 0.75 (0.71) 119 1.1 (0.77) 19.8 % -0.47 [ -0.72, -0.22 ]
Subtotal (95% CI) 147 131 27.9 % -0.59 [ -1.03, -0.15 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.63 (P = 0.0084)
3 12 to 18 years
Findling 2010 145 17.7 (12.2) 72 27.7 (12.75) 18.8 % -0.80 [ -1.10, -0.51 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 20.4 % 0.04 [ -0.18, 0.27 ]
Wilens 2006b 87 16.62 (11.03) 90 21.4 (13.44) 18.7 % -0.39 [ -0.68, -0.09 ]
Subtotal (95% CI) 383 314 57.9 % -0.38 [ -0.88, 0.12 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 20.59, df = 2 (P = 0.00003); I2 =90%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 562 477 100.0 % -0.44 [ -0.74, -0.14 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 24.24, df = 5 (P = 0.00020); I2 =79%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Chi2 = 0.71, df = 2 (P = 0.70), I2 =0.0%
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Analysis 4.3. Comparison 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and
first-period cross-over trials, Outcome 3 Comorbidity versus no comorbidity.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-over trials
Outcome: 3 Comorbidity versus no comorbidity
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ADHD with comorbidity
Carlson 2007 9 -3.3 (20.9) 8 -4.3 (5.2) 2.6 % 0.06 [ -0.89, 1.01 ]
Childress 2009 57 16.4 (13.44) 63 30 (13.01) 5.7 % -1.02 [ -1.40, -0.64 ]
Coghill 2013 111 3.5295 (10.9979) 110 16.53 (10.9979) 6.3 % -1.18 [ -1.46, -0.89 ]
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 6.1 % -0.72 [ -1.04, -0.41 ]
Ialongo 1994 13 7.53 (7.41) 12 15.25 (7.27) 3.0 % -1.02 [ -1.86, -0.17 ]
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 6.5 % -0.35 [ -0.61, -0.08 ]
Kollins 2006 (PATS) 32 1.09 (0.8) 32 1.35 (0.77) 4.9 % -0.33 [ -0.82, 0.17 ]
Lehmkuhl 2002 43 0.9 (0.6557) 42 1.6 (0.6481) 5.2 % -1.06 [ -1.52, -0.61 ]
Newcorn 2008 220 -16.9 (13.1) 74 -7.3 (11.5) 6.4 % -0.75 [ -1.02, -0.48 ]
Palumbo 2008 29 -5.07 (6.79) 30 -3.2 (6.38) 4.8 % -0.28 [ -0.79, 0.23 ]
Pliszka 2000 20 0.81 (0.62) 18 1.49 (0.87) 3.9 % -0.89 [ -1.56, -0.22 ]
Riggs 2011 151 17 (14.3038) 152 16.4 (14.3518) 6.7 % 0.04 [ -0.18, 0.27 ]
Schachar 1997a 37 0.9 (0.7) 29 1.7 (0.7) 4.7 % -1.13 [ -1.65, -0.60 ]
Szobot 2004 19 11.9 (6.1) 17 16.4 (6.2) 3.8 % -0.72 [ -1.39, -0.04 ]
Taylor 1987 39 0.58 (0.41) 39 1.17 (0.78) 5.1 % -0.94 [ -1.41, -0.47 ]
Van der Meere 1999a 24 73.6 (12.7133) 24 83.1 (12.7133) 4.3 % -0.73 [ -1.32, -0.15 ]
Wolraich 2001 81 5.7 (3.84) 46 9.87 (4.09) 5.7 % -1.05 [ -1.44, -0.67 ]
Zeni 2009 9 1.2022 (0.65764) 6 1.93 (0.69847) 2.1 % -1.02 [ -2.14, 0.10 ]
Subtotal (95% CI) 1090 891 88.0 % -0.72 [ -0.94, -0.51 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 78.37, df = 17 (P<0.00001); I2 =78%
Test for overall effect: Z = 6.54 (P < 0.00001)
2 ADHD without comorbidity
Findling 2010 143 36.52 (17.6537) 72 50 (17.6537) 6.3 % -0.76 [ -1.05, -0.47 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 5.7 % -0.58 [ -0.96, -0.21 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 200 129 12.0 % -0.69 [ -0.92, -0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 5.89 (P < 0.00001)
Total (95% CI) 1290 1020 100.0 % -0.72 [ -0.91, -0.53 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 79.07, df = 19 (P<0.00001); I2 =76%
Test for overall effect: Z = 7.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 4.4. Comparison 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and
first-period cross-over trials, Outcome 4 Subtypes ADHD: ADHD Rating Scale (parent-, teacher- or
independent assessor-rated).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-over trials
Outcome: 4 Subtypes ADHD: ADHD Rating Scale (parent-, teacher- or independent assessor-rated)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combined ADHD
Jensen 1999 (MTA) 114 0.21 (0.2) 107 0.29 (0.26) 50.0 % -0.35 [ -0.61, -0.08 ]
Riggs 2011 169 18.9 (1.3) 169 16.5 (1.6) 50.0 % 1.64 [ 1.40, 1.89 ]
Subtotal (95% CI) 283 276 100.0 % 0.65 [ -1.30, 2.60 ]
Heterogeneity: Tau2 = 1.96; Chi2 = 115.32, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.65 (P = 0.51)
2 Inattentive ADHD
Riggs 2011 102 16.8 (1.7) 102 19.1 (1.8) 100.0 % -1.31 [ -1.61, -1.01 ]
Subtotal (95% CI) 102 102 100.0 % -1.31 [ -1.61, -1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.79, df = 1 (P = 0.05), I2 =74%
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Analysis 4.5. Comparison 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and
first-period cross-over trials, Outcome 5 Cross-over trials: first-period data versus endpoint data (parent-,
independent assessor- and teacher-rated).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 4 Additional subgroup analyses of ADHD symptoms: parallel-group trials and first-period cross-over trials
Outcome: 5 Cross-over trials: first-period data versus endpoint data (parent-, independent assessor- and teacher-rated)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 First-period data
Do¨pfner 2004 82 0.441 (0.427) 82 0.86 (0.689) 43.6 % -0.72 [ -1.04, -0.41 ]
Moshe 2012 57 58 (10.3) 57 64.7 (12.5) 31.0 % -0.58 [ -0.96, -0.21 ]
Taylor 1987 39 0.54 (1.04) 39 1.22 (1.3) 21.2 % -0.57 [ -1.03, -0.12 ]
Zeni 2009 9 1.2789 (0.45518) 7 1.75 (0.90373) 4.2 % -0.65 [ -1.68, 0.37 ]
Subtotal (95% CI) 187 185 100.0 % -0.64 [ -0.85, -0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 6.05 (P < 0.00001)
2 Endpoint data
Do¨pfner 2004 82 0.374 (0.366) 82 1.08 (0.751) 37.7 % -1.19 [ -1.52, -0.86 ]
Moshe 2012 57 55.5 (9.5) 57 62.1 (7.9) 31.8 % -0.75 [ -1.13, -0.37 ]
Taylor 1987 39 0.85 (1) 39 1.59 (1.04) 24.5 % -0.72 [ -1.18, -0.26 ]
Zeni 2009 9 0.8911 (0.72428) 7 1.7 (1.0996) 6.0 % -0.85 [ -1.89, 0.20 ]
Subtotal (95% CI) 187 185 100.0 % -0.91 [ -1.18, -0.65 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 4.07, df = 3 (P = 0.25); I2 =26%
Test for overall effect: Z = 6.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.47, df = 1 (P = 0.12), I2 =60%
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Analysis 5.1. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 1 Number of serious adverse events (SAE).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 1 Number of serious adverse events (SAE)
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Carlson 2007 1/87 0/90 6.5 % 3.10 [ 0.13, 75.14 ]
Childress 2009 1/182 0/63 6.5 % 1.05 [ 0.04, 25.43 ]
Coghill 2013 2/110 3/111 21.1 % 0.67 [ 0.11, 3.95 ]
Findling 2010 3/145 0/72 7.6 % 3.50 [ 0.18, 66.86 ]
Jacobi-Polishook 2009 0/12 0/12 Not estimable
Lehmkuhl 2002 1/43 0/42 6.6 % 2.93 [ 0.12, 70.00 ]
Palumbo 2008 1/29 0/30 6.6 % 3.10 [ 0.13, 73.14 ]
Riggs 2011 4/151 7/152 45.2 % 0.58 [ 0.17, 1.92 ]
Wolraich 2001 0/160 0/41 Not estimable
Total (95% CI) 919 613 100.0 % 0.98 [ 0.44, 2.22 ]
Total events: 13 (Methylphenidate), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.11, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 2 Nervous system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 2 Nervous system
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Aggression
Riggs 2011 1/151 2/152 20.0 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 151 152 20.0 % 0.50 [ 0.05, 5.49 ]
Total events: 1 (Methylphenidate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
2 Concussion
Riggs 2011 0/151 1/152 11.2 % 0.34 [ 0.01, 8.17 ]
Subtotal (95% CI) 151 152 11.2 % 0.34 [ 0.01, 8.17 ]
Total events: 0 (Methylphenidate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 Loss of consciousness
Coghill 2013 0/111 1/110 11.2 % 0.33 [ 0.01, 8.02 ]
Subtotal (95% CI) 111 110 11.2 % 0.33 [ 0.01, 8.02 ]
Total events: 0 (Methylphenidate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 Psychosis
Childress 2009 1/188 0/65 11.3 % 1.05 [ 0.04, 25.40 ]
Green 2011 0/22 0/12 Not estimable
Palumbo 2008 0/61 0/61 Not estimable
Riggs 2011 1/151 0/152 11.2 % 3.02 [ 0.12, 73.54 ]
Subtotal (95% CI) 422 290 22.5 % 1.78 [ 0.19, 16.96 ]
Total events: 2 (Methylphenidate), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
5 Syncope
Coghill 2013 1/111 0/110 11.2 % 2.97 [ 0.12, 72.20 ]
Findling 2010 (1) 2/145 0/72 12.5 % 2.50 [ 0.12, 51.40 ]
Riggs 2011 0/151 1/152 11.2 % 0.34 [ 0.01, 8.17 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 407 334 35.0 % 1.39 [ 0.23, 8.47 ]
Total events: 3 (Methylphenidate), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 1242 1038 100.0 % 0.87 [ 0.30, 2.53 ]
Total events: 6 (Methylphenidate), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.87, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Chi2 = 1.54, df = 4 (P = 0.82), I2 =0.0%
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Analysis 5.3. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 3 Digestive system: gastrointestinal disorders.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 3 Digestive system: gastrointestinal disorders
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Coghill 2013 0/111 0/110 Not estimable
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 4 Urinary system: kidney infection.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 4 Urinary system: kidney infection
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Riggs 2011 1/151 0/152 3.02 [ 0.12, 73.54 ]
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 5 Circulatory and respiratory systems: asthma.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 5 Circulatory and respiratory systems: asthma
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Riggs 2011 0/151 1/152 0.34 [ 0.01, 8.17 ]
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 6 Immune system: cyst rupture.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 6 Immune system: cyst rupture
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Riggs 2011 1/151 0/152 3.02 [ 0.12, 73.54 ]
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Number of serious adverse events: parallel-group trials and first-period cross-
over trials, Outcome 7 Other: drug toxicity.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 5 Number of serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 7 Other: drug toxicity
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Riggs 2011 0/151 1/152 100.0 % 0.34 [ 0.01, 8.17 ]
Total (95% CI) 151 152 100.0 % 0.34 [ 0.01, 8.17 ]
Total events: 0 (Methylphenidate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Number of serious adverse events: cross-over trials (endpoint data), Outcome 1
Number of serious adverse events (SAE).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 6 Number of serious adverse events: cross-over trials (endpoint data)
Outcome: 1 Number of serious adverse events (SAE)
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Brams 2008 0/86 0/86 Not estimable
Brams 2012 2/163 0/159 26.5 % 4.88 [ 0.24, 100.82 ]
Buitelaar 1995 1/26 0/11 24.8 % 1.33 [ 0.06, 30.42 ]
Cox 2006 0/35 0/35 Not estimable
Grizenko 2012 0/430 0/430 Not estimable
Schachar 2008 0/18 1/18 24.7 % 0.33 [ 0.01, 7.68 ]
Silva 2008 1/68 0/68 24.0 % 3.00 [ 0.12, 72.37 ]
Wigal 2013 0/44 0/44 Not estimable
Total (95% CI) 870 851 100.0 % 1.62 [ 0.34, 7.71 ]
Total events: 4 (Methylphenidate), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Number of serious adverse events: cross-over trials (endpoint data), Outcome 2
Hallucinations/psychosis.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 6 Number of serious adverse events: cross-over trials (endpoint data)
Outcome: 2 Hallucinations/psychosis
Study or subgroup Methylphenidate Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Buitelaar 1995 1/26 0/11 33.5 % 1.33 [ 0.06, 30.42 ]
Pelham 1999 1/21 0/21 33.1 % 3.00 [ 0.13, 69.70 ]
Pelham 2005 0/36 0/36 Not estimable
Schachar 2008 0/18 1/18 33.3 % 0.33 [ 0.01, 7.68 ]
Total (95% CI) 101 86 100.0 % 1.10 [ 0.18, 6.72 ]
Total events: 2 (Methylphenidate), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 1 Total number of non-serious adverse events.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 1 Total number of non-serious adverse events
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Biederman 2003 5/65 4/71 1.3 % 1.37 [ 0.38, 4.87 ]
Carlson 2007 5/9 5/8 2.7 % 0.89 [ 0.40, 1.97 ]
Childress 2009 116/182 36/63 7.2 % 1.12 [ 0.88, 1.42 ]
Coghill 2013 72/111 63/110 7.5 % 1.13 [ 0.92, 1.40 ]
Findling 2006 71/133 38/46 7.6 % 0.65 [ 0.53, 0.79 ]
Findling 2008 63/91 49/85 7.3 % 1.20 [ 0.96, 1.51 ]
Findling 2010 112/145 40/70 7.4 % 1.35 [ 1.08, 1.69 ]
Greenhill 2002 80/155 61/161 7.1 % 1.36 [ 1.06, 1.75 ]
Greenhill 2006 40/53 27/47 6.7 % 1.31 [ 0.98, 1.76 ]
Jacobi-Polishook 2009 0/12 0/12 Not estimable
Lehmkuhl 2002 18/43 10/42 3.5 % 1.76 [ 0.92, 3.35 ]
Newcorn 2008 146/219 40/74 7.3 % 1.23 [ 0.98, 1.55 ]
Palumbo 2008 17/29 12/30 4.3 % 1.47 [ 0.86, 2.50 ]
Pliszka 2000 10/20 5/17 2.4 % 1.70 [ 0.72, 4.01 ]
Riggs 2011 70/151 64/152 7.1 % 1.10 [ 0.85, 1.42 ]
Tourette’s Syndrome Study Group 2002 4/37 2/33 0.8 % 1.78 [ 0.35, 9.12 ]
Tucker 2009 47/53 15/56 5.1 % 3.31 [ 2.12, 5.16 ]
Wigal 2004 80/90 21/42 6.5 % 1.78 [ 1.30, 2.43 ]
Wilens 2006b 14/87 12/90 3.1 % 1.21 [ 0.59, 2.46 ]
Wolraich 2001 56/160 10/46 3.9 % 1.61 [ 0.89, 2.90 ]
Zeni 2009 2/16 4/16 0.9 % 0.50 [ 0.11, 2.35 ]
Total (95% CI) 1861 1271 100.0 % 1.29 [ 1.10, 1.51 ]
Total events: 1028 (Methylphenidate), 518 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 69.75, df = 19 (P<0.00001); I2 =73%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 2 Subgroup analysis: total number of non-serious adverse events according to dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 2 Subgroup analysis: total number of non-serious adverse events according to dose
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Low dose
Childress 2009 40/64 36/63 6.4 % 1.09 [ 0.82, 1.46 ]
Jacobi-Polishook 2009 0/12 0/12 Not estimable
Subtotal (95% CI) 76 75 6.4 % 1.09 [ 0.82, 1.46 ]
Total events: 40 (Methylphenidate), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 High dose
Carlson 2007 5/9 5/8 2.5 % 0.89 [ 0.40, 1.97 ]
Childress 2009 41/58 36/63 6.5 % 1.24 [ 0.94, 1.62 ]
Coghill 2013 72/111 63/110 7.1 % 1.13 [ 0.92, 1.40 ]
Greenhill 2002 80/155 61/161 6.7 % 1.36 [ 1.06, 1.75 ]
Newcorn 2008 146/219 40/74 6.9 % 1.23 [ 0.98, 1.55 ]
Pliszka 2000 10/20 5/17 2.2 % 1.70 [ 0.72, 4.01 ]
Riggs 2011 70/151 64/152 6.7 % 1.10 [ 0.85, 1.42 ]
Tourette’s Syndrome Study Group 2002 4/37 2/33 0.8 % 1.78 [ 0.35, 9.12 ]
Wilens 2006b 14/87 12/90 2.9 % 1.21 [ 0.59, 2.46 ]
Wolraich 2001 56/160 10/46 3.6 % 1.61 [ 0.89, 2.90 ]
Subtotal (95% CI) 1007 754 46.0 % 1.22 [ 1.10, 1.35 ]
Total events: 498 (Methylphenidate), 298 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.12, df = 9 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
3 Unknown dose
Biederman 2003 5/65 4/71 1.2 % 1.37 [ 0.38, 4.87 ]
Findling 2006 71/133 38/46 7.2 % 0.65 [ 0.53, 0.79 ]
Findling 2008 63/91 49/85 7.0 % 1.20 [ 0.96, 1.51 ]
Findling 2010 112/145 40/70 7.0 % 1.35 [ 1.08, 1.69 ]
Greenhill 2006 40/53 27/47 6.3 % 1.31 [ 0.98, 1.76 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lehmkuhl 2002 18/43 10/42 3.2 % 1.76 [ 0.92, 3.35 ]
Palumbo 2008 17/29 12/30 4.0 % 1.47 [ 0.86, 2.50 ]
Tucker 2009 47/53 15/56 4.8 % 3.31 [ 2.12, 5.16 ]
Wigal 2004 80/90 21/42 6.1 % 1.78 [ 1.30, 2.43 ]
Zeni 2009 2/16 4/16 0.8 % 0.50 [ 0.11, 2.35 ]
Subtotal (95% CI) 718 505 47.7 % 1.37 [ 1.01, 1.87 ]
Total events: 455 (Methylphenidate), 220 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 65.25, df = 9 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.00 (P = 0.046)
Total (95% CI) 1801 1334 100.0 % 1.28 [ 1.11, 1.49 ]
Total events: 993 (Methylphenidate), 554 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 69.85, df = 20 (P<0.00001); I2 =71%
Test for overall effect: Z = 3.30 (P = 0.00098)
Test for subgroup differences: Chi2 = 1.11, df = 2 (P = 0.57), I2 =0.0%
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Analysis 7.3. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 3 Nervous system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 3 Nervous system
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Affective
Findling 2008 91 85 1.9114 (1.5194) 18.9 % 6.76 [ 0.34, 132.87 ]
Greenhill 2006 53 47 1.5286 (1.5622) 18.2 % 4.61 [ 0.22, 98.54 ]
Lin 2014 36 78 2.368 (1.5363) 18.6 % 10.68 [ 0.53, 216.83 ]
Schachar 1997a 0 0 -0.4716 (0.521) 44.2 % 0.62 [ 0.22, 1.73 ]
Subtotal (95% CI) 180 210 100.0 % 2.39 [ 0.48, 11.96 ]
Heterogeneity: Tau2 = 1.25; Chi2 = 5.63, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Aggression
Lin 2014 36 78 1.4663 (1.2081) 35.3 % 4.33 [ 0.41, 46.25 ]
Riggs 2011 151 152 -0.5672 (0.4902) 64.7 % 0.57 [ 0.22, 1.48 ]
Subtotal (95% CI) 187 230 100.0 % 1.16 [ 0.17, 7.80 ]
Heterogeneity: Tau2 = 1.22; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Apathy
Palumbo 2008 29 30 -0.2231 (0.728) 100.0 % 0.80 [ 0.19, 3.33 ]
Subtotal (95% CI) 29 30 100.0 % 0.80 [ 0.19, 3.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
4 Confusion
Childress 2009 182 63 -1.0821 (1.0109) 34.1 % 0.34 [ 0.05, 2.46 ]
Riggs 2011 151 152 0.5773 (0.3849) 65.9 % 1.78 [ 0.84, 3.79 ]
Subtotal (95% CI) 333 215 100.0 % 1.01 [ 0.22, 4.73 ]
Heterogeneity: Tau2 = 0.79; Chi2 = 2.35, df = 1 (P = 0.13); I2 =58%
Test for overall effect: Z = 0.01 (P = 0.99)
5 Depression
Palumbo 2008 29 30 -0.1823 (0.6708) 100.0 % 0.83 [ 0.22, 3.10 ]
Subtotal (95% CI) 29 30 100.0 % 0.83 [ 0.22, 3.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
6 Dizziness
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Childress 2009 182 63 0.5604 (1.1053) 34.8 % 1.75 [ 0.20, 15.28 ]
Coghill 2013 111 110 0.6931 (1.2322) 28.0 % 2.00 [ 0.18, 22.38 ]
Findling 2010 145 72 1.4221 (1.0707) 37.1 % 4.15 [ 0.51, 33.81 ]
Subtotal (95% CI) 438 245 100.0 % 2.50 [ 0.70, 8.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
7 Drowsiness
Greenhill 2002 155 161 0.2723 (0.2508) 81.3 % 1.31 [ 0.80, 2.15 ]
Newcorn 2008 219 74 -0.8203 (0.7759) 8.5 % 0.44 [ 0.10, 2.01 ]
Tourette’s Syndrome Study Group 2002 37 33 0.7196 (0.8827) 6.6 % 2.05 [ 0.36, 11.58 ]
Wigal 2004 90 42 1.0986 (1.1756) 3.7 % 3.00 [ 0.30, 30.05 ]
Subtotal (95% CI) 501 310 100.0 % 1.27 [ 0.82, 1.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.71, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
8 Emotional lability
Wigal 2004 90 42 0.8804 (1.1118) 100.0 % 2.41 [ 0.27, 21.32 ]
Subtotal (95% CI) 90 42 100.0 % 2.41 [ 0.27, 21.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
9 Fatigue
Childress 2009 182 63 -0.3778 (0.8786) 14.9 % 0.69 [ 0.12, 3.84 ]
Coghill 2013 0 0 -1.1263 (1.1627) 9.5 % 0.32 [ 0.03, 3.17 ]
Greenhill 2006 53 47 -0.1252 (1.0207) 11.8 % 0.88 [ 0.12, 6.52 ]
Lin 2014 36 78 1.0609 (0.7367) 19.3 % 2.89 [ 0.68, 12.24 ]
Palumbo 2008 29 30 -2.0161 (1.5349) 5.8 % 0.13 [ 0.01, 2.70 ]
Pliszka 2000 20 17 0.6286 (0.9376) 13.5 % 1.87 [ 0.30, 11.78 ]
Riggs 2011 151 152 -1.0533 (0.5957) 25.4 % 0.35 [ 0.11, 1.12 ]
Subtotal (95% CI) 471 387 100.0 % 0.76 [ 0.36, 1.63 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 7.78, df = 6 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.70 (P = 0.48)
10 Headache
Biederman 2003 65 71 -0.6179 (1.237) 1.5 % 0.54 [ 0.05, 6.09 ]
Carlson 2007 9 8 -1.9889 (1.6307) 0.9 % 0.14 [ 0.01, 3.34 ]
Childress 2009 182 63 -0.0562 (0.4415) 8.6 % 0.95 [ 0.40, 2.25 ]
Coghill 2013 111 110 -0.0113 (0.3369) 12.2 % 0.99 [ 0.51, 1.91 ]
Findling 2006 133 46 1.2365 (0.7661) 3.6 % 3.44 [ 0.77, 15.46 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Findling 2010 109 53 -0.4599 (0.4983) 7.2 % 0.63 [ 0.24, 1.68 ]
Greenhill 2002 155 161 0.3893 (0.3418) 12.0 % 1.48 [ 0.76, 2.88 ]
Greenhill 2006 53 47 1.0043 (0.5707) 5.9 % 2.73 [ 0.89, 8.35 ]
Newcorn 2008 219 74 0.2098 (0.4505) 8.4 % 1.23 [ 0.51, 2.98 ]
Palumbo 2008 29 30 -1.135 (1.1858) 1.6 % 0.32 [ 0.03, 3.28 ]
Pliszka 2000 20 17 -1.257 (1.665) 0.8 % 0.28 [ 0.01, 7.44 ]
Riggs 2011 151 152 0.1725 (0.2316) 17.6 % 1.19 [ 0.75, 1.87 ]
Tucker 2009 53 56 2.2713 (0.7846) 3.4 % 9.69 [ 2.08, 45.11 ]
Wigal 2004 90 42 0.794 (0.5906) 5.5 % 2.21 [ 0.70, 7.04 ]
Wilens 2006b 87 90 -0.6931 (0.7237) 3.9 % 0.50 [ 0.12, 2.07 ]
Wolraich 2001 160 46 -0.0931 (0.5421) 6.3 % 0.91 [ 0.31, 2.64 ]
Zeni 2009 16 16 0.7075 (2.0897) 0.5 % 2.03 [ 0.03, 121.90 ]
Subtotal (95% CI) 1642 1082 100.0 % 1.22 [ 0.90, 1.64 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 20.74, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 1.26 (P = 0.21)
11 Insomnia
Findling 2008 91 85 0.5232 (0.6458) 37.2 % 1.69 [ 0.48, 5.98 ]
Lin 2014 36 78 1.1097 (0.5498) 41.0 % 3.03 [ 1.03, 8.91 ]
Palumbo 2008 29 30 -1.7228 (1.1295) 21.8 % 0.18 [ 0.02, 1.63 ]
Subtotal (95% CI) 156 193 100.0 % 1.31 [ 0.35, 4.93 ]
Heterogeneity: Tau2 = 0.81; Chi2 = 5.09, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.40 (P = 0.69)
12 Irritability
Carlson 2007 9 12 -0.9076 (1.6908) 1.2 % 0.40 [ 0.01, 11.09 ]
Childress 2009 182 63 1.1637 (1.4979) 1.5 % 3.20 [ 0.17, 60.31 ]
Coghill 2013 111 110 2.2247 (1.4969) 1.5 % 9.25 [ 0.49, 173.92 ]
Findling 2006 133 46 0.5641 (1.1091) 2.8 % 1.76 [ 0.20, 15.45 ]
Findling 2010 109 53 -0.3374 (0.6684) 7.6 % 0.71 [ 0.19, 2.64 ]
Greenhill 2002 155 161 -0.1569 (0.2256) 66.9 % 0.85 [ 0.55, 1.33 ]
Greenhill 2006 53 47 0.59 (1.2415) 2.2 % 1.80 [ 0.16, 20.56 ]
Lin 2014 36 78 1.1787 (0.6132) 9.1 % 3.25 [ 0.98, 10.81 ]
Newcorn 2008 219 74 1.5275 (1.0466) 3.1 % 4.61 [ 0.59, 35.83 ]
Pliszka 2000 20 18 0.3448 (0.9771) 3.6 % 1.41 [ 0.21, 9.58 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Zeni 2009 16 16 0.1995 (2.382) 0.6 % 1.22 [ 0.01, 130.08 ]
Subtotal (95% CI) 1043 678 100.0 % 1.11 [ 0.77, 1.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.95, df = 10 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
13 Nervousness
Palumbo 2008 29 30 0.3032 (0.7281) 46.3 % 1.35 [ 0.33, 5.64 ]
Riggs 2011 151 152 1.4558 (0.6562) 53.7 % 4.29 [ 1.18, 15.52 ]
Subtotal (95% CI) 180 182 100.0 % 2.52 [ 0.82, 7.76 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.61 (P = 0.11)
14 Pain
Wigal 2004 90 42 0.6455 (1.134) 100.0 % 1.91 [ 0.21, 17.60 ]
Subtotal (95% CI) 90 42 100.0 % 1.91 [ 0.21, 17.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
15 Picking at skin or fingers, nail biting, lip or cheek chewing
Greenhill 2002 155 161 0.0148 (0.2645) 100.0 % 1.01 [ 0.60, 1.70 ]
Subtotal (95% CI) 155 161 100.0 % 1.01 [ 0.60, 1.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
16 Sad, tearful or depressed
Childress 2009 182 63 0.5647 (1.556) 2.6 % 1.76 [ 0.08, 37.13 ]
Greenhill 2002 155 161 0.284 (0.2585) 93.0 % 1.33 [ 0.80, 2.20 ]
Lin 2014 36 78 2.368 (1.5363) 2.6 % 10.68 [ 0.53, 216.83 ]
Zeni 2009 16 16 0.0219 (1.873) 1.8 % 1.02 [ 0.03, 40.16 ]
Subtotal (95% CI) 389 318 100.0 % 1.41 [ 0.86, 2.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
17 Somnolence
Lin 2014 36 78 -1.6394 (1.4636) 33.4 % 0.19 [ 0.01, 3.42 ]
Palumbo 2008 29 30 0.0364 (1.0357) 66.6 % 1.04 [ 0.14, 7.90 ]
Subtotal (95% CI) 65 108 100.0 % 0.59 [ 0.11, 3.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
18 Trouble sleeping or sleep problems
Biederman 2003 65 71 1.7281 (1.5588) 1.2 % 5.63 [ 0.27, 119.50 ]
Carlson 2007 9 12 -0.9076 (1.6908) 1.0 % 0.40 [ 0.01, 11.09 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Childress 2009 182 63 1.2082 (0.7603) 4.9 % 3.35 [ 0.75, 14.86 ]
Coghill 2013 111 110 3.0196 (1.4574) 1.3 % 20.48 [ 1.18, 356.40 ]
Findling 2006 133 46 1.3814 (1.487) 1.3 % 3.98 [ 0.22, 73.40 ]
Findling 2008 91 85 0.5232 (0.6458) 6.8 % 1.69 [ 0.48, 5.98 ]
Findling 2010 145 72 -0.0072 (0.7223) 5.5 % 0.99 [ 0.24, 4.09 ]
Greenhill 2002 155 161 0.4327 (0.2529) 44.6 % 1.54 [ 0.94, 2.53 ]
Greenhill 2006 53 47 0.1801 (0.7915) 4.6 % 1.20 [ 0.25, 5.65 ]
Newcorn 2008 219 74 1.8154 (1.038) 2.6 % 6.14 [ 0.80, 46.99 ]
Riggs 2011 151 152 0.1845 (0.344) 24.1 % 1.20 [ 0.61, 2.36 ]
Wilens 2006b 87 90 2.278 (1.498) 1.3 % 9.76 [ 0.52, 183.83 ]
Zeni 2009 16 16 -2.304 (2.035) 0.7 % 0.10 [ 0.00, 5.39 ]
Subtotal (95% CI) 1417 999 100.0 % 1.60 [ 1.15, 2.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.98, df = 12 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0052)
19 Tics or nervous movements
Coghill 2013 111 110 0.4055 (0.923) 15.0 % 1.50 [ 0.25, 9.16 ]
Findling 2006 133 46 -2.7081 (1.5588) 9.1 % 0.07 [ 0.00, 1.41 ]
Findling 2008 91 85 1.0418 (1.6399) 8.5 % 2.83 [ 0.11, 70.52 ]
Greenhill 2002 155 161 0.3791 (0.4789) 20.1 % 1.46 [ 0.57, 3.73 ]
Pliszka 2000 19 16 -1.3282 (1.6681) 8.4 % 0.26 [ 0.01, 6.97 ]
Schachar 1997a 37 29 1.554 (0.2474) 22.1 % 4.73 [ 2.91, 7.68 ]
Wolraich 2001 160 46 -2.7175 (1.1314) 12.7 % 0.07 [ 0.01, 0.61 ]
Zeni 2009 16 16 -0.6349 (2.7003) 4.1 % 0.53 [ 0.00, 105.38 ]
Subtotal (95% CI) 722 509 100.0 % 0.85 [ 0.26, 2.79 ]
Heterogeneity: Tau2 = 1.59; Chi2 = 25.88, df = 7 (P = 0.00053); I2 =73%
Test for overall effect: Z = 0.26 (P = 0.79)
20 Worried or anxious
Childress 2009 182 63 0.9068 (1.5189) 2.8 % 2.48 [ 0.13, 48.61 ]
Greenhill 2002 155 161 0.284 (0.2585) 95.0 % 1.33 [ 0.80, 2.20 ]
Pliszka 2000 19 16 0.9842 (1.6677) 2.3 % 2.68 [ 0.10, 70.30 ]
Subtotal (95% CI) 356 240 100.0 % 1.37 [ 0.84, 2.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 10.92, df = 19 (P = 0.93), I2 =0.0%
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Analysis 7.4. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 4 Digestive system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 4 Digestive system
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Decreased appetite
Biederman 2003 2/65 0/71 1.3 % 5.45 [ 0.27, 111.54 ]
Childress 2009 22/182 3/63 6.9 % 2.54 [ 0.79, 8.19 ]
Coghill 2013 17/111 3/110 6.7 % 5.62 [ 1.69, 18.62 ]
Findling 2006 3/133 0/46 1.4 % 2.46 [ 0.13, 46.65 ]
Findling 2008 17/91 4/85 8.1 % 3.97 [ 1.39, 11.32 ]
Findling 2010 37/145 1/72 2.9 % 18.37 [ 2.57, 131.23 ]
Greenhill 2002 73/155 33/161 21.8 % 2.30 [ 1.62, 3.25 ]
Greenhill 2006 16/53 4/47 8.4 % 3.55 [ 1.28, 9.87 ]
Lin 2014 17/36 3/78 7.0 % 12.28 [ 3.84, 39.25 ]
Newcorn 2008 37/219 2/74 5.3 % 6.25 [ 1.54, 25.31 ]
Pliszka 2000 3/20 0/18 1.4 % 6.33 [ 0.35, 114.81 ]
Riggs 2011 25/151 9/152 12.8 % 2.80 [ 1.35, 5.79 ]
Tucker 2009 20/53 0/56 1.6 % 43.28 [ 2.68, 698.02 ]
Wigal 2004 9/90 0/42 1.5 % 8.98 [ 0.53, 150.71 ]
Wilens 2006b 2/87 0/90 1.3 % 5.17 [ 0.25, 106.18 ]
Wolraich 2001 33/160 6/46 11.4 % 1.58 [ 0.71, 3.54 ]
Subtotal (95% CI) 1751 1211 100.0 % 3.66 [ 2.56, 5.23 ]
Total events: 333 (Methylphenidate), 68 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 20.88, df = 15 (P = 0.14); I2 =28%
Test for overall effect: Z = 7.13 (P < 0.00001)
2 Decreased weight
Carlson 2007 1/8 1/9 14.8 % 1.13 [ 0.08, 15.19 ]
Childress 2009 4/182 0/63 11.8 % 3.15 [ 0.17, 57.65 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Coghill 2013 5/111 0/110 12.0 % 10.90 [ 0.61, 194.82 ]
Findling 2008 7/91 0/85 12.3 % 14.02 [ 0.81, 241.82 ]
Lin 2014 4/36 0/78 11.9 % 19.22 [ 1.06, 347.68 ]
Wigal 2004 4/44 2/42 37.0 % 1.91 [ 0.37, 9.88 ]
Subtotal (95% CI) 472 387 100.0 % 3.89 [ 1.43, 10.59 ]
Total events: 25 (Methylphenidate), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.05, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0077)
3 Diarrhoea
Childress 2009 6/182 2/63 36.0 % 1.04 [ 0.22, 5.01 ]
Coghill 2013 2/111 3/110 28.5 % 0.66 [ 0.11, 3.88 ]
Greenhill 2006 2/53 1/47 15.9 % 1.77 [ 0.17, 18.94 ]
Lin 2014 0/36 2/78 9.8 % 0.43 [ 0.02, 8.67 ]
Wilens 2006b 2/87 0/90 9.8 % 5.17 [ 0.25, 106.18 ]
Subtotal (95% CI) 469 388 100.0 % 1.07 [ 0.41, 2.74 ]
Total events: 12 (Methylphenidate), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
4 Dyspepsia
Greenhill 2006 4/53 2/47 31.4 % 1.77 [ 0.34, 9.25 ]
Palumbo 2008 7/29 4/30 68.6 % 1.81 [ 0.59, 5.53 ]
Subtotal (95% CI) 82 77 100.0 % 1.80 [ 0.71, 4.54 ]
Total events: 11 (Methylphenidate), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
5 Increased appetite
Findling 2006 0/133 2/46 100.0 % 0.07 [ 0.00, 1.43 ]
Subtotal (95% CI) 133 46 100.0 % 0.07 [ 0.00, 1.43 ]
Total events: 0 (Methylphenidate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
6 Nausea
Carlson 2007 0/9 1/8 1.9 % 0.30 [ 0.01, 6.47 ]
Childress 2009 10/182 5/63 14.4 % 0.69 [ 0.25, 1.95 ]
Coghill 2013 8/111 3/110 9.7 % 2.64 [ 0.72, 9.70 ]
Findling 2008 7/91 2/85 7.1 % 3.27 [ 0.70, 15.30 ]
Findling 2010 14/145 2/72 7.9 % 3.48 [ 0.81, 14.88 ]
Greenhill 2006 6/53 3/47 9.3 % 1.77 [ 0.47, 6.70 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lin 2014 3/36 4/78 8.0 % 1.63 [ 0.38, 6.89 ]
Newcorn 2008 13/219 6/74 17.2 % 0.73 [ 0.29, 1.86 ]
Riggs 2011 8/151 9/152 17.3 % 0.89 [ 0.35, 2.26 ]
Wigal 2004 10/90 1/42 4.2 % 4.67 [ 0.62, 35.28 ]
Wilens 2006b 1/87 2/90 3.1 % 0.52 [ 0.05, 5.60 ]
Subtotal (95% CI) 1174 821 100.0 % 1.30 [ 0.85, 1.99 ]
Total events: 80 (Methylphenidate), 38 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.06, df = 10 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.21 (P = 0.22)
7 Stomachache
Carlson 2007 0/9 1/8 0.7 % 0.30 [ 0.01, 6.47 ]
Childress 2009 23/182 7/63 10.9 % 1.14 [ 0.51, 2.52 ]
Coghill 2013 4/111 6/110 4.5 % 0.66 [ 0.19, 2.28 ]
Findling 2006 9/133 3/46 4.3 % 1.04 [ 0.29, 3.67 ]
Greenhill 2002 36/155 25/161 32.6 % 1.50 [ 0.94, 2.37 ]
Greenhill 2006 3/53 0/47 0.8 % 6.22 [ 0.33, 117.41 ]
Lin 2014 8/36 7/78 7.9 % 2.48 [ 0.97, 6.30 ]
Newcorn 2008 22/219 4/74 6.5 % 1.86 [ 0.66, 5.22 ]
Pliszka 2000 1/20 0/18 0.7 % 2.71 [ 0.12, 62.70 ]
Riggs 2011 25/151 26/152 27.5 % 0.97 [ 0.59, 1.60 ]
Wigal 2004 4/90 1/42 1.5 % 1.87 [ 0.22, 16.19 ]
Wilens 2006b 1/87 2/90 1.2 % 0.52 [ 0.05, 5.60 ]
Wolraich 2001 10/160 0/46 0.9 % 6.13 [ 0.37, 102.68 ]
Subtotal (95% CI) 1406 935 100.0 % 1.30 [ 1.00, 1.69 ]
Total events: 146 (Methylphenidate), 82 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.38, df = 12 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
8 Vomiting
Biederman 2003 0/65 2/71 2.0 % 0.22 [ 0.01, 4.46 ]
Carlson 2007 1/9 1/8 2.7 % 0.89 [ 0.07, 12.00 ]
Childress 2009 11/182 0/63 2.3 % 8.04 [ 0.48, 134.55 ]
Coghill 2013 4/111 1/110 3.8 % 3.96 [ 0.45, 34.90 ]
Findling 2006 4/133 2/46 6.6 % 0.69 [ 0.13, 3.65 ]
Findling 2008 9/91 4/85 14.0 % 2.10 [ 0.67, 6.57 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Greenhill 2006 2/53 2/47 4.9 % 0.89 [ 0.13, 6.05 ]
Lin 2014 1/36 3/78 3.7 % 0.72 [ 0.08, 6.71 ]
Newcorn 2008 8/219 4/74 13.3 % 0.68 [ 0.21, 2.18 ]
Riggs 2011 16/151 14/152 39.2 % 1.15 [ 0.58, 2.27 ]
Wigal 2004 6/90 2/42 7.5 % 1.40 [ 0.29, 6.65 ]
Subtotal (95% CI) 1140 776 100.0 % 1.17 [ 0.76, 1.79 ]
Total events: 62 (Methylphenidate), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.79, df = 10 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 7.5. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 5 Circulatory and respiratory systems.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 5 Circulatory and respiratory systems
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 ECG: prolonged QT-interval
Childress 2009 182 63 -0.3727 (1.2336) 57.0 % 0.69 [ 0.06, 7.73 ]
Coghill 2013 111 110 -0.0091 (1.4207) 43.0 % 0.99 [ 0.06, 16.05 ]
Subtotal (95% CI) 293 173 100.0 % 0.81 [ 0.13, 5.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 ECG: tachycardia
Childress 2009 182 63 0.0384 (1.1641) 100.0 % 1.04 [ 0.11, 10.18 ]
Subtotal (95% CI) 182 63 100.0 % 1.04 [ 0.11, 10.18 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
3 Cough
Coghill 2013 111 110 2.8987 (1.4616) 7.5 % 18.15 [ 1.03, 318.42 ]
Findling 2006 133 46 -0.3825 (0.8834) 17.4 % 0.68 [ 0.12, 3.85 ]
Newcorn 2008 219 74 -0.4102 (0.6277) 27.9 % 0.66 [ 0.19, 2.27 ]
Riggs 2011 151 152 -0.1868 (0.3606) 47.1 % 0.83 [ 0.41, 1.68 ]
Subtotal (95% CI) 614 382 100.0 % 0.95 [ 0.41, 2.18 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 4.60, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 0.12 (P = 0.91)
4 Nasal congestion
Findling 2008 91 85 1.0521 (1.1647) 9.6 % 2.86 [ 0.29, 28.07 ]
Riggs 2011 151 152 0.0792 (0.3793) 90.4 % 1.08 [ 0.51, 2.28 ]
Subtotal (95% CI) 242 237 100.0 % 1.19 [ 0.59, 2.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
5 Pharyngolaryngeal pain
Riggs 2011 151 152 0.1141 (0.3264) 100.0 % 1.12 [ 0.59, 2.13 ]
Subtotal (95% CI) 151 152 100.0 % 1.12 [ 0.59, 2.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
6 Supraventricular extrasystoles
Carlson 2007 9 8 1.0986 (1.7035) 100.0 % 3.00 [ 0.11, 84.55 ]
Subtotal (95% CI) 9 8 100.0 % 3.00 [ 0.11, 84.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
7 Upper respiratory tract infection
Findling 2010 145 72 0.069 (0.4823) 100.0 % 1.07 [ 0.42, 2.76 ]
Subtotal (95% CI) 145 72 100.0 % 1.07 [ 0.42, 2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.63, df = 6 (P = 1.00), I2 =0.0%
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Analysis 7.6. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 6 Skeletal and muscular systems.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 6 Skeletal and muscular systems
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Arthralgia
Riggs 2011 6/151 9/152 100.0 % 0.67 [ 0.24, 1.84 ]
Subtotal (95% CI) 151 152 100.0 % 0.67 [ 0.24, 1.84 ]
Total events: 6 (Methylphenidate), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
2 Asthenia
Wilens 2006b 0/87 2/90 100.0 % 0.21 [ 0.01, 4.25 ]
Subtotal (95% CI) 87 90 100.0 % 0.21 [ 0.01, 4.25 ]
Total events: 0 (Methylphenidate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
3 Back pain
Riggs 2011 12/151 15/152 100.0 % 0.81 [ 0.39, 1.66 ]
Subtotal (95% CI) 151 152 100.0 % 0.81 [ 0.39, 1.66 ]
Total events: 12 (Methylphenidate), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
4 Myalgia
Riggs 2011 6/151 10/152 100.0 % 0.60 [ 0.23, 1.62 ]
Subtotal (95% CI) 151 152 100.0 % 0.60 [ 0.23, 1.62 ]
Total events: 6 (Methylphenidate), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
5 Toothache
Riggs 2011 10/151 10/152 100.0 % 1.01 [ 0.43, 2.35 ]
Subtotal (95% CI) 151 152 100.0 % 1.01 [ 0.43, 2.35 ]
Total events: 10 (Methylphenidate), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
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Analysis 7.7. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 7 Immune system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 7 Immune system
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Gastroenteritis
Coghill 2013 3/111 1/110 47.3 % 2.97 [ 0.31, 28.14 ]
Greenhill 2006 2/53 0/47 26.4 % 4.44 [ 0.22, 90.29 ]
Lin 2014 2/36 0/78 26.4 % 10.68 [ 0.53, 216.83 ]
Subtotal (95% CI) 200 235 100.0 % 4.63 [ 0.99, 21.72 ]
Total events: 7 (Methylphenidate), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Influenza
Coghill 2013 3/111 0/110 13.4 % 6.94 [ 0.36, 132.75 ]
Greenhill 2006 2/53 4/47 32.6 % 0.44 [ 0.09, 2.31 ]
Riggs 2011 5/151 11/152 54.0 % 0.46 [ 0.16, 1.29 ]
Subtotal (95% CI) 315 309 100.0 % 0.65 [ 0.20, 2.10 ]
Total events: 10 (Methylphenidate), 15 (Control)
Heterogeneity: Tau2 = 0.38; Chi2 = 3.02, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Nasopharyngitis
Coghill 2013 14/111 8/110 26.3 % 1.73 [ 0.76, 3.97 ]
Findling 2006 2/133 3/46 7.2 % 0.23 [ 0.04, 1.34 ]
Findling 2008 4/91 2/85 7.9 % 1.87 [ 0.35, 9.94 ]
Greenhill 2006 5/53 3/47 11.3 % 1.48 [ 0.37, 5.85 ]
Riggs 2011 23/151 23/152 47.2 % 1.01 [ 0.59, 1.71 ]
Subtotal (95% CI) 539 440 100.0 % 1.15 [ 0.70, 1.87 ]
Total events: 48 (Methylphenidate), 39 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 4.85, df = 4 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.54 (P = 0.59)
4 Otitis media
Greenhill 2006 2/53 1/47 100.0 % 1.77 [ 0.17, 18.94 ]
Subtotal (95% CI) 53 47 100.0 % 1.77 [ 0.17, 18.94 ]
Total events: 2 (Methylphenidate), 1 (Control)
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
5 Pharyngitis
Findling 2006 4/133 0/46 30.4 % 3.16 [ 0.17, 57.53 ]
Lin 2014 2/36 2/78 69.6 % 2.17 [ 0.32, 14.78 ]
Subtotal (95% CI) 169 124 100.0 % 2.43 [ 0.49, 12.05 ]
Total events: 6 (Methylphenidate), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
6 Pyrexia
Coghill 2013 5/111 0/110 47.9 % 10.90 [ 0.61, 194.82 ]
Findling 2006 1/133 3/46 52.1 % 0.12 [ 0.01, 1.08 ]
Subtotal (95% CI) 244 156 100.0 % 1.02 [ 0.01, 87.72 ]
Total events: 6 (Methylphenidate), 3 (Control)
Heterogeneity: Tau2 = 8.61; Chi2 = 5.97, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.01 (P = 0.99)
7 Rhinitis
Wigal 2004 11/90 4/42 100.0 % 1.28 [ 0.43, 3.79 ]
Subtotal (95% CI) 90 42 100.0 % 1.28 [ 0.43, 3.79 ]
Total events: 11 (Methylphenidate), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
8 Upper respiratory tract infection - not otherwise specified (NOS)
Coghill 2013 1/111 2/110 5.4 % 0.50 [ 0.05, 5.39 ]
Findling 2006 6/133 1/46 7.0 % 2.08 [ 0.26, 16.78 ]
Greenhill 2006 5/53 3/47 16.1 % 1.48 [ 0.37, 5.85 ]
Lin 2014 4/36 4/78 17.3 % 2.17 [ 0.57, 8.18 ]
Riggs 2011 12/151 13/152 54.1 % 0.93 [ 0.44, 1.97 ]
Subtotal (95% CI) 484 433 100.0 % 1.19 [ 0.68, 2.06 ]
Total events: 28 (Methylphenidate), 23 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.08, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
9 Viral infection NOS
Findling 2006 0/133 2/46 11.4 % 0.07 [ 0.00, 1.43 ]
Riggs 2011 18/151 14/152 52.9 % 1.29 [ 0.67, 2.51 ]
Wigal 2004 5/90 4/42 35.6 % 0.58 [ 0.17, 2.06 ]
Subtotal (95% CI) 374 240 100.0 % 0.70 [ 0.23, 2.15 ]
Total events: 23 (Methylphenidate), 20 (Control)
Heterogeneity: Tau2 = 0.51; Chi2 = 4.26, df = 2 (P = 0.12); I2 =53%
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 7.8. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 8 Height.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 8 Height
Study or subgroup Methylphenidate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Findling 2010 143 0.53 (1.21) 72 0.61 (1.27) -0.08 [ -0.43, 0.27 ]
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Analysis 7.9. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 9 Weight.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 9 Weight
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Carlson 2007 9 -0.89 (1.71) 8 -0.05 (0.47) 11.0 % -0.62 [ -1.60, 0.36 ]
Coghill 2013 111 -1.3 (1.4) 110 0.7 (1) 23.2 % -1.64 [ -1.94, -1.33 ]
Findling 2010 143 -1.9 (3.87) 72 1.77 (4.385) 23.4 % -0.90 [ -1.20, -0.61 ]
Newcorn 2008 219 -0.9 (1.3) 74 1.1 (1.3) 23.5 % -1.53 [ -1.83, -1.24 ]
Palumbo 2008 29 0.3 (2.3) 30 1.4 (1.6) 18.9 % -0.55 [ -1.07, -0.03 ]
Total (95% CI) 511 294 100.0 % -1.12 [ -1.55, -0.70 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 23.63, df = 4 (P = 0.00009); I2 =83%
Test for overall effect: Z = 5.15 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 10 BMI.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 10 BMI
Study or subgroup Methylphenidate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Findling 2010 143 -0.29 (0.763) 72 0.31 (0.883) -0.60 [ -0.84, -0.36 ]
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Analysis 7.11. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 11 Vital signs.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 11 Vital signs
Study or subgroup Methylphenidate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Diastolic blood pressure (mmHg)
Arnold 2004 35 0 (7.1) 40 0.2 (6.8) 4.9 % -0.20 [ -3.36, 2.96 ]
Carlson 2007 9 3 (8.5) 8 -1.83 (7.5) 1.7 % 4.83 [ -2.78, 12.44 ]
Coghill 2013 111 1.7 (9.9) 110 1.2 (8.7) 5.9 % 0.50 [ -1.96, 2.96 ]
Jensen 1999 (MTA) 125 67.6 (9.6) 115 67.8 (8.8) 6.0 % -0.20 [ -2.53, 2.13 ]
Kollins 2006 (PATS) 61 61.8 (8.4) 53 61 (10.8) 4.4 % 0.80 [ -2.79, 4.39 ]
Newcorn 2008 219 3.1 (8.4) 74 0.4 (7.8) 6.4 % 2.70 [ 0.60, 4.80 ]
Palumbo 2008 29 0.1 (10.3) 30 0.3 (6.3) 3.6 % -0.20 [ -4.57, 4.17 ]
Van der Meere 1999a 24 69.5 (5.3) 24 68.5 (9.6) 3.6 % 1.00 [ -3.39, 5.39 ]
Subtotal (95% CI) 613 454 36.6 % 0.94 [ -0.12, 2.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.52, df = 7 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
2 Systolic blood pressure (mmHg)
Arnold 2004 35 2.6 (11.6) 40 3.1 (9.5) 3.2 % -0.50 [ -5.34, 4.34 ]
Carlson 2007 9 2.1 (11.2) 8 -0.25 (10) 1.1 % 2.35 [ -7.73, 12.43 ]
Coghill 2013 111 0.3 (11.1) 110 1 (9.6) 5.5 % -0.70 [ -3.44, 2.04 ]
Jensen 1999 (MTA) 125 102.4 (9.7) 115 104.1 (10.6) 5.7 % -1.70 [ -4.28, 0.88 ]
Kollins 2006 (PATS) 61 101.6 (9.4) 53 99.4 (10.7) 4.3 % 2.20 [ -1.52, 5.92 ]
Newcorn 2008 219 2.4 (9.7) 74 1.3 (8) 6.2 % 1.10 [ -1.13, 3.33 ]
Palumbo 2008 29 -0.5 (9.5) 30 0.1 (8.6) 3.4 % -0.60 [ -5.23, 4.03 ]
Van der Meere 1999a 24 103.9 (9.5) 24 105 (9.7) 2.8 % -1.10 [ -6.53, 4.33 ]
Subtotal (95% CI) 613 454 32.1 % -0.05 [ -1.25, 1.16 ]
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Study or subgroup Methylphenidate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 4.66, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
3 Pulse or heart rate (bpm)
Arnold 2004 35 5.4 (12.2) 40 1.9 (10.7) 2.9 % 3.50 [ -1.73, 8.73 ]
Carlson 2007 9 5 (12.6) 8 -2 (12.3) 0.8 % 7.00 [ -4.85, 18.85 ]
Coghill 2013 111 5 (12.8) 110 -1.1 (9.6) 5.2 % 6.10 [ 3.12, 9.08 ]
Findling 2010 143 5.1 (12.53) 72 -1.7 (9.03) 5.2 % 6.80 [ 3.87, 9.73 ]
Jensen 1999 (MTA) 128 84.2 (12.4) 118 78.9 (12.9) 4.9 % 5.30 [ 2.13, 8.47 ]
Kollins 2006 (PATS) 61 94.3 (10.8) 53 98.3 (11.8) 3.8 % -4.00 [ -8.18, 0.18 ]
Newcorn 2008 219 3 (11.8) 74 0.4 (12) 5.0 % 2.60 [ -0.55, 5.75 ]
Palumbo 2008 29 -0.3 (10.3) 30 -1.2 (7.3) 3.4 % 0.90 [ -3.67, 5.47 ]
Subtotal (95% CI) 735 505 31.3 % 3.41 [ 0.87, 5.94 ]
Heterogeneity: Tau2 = 8.54; Chi2 = 22.96, df = 7 (P = 0.002); I2 =70%
Test for overall effect: Z = 2.64 (P = 0.0084)
Total (95% CI) 1961 1413 100.0 % 1.41 [ 0.30, 2.52 ]
Heterogeneity: Tau2 = 3.93; Chi2 = 53.40, df = 23 (P = 0.00032); I2 =57%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 6.04, df = 2 (P = 0.05), I2 =67%
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Analysis 7.12. Comparison 7 Number of non-serious adverse events: parallel-group trials and first-period
cross-over trials, Outcome 12 Other.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 7 Number of non-serious adverse events: parallel-group trials and first-period cross-over trials
Outcome: 12 Other
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Accidental injury
Coghill 2013 4/111 1/110 8.5 % 3.96 [ 0.45, 34.90 ]
Riggs 2011 7/151 9/152 19.4 % 0.78 [ 0.30, 2.05 ]
Wigal 2004 6/90 3/42 15.1 % 0.93 [ 0.25, 3.55 ]
Subtotal (95% CI) 352 304 43.0 % 0.99 [ 0.48, 2.07 ]
Total events: 17 (Methylphenidate), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
2 Epistasis
Wigal 2004 4/90 0/42 5.5 % 4.25 [ 0.23, 77.22 ]
Subtotal (95% CI) 90 42 5.5 % 4.25 [ 0.23, 77.22 ]
Total events: 4 (Methylphenidate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 Excoriation
Riggs 2011 14/151 4/152 17.9 % 3.52 [ 1.19, 10.46 ]
Subtotal (95% CI) 151 152 17.9 % 3.52 [ 1.19, 10.46 ]
Total events: 14 (Methylphenidate), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
4 Overdose
Coghill 2013 1/111 0/110 4.7 % 2.97 [ 0.12, 72.20 ]
Subtotal (95% CI) 111 110 4.7 % 2.97 [ 0.12, 72.20 ]
Total events: 1 (Methylphenidate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
5 Skin disorder (rash)
Carlson 2007 1/9 0/12 5.0 % 3.90 [ 0.18, 85.93 ]
Findling 2006 0/133 2/46 5.2 % 0.07 [ 0.00, 1.43 ]
Subtotal (95% CI) 142 58 10.1 % 0.52 [ 0.01, 26.44 ]
Total events: 1 (Methylphenidate), 2 (Control)
Heterogeneity: Tau2 = 5.64; Chi2 = 3.32, df = 1 (P = 0.07); I2 =70%
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.33 (P = 0.74)
6 Skin laceration
Riggs 2011 5/151 12/152 18.7 % 0.42 [ 0.15, 1.16 ]
Subtotal (95% CI) 151 152 18.7 % 0.42 [ 0.15, 1.16 ]
Total events: 5 (Methylphenidate), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 997 818 100.0 % 1.20 [ 0.56, 2.57 ]
Total events: 42 (Methylphenidate), 31 (Control)
Heterogeneity: Tau2 = 0.53; Chi2 = 14.76, df = 8 (P = 0.06); I2 =46%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 9.26, df = 5 (P = 0.10), I2 =46%
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Analysis 8.1. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 1 Total number of non-serious adverse events.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 1 Total number of non-serious adverse events
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Barkley 2000 35 35 0.1084 (0.2392) 9.4 % 1.11 [ 0.70, 1.78 ]
Brams 2008 86 86 -0.2944 (0.3851) 4.6 % 0.74 [ 0.35, 1.58 ]
Brams 2012 162 159 0.6095 (0.2714) 7.9 % 1.84 [ 1.08, 3.13 ]
Brown 1988 11 11 -0.086 (0.4266) 3.9 % 0.92 [ 0.40, 2.12 ]
Brown 1991 22 22 -0.0044 (0.3015) 6.8 % 1.00 [ 0.55, 1.80 ]
Cox 2006 35 35 -1.1272 (1.6504) 0.3 % 0.32 [ 0.01, 8.23 ]
DuPaul 1996 24 24 0.1544 (0.2891) 7.2 % 1.17 [ 0.66, 2.06 ]
Do¨pfner 2004 82 82 0.0673 (0.3669) 5.0 % 1.07 [ 0.52, 2.20 ]
Fine 1993 12 12 0.4089 (0.4133) 4.1 % 1.51 [ 0.67, 3.38 ]
Kolko 1999 16 16 -0.3132 (0.356) 5.2 % 0.73 [ 0.36, 1.47 ]
McGough 2006 80 80 0.3895 (0.3622) 5.1 % 1.48 [ 0.73, 3.00 ]
Muniz 2008 84 83 1.7574 (0.6534) 1.8 % 5.80 [ 1.61, 20.86 ]
Murray 2011 67 67 0.6366 (0.5792) 2.2 % 1.89 [ 0.61, 5.88 ]
Musten 1997 41 41 0.779 (0.2295) 9.9 % 2.18 [ 1.39, 3.42 ]
Quinn 2004 31 31 0 (0.5215) 2.7 % 1.00 [ 0.36, 2.78 ]
Silva 2006 54 54 0.2973 (0.4466) 3.6 % 1.35 [ 0.56, 3.23 ]
Silva 2008 68 68 0 (0.4657) 3.3 % 1.00 [ 0.40, 2.49 ]
Solanto 2009 30 30 0.5932 (0.2642) 8.2 % 1.81 [ 1.08, 3.04 ]
Taylor 1987 38 38 -0.3991 (0.7464) 1.4 % 0.67 [ 0.16, 2.90 ]
Wigal 2013 44 44 0.9555 (0.5889) 2.2 % 2.60 [ 0.82, 8.25 ]
Zeni 2009 16 16 0.2302 (0.3549) 5.3 % 1.26 [ 0.63, 2.52 ]
Total (95% CI) 1038 1034 100.0 % 1.33 [ 1.11, 1.58 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 24.46, df = 20 (P = 0.22); I2 =18%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 2 Subgroup analysis: total number of non-serious adverse events according to dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 2 Subgroup analysis: total number of non-serious adverse events according to dose
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Barkley 2000 35 35 0.1084 (0.2392) 6.7 % 1.11 [ 0.70, 1.78 ]
Brams 2008 86 86 -0.2944 (0.3851) 2.8 % 0.74 [ 0.35, 1.58 ]
Brams 2012 162 159 0.2542 (0.2825) 5.0 % 1.29 [ 0.74, 2.24 ]
Brown 1988 11 11 -0.6469 (0.4398) 2.2 % 0.52 [ 0.22, 1.24 ]
Brown 1991 22 22 -0.0044 (0.3015) 4.4 % 1.00 [ 0.55, 1.80 ]
DuPaul 1996 24 24 0.1544 (0.2891) 4.8 % 1.17 [ 0.66, 2.06 ]
Fine 1993 12 12 0.0501 (0.4083) 2.5 % 1.05 [ 0.47, 2.34 ]
Kolko 1999 16 16 0.0398 (0.3536) 3.3 % 1.04 [ 0.52, 2.08 ]
McGough 2006 80 80 0.3895 (0.3622) 3.1 % 1.48 [ 0.73, 3.00 ]
Muniz 2008 83 83 1.0454 (0.6958) 0.9 % 2.84 [ 0.73, 11.12 ]
Musten 1997 41 41 0.2035 (0.2215) 7.7 % 1.23 [ 0.79, 1.89 ]
Quinn 2004 31 31 0 (0.5215) 1.6 % 1.00 [ 0.36, 2.78 ]
Silva 2006 54 54 0.2973 (0.4466) 2.1 % 1.35 [ 0.56, 3.23 ]
Silva 2008 68 68 0 (0.4657) 1.9 % 1.00 [ 0.40, 2.49 ]
Solanto 2009 30 30 0.0982 (0.2584) 5.9 % 1.10 [ 0.66, 1.83 ]
Zeni 2009 16 16 0.0994 (0.3538) 3.3 % 1.10 [ 0.55, 2.21 ]
Subtotal (95% CI) 771 768 58.2 % 1.11 [ 0.94, 1.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.41, df = 15 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 High dose
Brams 2012 162 159 0.618 (0.2715) 5.4 % 1.86 [ 1.09, 3.16 ]
Brown 1988 11 11 -0.086 (0.4266) 2.3 % 0.92 [ 0.40, 2.12 ]
Cox 2006 35 35 -1.1272 (1.6504) 0.2 % 0.32 [ 0.01, 8.23 ]
DuPaul 1996 24 24 0.2691 (0.2901) 4.8 % 1.31 [ 0.74, 2.31 ]
Fine 1993 12 12 0.4089 (0.4133) 2.5 % 1.51 [ 0.67, 3.38 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kolko 1999 16 16 -0.3132 (0.356) 3.3 % 0.73 [ 0.36, 1.47 ]
Muniz 2008 84 83 1.7574 (0.6534) 1.0 % 5.80 [ 1.61, 20.86 ]
Murray 2011 67 67 0.6366 (0.5792) 1.3 % 1.89 [ 0.61, 5.88 ]
Musten 1997 41 41 0.7384 (0.2286) 7.3 % 2.09 [ 1.34, 3.28 ]
Solanto 2009 30 30 0.6142 (0.2646) 5.6 % 1.85 [ 1.10, 3.10 ]
Wigal 2013 44 44 0.9555 (0.5889) 1.2 % 2.60 [ 0.82, 8.25 ]
Zeni 2009 16 16 0.2302 (0.3549) 3.3 % 1.26 [ 0.63, 2.52 ]
Subtotal (95% CI) 542 538 38.0 % 1.57 [ 1.22, 2.01 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 15.05, df = 11 (P = 0.18); I2 =27%
Test for overall effect: Z = 3.55 (P = 0.00039)
3 Unknown dose
Do¨pfner 2004 82 82 0.0673 (0.3669) 3.1 % 1.07 [ 0.52, 2.20 ]
Taylor 1987 38 38 -0.3991 (0.7464) 0.8 % 0.67 [ 0.16, 2.90 ]
Subtotal (95% CI) 120 120 3.8 % 0.98 [ 0.51, 1.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 1433 1426 100.0 % 1.26 [ 1.11, 1.44 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 30.92, df = 29 (P = 0.37); I2 =6%
Test for overall effect: Z = 3.54 (P = 0.00041)
Test for subgroup differences: Chi2 = 5.68, df = 2 (P = 0.06), I2 =65%
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Analysis 8.3. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 3 Nervous system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 3 Nervous system
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Aggression
Kollins 2006 (PATS) 136 160 -0.3213 (0.5824) 75.0 % 0.73 [ 0.23, 2.27 ]
Schulz 2010 147 146 -1.6443 (1.1018) 25.0 % 0.19 [ 0.02, 1.67 ]
Subtotal (95% CI) 283 306 100.0 % 0.52 [ 0.17, 1.60 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 1.13, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Agitation
Quinn 2004 31 31 0.1622 (0.5701) 100.0 % 1.18 [ 0.38, 3.60 ]
Subtotal (95% CI) 31 31 100.0 % 1.18 [ 0.38, 3.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 Anger
Fitzpatrick 1992a 19 19 -1.8216 (0.8802) 9.7 % 0.16 [ 0.03, 0.91 ]
Klorman 1990 48 48 -0.5199 (0.4601) 35.3 % 0.59 [ 0.24, 1.47 ]
Rapport 2008 65 65 -0.7918 (0.3688) 55.0 % 0.45 [ 0.22, 0.93 ]
Subtotal (95% CI) 132 132 100.0 % 0.45 [ 0.26, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.72, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
4 Behavioural complaints
Gorman 2006 41 41 -0.5936 (0.2259) 100.0 % 0.55 [ 0.35, 0.86 ]
Subtotal (95% CI) 41 41 100.0 % 0.55 [ 0.35, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0086)
5 Buccal or lingual movements
Borcherding 1990 45 45 0.2804 (0.2119) 67.9 % 1.32 [ 0.87, 2.01 ]
Pelham 1999 25 25 0 (1.4434) 3.4 % 1.00 [ 0.06, 16.93 ]
Pelham 2005 36 36 1.1264 (1.6499) 2.6 % 3.08 [ 0.12, 78.27 ]
Smith 1998 45 45 -0.6295 (0.4635) 26.1 % 0.53 [ 0.21, 1.32 ]
Subtotal (95% CI) 151 151 100.0 % 1.06 [ 0.62, 1.79 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 3.56, df = 3 (P = 0.31); I2 =16%
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.20 (P = 0.84)
6 Compulsive acts
Borcherding 1990 45 45 0.943 (0.293) 100.0 % 2.57 [ 1.45, 4.56 ]
Subtotal (95% CI) 45 45 100.0 % 2.57 [ 1.45, 4.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.0013)
7 Daydreaming
Fine 1993 12 12 -0.0145 (0.4083) 24.5 % 0.99 [ 0.44, 2.19 ]
Ramtvedt 2013 34 34 -0.5681 (0.2477) 66.5 % 0.57 [ 0.35, 0.92 ]
Rapport 2008 65 65 -0.4388 (0.6708) 9.1 % 0.64 [ 0.17, 2.40 ]
Subtotal (95% CI) 111 111 100.0 % 0.66 [ 0.44, 0.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
8 Dizziness
Barkley 1989 82 82 0.7319 (0.7251) 3.9 % 2.08 [ 0.50, 8.61 ]
DuPaul 1996 24 24 0.0787 (0.2888) 24.7 % 1.08 [ 0.61, 1.91 ]
Fine 1993 12 12 0.5948 (0.4189) 11.7 % 1.81 [ 0.80, 4.12 ]
Pelham 2001a 68 68 1.1133 (1.642) 0.8 % 3.04 [ 0.12, 76.06 ]
Ramtvedt 2013 34 34 0 (0.2425) 35.0 % 1.00 [ 0.62, 1.61 ]
Rapport 2008 65 65 0.9651 (0.8559) 2.8 % 2.63 [ 0.49, 14.05 ]
Stein 1996 25 25 0 (1.4434) 1.0 % 1.00 [ 0.06, 16.93 ]
Stein 2003 47 47 0.5573 (0.7615) 3.6 % 1.75 [ 0.39, 7.77 ]
Zeni 2009 16 16 -0.082 (0.3537) 16.5 % 0.92 [ 0.46, 1.84 ]
Subtotal (95% CI) 373 373 100.0 % 1.17 [ 0.89, 1.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.19, df = 8 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
9 Drowsiness: dull, tired, listless or sleepy
Barkley 1989 82 82 0.0796 (0.3991) 8.7 % 1.08 [ 0.50, 2.37 ]
Buitelaar 1995 26 11 0.8675 (1.1609) 1.4 % 2.38 [ 0.24, 23.17 ]
Bukstein 1998 18 18 0.1588 (0.3339) 10.9 % 1.17 [ 0.61, 2.26 ]
Carlson 1995 12 12 0 (1.0954) 1.6 % 1.00 [ 0.12, 8.56 ]
Chronis 2003 21 21 -1.5488 (1.1657) 1.4 % 0.21 [ 0.02, 2.09 ]
DuPaul 1996 24 24 -0.324 (0.2907) 12.7 % 0.72 [ 0.41, 1.28 ]
Findling 2007 13 13 -2.4749 (1.5371) 0.8 % 0.08 [ 0.00, 1.71 ]
Fine 1993 12 12 0.0719 (0.4084) 8.4 % 1.07 [ 0.48, 2.39 ]
Muniz 2008 84 83 1.0986 (1.6403) 0.7 % 3.00 [ 0.12, 74.70 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Musten 1997 41 41 1.76 (0.9632) 2.0 % 5.81 [ 0.88, 38.39 ]
Overtoom 2003 16 16 0 (1.4606) 0.9 % 1.00 [ 0.06, 17.51 ]
Pearson 2013 24 24 0.7376 (1.2605) 1.2 % 2.09 [ 0.18, 24.73 ]
Pelham 1990a 22 22 0 (1.4475) 0.9 % 1.00 [ 0.06, 17.07 ]
Pelham 2005 36 36 1.9459 (1.1084) 1.6 % 7.00 [ 0.80, 61.46 ]
Quinn 2004 31 31 -0.6852 (0.5952) 4.8 % 0.50 [ 0.16, 1.62 ]
Ramtvedt 2013 34 34 -0.2237 (0.2433) 15.0 % 0.80 [ 0.50, 1.29 ]
Silva 2006 54 54 1.6468 (1.5612) 0.8 % 5.19 [ 0.24, 110.69 ]
Smith 1998 45 45 -1.3728 (0.5356) 5.6 % 0.25 [ 0.09, 0.72 ]
Stein 1996 25 25 -0.2719 (0.74) 3.3 % 0.76 [ 0.18, 3.25 ]
Stein 2003 47 47 0.5736 (0.4612) 7.1 % 1.77 [ 0.72, 4.38 ]
Zeni 2009 16 16 0.222 (0.3548) 10.1 % 1.25 [ 0.62, 2.50 ]
Subtotal (95% CI) 683 667 100.0 % 0.97 [ 0.73, 1.28 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 25.33, df = 20 (P = 0.19); I2 =21%
Test for overall effect: Z = 0.23 (P = 0.81)
10 Euphoria
Barkley 1989 82 82 0.05 (0.3164) 35.6 % 1.05 [ 0.57, 1.95 ]
Fine 1993 12 12 -0.0847 (0.4085) 22.2 % 0.92 [ 0.41, 2.05 ]
Pearson 2013 24 24 -1.1403 (1.6583) 1.4 % 0.32 [ 0.01, 8.25 ]
Stein 1996 25 25 -1.048 (0.7597) 6.7 % 0.35 [ 0.08, 1.55 ]
Stein 2011 42 45 1.2763 (0.8472) 5.4 % 3.58 [ 0.68, 18.86 ]
Zeni 2009 16 16 0.2756 (0.3555) 28.7 % 1.32 [ 0.66, 2.64 ]
Subtotal (95% CI) 201 204 100.0 % 1.06 [ 0.72, 1.57 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.21, df = 5 (P = 0.39); I2 =4%
Test for overall effect: Z = 0.31 (P = 0.76)
11 Headache
Barkley 1989 82 82 0.7521 (0.4461) 4.4 % 2.12 [ 0.88, 5.09 ]
Brams 2008 86 86 0.4174 (0.9259) 1.0 % 1.52 [ 0.25, 9.32 ]
Brams 2012 163 159 0.8473 (0.6993) 1.8 % 2.33 [ 0.59, 9.19 ]
Buitelaar 1995 26 11 -0.4543 (0.8402) 1.3 % 0.63 [ 0.12, 3.30 ]
Bukstein 1998 18 18 -0.0726 (0.312) 9.1 % 0.93 [ 0.50, 1.71 ]
Carlson 1995 12 12 -0.7885 (1.3003) 0.5 % 0.45 [ 0.04, 5.81 ]
Chronis 2003 21 21 -2.4031 (1.5251) 0.4 % 0.09 [ 0.00, 1.80 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
DuPaul 1996 24 24 -0.10884 (0.6628) 2.0 % 0.90 [ 0.24, 3.29 ]
Fine 1993 12 12 0.2612 (0.4103) 5.2 % 1.30 [ 0.58, 2.90 ]
Fitzpatrick 1992a 19 19 0 (1.0572) 0.8 % 1.00 [ 0.13, 7.94 ]
Klorman 1990 48 48 0.7621 (0.7389) 1.6 % 2.14 [ 0.50, 9.12 ]
McBride 1988a 48 48 0.4274 (0.9366) 1.0 % 1.53 [ 0.24, 9.61 ]
McGough 2006 80 80 0 (0.8323) 1.3 % 1.00 [ 0.20, 5.11 ]
Muniz 2008 84 83 2.6267 (1.476) 0.4 % 13.83 [ 0.77, 249.54 ]
Murray 2011 67 67 0.7244 (0.8839) 1.1 % 2.06 [ 0.36, 11.67 ]
Musten 1997 41 41 0.4374 (0.2236) 17.7 % 1.55 [ 1.00, 2.40 ]
Pearson 2013 24 24 0.7885 (0.9195) 1.0 % 2.20 [ 0.36, 13.34 ]
Pelham 1990a 22 22 -1.7025 (1.579) 0.4 % 0.18 [ 0.01, 4.02 ]
Pelham 1999 25 25 1.5198 (1.1573) 0.7 % 4.57 [ 0.47, 44.17 ]
Pelham 2001a 68 68 -0.4665 (0.4361) 4.6 % 0.63 [ 0.27, 1.47 ]
Pelham 2005 36 36 0.5733 (0.7719) 1.5 % 1.77 [ 0.39, 8.05 ]
Quinn 2004 31 31 -1.675 (1.5702) 0.4 % 0.19 [ 0.01, 4.07 ]
Ramtvedt 2013 34 34 0.1156 (0.2428) 15.0 % 1.12 [ 0.70, 1.81 ]
Rapport 2008 65 65 0.1712 (0.5863) 2.6 % 1.19 [ 0.38, 3.74 ]
Schachar 2008 18 18 0 (1.4552) 0.4 % 1.00 [ 0.06, 17.32 ]
Schulz 2010 147 146 0.3436 (0.5976) 2.5 % 1.41 [ 0.44, 4.55 ]
Silva 2005a 54 53 0.6931 (1.2403) 0.6 % 2.00 [ 0.18, 22.74 ]
Silva 2006 54 54 -1.1371 (1.1712) 0.6 % 0.32 [ 0.03, 3.18 ]
Silva 2008 68 68 0 (1.4247) 0.4 % 1.00 [ 0.06, 16.32 ]
Smith 1998 45 45 -0.2076 (0.646) 2.1 % 0.81 [ 0.23, 2.88 ]
Stein 1996 25 25 0.9045 (0.6939) 1.8 % 2.47 [ 0.63, 9.63 ]
Stein 2003 47 47 0.0934 (0.4323) 4.7 % 1.10 [ 0.47, 2.56 ]
Stein 2011 42 45 1.1906 (1.647) 0.3 % 3.29 [ 0.13, 82.99 ]
Swanson 2004b 181 183 0.1712 (0.5665) 2.8 % 1.19 [ 0.39, 3.60 ]
Wigal 2014 21 22 1.9904 (1.4822) 0.4 % 7.32 [ 0.40, 133.68 ]
Wilens 2010 30 30 1.7579 (1.1289) 0.7 % 5.80 [ 0.63, 53.01 ]
Zeni 2009 16 16 -0.393 (0.3574) 6.9 % 0.68 [ 0.34, 1.36 ]
Subtotal (95% CI) 1884 1868 100.0 % 1.21 [ 1.01, 1.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 29.25, df = 36 (P = 0.78); I2 =0.0%
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.02 (P = 0.043)
12 Insomnia or sleep problems
Barkley 1989 82 82 1.1626 (0.3272) 5.8 % 3.20 [ 1.68, 6.07 ]
Brams 2012 163 159 1.9397 (1.516) 0.8 % 6.96 [ 0.36, 135.78 ]
Buitelaar 1995 26 11 0.5108 (0.7879) 2.3 % 1.67 [ 0.36, 7.81 ]
Castellanos 1997 22 22 0.7419 (1.264) 1.0 % 2.10 [ 0.18, 25.01 ]
Chronis 2003 21 21 -0.2838 (0.7559) 2.4 % 0.75 [ 0.17, 3.31 ]
Corkum 2008 21 21 1.0814 (0.3326) 5.8 % 2.95 [ 1.54, 5.66 ]
DuPaul 1996 24 24 0.3083 (0.2905) 6.3 % 1.36 [ 0.77, 2.41 ]
Findling 2007 16 16 1.1575 (0.9286) 1.8 % 3.18 [ 0.52, 19.64 ]
Fine 1993 12 12 0.346 (0.4119) 4.9 % 1.41 [ 0.63, 3.17 ]
Fitzpatrick 1992a 19 19 1.3555 (0.7821) 2.3 % 3.88 [ 0.84, 17.96 ]
Klorman 1990 48 48 0.1582 (0.5632) 3.5 % 1.17 [ 0.39, 3.53 ]
Kollins 2006 (PATS) 136 160 0.1782 (0.4108) 4.9 % 1.20 [ 0.53, 2.67 ]
Manos 1999 177 177 0.8952 (0.5001) 4.0 % 2.45 [ 0.92, 6.52 ]
Muniz 2008 84 83 1.0986 (1.6403) 0.7 % 3.00 [ 0.12, 74.70 ]
Musten 1997 41 41 -0.7228 (0.2283) 7.0 % 0.49 [ 0.31, 0.76 ]
Pearson 2013 24 24 1.335 (0.6475) 3.0 % 3.80 [ 1.07, 13.52 ]
Pelham 1990a 22 22 1.5404 (1.4475) 0.8 % 4.67 [ 0.27, 79.63 ]
Pelham 1999 25 25 0.8398 (0.7734) 2.3 % 2.32 [ 0.51, 10.54 ]
Pelham 2001a 68 68 -0.3687 (0.6125) 3.2 % 0.69 [ 0.21, 2.30 ]
Pelham 2005 36 36 0.9765 (0.7355) 2.5 % 2.66 [ 0.63, 11.22 ]
Ramtvedt 2013 34 34 0.2796 (0.2438) 6.8 % 1.32 [ 0.82, 2.13 ]
Rapport 2008 65 65 -0.3704 (0.6138) 3.2 % 0.69 [ 0.21, 2.30 ]
Sharp 1999 48 48 0.7902 (0.4528) 4.5 % 2.20 [ 0.91, 5.35 ]
Silva 2006 54 54 1.6468 (1.5612) 0.7 % 5.19 [ 0.24, 110.69 ]
Stein 1996 25 25 0.4855 (0.5718) 3.5 % 1.62 [ 0.53, 4.98 ]
Stein 2003 47 47 0.7816 (0.4222) 4.8 % 2.18 [ 0.96, 5.00 ]
Stein 2011 42 45 0.5031 (0.9393) 1.7 % 1.65 [ 0.26, 10.42 ]
Swanson 2004b 181 183 -0.6988 (0.715) 2.6 % 0.50 [ 0.12, 2.02 ]
Wigal 2014 21 22 -1.0542 (1.6055) 0.7 % 0.35 [ 0.01, 8.11 ]
Wilens 2010 30 30 3.1374 (1.4815) 0.8 % 23.04 [ 1.26, 420.35 ]
0.002 0.1 1 10 500
Favours methylphenidate Favours control
(Continued . . . )
689Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Zeni 2009 16 16 -0.0382 (0.3536) 5.5 % 0.96 [ 0.48, 1.92 ]
Subtotal (95% CI) 1630 1640 100.0 % 1.57 [ 1.20, 2.06 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 56.48, df = 30 (P = 0.002); I2 =47%
Test for overall effect: Z = 3.27 (P = 0.0011)
13 Irritability
Barkley 1989 82 82 -0.2853 (0.3386) 6.7 % 0.75 [ 0.39, 1.46 ]
Buitelaar 1995 26 11 0.1699 (0.7993) 3.0 % 1.19 [ 0.25, 5.68 ]
Bukstein 1998 18 18 0.1478 (0.3338) 6.8 % 1.16 [ 0.60, 2.23 ]
Chronis 2003 21 21 -1.0986 (0.7766) 3.1 % 0.33 [ 0.07, 1.53 ]
DuPaul 1996 24 24 0.1088 (1.4634) 1.1 % 1.11 [ 0.06, 19.63 ]
Findling 2007 16 16 -0.9555 (0.8228) 2.9 % 0.38 [ 0.08, 1.93 ]
Fine 1993 12 12 0.1065 (0.4086) 6.0 % 1.11 [ 0.50, 2.48 ]
Kollins 2006 (PATS) 136 160 -0.0409 (0.4654) 5.4 % 0.96 [ 0.39, 2.39 ]
Manos 1999 177 177 -0.4727 (0.2723) 7.5 % 0.62 [ 0.37, 1.06 ]
Musten 1997 41 41 0.0646 (0.2209) 8.0 % 1.07 [ 0.69, 1.64 ]
Pearson 2013 24 24 -0.5261 (0.5961) 4.3 % 0.59 [ 0.18, 1.90 ]
Pelham 1990a 22 22 -1.0788 (0.8993) 2.5 % 0.34 [ 0.06, 1.98 ]
Pelham 1999 25 25 -0.9045 (0.6939) 3.6 % 0.40 [ 0.10, 1.58 ]
Pelham 2005 36 36 1.7308 (1.1229) 1.8 % 5.65 [ 0.62, 50.99 ]
Ramtvedt 2013 34 34 -0.2417 (0.2435) 7.8 % 0.79 [ 0.49, 1.27 ]
Silva 2006 54 54 -2.0025 (1.5243) 1.1 % 0.13 [ 0.01, 2.68 ]
Smith 1998 45 45 -1.7518 (0.4723) 5.3 % 0.17 [ 0.07, 0.44 ]
Stein 1996 25 25 2.1401 (0.6587) 3.8 % 8.50 [ 2.34, 30.91 ]
Stein 2003 47 47 0.6613 (0.4397) 5.7 % 1.94 [ 0.82, 4.59 ]
Swanson 2004b 181 183 -0.9219 (0.8433) 2.8 % 0.40 [ 0.08, 2.08 ]
Wigal 2014 21 22 -1.0542 (1.6055) 1.0 % 0.35 [ 0.01, 8.11 ]
Wilens 2010 30 30 1.7579 (0.6928) 3.6 % 5.80 [ 1.49, 22.55 ]
Zeni 2009 16 16 0.6467 (0.3639) 6.5 % 1.91 [ 0.94, 3.90 ]
Subtotal (95% CI) 1113 1125 100.0 % 0.92 [ 0.66, 1.27 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 53.48, df = 22 (P = 0.00019); I2 =59%
Test for overall effect: Z = 0.52 (P = 0.60)
14 Nightmares
Barkley 1989 82 82 0.0759 (0.3897) 11.8 % 1.08 [ 0.50, 2.32 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Buitelaar 1995 26 11 -0.1823 (1.2813) 2.1 % 0.83 [ 0.07, 10.27 ]
DuPaul 1996 24 24 0.3165 (0.2906) 14.9 % 1.37 [ 0.78, 2.43 ]
Fine 1993 12 12 0.1168 (0.4087) 11.3 % 1.12 [ 0.50, 2.50 ]
Musten 1997 41 41 0.6716 (0.2273) 17.1 % 1.96 [ 1.25, 3.06 ]
Ramtvedt 2013 34 34 -0.1315 (0.2428) 16.6 % 0.88 [ 0.54, 1.41 ]
Stein 1996 25 25 -1.867 (0.8468) 4.3 % 0.15 [ 0.03, 0.81 ]
Stein 2003 47 47 -0.4346 (0.543) 8.2 % 0.65 [ 0.22, 1.88 ]
Stein 2011 42 45 1.1906 (1.647) 1.3 % 3.29 [ 0.13, 82.99 ]
Zeni 2009 16 16 -0.7008 (0.3657) 12.5 % 0.50 [ 0.24, 1.02 ]
Subtotal (95% CI) 349 337 100.0 % 0.97 [ 0.66, 1.42 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 19.43, df = 9 (P = 0.02); I2 =54%
Test for overall effect: Z = 0.15 (P = 0.88)
15 Overly meticulous
Sharp 1999 48 48 3.7079 (1.4555) 100.0 % 40.77 [ 2.35, 706.72 ]
Subtotal (95% CI) 48 48 100.0 % 40.77 [ 2.35, 706.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
16 Obsessive thinking
Borcherding 1990 45 45 0.8547 (0.2207) 100.0 % 2.35 [ 1.53, 3.62 ]
Subtotal (95% CI) 45 45 100.0 % 2.35 [ 1.53, 3.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.87 (P = 0.00011)
17 Picking at skin or fingers, nail biting, lip or cheek chewing
Barkley 1989 82 82 0.3861 (0.3607) 10.9 % 1.47 [ 0.73, 2.98 ]
Bukstein 1998 18 18 0.0814 (0.3335) 12.7 % 1.08 [ 0.56, 2.09 ]
Chronis 2003 21 21 -1.204 (1.1995) 1.0 % 0.30 [ 0.03, 3.15 ]
DuPaul 1996 24 24 -0.1887 (0.2894) 16.9 % 0.83 [ 0.47, 1.46 ]
Findling 2007 16 16 0.4796 (0.9908) 1.4 % 1.62 [ 0.23, 11.26 ]
Fine 1993 12 12 0.2948 (0.4109) 8.4 % 1.34 [ 0.60, 3.00 ]
Musten 1997 31 31 -0.0621 (0.2541) 21.9 % 0.94 [ 0.57, 1.55 ]
Pearson 2013 24 24 -0.7376 (1.2605) 0.9 % 0.48 [ 0.04, 5.66 ]
Pelham 1990a 22 22 -0.7419 (1.264) 0.9 % 0.48 [ 0.04, 5.67 ]
Pelham 1999 25 25 -1.1386 (1.6573) 0.5 % 0.32 [ 0.01, 8.25 ]
Pelham 2005 36 36 0 (1.4343) 0.7 % 1.00 [ 0.06, 16.63 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Smith 1998 45 45 0.5199 (0.5154) 5.3 % 1.68 [ 0.61, 4.62 ]
Stein 1996 25 25 -0.5055 (0.719) 2.7 % 0.60 [ 0.15, 2.47 ]
Stein 2003 47 47 0.5573 (0.5353) 4.9 % 1.75 [ 0.61, 4.99 ]
Zeni 2009 16 16 0.5609 (0.3614) 10.8 % 1.75 [ 0.86, 3.56 ]
Subtotal (95% CI) 444 444 100.0 % 1.12 [ 0.88, 1.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.76, df = 14 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
18 Repetitive language
Pearson 2013 24 24 0 (0.5774) 100.0 % 1.00 [ 0.32, 3.10 ]
Subtotal (95% CI) 24 24 100.0 % 1.00 [ 0.32, 3.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
19 Sad, tearful or depressed
Barkley 1989 82 82 -0.05 (0.3164) 11.0 % 0.95 [ 0.51, 1.77 ]
Buitelaar 1995 26 11 0.3448 (0.7926) 1.8 % 1.41 [ 0.30, 6.67 ]
Chronis 2003 21 21 -0.7444 (1.266) 0.7 % 0.48 [ 0.04, 5.68 ]
DuPaul 1996 24 24 -0.145 (1.0039) 1.1 % 0.87 [ 0.12, 6.19 ]
Findling 2007 16 16 -0.7621 (1.2799) 0.7 % 0.47 [ 0.04, 5.73 ]
Fine 1993 12 12 0.4139 (0.4134) 6.4 % 1.51 [ 0.67, 3.40 ]
Fitzpatrick 1992a 19 19 0.7503 (1.2706) 0.7 % 2.12 [ 0.18, 25.55 ]
Gadow 2007 31 31 0.0987 (0.2542) 17.0 % 1.10 [ 0.67, 1.82 ]
Klorman 1990 48 48 0 (1.0215) 1.1 % 1.00 [ 0.14, 7.40 ]
Manos 1999 177 177 -0.2261 (0.3895) 7.3 % 0.80 [ 0.37, 1.71 ]
McBride 1988a 48 48 2.3838 (1.0761) 1.0 % 10.85 [ 1.32, 89.38 ]
Musten 1997 41 41 1.543 (0.6075) 3.0 % 4.68 [ 1.42, 15.39 ]
Pearson 2013 24 24 0.3365 (0.8252) 1.6 % 1.40 [ 0.28, 7.06 ]
Pelham 1990a 22 22 -1.1441 (1.6606) 0.4 % 0.32 [ 0.01, 8.25 ]
Pelham 1999 25 25 0.7841 (0.9171) 1.3 % 2.19 [ 0.36, 13.22 ]
Pelham 2005 36 36 2.5452 (1.497) 0.5 % 12.75 [ 0.68, 239.67 ]
Ramtvedt 2013 34 34 0.0489 (0.2426) 18.7 % 1.05 [ 0.65, 1.69 ]
Rapport 2008 65 65 -1.6404 (1.5592) 0.5 % 0.19 [ 0.01, 4.12 ]
Sharp 1999 48 48 -0.2019 (0.45) 5.4 % 0.82 [ 0.34, 1.97 ]
Smith 1998 45 45 -0.3118 (0.7947) 1.7 % 0.73 [ 0.15, 3.48 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Stein 1996 25 25 -0.4953 (0.5778) 3.3 % 0.61 [ 0.20, 1.89 ]
Stein 2003 47 47 0.4344 (0.4185) 6.3 % 1.54 [ 0.68, 3.51 ]
Zeni 2009 16 16 0.3662 (0.3569) 8.6 % 1.44 [ 0.72, 2.90 ]
Subtotal (95% CI) 932 917 100.0 % 1.15 [ 0.94, 1.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 20.95, df = 22 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
20 Socially withdrawn - decreased interaction with others
Barkley 1989 82 82 -0.2669 (0.4233) 13.4 % 0.77 [ 0.33, 1.76 ]
Buitelaar 1995 26 11 0.8531 (1.5899) 1.7 % 2.35 [ 0.10, 52.94 ]
Chronis 2003 21 21 -0.7444 (1.266) 2.5 % 0.48 [ 0.04, 5.68 ]
DuPaul 1996 24 24 0.5805 (0.6628) 7.5 % 1.79 [ 0.49, 6.55 ]
Fine 1993 12 12 0.0483 (0.4083) 13.9 % 1.05 [ 0.47, 2.34 ]
Pelham 1999 25 25 -0.4499 (0.9603) 4.1 % 0.64 [ 0.10, 4.19 ]
Pelham 2005 36 36 2.0317 (1.5307) 1.8 % 7.63 [ 0.38, 153.21 ]
Ramtvedt 2013 34 34 0.1482 (0.2429) 21.0 % 1.16 [ 0.72, 1.87 ]
Smith 1998 45 45 -0.7161 (1.2434) 2.6 % 0.49 [ 0.04, 5.59 ]
Stein 1996 25 25 -1.4979 (0.8613) 5.0 % 0.22 [ 0.04, 1.21 ]
Stein 2003 47 47 0.5242 (0.462) 12.1 % 1.69 [ 0.68, 4.18 ]
Zeni 2009 16 16 1.2716 (0.3922) 14.5 % 3.57 [ 1.65, 7.69 ]
Subtotal (95% CI) 393 378 100.0 % 1.24 [ 0.82, 1.87 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 16.66, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 1.01 (P = 0.31)
21 Sleep efficiency (SEF)
Schwartz 2004 44 44 -0.8163 (2.053) 71.5 % 0.44 [ 0.01, 24.72 ]
Tirosh 1993b 10 10 -0.5623 (3.254) 28.5 % 0.57 [ 0.00, 335.43 ]
Subtotal (95% CI) 54 54 100.0 % 0.48 [ 0.02, 14.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
22 Stares a lot
Barkley 1989 82 82 -0.0516 (0.3211) 18.5 % 0.95 [ 0.51, 1.78 ]
DuPaul 1996 24 24 0.031 (1.0056) 2.4 % 1.03 [ 0.14, 7.40 ]
Findling 2007 16 16 0.0013 (1.069) 2.2 % 1.00 [ 0.12, 8.14 ]
Manos 1999 177 177 -1.1079 (0.4874) 9.3 % 0.33 [ 0.13, 0.86 ]
Musten 1997 41 41 0.1802 (0.2213) 30.6 % 1.20 [ 0.78, 1.85 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Pearson 2013 24 24 -0.7885 (0.9195) 2.9 % 0.45 [ 0.07, 2.76 ]
Stein 1996 25 25 0.1784 (0.5979) 6.5 % 1.20 [ 0.37, 3.86 ]
Stein 2003 47 47 0 (0.4127) 12.4 % 1.00 [ 0.45, 2.25 ]
Zeni 2009 16 16 0.6164 (0.363) 15.3 % 1.85 [ 0.91, 3.77 ]
Subtotal (95% CI) 452 452 100.0 % 1.03 [ 0.75, 1.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.42, df = 8 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.16 (P = 0.87)
23 Tics or nervous movements
Barkley 1989 82 82 0.5546 (0.3769) 9.9 % 1.74 [ 0.83, 3.64 ]
Borcherding 1990 45 45 0.9433 (0.363) 10.5 % 2.57 [ 1.26, 5.23 ]
Buitelaar 1995 26 11 1.2313 (1.5541) 0.7 % 3.43 [ 0.16, 72.04 ]
Chronis 2003 21 21 -0.7444 (1.266) 1.0 % 0.48 [ 0.04, 5.68 ]
Findling 2007 16 16 1.7386 (1.5905) 0.7 % 5.69 [ 0.25, 128.50 ]
Gadow 2007 71 71 0.05492 (0.9894) 1.7 % 1.06 [ 0.15, 7.35 ]
Musten 1997 41 41 0.2598 (0.2218) 21.6 % 1.30 [ 0.84, 2.00 ]
Pearson 2013 24 24 1.1403 (1.6583) 0.6 % 3.13 [ 0.12, 80.68 ]
Pelham 1990a 22 22 0.7419 (1.264) 1.0 % 2.10 [ 0.18, 25.01 ]
Pelham 1999 25 25 -1.6911 (1.5754) 0.7 % 0.18 [ 0.01, 4.04 ]
Pelham 2001a 68 68 2.2574 (1.5008) 0.7 % 9.56 [ 0.50, 181.08 ]
Quinn 2004 31 31 -1.1676 (1.1842) 1.2 % 0.31 [ 0.03, 3.17 ]
Ramtvedt 2013 34 34 0 (0.2425) 19.3 % 1.00 [ 0.62, 1.61 ]
Sharp 1999 48 48 0.7773 (0.5222) 5.6 % 2.18 [ 0.78, 6.05 ]
Smith 1998 45 45 -0.7958 (0.653) 3.7 % 0.45 [ 0.13, 1.62 ]
Stein 1996 25 25 -0.6061 (0.793) 2.6 % 0.55 [ 0.12, 2.58 ]
Stein 2003 47 47 -0.1438 (0.5367) 5.3 % 0.87 [ 0.30, 2.48 ]
Tannock 1993 22 22 1.5404 (0.8715) 2.2 % 4.67 [ 0.85, 25.75 ]
Zeni 2009 16 16 0.2995 (0.3558) 10.9 % 1.35 [ 0.67, 2.71 ]
Subtotal (95% CI) 709 694 100.0 % 1.33 [ 1.03, 1.72 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 19.92, df = 18 (P = 0.34); I2 =10%
Test for overall effect: Z = 2.20 (P = 0.028)
24 Unusual blinking
Pearson 2013 24 24 1.1403 (1.6583) 100.0 % 3.13 [ 0.12, 80.68 ]
Subtotal (95% CI) 24 24 100.0 % 3.13 [ 0.12, 80.68 ]
Heterogeneity: not applicable
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.69 (P = 0.49)
25 Worried or anxious
Barkley 1989 82 82 -0.2472 (0.3149) 8.3 % 0.78 [ 0.42, 1.45 ]
Buitelaar 1995 26 11 -0.2007 (0.6885) 3.8 % 0.82 [ 0.21, 3.15 ]
Bukstein 1998 18 18 -0.0629 (0.3334) 8.0 % 0.94 [ 0.49, 1.80 ]
Chronis 2003 21 21 -0.7444 (1.266) 1.4 % 0.48 [ 0.04, 5.68 ]
DuPaul 1996 24 24 -0.2589 (0.29) 8.7 % 0.77 [ 0.44, 1.36 ]
Findling 2007 0 0 0 (0.9058) 2.5 % 1.00 [ 0.17, 5.90 ]
Fine 1993 12 12 -0.0299 (0.4083) 6.8 % 0.97 [ 0.44, 2.16 ]
Kollins 2006 (PATS) 136 160 0.1648 (1.0069) 2.1 % 1.18 [ 0.16, 8.48 ]
Manos 1999 177 177 -0.5356 (0.3985) 7.0 % 0.59 [ 0.27, 1.28 ]
Musten 1997 31 31 -1.2106 (0.2777) 8.9 % 0.30 [ 0.17, 0.51 ]
Pearson 2013 24 24 0.5108 (0.7226) 3.5 % 1.67 [ 0.40, 6.87 ]
Pelham 1990a 22 22 -1.1441 (1.6606) 0.9 % 0.32 [ 0.01, 8.25 ]
Pelham 1999 25 25 0 (1.4434) 1.1 % 1.00 [ 0.06, 16.93 ]
Pelham 2005 36 36 1.6658 (1.5673) 1.0 % 5.29 [ 0.25, 114.17 ]
Quinn 2004 31 31 -0.4406 (0.9505) 2.3 % 0.64 [ 0.10, 4.15 ]
Ramtvedt 2013 34 34 0.2118 (0.2433) 9.5 % 1.24 [ 0.77, 1.99 ]
Smith 1998 45 45 -1.0325 (0.4966) 5.6 % 0.36 [ 0.13, 0.94 ]
Stein 1996 25 25 -0.6466 (0.5736) 4.8 % 0.52 [ 0.17, 1.61 ]
Stein 2003 47 47 -0.4279 (0.4153) 6.7 % 0.65 [ 0.29, 1.47 ]
Zeni 2009 16 16 1.3363 (0.396) 7.0 % 3.80 [ 1.75, 8.27 ]
Subtotal (95% CI) 832 841 100.0 % 0.82 [ 0.60, 1.12 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 39.12, df = 19 (P = 0.004); I2 =51%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 71.63, df = 24 (P = 0.00), I2 =66%
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Analysis 8.4. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 4 Digestive system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 4 Digestive system
Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Decreased appetite or loss of appetite
Barkley 1989 82 82 2.0087 (0.3836) 5.5 % 7.45 [ 3.51, 15.81 ]
Brams 2012 163 159 3.0829 (1.4519) 0.8 % 21.82 [ 1.27, 375.62 ]
Buitelaar 1995 26 11 -0.2007 (0.9521) 1.6 % 0.82 [ 0.13, 5.29 ]
Bukstein 1998 18 18 1.034 (0.1374) 9.2 % 2.81 [ 2.15, 3.68 ]
Castellanos 1997 22 22 1.1987 (1.1973) 1.1 % 3.32 [ 0.32, 34.65 ]
Chacko 2005 36 36 1.8777 (0.8172) 2.1 % 6.54 [ 1.32, 32.44 ]
Chronis 2003 21 21 0.47 (0.6905) 2.7 % 1.60 [ 0.41, 6.19 ]
DuPaul 1996 24 24 0.744 (1.101) 1.3 % 2.10 [ 0.24, 18.21 ]
Findling 2007 16 16 1.9196 (1.1652) 1.1 % 6.82 [ 0.69, 66.91 ]
Fine 1993 12 12 0.7101 (0.4234) 5.0 % 2.03 [ 0.89, 4.66 ]
Fitzpatrick 1992a 19 19 1.2164 (1.2047) 1.1 % 3.38 [ 0.32, 35.79 ]
Klorman 1990 48 48 1.1614 (0.5734) 3.5 % 3.19 [ 1.04, 9.83 ]
Kollins 2006 (PATS) 136 160 0.0092 (0.4119) 5.1 % 1.01 [ 0.45, 2.26 ]
Manos 1999 177 177 0.9993 (0.375) 5.6 % 2.72 [ 1.30, 5.66 ]
McBride 1988a 48 48 2.0825 (1.0902) 1.3 % 8.02 [ 0.95, 67.98 ]
McGough 2006 80 80 1.6346 (1.5573) 0.7 % 5.13 [ 0.24, 108.51 ]
Muniz 2008 84 83 1.0986 (1.6403) 0.6 % 3.00 [ 0.12, 74.70 ]
Musten 1997 41 41 1.1853 (0.2404) 7.6 % 3.27 [ 2.04, 5.24 ]
Pearson 2013 24 24 2.6247 (1.1051) 1.2 % 13.80 [ 1.58, 120.38 ]
Pelham 1990a 22 22 1.4061 (0.6649) 2.8 % 4.08 [ 1.11, 15.02 ]
Pelham 1999 25 25 1.0561 (0.8908) 1.8 % 2.88 [ 0.50, 16.48 ]
Pelham 2001a 68 68 1.5353 (0.6708) 2.8 % 4.64 [ 1.25, 17.29 ]
Pelham 2005 36 36 2.3812 (0.8039) 2.1 % 10.82 [ 2.24, 52.29 ]
Pelham 2011 10 10 0.539 (1.0494) 1.4 % 1.71 [ 0.22, 13.41 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ramtvedt 2013 34 34 0.5487 (0.2473) 7.5 % 1.73 [ 1.07, 2.81 ]
Rapport 2008 65 65 0.745 (0.4416) 4.8 % 2.11 [ 0.89, 5.01 ]
Schulz 2010 147 146 0.4055 (0.9204) 1.7 % 1.50 [ 0.25, 9.11 ]
Sharp 1999 48 48 4.1607 (1.4511) 0.8 % 64.12 [ 3.73, 1101.91 ]
Silva 2006 54 54 2.4941 (1.4901) 0.7 % 12.11 [ 0.65, 224.67 ]
Stein 1996 25 25 1.6982 (0.6183) 3.1 % 5.46 [ 1.63, 18.36 ]
Stein 2003 47 47 1.7318 (0.4546) 4.6 % 5.65 [ 2.32, 13.77 ]
Stein 2011 42 45 1.2192 (1.1755) 1.1 % 3.38 [ 0.34, 33.89 ]
Swanson 2004b 181 183 1.831 (1.0853) 1.3 % 6.24 [ 0.74, 52.36 ]
Wilens 2010 30 30 3.8514 (1.4711) 0.7 % 47.06 [ 2.63, 841.09 ]
Zeni 2009 16 16 -0.1902 (0.3545) 5.9 % 0.83 [ 0.41, 1.66 ]
Subtotal (95% CI) 1927 1935 100.0 % 3.04 [ 2.35, 3.94 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 56.81, df = 34 (P = 0.01); I2 =40%
Test for overall effect: Z = 8.47 (P < 0.00001)
2 Diarrhoea
Pelham 2001a 68 68 -1.1133 (1.642) 11.7 % 0.33 [ 0.01, 8.21 ]
Rapport 2008 65 65 -0.2397 (0.695) 65.2 % 0.79 [ 0.20, 3.07 ]
Silva 2008 68 68 -1.1289 (1.1678) 23.1 % 0.32 [ 0.03, 3.19 ]
Subtotal (95% CI) 201 201 100.0 % 0.58 [ 0.19, 1.74 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
3 Dry mouth
Carlson 1995 12 12 1.182 (1.6833) 6.5 % 3.26 [ 0.12, 88.34 ]
Klorman 1990 48 48 1.4523 (1.1375) 14.1 % 4.27 [ 0.46, 39.72 ]
Pearson 2013 24 24 1.6946 (1.5765) 7.4 % 5.44 [ 0.25, 119.64 ]
Pelham 1990a 22 22 0 (1.4475) 8.7 % 1.00 [ 0.06, 17.07 ]
Rapport 2008 65 65 -0.2864 (0.5376) 63.3 % 0.75 [ 0.26, 2.15 ]
Subtotal (95% CI) 171 171 100.0 % 1.25 [ 0.54, 2.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.29, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
4 Dyspepsia
Quinn 2004 31 31 -1.4917 (1.1491) 100.0 % 0.22 [ 0.02, 2.14 ]
Subtotal (95% CI) 31 31 100.0 % 0.22 [ 0.02, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
5 Nausea
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Buitelaar 1995 26 11 -0.2007 (0.9521) 4.9 % 0.82 [ 0.13, 5.29 ]
Carlson 1995 12 12 1.182 (1.6833) 1.6 % 3.26 [ 0.12, 88.34 ]
Fitzpatrick 1992a 19 19 1.1513 (1.6649) 1.6 % 3.16 [ 0.12, 82.64 ]
Klorman 1990 48 48 -1.1194 (1.6457) 1.6 % 0.33 [ 0.01, 8.22 ]
McGough 2006 80 80 1.9839 (1.5202) 1.9 % 7.27 [ 0.37, 143.08 ]
Muniz 2008 84 83 1.0986 (1.6403) 1.7 % 3.00 [ 0.12, 74.70 ]
Pearson 2013 24 24 0 (1.4446) 2.1 % 1.00 [ 0.06, 16.97 ]
Ramtvedt 2013 34 34 0.3894 (0.245) 74.1 % 1.48 [ 0.91, 2.39 ]
Rapport 2008 65 65 0.61 (0.6531) 10.4 % 1.84 [ 0.51, 6.62 ]
Subtotal (95% CI) 392 376 100.0 % 1.52 [ 1.00, 2.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.11, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
6 Increased appetite
Pelham 2001a 68 68 -1.6226 (0.4717) 100.0 % 0.20 [ 0.08, 0.50 ]
Subtotal (95% CI) 68 68 100.0 % 0.20 [ 0.08, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00058)
7 Stomachache
Barkley 1989 82 82 0.8936 (0.3673) 6.6 % 2.44 [ 1.19, 5.02 ]
Brams 2008 86 86 -0.2998 (0.7795) 2.1 % 0.74 [ 0.16, 3.41 ]
Brams 2012 163 159 0.163 (0.6161) 3.1 % 1.18 [ 0.35, 3.94 ]
Buitelaar 1995 26 11 -1.0561 (0.9139) 1.6 % 0.35 [ 0.06, 2.09 ]
Bukstein 1998 18 18 1.2335 (0.2601) 9.4 % 3.43 [ 2.06, 5.72 ]
Carlson 1995 12 12 0.5108 (1.022) 1.3 % 1.67 [ 0.22, 12.35 ]
Chronis 2003 21 21 -0.3448 (0.8353) 1.8 % 0.71 [ 0.14, 3.64 ]
DuPaul 1996 24 24 0.39908 (0.7796) 2.1 % 1.49 [ 0.32, 6.87 ]
Findling 2007 16 16 1.2417 (1.2153) 0.9 % 3.46 [ 0.32, 37.47 ]
Fine 1993 12 12 0.4263 (0.4138) 5.6 % 1.53 [ 0.68, 3.45 ]
Fitzpatrick 1992a 19 19 1.1513 (1.6649) 0.5 % 3.16 [ 0.12, 82.64 ]
Klorman 1990 48 48 0 (0.8433) 1.8 % 1.00 [ 0.19, 5.22 ]
Kollins 2006 (PATS) 136 160 -0.5411 (0.874) 1.7 % 0.58 [ 0.10, 3.23 ]
Manos 1999 177 177 1.525 (0.5664) 3.6 % 4.60 [ 1.51, 13.95 ]
Muniz 2008 84 83 1.0986 (1.6403) 0.5 % 3.00 [ 0.12, 74.70 ]
Murray 2011 67 67 0.7244 (0.8839) 1.7 % 2.06 [ 0.36, 11.67 ]
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Study or subgroup Methylphenidate Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Musten 1997 41 41 -0.2844 (0.222) 10.7 % 0.75 [ 0.49, 1.16 ]
Pearson 2013 24 24 1.1896 (1.1935) 1.0 % 3.29 [ 0.32, 34.08 ]
Pelham 1990a 22 22 -0.4568 (0.9675) 1.4 % 0.63 [ 0.10, 4.22 ]
Pelham 1999 25 25 1.6911 (1.5754) 0.6 % 5.43 [ 0.25, 118.96 ]
Pelham 2001a 68 68 0.1346 (0.5194) 4.1 % 1.14 [ 0.41, 3.17 ]
Pelham 2005 36 36 2.0317 (1.5307) 0.6 % 7.63 [ 0.38, 153.21 ]
Ramtvedt 2013 34 34 0.3042 (0.244) 10.0 % 1.36 [ 0.84, 2.19 ]
Rapport 2008 65 65 0.1509 (0.5501) 3.7 % 1.16 [ 0.40, 3.42 ]
Schulz 2010 147 146 1.0986 (1.6372) 0.5 % 3.00 [ 0.12, 74.25 ]
Silva 2006 54 54 1.1371 (1.1712) 1.0 % 3.12 [ 0.31, 30.96 ]
Smith 1998 45 45 1.1076 (0.7136) 2.4 % 3.03 [ 0.75, 12.26 ]
Stein 1996 25 25 0.2719 (0.74) 2.3 % 1.31 [ 0.31, 5.60 ]
Stein 2003 47 47 1.0578 (0.4518) 5.0 % 2.88 [ 1.19, 6.98 ]
Stein 2011 42 45 1.7827 (1.1179) 1.1 % 5.95 [ 0.66, 53.18 ]
Swanson 2004b 181 183 0.3105 (0.5505) 3.7 % 1.36 [ 0.46, 4.01 ]
Wigal 2014 21 22 0.7397 (1.1861) 1.0 % 2.10 [ 0.20, 21.42 ]
Zeni 2009 16 16 0.429 (0.3582) 6.8 % 1.54 [ 0.76, 3.10 ]
Subtotal (95% CI) 1884 1893 100.0 % 1.61 [ 1.27, 2.04 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 41.01, df = 32 (P = 0.13); I2 =22%
Test for overall effect: Z = 3.97 (P = 0.000073)
8 Vomiting
Muniz 2008 84 83 1.0986 (1.6403) 14.7 % 3.00 [ 0.12, 74.70 ]
Pelham 2001a 68 68 0 (1.015) 38.5 % 1.00 [ 0.14, 7.31 ]
Swanson 2004b 181 183 -1.3919 (1.123) 31.4 % 0.25 [ 0.03, 2.25 ]
Wigal 2014 21 22 1.1431 (1.6055) 15.4 % 3.14 [ 0.13, 72.95 ]
Subtotal (95% CI) 354 356 100.0 % 0.90 [ 0.26, 3.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.47, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 48.70, df = 7 (P = 0.00), I2 =86%
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Analysis 8.5. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 5 Urinary system: urinary incontinence.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 5 Urinary system: urinary incontinence
Study or subgroup Methylphenidate Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pelham 2001a 1/68 2/68 0.50 [ 0.05, 5.39 ]
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Analysis 8.6. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 6 Skeletal and muscular system: somatic complaints.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 6 Skeletal and muscular system: somatic complaints
Study or subgroup Methylphenidate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gorman 2006 41 1.14 (0.15) 41 0.29 (0.1) 0.85 [ 0.79, 0.91 ]
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Analysis 8.7. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 7 Immune system.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 7 Immune system
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Allergic rhinitis
McGough 2006 2/80 0/80 21.0 % 5.00 [ 0.24, 102.53 ]
Pelham 2001a 1/68 0/68 18.9 % 3.00 [ 0.12, 72.37 ]
Silva 2008 1/68 2/68 33.9 % 0.50 [ 0.05, 5.39 ]
Wigal 2014 1/21 1/22 26.2 % 1.05 [ 0.07, 15.69 ]
Subtotal (95% CI) 237 238 100.0 % 1.38 [ 0.35, 5.51 ]
Total events: 5 (Methylphenidate), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
2 Fever
Pearson 2013 0/24 1/24 48.2 % 0.33 [ 0.01, 7.80 ]
Wigal 2014 2/21 0/22 51.8 % 5.23 [ 0.27, 102.87 ]
Subtotal (95% CI) 45 46 100.0 % 1.39 [ 0.09, 20.56 ]
Total events: 2 (Methylphenidate), 1 (Control)
Heterogeneity: Tau2 = 1.34; Chi2 = 1.55, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.24 (P = 0.81)
3 Lymphadenitis
McGough 2006 2/80 0/80 52.6 % 5.00 [ 0.24, 102.53 ]
Silva 2008 1/68 0/68 47.4 % 3.00 [ 0.12, 72.37 ]
Subtotal (95% CI) 148 148 100.0 % 3.93 [ 0.44, 35.11 ]
Total events: 3 (Methylphenidate), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
4 Pharyngolaryngeal pain
McGough 2006 2/80 1/80 100.0 % 2.00 [ 0.19, 21.62 ]
Subtotal (95% CI) 80 80 100.0 % 2.00 [ 0.19, 21.62 ]
Total events: 2 (Methylphenidate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
5 Pharyngitis
Brams 2012 1/163 4/159 36.0 % 0.24 [ 0.03, 2.16 ]
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Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
McGough 2006 1/80 2/80 30.2 % 0.50 [ 0.05, 5.40 ]
Pelham 2001a 1/68 0/68 16.9 % 3.00 [ 0.12, 72.37 ]
Silva 2008 1/68 0/68 16.9 % 3.00 [ 0.12, 72.37 ]
Subtotal (95% CI) 379 375 100.0 % 0.71 [ 0.19, 2.62 ]
Total events: 4 (Methylphenidate), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.58, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
6 Upper respiratory tract infection
Brams 2012 3/163 4/159 29.5 % 0.73 [ 0.17, 3.22 ]
McGough 2006 0/80 3/80 7.5 % 0.14 [ 0.01, 2.72 ]
Murray 2011 1/67 1/67 8.6 % 1.00 [ 0.06, 15.66 ]
Pelham 2001a 2/68 3/68 21.0 % 0.67 [ 0.12, 3.86 ]
Silva 2008 3/68 5/68 33.5 % 0.60 [ 0.15, 2.41 ]
Subtotal (95% CI) 446 442 100.0 % 0.61 [ 0.27, 1.37 ]
Total events: 9 (Methylphenidate), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
0.005 0.1 1 10 200
Favours methylphenidate Favours control
702Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.8. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 8 Skin.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 8 Skin
Study or subgroup Methylphenidate Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Rash
McGough 2006 1/80 2/80 63.7 % 0.50 [ 0.05, 5.40 ]
Pearson 2013 1/24 0/24 36.3 % 3.00 [ 0.13, 70.16 ]
Subtotal (95% CI) 104 104 100.0 % 0.96 [ 0.14, 6.41 ]
Total events: 2 (Methylphenidate), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Skin laceration
Muniz 2008 1/84 0/83 100.0 % 2.96 [ 0.12, 71.75 ]
Subtotal (95% CI) 84 83 100.0 % 2.96 [ 0.12, 71.75 ]
Total events: 1 (Methylphenidate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 8.9. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 9 Vital signs.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 9 Vital signs
Study or subgroup Methylphenidate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Diastolic blood pressure (mmHg)
Brown 1984a 11 61.27 (2.87) 11 62 (3.35) 14.2 % -0.73 [ -3.34, 1.88 ]
Brown 1988 11 83 (4.51) 11 69 (15.93) 2.5 % 14.00 [ 4.22, 23.78 ]
Brown 1991 22 72 (12.65) 22 76 (15.23) 3.3 % -4.00 [ -12.27, 4.27 ]
Findling 2007 20 64.7 (8.6) 20 61.7 (10.4) 5.7 % 3.00 [ -2.91, 8.91 ]
Gadow 2007 71 64.5 (11) 71 60 (9) 11.6 % 4.50 [ 1.19, 7.81 ]
Pearson 2013 24 70.17 (7.5) 24 70.48 (8.3) 8.3 % -0.31 [ -4.79, 4.17 ]
Silva 2005a 54 66.8 (9.6) 54 65.5 (8.8) 11.1 % 1.30 [ -2.17, 4.77 ]
Stein 2011 90 63.96 (9.386) 101 64.53 (8.57) 14.4 % -0.57 [ -3.13, 1.99 ]
Tannock 1989 12 66.6 (5.7) 12 63.8 (4.8) 8.9 % 2.80 [ -1.42, 7.02 ]
Urman 1995 34 75.8 (5.3) 34 74.1 (5.5) 14.4 % 1.70 [ -0.87, 4.27 ]
Zeiner 1999 23 66.9 (12.2) 23 68.7 (8.1) 5.6 % -1.80 [ -7.78, 4.18 ]
Subtotal (95% CI) 372 383 100.0 % 1.23 [ -0.39, 2.86 ]
Heterogeneity: Tau2 = 3.06; Chi2 = 18.25, df = 10 (P = 0.05); I2 =45%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Systolic blood pressure (mmHg)
Brown 1984a 11 92.36 (5.57) 11 92.73 (3.38) 10.7 % -0.37 [ -4.22, 3.48 ]
Brown 1988 11 98 (1.54) 11 94.66 (3.88) 14.9 % 3.34 [ 0.87, 5.81 ]
Brown 1991 22 119.5 (8.23) 22 124 (4.9) 10.3 % -4.50 [ -8.50, -0.50 ]
Findling 2007 20 114.9 (11.7) 20 118.1 (6.2) 6.7 % -3.20 [ -9.00, 2.60 ]
Gadow 2007 71 104.3 (15.2) 71 99 (17.9) 7.3 % 5.30 [ -0.16, 10.76 ]
Pearson 2013 24 103.6 (9.4) 24 105.7 (10.3) 7.1 % -2.10 [ -7.68, 3.48 ]
Silva 2005a 54 104.7 (9.4) 54 101.8 (10) 11.3 % 2.90 [ -0.76, 6.56 ]
Stein 2011 90 103.96 (12.017) 101 103.25 (11.725) 12.1 % 0.71 [ -2.67, 4.09 ]
Tannock 1989 12 104.4 (9.8) 12 100.7 (8.9) 4.6 % 3.70 [ -3.79, 11.19 ]
Urman 1995 34 105 (9.2) 34 104.5 (7.8) 10.2 % 0.50 [ -3.55, 4.55 ]
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Study or subgroup Methylphenidate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zeiner 1999 23 111.8 (14.3) 23 114.3 (10.8) 4.8 % -2.50 [ -9.82, 4.82 ]
Subtotal (95% CI) 372 383 100.0 % 0.53 [ -1.30, 2.36 ]
Heterogeneity: Tau2 = 4.28; Chi2 = 19.25, df = 10 (P = 0.04); I2 =48%
Test for overall effect: Z = 0.57 (P = 0.57)
3 Pulse or heart rate (bpm)
Brown 1984a 11 86.82 (8.59) 11 82.91 (8.3) 5.7 % 3.91 [ -3.15, 10.97 ]
Brown 1988 11 82.5 (3.2) 11 71.83 (3.81) 11.3 % 10.67 [ 7.73, 13.61 ]
Brown 1991 7 87.25 (8.54) 7 89 (9.63) 3.8 % -1.75 [ -11.28, 7.78 ]
Findling 2007 20 91.4 (14.3) 20 89.5 (12) 4.7 % 1.90 [ -6.28, 10.08 ]
Gadow 1995 34 93.5 (13.9) 34 85.5 (10) 7.2 % 8.00 [ 2.24, 13.76 ]
Gadow 2007 71 91.6 (14.8) 71 86 (11.9) 9.0 % 5.60 [ 1.18, 10.02 ]
Pearson 2013 24 97.43 (15.8) 24 89.57 (17.3) 3.9 % 7.86 [ -1.51, 17.23 ]
Rapport 1987 47 94.2 (11.2) 47 86.2 (9.3) 9.4 % 8.00 [ 3.84, 12.16 ]
Silva 2005a 54 90.6 (12.4) 54 88.2 (8.5) 9.6 % 2.40 [ -1.61, 6.41 ]
Stein 2011 89 73.2 (9.853) 98 72.72 (11.801) 11.1 % 0.48 [ -2.63, 3.59 ]
Tannock 1989 12 96.3 (12.3) 12 91.9 (12) 3.7 % 4.40 [ -5.32, 14.12 ]
Tannock 1995a 28 95.9 (8.9) 28 91.7 (10.3) 8.1 % 4.20 [ -0.84, 9.24 ]
Urman 1995 34 91.2 (12.4) 34 86.1 (9.8) 7.7 % 5.10 [ -0.21, 10.41 ]
Zeiner 1999 23 75.8 (15.5) 23 69.6 (13.1) 4.7 % 6.20 [ -2.09, 14.49 ]
Subtotal (95% CI) 465 474 100.0 % 5.06 [ 2.88, 7.24 ]
Heterogeneity: Tau2 = 8.67; Chi2 = 30.01, df = 13 (P = 0.005); I2 =57%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.88, df = 2 (P = 0.00), I2 =82%
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Analysis 8.10. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 10 Height (cm).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 10 Height (cm)
Study or subgroup Methylphenidate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zeiner 1999 23 150.4 (11.2) 23 148.3 (9.4) 2.10 [ -3.88, 8.08 ]
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Analysis 8.11. Comparison 8 Number of non-serious adverse events: cross-over trials (endpoint data),
Outcome 11 Weight.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 8 Number of non-serious adverse events: cross-over trials (endpoint data)
Outcome: 11 Weight
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 1988 11 103.66 (4.63) 11 102.16 (4.4) 4.1 % 0.32 [ -0.52, 1.16 ]
Gadow 2007 71 77.8 (31.6) 71 79.3 (32.3) 26.9 % -0.05 [ -0.38, 0.28 ]
Gorman 2006 41 36.09 (1.99) 41 36.54 (2.01) 15.4 % -0.22 [ -0.66, 0.21 ]
Pearson 2013 24 32.47 (8.8) 24 33.03 (8.6) 9.1 % -0.06 [ -0.63, 0.50 ]
Stein 2011 88 49.716 (18.9817) 102 51.62 (22.2636) 35.8 % -0.09 [ -0.38, 0.19 ]
Zeiner 1999 23 42 (10.2) 23 40.3 (8) 8.7 % 0.18 [ -0.40, 0.76 ]
Total (95% CI) 258 272 100.0 % -0.06 [ -0.23, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.04, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Teacher-rated general behaviour, Outcome 1 All parallel-group trials and first-
period cross-over trials: risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 1 All parallel-group trials and first-period cross-over trials: risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 19.6 % -0.84 [ -1.21, -0.46 ]
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 50.3 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 4.1 % -0.67 [ -1.48, 0.14 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 6.9 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 19.0 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Total (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Teacher-rated general behaviour, Outcome 2 Subgroup analysis: types of scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 2 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Conners’ Global Index - Teacher (CGI-T)
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 50.3 % -0.91 [ -1.14, -0.68 ]
Subtotal (95% CI) 155 159 50.3 % -0.91 [ -1.14, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.68 (P < 0.00001)
2 Groninger Behaviour Observation Scale (GBOS)
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 6.9 % -0.84 [ -1.46, -0.21 ]
Subtotal (95% CI) 22 21 6.9 % -0.84 [ -1.46, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
3 Conners’ Teacher Rating Scale - Conduct problems
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 4.1 % -0.67 [ -1.48, 0.14 ]
Subtotal (95% CI) 13 12 4.1 % -0.67 [ -1.48, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
4 IOWA Conners’ Rating Scale - Oppositional/Defiant (IOWA-O/D)
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 19.6 % -0.84 [ -1.21, -0.46 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 19.0 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 201 85 38.6 % -0.86 [ -1.12, -0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 6.31 (P < 0.00001)
Total (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.38, df = 3 (P = 0.94), I2 =0.0%
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Analysis 9.3. Comparison 9 Teacher-rated general behaviour, Outcome 3 Subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 3 Subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Ialongo 1994 16 3.85 (3.95) 12 5.83 (5) 4.5 % -0.43 [ -1.19, 0.32 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 6.6 % -0.84 [ -1.46, -0.21 ]
Subtotal (95% CI) 38 33 11.1 % -0.67 [ -1.16, -0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0062)
2 High dose
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 48.0 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 4.0 % -0.67 [ -1.48, 0.14 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 18.2 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 249 217 70.2 % -0.89 [ -1.08, -0.70 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 9.05 (P < 0.00001)
3 Unknown dose
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 18.7 % -0.84 [ -1.21, -0.46 ]
Subtotal (95% CI) 120 39 18.7 % -0.84 [ -1.21, -0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
Total (95% CI) 407 289 100.0 % -0.85 [ -1.02, -0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.66, df = 2 (P = 0.72), I2 =0.0%
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Analysis 9.4. Comparison 9 Teacher-rated general behaviour, Outcome 4 Subgroup analysis: duration of
treatment.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 4 Subgroup analysis: duration of treatment
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short term (up to 6 months)
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 19.6 % -0.84 [ -1.21, -0.46 ]
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 50.3 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 4.1 % -0.67 [ -1.48, 0.14 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 6.9 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 19.0 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
2 Long term (over 6 months)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Teacher-rated general behaviour, Outcome 5 Subgroup analysis: parallel-group
trials versus first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 5 Subgroup analysis: parallel-group trials versus first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 19.6 % -0.84 [ -1.21, -0.46 ]
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 50.3 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 4.1 % -0.67 [ -1.48, 0.14 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 6.9 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 19.0 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
2 First-period cross-over trials
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 391 277 100.0 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.6. Comparison 9 Teacher-rated general behaviour, Outcome 6 General behaviour, cross-over
trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 6 General behaviour, cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Brown 1991 22 0.44 (0.7) 22 0.35 (0.42) 2.3 % 0.15 [ -0.44, 0.75 ]
Fabiano 2007 48 0.5 (1.09) 48 1.68 (2.3) 4.8 % -0.65 [ -1.06, -0.24 ]
Fitzpatrick 1992a 19 0.31 (0.5) 19 0.7 (0.72) 1.9 % -0.62 [ -1.27, 0.04 ]
Gadow 1995 34 2.6 (3.4) 34 4.3 (3.7) 3.5 % -0.47 [ -0.96, 0.01 ]
Gadow 2007 71 1.7 (2.8) 71 3.4 (3.7) 7.3 % -0.52 [ -0.85, -0.18 ]
Gadow 2011 54 2.6 (3) 54 4.2 (3.8) 5.6 % -0.46 [ -0.85, -0.08 ]
Kolko 1999 22 2.6 (2.8) 22 5.7 (5.2) 2.2 % -0.73 [ -1.34, -0.12 ]
Lufi 2007 19 8.59 (9.73) 19 14 (12.68) 2.0 % -0.47 [ -1.11, 0.18 ]
Pelham 1993a 31 0.8 (1.4) 31 4 (4.3) 2.9 % -0.99 [ -1.52, -0.46 ]
Pelham 1999 25 0.6 (1) 25 2.6 (2.6) 2.3 % -1.00 [ -1.59, -0.41 ]
Pelham 2002 136 0.5 (1.1) 136 1.9 (2.7) 13.7 % -0.68 [ -0.92, -0.43 ]
Pelham 2005 29 0.6 (1.1) 29 1.9 (2.7) 2.9 % -0.62 [ -1.15, -0.09 ]
Smith 1998 45 0.9 (1.8) 45 2.5 (3.4) 4.6 % -0.58 [ -1.01, -0.16 ]
Subtotal (95% CI) 555 555 56.0 % -0.60 [ -0.72, -0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.82, df = 12 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 9.69 (P < 0.00001)
2 High dose
Chronis 2003 21 0.4 (0.5) 21 2.9 (2.8) 1.9 % -1.22 [ -1.88, -0.56 ]
Fabiano 2007 48 0.4 (1.22) 48 1.68 (2.3) 4.8 % -0.69 [ -1.10, -0.28 ]
Fitzpatrick 1992a 19 0.26 (0.31) 19 0.7 (0.72) 1.9 % -0.78 [ -1.44, -0.12 ]
Gadow 1995 34 1.4 (2) 34 4.3 (3.7) 3.2 % -0.96 [ -1.47, -0.46 ]
Gadow 2007 71 1.1 (1.9) 71 3.4 (3.7) 7.0 % -0.78 [ -1.12, -0.44 ]
Gadow 2011 54 1.6 (2.1) 54 4.2 (3.8) 5.3 % -0.84 [ -1.24, -0.45 ]
Kolko 1999 22 2.7 (3.5) 22 5.7 (5.2) 2.2 % -0.66 [ -1.27, -0.06 ]
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(. . . Continued)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 1993a 31 0.4 (1) 31 4 (4.3) 2.8 % -1.14 [ -1.68, -0.60 ]
Pelham 2001a 68 1.99 (3.03) 68 5.09 (4.85) 6.7 % -0.76 [ -1.11, -0.41 ]
Pelham 2005 29 0.4 (1.1) 29 1.9 (2.7) 2.9 % -0.72 [ -1.25, -0.19 ]
Pelham 2011 10 4.7 (4.3) 10 9 (5) 0.9 % -0.88 [ -1.81, 0.05 ]
Smith 1998 45 0.6 (1.2) 45 2.5 (3.4) 4.5 % -0.74 [ -1.17, -0.31 ]
Subtotal (95% CI) 452 452 44.0 % -0.82 [ -0.95, -0.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.17, df = 11 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 11.76 (P < 0.00001)
Total (95% CI) 1007 1007 100.0 % -0.69 [ -0.78, -0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 21.62, df = 24 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 15.05 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.63, df = 1 (P = 0.02), I2 =82%
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Analysis 9.7. Comparison 9 Teacher-rated general behaviour, Outcome 7 Subgroup analysis: general
behaviour, cross-over trials (endpoint data): risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 7 Subgroup analysis: general behaviour, cross-over trials (endpoint data): risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Brown 1991 22 0.44 (0.7) 22 0.35 (0.42) 3.8 % 0.15 [ -0.44, 0.75 ]
Chronis 2003 21 0.4 (0.5) 21 2.9 (2.8) 3.0 % -1.22 [ -1.88, -0.56 ]
Fabiano 2007 48 0.4 (1.22) 48 1.68 (2.3) 7.6 % -0.69 [ -1.10, -0.28 ]
Fitzpatrick 1992a 19 0.26 (0.31) 19 0.7 (0.72) 3.1 % -0.78 [ -1.44, -0.12 ]
Gadow 1995 34 1.4 (2) 34 4.3 (3.7) 5.2 % -0.96 [ -1.47, -0.46 ]
Gadow 2007 71 1.1 (1.9) 71 3.4 (3.7) 10.8 % -0.78 [ -1.12, -0.44 ]
Gadow 2011 54 1.6 (2.1) 54 4.2 (3.8) 8.3 % -0.84 [ -1.24, -0.45 ]
Kolko 1999 22 2.7 (3.5) 22 5.7 (5.2) 3.6 % -0.66 [ -1.27, -0.06 ]
Lufi 2007 19 8.59 (9.73) 19 14 (12.68) 3.2 % -0.47 [ -1.11, 0.18 ]
Pelham 1993a 31 0.4 (1) 31 4 (4.3) 4.6 % -1.14 [ -1.68, -0.60 ]
Pelham 1999 25 0.6 (1) 25 2.6 (2.6) 3.8 % -1.00 [ -1.59, -0.41 ]
Pelham 2001a 68 1.99 (3.03) 68 5.09 (4.85) 10.4 % -0.76 [ -1.11, -0.41 ]
Pelham 2002 136 0.5 (1.1) 136 1.9 (2.7) 19.4 % -0.68 [ -0.92, -0.43 ]
Pelham 2005 29 0.4 (1.1) 29 1.9 (2.7) 4.7 % -0.72 [ -1.25, -0.19 ]
Pelham 2011 10 4.7 (4.3) 10 9 (5) 1.6 % -0.88 [ -1.81, 0.05 ]
Smith 1998 45 0.6 (1.2) 45 2.5 (3.4) 7.1 % -0.74 [ -1.17, -0.31 ]
Subtotal (95% CI) 654 654 100.0 % -0.75 [ -0.87, -0.63 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 15.80, df = 15 (P = 0.40); I2 =5%
Test for overall effect: Z = 12.53 (P < 0.00001)
Total (95% CI) 654 654 100.0 % -0.75 [ -0.87, -0.63 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 15.80, df = 15 (P = 0.40); I2 =5%
Test for overall effect: Z = 12.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Teacher-rated general behaviour, Outcome 8 Subgroup analysis: all parallel-
group trials and first-period cross-over trials (teacher-rated) versus cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 9 Teacher-rated general behaviour
Outcome: 8 Subgroup analysis: all parallel-group trials and first-period cross-over trials (teacher-rated) versus cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All parallel-group trials and first-period cross-over trials
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 6.2 % -0.84 [ -1.21, -0.46 ]
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 16.0 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 1.3 % -0.67 [ -1.48, 0.14 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 2.2 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 6.1 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 391 277 31.8 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
2 Cross-over trials (endpoint data)
Brown 1991 22 0.44 (0.7) 22 0.35 (0.42) 2.5 % 0.15 [ -0.44, 0.75 ]
Chronis 2003 21 0.4 (0.5) 21 2.9 (2.8) 2.0 % -1.22 [ -1.88, -0.56 ]
Fabiano 2007 48 0.4 (1.22) 48 1.68 (2.3) 5.1 % -0.69 [ -1.10, -0.28 ]
Fitzpatrick 1992a 19 0.26 (0.31) 19 0.7 (0.72) 2.0 % -0.78 [ -1.44, -0.12 ]
Gadow 1995 34 1.4 (2) 34 4.3 (3.7) 3.4 % -0.96 [ -1.47, -0.46 ]
Gadow 2007 71 1.1 (1.9) 71 3.4 (3.7) 7.4 % -0.78 [ -1.12, -0.44 ]
Gadow 2011 54 1.6 (2.1) 54 4.2 (3.8) 5.6 % -0.84 [ -1.24, -0.45 ]
Kolko 1999 22 2.7 (3.5) 22 5.7 (5.2) 2.3 % -0.66 [ -1.27, -0.06 ]
Lufi 2007 19 8.59 (9.73) 19 14 (12.68) 2.1 % -0.47 [ -1.11, 0.18 ]
Pelham 1993a 31 0.4 (1) 31 4 (4.3) 3.0 % -1.14 [ -1.68, -0.60 ]
Pelham 1999 25 0.6 (1) 25 2.6 (2.6) 2.5 % -1.00 [ -1.59, -0.41 ]
Pelham 2001a 68 1.99 (3.03) 68 5.09 (4.85) 7.1 % -0.76 [ -1.11, -0.41 ]
Pelham 2002 136 0.5 (1.1) 136 1.9 (2.7) 14.5 % -0.68 [ -0.92, -0.43 ]
Pelham 2005 29 0.4 (1.1) 29 1.9 (2.7) 3.1 % -0.72 [ -1.25, -0.19 ]
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Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pelham 2011 10 4.7 (4.3) 10 9 (5) 1.0 % -0.88 [ -1.81, 0.05 ]
Smith 1998 45 0.6 (1.2) 45 2.5 (3.4) 4.7 % -0.74 [ -1.17, -0.31 ]
Subtotal (95% CI) 654 654 68.2 % -0.75 [ -0.87, -0.63 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 15.80, df = 15 (P = 0.40); I2 =5%
Test for overall effect: Z = 12.53 (P < 0.00001)
Total (95% CI) 1045 931 100.0 % -0.79 [ -0.88, -0.70 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 17.73, df = 20 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 16.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.45, df = 1 (P = 0.23), I2 =31%
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Analysis 10.1. Comparison 10 Independent assessor-rated general behaviour, Outcome 1 General
behaviour, cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 10 Independent assessor-rated general behaviour
Outcome: 1 General behaviour, cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Chronis 2003 21 3.1 (2.4) 21 4.4 (3.2) 4.8 % -0.45 [ -1.06, 0.16 ]
Fabiano 2007 48 1.7 (2.5) 48 3.3 (3.3) 9.0 % -0.54 [ -0.95, -0.13 ]
Pelham 1999 25 1.1 (1.1) 25 5.2 (4.2) 4.8 % -1.31 [ -1.93, -0.70 ]
Pelham 2002 136 1.7 (1.3) 136 3.3 (2.8) 15.9 % -0.73 [ -0.98, -0.49 ]
Pelham 2005 29 2.3 (2.2) 29 2.9 (2.2) 6.4 % -0.27 [ -0.79, 0.25 ]
Pelham 2014 47 2.1 (2.4) 47 3.3 (3.3) 9.0 % -0.41 [ -0.82, 0.00 ]
Schulz 2010 146 35.6 (21) 145 44.6 (23.7) 16.7 % -0.40 [ -0.63, -0.17 ]
Subtotal (95% CI) 452 451 66.5 % -0.56 [ -0.76, -0.36 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 11.26, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 5.46 (P < 0.00001)
2 High dose
Chronis 2003 21 2.2 (1.6) 21 4.4 (3.2) 4.6 % -0.85 [ -1.49, -0.22 ]
Fabiano 2007 48 1.1 (1.5) 48 3.3 (3.3) 8.7 % -0.85 [ -1.27, -0.43 ]
Pelham 2005 29 2 (1.6) 29 2.9 (2.2) 6.3 % -0.46 [ -0.98, 0.06 ]
Pelham 2014 47 1.1 (1.5) 47 3.3 (3.3) 8.5 % -0.85 [ -1.27, -0.43 ]
Whalen 1990 24 3.25 (4.81) 24 4.79 (3.9) 5.4 % -0.35 [ -0.92, 0.22 ]
Subtotal (95% CI) 169 169 33.5 % -0.71 [ -0.93, -0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.50, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 6.27 (P < 0.00001)
Total (95% CI) 621 620 100.0 % -0.60 [ -0.75, -0.46 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 16.14, df = 11 (P = 0.14); I2 =32%
Test for overall effect: Z = 7.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 10.2. Comparison 10 Independent assessor-rated general behaviour, Outcome 2 Subgroup
analysis: general behaviour, cross-over trials (endpoint data): risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 10 Independent assessor-rated general behaviour
Outcome: 2 Subgroup analysis: general behaviour, cross-over trials (endpoint data): risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Chronis 2003 21 2.2 (1.6) 21 4.4 (3.2) 7.3 % -0.85 [ -1.49, -0.22 ]
Fabiano 2007 48 1.1 (1.5) 48 3.3 (3.3) 12.7 % -0.85 [ -1.27, -0.43 ]
Pelham 1999 25 1.1 (1.1) 25 5.2 (4.2) 7.7 % -1.31 [ -1.93, -0.70 ]
Pelham 2002 136 1.7 (1.3) 136 3.3 (2.8) 20.4 % -0.73 [ -0.98, -0.49 ]
Pelham 2005 29 2 (1.6) 29 2.9 (2.2) 9.7 % -0.46 [ -0.98, 0.06 ]
Pelham 2014 47 1.1 (1.5) 47 3.3 (3.3) 12.6 % -0.85 [ -1.27, -0.43 ]
Schulz 2010 146 35.6 (21) 145 44.6 (23.7) 21.1 % -0.40 [ -0.63, -0.17 ]
Whalen 1990 24 3.25 (4.81) 24 4.79 (3.9) 8.6 % -0.35 [ -0.92, 0.22 ]
Subtotal (95% CI) 476 475 100.0 % -0.69 [ -0.88, -0.49 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.05, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 6.81 (P < 0.00001)
Total (95% CI) 476 475 100.0 % -0.69 [ -0.88, -0.49 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.05, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 6.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Independent assessor-rated general behaviour, Outcome 3 Subgroup
analysis: all parallel-group trials and first-period cross-over trials (independent assessor-rated) compared with
cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 10 Independent assessor-rated general behaviour
Outcome: 3 Subgroup analysis: all parallel-group trials and first-period cross-over trials (independent assessor-rated) compared with cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials and first-period cross-over trials
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Cross-over trials (endpoint data)
Chronis 2003 21 2.2 (1.6) 21 4.4 (3.2) 7.3 % -0.85 [ -1.49, -0.22 ]
Fabiano 2007 48 1.1 (1.5) 48 3.3 (3.3) 12.7 % -0.85 [ -1.27, -0.43 ]
Pelham 1999 25 1.1 (1.1) 25 5.2 (4.2) 7.7 % -1.31 [ -1.93, -0.70 ]
Pelham 2002 136 1.7 (1.3) 136 3.3 (2.8) 20.4 % -0.73 [ -0.98, -0.49 ]
Pelham 2005 29 2 (1.6) 29 2.9 (2.2) 9.7 % -0.46 [ -0.98, 0.06 ]
Pelham 2014 47 1.1 (1.5) 47 3.3 (3.3) 12.6 % -0.85 [ -1.27, -0.43 ]
Schulz 2010 146 35.6 (21) 145 44.6 (23.7) 21.1 % -0.40 [ -0.63, -0.17 ]
Whalen 1990 24 3.25 (4.81) 24 4.79 (3.9) 8.6 % -0.35 [ -0.92, 0.22 ]
Subtotal (95% CI) 476 475 100.0 % -0.69 [ -0.88, -0.49 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.05, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 6.81 (P < 0.00001)
Total (95% CI) 476 475 100.0 % -0.69 [ -0.88, -0.49 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.05, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 6.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Parent-rated general behaviour, Outcome 1 All parallel-group trials and first-
period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 1 All parallel-group trials and first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Parent-rated general behaviour, Outcome 2 Subgroup analysis: risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 2 Subgroup analysis: risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Parent-rated general behaviour, Outcome 3 Subgroup analysis: types of
scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 3 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 The Weekly Parent Ratings of Evening and Morning Behaviour (WPREMB) - Revised
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Subtotal (95% CI) 9 8 5.9 % 0.50 [ -0.47, 1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
2 Conners’ Global Index (CGI) - Parent
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Subtotal (95% CI) 175 177 44.3 % -0.41 [ -0.63, -0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.85 (P = 0.00012)
3 Swanson, Nolan and Pelham, Fourth Edition - Oppositional (SNAP-IV-Oppositional)
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 9 6 4.8 % -0.86 [ -1.95, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
4 IOWA Conners’ Rating Scale - Oppositional/Defiant (IOWA-I/O)
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Subtotal (95% CI) 201 85 45.1 % -0.75 [ -1.01, -0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.59 (P < 0.00001)
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 8.52, df = 3 (P = 0.04), I2 =65%
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Analysis 11.4. Comparison 11 Parent-rated general behaviour, Outcome 4 Subgroup analysis: parallel-group
trials compared with first-period cross-over trials.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 4 Subgroup analysis: parallel-group trials compared with first-period cross-over trials
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Parallel-group trials
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Subtotal (95% CI) 385 270 95.2 % -0.51 [ -0.78, -0.23 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.30, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 3.62 (P = 0.00029)
2 First-period cross-over trials
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 9 6 4.8 % -0.86 [ -1.95, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 11.5. Comparison 11 Parent-rated general behaviour, Outcome 5 Subgroup analysis: duration of
treatment.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 5 Subgroup analysis: duration of treatment
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short term (up to 6 months)
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
2 Long term (over 6 months)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Parent-rated general behaviour, Outcome 6 Subgroup analysis: dose.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 6 Subgroup analysis: dose
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High dose
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 5.9 % 0.50 [ -0.47, 1.47 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 32.8 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 11.5 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 22.4 % -0.78 [ -1.16, -0.41 ]
Subtotal (95% CI) 265 231 72.6 % -0.42 [ -0.77, -0.08 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 6.88, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 2.39 (P = 0.017)
3 Unknown dose
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 22.7 % -0.72 [ -1.09, -0.35 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 4.8 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 129 45 27.4 % -0.73 [ -1.08, -0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000040)
Total (95% CI) 394 276 100.0 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
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Analysis 11.7. Comparison 11 Parent-rated general behaviour, Outcome 7 General behaviour, cross-over
trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 7 General behaviour, cross-over trials (endpoint data)
Study or subgroup Methylphenidate Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low dose
Findling 2007 16 56 (8) 16 73.9 (19.4) 5.5 % -1.18 [ -1.93, -0.42 ]
Fitzpatrick 1992a 19 0.68 (0.53) 19 1.15 (0.61) 7.2 % -0.81 [ -1.47, -0.14 ]
Gadow 1995 34 1.9 (1.7) 34 2.4 (2) 13.3 % -0.27 [ -0.74, 0.21 ]
Pelham 1999 25 1.2 (1.4) 25 2.5 (2.1) 9.5 % -0.72 [ -1.29, -0.14 ]
Pelham 2005 30 1.3 (1.1) 30 2.5 (2.2) 11.3 % -0.68 [ -1.20, -0.16 ]
Subtotal (95% CI) 124 124 46.7 % -0.65 [ -0.93, -0.38 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.60, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 4.61 (P < 0.00001)
2 High dose
Fitzpatrick 1992a 19 0.6 (0.39) 19 1.15 (0.61) 6.8 % -1.05 [ -1.73, -0.37 ]
Gadow 1995 34 1.5 (1.7) 34 2.4 (2) 13.0 % -0.48 [ -0.96, 0.00 ]
Pelham 2001a 68 5.26 (3.85) 68 8.85 (4.04) 22.8 % -0.90 [ -1.26, -0.55 ]
Pelham 2005 30 0.8 (1.1) 30 2.5 (2.2) 10.7 % -0.96 [ -1.50, -0.43 ]
Subtotal (95% CI) 151 151 53.3 % -0.83 [ -1.07, -0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 6.90 (P < 0.00001)
Total (95% CI) 275 275 100.0 % -0.75 [ -0.93, -0.56 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.57, df = 8 (P = 0.38); I2 =7%
Test for overall effect: Z = 8.05 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
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Analysis 11.8. Comparison 11 Parent-rated general behaviour, Outcome 8 Subgroup analysis: general
behaviour, cross-over trials (endpoint data): risk of bias.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 8 Subgroup analysis: general behaviour, cross-over trials (endpoint data): risk of bias
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High risk of bias
Findling 2007 16 56 (8) 16 73.9 (19.4) 7.7 % -1.18 [ -1.93, -0.42 ]
Fitzpatrick 1992a 19 0.6 (0.39) 19 1.15 (0.61) 9.4 % -1.05 [ -1.73, -0.37 ]
Gadow 1995 34 1.5 (1.7) 34 2.4 (2) 18.9 % -0.48 [ -0.96, 0.00 ]
Pelham 1999 25 1.2 (1.4) 25 2.5 (2.1) 13.4 % -0.72 [ -1.29, -0.14 ]
Pelham 2001a 68 5.26 (3.85) 68 8.85 (4.04) 35.3 % -0.90 [ -1.26, -0.55 ]
Pelham 2005 30 0.8 (1.1) 30 2.5 (2.2) 15.3 % -0.96 [ -1.50, -0.43 ]
Subtotal (95% CI) 192 192 100.0 % -0.84 [ -1.05, -0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.78, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 7.87 (P < 0.00001)
Total (95% CI) 192 192 100.0 % -0.84 [ -1.05, -0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.78, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 7.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.9. Comparison 11 Parent-rated general behaviour, Outcome 9 Subgroup analysis: all parallel-
group trials and first-period cross-over trials (parent-rated) compared with cross-over trials (endpoint data).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 11 Parent-rated general behaviour
Outcome: 9 Subgroup analysis: all parallel-group trials and first-period cross-over trials (parent-rated) compared with cross-over trials (endpoint data)
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All parallel-group trials and first-period cross-over trials
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 3.1 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 12.1 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 17.7 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 6.0 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 11.9 % -0.78 [ -1.16, -0.41 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 2.5 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 394 276 53.3 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
2 Cross-over trials (endpoint data)
Findling 2007 16 56 (8) 16 73.9 (19.4) 4.7 % -1.18 [ -1.93, -0.42 ]
Fitzpatrick 1992a 19 0.6 (0.39) 19 1.15 (0.61) 5.5 % -1.05 [ -1.73, -0.37 ]
Gadow 1995 34 1.5 (1.7) 34 2.4 (2) 9.0 % -0.48 [ -0.96, 0.00 ]
Pelham 1999 25 1.2 (1.4) 25 2.5 (2.1) 7.1 % -0.72 [ -1.29, -0.14 ]
Pelham 2001a 68 5.26 (3.85) 68 8.85 (4.04) 12.7 % -0.90 [ -1.26, -0.55 ]
Pelham 2005 30 0.8 (1.1) 30 2.5 (2.2) 7.8 % -0.96 [ -1.50, -0.43 ]
Subtotal (95% CI) 192 192 46.7 % -0.84 [ -1.05, -0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.78, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 7.87 (P < 0.00001)
Total (95% CI) 586 468 100.0 % -0.68 [ -0.86, -0.50 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 18.02, df = 11 (P = 0.08); I2 =39%
Test for overall effect: Z = 7.30 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.56, df = 1 (P = 0.06), I2 =72%
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Analysis 12.1. Comparison 12 Additional subgroup analyses of general behaviour: parallel-group trials and
first-period cross-over trials, Outcome 1 Comparisions of raters.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 12 Additional subgroup analyses of general behaviour: parallel-group trials and first-period cross-over trials
Outcome: 1 Comparisions of raters
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Teacher-rated
Findling 2006 120 2.3 (2.7386) 39 4.6 (2.7478) 11.4 % -0.84 [ -1.21, -0.46 ]
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 16.8 % -0.91 [ -1.14, -0.68 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 3.9 % -0.67 [ -1.48, 0.14 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 5.8 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 11.3 % -0.88 [ -1.25, -0.50 ]
Subtotal (95% CI) 391 277 49.2 % -0.87 [ -1.04, -0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
2 Independent assessor-rated
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Parent-rated
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 2.8 % 0.50 [ -0.47, 1.47 ]
Findling 2006 120 4.6 (3.1768) 39 6.9 (3.1849) 11.5 % -0.72 [ -1.09, -0.35 ]
Greenhill 2002 155 7.4 (5.9) 159 10.1 (6.7) 17.2 % -0.43 [ -0.65, -0.20 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 5.6 % -0.32 [ -0.96, 0.32 ]
Wolraich 2001 81 4.81 (3.87) 46 8.09 (4.63) 11.4 % -0.78 [ -1.16, -0.41 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 2.3 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 394 276 50.8 % -0.53 [ -0.78, -0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.67, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 4.09 (P = 0.000043)
Total (95% CI) 785 553 100.0 % -0.69 [ -0.86, -0.52 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 17.93, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 7.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.10, df = 1 (P = 0.02), I2 =80%
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Analysis 12.2. Comparison 12 Additional subgroup analyses of general behaviour: parallel-group trials and
first-period cross-over trials, Outcome 2 Comorbidity versus no comorbidity.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 12 Additional subgroup analyses of general behaviour: parallel-group trials and first-period cross-over trials
Outcome: 2 Comorbidity versus no comorbidity
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ADHD with comorbidity
Carlson 2007 9 1.9 (9.4) 8 -2.1 (4.8) 6.7 % 0.50 [ -0.47, 1.47 ]
Ialongo 1994 13 3.07 (2.78) 12 5.83 (5) 8.9 % -0.67 [ -1.48, 0.14 ]
Pliszka 2000 20 1.28 (0.72) 18 1.54 (0.88) 12.6 % -0.32 [ -0.96, 0.32 ]
Van der Meere 1999a 22 37.8 (5.8543) 21 42.8 (5.8543) 13.0 % -0.84 [ -1.46, -0.21 ]
Wolraich 2001 81 1.78 (2.99) 46 5.21 (5.12) 22.6 % -0.88 [ -1.25, -0.50 ]
Zeni 2009 9 0.9444 (0.61798) 6 1.6 (0.85346) 5.5 % -0.86 [ -1.95, 0.23 ]
Subtotal (95% CI) 154 111 69.2 % -0.59 [ -0.95, -0.23 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 8.25, df = 5 (P = 0.14); I2 =39%
Test for overall effect: Z = 3.23 (P = 0.0013)
2 ADHD without comorbidity
Greenhill 2002 155 4.9 (4.66) 159 10.3 (6.92) 30.8 % -0.91 [ -1.14, -0.68 ]
Subtotal (95% CI) 155 159 30.8 % -0.91 [ -1.14, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.68 (P < 0.00001)
Total (95% CI) 309 270 100.0 % -0.70 [ -0.98, -0.43 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 10.19, df = 6 (P = 0.12); I2 =41%
Test for overall effect: Z = 4.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.13, df = 1 (P = 0.14), I2 =53%
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Analysis 12.3. Comparison 12 Additional subgroup analyses of general behaviour: parallel-group trials and
first-period cross-over trials, Outcome 3 Cross-over trials: first-period data versus endpoint data (teacher-,
parent-, and independent assessor-rated).
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 12 Additional subgroup analyses of general behaviour: parallel-group trials and first-period cross-over trials
Outcome: 3 Cross-over trials: first-period data versus endpoint data (teacher-, parent-, and independent assessor-rated)
Study or subgroup Methylphenidate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 First-period data
Zeni 2009 9 0.8911 (0.72428) 7 1.7 (1.0996) 100.0 % -0.81 [ -1.75, 0.13 ]
Subtotal (95% CI) 9 7 100.0 % -0.81 [ -1.75, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
2 Endpoint data
Zeni 2009 6 1.06 (0.78442) 8 0.92 (0.83766) 100.0 % 0.14 [ -0.71, 1.00 ]
Subtotal (95% CI) 6 8 100.0 % 0.14 [ -0.71, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 2.14, df = 1 (P = 0.14), I2 =53%
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Analysis 13.1. Comparison 13 Quality of life: parallel-group trials and first-period cross-over trials,
Outcome 1 Subgroup analysis: types of scales.
Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Comparison: 13 Quality of life: parallel-group trials and first-period cross-over trials
Outcome: 1 Subgroup analysis: types of scales
Study or subgroup Methylphenidate Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Child Health Questionnaire (CHQ)
Newcorn 2008 193 7.8 (12.7) 64 1 (12) 43.5 % 0.54 [ 0.25, 0.83 ]
Subtotal (95% CI) 193 64 43.5 % 0.54 [ 0.25, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00022)
2 Children s Global Assessment Scale (CGAS)
Szobot 2004 19 69.1 (11.3) 17 59.7 (12.1) 7.7 % 0.79 [ 0.10, 1.47 ]
Subtotal (95% CI) 19 17 7.7 % 0.79 [ 0.10, 1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
3 Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF)
Coghill 2013 111 7.1 (11.5892) 110 -0.2 (11.2223) 48.8 % 0.64 [ 0.37, 0.91 ]
Subtotal (95% CI) 111 110 48.8 % 0.64 [ 0.37, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.62 (P < 0.00001)
Total (95% CI) 323 191 100.0 % 0.61 [ 0.42, 0.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 6.30 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.52, df = 2 (P = 0.77), I2 =0.0%
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Table 1. ADHD symptoms - rating scales
Name of scale Abbreviation Reference
AbbreviatedConners’ Rating Scales, Parent
(ACPRS) and Teacher (ACTRS),
including Abbreviated Parent Rating Scale
(APRS) and Teacher Rating Scale, Hyper-
kinesis Index and ADHD and Emotional
ACRS Conners 1997a
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Table 1. ADHD symptoms - rating scales (Continued)
Lability subscales
Abbreviated Symptom Questionnaire, in-
cluding ASQ Teacher and ASQ Parent
ASQ Conners 1995
Academic Performance Rating Scale APRS DuPaul 1991a
The ADD/HComprehensive Teacher Rat-
ing Scale
ACTeRS Ullmann 1984
ADHD/ODD Rating Scale, Parent- and
Teacher-Rated
ADHD-RS Barkley 1998
ADHD Rating Scale, including ADHD
Rating Scale Parent and Teacher Ratings
ADHD-RS DuPaul 1991a
ADHDRating Scale-IV, includingADHD
Rating Scale-IV Parent and Teacher Ver-
sions
ADHD-RS-IV DuPaul 1991a
Brief Psychiatric Rating Scale for Children BPRS Gale 1986
Child Attention Problems Rating Scale CAP Achenbach 1986
Child Attention Profile CAP Barkley 1988b
Child Behavior Rating Form NCBHF Aman 1996
Child Symptom Inventory CSI Gadow 1994
Children’s Psychiatric Rating Scale CPRS Pfefferbaum-Levine 1983
Conners’ Abbreviated Hyperactivity Ques-
tionnaire
C-HI Conners 1997a
Conners’ Abbreviated Questionnaire ASQ Conners 1995
Conners’ Abbreviated Parent Teacher
Questionnaire
APTQ Rowe 1997
Conners’ Abbreviated Rating Scale ABRS Conners 1997a
Conners’ Abbreviated SymptomQuestion-
naire
ASQ Conners 1995
Conners Abbreviated Symptom Question-
naire for Parents
ASQ-Parent Conners 1995
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Table 1. ADHD symptoms - rating scales (Continued)
Conners’ Abbreviated SymptomQuestion-
naire for Teachers
ASQ-Teacher Conners 1997a
Conners’ Abbreviated Teacher Rating Scale ABTRS Conners 2001
Conners’ ADHD/DSM-IV Scales Adoles-
cent
CADS-A Conners 1997b
Conners’ ADHD/DSM-IV Scales Parent CADS-P, CADS-P DSM-IV Conners 1997a
Conners’ ADHD/DSM-IV Scale Teacher,
including Inattentive and Hyperactive-Im-
pulsive subscales
CADS-T, CADS-T DSM-IV Conners 1997a
Conners’ Rating Scale -Revised, Parent and
Teacher: Hyperactivity and Conduct Fac-
tors score
CPRS-R and CTRS-R Goyette 1978
Conners’ Hyperactivity Index, Parent and
Teacher, including abbreviated versions
CPRS/CTRS-Hyperactivity index Conners 1997a
Conners’ Hyperkinesis Index - Milich 1980
Conners, Loney and Milich Scale CLAM Milich 1980
Conners’ Parent and Teacher Rating Scale
- Revised, Short Form
CRS-R:S Conners 1997a
Conners’ Parent Rating Scale, including
abbreviated versions
CPRS Conners 1998b
Conners’ Parent Rating Scale - Revised CPRS-R Conners 1997a
Conners’ Parent Rating Scale - Revised,
Short Form
CPRS-R:S Conners 1997a
Conners’ Parent Rating Scale - Revised,
Long Version
CPRS-R:L Conners 1997a
Conners’ Rating Scale - Revised CRS-R Conners 1997a
Conners’ Short Form Rating Scale, Parent
and Teacher
- Conners 1997a
Conners’ Teacher Rating Scale CTRS Conners 1998a
Conners’ Teacher Rating Scale - Revised,
Long Version
CTRS-R:L Conners 1998a
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Table 1. ADHD symptoms - rating scales (Continued)
Diagnostic and Statistical Manual of Men-
tal Disorders Total
DSM-IV APA 1994
Diagnostiksystem
für Psychische Störungen im Kindes - und
Jugendalter nach ICD-10 und DSM-IV,
Parental Questionnaire of ADHD symp-
toms
DISYPS Döpfner 2000
Fremdbeurteilungsbogen für
Hyperkinetische Störungen
FBB-HKS Döpfner 2008
German Teacher’s report on ADHD symp-
toms
FBB-HKS of the DISYPS Döpfner 2000
Hyperactivity Index of the Revised Con-
ners Parent and Teacher Rating Scales
- Goyette 1978
IOWA Conners Parent Rating Scale, in-
cluding abbreviated versions
IOWA CPRS Loney 1982
IOWA Conners Teacher Rating Scale, in-
cluding abbreviated versions
IOWA CTRS Loney 1982
IOWAConners Teacher Rating Scale, Inat-
tention/Overactivity (I/O) and Opposi-
tional/Defiant (O/D) subscales
IOWA-I/O and O/D subscales Loney 1982
IOWA Inattention/Overactivity and Ag-
gression/Noncompliance scales - Parent
and Teacher rating
IOWA Loney 1982
Lehrer-Fragenbogen von Steinhausen LF Steinhausen 1993
Loney’s Time on Task Scale, Hyperactivity,
Attention and Aggression subscales
TOTS Fitzpatrick 1992b
Modified Conner Scale Parent and Teacher ACR Conners 1997a
Mothers’ Objective Method for Subgroup-
ing
MOMS Loney 1984
Parent Symptom Checklist PSC ADHD Döpfner 2000
Parental Account of Children’s Symptoms PACS Chen 2006
Restricted Academic Situation Scale RASS Fischer 1998
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Table 1. ADHD symptoms - rating scales (Continued)
Schedule for Affective Disorders and
Schizophrenia
K-SADS/ K-SADS-E for diagnosis Chambers 1985
Schedule for Non-adaptive and Adaptive
Personality
SNAP Clark 1993; Clark 1996
Swanson, Nolan, and Pelham - IV SNAP-
ADHD Rating scale
SNAP-ADHD Swanson 1992
Swanson, Nolan, and Pelham - IV SNAP-
IV (Brazilian Version)
SNAP-IV Clark 1993; Clark 1996
Swanson, Kotkin, Atkins, M-Flynn, Pel-
hamScale (SKAMPcombined, SKAMPat-
tention, and SKAMP deportment)
SKAMP (SKAMP combined, SKAMP at-
tention, and SKAMP deportment)
Wigal 1998; Murray 2009
Teacher Self-control Rating Scale SCRS Kendall 1979
Turgay - DSM-IV Scale, Parent T-DSM-IV Scale, Parent Turgay 1994; Ercan 2001
Turgay - DSM-IV Scale, Teacher T-DSM-IV Scale, Teacher Turgay 1994; Ercan 2001
Teacher Hyperactivity Index THI Achenbach 1991b
Teacher Symptom Checklist TSC Döpfner 2000
Vanderbilt ADHD Rating Scale VADP(T)RS Wolraich 2003
Wender Utah Rating Scale WURS Ward 1993
Wide Range Achievement Test WRAT-4 Wilkinson 2006
Wide Range Achievement Test Revised WRAT-R Woodcock 2001
ADD/H: Attention deficit disorder with hyperactivity.
ADHD: Attention deficit hyperactivity disorder.
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
ODD: Oppositional defiant disorder.
Table 2. Table 2: General behaviour rating scales
Name of scale Abbreviation Reference
Achenbach Child Behaviour Checklist CBCL Achenbach 1991a
Achenbach’s Teacher Report ATRF Achenbach 1991b; Achenbach 2001
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Table 2. Table 2: General behaviour rating scales (Continued)
ADHD Rating Scale ADHD-RS DuPaul 1991a
ADHD School Observation Code ADHD-SOC Gadow 1996
Barkley Scales, Disruptive Behavior Disor-
ders Rating Scale
- Barkley 1991a
Child Attention Problems Scale CAP Barkley 1991
Child Attention Profile CAP Barkley 1988b
Child Behavior Checklist CBCL Achenbach 1991a
Child Health Questionnaire CHQ Landgraf 1998
Child and Adolescent Psychiatric Assess-
ment, selected items
CAPA Angold 1995
Children’s Psychiatric Rating Scale CPRS Fish 1985
Classroom Observation Code (Abikoff
Classroom Observational System)
COC Abikoff 1980
Code for Observing Social Activity COSA Sprafkin 1986
Conners’ Child Behavior Scale UC-CCBS Ladd 1996
Conners’ Global Index Scale CGI-S Conners 1998a
Conners’ Global Index - Parent CGI-P Conners 1997a
Conners’ Global Index - Teacher CGI-T Conners 1998a
Conners’, Loney and Milich Scale CLAM Milich 1980
Conners’ Parent Questionnaire CPQ Conners 1995
Conners’ Parent Rating Scale CPRS Conners 1998b
Conners’ Teacher Rating Scale CTRS Conners 1998a
Conners’ Teacher Rating Conduct Prob-
lems
- Miller 1997
Disruptive Behavior Disorders Rating
Scale, Parent- and Teacher-Rated
DBS Mendelsohn 1978
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Table 2. Table 2: General behaviour rating scales (Continued)
Disruptive Behavior Disorders Rating
Scale
DBD Silva 2005b
Groninger Behaviour Observation Scale GOO and GBO Van der Meere 1999b
Groninger Behaviour Checklists, Parent
and Teacher Versions of the abbreviated
Groninger
GGGS and GGBS Van der Meere 1999b
Hillside Behavior Rating Scale HBRS Gittleman-Klein 1976
Home Situations Questionnaire HSQ Barkley 1987
Home Situations Questionnaire - Revised HSQ-R DuPaul 1992
Humphrey’s Teacher Self-Control Rating
Scale
TSCRS Humphrey 1982
Hyperactivity Index from the Conners Re-
vised Teacher Rating Scale
CTRS-R-Hyperactivity Index Goyette 1978
Impairment Rating Scale IRS Fabiano 2006
Inpatient Global Rating Scale, Revised IGRS Conners 1985
InpatientGlobal Rating Scale, Somatic fac-
tor
IGRS-S Conners 1985
IOWA Conners’ Rating Scale, Opposi-
tional/Defiant (O/D) subscales
IOWA-O/D subscales Loney 1982
Nisonger Child Behavior Rating Form NCBRF Aman 1996
Paired Associates Learning PAL Wechsler 1945
Parent Global Assessment for Improve-
ment
PGA McGough 2006a
Peer Conflict Scale PCS Marsee 2007
Personality Inventory for Children PIC Lachar 1986
School Situations Questionnaire SSQ Barkley 1987
School Situations Questionnaire - Revised SSQ-R DuPaul 1992
Schedule for Nonadaptive and Adaptive
Personality
SNAP Clark 1993; Clark 1996
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Table 2. Table 2: General behaviour rating scales (Continued)
Strengths and Weaknesses of ADHD
Symptoms and Normal Behavior Scale,
Parent and Teacher
SWAN Swanson 2006; Polderman 2007
Subjective Treatment Emergent Symptom
Scale
STESS-R Guy 1976
Swanson, Nolan and Pelham, Fourth Edi-
tion
SNAP-IV Bussing 2008
Teachers Report Form TRF Achenbach 1991b
Telephone Interview Probe (Parent and
Teacher)
TIP Corkum 2007
Vanderbilt ADHD rating scales: Vander-
bilt ADHDDiagnostic Parent Rating Scale
andVanderbilt ADHDDiagnostic Teacher
Rating Scale
VADPRS and VADTRS Wolraich 2003
Wahler,House and Stambaugh’s Ecobehav-
ioral Assessment System
ECO Wahler 1976
TheWeekly Parent Ratings of Evening and
Morning Behaviour
WREMB-R Kelsey 2004
Werry-Weiss-Peters Activity Rating Scale WWP Routh 1978
Woodcock-Johnson Achievement Battery WJ-III Ach Woodcock 2001
ADHD: attention deficit hyperactivity disorder.
Table 3. Table 3: Quality of life ratings scales
Name of scale Abbreviation Reference
ADHD Impact Module-Child AIM-C AIM-C 2013
Child Impact Scale andHome Impact Scale CIS/HIS Landgraf 2002
ChildHealth and Illness Profile, Child Edi-
tion: Parent Report Form
CHIP-CE:PRF Riley 2004
Child Health Questionnaire CHQ-P Landgraf 1998
Children’s Global Assessment Scale CGAS Shaffer 1983
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Table 3. Table 3: Quality of life ratings scales (Continued)
Comprehensive Psychopathological Rating
Scale
CPRS Aasberg 1978
Health Utilities Index - 2 HUI-2 Torrance 1982
ADHD: attention deficit hyperactivity disorder.
A P P E N D I C E S
Appendix 1. Search strategies
Database Search strategy
CENTRAL (Cochrane Library) Efficacy
#1 MeSH descriptor Methylphenidate explode all trees
#2 Methylphenidate
#3 Attenta
#4 Biphentin
#5 Calocain
#6 Centedrin*
#7 Concerta
#8 Daytrana
#9 Dexmethylphenidat*
#10 Equasym
#11 Focalin
#12 Medikinet
#13 Meridil
#14 Metadate
#15 Methyl phenidat*
#16 Methyl phenidylacetat*
#17 Methylfenid*
#18 Methylin
#19 Methylofenidan
#20 Methylphenid*
#21 Methyl phenidyl acetat*
#22 Methypatch
#23 Metilfenidato
#24 Motiron
#25 MPH
#26 Penid
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(Continued)
#27 Phenidyl hydrochlorid*
#28 Phenidylat*
#29 Plimasin*
#30 PMS-Methylphenid*
#31 Richter Works
#32 Riphenidat*
#33 Ritalin*
#34 Rubifen
#35 Stimdat*
#36 Tsentedrin*
#37 Elmifiten or Medikid or Omozin or Quazym or Tifinidat or Tranquilyn
#38 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #
22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #
32 OR #33 OR #34 OR #35 OR #36 OR #37)
#39 MeSH descriptor Child explode all trees
#40 MeSH descriptor Adolescent explode all trees
#41 MeSH descriptor Infant explode all trees
#42(child* OR boy* OR girl* OR adolescen* OR teen* OR preschool OR pre school OR
infant* OR baby OR babies OR toddler* OR school child* or youth*)
#43 (#39 OR #40 OR #41 OR #42)
#44 (#38 AND #43)
#45MeSH descriptor Attention Deficit and Disruptive Behavior Disorders explode all trees
#46 (ADHD):ti,ab,kw
#47 (ADDH):ti,ab,kw
#48 (ADHS):ti,ab,kw
#49 (“AD/HD”):ti,ab,kw
#50 ((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw
#51 (impulsiv* or inattentiv* or inattention*):ti,ab,kw
#52 ((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*)
or (defian* near/3 behav*)):ti,ab,kw
#53 MeSH descriptor Hyperkinesis explode all trees
#54 (hyperkine*):ti,ab,kw
#55 ((minimal near/3 brain near/3 (disorder* or dysfunct* or damage*))):ti,ab,kw
#56 (hyperactiv*):ti,ab,kw
#57 (#45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54
OR #55 OR #56)
#58 (#44 AND #57)
Adverse events
#1 MeSH descriptor Methylphenidate explode all trees
#2 Methylphenidate
#3 Attenta
#4 Biphentin
#5 Calocain
#6 Centedrin*
#7 Concerta
#8 Daytrana
#9 Dexmethylphenidat*
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(Continued)
#10 Equasym
#11 Focalin
#12 Medikinet
#13 Meridil
#14 Metadate
#15 Methyl phenidat*
#16 Methyl phenidylacetat*
#17 Methylfenid*
#18 Methylin
#19 Methylofenidan
#20 Methylphenid*
#21 Methyl phenidyl acetat*
#22 Methypatch
#23 Metilfenidato
#24 Motiron
#25 MPH
#26 Penid
#27 Phenidyl hydrochlorid*
#28 Phenidylat*
#29 Plimasin*
#30 PMS-Methylphenid*
#31 Richter Works
#32 Riphenidat*
#33 Ritalin*
#34 Rubifen
#35 Stimdat*
#36 Tsentedrin*
#37 elmifiten or medikid or Omozin or Quazym or Tifinidat or Tranquilyn
#38 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #
22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR (#29 AND # ) OR #30 OR #
31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37)
#39 Any MeSH descriptor with qualifiers: AE,DE,CI
#40 (safe or safety or adverse or tolerability or toxicity or toxic or adrs or adr or tolerance
or tolerate or harm or harms or harmful or complication* or risk or risks):ti,ab
#41 (side next effect):ti,ab
#42 (undesirable next effect):ti,ab
#43 (treatment next emergent):ti,ab
#44(unintended next event):ti,ab
#45 (unintended next effect):ti,ab
#46 (#39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 MeSH descriptor Child explode all trees
#48 MeSH descriptor Adolescent explode all trees
#49 MeSH descriptor Infant explode all trees
#50 (child* OR boy* OR girl* OR adolescen* OR teen* OR preschool OR pre school OR
infant* OR baby OR babies OR toddler* OR school child* or youth*)
#51 MeSH descriptor Mood Disorders explode all trees
#52 (depression):ti,ab,kw or (depressive):ti,ab,kw
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(Continued)
#53 MeSH descriptor Psychotic Disorders explode all trees
#54 (psychosis or (psychotic near/4 symptom*)):ti,ab,kw
#55 MeSH descriptor Body Weight explode all trees
#56 MeSH descriptor Anorexia explode all trees
#57 ((loss or lose or losing or decreas* or reduc*) near/3 (weight or appetite)):ti,ab,kw
#58 (loss near/3 weight):ti,ab,kw
#59 ((reduc* or retard* or inhibit* or deficit*) near/4 growth):ti,ab,kw
#60 MeSH descriptor Hypertension explode all trees
#61 MeSH descriptor Heart Rate explode all trees
#62 MeSH descriptor Tachycardia explode all trees
#63 (increas* near/4 (heart rate or pulse or blood pressure)):ti,ab,kw
#64 MeSH descriptor Death, Sudden explode all trees
#65 (death):ti,ab,kw
#66 MeSH descriptor Infertility explode all trees
#67 (((loss or reduc*) near/4 fertility) or infertility):ti,ab,kw
#68 MeSH descriptor Carcinogens explode all trees
#69 MeSH descriptor Neoplasms explode all trees
#70 ((risk near/2 cancer) or (cytogenetic near/2 effect*)):ti,ab,kw
#71 (#46 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59
OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69
OR #70)
#72 (#47 OR #48 OR #49 OR #50)
#73 (#38 AND #71 AND #72)
Ovid MEDLINE Efficacy
1. exp “attention deficit and disruptive behavior disorders”/
2. adhd.mp.
3. addh.mp.
4. adhs.mp.
5. (ad adj hd).mp.
6. ((attention* or behav*) adj3 (defic* or dysfunc* or disorder*)).mp.
7. ((disrupt* adj3 disorder*) or (disrupt* adj3 behav*) or (defian* adj3 disorder*) or (defian*
adj3 behav*)).mp.
8. (impulsiv* or inattentiv* or inattention*).mp.
9. hyperactiv*.mp.
10. hyperkinesis*.mp.
11. exp Hyperkinesis/
12. (minimal adj brain adj3 disorder*).mp.
13. (minimal adj brain adj3 dysfunction*).mp.
14. (minimal adj brain adj3 damage*).mp.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized controlled trials.mp.
19. random allocation.mp.
20. double blind method.mp.
21. single blind method.mp.
22. clinical trial.pt.
23. (clin* adj25 trial*).ti,ab.
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(Continued)
24. ((singl* or doubl* or tripl* or trebl*) adj25 (blind* or mask* or dummy*)).mp.
25. exp Clinical Trial/
26. placebos.mp.
27. placebo*.ti,ab.
28. random*.ti,ab.
29. comparative trial.mp.
30. Evaluation Studies as Topic/
31. exp Clinical Trials as Topic/
32. follow up studies.mp.
33. prospective studies.mp.
34. (control* or prospectiv* or volunteer*).ti,ab.
35. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32 or 33 or 34
36. 15 and 35
37. Methylphenidate.mp. or Methylphenidate/
38. Attenta.mp.
39. Biphentin.mp.
40. Calocain.mp.
41. Centedrin*.mp.
42. Concerta.mp.
43. Daytrana.mp.
44. Dexmethylphenidat*.mp.
45. Elmifiten.mp.
46. Equasym.mp.
47. Focalin.mp.
48. Medikid.mp.
49. Medikinet.mp.
50. Meridil.mp.
51. Metadate.mp.
52. Methyl phenidat*.mp.
53. Methyl phenidylacetat*.mp.
54. Methylfenid*.mp.
55. Methylin.mp.
56. Methylofenidan.mp.
57. Methylphenid*.mp.
58. Methyl phenidyl acetat*.mp.
59. Methypatch.mp.
60. Metilfenidato.mp.
61. Motiron.mp.
62. MPH.mp.
63. Penid.mp.
64. Omozin.mp.
65. Quazym.mp.
66. Phenidyl hydrochlorid*.mp.
67. Phenidylat*.mp.
68. Plimasin*.mp.
69. PMS-Methylphenid*.mp.
70. Richter Works.mp.
744Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
71. Riphenidat*.mp.
72. Ritalin*.mp.
73. Rubifen.mp.
74. Stimdat*.mp.
75. Tifinidat.mp.
76. Tranquilyn.mp.
77. Tsentedrin*.mp.
78. 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66
or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77
79. 36 and 78
80. exp Child/
81. exp Adolescent/
82. exp Infant/
83. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
84. 80 or 81 or 82 or 83
85. 79 and 84
86. 85 and 79 and 84
Adverse events
1. Methylphenidate.mp. or Methylphenidate/
2. Attenta.mp.
3. Biphentin.mp.
4. Calocain.mp.
5. Centedrin*.mp.
6. Concerta.mp.
7. Daytrana.mp.
8. Dexmethylphenidat*.mp.
9. Elmifiten.mp.
10. Equasym.mp.
11. Focalin.mp.
12. Medikid.mp.
13. Medikinet.mp.
14. Meridil.mp.
15. Metadate.mp.
16. Methyl phenidat*.mp.
17. Methyl phenidylacetat*.mp.
18. Methylfenid*.mp.
19. Methylin.mp.
20. Methylofenidan.mp.
21. Methylphenid*.mp.
22. Methyl phenidyl acetat*.mp.
23. Methypatch.mp.
24. Metilfenidato.mp.
25. Motiron.mp.
26. MPH.mp.
27. Omozin.mp.
28. Penid.mp.
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(Continued)
29. Phenidyl hydrochlorid*.mp.
30. Phenidylat*.mp.
31. Plimasin*.mp.
32. PMS-Methylphenid*.mp.
33. Richter Works.mp.
34. Quazym.mp.
35. Riphenidat*.mp.
36. Ritalin*.mp.
37. Rubifen.mp.
38. Stimdat*.mp.
39. Tifinidat.mp.
40. Tranquilyn.mp.
41. Tsentedrin*.mp.
42. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
43. (ae or co or de).fs.
44. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1
emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm
or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (un-
intended adj1 effect*)).ti,ab.
45. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or
outcomes)).ti,ab.
46. 43 or 44 or 45
47. exp Child/
48. exp Adolescent/
49. exp Infant/
50. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
51. 47 or 48 or 49 or 50
52. exp Mood Disorders/
53. (depression or depressive).ti,ab.
54. exp Psychotic Disorders/
55. (psychosis or (psychotic adj4 symptom*)).ti,ab.
56. exp Body Weight/ or Anorexia/
57. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab.
58. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab.
59. exp Hypertension/
60. Heart Rate/
61. exp tachycardia/
62. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab.
63. exp Death, Sudden/
64. death.ti,ab.
65. exp Infertility/
66. (((loss or reduc*) adj4 fertility) or infertility).ti,ab.
67. exp Carcinogens/
68. exp Neoplasms/
69. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab.
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(Continued)
70. 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66
or 67 or 68 or 69
71. 46 or 70
72. 42 and 51 and 71
73. Methylphenidate/ae, po, to
74. 51 and 73
75. 72 or 74
EMBASE (Ovid) Efficacy
1. exp Attention Deficit Disorder/
2. adhd.ti,ab.
3. addh.ti,ab.
4. ADHS.ti,ab.
5. (AD adj HD).ti,ab.
6. ((disrupt* adj3 disorder*) or (disrupt* adj3 behav*) or (defian* adj3 disorder*) or (defian*
adj3 behav*)).ti,ab.
7. ((attention* or behav*) adj3 (defic* or dysfunc* or disorder*)).ti,ab.
8. (impulsiv* or inattentiv* or inattention*).ti,ab.
9. exp Hyperactivity/
10. Hyperkinesia/
11. hyperactiv*.ti,ab.
12. hyperkinesis*.ti,ab.
13. (minimal adj brain adj3 disorder*).ti,ab.
14. (minimal adj brain adj3 dysfunction*).ti,ab.
15. (minimal adj brain adj3 damage*).ti,ab.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or
13 or 14 or 15
17. controlled trial.de.
18. clinical trial.de.
19. major clinical trial.de.
20. randomized controlled trial.de.
21. double blind procedure.de.
22. clinical article.de.
23. random*.mp.
24. control*.mp.
25. follow up.mp.
26. ((singl* or doubl* or tripl* or trebl*) adj (blind* or mask* or dummy)).mp.
27. placebo*.mp.
28. (clinic* adj (trial* or trial or studies*)).mp.
29. exp comparative trial/
30. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. 16 and 30
32. methylphenidate.mp. or METHYLPHENIDATE/
33. Attenta.mp.
34. Biphentin.mp.
35. Calocain.mp.
36. Centedrin*.mp.
37. Concerta.mp.
38. Daytrana.mp.
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39. Dexmethylphenidat*.mp.
40. Elmifiten.mp.
41. Equasym.mp.
42. Focalin.mp.
43. Medikid.mp.
44. Medikinet.mp.
45. Meridil.mp.
46. Metadate.mp.
47. Methyl phenidat*.mp.
48. Methyl phenidylacetat*.mp.
49. Methylfenid*.mp.
50. Methylin.mp.
51. Methylofenidan.mp.
52. Methylphenid*.mp.
53. Methyl phenidyl acetat*.mp.
54. Methypatch.mp.
55. Metilfenidato.mp.
56. Motiron.mp.
57. MPH.mp.
58. Omozin.mp.
59. Penid.mp.
60. Phenidyl hydrochlorid*.mp.
61. Phenidylat*.mp.
62. Plimasin*.mp.
63. PMS-Methylphenid*.mp.
64. Quazym.mp.
65. Richter Works.mp.
66. Riphenidat*.mp.
67. Ritalin*.mp.
68. Rubifen.mp.
69. Stimdat*.mp.
70. Tifinidat.mp.
71. Tranquilyn.mp.
72. Tsentedrin*.mp.
73. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61
or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72
74. 31 and 73
75. exp child/
76. exp adolescent/
77. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
78. 75 or 76 or 77
79. 74 and 78
Adverse events
1 Methylphenidate.mp.
2 Attenta.mp.
3 Biphentin.mp.
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4 Calocain.mp.
5 Centedrin*.mp.
6 Concerta.mp.
7 Daytrana.mp.
8 Dexmethylphenidat*.mp.
9 Elmifiten.mp.
10 Equasym.mp.
11 Focalin.mp.
12 Medikid.mp.
13 Medikinet.mp.
14 Meridil.mp.
15 Metadate.mp.
16 Methyl phenidat*.mp.
17 Methyl phenidylacetat*.mp.
18 Methylfenid*.mp.
19 Methylin.mp.
20 Methylofenidan.mp.
21 Methylphenid*.mp.
22 Methyl phenidyl acetat*.mp.
23 Methypatch.mp.
24 Metilfenidato.mp.
25 Motiron.mp.
26 MPH.mp.
27 Omozin.mp.
28 Penid.mp.
29 Phenidyl hydrochlorid*.mp.
30 Phenidylat*.mp.
31 Plimasin*.mp.
32 PMS-Methylphenid*.mp.
33 Richter Works.mp.
34 Riphenidat*.mp.
35 Ritalin*.mp.
36 Rubifen.mp.
37 Tifinidat.mp.
38 Stimdat*.mp.
39 Tranquilyn.mp.
40 Tsentedrin*.mp.
41 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
42 (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emer-
gent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or
harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unin-
tended adj1 effect*)).ti,ab.
43 (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or
outcomes)).ti,ab.
44 exp adverse drug reaction/
45 exp side-effect/
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46 42 or 43 or 44 or 45
47 methylphenidate/ae, to
48 exp mood disorder/si
49 (depression or depressive).ti,ab.
50 exp psychosis/si
51 (psychosis or (psychotic adj4 symptom*)).ti,ab.
52 growth retardation/ or growth inhibition/
53 ((loss or lose or losing or reduc*) adj3 weight).ti,ab.
54 ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab.
55 hypertension/si
56 heart rate/
57 cardiovascular effect/
58 tachycardia/si
59 (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab.
60 Sudden death/
61 death.ti,ab.
62 infertility/si
63 (((loss or reduc*) adj4 fertility) or infertility).ti,ab.
64 cancer risk/
65 carcinogenicity/
66 chromosome aberration/si
67 childhood cancer/si
68 ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab.
69 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
or 63 or 64 or 65 or 66 or 67 or 68
70 exp child/
71 exp adolescent/
72 (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
73 70 or 71 or 72
74 46 or 69
75 41 and 74
76 47 or 75
77 73 and 76
CINAHL (EBSCOhost) Broad strategy to capture both efficacy and adverse events studies
S43 S37 and S42
S42 S38 or S39 or S40 or S41
S41 (child* OR boy* OR girl* OR adolescen* OR teen* OR preschool OR pre school OR
infant* OR baby OR babies OR toddler* OR school child* or youth*)
S40 (MH “Adolescence+”)
S39 (MH “Infant+”)
S38 (MH “Child+”)
S37 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14
or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or
S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36
S36 Tsentedrin* or Tranquilyn
S35 Stimdat* or Tifinidat
S34 Rubifen
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S33 Ritalin*
S32 Riphenidat*
S31 Richter Works
S30 PMS-Methylphenid* or Quazym
S29 Plimasin*
S28 Phenidylat*
S27 Phenidyl hydrochlorid*
S26 Penid or Omozin
S25 MPH
S24 Motiron
S23 Metilfenidato
S22 Methypatch
S21 Methyl phenidyl acetat*
S20 Methylphenid*
S19 Methylofenidan
S18 Methylin
S17 Methylfenid*
S16 Methyl phenidylacetat*
S15 Methyl phenidat*
S14 Metadate
S13 Meridil
S12 Medikinet
S11 Focalin or Medikid
S10 Equasym
S9 Dexmethylphenidat* or Elmifiten
S8 Daytrana
S7 Concerta
S6 Centedrin*
S5 Calocain
S4 Biphentin
S3 Attenta
S2 Methylphenidate
S1 (MH “Methylphenidate”)
PsycINFO (Ovid) Efficacy
1. exp attention deficit disorder/
2. adhd.ti,ab.
3. addh.ti,ab.
4. ADHS.ti,ab.
5. (AD adj HD).ti,ab.
6. ((attention* or behav*) adj3 (defic* or dysfunc* or disorder*)).ti,ab.
7. ((disrupt* adj3 disorder*) or (disrupt* adj3 behav*) or (defian* adj3 disorder*) or (defian*
adj3 behav*)).ti,ab.
8. (impulsiv* or inattentiv* or inattention*).ti,ab.
9. hyperactiv*.ti,ab.
10. hyperkinesis*.ti,ab.
11. exp Hyperkinesis/
12. (minimal adj brain adj3 disorder*).ti,ab.
13. (minimal adj brain adj3 dysfunction*).ti,ab.
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14. (minimal adj brain adj3 damage*).ti,ab.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. random*.mp.
17. ((singl* or doubl* or trebl* or tripl*) adj25 (blind* or dummy or mask*)).mp.
18. placebo*.mp.
19. crossover.mp.
20. assign*.mp.
21. allocat*.mp.
22. ((clin* or control* or compar* or evaluat* or prospectiv*) adj25 (trial* or studi* or trial)
).mp.
23. exp placebo/
24. exp treatment effectiveness evaluation/
25. exp mental health program evaluation/
26. exp experimental design/
27. versus.id.
28. vs.id.
29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 15 and 29
31. Methylphenidate.mp. or Methylphenidate/
32. Attenta.mp.
33. Biphentin.mp.
34. Calocain.mp.
35. Centedrin*.mp.
36. Concerta.mp.
37. Daytrana.mp.
38. Dexmethylphenidat*.mp.
39. Elmifiten.mp.
40. Equasym.mp.
41. Focalin.mp.
42. Medikid.mp.
43. Medikinet.mp.
44. Meridil.mp.
45. Metadate.mp.
46. Methyl phenidat*.mp.
47. Methyl phenidylacetat*.mp.
48. Methylfenid*.mp.
49. Methylin.mp.
50. Methylofenidan.mp.
51. Methylphenid*.mp.
52. Methyl phenidyl acetat*.mp.
53. Methypatch.mp.
54. Metilfenidato.mp.
55. Motiron.mp.
56. MPH.mp.
57. Omozin.mp.
58. Penid.mp.
59. Phenidyl hydrochlorid*.mp.
60. Phenidylat*.mp.
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61. Plimasin*.mp.
62. PMS-Methylphenid*.mp.
63. Quazym.mp.
64. Richter Works.mp.
65. Riphenidat*.mp.
66. Ritalin*.mp.
67. Rubifen.mp.
68. Stimdat*.mp.
69. Tifinidat.mp.
70. Tranquilyn.mp.
71. Tsentedrin*.mp.
72. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 73. 30 and 72
74. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
75. 73 and 74
Adverse events
1. Methylphenidate.mp. or Methylphenidate/
2. Attenta.mp.
3. Biphentin.mp.
4. Calocain.mp.
5. Centedrin*.mp.
6. Concerta.mp.
7. Daytrana.mp.
8. Dexmethylphenidat*.mp.
9. Elmifiten.mp.
10. Equasym.mp.
11. Focalin.mp.
12. Medikid.mp.
13. Medikinet.mp.
14. Meridil.mp.
15. Metadate.mp.
16. Methyl phenidat*.mp.
17. Methyl phenidylacetat*.mp.
18. Methylfenid*.mp.
19. Methylin.mp.
20. Methylofenidan.mp.
21. Methylphenid*.mp.
22. Methyl phenidyl acetat*.mp.
23. Methypatch.mp.
24. Metilfenidato.mp.
25. Motiron.mp.
26. MPH.mp.
27. Omozin.mp.
28. Penid.mp.
29. Phenidyl hydrochlorid*.mp.
30. Phenidylat*.mp.
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31. Plimasin*.mp.
32. PMS-Methylphenid*.mp.
33. Quazym.mp.
34. Richter Works.mp.
35. Riphenidat*.mp.
36. Ritalin*.mp.
37. Rubifen.mp.
38. Stimdat*.mp.
39. Tifinidat.mp.
40. Tranquilyn.mp.
41. Tsentedrin*.mp.
42. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
43. “Side effects (Drug)”/
44. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1
emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm
or harms or harmful or complication* or risk or risks or (unintended adj1
event*) or (unintended adj1 effect*)).ti,ab.
45. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or
outcomes)).ti,ab.
46. 43 or 44 or 45
47. exp major depression/ or affective disorders/
48. (depression or depressive).ti,ab.
49. exp psychosis/
50. (psychosis or (psychotic adj4 symptom*)).ti,ab.
51. exp body weight/
52. exp appetite depressing drugs/
53. Appetite/
54. ((loss or lose or losing or decreas* or reduc*) adj3 (weight or appetite)).ti,ab.
55. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab.
56. exp appetite depressing drugs/
57. Appetite/
58. exp cardiovascular disorders/
59. exp heart rate affecting drugs/
60. Heart rate/
61. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab.
62. “death and dying”/
63. death.ti,ab.
64. exp infertility/
65. (((loss or reduc*) adj4 fertility) or infertility).ti,ab.
66. exp neoplasms/
67. Carcinogens/
68. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab.
69. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61
or 62 or 63 or 64 or 65 or 66 or 67 or 68
70. 46 or 69
71. 42 and 70
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72. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or
baby or babies or toddler* or school child* or youth*).mp.
73. 71 and 72
CPCI-S, CPCI-SSH
(Web of Science)
Broad strategy to capture both efficacy and adverse events studies
#2 AND #1
#2 TS=(child* or boy* or girl* or adolescen* or teen* or preschool* or “pre school*” or
infant* or baby or babies or toddler* or “school child*” or schoolchild* or youth*)
#1 TS=(Methylphenidate or Attenta or Biphentin or Calocain or Centedrin* or Concerta
or Daytrana or Dexmethylphenidat* or Elmifiten or Equasym or Focalin or Medikid or
Medikinet or Meridil or Metadate or “Methyl phenidat*” or “Methyl phenidylacetat” or
Methylfenid or Methylin or Methylofenidan or Methylphenid* or “Methyl phenidyl ac-
etat*” or Methypatch or Metilfenidato orMotiron orMPH or Penid or Omozin or Quazym
or “Phenidyl hydrochlorid*” or Phenidylat* or Plimasin* or “PMS-Methylphenid* ” or
“Richter Works” or Riphenidat* or Ritalin* or Rubifen or Stimdat* or Tifinidat or Tran-
quilyn or Tsentedrin*)
ClinicalTrials.gov Advanced search:MethylphenidateOR concerta ORdaytranaORdexmethylphenidateOR
equasym OR focalin OR medikinet OR MPH OR Ritalin
Studies with results
Age group: Child
WHO ICTRP (who.int/ictrp/en Intervention: Methylphenidate OR concerta OR daytrana OR dexmethylphenidate OR
equasym OR focalin OR medikinet OR MPH OR Ritalin
Status: all
Children
CENTRAL: Cochrane Central Register of Controlled Trials.
CINAHL: Cumulative Index to Nursing and Allied Health Literature.
CPCI-S: Conference Proceedings Citation Index - Science.
CPCI-SSH: Conference Proceedings Citation Index - Social Science & Humanities.
WHO ICTRP: World Health Organisation International Clinical Trials Registry Platform.
Appendix 2. Letter to pharmaceutical companies
To whom it might concern,
Date: June 2013
The Cochrane Methylphenidate Group
Psychiatric Research Unit
Toftebakken 9
4000 Roskilde, Denmark
Ole Jakob Storebø
Email: ojst@regionsjaelland.dk
Phone: +45 25119901
Web: regionsjaelland.dk/psykforsk
Regarding: Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - a Cochrane
systematic review.
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On behalf of the Cochrane Methylphenidate Group we address you in order to request your assistance. We are elaborating a systematic
review on the effect of methylphenidate treatment for children and adolescents with ADHD. We have been entrusted the elaboration
of this review by The Cochrane Developmental, Psychosocial and Learning Problems Group.
The Cochrane systematic review intends to include all relevant literature empirically describing both the positive and possibly negative
effects of the medical treatment. We believe the elaboration of this review is in common interest of patients, doctors and manufacturers
of methylphenidate. Furthermore, it is an important ethical issue. The results from this review will, in the future, guide authorities,
clinicians and researchers when it comes to considering the use of methylphenidate in the treatment for children and adolescents with
ADHD.
The Cochrane review will be comprehensive. The currently included studies come from our search for literature through international,
scientific databases [1]. However, the published literature only provides us with limited and possibly selective knowledge, since it is
unlikely that all studies and data are available through these databases. By contacting authors of significant publications, experts in the
field and pharmaceutical companies, we hope to be informed of additional studies, published as well as unpublished. We have been
inspired by this approach used in other Cochrane systematic reviews investigating medical preparations for other widespread diseases
as ADHD.
We hope you will assist us with providing data that are relevant for our review. As previously noted, we are interested in data regarding
both positive and negative effects of methylphenidate from both observational studies and randomised clinical trials, regardless of the
year the data were recorded or published.
It is important for us to point out that we are not investigating specific methylphenidate preparations but simply the effect of the active
substance, methylphenidate. Thus, we will not refer to or recommend any specific methylphenidate preparation or drug company.
However, we will state which companies we have been in contact with, and which of these who have assisted us with data.
If possible, we would be very pleased to meet a representative from your company.
Enclosed to this letter are our protocol, a recommendation fromThe Cochrane Developmental, Psychosocial and Learning Problems Group
and a list of the currently included studies in our review.
We are hoping to hear from you. If you have any questions, please contact us.
On behalf of
The Cochrane Developmental, Psychosocial and Learning Problems Group
The Cochrane Methylphenidate Group
Ole Jakob Storebø
Project coordinator, Ph.D, Senior Scientist
Phone: +45 25119901
E-mail: ojst@regionsjaelland.dk
Erik Simonsen
Professor of Psychiatry, PhD, Dr.h.c.
Psychiatric Research Unit
Region Zealand
Toftebakken 9, 4000 Roskilde, Denmark
Christian Gluud
MD, dr. Med. Sci.,
Head of Department, Copenhagen Trial Unit,
Centre for Clinical Intervention Research,
Copenhagen University Hospital, Denmark
Per Hove Thomsen
Professor, MD, DMSc
Department of Children and Youth Psychiatry, Aarhus University Hospital
[1] Cochrane Central Register of Controlled Trials (CENTRAL) part of The Cochrane Library, MEDLINE, PsycINFO, EMBASE,
CINAHL, ISI Conference Proceedings Citation Index (Science, and Social Science and Humanities), Clinical Trials.gov, and Interna-
tional Clinical Trials Registry Platform (ICTRP)
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Appendix 3. Data extraction sheet RCTs - parallel-group trials
Version 09.04.2014
Source
Trial ID (e.g. Plizska 2000)
Trial registry with ID Search clinicaltrials.gov (from 2008 -) and who.int/ictrp/en(from 2004 -)
Full citation
Form filled by
Author contact information
Other publications on same trial
ID:identif ier.
Eligibility
Confirm eligibility Yes No Awaiting assessment
Correspondence
Correspondence required
Method
Cluster-randomised Yes/no
Intervention (n (number)) =, control (n) =
Location (e.g. hospital, out-clinic) -
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(Continued)
Summary (method) Parallel trial with 2 arms:
1. Methylphenidate
2. Control
Participants
Summary (participants) Number of participants screened
Number of participants included
Number of participants randomly assigned to methylphenidate and control
Number of participants followed up in each arm: methylphenidate and control
Number of withdrawals in each arm: Methylphenidate and control
Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) diagnosis of attention
deficit hyperactivity disorder (ADHD) (combined (%), hyperactive-impulsive (%), inattentive (%))
Age (years) (mean, range)
IQ (mean, range)
Sex (male, female)
Methylphenidate naive (%/number)
Ethnicity (Caucasian (%), African American (%), Asian (%), Hispanic (%), other (%))
Country
Comorbidity (type %)
Comedication (no/yes)
Sociodemographics (e.g. double or single parent family, low, middle or upper class)
Inclusion criteria
Exclusion criteria
Interventions
Participants were randomly assigned to type of (e.g. immediate-release (IR), extended-release (ER)) (dex-) methylphenidate or control
Methylphenidate dosage: Mean (standard deviation (SD))
Administration schedule: time points
Duration of intervention
Titration period: none/duration initiated before/after randomisation
Treatment compliance
Outcome listing
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(Our outcomes according to our protocol: short, general description)
ADHD symptoms
Measure instrument (e.g. ADHD Rating Scale (ADHD-RS); Swanson, Kotkin, Atkins, M-Flynn and Pelham (SKAMP) Scale),
parent-/teacher-/independent assessor-rated, time point
General behaviour
Measure instrument (e.g. Child Behavior Checklist (CBCL)), parent-/teacher-/independent assessor-rated, time point
Quality of life
Measure instrument, parent-/teacher-/independent assessor-rated, time point
Serious adverse events
Type of outcome/adverse event, measure method/instrument, parent-/teacher-/independent assessor-rated, time point
Non-serious adverse events
Type of outcome/adverse event, measure method/instrument, parent-/teacher-/independent assessor-rated, time point
Outcomes (positive effects)
*e.g. copy of table from article*
Outcomes (adverse events)
*e.g. copy of table from article*
Outcomes
specified
Type of adverse
events/responses
Total numbers Mean SD Time point
Serious adverse
events (temporal as-
sociation, but not
necessarily causal re-
lationship)
Serious adverse reac-
tion (response to the
drug)
Non-serious adverse
events (temporal as-
sociation)
Risk of bias
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Item Quote Risk of bias (high, unclear, low)
Random sequence generation/generation
of allocation sequence (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel
(performance bias)
Blinding of outcome assessment (detection
bias)
Incomplete outcome data (intention-to-
treat (ITT), imputation method) (attrition
bias)
Selective outcome reporting (according to
protocol?)
Vested interest
Other sources of bias Authors’ affiliations (e.g. Novartis)
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders)
Notes
Sample calculation
Ethics approval
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-responders/children who have previously experi-
enced adverse events while taking methylphenidate
Any withdrawals due to adverse events
Comments from trial authors
Key conclusions of trial authors
Comments from review authors
Supplemental information/data received through personal email correspondence with trial authors in *month* 2014
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Appendix 4. Data extraction sheet RCTs - cross-over trials
Version 09.04.2014
Source
Trial ID (e.g. Plizska 2000)
Trial registry with ID Search clinicaltrials.gov (from 2008 -) and
who.int/ictrp/en (from 2004 -)
Full citation
Form filled by Date and name
Author contact information
Other publications on same trial
Eligibility
Confirm eligibility Yes No Awaiting assessment
Correspondence
Correspondence required Data for each intervention period
Method
Cluster-randomised Yes/No
Intervention (number (n)) =, control (n) =
Location (e.g. hospital, out-clinic)
Ethics approval Yes/No/No information
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(Continued)
Summary (method) Cross-over trial with 2 interventions:
1. Methylphenidate
2. Control
Phases
Participants
Summary (participants) Number of participants screened
Number of participants included
Participants were randomly assigned to 1 of X possible drug condition orders
Number of participants followed up
Number of withdrawals
Diagnostic and Statistical Manual ofMentalDisorders (DSM) or International Classification of Diseases (ICD)
diagnosis of ADHD (combined (%), hyperactive-impulsive (%), inattentive (%))
Age (years) (mean, range)
IQ (mean, range)
Sex (male, female)
Methylphenidate naive (%/number)
Ethnicity (Caucasian (%), African-american (%), Asian (%), Hispanic (%), other (%))
Country
Comorbidity (type %)
Comedication (no/yes)
Sociodemographics (e.g. double- or single-parent family, low, middle or upper class)
Inclusion criteria
Exclusion criteria
Interventions
Participants were randomly assigned to 1 of X possible drug condition orders of methylphenidate and control
Methylphenidate dosage: Mean (standard deviation (SD))
Administration schedule: time points
Duration of each medication condition
Washout before trial initiation
Medication-free period between interventions
Titration period: none/duration initiated before/after randomisation
Treatment compliance
Outcome listing
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(Our outcomes according to our protocol: short, general description)
ADHD symptoms
Measure instrument (e.g. ADHDRating Scale (ADHD-RS), Swanson, Kotkin, Atkins,M-Flynn and Pelham (SKAMP) scale), parent-
/teacher-/independent assessor-rated, time point
General behaviour
Measure instrument (e.g. Child Behavior Checklist (CBCL)), parent-/teacher-/independent assessor-rated, time point
Quality of life
Measure instrument, parent-/teacher-/independent assessor-rated, time point
Serious adverse events
Type of outcome/adverse event, measure method/instrument, parent- /teacher-/independent assessor-rated, time point
Non-serious adverse events
Type of outcome/adverse event, measure method/instrument, parent- /teacher-/independent assessor-rated, time point
Outcomes (positive effects)
*e.g. copy of table from article*
Outcomes (adverse events)
*e.g. copy of table from article*
Outcomes
specified
Types of adverse
events/responses
Total numbers Mean SD Time point
Serious adverse
events (temporal as-
sociation, but not
necessarily causal re-
lationship)
Serious adverse reac-
tion (response to the
drug)
Non-serious adverse
events (temporal as-
sociation)
Risk of bias
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Item Quote Risk of bias (high, unclear, low)
Random sequence generation/generation
of allocation sequence (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel
(performance bias)
Blinding of outcome assessment (detection
bias)
Incomplete outcome data (intention-to-
treat (ITT), imputation method) (attrition
bias)
Exclusion of placebo responders etc.
: methylphenidate non-responders (after
randomisation)
Selective outcome reporting (according to
protocol?)
Vested interest
Other sources of bias Authors’ affiliations (e.g. Novartis)
Selection bias (e.g. titration after randomi-
sation → exclusion of methylphenidate
non-responders or placebo responders)
Notes
Sample calculation
Ethics approval
Comments from trial authors
Key conclusions of trial authors
Comments from review authors
Inclusion of methylphenidate responders only/exclusion of methylphenidate non-responders/children who have previously experi-
enced adverse events while taking methylphenidate
Any withdrawals due to adverse events
Supplemental information/data received through personal email correspondence with trial authors in *month* 2014
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WH A T ’ S N E W
Date Event Description
29 November 2016 Feedback has been incorporated This review was published in the Cochrane Library on 25 November 2015,
with abridged versions appearing in the BMJ on 26 November 2015 and
JAMA on 10 May 2016. These abridged reviews have received many com-
ments in editorials, ’letters to the editor’, articles, rapid responses, and blogs.
Interestingly, however, no comment has been directed to the full review in
the Cochrane Library. In order to inform readers of the Cochrane Library,
we have provided the links to these comments, as well as review authors’
responses, in the Feedback section below
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. Methods section. Criteria for considering studies for this review. Types of studies.
We decided to split the review into two systematic reviews. The present review deals with benefits and harms of methylphenidate
as reported by RCTs. Another systematic review is being prepared that will assess the risk of harms based on the findings of non-
randomised studies.
2. Methods section. Criteria for considering studies for this review. Types of participants.
We decided to include trials in which at least 75% of participants were 18 years of age or younger, and the mean age of the trial
population was 18 years of age or younger. We included two trials with such participants. The effects of methylphenidate intervention
on any outcome did not change when these two trials were removed from the analysis.
We decided to include trials in which at least 75% of participants had a normal intellectual quotient (IQ > 70). We included three
trials with such participants. The effects of methylphenidate intervention on any outcome did not change when these three trials were
removed from the analysis.
3. Methods section. Criteria for considering studies for this review. Types of outcome measures.
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Duration of studies. We changed the subdivision of duration from short term (≤ 6 months), medium term (6 to 12 months) and long
term (> 12 months) to short term (≤ 6 months) and long term (> 6 months) because no trials had a duration of between 6 and 12
months. Only one trial (Jensen 1999 (MTA)) provided data on a duration longer than six months (14 months). This change regarding
duration classification was included in analyses of ADHD symptoms and general behaviour.
4. Methods section. Search methods for identification of studies.
We did not search for dissertations in WorldCat, Networked Digital Library of Theses and Dissertations, OpenGrey, DART-Europe E-
theses Portal and Theses Canada. We did not contact the medical authorities in the European Union for information about beneficial
and adverse events. We did not ask for access to security updates and risk management plans of pharmaceutical companies.
5. Methods section. Data collection and analysis. Selection of studies and data extraction and management.
More review authors than stated in the protocol screened titles and abstracts, extracted data, entered data into RevMan and conducted
statistical analyses in RevMan.
6. Methods section. Data collection and analysis. Assessment of risk of bias in included studies.
Vested interests. We did not evaluate what effects might have been seen if the study author had conducted previous trials addressing
the same interventions.
7. Methods section. Data collection and analysis. Measures of treatment effect. Continuous data.
For the primary outcome of teacher-rated ADHD symptoms, we recalculated the SMD as MD on the ADHD-RS (DuPaul 1991a),
to check whether our result exceeded the minimum clinically important difference (MCID; Zhang 2005) for this specific rating scale.
This was not stated in the protocol.
For the secondary outcome of quality of life, we recalculated the SMD as MD on the CHQ (Landgraf 1998), to check whether our
results exceeded the MCID (Rentz 2005) for this specific rating scale. This was not stated in the protocol.
8. Methods section. Dealing with missing data.
We tried to obtain missing data by contacting the authors of the trials that were included in this review. When we were not able to
obtain missing data, we conducted analyses using available (incomplete) data. We had intended to assess the impact of missing data by
applying intention-to-treat as well as ’best-case scenario’ and ’worst-case scenario’ analyses. We could not use ’best-case scenario’ and
’worst-case scenario’ analyses in our assessment of benefits as there were no dichotomous outcomes. We decided not to use ’best-case
scenario’ and ’worst-case scenario’ analyses in our assessment of adverse events, because we evaluated these analyses to be imprecise due
to the high number of trials not reporting adverse events, and due to the high number of dropouts in the trials reporting adverse events.
Moreover, we were unable to conduct intention-to-treat analyses for continuous outcomes due to lack of data for imputing means.
9. Methods section. Data collection and analysis. Assessment of reporting bias.
We did not compare results extracted from published journal reports versus results obtained from other sources (including correspon-
dences) as a direct test for publication bias.
10. Methods section. Subgroup analysis and investigation of heterogeneity. Post hoc subgroup analyses.
1. Types of scales (e.g. Conners’ Teacher Rating Scale (CTRS; Conners 1998a) versus Strengths and Weaknesses of ADHD
Symptoms and Normal Behavior (SWAN) Scale (Swanson 2006).
2. Dose of methylphenidate (low dose (≤ 20 mg/d or ≤ 0.6 mg/kg/d) versus moderate/high dose (> 20 mg/d or > 0.6 mg/kg/d)).
3. Duration of treatment (short-term trials (≤ six months) versus long-term trials (> six months)).
4. Trial design (parallel-group trials versus cross-over trials (first period data and endpoint data)).
5. Medication status before randomisation (medication naive (> 80% of included participants were medication naive) versus not
medication naive (< 20% of included participants were medication naive)).
6. Risk of bias (trials with low risk of bias versus trials with high risk of bias).
7. Cohort selection bias (trials with cohort selection bias of all participants versus trials without cohort selection bias)
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11. Methods section. Data collection and analysis. Heterogeneity-adjusted required information size and Trial Sequential
Analysis.
We performed a Trial Sequential Analysis on the total number of serious adverse events and on the total number of non-serious adverse
events only, as they were the only outcomes with dichotomous data with a substantial number of outcomes. Trial Sequential Analysis
can be conducted on individual types of adverse events, but for this, the accrued information would represent a minute fraction of the
required information size (RIS). We were not able to conduct a Trial Sequential Analysis for teacher-, independent assessor- or parent-
rated outcomes, as the programme can be used only for MDs, not for SMDs.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Attention Deficit Disorder with Hyperactivity [∗drug therapy]; Central Nervous System Stimulants [adverse effects; ∗therapeutic use];
Methylphenidate [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Child; Female; Humans; Male
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